ID   FGFR1_MOUSE             Reviewed;         822 AA.
AC   P16092; E9Q2P4; Q01736; Q60830; Q61562; Q80T10; Q8CFK8; Q9QZM7;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 2.
DT   20-JAN-2016, entry version 180.
DE   RecName: Full=Fibroblast growth factor receptor 1;
DE            Short=FGFR-1;
DE            Short=bFGF-R-1;
DE            EC=2.7.10.1 {ECO:0000250|UniProtKB:P11362};
DE   AltName: Full=Basic fibroblast growth factor receptor 1;
DE   AltName: Full=MFR;
DE   AltName: Full=Proto-oncogene c-Fgr;
DE   AltName: CD_antigen=CD331;
DE   Flags: Precursor;
GN   Name=Fgfr1; Synonyms=Flg;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=1689490; DOI=10.1073/pnas.87.4.1596;
RA   Reid H.H., Wilks A.F., Bernard O.;
RT   "Two forms of the basic fibroblast growth factor receptor-like mRNA
RT   are expressed in the developing mouse brain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:1596-1600(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6).
RC   STRAIN=BALB/cJ; TISSUE=Brain;
RX   PubMed=2161096;
RA   Safran A., Avivi A., Orr-Urtereger A., Neufeld G., Lonai P., Givol D.,
RA   Yarden Y.;
RT   "The murine flg gene encodes a receptor for fibroblast growth
RT   factor.";
RL   Oncogene 5:635-643(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND ALTERNATIVE SPLICING.
RX   PubMed=1708247; DOI=10.1016/0006-291X(91)90885-B;
RA   Kouhara H., Kasayama S., Saito H., Matsumoto K., Sato B.;
RT   "Expression cDNA cloning of fibroblast growth factor (FGF) receptor in
RT   mouse breast cancer cells: a variant form in FGF-responsive
RT   transformed cells.";
RL   Biochem. Biophys. Res. Commun. 176:31-37(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=2161540; DOI=10.1073/pnas.87.11.4378;
RA   Mansukhani A., Moscatelli D., Talarico D., Levytska V., Basilico C.;
RT   "A murine fibroblast growth factor (FGF) receptor expressed in CHO
RT   cells is activated by basic FGF and Kaposi FGF.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4378-4382(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RC   STRAIN=Swiss Webster; TISSUE=Embryonic heart;
RX   PubMed=7897669; DOI=10.1006/jmcc.1994.1164;
RA   Jin Y., Pasumarthi K.B., Bock M.E., Lytras A., Kardami E.,
RA   Cattini P.A.;
RT   "Cloning and expression of fibroblast growth factor receptor-1
RT   isoforms in the mouse heart: evidence for isoform switching during
RT   heart development.";
RL   J. Mol. Cell. Cardiol. 26:1449-1459(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), SUBCELLULAR LOCATION, FUNCTION
RP   AS FGF7 RECEPTOR AND IN ACTIVATION OF SIGNALING PATHWAYS, INTERACTION
RP   WITH FGF1; FGF2; FGF7 AND FGF10, GLYCOSYLATION, TISSUE SPECIFICITY,
RP   AND ALTERNATIVE SPLICING.
RC   STRAIN=BALB/cJ;
RX   PubMed=10821861; DOI=10.1074/jbc.275.21.16091;
RA   Beer H.-D., Vindevoghel L., Gait M.J., Revest J.-M., Duan D.R.,
RA   Mason I., Dickson C., Werner S.;
RT   "Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally
RT   occurring functional receptor for FGFs that is preferentially
RT   expressed in the skin and the brain.";
RL   J. Biol. Chem. 275:16091-16097(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   STRAIN=C57BL/6J; TISSUE=Placenta;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   STRAIN=FVB/N; TISSUE=Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-15, AND ALTERNATIVE SPLICING.
RX   PubMed=7802632; DOI=10.1006/bbrc.1994.2773;
RA   Harada T., Saito H., Kouhara H., Kurebayashi S., Kasayama S.,
RA   Terakawa N., Kishimoto T., Sato B.;
RT   "Murine fibroblast growth factor receptor 1 gene generates multiple
RT   messenger RNAs containing two open reading frames via alternative
RT   splicing.";
RL   Biochem. Biophys. Res. Commun. 205:1057-1063(1994).
RN   [11]
RP   INTERACTION WITH FGF1; FGF2; FGF4; FGF5; FGF6, AND FUNCTION IN CELL
RP   PROLIFERATION.
RX   PubMed=1309590;
RA   Ornitz D.M., Yayon A., Flanagan J.G., Svahn C.M., Levi E., Leder P.;
RT   "Heparin is required for cell-free binding of basic fibroblast growth
RT   factor to a soluble receptor and for mitogenesis in whole cells.";
RL   Mol. Cell. Biol. 12:240-247(1992).
RN   [12]
RP   DISRUPTION PHENOTYPE, AND FUNCTION DURING EMBRYONIC DEVELOPMENT.
RX   PubMed=8001822; DOI=10.1101/gad.8.24.3032;
RA   Yamaguchi T.P., Harpal K., Henkemeyer M., Rossant J.;
RT   "fgfr-1 is required for embryonic growth and mesodermal patterning
RT   during mouse gastrulation.";
RL   Genes Dev. 8:3032-3044(1994).
RN   [13]
RP   DISRUPTION PHENOTYPE, AND FUNCTION DURING EMBRYONIC DEVELOPMENT.
RX   PubMed=8001823; DOI=10.1101/gad.8.24.3045;
RA   Deng C.X., Wynshaw-Boris A., Shen M.M., Daugherty C., Ornitz D.M.,
RA   Leder P.;
RT   "Murine FGFR-1 is required for early postimplantation growth and axial
RT   organization.";
RL   Genes Dev. 8:3045-3057(1994).
RN   [14]
RP   SUBUNIT, AND LIGAND SPECIFICITY.
RX   PubMed=8663044; DOI=10.1074/jbc.271.25.15292;
RA   Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A.,
RA   Coulier F., Gao G., Goldfarb M.;
RT   "Receptor specificity of the fibroblast growth factor family.";
RL   J. Biol. Chem. 271:15292-15297(1996).
RN   [15]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=10896947; DOI=10.1074/jbc.M910132199;
RA   Chikazu D., Hakeda Y., Ogata N., Nemoto K., Itabashi A., Takato T.,
RA   Kumegawa M., Nakamura K., Kawaguchi H.;
RT   "Fibroblast growth factor (FGF)-2 directly stimulates mature
RT   osteoclast function through activation of FGF receptor 1 and p42/p44
RT   MAP kinase.";
RL   J. Biol. Chem. 275:31444-31450(2000).
RN   [16]
RP   INTERACTION WITH SHB.
RX   PubMed=12181353; DOI=10.1091/mbc.E02-02-0103;
RA   Cross M.J., Lu L., Magnusson P., Nyqvist D., Holmqvist K., Welsh M.,
RA   Claesson-Welsh L.;
RT   "The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and
RT   regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in
RT   endothelial cells.";
RL   Mol. Biol. Cell 13:2881-2893(2002).
RN   [17]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15383174; DOI=10.1089/dna.2004.23.538;
RA   Reilly J.F., Mizukoshi E., Maher P.A.;
RT   "Ligand dependent and independent internalization and nuclear
RT   translocation of fibroblast growth factor (FGF) receptor 1.";
RL   DNA Cell Biol. 23:538-548(2004).
RN   [18]
RP   INTERACTION WITH FLRT1; FLRT2 AND FLRT3.
RX   PubMed=16872596; DOI=10.1016/j.ydbio.2006.04.004;
RA   Haines B.P., Wheldon L.M., Summerbell D., Heath J.K., Rigby P.W.J.;
RT   "Regulated expression of FLRT genes implies a functional role in the
RT   regulation of FGF signalling during mouse development.";
RL   Dev. Biol. 297:14-25(2006).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH KL AND FGF23.
RX   PubMed=17086194; DOI=10.1038/nature05315;
RA   Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K.,
RA   Fujita T., Fukumoto S., Yamashita T.;
RT   "Klotho converts canonical FGF receptor into a specific receptor for
RT   FGF23.";
RL   Nature 444:770-774(2006).
RN   [20]
RP   INTERACTION WITH SOX2 AND SOX3.
RX   PubMed=17728342; DOI=10.1242/dev.007906;
RA   Rizzoti K., Lovell-Badge R.;
RT   "SOX3 activity during pharyngeal segmentation is required for
RT   craniofacial morphogenesis.";
RL   Development 134:3437-3448(2007).
RN   [21]
RP   INTERACTION WITH KLB.
RX   PubMed=17452648; DOI=10.1073/pnas.0701600104;
RA   Ogawa Y., Kurosu H., Yamamoto M., Nandi A., Rosenblatt K.P., Goetz R.,
RA   Eliseenkova A.V., Mohammadi M., Kuro-o M.;
RT   "BetaKlotho is required for metabolic activity of fibroblast growth
RT   factor 21.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:7432-7437(2007).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-317.
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [24]
RP   STRUCTURE BY NMR OF 25-119.
RX   PubMed=16731982; DOI=10.1110/ps.062207906;
RA   Kiselyov V.V., Bock E., Berezin V., Poulsen F.M.;
RT   "NMR structure of the first Ig module of mouse FGFR1.";
RL   Protein Sci. 15:1512-1515(2006).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for fibroblast growth factors and plays an essential role
CC       in the regulation of embryonic development, cell proliferation,
CC       differentiation and migration. Required for normal mesoderm
CC       patterning and correct axial organization during embryonic
CC       development, normal skeletogenesis and normal development of the
CC       gonadotropin-releasing hormone (GnRH) neuronal system.
CC       Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to
CC       the activation of several signaling cascades. Activation of PLCG1
CC       leads to the production of the cellular signaling molecules
CC       diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation
CC       of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and
CC       mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP
CC       kinase signaling pathway, as well as of the AKT1 signaling
CC       pathway. Promotes phosphorylation of SHC1, STAT1 and PTPN11/SHP2.
CC       In the nucleus, enhances RPS6KA1 and CREB1 activity and
CC       contributes to the regulation of transcription. FGFR1 signaling is
CC       down-regulated by IL17RD/SEF, and by FGFR1 ubiquitination,
CC       internalization and degradation (By similarity).
CC       {ECO:0000250|UniProtKB:P11362, ECO:0000269|PubMed:10821861,
CC       ECO:0000269|PubMed:10896947, ECO:0000269|PubMed:1309590,
CC       ECO:0000269|PubMed:17086194, ECO:0000269|PubMed:8001822,
CC       ECO:0000269|PubMed:8001823}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Ligand binding leads to dimerization and
CC       activation by sequential autophosphorylation on tyrosine residues
CC       (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts
CC       predominantly with FGF1 and FGF2, but can also interact with FGF3,
CC       FGF4, FGF5, FGF6, FGF8, FGF10, FGF19, FGF21, FGF22 and FGF23 (in
CC       vitro) (PubMed:10821861, PubMed:1309590, PubMed:17086194). Ligand
CC       specificity is determined by tissue-specific expression of
CC       isoforms, and differences in the third Ig-like domain are crucial
CC       for ligand specificity. Affinity for fibroblast growth factors
CC       (FGFs) is increased by heparan sulfate glycosaminoglycans that
CC       function as coreceptors. Likewise, KLB increases the affinity for
CC       FGF19, FGF21 and FGF23. Interacts (phosphorylated on Tyr-766) with
CC       PLCG1 (via SH2 domains). Interacts with FRS2. Interacts with
CC       RPS6KA1. Interacts (via C-terminus) with NEDD4 (via WW3 domain).
CC       Interacts with KL (PubMed:17086194). Interacts with SHB (via SH2
CC       domain) (PubMed:12181353). Interacts with GRB10 (By similarity).
CC       Interacts with ANOS1; this interaction does not interfere with
CC       FGF2-binding to FGFR1, but prevents binding of heparin-bound FGF2
CC       (By similarity). Interacts with SOX2 and SOX3 (PubMed:17728342).
CC       Interacts with FLRT1, FLRT2 and FLRT3 (PubMed:16872596).
CC       {ECO:0000250|UniProtKB:P11362, ECO:0000269|PubMed:10821861,
CC       ECO:0000269|PubMed:12181353, ECO:0000269|PubMed:1309590,
CC       ECO:0000269|PubMed:16872596, ECO:0000269|PubMed:17086194,
CC       ECO:0000269|PubMed:17452648, ECO:0000269|PubMed:17728342,
CC       ECO:0000269|PubMed:8663044}.
CC   -!- INTERACTION:
CC       P13596:Ncam1 (xeno); NbExp=2; IntAct=EBI-7953898, EBI-916499;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Nucleus. Cytoplasm, cytosol. Cytoplasmic vesicle.
CC       Note=After ligand binding, both receptor and ligand are rapidly
CC       internalized. Can translocate to the nucleus after
CC       internalization, or by translocation from the endoplasmic
CC       reticulum or Golgi apparatus to the cytosol, and from there to the
CC       nucleus.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 5: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1; Synonyms=FGFR1-IIIc, Long;
CC         IsoId=P16092-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P16092-2; Sequence=VSP_002962;
CC       Name=3; Synonyms=Variant;
CC         IsoId=P16092-3; Sequence=VSP_002961, VSP_002963;
CC       Name=4;
CC         IsoId=P16092-4; Sequence=VSP_002962, VSP_002963;
CC       Name=5; Synonyms=FGFR1-IIIb;
CC         IsoId=P16092-5; Sequence=VSP_002962, VSP_002963, VSP_041919,
CC                                  VSP_041920, VSP_041921, VSP_041922;
CC       Name=6;
CC         IsoId=P16092-6; Sequence=VSP_002963;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC       {ECO:0000269|PubMed:10821861}.
CC   -!- DOMAIN: The second and third Ig-like domains directly interact
CC       with fibroblast growth factors (FGF) and heparan sulfate
CC       proteoglycans. Isoforms lacking the first Ig-like domain have
CC       higher affinity for fibroblast growth factors (FGF) and heparan
CC       sulfate proteoglycans than isoforms with all three Ig-like domains
CC       (By similarity). {ECO:0000250}.
CC   -!- PTM: Autophosphorylated. Binding of FGF family members together
CC       with heparan sulfate proteoglycan or heparin promotes receptor
CC       dimerization and autophosphorylation on tyrosine residues.
CC       Autophosphorylation occurs in trans between the two FGFR molecules
CC       present in the dimer and proceeds in a highly ordered manner.
CC       Initial autophosphorylation at Tyr-653 increases the kinase
CC       activity by a factor of 50 to 100. After this, Tyr-583 becomes
CC       phosphorylated, followed by phosphorylation of Tyr-463, Tyr-766,
CC       Tyr-583 and Tyr-585. In a third stage, Tyr-654 is
CC       autophosphorylated, resulting in a further tenfold increase of
CC       kinase activity. Phosphotyrosine residues provide docking sites
CC       for interacting proteins and so are crucial for FGFR1 function and
CC       its regulation (By similarity). {ECO:0000250|UniProtKB:P11362}.
CC   -!- PTM: Ubiquitinated. FGFR1 is rapidly ubiquitinated by NEDD4 after
CC       autophosphorylation, leading to internalization and lysosomal
CC       degradation. CBL is recruited to activated FGFR1 via FRS2 and
CC       GRB2, and mediates ubiquitination and subsequent degradation of
CC       FGFR1 (By similarity). {ECO:0000250|UniProtKB:P11362}.
CC   -!- PTM: N-glycosylated in the endoplasmic reticulum. The N-glycan
CC       chains undergo further maturation to an Endo H-resistant form in
CC       the Golgi apparatus. {ECO:0000269|PubMed:10821861,
CC       ECO:0000269|PubMed:19349973}.
CC   -!- DISRUPTION PHENOTYPE: Embryonic lethality around gastrulation, due
CC       to growth defects during early embryonic development and aberrant
CC       mesoderm patterning. {ECO:0000269|PubMed:8001822,
CC       ECO:0000269|PubMed:8001823}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fibroblast growth factor receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB32845.1; Type=Miscellaneous discrepancy; Note=Proposes two coding sequences for the same mRNA.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M28998; AAA37290.1; -; mRNA.
DR   EMBL; X51893; CAA36175.1; -; mRNA.
DR   EMBL; M65053; AAA37620.1; -; mRNA.
DR   EMBL; M33760; AAA37622.1; -; mRNA.
DR   EMBL; U23445; AAC52183.1; -; mRNA.
DR   EMBL; AF176552; AAF05312.1; -; mRNA.
DR   EMBL; AK028354; BAC25899.1; -; mRNA.
DR   EMBL; S74765; AAB32845.1; ALT_SEQ; mRNA.
DR   EMBL; AC160526; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC033447; AAH33447.1; -; mRNA.
DR   CCDS; CCDS40304.1; -. [P16092-2]
DR   CCDS; CCDS52526.1; -. [P16092-1]
DR   CCDS; CCDS57614.1; -. [P16092-6]
DR   PIR; A34849; TVMSFG.
DR   PIR; B42057; B42057.
DR   PIR; I49293; I49293.
DR   PIR; JH0393; JH0393.
DR   RefSeq; NP_001073377.1; NM_001079908.2. [P16092-6]
DR   RefSeq; NP_001073378.1; NM_001079909.2. [P16092-2]
DR   RefSeq; NP_034336.2; NM_010206.3. [P16092-1]
DR   RefSeq; XP_006509073.1; XM_006509010.2. [P16092-1]
DR   RefSeq; XP_006509075.1; XM_006509012.1. [P16092-1]
DR   RefSeq; XP_011240423.1; XM_011242121.1. [P16092-4]
DR   UniGene; Mm.265716; -.
DR   PDB; 2CKN; NMR; -; A=25-119.
DR   PDBsum; 2CKN; -.
DR   ProteinModelPortal; P16092; -.
DR   SMR; P16092; 25-119, 147-397, 420-801.
DR   BioGrid; 199656; 4.
DR   DIP; DIP-6033N; -.
DR   IntAct; P16092; 6.
DR   MINT; MINT-2635590; -.
DR   STRING; 10090.ENSMUSP00000081041; -.
DR   BindingDB; P16092; -.
DR   ChEMBL; CHEMBL3960; -.
DR   iPTMnet; P16092; -.
DR   PhosphoSite; P16092; -.
DR   MaxQB; P16092; -.
DR   PaxDb; P16092; -.
DR   PRIDE; P16092; -.
DR   Ensembl; ENSMUST00000084027; ENSMUSP00000081041; ENSMUSG00000031565. [P16092-1]
DR   Ensembl; ENSMUST00000117179; ENSMUSP00000113909; ENSMUSG00000031565. [P16092-6]
DR   Ensembl; ENSMUST00000119398; ENSMUSP00000113855; ENSMUSG00000031565. [P16092-2]
DR   Ensembl; ENSMUST00000167764; ENSMUSP00000131343; ENSMUSG00000031565. [P16092-5]
DR   Ensembl; ENSMUST00000178276; ENSMUSP00000137515; ENSMUSG00000031565. [P16092-5]
DR   GeneID; 14182; -.
DR   KEGG; mmu:14182; -.
DR   UCSC; uc009lfy.2; mouse. [P16092-1]
DR   UCSC; uc009lga.2; mouse. [P16092-2]
DR   UCSC; uc033jet.1; mouse. [P16092-4]
DR   CTD; 2260; -.
DR   MGI; MGI:95522; Fgfr1.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000263410; -.
DR   HOVERGEN; HBG000345; -.
DR   InParanoid; P16092; -.
DR   KO; K04362; -.
DR   OrthoDB; EOG7NGQ9N; -.
DR   PhylomeDB; P16092; -.
DR   TreeFam; TF316307; -.
DR   BRENDA; 2.7.10.1; 3474.
DR   Reactome; R-MMU-109704; PI3K Cascade.
DR   Reactome; R-MMU-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-MMU-190370; FGFR1b ligand binding and activation.
DR   Reactome; R-MMU-190373; FGFR1c ligand binding and activation.
DR   Reactome; R-MMU-190374; FGFR1c and Klotho ligand binding and activation.
DR   Reactome; R-MMU-445144; Signal transduction by L1.
DR   Reactome; R-MMU-5654219; Phospholipase C-mediated cascade: FGFR1.
DR   Reactome; R-MMU-5654688; SHC-mediated cascade:FGFR1.
DR   Reactome; R-MMU-5654689; PI-3K cascade:FGFR1.
DR   Reactome; R-MMU-5654693; FRS-mediated FGFR1 signaling.
DR   Reactome; R-MMU-5654726; Negative regulation of FGFR1 signaling.
DR   Reactome; R-MMU-5673001; RAF/MAP kinase cascade.
DR   ChiTaRS; Fgfr1; mouse.
DR   EvolutionaryTrace; P16092; -.
DR   NextBio; 285378; -.
DR   PRO; PR:P16092; -.
DR   Proteomes; UP000000589; Chromosome 8.
DR   Bgee; P16092; -.
DR   CleanEx; MM_FGFR1; -.
DR   CleanEx; MM_FLG; -.
DR   ExpressionAtlas; P16092; baseline and differential.
DR   Genevisible; P16092; MM.
DR   GO; GO:0016023; C:cytoplasmic membrane-bounded vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; ISO:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IPI:UniProtKB.
DR   GO; GO:0005007; F:fibroblast growth factor-activated receptor activity; IDA:MGI.
DR   GO; GO:0008201; F:heparin binding; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:MGI.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; ISO:MGI.
DR   GO; GO:0001525; P:angiogenesis; IGI:MGI.
DR   GO; GO:0060117; P:auditory receptor cell development; IMP:MGI.
DR   GO; GO:0048514; P:blood vessel morphogenesis; IMP:MGI.
DR   GO; GO:0007420; P:brain development; IMP:MGI.
DR   GO; GO:0060445; P:branching involved in salivary gland morphogenesis; IMP:MGI.
DR   GO; GO:0048469; P:cell maturation; IMP:MGI.
DR   GO; GO:0002062; P:chondrocyte differentiation; IGI:MGI.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; IMP:MGI.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IGI:MGI.
DR   GO; GO:0035607; P:fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development; IMP:UniProtKB.
DR   GO; GO:0048699; P:generation of neurons; IMP:MGI.
DR   GO; GO:0001701; P:in utero embryonic development; IGI:MGI.
DR   GO; GO:0042472; P:inner ear morphogenesis; IMP:MGI.
DR   GO; GO:0030324; P:lung development; IMP:MGI.
DR   GO; GO:0060484; P:lung-associated mesenchyme development; IGI:MGI.
DR   GO; GO:0048762; P:mesenchymal cell differentiation; IGI:MGI.
DR   GO; GO:0030901; P:midbrain development; IMP:MGI.
DR   GO; GO:0042474; P:middle ear morphogenesis; IMP:MGI.
DR   GO; GO:0021837; P:motogenic signaling involved in postnatal olfactory bulb interneuron migration; IEA:Ensembl.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:MGI.
DR   GO; GO:0045668; P:negative regulation of osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:UniProtKB.
DR   GO; GO:0031175; P:neuron projection development; IEA:Ensembl.
DR   GO; GO:0021769; P:orbitofrontal cortex development; IMP:UniProtKB.
DR   GO; GO:0001759; P:organ induction; IMP:MGI.
DR   GO; GO:0042473; P:outer ear morphogenesis; IMP:MGI.
DR   GO; GO:0048339; P:paraxial mesoderm development; IGI:MGI.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; IGI:MGI.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISO:MGI.
DR   GO; GO:0090080; P:positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway; IGI:MGI.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IMP:MGI.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IGI:MGI.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0060665; P:regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling; IDA:MGI.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:MGI.
DR   GO; GO:2001239; P:regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:MGI.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:MGI.
DR   GO; GO:0048378; P:regulation of lateral mesodermal cell fate specification; IGI:MGI.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0007435; P:salivary gland morphogenesis; IMP:MGI.
DR   GO; GO:0007605; P:sensory perception of sound; IMP:MGI.
DR   GO; GO:0019827; P:stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0001657; P:ureteric bud development; IGI:MGI.
DR   GO; GO:0060979; P:vasculogenesis involved in coronary vascular morphogenesis; TAS:DFLAT.
DR   GO; GO:0021847; P:ventricular zone neuroblast division; IMP:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR028174; FGF_rcpt_1.
DR   InterPro; IPR016248; FGF_rcpt_fam.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   PANTHER; PTHR24416:SF131; PTHR24416:SF131; 1.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000628; FGFR; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Cytoplasm; Cytoplasmic vesicle; Disulfide bond;
KW   Glycoprotein; Heparin-binding; Immunoglobulin domain; Kinase;
KW   Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     21       {ECO:0000255}.
FT   CHAIN        22    822       Fibroblast growth factor receptor 1.
FT                                /FTId=PRO_0000016781.
FT   TOPO_DOM     22    376       Extracellular. {ECO:0000255}.
FT   TRANSMEM    377    397       Helical. {ECO:0000255}.
FT   TOPO_DOM    398    822       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       25    119       Ig-like C2-type 1.
FT   DOMAIN      158    246       Ig-like C2-type 2.
FT   DOMAIN      255    357       Ig-like C2-type 3.
FT   DOMAIN      478    767       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     484    490       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     562    564       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      160    177       Heparin-binding.
FT   ACT_SITE    623    623       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     514    514       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     568    568       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     627    627       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     641    641       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        766    766       Mediates interaction with PLCG1 and SHB.
FT                                {ECO:0000250}.
FT   MOD_RES     463    463       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     583    583       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     585    585       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     653    653       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     654    654       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     730    730       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     766    766       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     77     77       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    117    117       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    227    227       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    240    240       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    264    264       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    296    296       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    317    317       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    330    330       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     55    101       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    178    230       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    277    341       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ      30     30       Q -> QGSSSWPLWVAAA (in isoform 3).
FT                                {ECO:0000303|PubMed:1708247}.
FT                                /FTId=VSP_002961.
FT   VAR_SEQ      31    119       Missing (in isoform 2, isoform 4 and
FT                                isoform 5). {ECO:0000303|PubMed:10821861,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:16141072,
FT                                ECO:0000303|PubMed:2161540,
FT                                ECO:0000303|PubMed:7897669}.
FT                                /FTId=VSP_002962.
FT   VAR_SEQ     148    149       Missing (in isoform 3, isoform 4, isoform
FT                                5 and isoform 6).
FT                                {ECO:0000303|PubMed:10821861,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:1708247,
FT                                ECO:0000303|PubMed:2161096}.
FT                                /FTId=VSP_002963.
FT   VAR_SEQ     313    323       TAGVNTTDKEM -> HSGINSSDA (in isoform 5).
FT                                {ECO:0000303|PubMed:10821861}.
FT                                /FTId=VSP_041919.
FT   VAR_SEQ     327    336       HLRNVSFEDA -> TLFNVTEAQS (in isoform 5).
FT                                {ECO:0000303|PubMed:10821861}.
FT                                /FTId=VSP_041920.
FT   VAR_SEQ     340    352       TCLAGNSIGLSHH -> VCKVSNYIGEANQ (in
FT                                isoform 5).
FT                                {ECO:0000303|PubMed:10821861}.
FT                                /FTId=VSP_041921.
FT   VAR_SEQ     359    360       LE -> TRPVAK (in isoform 5).
FT                                {ECO:0000303|PubMed:10821861}.
FT                                /FTId=VSP_041922.
FT   CONFLICT    229    229       T -> S (in Ref. 4; AAA37622).
FT                                {ECO:0000305}.
FT   CONFLICT    256    258       ILQ -> HPS (in Ref. 1; AAA37290 and 3;
FT                                AAA37620). {ECO:0000305}.
FT   CONFLICT    265    265       K -> E (in Ref. 5; AAC52183).
FT                                {ECO:0000305}.
FT   CONFLICT    270    270       G -> A (in Ref. 4; AAA37622).
FT                                {ECO:0000305}.
FT   CONFLICT    387    387       I -> M (in Ref. 3; AAA37620).
FT                                {ECO:0000305}.
FT   CONFLICT    440    440       G -> A (in Ref. 2; CAA36175).
FT                                {ECO:0000305}.
FT   CONFLICT    457    457       L -> P (in Ref. 5; AAC52183).
FT                                {ECO:0000305}.
FT   CONFLICT    508    508       V -> L (in Ref. 3; AAA37620).
FT                                {ECO:0000305}.
FT   CONFLICT    544    544       I -> M (in Ref. 4; AAA37622).
FT                                {ECO:0000305}.
FT   CONFLICT    549    549       G -> E (in Ref. 6; AAF05312).
FT                                {ECO:0000305}.
FT   CONFLICT    753    753       D -> V (in Ref. 6; AAF05312).
FT                                {ECO:0000305}.
FT   CONFLICT    756    756       R -> H (in Ref. 1; AAA37290).
FT                                {ECO:0000305}.
FT   CONFLICT    763    763       N -> S (in Ref. 5; AAC52183).
FT                                {ECO:0000305}.
FT   CONFLICT    765    765       E -> D (in Ref. 4; AAA37622).
FT                                {ECO:0000305}.
FT   STRAND       43     45       {ECO:0000244|PDB:2CKN}.
FT   STRAND       51     54       {ECO:0000244|PDB:2CKN}.
FT   STRAND       57     60       {ECO:0000244|PDB:2CKN}.
FT   STRAND       63     68       {ECO:0000244|PDB:2CKN}.
FT   STRAND       77     81       {ECO:0000244|PDB:2CKN}.
FT   STRAND       83     90       {ECO:0000244|PDB:2CKN}.
FT   HELIX        93     95       {ECO:0000244|PDB:2CKN}.
FT   STRAND       96    105       {ECO:0000244|PDB:2CKN}.
FT   STRAND      108    118       {ECO:0000244|PDB:2CKN}.
SQ   SEQUENCE   822 AA;  91981 MW;  D5A4695FA680926B CRC64;
     MWGWKCLLFW AVLVTATLCT ARPAPTLPEQ AQPWGVPVEV ESLLVHPGDL LQLRCRLRDD
     VQSINWLRDG VQLVESNRTR ITGEEVEVRD SIPADSGLYA CVTSSPSGSD TTYFSVNVSD
     ALPSSEDDDD DDDSSSEEKE TDNTKPNRRP VAPYWTSPEK MEKKLHAVPA AKTVKFKCPS
     SGTPNPTLRW LKNGKEFKPD HRIGGYKVRY ATWSIIMDSV VPSDKGNYTC IVENEYGSIN
     HTYQLDVVER SPHRPILQAG LPANKTVALG SNVEFMCKVY SDPQPHIQWL KHIEVNGSKI
     GPDNLPYVQI LKTAGVNTTD KEMEVLHLRN VSFEDAGEYT CLAGNSIGLS HHSAWLTVLE
     ALEERPAVMT SPLYLEIIIY CTGAFLISCM LGSVIIYKMK SGTKKSDFHS QMAVHKLAKS
     IPLRRQVTVS ADSSASMNSG VLLVRPSRLS SSGTPMLAGV SEYELPEDPR WELPRDRLVL
     GKPLGEGCFG QVVLAEAIGL DKDKPNRVTK VAVKMLKSDA TEKDLSDLIS EMEMMKMIGK
     HKNIINLLGA CTQDGPLYVI VEYASKGNLR EYLQARRPPG LEYCYNPSHN PEEQLSSKDL
     VSCAYQVARG MEYLASKKCI HRDLAARNVL VTEDNVMKIA DFGLARDIHH IDYYKKTTNG
     RLPVKWMAPE ALFDRIYTHQ SDVWSFGVLL WEIFTLGGSP YPGVPVEELF KLLKEGHRMD
     KPSNCTNELY MMMRDCWHAV PSQRPTFKQL VEDLDRIVAL TSNQEYLDLS IPLDQYSPSF
     PDTRSSTCSS GEDSVFSHEP LPEEPCLPRH PTQLANSGLK RR
//
ID   TLR2_HUMAN              Reviewed;         784 AA.
AC   O60603; B3Y612; D1CS45; D1CS48; D1CS49; O15454; Q8NI00;
DT   31-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1998, sequence version 1.
DT   17-FEB-2016, entry version 176.
DE   RecName: Full=Toll-like receptor 2;
DE   AltName: Full=Toll/interleukin-1 receptor-like protein 4;
DE   AltName: CD_antigen=CD282;
DE   Flags: Precursor;
GN   Name=TLR2; Synonyms=TIL4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Leukocyte, and Prostate;
RX   PubMed=9596645;
RA   Chaudhary P.M., Ferguson C., Nguyen V., Nguyen O., Massa H.F., Eby M.,
RA   Jasmin A., Trask B.J., Hood L., Nelson P.S.;
RT   "Cloning and characterization of two Toll/Interleukin-1 receptor-like
RT   genes TIL3 and TIL4: evidence for a multi-gene receptor family in
RT   humans.";
RL   Blood 91:4020-4027(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9435236; DOI=10.1073/pnas.95.2.588;
RA   Rock F.L., Hardiman G., Timans J.C., Kastelein R.A., Bazan J.F.;
RT   "A family of human receptors structurally related to Drosophila
RT   Toll.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:588-593(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND RESPONSE TO LIPOPOLYSACCHARIDE.
RC   TISSUE=Fetal lung;
RX   PubMed=9751057; DOI=10.1038/26239;
RA   Yang R.-B., Mark M.R., Gray A.M., Huang A., Xie M.-H., Zhang M.,
RA   Goddard A.D., Wood W.I., Gurney A.L., Godowski P.J.;
RT   "Toll-like receptor-2 mediates lipopolysaccharide-induced cellular
RT   signalling.";
RL   Nature 395:284-288(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=18810425; DOI=10.1007/s00251-008-0332-0;
RA   Nakajima T., Ohtani H., Satta Y., Uno Y., Akari H., Ishida T.,
RA   Kimura A.;
RT   "Natural selection in the TLR-related genes in the course of primate
RT   evolution.";
RL   Immunogenetics 60:727-735(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS HIS-631 AND GLN-753.
RX   PubMed=19924287; DOI=10.1371/journal.pone.0007803;
RA   Georgel P., Macquin C., Bahram S.;
RT   "The heterogeneous allelic repertoire of human Toll-Like receptor
RT   (TLR) genes.";
RL   PLoS ONE 4:E7803-E7803(2009).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-586.
RA   Zhang L., Yu W.B., Ma Y.Y.;
RT   "Cloning and sequencing of extracellular domain and its N-terminal and
RT   C-terminal fragments of Toll-like receptor 2.";
RL   Di 4 Jun Yi Da Xue Xue Bao 23:1085-1089(2002).
RN   [9]
RP   FUNCTION.
RX   PubMed=10426996; DOI=10.1126/science.285.5428.736;
RA   Aliprantis A.O., Yang R.-B., Mark M.R., Suggett S., Devaux B.,
RA   Radolf J.D., Klimpel G.R., Godowski P.J., Zychlinsky A.;
RT   "Cell activation and apoptosis by bacterial lipoproteins through Toll-
RT   like receptor-2.";
RL   Science 285:736-739(1999).
RN   [10]
RP   FUNCTION.
RX   PubMed=11441107; DOI=10.4049/jimmunol.167.2.987;
RA   Bulut Y., Faure E., Thomas L., Equils O., Arditi M.;
RT   "Cooperation of Toll-like receptor 2 and 6 for cellular activation by
RT   soluble tuberculosis factor and Borrelia burgdorferi outer surface
RT   protein A lipoprotein: role of Toll-interacting protein and IL-1
RT   receptor signaling molecules in Toll-like receptor 2 signaling.";
RL   J. Immunol. 167:987-994(2001).
RN   [11]
RP   INTERACTION WITH TICAM1.
RX   PubMed=12471095; DOI=10.4049/jimmunol.169.12.6668;
RA   Yamamoto M., Sato S., Mori K., Hoshino K., Takeuchi O., Takeda K.,
RA   Akira S.;
RT   "A novel Toll/IL-1 receptor domain-containing adapter that
RT   preferentially activates the IFN-beta promoter in the Toll-like
RT   receptor signaling.";
RL   J. Immunol. 169:6668-6672(2002).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CD14; CD36; TLR1
RP   AND TLR6.
RX   PubMed=16880211; DOI=10.1074/jbc.M602794200;
RA   Triantafilou M., Gamper F.G., Haston R.M., Mouratis M.A., Morath S.,
RA   Hartung T., Triantafilou K.;
RT   "Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1
RT   heterodimers at the cell surface determines heterotypic associations
RT   with CD36 and intracellular targeting.";
RL   J. Biol. Chem. 281:31002-31011(2006).
RN   [13]
RP   GLYCOSYLATION AT ASN-114; ASN-199 AND ASN-442, AND MUTAGENESIS OF
RP   ASN-114; ASN-199; THR-416 AND ASN-442.
RX   PubMed=15173186; DOI=10.1074/jbc.M403830200;
RA   Weber A.N., Morse M.A., Gay N.J.;
RT   "Four N-linked glycosylation sites in human toll-like receptor 2
RT   cooperate to direct efficient biosynthesis and secretion.";
RL   J. Biol. Chem. 279:34589-34594(2004).
RN   [14]
RP   FUNCTION.
RX   PubMed=19362712; DOI=10.1016/j.cellimm.2009.03.008;
RA   Drage M.G., Pecora N.D., Hise A.G., Febbraio M., Silverstein R.L.,
RA   Golenbock D.T., Boom W.H., Harding C.V.;
RT   "TLR2 and its co-receptors determine responses of macrophages and
RT   dendritic cells to lipoproteins of Mycobacterium tuberculosis.";
RL   Cell. Immunol. 258:29-37(2009).
RN   [15]
RP   INTERACTION WITH ATG16L1.
RX   PubMed=23376921; DOI=10.1038/emboj.2013.8;
RA   Boada-Romero E., Letek M., Fleischer A., Pallauf K., Ramon-Barros C.,
RA   Pimentel-Muinos F.X.;
RT   "TMEM59 defines a novel ATG16L1-binding motif that promotes local
RT   activation of LC3.";
RL   EMBO J. 32:566-582(2013).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 639-784, AND MUTAGENESIS.
RX   PubMed=11081518; DOI=10.1038/35040600;
RA   Xu Y., Tao X., Shen B., Horng T., Medzhitov R., Manley J.L., Tong L.;
RT   "Structural basis for signal transduction by the Toll/interleukin-1
RT   receptor domains.";
RL   Nature 408:111-115(2000).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-509 IN COMPLEX WITH TLR1
RP   AND BACTERIAL LIPOPEPTIDE ANALOG, DISULFIDE BONDS, GLYCOSYLATION AT
RP   ASN-114; ASN-199; ASN-414 AND ASN-442, AND FUNCTION.
RX   PubMed=17889651; DOI=10.1016/j.cell.2007.09.008;
RA   Jin M.S., Kim S.E., Heo J.Y., Lee M.E., Kim H.M., Paik S.-G., Lee H.,
RA   Lee J.-O.;
RT   "Crystal structure of the TLR1-TLR2 heterodimer induced by binding of
RT   a tri-acylated lipopeptide.";
RL   Cell 130:1071-1082(2007).
RN   [18]
RP   VARIANT TRP-677, AND ASSOCIATION WITH LEPROSIS.
RX   PubMed=11476982; DOI=10.1111/j.1574-695X.2001.tb01586.x;
RA   Kang T.-J., Chae G.-T.;
RT   "Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous
RT   leprosy patients.";
RL   FEMS Immunol. Med. Microbiol. 31:53-58(2001).
RN   [19]
RP   VARIANT TRP-677, AND ASSOCIATION WITH LEPROSIS.
RX   PubMed=12646604; DOI=10.4049/jimmunol.170.7.3451;
RA   Bochud P.-Y., Hawn T.R., Aderem A.;
RT   "A Toll-like receptor 2 polymorphism that is associated with
RT   lepromatous leprosy is unable to mediate mycobacterial signaling.";
RL   J. Immunol. 170:3451-3454(2003).
RN   [20]
RP   VARIANTS ASP-89; ILE-411; HIS-571; HIS-631; ARG-636 AND GLN-753, AND
RP   CHARACTERIZATION OF VARIANTS ILE-411; HIS-631 AND GLN-753.
RX   PubMed=21618349; DOI=10.1002/humu.21486;
RA   Ben-Ali M., Corre B., Manry J., Barreiro L.B., Quach H., Boniotto M.,
RA   Pellegrini S., Quintana-Murci L.;
RT   "Functional characterization of naturally occurring genetic variants
RT   in the human TLR1-2-6 gene family.";
RL   Hum. Mutat. 32:643-652(2011).
CC   -!- FUNCTION: Cooperates with LY96 to mediate the innate immune
CC       response to bacterial lipoproteins and other microbial cell wall
CC       components. Cooperates with TLR1 or TLR6 to mediate the innate
CC       immune response to bacterial lipoproteins or lipopeptides
CC       (PubMed:17889651). Acts via MYD88 and TRAF6, leading to NF-kappa-B
CC       activation, cytokine secretion and the inflammatory response. May
CC       also promote apoptosis in response to lipoproteins
CC       (PubMed:10426996). Recognizes mycoplasmal macrophage-activating
CC       lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF),
CC       phenol-soluble modulin (PSM) and B.burgdorferi outer surface
CC       protein A lipoprotein (OspA-L) cooperatively with TLR6
CC       (PubMed:11441107). Acts as a receptor for M.tuberculosis
CC       lipoproteins LprA, LprG, LpqH and PhoS1 (pstS1), some lipoproteins
CC       are dependent on other coreceptors (TLR1, CD14 and/or CD36).The
CC       lipoproteins act as agonists to modulate antigen presenting cell
CC       functions in response to the pathogen (PubMed:19362712). Forms
CC       activation clusters composed of several receptors depending on the
CC       ligand, these clusters trigger signaling from the cell surface and
CC       subsequently are targeted to the Golgi in a lipid-raft dependent
CC       pathway. Forms the cluster TLR2:TLR6:CD14:CD36 in response to
CC       diacylated lipopeptides and TLR2:TLR1:CD14 in response to
CC       triacylated lipopeptides (PubMed:16880211).
CC       {ECO:0000250|UniProtKB:Q9QUN7, ECO:0000269|PubMed:10426996,
CC       ECO:0000269|PubMed:11441107, ECO:0000269|PubMed:16880211,
CC       ECO:0000269|PubMed:17889651, ECO:0000269|PubMed:19362712}.
CC   -!- SUBUNIT: Interacts with LY96, TLR1 and TLR6 (via extracellular
CC       domain) (PubMed:17889651). TLR2 seems to exist in heterodimers
CC       with either TLR1 or TLR6 before stimulation by the ligand. The
CC       heterodimers form bigger oligomers in response to their
CC       corresponding ligands as well as further heterotypic associations
CC       with other receptors such as CD14 and/or CD36 (PubMed:16880211).
CC       Binds MYD88 (via TIR domain). Interacts with TICAM1
CC       (PubMed:12471095). Interacts with CNPY3 (By similarity). Interacts
CC       with ATG16L1 (PubMed:23376921). {ECO:0000250|UniProtKB:Q9QUN7,
CC       ECO:0000269|PubMed:12471095, ECO:0000269|PubMed:16880211,
CC       ECO:0000269|PubMed:17889651, ECO:0000269|PubMed:23376921}.
CC   -!- INTERACTION:
CC       P00533:EGFR; NbExp=2; IntAct=EBI-973722, EBI-297353;
CC       C3PTT6:PAUF; NbExp=3; IntAct=EBI-973722, EBI-3505892;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000250|UniProtKB:Q9QUN7};
CC       Single-pass type I membrane protein {ECO:0000255}. Cytoplasmic
CC       vesicle, phagosome membrane {ECO:0000250|UniProtKB:Q9QUN7};
CC       Single-pass type I membrane protein {ECO:0000255}. Membrane raft
CC       {ECO:0000269|PubMed:16880211}. Note=Does not reside in lipid rafts
CC       before stimulation but accumulates increasingly in the raft upon
CC       the presence of the microbial ligand. In response to diacylated
CC       lipoproteins, TLR2:TLR6 heterodimers are recruited in lipid rafts,
CC       this recruitment determine the intracellular targeting to the
CC       Golgi apparatus. Triacylated lipoproteins induce the same
CC       mechanism for TLR2:TLR1 heterodimers.
CC       {ECO:0000269|PubMed:16880211}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in peripheral blood
CC       leukocytes, in particular in monocytes, in bone marrow, lymph node
CC       and in spleen. Also detected in lung and in fetal liver. Levels
CC       are low in other tissues.
CC   -!- DOMAIN: Ester-bound lipid substrates are bound through a crevice
CC       formed between the LRR 11 and LRR 12. {ECO:0000250}.
CC   -!- DOMAIN: The ATG16L1-binding motif mediates interaction with
CC       ATG16L1. {ECO:0000269|PubMed:23376921}.
CC   -!- PTM: Glycosylation of Asn-442 is critical for secretion of the N-
CC       terminal ectodomain of TLR2. {ECO:0000269|PubMed:15173186,
CC       ECO:0000269|PubMed:17889651}.
CC   -!- POLYMORPHISM: Genetic variations in TLR2 are associated with
CC       susceptibility to leprosy [MIM:246300]. Leprosy is a chronic
CC       disease associated with depressed cellular (but not humoral)
CC       immunity, the bacterium requires a lower temperature than 37
CC       degrees Celsius and thrives particularly in peripheral Schwann
CC       cells and macrophages. The Trp-677 polymorphism in the
CC       intracellular domain of TLR2 has a role in susceptibility to
CC       lepromatous leprosy. Wild-type TLR2 mediates CD14-enhanced
CC       Mycobacterium leprae-dependent activation of NFKB1, but TLR2
CC       containing the Trp-677 polymorphism did not. The impaired function
CC       of the Trp-677 polymorphism provides a molecular mechanism for the
CC       poor cellular immune response associated with lepromatous leprosy.
CC       {ECO:0000269|PubMed:11476982, ECO:0000269|PubMed:12646604}.
CC   -!- SIMILARITY: Belongs to the Toll-like receptor family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 19 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 LRRCT domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 TIR domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00204}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF051152; AAC34377.1; -; mRNA.
DR   EMBL; U88878; AAC34133.1; -; mRNA.
DR   EMBL; AB445624; BAG55021.1; -; mRNA.
DR   EMBL; DQ012265; AAY85644.1; -; mRNA.
DR   EMBL; DQ012266; AAY85645.1; -; mRNA.
DR   EMBL; DQ012267; AAY85646.1; -; mRNA.
DR   EMBL; DQ012268; AAY85647.1; -; mRNA.
DR   EMBL; DQ012269; AAY85648.1; -; mRNA.
DR   EMBL; DQ012270; AAY85649.1; -; mRNA.
DR   EMBL; DQ012271; AAY85650.1; -; mRNA.
DR   EMBL; CH471056; EAX04952.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04953.1; -; Genomic_DNA.
DR   EMBL; BC033756; AAH33756.1; -; mRNA.
DR   EMBL; AF502291; AAM23001.1; -; mRNA.
DR   CCDS; CCDS3784.1; -.
DR   RefSeq; NP_003255.2; NM_003264.3.
DR   RefSeq; XP_005263250.1; XM_005263193.2.
DR   RefSeq; XP_005263251.1; XM_005263194.2.
DR   RefSeq; XP_005263252.1; XM_005263195.2.
DR   RefSeq; XP_005263253.1; XM_005263196.2.
DR   RefSeq; XP_005263254.1; XM_005263197.2.
DR   RefSeq; XP_011530517.1; XM_011532215.1.
DR   RefSeq; XP_011530518.1; XM_011532216.1.
DR   UniGene; Hs.519033; -.
DR   PDB; 1FYW; X-ray; 3.00 A; A=636-784.
DR   PDB; 1FYX; X-ray; 2.80 A; A=636-784.
DR   PDB; 1O77; X-ray; 3.20 A; A/B/C/D/E=639-784.
DR   PDB; 2Z7X; X-ray; 2.10 A; A=27-506.
DR   PDB; 2Z80; X-ray; 1.80 A; A/B=1-284.
DR   PDBsum; 1FYW; -.
DR   PDBsum; 1FYX; -.
DR   PDBsum; 1O77; -.
DR   PDBsum; 2Z7X; -.
DR   PDBsum; 2Z80; -.
DR   ProteinModelPortal; O60603; -.
DR   SMR; O60603; 27-553, 636-784.
DR   BioGrid; 112952; 23.
DR   DIP; DIP-35138N; -.
DR   IntAct; O60603; 20.
DR   MINT; MINT-3000106; -.
DR   STRING; 9606.ENSP00000260010; -.
DR   BindingDB; O60603; -.
DR   ChEMBL; CHEMBL3301399; -.
DR   DrugBank; DB00045; OspA lipoprotein.
DR   PhosphoSite; O60603; -.
DR   SwissPalm; O60603; -.
DR   BioMuta; TLR2; -.
DR   PaxDb; O60603; -.
DR   PRIDE; O60603; -.
DR   DNASU; 7097; -.
DR   Ensembl; ENST00000260010; ENSP00000260010; ENSG00000137462.
DR   GeneID; 7097; -.
DR   KEGG; hsa:7097; -.
DR   UCSC; uc003inq.3; human.
DR   CTD; 7097; -.
DR   GeneCards; TLR2; -.
DR   HGNC; HGNC:11848; TLR2.
DR   MalaCards; TLR2; -.
DR   MIM; 246300; phenotype.
DR   MIM; 603028; gene.
DR   neXtProt; NX_O60603; -.
DR   PharmGKB; PA36550; -.
DR   eggNOG; KOG4641; Eukaryota.
DR   eggNOG; COG4886; LUCA.
DR   GeneTree; ENSGT00760000119006; -.
DR   HOGENOM; HOG000110611; -.
DR   HOVERGEN; HBG108574; -.
DR   InParanoid; O60603; -.
DR   KO; K10159; -.
DR   OMA; HLILHMK; -.
DR   OrthoDB; EOG7SBNN7; -.
DR   PhylomeDB; O60603; -.
DR   TreeFam; TF351113; -.
DR   Reactome; R-HSA-1461957; Beta defensins.
DR   Reactome; R-HSA-166058; MyD88:Mal cascade initiated on plasma membrane.
DR   Reactome; R-HSA-168179; Toll Like Receptor TLR1:TLR2 Cascade.
DR   Reactome; R-HSA-168188; Toll Like Receptor TLR6:TLR2 Cascade.
DR   Reactome; R-HSA-5602498; MyD88 deficiency (TLR2/4).
DR   Reactome; R-HSA-5603041; IRAK4 deficiency (TLR2/4).
DR   SignaLink; O60603; -.
DR   EvolutionaryTrace; O60603; -.
DR   GeneWiki; TLR_2; -.
DR   GenomeRNAi; 7097; -.
DR   NextBio; 27765; -.
DR   PRO; PR:O60603; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; O60603; -.
DR   CleanEx; HS_TLR2; -.
DR   Genevisible; O60603; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0031226; C:intrinsic component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0035354; C:Toll-like receptor 1-Toll-like receptor 2 protein complex; IDA:MGI.
DR   GO; GO:0035355; C:Toll-like receptor 2-Toll-like receptor 6 protein complex; IEA:Ensembl.
DR   GO; GO:0042498; F:diacyl lipopeptide binding; IEA:Ensembl.
DR   GO; GO:0001530; F:lipopolysaccharide binding; IDA:UniProtKB.
DR   GO; GO:0001875; F:lipopolysaccharide receptor activity; TAS:UniProtKB.
DR   GO; GO:0070891; F:lipoteichoic acid binding; IEA:Ensembl.
DR   GO; GO:0042834; F:peptidoglycan binding; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:MGI.
DR   GO; GO:0004872; F:receptor activity; IDA:UniProtKB.
DR   GO; GO:0008329; F:signaling pattern recognition receptor activity; IDA:UniProtKB.
DR   GO; GO:0035325; F:Toll-like receptor binding; IPI:UniProtKB.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IEA:InterPro.
DR   GO; GO:0042497; F:triacyl lipopeptide binding; IDA:MGI.
DR   GO; GO:0006915; P:apoptotic process; TAS:ProtInc.
DR   GO; GO:0002752; P:cell surface pattern recognition receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0071221; P:cellular response to bacterial lipopeptide; TAS:BHF-UCL.
DR   GO; GO:0071726; P:cellular response to diacyl bacterial lipopeptide; IDA:UniProtKB.
DR   GO; GO:0071223; P:cellular response to lipoteichoic acid; IDA:MGI.
DR   GO; GO:0071224; P:cellular response to peptidoglycan; IEA:Ensembl.
DR   GO; GO:0071727; P:cellular response to triacyl bacterial lipopeptide; IDA:UniProtKB.
DR   GO; GO:0042892; P:chloramphenicol transport; IEA:Ensembl.
DR   GO; GO:0002374; P:cytokine secretion involved in immune response; IMP:CACAO.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IDA:UniProtKB.
DR   GO; GO:0042496; P:detection of diacyl bacterial lipopeptide; IDA:MGI.
DR   GO; GO:0042495; P:detection of triacyl bacterial lipopeptide; IDA:MGI.
DR   GO; GO:0007252; P:I-kappaB phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0052063; P:induction by symbiont of defense-related host nitric oxide production; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; TAS:BHF-UCL.
DR   GO; GO:0032613; P:interleukin-10 production; IDA:CACAO.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; TAS:GOC.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0044130; P:negative regulation of growth of symbiont in host; IEA:Ensembl.
DR   GO; GO:0032695; P:negative regulation of interleukin-12 production; IEA:Ensembl.
DR   GO; GO:0032700; P:negative regulation of interleukin-17 production; IEA:Ensembl.
DR   GO; GO:0032722; P:positive regulation of chemokine production; IDA:BHF-UCL.
DR   GO; GO:0050715; P:positive regulation of cytokine secretion; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; ISS:BHF-UCL.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; ISS:BHF-UCL.
DR   GO; GO:0032741; P:positive regulation of interleukin-18 production; ISS:BHF-UCL.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:BHF-UCL.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; IDA:BHF-UCL.
DR   GO; GO:0002687; P:positive regulation of leukocyte migration; IEA:Ensembl.
DR   GO; GO:0060907; P:positive regulation of macrophage cytokine production; IEA:Ensembl.
DR   GO; GO:0042346; P:positive regulation of NF-kappaB import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; ISS:BHF-UCL.
DR   GO; GO:0034123; P:positive regulation of toll-like receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:BHF-UCL.
DR   GO; GO:0042535; P:positive regulation of tumor necrosis factor biosynthetic process; IEA:Ensembl.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; ISS:BHF-UCL.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0002730; P:regulation of dendritic cell cytokine production; IEA:Ensembl.
DR   GO; GO:0002238; P:response to molecule of fungal origin; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:UniProtKB.
DR   GO; GO:0034134; P:toll-like receptor 2 signaling pathway; TAS:Reactome.
DR   GO; GO:0034142; P:toll-like receptor 4 signaling pathway; TAS:Reactome.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038123; P:toll-like receptor TLR1:TLR2 signaling pathway; TAS:Reactome.
DR   GO; GO:0038124; P:toll-like receptor TLR6:TLR2 signaling pathway; TAS:Reactome.
DR   Gene3D; 3.40.50.10140; -; 1.
DR   Gene3D; 3.80.10.10; -; 3.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR000157; TIR_dom.
DR   InterPro; IPR027185; TLR2.
DR   InterPro; IPR017241; Toll-like_receptor.
DR   PANTHER; PTHR24365:SF17; PTHR24365:SF17; 1.
DR   Pfam; PF13855; LRR_8; 2.
DR   Pfam; PF01463; LRRCT; 1.
DR   Pfam; PF01582; TIR; 1.
DR   PIRSF; PIRSF037595; Toll-like_receptor; 1.
DR   SMART; SM00369; LRR_TYP; 2.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00255; TIR; 1.
DR   SUPFAM; SSF52058; SSF52058; 1.
DR   SUPFAM; SSF52200; SSF52200; 1.
DR   PROSITE; PS51450; LRR; 11.
DR   PROSITE; PS50104; TIR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Cytoplasmic vesicle; Disulfide bond;
KW   Glycoprotein; Immunity; Inflammatory response; Innate immunity;
KW   Leucine-rich repeat; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    784       Toll-like receptor 2.
FT                                /FTId=PRO_0000034710.
FT   TOPO_DOM     19    588       Extracellular. {ECO:0000255}.
FT   TRANSMEM    589    609       Helical. {ECO:0000255}.
FT   TOPO_DOM    610    784       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       54     77       LRR 1.
FT   REPEAT       78    101       LRR 2.
FT   REPEAT      102    125       LRR 3.
FT   REPEAT      126    150       LRR 4.
FT   REPEAT      151    175       LRR 5.
FT   REPEAT      176    199       LRR 6.
FT   REPEAT      200    223       LRR 7.
FT   REPEAT      224    250       LRR 8.
FT   REPEAT      251    278       LRR 9.
FT   REPEAT      279    308       LRR 10.
FT   REPEAT      309    337       LRR 11.
FT   REPEAT      338    361       LRR 12.
FT   REPEAT      362    388       LRR 13.
FT   REPEAT      389    414       LRR 14.
FT   REPEAT      415    437       LRR 15.
FT   REPEAT      438    457       LRR 16.
FT   REPEAT      458    478       LRR 17.
FT   REPEAT      479    500       LRR 18.
FT   REPEAT      501    524       LRR 19.
FT   DOMAIN      525    579       LRRCT.
FT   DOMAIN      639    784       TIR. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00204}.
FT   MOTIF       761    778       ATG16L1-binding motif.
FT   SITE        349    349       Interaction with bacterial lipopeptide.
FT   CARBOHYD    114    114       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15173186,
FT                                ECO:0000269|PubMed:17889651}.
FT   CARBOHYD    199    199       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15173186,
FT                                ECO:0000269|PubMed:17889651}.
FT   CARBOHYD    414    414       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17889651}.
FT   CARBOHYD    442    442       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15173186,
FT                                ECO:0000269|PubMed:17889651}.
FT   DISULFID     30     36       {ECO:0000269|PubMed:17889651}.
FT   DISULFID    353    382       {ECO:0000269|PubMed:17889651}.
FT   DISULFID    432    454       {ECO:0000269|PubMed:17889651}.
FT   VARIANT      89     89       N -> D. {ECO:0000269|PubMed:21618349}.
FT                                /FTId=VAR_066349.
FT   VARIANT     411    411       T -> I (reduces TLR2-mediated NF-kappa-B
FT                                activation; dbSNP:rs5743699).
FT                                {ECO:0000269|PubMed:21618349}.
FT                                /FTId=VAR_026765.
FT   VARIANT     571    571       R -> H (in dbSNP:rs61735277).
FT                                {ECO:0000269|PubMed:21618349}.
FT                                /FTId=VAR_066350.
FT   VARIANT     579    579       R -> H (in dbSNP:rs5743703).
FT                                /FTId=VAR_026766.
FT   VARIANT     631    631       P -> H (reduces TLR2-mediated NF-kappa-B
FT                                activation; dbSNP:rs5743704).
FT                                {ECO:0000269|PubMed:19924287,
FT                                ECO:0000269|PubMed:21618349}.
FT                                /FTId=VAR_024663.
FT   VARIANT     636    636       S -> R (in dbSNP:rs137853177).
FT                                {ECO:0000269|PubMed:21618349}.
FT                                /FTId=VAR_066351.
FT   VARIANT     677    677       R -> W. {ECO:0000269|PubMed:11476982,
FT                                ECO:0000269|PubMed:12646604}.
FT                                /FTId=VAR_031236.
FT   VARIANT     715    715       Y -> N (in dbSNP:rs5743706).
FT                                /FTId=VAR_052360.
FT   VARIANT     753    753       R -> Q (reduces TLR2-mediated NF-kappa-B
FT                                activation; dbSNP:rs5743708).
FT                                {ECO:0000269|PubMed:19924287,
FT                                ECO:0000269|PubMed:21618349}.
FT                                /FTId=VAR_031237.
FT   MUTAGEN     114    114       N->S: Prevents addition of N-glycans.
FT                                Reduces secretion of the N-terminal
FT                                ectodomain.
FT                                {ECO:0000269|PubMed:15173186}.
FT   MUTAGEN     199    199       N->D: Prevents addition of N-glycans.
FT                                Reduces secretion of the N-terminal
FT                                ectodomain.
FT                                {ECO:0000269|PubMed:15173186}.
FT   MUTAGEN     416    416       T->A: Prevents addition of N-glycans.
FT                                Reduces secretion of the N-terminal
FT                                ectodomain.
FT                                {ECO:0000269|PubMed:15173186}.
FT   MUTAGEN     442    442       N->D: Prevents addition of N-glycans.
FT                                Prevents secretion of the N-terminal
FT                                ectodomain.
FT                                {ECO:0000269|PubMed:15173186}.
FT   MUTAGEN     681    681       P->F: Abolishes the interaction with
FT                                MYD88. No effect on oligomerization or on
FT                                the structure of the TIR domain.
FT                                {ECO:0000269|PubMed:11081518}.
FT   CONFLICT     59     59       L -> Q (in Ref. 8; AAM23001).
FT                                {ECO:0000305}.
FT   CONFLICT     68     68       S -> C (in Ref. 8; AAM23001).
FT                                {ECO:0000305}.
FT   CONFLICT    726    726       D -> E (in Ref. 2; AAC34133).
FT                                {ECO:0000305}.
FT   STRAND       34     37       {ECO:0000244|PDB:2Z80}.
FT   STRAND       56     58       {ECO:0000244|PDB:2Z80}.
FT   TURN         69     74       {ECO:0000244|PDB:2Z80}.
FT   STRAND       80     82       {ECO:0000244|PDB:2Z80}.
FT   TURN         93     98       {ECO:0000244|PDB:2Z80}.
FT   STRAND      104    106       {ECO:0000244|PDB:2Z80}.
FT   HELIX       117    120       {ECO:0000244|PDB:2Z80}.
FT   STRAND      127    130       {ECO:0000244|PDB:2Z80}.
FT   STRAND      137    139       {ECO:0000244|PDB:2Z80}.
FT   STRAND      153    161       {ECO:0000244|PDB:2Z80}.
FT   TURN        167    172       {ECO:0000244|PDB:2Z80}.
FT   STRAND      175    183       {ECO:0000244|PDB:2Z80}.
FT   TURN        191    196       {ECO:0000244|PDB:2Z80}.
FT   STRAND      198    206       {ECO:0000244|PDB:2Z80}.
FT   HELIX       213    220       {ECO:0000244|PDB:2Z80}.
FT   TURN        221    223       {ECO:0000244|PDB:2Z80}.
FT   STRAND      224    231       {ECO:0000244|PDB:2Z80}.
FT   STRAND      253    258       {ECO:0000244|PDB:2Z80}.
FT   STRAND      260    262       {ECO:0000244|PDB:2Z7X}.
FT   HELIX       263    274       {ECO:0000244|PDB:2Z80}.
FT   STRAND      281    283       {ECO:0000244|PDB:2Z80}.
FT   STRAND      288    291       {ECO:0000244|PDB:2Z7X}.
FT   STRAND      311    316       {ECO:0000244|PDB:2Z7X}.
FT   HELIX       322    324       {ECO:0000244|PDB:2Z7X}.
FT   HELIX       329    334       {ECO:0000244|PDB:2Z7X}.
FT   STRAND      340    346       {ECO:0000244|PDB:2Z7X}.
FT   HELIX       353    358       {ECO:0000244|PDB:2Z7X}.
FT   STRAND      364    366       {ECO:0000244|PDB:2Z7X}.
FT   HELIX       374    380       {ECO:0000244|PDB:2Z7X}.
FT   STRAND      391    393       {ECO:0000244|PDB:2Z7X}.
FT   HELIX       402    408       {ECO:0000244|PDB:2Z7X}.
FT   HELIX       409    411       {ECO:0000244|PDB:2Z7X}.
FT   STRAND      417    419       {ECO:0000244|PDB:2Z7X}.
FT   STRAND      440    442       {ECO:0000244|PDB:2Z7X}.
FT   STRAND      460    463       {ECO:0000244|PDB:2Z7X}.
FT   STRAND      481    483       {ECO:0000244|PDB:2Z7X}.
FT   HELIX       495    497       {ECO:0000244|PDB:2Z7X}.
FT   STRAND      503    505       {ECO:0000244|PDB:2Z7X}.
FT   STRAND      641    646       {ECO:0000244|PDB:1FYX}.
FT   HELIX       649    651       {ECO:0000244|PDB:1FYX}.
FT   HELIX       652    656       {ECO:0000244|PDB:1FYX}.
FT   HELIX       658    663       {ECO:0000244|PDB:1FYX}.
FT   STRAND      666    668       {ECO:0000244|PDB:1FYX}.
FT   STRAND      672    674       {ECO:0000244|PDB:1FYX}.
FT   HELIX       675    678       {ECO:0000244|PDB:1FYX}.
FT   STRAND      681    683       {ECO:0000244|PDB:1FYX}.
FT   HELIX       685    695       {ECO:0000244|PDB:1FYX}.
FT   STRAND      696    703       {ECO:0000244|PDB:1FYX}.
FT   HELIX       705    711       {ECO:0000244|PDB:1FYX}.
FT   HELIX       713    716       {ECO:0000244|PDB:1FYX}.
FT   TURN        717    719       {ECO:0000244|PDB:1O77}.
FT   HELIX       720    722       {ECO:0000244|PDB:1O77}.
FT   TURN        723    725       {ECO:0000244|PDB:1FYW}.
FT   HELIX       726    728       {ECO:0000244|PDB:1FYX}.
FT   STRAND      733    738       {ECO:0000244|PDB:1FYX}.
FT   TURN        742    744       {ECO:0000244|PDB:1FYX}.
FT   HELIX       750    758       {ECO:0000244|PDB:1FYX}.
FT   STRAND      761    763       {ECO:0000244|PDB:1FYX}.
FT   HELIX       768    770       {ECO:0000244|PDB:1FYX}.
FT   HELIX       771    783       {ECO:0000244|PDB:1FYX}.
SQ   SEQUENCE   784 AA;  89838 MW;  7DBE6B24CF1FAF8B CRC64;
     MPHTLWMVWV LGVIISLSKE ESSNQASLSC DRNGICKGSS GSLNSIPSGL TEAVKSLDLS
     NNRITYISNS DLQRCVNLQA LVLTSNGINT IEEDSFSSLG SLEHLDLSYN YLSNLSSSWF
     KPLSSLTFLN LLGNPYKTLG ETSLFSHLTK LQILRVGNMD TFTKIQRKDF AGLTFLEELE
     IDASDLQSYE PKSLKSIQNV SHLILHMKQH ILLLEIFVDV TSSVECLELR DTDLDTFHFS
     ELSTGETNSL IKKFTFRNVK ITDESLFQVM KLLNQISGLL ELEFDDCTLN GVGNFRASDN
     DRVIDPGKVE TLTIRRLHIP RFYLFYDLST LYSLTERVKR ITVENSKVFL VPCLLSQHLK
     SLEYLDLSEN LMVEEYLKNS ACEDAWPSLQ TLILRQNHLA SLEKTGETLL TLKNLTNIDI
     SKNSFHSMPE TCQWPEKMKY LNLSSTRIHS VTGCIPKTLE ILDVSNNNLN LFSLNLPQLK
     ELYISRNKLM TLPDASLLPM LLVLKISRNA ITTFSKEQLD SFHTLKTLEA GGNNFICSCE
     FLSFTQEQQA LAKVLIDWPA NYLCDSPSHV RGQQVQDVRL SVSECHRTAL VSGMCCALFL
     LILLTGVLCH RFHGLWYMKM MWAWLQAKRK PRKAPSRNIC YDAFVSYSER DAYWVENLMV
     QELENFNPPF KLCLHKRDFI PGKWIIDNII DSIEKSHKTV FVLSENFVKS EWCKYELDFS
     HFRLFDENND AAILILLEPI EKKAIPQRFC KLRKIMNTKT YLEWPMDEAQ REGFWVNLRA
     AIKS
//
ID   GRIA1_RAT               Reviewed;         907 AA.
AC   P19490;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   16-MAY-2006, sequence version 2.
DT   17-FEB-2016, entry version 165.
DE   RecName: Full=Glutamate receptor 1;
DE            Short=GluR-1;
DE   AltName: Full=AMPA-selective glutamate receptor 1;
DE   AltName: Full=GluR-A;
DE   AltName: Full=GluR-K1;
DE   AltName: Full=Glutamate receptor ionotropic, AMPA 1;
DE            Short=GluA1;
DE   Flags: Precursor;
GN   Name=Gria1; Synonyms=Glur1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM FLOP).
RC   TISSUE=Forebrain;
RX   PubMed=2480522; DOI=10.1038/342643a0;
RA   Hollmann M., O'Shea-Greenfield A., Rogers S.W., Heinemann S.F.;
RT   "Cloning by functional expression of a member of the glutamate
RT   receptor family.";
RL   Nature 342:643-648(1989).
RN   [2]
RP   SEQUENCE REVISION.
RA   Hartley M.;
RL   Submitted (JUL-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM FLOP).
RC   TISSUE=Brain;
RX   PubMed=2166337; DOI=10.1126/science.2166337;
RA   Keinaenen K., Wisden W., Sommer B., Werner P., Herb A., Verdoorn T.A.,
RA   Sakmann B., Seeburg P.H.;
RT   "A family of AMPA-selective glutamate receptors.";
RL   Science 249:556-560(1990).
RN   [4]
RP   SEQUENCE REVISION TO 67; 248; 698; 710; 789 AND 893.
RA   Keinaenen K., Wisden W., Sommer B., Werner P., Herb A., Verdoorn T.A.,
RA   Sakmann B., Seeburg P.H.;
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM FLOP).
RX   PubMed=2168579; DOI=10.1126/science.2168579;
RA   Boulter J., Hollmann M., O'Shea-Greenfield A., Hartley M.,
RA   Deneris E.S., Maron C., Heinemann S.F.;
RT   "Molecular cloning and functional expression of glutamate receptor
RT   subunit genes.";
RL   Science 249:1033-1037(1990).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM FLIP), AND VARIANT THR-710.
RC   TISSUE=Brain;
RX   PubMed=1699275; DOI=10.1126/science.1699275;
RA   Sommer B., Keinaenen K., Verdoorn T.A., Wisden W., Burnashev N.,
RA   Herb A., Koehler M., Takagi T., Sakmann B., Seeburg P.H.;
RT   "Flip and flop: a cell-specific functional switch in glutamate-
RT   operated channels of the CNS.";
RL   Science 249:1580-1585(1990).
RN   [7]
RP   PHOSPHORYLATION AT SER-645.
RX   PubMed=7877986; DOI=10.1073/pnas.92.5.1376;
RA   Yakel J.L., Vissavajjhala P., Derkach V.A., Brickey D.A.,
RA   Soderling T.R.;
RT   "Identification of a Ca2+/calmodulin-dependent protein kinase II
RT   regulatory phosphorylation site in non-N-methyl-D-aspartate glutamate
RT   receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:1376-1380(1995).
RN   [8]
RP   VARIANT THR-710, AND PHOSPHORYLATION AT SER-710.
RX   PubMed=8848293; DOI=10.1016/0168-0102(95)00977-9;
RA   Nakazawa K., Tadakuma T., Nokihara K., Ito M.;
RT   "Antibody specific for phosphorylated AMPA-type glutamate receptors at
RT   GluR2 Ser-696.";
RL   Neurosci. Res. 24:75-86(1995).
RN   [9]
RP   PHOSPHORYLATION AT SER-849 AND SER-863, AND MUTAGENESIS OF SER-645 AND
RP   SER-849.
RX   PubMed=9405465; DOI=10.1074/jbc.272.51.32528;
RA   Mammen A.L., Kameyama K., Roche K.W., Huganir R.L.;
RT   "Phosphorylation of the alpha-amino-3-hydroxy-5-methylisoxazole4-
RT   propionic acid receptor GluR1 subunit by calcium/calmodulin-dependent
RT   kinase II.";
RL   J. Biol. Chem. 272:32528-32533(1997).
RN   [10]
RP   INTERACTION WITH DLG1.
RX   PubMed=9677374; DOI=10.1074/jbc.273.31.19518;
RA   Leonard A.S., Davare M.A., Horne M.C., Garner C.C., Hell J.W.;
RT   "SAP97 is associated with the alpha-amino-3-hydroxy-5-methylisoxazole-
RT   4-propionic acid receptor GluR1 subunit.";
RL   J. Biol. Chem. 273:19518-19524(1998).
RN   [11]
RP   INTERACTION WITH DLG1, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   MUTAGENESIS OF THR-905 AND LEU-907.
RX   PubMed=12070168; DOI=10.1074/jbc.M204354200;
RA   Cai C., Coleman S.K., Niemi K., Keinaenen K.;
RT   "Selective binding of synapse-associated protein 97 to GluR-A alpha-
RT   amino-5-hydroxy-3-methyl-4-isoxazole propionate receptor subunit is
RT   determined by a novel sequence motif.";
RL   J. Biol. Chem. 277:31484-31490(2002).
RN   [12]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND INTERACTION WITH CACNG2.
RX   PubMed=16793768; DOI=10.1074/jbc.M600679200;
RA   Bedoukian M.A., Weeks A.M., Partin K.M.;
RT   "Different domains of the AMPA receptor direct stargazin-mediated
RT   trafficking and stargazin-mediated modulation of kinetics.";
RL   J. Biol. Chem. 281:23908-23921(2006).
RN   [13]
RP   INTERACTION WITH LRFN1.
RX   PubMed=16630835; DOI=10.1016/j.neuron.2006.04.005;
RA   Ko J., Kim S., Chung H.S., Kim K., Han K., Kim H., Jun H.,
RA   Kaang B.-K., Kim E.;
RT   "SALM synaptic cell adhesion-like molecules regulate the
RT   differentiation of excitatory synapses.";
RL   Neuron 50:233-245(2006).
RN   [14]
RP   INTERACTION WITH CACNG5.
RX   PubMed=18817736; DOI=10.1016/j.neuron.2008.07.034;
RA   Kato A.S., Siuda E.R., Nisenbaum E.S., Bredt D.S.;
RT   "AMPA receptor subunit-specific regulation by a distinct family of
RT   type II TARPs.";
RL   Neuron 59:986-996(2008).
RN   [15]
RP   INTERACTION WITH CACNG5.
RX   PubMed=19234459; DOI=10.1038/nn.2266;
RA   Soto D., Coombs I.D., Renzi M., Zonouzi M., Farrant M.,
RA   Cull-Candy S.G.;
RT   "Selective regulation of long-form calcium-permeable AMPA receptors by
RT   an atypical TARP, gamma-5.";
RL   Nat. Neurosci. 12:277-285(2009).
RN   [16]
RP   ERRATUM.
RX   DOI=10.1038/nn0609-808c;
RA   Soto D., Coombs I.D., Renzi M., Zonouzi M., Farrant M.,
RA   Cull-Candy S.G.;
RL   Nat. Neurosci. 12:808-808(2009).
RN   [17]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=19265014; DOI=10.1126/science.1167852;
RA   Schwenk J., Harmel N., Zolles G., Bildl W., Kulik A., Heimrich B.,
RA   Chisaka O., Jonas P., Schulte U., Fakler B., Kloecker N.;
RT   "Functional proteomics identify cornichon proteins as auxiliary
RT   subunits of AMPA receptors.";
RL   Science 323:1313-1319(2009).
RN   [18]
RP   INTERACTION WITH CNIH2 AND CACNG2.
RX   PubMed=20805473; DOI=10.1073/pnas.1011706107;
RA   Shi Y., Suh Y.H., Milstein A.D., Isozaki K., Schmid S.M., Roche K.W.,
RA   Nicoll R.A.;
RT   "Functional comparison of the effects of TARPs and cornichons on AMPA
RT   receptor trafficking and gating.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:16315-16319(2010).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.21 ANGSTROMS) OF 890-907 IN COMPLEX WITH
RP   DLG1, AND INTERACTION WITH DLG1.
RX   PubMed=17069616; DOI=10.1111/j.1742-4658.2006.05521.x;
RA   von Ossowski I., Oksanen E., von Ossowski L., Cai C., Sundberg M.,
RA   Goldman A., Keinanen K.;
RT   "Crystal structure of the second PDZ domain of SAP97 in complex with a
RT   GluR-A C-terminal peptide.";
RL   FEBS J. 273:5219-5229(2006).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 22-392, SUBUNIT,
RP   GLYCOSYLATION AT ASN-249; ASN-257 AND ASN-363, AND DISULFIDE BOND.
RX   PubMed=21639859; DOI=10.1042/BJ20110801;
RA   Yao G., Zong Y., Gu S., Zhou J., Xu H., Mathews I.I., Jin R.;
RT   "Crystal structure of the glutamate receptor GluA1 N-terminal
RT   domain.";
RL   Biochem. J. 438:255-263(2011).
CC   -!- FUNCTION: Ionotropic glutamate receptor. L-glutamate acts as an
CC       excitatory neurotransmitter at many synapses in the central
CC       nervous system. Binding of the excitatory neurotransmitter L-
CC       glutamate induces a conformation change, leading to the opening of
CC       the cation channel, and thereby converts the chemical signal to an
CC       electrical impulse. The receptor then desensitizes rapidly and
CC       enters a transient inactive state, characterized by the presence
CC       of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8,
CC       shows resensitization which is characterized by a delayed
CC       accumulation of current flux upon continued application of
CC       glutamate. {ECO:0000269|PubMed:16793768,
CC       ECO:0000269|PubMed:19265014}.
CC   -!- SUBUNIT: Homotetramer or heterotetramer of pore-forming glutamate
CC       receptor subunits. Tetramers may be formed by the dimerization of
CC       dimers. Interacts with DLG1 via its C-terminus. Found in a complex
CC       with GRIA2, GRIA3, GRIA4, CNIH2, CNIH3, CACNG2, CACNG3, CACNG4,
CC       CACNG5, CACNG7 and CACNG8. Interacts with HIP1, RASGRF2, SYNDIG1
CC       and LRFN1. Interacts with SNX27 (via PDZ domain); the interaction
CC       is required for recycling to the plasma membrane when endocytosed
CC       and prevent degradation in lysosomes. Interacts (via PDZ-binding
CC       motif) with SHANK3 (via PDZ domain). {ECO:0000269|PubMed:12070168,
CC       ECO:0000269|PubMed:16630835, ECO:0000269|PubMed:16793768,
CC       ECO:0000269|PubMed:17069616, ECO:0000269|PubMed:18817736,
CC       ECO:0000269|PubMed:19234459, ECO:0000269|PubMed:19265014,
CC       ECO:0000269|PubMed:20805473, ECO:0000269|PubMed:21639859,
CC       ECO:0000269|PubMed:9677374}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-371642, EBI-371642;
CC       P10608:Adrb2; NbExp=3; IntAct=EBI-371642, EBI-7090342;
CC       Q71RJ2:Cacng2; NbExp=2; IntAct=EBI-371642, EBI-8538384;
CC       P19491:Gria2; NbExp=3; IntAct=EBI-371642, EBI-77718;
CC       P70569:Myo5b; NbExp=2; IntAct=EBI-371642, EBI-975940;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Endoplasmic reticulum membrane; Multi-pass membrane protein. Cell
CC       junction, synapse, postsynaptic cell membrane; Multi-pass membrane
CC       protein. Cell junction, synapse, postsynaptic cell membrane,
CC       postsynaptic density {ECO:0000250}. Cell projection, dendrite
CC       {ECO:0000250}. Cell projection, dendritic spine {ECO:0000250}.
CC       Note=Interaction with CACNG2, CNIH2 and CNIH3 promotes cell
CC       surface expression.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Flop;
CC         IsoId=P19490-1; Sequence=Displayed;
CC       Name=Flip;
CC         IsoId=P19490-2; Sequence=VSP_000097, VSP_000098, VSP_000099,
CC                                  VSP_000100, VSP_000101;
CC   -!- TISSUE SPECIFICITY: Detected in cerebellum (at protein level).
CC       {ECO:0000269|PubMed:12070168}.
CC   -!- DOMAIN: The M4 transmembrane segment mediates tetramerization and
CC       is required for cell surface expression. {ECO:0000250}.
CC   -!- PTM: Palmitoylated. Depalmitoylated upon glutamate stimulation.
CC       Cys-603 palmitoylation leads to Golgi retention and decreased cell
CC       surface expression. In contrast, Cys-829 palmitoylation does not
CC       affect cell surface expression but regulates stimulation-dependent
CC       endocytosis (By similarity). {ECO:0000250}.
CC   -!- POLYMORPHISM: Both variants Ser-710 and Thr-710 are phosphorylated
CC       at this position.
CC   -!- MISCELLANEOUS: The postsynaptic actions of Glu are mediated by a
CC       variety of receptors that are named according to their selective
CC       agonists. This receptor binds AMPA (quisqualate) > glutamate >
CC       kainate.
CC   -!- SIMILARITY: Belongs to the glutamate-gated ion channel
CC       (TC 1.A.10.1) family. GRIA1 subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X17184; CAA35050.1; -; mRNA.
DR   EMBL; M36418; AAA41243.2; -; mRNA.
DR   EMBL; M38060; AAA63479.1; -; mRNA.
DR   PIR; A40170; A40170.
DR   PIR; S07059; ACRTK1.
DR   RefSeq; NP_113796.1; NM_031608.1. [P19490-1]
DR   UniGene; Rn.29971; -.
DR   PDB; 2AWW; X-ray; 2.21 A; C=890-907.
DR   PDB; 3SAJ; X-ray; 2.50 A; A/B/C/D=22-392.
DR   PDBsum; 2AWW; -.
DR   PDBsum; 3SAJ; -.
DR   ProteinModelPortal; P19490; -.
DR   SMR; P19490; 406-520, 645-788.
DR   BioGrid; 248399; 6.
DR   DIP; DIP-30929N; -.
DR   IntAct; P19490; 18.
DR   MINT; MINT-726538; -.
DR   BindingDB; P19490; -.
DR   ChEMBL; CHEMBL2093871; -.
DR   TCDB; 1.A.10.1.1; the glutamate-gated ion channel (gic) family of neurotransmitter receptors.
DR   iPTMnet; P19490; -.
DR   PhosphoSite; P19490; -.
DR   SwissPalm; P19490; -.
DR   PRIDE; P19490; -.
DR   GeneID; 50592; -.
DR   KEGG; rno:50592; -.
DR   UCSC; RGD:621531; rat. [P19490-1]
DR   CTD; 2890; -.
DR   RGD; 621531; Gria1.
DR   HOVERGEN; HBG051839; -.
DR   InParanoid; P19490; -.
DR   KO; K05197; -.
DR   PhylomeDB; P19490; -.
DR   EvolutionaryTrace; P19490; -.
DR   NextBio; 610434; -.
DR   PRO; PR:P19490; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0032281; C:AMPA glutamate receptor complex; IDA:UniProtKB.
DR   GO; GO:0032279; C:asymmetric synapse; IDA:RGD.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0009986; C:cell surface; IDA:RGD.
DR   GO; GO:0005829; C:cytosol; IDA:RGD.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0043198; C:dendritic shaft; IDA:UniProtKB.
DR   GO; GO:0043197; C:dendritic spine; IDA:RGD.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0060076; C:excitatory synapse; IDA:BHF-UCL.
DR   GO; GO:0008328; C:ionotropic glutamate receptor complex; TAS:UniProtKB.
DR   GO; GO:0031594; C:neuromuscular junction; IDA:RGD.
DR   GO; GO:0043005; C:neuron projection; IDA:RGD.
DR   GO; GO:0044309; C:neuron spine; IDA:RGD.
DR   GO; GO:0043025; C:neuronal cell body; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:RGD.
DR   GO; GO:0014069; C:postsynaptic density; IDA:RGD.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043234; C:protein complex; IDA:RGD.
DR   GO; GO:0045202; C:synapse; IMP:UniProtKB.
DR   GO; GO:0008179; F:adenylate cyclase binding; IDA:RGD.
DR   GO; GO:0004971; F:AMPA glutamate receptor activity; IDA:UniProtKB.
DR   GO; GO:0031698; F:beta-2 adrenergic receptor binding; IPI:RGD.
DR   GO; GO:0005234; F:extracellular-glutamate-gated ion channel activity; IEA:InterPro.
DR   GO; GO:0001965; F:G-protein alpha-subunit binding; IPI:RGD.
DR   GO; GO:0031681; F:G-protein beta-subunit binding; IDA:RGD.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004970; F:ionotropic glutamate receptor activity; IDA:RGD.
DR   GO; GO:0031489; F:myosin V binding; IPI:RGD.
DR   GO; GO:0030165; F:PDZ domain binding; IPI:RGD.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:RGD.
DR   GO; GO:0042803; F:protein homodimerization activity; TAS:UniProtKB.
DR   GO; GO:0051018; F:protein kinase A binding; IDA:RGD.
DR   GO; GO:0019901; F:protein kinase binding; IPI:RGD.
DR   GO; GO:0031267; F:small GTPase binding; IPI:RGD.
DR   GO; GO:0071418; P:cellular response to amine stimulus; IEP:RGD.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IEP:RGD.
DR   GO; GO:0071359; P:cellular response to dsRNA; IEP:RGD.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEP:RGD.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0071375; P:cellular response to peptide hormone stimulus; IEP:RGD.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; IDA:GOC.
DR   GO; GO:0007616; P:long-term memory; IMP:RGD.
DR   GO; GO:0050804; P:modulation of synaptic transmission; IDA:UniProtKB.
DR   GO; GO:0019228; P:neuronal action potential; IMP:UniProtKB.
DR   GO; GO:0045838; P:positive regulation of membrane potential; IMP:RGD.
DR   GO; GO:0050806; P:positive regulation of synaptic transmission; IMP:UniProtKB.
DR   GO; GO:0031623; P:receptor internalization; IDA:UniProtKB.
DR   GO; GO:0001919; P:regulation of receptor recycling; IMP:UniProtKB.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; IMP:UniProtKB.
DR   GO; GO:0046685; P:response to arsenic-containing substance; IEP:RGD.
DR   GO; GO:0042220; P:response to cocaine; IEP:RGD.
DR   GO; GO:0042493; P:response to drug; IEP:RGD.
DR   GO; GO:0051602; P:response to electrical stimulus; IEP:RGD.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0060992; P:response to fungicide; IEP:RGD.
DR   GO; GO:0010226; P:response to lithium ion; IEP:UniProtKB.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0043434; P:response to peptide hormone; IEP:RGD.
DR   GO; GO:0009636; P:response to toxic substance; IMP:RGD.
DR   GO; GO:0021510; P:spinal cord development; IEP:RGD.
DR   GO; GO:0035249; P:synaptic transmission, glutamatergic; NAS:UniProtKB.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR019594; Glu/Gly-bd.
DR   InterPro; IPR001508; Iono_rcpt_met.
DR   InterPro; IPR001320; Iontro_rcpt.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF00060; Lig_chan; 1.
DR   Pfam; PF10613; Lig_chan-Glu_bd; 1.
DR   PRINTS; PR00177; NMDARECEPTOR.
DR   SMART; SM00918; Lig_chan-Glu_bd; 1.
DR   SMART; SM00079; PBPe; 1.
DR   SUPFAM; SSF53822; SSF53822; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell junction; Cell membrane;
KW   Cell projection; Complete proteome; Disulfide bond;
KW   Endoplasmic reticulum; Glycoprotein; Ion channel; Ion transport;
KW   Ligand-gated ion channel; Lipoprotein; Membrane; Palmitate;
KW   Phosphoprotein; Polymorphism; Postsynaptic cell membrane; Receptor;
KW   Reference proteome; Signal; Synapse; Transmembrane;
KW   Transmembrane helix; Transport.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    907       Glutamate receptor 1.
FT                                /FTId=PRO_0000011531.
FT   TOPO_DOM     19    536       Extracellular. {ECO:0000250}.
FT   TRANSMEM    537    557       Helical. {ECO:0000250}.
FT   TOPO_DOM    558    584       Cytoplasmic. {ECO:0000250}.
FT   INTRAMEM    585    600       Helical; Pore-forming. {ECO:0000250}.
FT   INTRAMEM    601    603       {ECO:0000250}.
FT   TOPO_DOM    604    609       Cytoplasmic. {ECO:0000250}.
FT   TRANSMEM    610    630       Helical. {ECO:0000250}.
FT   TOPO_DOM    631    805       Extracellular. {ECO:0000250}.
FT   TRANSMEM    806    826       Helical; Name=M4. {ECO:0000250}.
FT   TOPO_DOM    827    907       Cytoplasmic. {ECO:0000250}.
FT   REGION      492    494       Glutamate binding. {ECO:0000250}.
FT   REGION      668    669       Glutamate binding. {ECO:0000250}.
FT   MOTIF       904    907       PDZ-binding.
FT   BINDING     464    464       Glutamate. {ECO:0000250}.
FT   BINDING     499    499       Glutamate. {ECO:0000250}.
FT   BINDING     719    719       Glutamate. {ECO:0000250}.
FT   MOD_RES     645    645       Phosphoserine.
FT                                {ECO:0000269|PubMed:7877986}.
FT   MOD_RES     710    710       Phosphoserine; by PKC.
FT                                {ECO:0000269|PubMed:8848293}.
FT   MOD_RES     849    849       Phosphoserine; by PKC, PKA and CAMK2.
FT                                {ECO:0000269|PubMed:9405465}.
FT   MOD_RES     863    863       Phosphoserine; by PKC and PKA.
FT                                {ECO:0000269|PubMed:9405465}.
FT   LIPID       603    603       S-palmitoyl cysteine. {ECO:0000250}.
FT   LIPID       829    829       S-palmitoyl cysteine. {ECO:0000250}.
FT   CARBOHYD     63     63       N-linked (GlcNAc...).
FT   CARBOHYD    249    249       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21639859}.
FT   CARBOHYD    257    257       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21639859}.
FT   CARBOHYD    363    363       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21639859}.
FT   CARBOHYD    401    401       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    406    406       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     75    323       {ECO:0000269|PubMed:21639859}.
FT   DISULFID    732    787       {ECO:0000250}.
FT   VAR_SEQ     758    758       N -> G (in isoform Flip).
FT                                {ECO:0000303|PubMed:1699275}.
FT                                /FTId=VSP_000097.
FT   VAR_SEQ     768    768       N -> S (in isoform Flip).
FT                                {ECO:0000303|PubMed:1699275}.
FT                                /FTId=VSP_000098.
FT   VAR_SEQ     772    772       L -> V (in isoform Flip).
FT                                {ECO:0000303|PubMed:1699275}.
FT                                /FTId=VSP_000099.
FT   VAR_SEQ     778    778       N -> S (in isoform Flip).
FT                                {ECO:0000303|PubMed:1699275}.
FT                                /FTId=VSP_000100.
FT   VAR_SEQ     790    793       GGGD -> KDSG (in isoform Flip).
FT                                {ECO:0000303|PubMed:1699275}.
FT                                /FTId=VSP_000101.
FT   VARIANT     710    710       S -> T. {ECO:0000269|PubMed:1699275,
FT                                ECO:0000269|PubMed:8848293}.
FT   MUTAGEN     645    645       S->A: No effect on phosphorylation by
FT                                CaMK2. {ECO:0000269|PubMed:9405465}.
FT   MUTAGEN     849    849       S->A: Abolishes phosphorylation by CaMK2.
FT                                {ECO:0000269|PubMed:9405465}.
FT   MUTAGEN     905    905       T->A: Loss of interaction with DLG1.
FT                                {ECO:0000269|PubMed:12070168}.
FT   MUTAGEN     907    907       L->A: Loss of interaction with DLG1.
FT                                {ECO:0000269|PubMed:12070168}.
FT   CONFLICT     67     67       S -> T (in Ref. 6; AAA63479).
FT                                {ECO:0000305}.
FT   CONFLICT    248    248       A -> R (in Ref. 6; AAA63479).
FT                                {ECO:0000305}.
FT   CONFLICT    698    698       R -> L (in Ref. 6; AAA63479).
FT                                {ECO:0000305}.
FT   STRAND       23     32       {ECO:0000244|PDB:3SAJ}.
FT   STRAND       34     36       {ECO:0000244|PDB:3SAJ}.
FT   HELIX        37     46       {ECO:0000244|PDB:3SAJ}.
FT   STRAND       51     61       {ECO:0000244|PDB:3SAJ}.
FT   HELIX        67     79       {ECO:0000244|PDB:3SAJ}.
FT   STRAND       85     87       {ECO:0000244|PDB:3SAJ}.
FT   HELIX        91    104       {ECO:0000244|PDB:3SAJ}.
FT   STRAND      108    110       {ECO:0000244|PDB:3SAJ}.
FT   STRAND      122    124       {ECO:0000244|PDB:3SAJ}.
FT   HELIX       130    139       {ECO:0000244|PDB:3SAJ}.
FT   STRAND      144    149       {ECO:0000244|PDB:3SAJ}.
FT   HELIX       156    168       {ECO:0000244|PDB:3SAJ}.
FT   STRAND      171    176       {ECO:0000244|PDB:3SAJ}.
FT   HELIX       177    179       {ECO:0000244|PDB:3SAJ}.
FT   HELIX       183    187       {ECO:0000244|PDB:3SAJ}.
FT   TURN        188    191       {ECO:0000244|PDB:3SAJ}.
FT   STRAND      196    203       {ECO:0000244|PDB:3SAJ}.
FT   HELIX       206    208       {ECO:0000244|PDB:3SAJ}.
FT   HELIX       209    218       {ECO:0000244|PDB:3SAJ}.
FT   STRAND      225    233       {ECO:0000244|PDB:3SAJ}.
FT   HELIX       235    237       {ECO:0000244|PDB:3SAJ}.
FT   HELIX       240    245       {ECO:0000244|PDB:3SAJ}.
FT   STRAND      250    254       {ECO:0000244|PDB:3SAJ}.
FT   HELIX       261    276       {ECO:0000244|PDB:3SAJ}.
FT   HELIX       288    309       {ECO:0000244|PDB:3SAJ}.
FT   HELIX       334    342       {ECO:0000244|PDB:3SAJ}.
FT   STRAND      346    348       {ECO:0000244|PDB:3SAJ}.
FT   STRAND      351    353       {ECO:0000244|PDB:3SAJ}.
FT   STRAND      359    361       {ECO:0000244|PDB:3SAJ}.
FT   STRAND      366    372       {ECO:0000244|PDB:3SAJ}.
FT   STRAND      375    383       {ECO:0000244|PDB:3SAJ}.
FT   TURN        384    386       {ECO:0000244|PDB:3SAJ}.
FT   STRAND      387    390       {ECO:0000244|PDB:3SAJ}.
FT   STRAND      905    907       {ECO:0000244|PDB:2AWW}.
SQ   SEQUENCE   907 AA;  101579 MW;  2D4CFA7CCD532838 CRC64;
     MPYIFAFFCT GFLGAVVGAN FPNNIQIGGL FPNQQSQEHA AFRFALSQLT EPPKLLPQID
     IVNISDSFEM TYRFCSQFSK GVYAIFGFYE RRTVNMLTSF CGALHVCFIT PSFPVDTSNQ
     FVLQLRPELQ EALISIIDHY KWQTFVYIYD ADRGLSVLQR VLDTAAEKNW QVTAVNILTT
     TEEGYRMLFQ DLEKKKERLV VVDCESERLN AILGQIVKLE KNGIGYHYIL ANLGFMDIDL
     NKFKESGANV TGFQLVNYTD TIPARIMQQW RTSDSRDHTR VDWKRPKYTS ALTYDGVKVM
     AEAFQSLRRQ RIDISRRGNA GDCLANPAVP WGQGIDIQRA LQQVRFEGLT GNVQFNEKGR
     RTNYTLHVIE MKHDGIRKIG YWNEDDKFVP AATDAQAGGD NSSVQNRTYI VTTILEDPYV
     MLKKNANQFE GNDRYEGYCV ELAAEIAKHV GYSYRLEIVS DGKYGARDPD TKAWNGMVGE
     LVYGRADVAV APLTITLVRE EVIDFSKPFM SLGISIMIKK PQKSKPGVFS FLDPLAYEIW
     MCIVFAYIGV SVVLFLVSRF SPYEWHSEEF EEGRDQTTSD QSNEFGIFNS LWFSLGAFMQ
     QGCDISPRSL SGRIVGGVWW FFTLIIISSY TANLAAFLTV ERMVSPIESA EDLAKQTEIA
     YGTLEAGSTK EFFRRSKIAV FEKMWTYMKS AEPSVFVRTT EEGMIRVRKS KGKYAYLLES
     TMNEYIEQRK PCDTMKVGGN LDSKGYGIAT PKGSALRNPV NLAVLKLNEQ GLLDKLKNKW
     WYDKGECGSG GGDSKDKTSA LSLSNVAGVF YILIGGLGLA MLVALIEFCY KSRSESKRMK
     GFCLIPQQSI NEAIRTSTLP RNSGAGASGG GGSGENGRVV SQDFPKSMQS IPCMSHSSGM
     PLGATGL
//
ID   NOTC3_HUMAN             Reviewed;        2321 AA.
AC   Q9UM47; Q9UEB3; Q9UPL3; Q9Y6L8;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   08-FEB-2011, sequence version 2.
DT   20-JAN-2016, entry version 167.
DE   RecName: Full=Neurogenic locus notch homolog protein 3;
DE            Short=Notch 3;
DE   Contains:
DE     RecName: Full=Notch 3 extracellular truncation;
DE   Contains:
DE     RecName: Full=Notch 3 intracellular domain;
DE   Flags: Precursor;
GN   Name=NOTCH3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-2223.
RX   PubMed=8878478; DOI=10.1038/383707a0;
RA   Joutel A., Corpechot C., Ducros A., Vahedi K., Chabriat H., Mouton P.,
RA   Alamowitch S., Domenga V., Cecillion M., Marechal E., Maciazek J.,
RA   Vayssiere C., Cruaud C., Cabanis E.-A., Ruchoux M.M., Weissenbach J.,
RA   Bach J.-F., Bousser M.-G., Tournier-Lasserve E.;
RT   "Notch3 mutations in CADASIL, a hereditary adult-onset condition
RT   causing stroke and dementia.";
RL   Nature 383:707-710(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Gunel M., Artavanis-Tsakonas S.;
RL   Submitted (APR-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [4]
RP   IDENTIFICATION OF LIGANDS.
RX   PubMed=10079256; DOI=10.1016/S0002-9440(10)65325-4;
RA   Gray G.E., Mann R.S., Mitsiadis E., Henrique D., Carcangiu M.-L.,
RA   Banks A., Leiman J., Ward D., Ish-Horowitz D., Artavanis-Tsakonas S.;
RT   "Human ligands of the Notch receptor.";
RL   Am. J. Pathol. 154:785-794(1999).
RN   [5]
RP   INTERACTION WITH MAML1.
RX   PubMed=11101851; DOI=10.1038/82644;
RA   Wu L., Aster J.C., Blacklow S.C., Lake R., Artavanis-Tsakonas S.,
RA   Griffin J.D.;
RT   "MAML1, a human homologue of Drosophila mastermind, is a
RT   transcriptional co-activator for NOTCH receptors.";
RL   Nat. Genet. 26:484-489(2000).
RN   [6]
RP   INTERACTION WITH MAML2 AND MAML3.
RX   PubMed=12370315; DOI=10.1128/MCB.22.21.7688-7700.2002;
RA   Wu L., Sun T., Kobayashi K., Gao P., Griffin J.D.;
RT   "Identification of a family of mastermind-like transcriptional
RT   coactivators for mammalian notch receptors.";
RL   Mol. Cell. Biol. 22:7688-7700(2002).
RN   [7]
RP   INTERACTION WITH PSMA1.
RX   PubMed=17292860; DOI=10.1016/j.bbrc.2007.01.151;
RA   Zhang Y., Jia L., Lee S.J., Wang M.M.;
RT   "Conserved signal peptide of Notch3 inhibits interaction with
RT   proteasome.";
RL   Biochem. Biophys. Res. Commun. 355:245-251(2007).
RN   [8]
RP   INTERACTION WITH HIF1AN.
RX   PubMed=17573339; DOI=10.1074/jbc.M704102200;
RA   Coleman M.L., McDonough M.A., Hewitson K.S., Coles C., Mecinovic J.,
RA   Edelmann M., Cook K.M., Cockman M.E., Lancaster D.E., Kessler B.M.,
RA   Oldham N.J., Ratcliffe P.J., Schofield C.J.;
RT   "Asparaginyl hydroxylation of the Notch ankyrin repeat domain by
RT   factor inhibiting hypoxia-inducible factor.";
RL   J. Biol. Chem. 282:24027-24038(2007).
RN   [9]
RP   HYDROXYLATION BY HIF1AN.
RX   PubMed=18299578; DOI=10.1073/pnas.0711591105;
RA   Zheng X., Linke S., Dias J.M., Zheng X., Gradin K., Wallis T.P.,
RA   Hamilton B.R., Gustafsson M., Ruas J.L., Wilkins S., Bilton R.L.,
RA   Brismar K., Whitelaw M.L., Pereira T., Gorman J.J., Ericson J.,
RA   Peet D.J., Lendahl U., Poellinger L.;
RT   "Interaction with factor inhibiting HIF-1 defines an additional mode
RT   of cross-coupling between the Notch and hypoxia signaling pathways.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3368-3373(2008).
RN   [10]
RP   VARIANTS CADASIL TYR-49; CYS-71; CYS-90; CYS-110; CYS-133; CYS-141;
RP   ARG-146; CYS-153; CYS-169; CYS-171; CYS-182; ARG-185; SER-212;
RP   GLY-222; TYR-224; CYS-258; TYR-542; CYS-558; CYS-578; CYS-728;
RP   CYS-985; CYS-1006; CYS-1031; CYS-1231 AND ARG-1261, AND VARIANTS
RP   ARG-170; LEU-496; GLN-1133; MET-1183 AND VAL-2223.
RX   PubMed=9388399; DOI=10.1016/S0140-6736(97)08083-5;
RA   Joutel A., Vahedi K., Corpechot C., Troesch A., Chabriat H.,
RA   Vayssiere C., Cruaud C., Maciazek J., Weissenbach J., Bousser M.-G.,
RA   Bach J.-F., Tournier-Lasserve E.;
RT   "Strong clustering and stereotyped nature of Notch3 mutations in
RT   CADASIL patients.";
RL   Lancet 350:1511-1515(1997).
RN   [11]
RP   VARIANTS CADASIL CYS-90; PHE-117; CYS-133; CYS-141; CYS-169; TYR-174;
RP   CYS-182 AND ARG-183.
RX   PubMed=10227618; DOI=10.1212/WNL.52.7.1361;
RA   Dichgans M., Filippi M., Bruening R., Iannucci G., Berchtenbreiter C.,
RA   Minicucci L., Uttner I., Crispin A., Ludwig H., Gasser T.,
RA   Yousry T.A.;
RT   "Quantitative MRI in CADASIL: correlation with disability and
RT   cognitive performance.";
RL   Neurology 52:1361-1367(1999).
RN   [12]
RP   VARIANTS CADASIL CYS-133; CYS-141; CYS-153; CYS-182; CYS-207; CYS-544
RP   AND ARG-1015.
RX   PubMed=10371548; DOI=10.1212/WNL.52.9.1913;
RG   Dutch CADASIL research group;
RA   Lesnik Oberstein S.A.J., Ferrari M.D., Bakker E., van Gestel J.,
RA   Kneppers A.L.J., Frants R.R., Breuning M.H., Haan J.;
RT   "Diagnostic Notch3 sequence analysis in CADASIL: three new mutations
RT   in Dutch patients. Dutch CADASIL Research Group.";
RL   Neurology 52:1913-1915(1999).
RN   [13]
RP   VARIANTS CADASIL 80-ASP--SER-84 DEL; CYS-90; PHE-93; CYS-110; PHE-117;
RP   PHE-123; CYS-133; CYS-141; SER-144; TYR-144; CYS-150; 153-ARG--CYS-155
RP   DEL; CYS-153; CYS-169; TYR-174; CYS-182; ARG-183; SER-183; ARG-185 AND
RP   PHE-194.
RX   PubMed=10854111; DOI=10.1038/sj.ejhg.5200460;
RA   Dichgans M., Ludwig H., Mueller-Hoecker J., Messerschmidt A.,
RA   Gasser T.;
RT   "Small in-frame deletions and missense mutations in CADASIL: 3D models
RT   predict misfolding of Notch3 EGF-like repeat domains.";
RL   Eur. J. Hum. Genet. 8:280-285(2000).
RN   [14]
RP   VARIANT CADASIL PHE-144.
RX   PubMed=11058919;
RX   DOI=10.1002/1098-1004(200011)16:5<449::AID-HUMU26>3.3.CO;2-9;
RA   Grigg R., Lea R., Sullivan A.A., Curtain R., MacMillian J.,
RA   Griffiths L.;
RT   "Identification of a novel mutation C144F in the Notch3 gene in an
RT   Australian CADASIL pedigree.";
RL   Hum. Mutat. 16:449-450(2000).
RN   [15]
RP   VARIANTS CADASIL TYR-49; CYS-54; CYS-90; CYS-110; 114-GLY--PRO-120
RP   DEL; TYR-123; CYS-133; CYS-141; ARG-146; CYS-153; SER-162; CYS-169;
RP   TYR-174; CYS-180; CYS-182; ARG-185; TYR-194; TYR-206; CYS-207;
RP   SER-212; GLY-222; TYR-224; CYS-258; TYR-542; CYS-558; CYS-578;
RP   CYS-607; CYS-728; CYS-984; CYS-985; CYS-1006; CYS-1031; CYS-1231 AND
RP   ARG-1261.
RX   PubMed=11102981;
RX   DOI=10.1002/1098-1004(200012)16:6<518::AID-HUMU9>3.3.CO;2-H;
RA   Escary J.-L., Cecillon M., Maciazek J., Lathrop M.,
RA   Tournier-Lasserve E., Joutel A.;
RT   "Evaluation of DHPLC analysis in mutational scanning of Notch3, a gene
RT   with a high G-C content.";
RL   Hum. Mutat. 16:518-526(2000).
RN   [16]
RP   VARIANT CADASIL 114-GLY--PRO-120 DEL.
RX   PubMed=10802807; DOI=10.1212/WNL.54.9.1874;
RA   Joutel A., Chabriat H., Vahedi K., Domenga V., Vayssiere C.,
RA   Ruchoux M.M., Lucas C., Leys D., Bousser M.-G., Tournier-Lasserve E.;
RT   "Splice site mutation causing a seven amino acid Notch3 in-frame
RT   deletion in CADASIL.";
RL   Neurology 54:1874-1875(2000).
RN   [17]
RP   VARIANT CADASIL CYS-332.
RX   PubMed=11559313; DOI=10.1001/archneur.58.9.1418;
RA   Oliveri R.L., Muglia M., De Stefano N., Mazzei R., Labate A.,
RA   Conforti F.L., Patitucci A., Gabriele A.L., Tagarelli G.,
RA   Magariello A., Zappia M., Gambardella A., Federico A., Quattrone A.;
RT   "A novel mutation in the Notch3 gene in an Italian family with
RT   cerebral autosomal dominant arteriopathy with subcortical infarcts and
RT   leukoencephalopathy: genetic and magnetic resonance spectroscopic
RT   findings.";
RL   Arch. Neurol. 58:1418-1422(2001).
RN   [18]
RP   VARIANTS CADASIL CYS-110; CYS-133; TRP-134; CYS-141; CYS-153; CYS-182;
RP   GLY-185; CYS-207; SER-212; GLY-222; SER-428; CYS-558; CYS-985 AND
RP   CYS-1063.
RX   PubMed=11755616; DOI=10.1016/S0140-6736(01)07142-2;
RA   Joutel A., Favrole P., Labauge P., Chabriat H., Lescoat C.,
RA   Andreux F., Domenga V., Cecillon M., Vahedi K., Ducros A.,
RA   Cave-Riant F., Bousser M.G., Tournier-Lasserve E.;
RT   "Skin biopsy immunostaining with a Notch3 monoclonal antibody for
RT   CADASIL diagnosis.";
RL   Lancet 358:2049-2051(2001).
RN   [19]
RP   VARIANT CADASIL TRP-134.
RX   PubMed=11810186; DOI=10.1007/s004010100439;
RA   Feuerhake F., Volk B., Ostertag C.B., Jungling F.D., Kassubek J.,
RA   Orszagh M., Dichgans M.;
RT   "Reversible coma with raised intracranial pressure: an unusual
RT   clinical manifestation of CADASIL.";
RL   Acta Neuropathol. 103:188-192(2002).
RN   [20]
RP   VARIANTS CADASIL ARG-76; TYR-93; TYR-128; CYS-142; ARG-194; TYR-222;
RP   SER-233; ARG-251; CYS-420; GLY-440; CYS-449; CYS-953 AND CYS-1021.
RX   PubMed=12146805;
RA   Kalimo H., Ruchoux M.-M., Viitanen M., Kalaria R.N.;
RT   "CADASIL: a common form of hereditary arteriopathy causing brain
RT   infarcts and dementia.";
RL   Brain Pathol. 12:371-384(2002).
RN   [21]
RP   VARIANT CADASIL ARG-455.
RX   PubMed=12136071; DOI=10.1212/WNL.59.2.277;
RA   Arboleda-Velasquez J.F., Lopera F., Lopez E., Frosch M.P.,
RA   Sepulveda-Falla D., Gutierrez J.E., Vargas S., Medina M.,
RA   Martinez De Arrieta C., Lebo R.V., Slaugenhaupt S.A., Betensky R.A.,
RA   Villegas A., Arcos-Burgos M., Rivera D., Restrepo J.C., Kosik K.S.;
RT   "C455R notch3 mutation in a Colombian CADASIL kindred with early onset
RT   of stroke.";
RL   Neurology 59:277-279(2002).
RN   [22]
RP   VARIANT CADASIL TYR-67.
RX   PubMed=12589106;
RA   Moon S.-Y., Kim H.-Y., Seok J.-I., Kwon J.-C., Ki C.-S., Kim J.-W.,
RA   Suh Y.-L., Na D.L.;
RT   "A novel mutation (C67Y)in the NOTCH3 gene in a Korean CADASIL
RT   patient.";
RL   J. Korean Med. Sci. 18:141-144(2003).
RN   [23]
RP   VARIANTS CADASIL CYS-90; CYS-133; CYS-169; ARG-174; PHE-174 AND
RP   LYS-213.
RX   PubMed=12810003; DOI=10.1016/S0022-510X(03)00109-6;
RA   Santa Y., Uyama E., Chui D.H., Arima M., Kotorii S., Takahashi K.,
RA   Tabira T.;
RT   "Genetic, clinical and pathological studies of CADASIL in Japan: a
RT   partial contribution of Notch3 mutations and implications of smooth
RT   muscle cell degeneration for the pathogenesis.";
RL   J. Neurol. Sci. 212:79-84(2003).
RN   [24]
RP   VARIANTS CADASIL ARG-76; CYS-90; CYS-110; CYS-141; CYS-153; CYS-169;
RP   CYS-182; ARG-183; CYS-189; SER-194; CYS-207; ARG-251; CYS-332;
RP   GLY-440; CYS-607; CYS-953 AND CYS-1231.
RX   PubMed=15229130; DOI=10.1093/brain/awh223;
RA   Singhal S., Bevan S., Barrick T., Rich P., Markus H.S.;
RT   "The influence of genetic and cardiovascular risk factors on the
RT   CADASIL phenotype.";
RL   Brain 127:2031-2038(2004).
RN   [25]
RP   VARIANTS CADASIL GLY-43; PHE-49; CYS-60; SER-65; TRP-76;
RP   77-GLN--CYS-82 DEL; 80-ASP--SER-84 DEL; ARG-87; TYR-87; CYS-90;
RP   PHE-93; TRP-106; TYR-108; CYS-110; PHE-117; PHE-123; CYS-133; TRP-134;
RP   CYS-141; SER-144; TYR-144; CYS-145; CYS-149; CYS-150; 153-ARG--155-CYS
RP   DEL; CYS-153; SER-155; CYS-169; ARG-174; TYR-174; CYS-182; ARG-183;
RP   SER-183; PHE-183; ARG-185; PHE-194; TYR-201; CYS-207; TYR-233;
RP   239-ASP--ASP-253 DEL; SER-240; ARG-245; TYR-260; CYS-332; CYS-335;
RP   CYS-337; SER-379; ARG-395; CYS-421; TYR-428; ARG-440; SER-446;
RP   TYR-484; TYR-495; ARG-511; TYR-549; CYS-558; CYS-985 AND TYR-1261.
RX   PubMed=15364702; DOI=10.1093/brain/awh282;
RA   Opherk C., Peters N., Herzog J., Luedtke R., Dichgans M.;
RT   "Long-term prognosis and causes of death in CADASIL: a retrospective
RT   study in 411 patients.";
RL   Brain 127:2533-2539(2004).
RN   [26]
RP   VARIANT CADASIL CYS-133.
RX   PubMed=15378071; DOI=10.1038/sj.ejhg.5201221;
RA   Mykkaenen K., Savontaus M.L., Juvonen V., Sistonen P., Tuisku S.,
RA   Tuominen S., Penttinen M., Lundkvist J., Viitanen M., Kalimo H.,
RA   Peoyhoenen M.;
RT   "Detection of the founder effect in Finnish CADASIL families.";
RL   Eur. J. Hum. Genet. 12:813-819(2004).
RN   [27]
RP   VARIANT CADASIL TRP-108.
RX   PubMed=15300988;
RA   Rojas-Marcos I., Encarnacion M., Martinez-Yelamos S., Ferrer I.,
RA   Arbizu T., Gil-Peralta A., Garcia-Lozano J.R.;
RT   "Gene symbol: NOTCH3. Disease: CADASIL.";
RL   Hum. Genet. 115:175-175(2004).
RN   [28]
RP   VARIANTS CADASIL GLY-43; PHE-49; CYS-60; SER-65; TRP-76;
RP   80-ASP--SER-84 DEL; ARG-87; CYS-90; PHE-93; TYR-108; CYS-110; PHE-117;
RP   PHE-123; CYS-133; TRP-134; CYS-141; SER-144; TYR-144; CYS-149;
RP   CYS-150; CYS-153; 153-ARG--CYS-155 DEL; CYS-169; ARG-174; TYR-174;
RP   CYS-182; SER-183; PHE-183; ARG-185; PHE-194; CYS-207; TYR-233;
RP   SER-240; ARG-245; TYR-260; 239-ASP--ASP-253 DEL; CYS-319; CYS-332;
RP   CYS-335; CYS-337; SER-379; ARG-395; CYS-421; TYR-428; ARG-440;
RP   PHE-484; TYR-495; ARG-511; TYR-549; CYS-558; CYS-728; SER-775; CYS-985
RP   AND TYR-1261.
RX   PubMed=16009764; DOI=10.1001/archneur.62.7.1091;
RA   Peters N., Opherk C., Bergmann T., Castro M., Herzog J., Dichgans M.;
RT   "Spectrum of mutations in biopsy-proven CADASIL: implications for
RT   diagnostic strategies.";
RL   Arch. Neurol. 62:1091-1094(2005).
RN   [29]
RP   VARIANT CADASIL CYS-118.
RX   PubMed=15818833;
RA   Soong B.W., Lee Y.-C., Lu Y.-C.;
RT   "Gene symbol: NOTCH3. Disease: cerebral autosomal dominant
RT   arteriopathy with subcortical infarcts and leukoencephalopathy.";
RL   Hum. Genet. 116:242-242(2005).
RN   [30]
RP   VARIANT BRAIN SMALL-VESSEL-DISEASE PRO-1515.
RX   PubMed=18273901; DOI=10.1002/humu.9527;
RA   Fouillade C., Chabriat H., Riant F., Mine M., Arnoud M., Magy L.,
RA   Bousser M.G., Tournier-Lasserve E., Joutel A.;
RT   "Activating NOTCH3 mutation in a patient with small-vessel-disease of
RT   the brain.";
RL   Hum. Mutat. 29:452-452(2008).
RN   [31]
RP   VARIANT IMF2 PRO-1519.
RX   PubMed=23731542; DOI=10.1016/j.ajhg.2013.04.024;
RA   Martignetti J.A., Tian L., Li D., Ramirez M.C., Camacho-Vanegas O.,
RA   Camacho S.C., Guo Y., Zand D.J., Bernstein A.M., Masur S.K., Kim C.E.,
RA   Otieno F.G., Hou C., Abdel-Magid N., Tweddale B., Metry D.,
RA   Fournet J.C., Papp E., McPherson E.W., Zabel C., Vaksmann G.,
RA   Morisot C., Keating B., Sleiman P.M., Cleveland J.A., Everman D.B.,
RA   Zackai E., Hakonarson H.;
RT   "Mutations in PDGFRB cause autosomal-dominant infantile
RT   myofibromatosis.";
RL   Am. J. Hum. Genet. 92:1001-1007(2013).
RN   [32]
RP   VARIANT CADASIL CYS-710.
RX   PubMed=24000151; DOI=10.1002/humu.22432;
RA   Rutten J.W., Boon E.M., Liem M.K., Dauwerse J.G., Pont M.J.,
RA   Vollebregt E., Maat-Kievit A.J., Ginjaar H.B., Lakeman P.,
RA   van Duinen S.G., Terwindt G.M., Lesnik Oberstein S.A.;
RT   "Hypomorphic NOTCH3 alleles do not cause CADASIL in humans.";
RL   Hum. Mutat. 34:1486-1489(2013).
CC   -!- FUNCTION: Functions as a receptor for membrane-bound ligands
CC       Jagged1, Jagged2 and Delta1 to regulate cell-fate determination.
CC       Upon ligand activation through the released notch intracellular
CC       domain (NICD) it forms a transcriptional activator complex with
CC       RBPJ/RBPSUH and activates genes of the enhancer of split locus.
CC       Affects the implementation of differentiation, proliferation and
CC       apoptotic programs (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Heterodimer of a C-terminal fragment N(TM) and a N-
CC       terminal fragment N(EC) which are probably linked by disulfide
CC       bonds (By similarity). Interacts with MAML1, MAML2 and MAML3 which
CC       act as transcriptional coactivators for NOTCH3. Interacts with
CC       PSMA1. Interacts with HIF1AN. {ECO:0000250,
CC       ECO:0000269|PubMed:11101851, ECO:0000269|PubMed:12370315,
CC       ECO:0000269|PubMed:17292860, ECO:0000269|PubMed:17573339}.
CC   -!- INTERACTION:
CC       Q9R1P4:Psma1 (xeno); NbExp=2; IntAct=EBI-1236377, EBI-991653;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein.
CC   -!- SUBCELLULAR LOCATION: Notch 3 intracellular domain: Nucleus.
CC       Note=Following proteolytical processing NICD is translocated to
CC       the nucleus.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed in fetal and adult
CC       tissues.
CC   -!- PTM: Synthesized in the endoplasmic reticulum as an inactive form
CC       which is proteolytically cleaved by a furin-like convertase in the
CC       trans-Golgi network before it reaches the plasma membrane to yield
CC       an active, ligand-accessible form. Cleavage results in a C-
CC       terminal fragment N(TM) and a N-terminal fragment N(EC). Following
CC       ligand binding, it is cleaved by TNF-alpha converting enzyme
CC       (TACE) to yield a membrane-associated intermediate fragment called
CC       notch extracellular truncation (NEXT). This fragment is then
CC       cleaved by presenilin dependent gamma-secretase to release a
CC       notch-derived peptide containing the intracellular domain (NICD)
CC       from the membrane (By similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylated. {ECO:0000250}.
CC   -!- PTM: Hydroxylated by HIF1AN. {ECO:0000269|PubMed:18299578}.
CC   -!- DISEASE: Cerebral arteriopathy with subcortical infarcts and
CC       leukoencephalopathy, autosomal dominant (CADASIL) [MIM:125310]: A
CC       cerebrovascular disease characterized by multiple subcortical
CC       infarcts, pseudobulbar palsy, dementia, and the presence of
CC       granular deposits in small cerebral arteries producing ischemic
CC       stroke. {ECO:0000269|PubMed:10227618, ECO:0000269|PubMed:10371548,
CC       ECO:0000269|PubMed:10802807, ECO:0000269|PubMed:10854111,
CC       ECO:0000269|PubMed:11058919, ECO:0000269|PubMed:11102981,
CC       ECO:0000269|PubMed:11559313, ECO:0000269|PubMed:11755616,
CC       ECO:0000269|PubMed:11810186, ECO:0000269|PubMed:12136071,
CC       ECO:0000269|PubMed:12146805, ECO:0000269|PubMed:12589106,
CC       ECO:0000269|PubMed:12810003, ECO:0000269|PubMed:15229130,
CC       ECO:0000269|PubMed:15300988, ECO:0000269|PubMed:15364702,
CC       ECO:0000269|PubMed:15378071, ECO:0000269|PubMed:15818833,
CC       ECO:0000269|PubMed:16009764, ECO:0000269|PubMed:24000151,
CC       ECO:0000269|PubMed:9388399}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Myofibromatosis, infantile 2 (IMF2) [MIM:615293]: A rare
CC       mesenchymal disorder characterized by the development of benign
CC       tumors in the skin, striated muscles, bones, and, more rarely,
CC       visceral organs. Subcutaneous or soft tissue nodules commonly
CC       involve the skin of the head, neck, and trunk. Skeletal and
CC       muscular lesions occur in about half of the patients. Lesions may
CC       be solitary or multicentric, and they may be present at birth or
CC       become apparent in early infancy or occasionally in adult life.
CC       Visceral lesions are associated with high morbidity and mortality.
CC       {ECO:0000269|PubMed:23731542}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the NOTCH family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 5 ANK repeats. {ECO:0000255|PROSITE-
CC       ProRule:PRU00023}.
CC   -!- SIMILARITY: Contains 34 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 3 LNR (Lin/Notch) repeats.
CC       {ECO:0000255|PROSITE-ProRule:PRU00525}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NOTCH3ID41557ch19p13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U97669; AAB91371.1; -; mRNA.
DR   EMBL; AF058900; AAC14346.1; -; Genomic_DNA.
DR   EMBL; AF058881; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058882; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058883; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058884; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058885; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058886; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058887; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058888; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058889; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058890; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058891; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058892; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058893; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058894; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058895; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058896; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058897; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058898; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AF058899; AAC14346.1; JOINED; Genomic_DNA.
DR   EMBL; AC004257; AAC04897.1; -; Genomic_DNA.
DR   EMBL; AC004663; AAC15789.1; -; Genomic_DNA.
DR   CCDS; CCDS12326.1; -.
DR   PIR; S78549; S78549.
DR   RefSeq; NP_000426.2; NM_000435.2.
DR   UniGene; Hs.8546; -.
DR   PDB; 4ZLP; X-ray; 2.48 A; A/B=1378-1640.
DR   PDBsum; 4ZLP; -.
DR   ProteinModelPortal; Q9UM47; -.
DR   SMR; Q9UM47; 391-505, 1385-1637, 1791-2026.
DR   BioGrid; 110916; 60.
DR   DIP; DIP-39827N; -.
DR   IntAct; Q9UM47; 14.
DR   MINT; MINT-2822317; -.
DR   STRING; 9606.ENSP00000263388; -.
DR   GuidetoPHARMACOLOGY; 2860; -.
DR   iPTMnet; Q9UM47; -.
DR   PhosphoSite; Q9UM47; -.
DR   BioMuta; NOTCH3; -.
DR   DMDM; 322510053; -.
DR   MaxQB; Q9UM47; -.
DR   PaxDb; Q9UM47; -.
DR   PRIDE; Q9UM47; -.
DR   Ensembl; ENST00000263388; ENSP00000263388; ENSG00000074181.
DR   GeneID; 4854; -.
DR   KEGG; hsa:4854; -.
DR   UCSC; uc002nan.3; human.
DR   CTD; 4854; -.
DR   GeneCards; NOTCH3; -.
DR   GeneReviews; NOTCH3; -.
DR   H-InvDB; HIX0040142; -.
DR   H-InvDB; HIX0174419; -.
DR   HGNC; HGNC:7883; NOTCH3.
DR   HPA; CAB005393; -.
DR   HPA; HPA044392; -.
DR   MalaCards; NOTCH3; -.
DR   MIM; 125310; phenotype.
DR   MIM; 600276; gene.
DR   MIM; 615293; phenotype.
DR   neXtProt; NX_Q9UM47; -.
DR   Orphanet; 136; CADASIL.
DR   Orphanet; 2591; Infantile myofibromatosis.
DR   PharmGKB; PA31685; -.
DR   eggNOG; ENOG410IR7G; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   GeneTree; ENSGT00810000125346; -.
DR   HOGENOM; HOG000234369; -.
DR   HOVERGEN; HBG052650; -.
DR   InParanoid; Q9UM47; -.
DR   KO; K02599; -.
DR   OMA; ADHFADG; -.
DR   OrthoDB; EOG7992RD; -.
DR   PhylomeDB; Q9UM47; -.
DR   TreeFam; TF351641; -.
DR   Reactome; R-HSA-1912399; Pre-NOTCH Processing in the Endoplasmic Reticulum.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-1912420; Pre-NOTCH Processing in Golgi.
DR   Reactome; R-HSA-1980148; Signaling by NOTCH3.
DR   Reactome; R-HSA-350054; Notch-HLH transcription pathway.
DR   SignaLink; Q9UM47; -.
DR   ChiTaRS; NOTCH3; human.
DR   GeneWiki; Notch_3; -.
DR   GenomeRNAi; 4854; -.
DR   NextBio; 18698; -.
DR   PRO; PR:Q9UM47; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; Q9UM47; -.
DR   CleanEx; HS_NOTCH3; -.
DR   ExpressionAtlas; Q9UM47; baseline and differential.
DR   Genevisible; Q9UM47; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0048844; P:artery morphogenesis; IEA:Ensembl.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0010467; P:gene expression; TAS:Reactome.
DR   GO; GO:0072104; P:glomerular capillary formation; IEA:Ensembl.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0048663; P:neuron fate commitment; IEA:Ensembl.
DR   GO; GO:0007220; P:Notch receptor processing; TAS:Reactome.
DR   GO; GO:0007219; P:Notch signaling pathway; TAS:Reactome.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   Gene3D; 1.25.40.20; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR024600; DUF3454_notch.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR022331; Notch_3.
DR   InterPro; IPR000800; Notch_dom.
DR   InterPro; IPR010660; Notch_NOD_dom.
DR   InterPro; IPR011656; Notch_NODP_dom.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF11936; DUF3454; 1.
DR   Pfam; PF00008; EGF; 19.
DR   Pfam; PF07645; EGF_CA; 7.
DR   Pfam; PF12661; hEGF; 2.
DR   Pfam; PF06816; NOD; 1.
DR   Pfam; PF07684; NODP; 1.
DR   Pfam; PF00066; Notch; 3.
DR   PRINTS; PR01452; LNOTCHREPEAT.
DR   PRINTS; PR01986; NOTCH3.
DR   SMART; SM00248; ANK; 6.
DR   SMART; SM00181; EGF; 15.
DR   SMART; SM00179; EGF_CA; 19.
DR   SMART; SM00004; NL; 3.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF57184; SSF57184; 4.
DR   SUPFAM; SSF90193; SSF90193; 3.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 4.
DR   PROSITE; PS00010; ASX_HYDROXYL; 18.
DR   PROSITE; PS00022; EGF_1; 33.
DR   PROSITE; PS01186; EGF_2; 25.
DR   PROSITE; PS50026; EGF_3; 34.
DR   PROSITE; PS01187; EGF_CA; 16.
DR   PROSITE; PS50258; LNR; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; ANK repeat; Cell membrane; Complete proteome;
KW   Developmental protein; Differentiation; Disease mutation;
KW   Disulfide bond; EGF-like domain; Glycoprotein; Membrane;
KW   Notch signaling pathway; Nucleus; Phosphoprotein; Polymorphism;
KW   Receptor; Reference proteome; Repeat; Signal; Transcription;
KW   Transcription regulation; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     39       {ECO:0000255}.
FT   CHAIN        40   2321       Neurogenic locus notch homolog protein 3.
FT                                /FTId=PRO_0000007692.
FT   CHAIN      1629   2321       Notch 3 extracellular truncation.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000007693.
FT   CHAIN      1662   2321       Notch 3 intracellular domain.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000007694.
FT   TOPO_DOM     40   1643       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1644   1664       Helical. {ECO:0000255}.
FT   TOPO_DOM   1665   2321       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       40     77       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN       78    118       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      119    156       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      158    195       EGF-like 4; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      197    234       EGF-like 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      236    272       EGF-like 6; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      274    312       EGF-like 7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      314    350       EGF-like 8; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      351    389       EGF-like 9. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      391    429       EGF-like 10; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      431    467       EGF-like 11; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      469    505       EGF-like 12; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      507    543       EGF-like 13; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      545    580       EGF-like 14; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      582    618       EGF-like 15; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      620    655       EGF-like 16; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      657    693       EGF-like 17; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      695    730       EGF-like 18. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      734    770       EGF-like 19. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      771    808       EGF-like 20. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      810    847       EGF-like 21; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      849    885       EGF-like 22; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      887    922       EGF-like 23; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      924    960       EGF-like 24. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      962    998       EGF-like 25. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1000   1034       EGF-like 26. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1047   1082       EGF-like 27. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1084   1120       EGF-like 28. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1122   1158       EGF-like 29; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1160   1203       EGF-like 30; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1205   1244       EGF-like 31. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1246   1287       EGF-like 32. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1289   1325       EGF-like 33. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1335   1373       EGF-like 34. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     1387   1427       LNR 1.
FT   REPEAT     1428   1458       LNR 2.
FT   REPEAT     1467   1505       LNR 3.
FT   REPEAT     1838   1867       ANK 1.
FT   REPEAT     1871   1901       ANK 2.
FT   REPEAT     1905   1934       ANK 3.
FT   REPEAT     1938   1967       ANK 4.
FT   REPEAT     1971   2000       ANK 5.
FT   SITE       1571   1572       Cleavage; by furin-like protease.
FT                                {ECO:0000250}.
FT   CARBOHYD   1179   1179       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1336   1336       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1438   1438       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     43     55       {ECO:0000250}.
FT   DISULFID     49     65       {ECO:0000250}.
FT   DISULFID     67     76       {ECO:0000250}.
FT   DISULFID     82     93       {ECO:0000250}.
FT   DISULFID     87    106       {ECO:0000250}.
FT   DISULFID    108    117       {ECO:0000250}.
FT   DISULFID    123    134       {ECO:0000250}.
FT   DISULFID    128    144       {ECO:0000250}.
FT   DISULFID    146    155       {ECO:0000250}.
FT   DISULFID    162    174       {ECO:0000250}.
FT   DISULFID    168    183       {ECO:0000250}.
FT   DISULFID    185    194       {ECO:0000250}.
FT   DISULFID    201    212       {ECO:0000250}.
FT   DISULFID    206    222       {ECO:0000250}.
FT   DISULFID    224    233       {ECO:0000250}.
FT   DISULFID    240    251       {ECO:0000250}.
FT   DISULFID    245    260       {ECO:0000250}.
FT   DISULFID    262    271       {ECO:0000250}.
FT   DISULFID    278    291       {ECO:0000250}.
FT   DISULFID    285    300       {ECO:0000250}.
FT   DISULFID    302    311       {ECO:0000250}.
FT   DISULFID    318    329       {ECO:0000250}.
FT   DISULFID    323    338       {ECO:0000250}.
FT   DISULFID    340    349       {ECO:0000250}.
FT   DISULFID    355    366       {ECO:0000250}.
FT   DISULFID    360    377       {ECO:0000250}.
FT   DISULFID    379    388       {ECO:0000250}.
FT   DISULFID    395    408       {ECO:0000250}.
FT   DISULFID    402    417       {ECO:0000250}.
FT   DISULFID    419    428       {ECO:0000250}.
FT   DISULFID    435    446       {ECO:0000250}.
FT   DISULFID    440    455       {ECO:0000250}.
FT   DISULFID    457    466       {ECO:0000250}.
FT   DISULFID    473    484       {ECO:0000250}.
FT   DISULFID    478    493       {ECO:0000250}.
FT   DISULFID    495    504       {ECO:0000250}.
FT   DISULFID    511    522       {ECO:0000250}.
FT   DISULFID    516    531       {ECO:0000250}.
FT   DISULFID    533    542       {ECO:0000250}.
FT   DISULFID    549    559       {ECO:0000250}.
FT   DISULFID    554    568       {ECO:0000250}.
FT   DISULFID    570    579       {ECO:0000250}.
FT   DISULFID    586    597       {ECO:0000250}.
FT   DISULFID    591    606       {ECO:0000250}.
FT   DISULFID    608    617       {ECO:0000250}.
FT   DISULFID    624    634       {ECO:0000250}.
FT   DISULFID    629    643       {ECO:0000250}.
FT   DISULFID    645    654       {ECO:0000250}.
FT   DISULFID    661    672       {ECO:0000250}.
FT   DISULFID    666    681       {ECO:0000250}.
FT   DISULFID    683    692       {ECO:0000250}.
FT   DISULFID    699    709       {ECO:0000250}.
FT   DISULFID    704    718       {ECO:0000250}.
FT   DISULFID    720    729       {ECO:0000250}.
FT   DISULFID    738    749       {ECO:0000250}.
FT   DISULFID    743    758       {ECO:0000250}.
FT   DISULFID    760    769       {ECO:0000250}.
FT   DISULFID    775    786       {ECO:0000250}.
FT   DISULFID    780    796       {ECO:0000250}.
FT   DISULFID    798    807       {ECO:0000250}.
FT   DISULFID    814    826       {ECO:0000250}.
FT   DISULFID    820    835       {ECO:0000250}.
FT   DISULFID    837    846       {ECO:0000250}.
FT   DISULFID    853    864       {ECO:0000250}.
FT   DISULFID    858    873       {ECO:0000250}.
FT   DISULFID    875    884       {ECO:0000250}.
FT   DISULFID    891    901       {ECO:0000250}.
FT   DISULFID    896    910       {ECO:0000250}.
FT   DISULFID    912    921       {ECO:0000250}.
FT   DISULFID    928    939       {ECO:0000250}.
FT   DISULFID    933    948       {ECO:0000250}.
FT   DISULFID    950    959       {ECO:0000250}.
FT   DISULFID    966    977       {ECO:0000250}.
FT   DISULFID    971    986       {ECO:0000250}.
FT   DISULFID    988    997       {ECO:0000250}.
FT   DISULFID   1004   1015       {ECO:0000250}.
FT   DISULFID   1009   1022       {ECO:0000250}.
FT   DISULFID   1024   1033       {ECO:0000250}.
FT   DISULFID   1040   1061       {ECO:0000250}.
FT   DISULFID   1055   1070       {ECO:0000250}.
FT   DISULFID   1072   1081       {ECO:0000250}.
FT   DISULFID   1088   1099       {ECO:0000250}.
FT   DISULFID   1093   1108       {ECO:0000250}.
FT   DISULFID   1110   1119       {ECO:0000250}.
FT   DISULFID   1126   1137       {ECO:0000250}.
FT   DISULFID   1131   1146       {ECO:0000250}.
FT   DISULFID   1148   1157       {ECO:0000250}.
FT   DISULFID   1164   1182       {ECO:0000250}.
FT   DISULFID   1176   1191       {ECO:0000250}.
FT   DISULFID   1193   1202       {ECO:0000250}.
FT   DISULFID   1209   1222       {ECO:0000250}.
FT   DISULFID   1214   1232       {ECO:0000250}.
FT   DISULFID   1234   1243       {ECO:0000250}.
FT   DISULFID   1250   1261       {ECO:0000250}.
FT   DISULFID   1255   1275       {ECO:0000250}.
FT   DISULFID   1277   1286       {ECO:0000250}.
FT   DISULFID   1293   1304       {ECO:0000250}.
FT   DISULFID   1298   1313       {ECO:0000250}.
FT   DISULFID   1315   1324       {ECO:0000250}.
FT   DISULFID   1339   1350       {ECO:0000250}.
FT   DISULFID   1344   1361       {ECO:0000250}.
FT   DISULFID   1363   1372       {ECO:0000250}.
FT   DISULFID   1387   1410       {ECO:0000250}.
FT   DISULFID   1392   1405       {ECO:0000250}.
FT   DISULFID   1401   1417       {ECO:0000250}.
FT   DISULFID   1428   1451       {ECO:0000250}.
FT   DISULFID   1433   1446       {ECO:0000250}.
FT   DISULFID   1442   1458       {ECO:0000250}.
FT   DISULFID   1467   1493       {ECO:0000250}.
FT   DISULFID   1475   1488       {ECO:0000250}.
FT   DISULFID   1484   1500       {ECO:0000250}.
FT   VARIANT      43     43       C -> G (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044230.
FT   VARIANT      49     49       C -> F (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044231.
FT   VARIANT      49     49       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012871.
FT   VARIANT      54     54       R -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981}.
FT                                /FTId=VAR_044232.
FT   VARIANT      60     60       S -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044233.
FT   VARIANT      65     65       C -> S (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044234.
FT   VARIANT      67     67       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:12589106}.
FT                                /FTId=VAR_044235.
FT   VARIANT      71     71       W -> C (in CADASIL; dbSNP:rs28937321).
FT                                {ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012872.
FT   VARIANT      76     76       C -> R (in CADASIL).
FT                                {ECO:0000269|PubMed:12146805,
FT                                ECO:0000269|PubMed:15229130}.
FT                                /FTId=VAR_044236.
FT   VARIANT      76     76       C -> W (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044237.
FT   VARIANT      77     82       Missing (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702}.
FT                                /FTId=VAR_044238.
FT   VARIANT      80     84       Missing (in CADASIL).
FT                                {ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044239.
FT   VARIANT      87     87       C -> R (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044240.
FT   VARIANT      87     87       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702}.
FT                                /FTId=VAR_044241.
FT   VARIANT      90     90       R -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:10227618,
FT                                ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:12810003,
FT                                ECO:0000269|PubMed:15229130,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012873.
FT   VARIANT      93     93       C -> F (in CADASIL).
FT                                {ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044242.
FT   VARIANT      93     93       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:12146805}.
FT                                /FTId=VAR_044243.
FT   VARIANT     106    106       C -> W (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702}.
FT                                /FTId=VAR_044244.
FT   VARIANT     108    108       C -> W (in CADASIL).
FT                                {ECO:0000269|PubMed:15300988}.
FT                                /FTId=VAR_044245.
FT   VARIANT     108    108       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044246.
FT   VARIANT     110    110       R -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:11755616,
FT                                ECO:0000269|PubMed:15229130,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012874.
FT   VARIANT     114    120       Missing (in CADASIL).
FT                                {ECO:0000269|PubMed:10802807,
FT                                ECO:0000269|PubMed:11102981}.
FT                                /FTId=VAR_012875.
FT   VARIANT     117    117       C -> F (in CADASIL).
FT                                {ECO:0000269|PubMed:10227618,
FT                                ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044247.
FT   VARIANT     118    118       S -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:15818833}.
FT                                /FTId=VAR_044248.
FT   VARIANT     123    123       C -> F (in CADASIL).
FT                                {ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044249.
FT   VARIANT     123    123       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981}.
FT                                /FTId=VAR_044250.
FT   VARIANT     128    128       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:12146805}.
FT                                /FTId=VAR_044251.
FT   VARIANT     133    133       R -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:10227618,
FT                                ECO:0000269|PubMed:10371548,
FT                                ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:11755616,
FT                                ECO:0000269|PubMed:12810003,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:15378071,
FT                                ECO:0000269|PubMed:16009764,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012876.
FT   VARIANT     134    134       C -> W (in CADASIL).
FT                                {ECO:0000269|PubMed:11755616,
FT                                ECO:0000269|PubMed:11810186,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044252.
FT   VARIANT     141    141       R -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:10227618,
FT                                ECO:0000269|PubMed:10371548,
FT                                ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:11755616,
FT                                ECO:0000269|PubMed:15229130,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012877.
FT   VARIANT     142    142       F -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:12146805}.
FT                                /FTId=VAR_044253.
FT   VARIANT     144    144       C -> F (in CADASIL).
FT                                {ECO:0000269|PubMed:11058919}.
FT                                /FTId=VAR_044254.
FT   VARIANT     144    144       C -> S (in CADASIL).
FT                                {ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044255.
FT   VARIANT     144    144       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044256.
FT   VARIANT     145    145       S -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702}.
FT                                /FTId=VAR_044257.
FT   VARIANT     146    146       C -> R (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012878.
FT   VARIANT     149    149       G -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044258.
FT   VARIANT     150    150       Y -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044259.
FT   VARIANT     153    155       Missing (in CADASIL).
FT                                {ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044260.
FT   VARIANT     153    153       R -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:10371548,
FT                                ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:11755616,
FT                                ECO:0000269|PubMed:15229130,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012879.
FT   VARIANT     155    155       C -> S (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702}.
FT                                /FTId=VAR_044261.
FT   VARIANT     162    162       C -> S (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981}.
FT                                /FTId=VAR_044262.
FT   VARIANT     169    169       R -> C (in CADASIL; dbSNP:rs28933696).
FT                                {ECO:0000269|PubMed:10227618,
FT                                ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:12810003,
FT                                ECO:0000269|PubMed:15229130,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012880.
FT   VARIANT     170    170       H -> R (in dbSNP:rs147373451).
FT                                {ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012881.
FT   VARIANT     171    171       G -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012882.
FT   VARIANT     174    174       C -> F (in CADASIL).
FT                                {ECO:0000269|PubMed:12810003}.
FT                                /FTId=VAR_044263.
FT   VARIANT     174    174       C -> R (in CADASIL).
FT                                {ECO:0000269|PubMed:12810003,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044264.
FT   VARIANT     174    174       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:10227618,
FT                                ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044265.
FT   VARIANT     180    180       S -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981}.
FT                                /FTId=VAR_044266.
FT   VARIANT     182    182       R -> C (in CADASIL; dbSNP:rs28933697).
FT                                {ECO:0000269|PubMed:10227618,
FT                                ECO:0000269|PubMed:10371548,
FT                                ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:11755616,
FT                                ECO:0000269|PubMed:15229130,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012883.
FT   VARIANT     183    183       C -> F (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044267.
FT   VARIANT     183    183       C -> R (in CADASIL).
FT                                {ECO:0000269|PubMed:10227618,
FT                                ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:15229130,
FT                                ECO:0000269|PubMed:15364702}.
FT                                /FTId=VAR_044268.
FT   VARIANT     183    183       C -> S (in CADASIL).
FT                                {ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044269.
FT   VARIANT     185    185       C -> G (in CADASIL).
FT                                {ECO:0000269|PubMed:11755616}.
FT                                /FTId=VAR_044270.
FT   VARIANT     185    185       C -> R (in CADASIL).
FT                                {ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012884.
FT   VARIANT     189    189       Y -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:15229130}.
FT                                /FTId=VAR_044271.
FT   VARIANT     194    194       C -> F (in CADASIL).
FT                                {ECO:0000269|PubMed:10854111,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044272.
FT   VARIANT     194    194       C -> R (in CADASIL).
FT                                {ECO:0000269|PubMed:12146805}.
FT                                /FTId=VAR_044273.
FT   VARIANT     194    194       C -> S (in CADASIL).
FT                                {ECO:0000269|PubMed:15229130}.
FT                                /FTId=VAR_044274.
FT   VARIANT     194    194       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981}.
FT                                /FTId=VAR_044275.
FT   VARIANT     201    201       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702}.
FT                                /FTId=VAR_044276.
FT   VARIANT     206    206       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981}.
FT                                /FTId=VAR_044277.
FT   VARIANT     207    207       R -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:10371548,
FT                                ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:11755616,
FT                                ECO:0000269|PubMed:15229130,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044278.
FT   VARIANT     212    212       C -> S (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:11755616,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012885.
FT   VARIANT     213    213       R -> K (in CADASIL).
FT                                {ECO:0000269|PubMed:12810003}.
FT                                /FTId=VAR_044279.
FT   VARIANT     222    222       C -> G (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:11755616,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012886.
FT   VARIANT     222    222       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:12146805}.
FT                                /FTId=VAR_044280.
FT   VARIANT     224    224       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012887.
FT   VARIANT     233    233       C -> S (in CADASIL).
FT                                {ECO:0000269|PubMed:12146805}.
FT                                /FTId=VAR_044281.
FT   VARIANT     233    233       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044282.
FT   VARIANT     239    253       Missing (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044283.
FT   VARIANT     240    240       C -> S (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044284.
FT   VARIANT     245    245       C -> R (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044285.
FT   VARIANT     251    251       C -> R (in CADASIL).
FT                                {ECO:0000269|PubMed:12146805,
FT                                ECO:0000269|PubMed:15229130}.
FT                                /FTId=VAR_044286.
FT   VARIANT     258    258       Y -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012888.
FT   VARIANT     260    260       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044287.
FT   VARIANT     319    319       A -> C (in CADASIL; requires 2 nucleotide
FT                                substitutions).
FT                                {ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044288.
FT   VARIANT     332    332       R -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:11559313,
FT                                ECO:0000269|PubMed:15229130,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044289.
FT   VARIANT     335    335       S -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044290.
FT   VARIANT     337    337       Y -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044291.
FT   VARIANT     379    379       C -> S (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044292.
FT   VARIANT     395    395       C -> R (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044293.
FT   VARIANT     420    420       G -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:12146805}.
FT                                /FTId=VAR_044294.
FT   VARIANT     421    421       R -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044295.
FT   VARIANT     428    428       C -> S (in CADASIL).
FT                                {ECO:0000269|PubMed:11755616}.
FT                                /FTId=VAR_044296.
FT   VARIANT     428    428       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044297.
FT   VARIANT     440    440       C -> G (in CADASIL).
FT                                {ECO:0000269|PubMed:12146805,
FT                                ECO:0000269|PubMed:15229130}.
FT                                /FTId=VAR_044298.
FT   VARIANT     440    440       C -> R (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044299.
FT   VARIANT     446    446       C -> S (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702}.
FT                                /FTId=VAR_044300.
FT   VARIANT     449    449       R -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:12146805}.
FT                                /FTId=VAR_044301.
FT   VARIANT     455    455       C -> R (in CADASIL; dbSNP:rs28933698).
FT                                {ECO:0000269|PubMed:12136071}.
FT                                /FTId=VAR_044302.
FT   VARIANT     484    484       C -> F (in CADASIL).
FT                                {ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044303.
FT   VARIANT     484    484       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702}.
FT                                /FTId=VAR_044304.
FT   VARIANT     495    495       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044305.
FT   VARIANT     496    496       P -> L (in dbSNP:rs11670799).
FT                                {ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012889.
FT   VARIANT     511    511       C -> R (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044306.
FT   VARIANT     542    542       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012890.
FT   VARIANT     544    544       R -> C (in CADASIL; dbSNP:rs201118034).
FT                                {ECO:0000269|PubMed:10371548}.
FT                                /FTId=VAR_044307.
FT   VARIANT     549    549       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044308.
FT   VARIANT     558    558       R -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:11755616,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012891.
FT   VARIANT     578    578       R -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012892.
FT   VARIANT     607    607       R -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:15229130}.
FT                                /FTId=VAR_044309.
FT   VARIANT     710    710       Y -> C (in CADASIL; found in a compound
FT                                heterozygote also carrying an intragenic
FT                                frameshift deletion).
FT                                {ECO:0000269|PubMed:24000151}.
FT                                /FTId=VAR_072080.
FT   VARIANT     728    728       R -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:16009764,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012893.
FT   VARIANT     775    775       C -> S (in CADASIL).
FT                                {ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044310.
FT   VARIANT     953    953       G -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:12146805,
FT                                ECO:0000269|PubMed:15229130}.
FT                                /FTId=VAR_044311.
FT   VARIANT     984    984       F -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981}.
FT                                /FTId=VAR_044312.
FT   VARIANT     985    985       R -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:11755616,
FT                                ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012894.
FT   VARIANT    1006   1006       R -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012895.
FT   VARIANT    1015   1015       C -> R (in CADASIL).
FT                                {ECO:0000269|PubMed:10371548}.
FT                                /FTId=VAR_044313.
FT   VARIANT    1020   1020       A -> P (in dbSNP:rs35769976).
FT                                /FTId=VAR_044314.
FT   VARIANT    1021   1021       Y -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:12146805}.
FT                                /FTId=VAR_044315.
FT   VARIANT    1031   1031       R -> C (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012896.
FT   VARIANT    1063   1063       D -> C (in CADASIL; requires 2 nucleotide
FT                                substitutions).
FT                                {ECO:0000269|PubMed:11755616}.
FT                                /FTId=VAR_044316.
FT   VARIANT    1133   1133       H -> Q (in dbSNP:rs112197217).
FT                                {ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012897.
FT   VARIANT    1183   1183       V -> M (in dbSNP:rs10408676).
FT                                {ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012898.
FT   VARIANT    1231   1231       R -> C (in CADASIL; dbSNP:rs201680145).
FT                                {ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:15229130,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012899.
FT   VARIANT    1261   1261       C -> R (in CADASIL).
FT                                {ECO:0000269|PubMed:11102981,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012900.
FT   VARIANT    1261   1261       C -> Y (in CADASIL).
FT                                {ECO:0000269|PubMed:15364702,
FT                                ECO:0000269|PubMed:16009764}.
FT                                /FTId=VAR_044317.
FT   VARIANT    1515   1515       L -> P (in brain small-vessel-disease;
FT                                exhibits increased NOTCH3 signaling in a
FT                                ligand-independent fashion).
FT                                {ECO:0000269|PubMed:18273901}.
FT                                /FTId=VAR_044318.
FT   VARIANT    1519   1519       L -> P (in IMF2).
FT                                {ECO:0000269|PubMed:23731542}.
FT                                /FTId=VAR_069927.
FT   VARIANT    2223   2223       A -> V (in dbSNP:rs1044009).
FT                                {ECO:0000269|PubMed:8878478,
FT                                ECO:0000269|PubMed:9388399}.
FT                                /FTId=VAR_012901.
FT   HELIX      1390   1395       {ECO:0000244|PDB:4ZLP}.
FT   STRAND     1398   1400       {ECO:0000244|PDB:4ZLP}.
FT   HELIX      1403   1405       {ECO:0000244|PDB:4ZLP}.
FT   HELIX      1408   1410       {ECO:0000244|PDB:4ZLP}.
FT   HELIX      1411   1414       {ECO:0000244|PDB:4ZLP}.
FT   TURN       1415   1420       {ECO:0000244|PDB:4ZLP}.
FT   TURN       1424   1427       {ECO:0000244|PDB:4ZLP}.
FT   HELIX      1433   1436       {ECO:0000244|PDB:4ZLP}.
FT   STRAND     1439   1441       {ECO:0000244|PDB:4ZLP}.
FT   HELIX      1444   1446       {ECO:0000244|PDB:4ZLP}.
FT   HELIX      1449   1456       {ECO:0000244|PDB:4ZLP}.
FT   TURN       1457   1459       {ECO:0000244|PDB:4ZLP}.
FT   HELIX      1462   1464       {ECO:0000244|PDB:4ZLP}.
FT   HELIX      1469   1478       {ECO:0000244|PDB:4ZLP}.
FT   STRAND     1481   1483       {ECO:0000244|PDB:4ZLP}.
FT   HELIX      1486   1488       {ECO:0000244|PDB:4ZLP}.
FT   TURN       1491   1494       {ECO:0000244|PDB:4ZLP}.
FT   HELIX      1495   1498       {ECO:0000244|PDB:4ZLP}.
FT   STRAND     1510   1519       {ECO:0000244|PDB:4ZLP}.
FT   HELIX      1521   1525       {ECO:0000244|PDB:4ZLP}.
FT   HELIX      1528   1539       {ECO:0000244|PDB:4ZLP}.
FT   STRAND     1541   1545       {ECO:0000244|PDB:4ZLP}.
FT   STRAND     1555   1559       {ECO:0000244|PDB:4ZLP}.
FT   STRAND     1577   1587       {ECO:0000244|PDB:4ZLP}.
FT   TURN       1595   1597       {ECO:0000244|PDB:4ZLP}.
FT   HELIX      1604   1616       {ECO:0000244|PDB:4ZLP}.
FT   STRAND     1626   1632       {ECO:0000244|PDB:4ZLP}.
SQ   SEQUENCE   2321 AA;  243631 MW;  3E70EC12A59CD638 CRC64;
     MGPGARGRRR RRRPMSPPPP PPPVRALPLL LLLAGPGAAA PPCLDGSPCA NGGRCTQLPS
     REAACLCPPG WVGERCQLED PCHSGPCAGR GVCQSSVVAG TARFSCRCPR GFRGPDCSLP
     DPCLSSPCAH GARCSVGPDG RFLCSCPPGY QGRSCRSDVD ECRVGEPCRH GGTCLNTPGS
     FRCQCPAGYT GPLCENPAVP CAPSPCRNGG TCRQSGDLTY DCACLPGFEG QNCEVNVDDC
     PGHRCLNGGT CVDGVNTYNC QCPPEWTGQF CTEDVDECQL QPNACHNGGT CFNTLGGHSC
     VCVNGWTGES CSQNIDDCAT AVCFHGATCH DRVASFYCAC PMGKTGLLCH LDDACVSNPC
     HEDAICDTNP VNGRAICTCP PGFTGGACDQ DVDECSIGAN PCEHLGRCVN TQGSFLCQCG
     RGYTGPRCET DVNECLSGPC RNQATCLDRI GQFTCICMAG FTGTYCEVDI DECQSSPCVN
     GGVCKDRVNG FSCTCPSGFS GSTCQLDVDE CASTPCRNGA KCVDQPDGYE CRCAEGFEGT
     LCDRNVDDCS PDPCHHGRCV DGIASFSCAC APGYTGTRCE SQVDECRSQP CRHGGKCLDL
     VDKYLCRCPS GTTGVNCEVN IDDCASNPCT FGVCRDGINR YDCVCQPGFT GPLCNVEINE
     CASSPCGEGG SCVDGENGFR CLCPPGSLPP LCLPPSHPCA HEPCSHGICY DAPGGFRCVC
     EPGWSGPRCS QSLARDACES QPCRAGGTCS SDGMGFHCTC PPGVQGRQCE LLSPCTPNPC
     EHGGRCESAP GQLPVCSCPQ GWQGPRCQQD VDECAGPAPC GPHGICTNLA GSFSCTCHGG
     YTGPSCDQDI NDCDPNPCLN GGSCQDGVGS FSCSCLPGFA GPRCARDVDE CLSNPCGPGT
     CTDHVASFTC TCPPGYGGFH CEQDLPDCSP SSCFNGGTCV DGVNSFSCLC RPGYTGAHCQ
     HEADPCLSRP CLHGGVCSAA HPGFRCTCLE SFTGPQCQTL VDWCSRQPCQ NGGRCVQTGA
     YCLCPPGWSG RLCDIRSLPC REAAAQIGVR LEQLCQAGGQ CVDEDSSHYC VCPEGRTGSH
     CEQEVDPCLA QPCQHGGTCR GYMGGYMCEC LPGYNGDNCE DDVDECASQP CQHGGSCIDL
     VARYLCSCPP GTLGVLCEIN EDDCGPGPPL DSGPRCLHNG TCVDLVGGFR CTCPPGYTGL
     RCEADINECR SGACHAAHTR DCLQDPGGGF RCLCHAGFSG PRCQTVLSPC ESQPCQHGGQ
     CRPSPGPGGG LTFTCHCAQP FWGPRCERVA RSCRELQCPV GVPCQQTPRG PRCACPPGLS
     GPSCRSFPGS PPGASNASCA AAPCLHGGSC RPAPLAPFFR CACAQGWTGP RCEAPAAAPE
     VSEEPRCPRA ACQAKRGDQR CDRECNSPGC GWDGGDCSLS VGDPWRQCEA LQCWRLFNNS
     RCDPACSSPA CLYDNFDCHA GGRERTCNPV YEKYCADHFA DGRCDQGCNT EECGWDGLDC
     ASEVPALLAR GVLVLTVLLP PEELLRSSAD FLQRLSAILR TSLRFRLDAH GQAMVFPYHR
     PSPGSEPRAR RELAPEVIGS VVMLEIDNRL CLQSPENDHC FPDAQSAADY LGALSAVERL
     DFPYPLRDVR GEPLEPPEPS VPLLPLLVAG AVLLLVILVL GVMVARRKRE HSTLWFPEGF
     SLHKDVASGH KGRREPVGQD ALGMKNMAKG ESLMGEVATD WMDTECPEAK RLKVEEPGMG
     AEEAVDCRQW TQHHLVAADI RVAPAMALTP PQGDADADGM DVNVRGPDGF TPLMLASFCG
     GALEPMPTEE DEADDTSASI ISDLICQGAQ LGARTDRTGE TALHLAARYA RADAAKRLLD
     AGADTNAQDH SGRTPLHTAV TADAQGVFQI LIRNRSTDLD ARMADGSTAL ILAARLAVEG
     MVEELIASHA DVNAVDELGK SALHWAAAVN NVEATLALLK NGANKDMQDS KEETPLFLAA
     REGSYEAAKL LLDHFANREI TDHLDRLPRD VAQERLHQDI VRLLDQPSGP RSPPGPHGLG
     PLLCPPGAFL PGLKAAQSGS KKSRRPPGKA GLGPQGPRGR GKKLTLACPG PLADSSVTLS
     PVDSLDSPRP FGGPPASPGG FPLEGPYAAA TATAVSLAQL GGPGRAGLGR QPPGGCVLSL
     GLLNPVAVPL DWARLPPPAP PGPSFLLPLA PGPQLLNPGT PVSPQERPPP YLAVPGHGEE
     YPAAGAHSSP PKARFLRVPS EHPYLTPSPE SPEHWASPSP PSLSDWSEST PSPATATGAM
     ATTTGALPAQ PLPLSVPSSL AQAQTQLGPQ PEVTPKRQVL A
//
ID   VGFR2_MOUSE             Reviewed;        1367 AA.
AC   P35918; C5H7S5;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   20-JAN-2016, entry version 165.
DE   RecName: Full=Vascular endothelial growth factor receptor 2;
DE            Short=VEGFR-2;
DE            EC=2.7.10.1;
DE   AltName: Full=Fetal liver kinase 1;
DE            Short=FLK-1;
DE   AltName: Full=Kinase NYK;
DE   AltName: Full=Protein-tyrosine kinase receptor flk-1;
DE   AltName: CD_antigen=CD309;
DE   Flags: Precursor;
GN   Name=Kdr; Synonyms=Flk-1, Flk1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH VEGFA.
RC   STRAIN=BALB/cJ; TISSUE=Embryo;
RX   PubMed=7681362; DOI=10.1016/0092-8674(93)90573-9;
RA   Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R.,
RA   Mueller N.P.H., Risau W., Ullrich A.;
RT   "High affinity VEGF binding and developmental expression suggest Flk-1
RT   as a major regulator of vasculogenesis and angiogenesis.";
RL   Cell 72:835-846(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   STRAIN=C3H/He; TISSUE=Fetal liver;
RX   PubMed=1717995; DOI=10.1073/pnas.88.20.9026;
RA   Mathews W., Jordan C.T., Gavin M., Jenkins N.A., Copeland N.G.,
RA   Lemishcka I.R.;
RT   "A receptor tyrosine kinase cDNA isolated from a population of
RT   enriched primitive hematopoietic cells and exhibiting close genetic
RT   linkage to c-kit.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:9026-9030(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RX   PubMed=8423988;
RA   Oelrichs R.B., Reid H.H., Bernard O., Ziemiecki A., Wilks A.F.;
RT   "NYK/FLK-1: a putative receptor protein tyrosine kinase isolated from
RT   E10 embryonic neuroepithelium is expressed in endothelial cells of the
RT   developing embryo.";
RL   Oncogene 8:11-18(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), INTERACTION WITH VEGFC,
RP   FUNCTION IN INHIBITING VEGFC SIGNALING, AND SUBCELLULAR LOCATION.
RC   STRAIN=C57BL/6J;
RX   PubMed=19668192; DOI=10.1038/nm.2018;
RA   Albuquerque R.J., Hayashi T., Cho W.G., Kleinman M.E., Dridi S.,
RA   Takeda A., Baffi J.Z., Yamada K., Kaneko H., Green M.G., Chappell J.,
RA   Wilting J., Weich H.A., Yamagami S., Amano S., Mizuki N.,
RA   Alexander J.S., Peterson M.L., Brekken R.A., Hirashima M., Capoor S.,
RA   Usui T., Ambati B.K., Ambati J.;
RT   "Alternatively spliced vascular endothelial growth factor receptor-2
RT   is an essential endogenous inhibitor of lymphatic vessel growth.";
RL   Nat. Med. 15:1023-1030(2009).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-15.
RX   PubMed=7559454; DOI=10.1074/jbc.270.39.23111;
RA   Patterson C., Perrella M.A., Hsieh C.-M., Yoshizumi M., Lee M.-E.,
RA   Harber E.;
RT   "Cloning and functional analysis of the promoter for KDR/flk-1, a
RT   receptor for vascular endothelial growth factor.";
RL   J. Biol. Chem. 270:23111-23118(1995).
RN   [6]
RP   FUNCTION, INTERACTION WITH VEGFA, AUTOPHOSPHORYLATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=8356051; DOI=10.1073/pnas.90.16.7533;
RA   Quinn T.P., Peters K.G., de Vries C., Ferrara N., Williams L.T.;
RT   "Fetal liver kinase 1 is a receptor for vascular endothelial growth
RT   factor and is selectively expressed in vascular endothelium.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:7533-7537(1993).
RN   [7]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=7596435; DOI=10.1038/376062a0;
RA   Shalaby F., Rossant J., Yamaguchi T.P., Gertsenstein M., Wu X.F.,
RA   Breitman M.L., Schuh A.C.;
RT   "Failure of blood-island formation and vasculogenesis in Flk-1-
RT   deficient mice.";
RL   Nature 376:62-66(1995).
RN   [8]
RP   DEVELOPMENTAL STAGE.
RX   PubMed=10878616;
RX   DOI=10.1002/1097-0177(200007)218:3<507::AID-DVDY1012>3.0.CO;2-5;
RA   Pepper M.S., Baetens D., Mandriota S.J., Di Sanza C., Oikemus S.,
RA   Lane T.F., Soriano J.V., Montesano R., Iruela-Arispe M.L.;
RT   "Regulation of VEGF and VEGF receptor expression in the rodent mammary
RT   gland during pregnancy, lactation, and involution.";
RL   Dev. Dyn. 218:507-524(2000).
RN   [9]
RP   FUNCTION, PHOSPHORYLATION AT TYR-1212, AND MUTAGENESIS OF TYR-1212.
RX   PubMed=12023952; DOI=10.1074/jbc.M110544200;
RA   Meyer R.D., Dayanir V., Majnoun F., Rahimi N.;
RT   "The presence of a single tyrosine residue at the carboxyl domain of
RT   vascular endothelial growth factor receptor-2/FLK-1 regulates its
RT   autophosphorylation and activation of signaling molecules.";
RL   J. Biol. Chem. 277:27081-27087(2002).
RN   [10]
RP   INTERACTION WITH FLT4, AND CATALYTIC ACTIVITY.
RX   PubMed=12881528; DOI=10.1074/jbc.M304499200;
RA   Dixelius J., Makinen T., Wirzenius M., Karkkainen M.J., Wernstedt C.,
RA   Alitalo K., Claesson-Welsh L.;
RT   "Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-
RT   3) heterodimerization with VEGFR-2 in primary lymphatic endothelial
RT   cells regulates tyrosine phosphorylation sites.";
RL   J. Biol. Chem. 278:40973-40979(2003).
RN   [11]
RP   INTERACTION WITH FLT1.
RX   PubMed=12796773; DOI=10.1038/nm884;
RA   Autiero M., Waltenberger J., Communi D., Kranz A., Moons L.,
RA   Lambrechts D., Kroll J., Plaisance S., De Mol M., Bono F., Kliche S.,
RA   Fellbrich G., Ballmer-Hofer K., Maglione D., Mayr-Beyrle U.,
RA   Dewerchin M., Dombrowski S., Stanimirovic D., Van Hummelen P.,
RA   Dehio C., Hicklin D.J., Persico G., Herbert J.M., Communi D.,
RA   Shibuya M., Collen D., Conway E.M., Carmeliet P.;
RT   "Role of PlGF in the intra- and intermolecular cross talk between the
RT   VEGF receptors Flt1 and Flk1.";
RL   Nat. Med. 9:936-943(2003).
RN   [12]
RP   INTERACTION WITH SHB, AND MUTAGENESIS OF TYR-1173.
RX   PubMed=15026417; DOI=10.1074/jbc.M312729200;
RA   Holmqvist K., Cross M.J., Rolny C., Haegerkvist R., Rahimi N.,
RA   Matsumoto T., Claesson-Welsh L., Welsh M.;
RT   "The adaptor protein shb binds to tyrosine 1175 in vascular
RT   endothelial growth factor (VEGF) receptor-2 and regulates VEGF-
RT   dependent cellular migration.";
RL   J. Biol. Chem. 279:22267-22275(2004).
RN   [13]
RP   FUNCTION, INTERACTION WITH CBL, UBIQUITINATION, PHOSPHORYLATION AT
RP   TYR-1052 AND TYR-1057, MUTAGENESIS OF LYS-866; SER-1188 AND SER-1191,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=15673613; DOI=10.1091/mbc.E04-08-0749;
RA   Singh A.J., Meyer R.D., Band H., Rahimi N.;
RT   "The carboxyl terminus of VEGFR-2 is required for PKC-mediated down-
RT   regulation.";
RL   Mol. Biol. Cell 16:2106-2118(2005).
RN   [14]
RP   INTERACTION WITH MYOF.
RX   PubMed=17702744; DOI=10.1074/jbc.M704798200;
RA   Bernatchez P.N., Acevedo L., Fernandez-Hernando C., Murata T.,
RA   Chalouni C., Kim J., Erdjument-Bromage H., Shah V., Gratton J.-P.,
RA   McNally E.M., Tempst P., Sessa W.C.;
RT   "Myoferlin regulates vascular endothelial growth factor receptor-2
RT   stability and function.";
RL   J. Biol. Chem. 282:30745-30753(2007).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL
RP   STAGE.
RX   PubMed=19635461; DOI=10.1016/j.bbrc.2009.07.108;
RA   Kanemura H., Satoh T., Bilasy S.E., Ueda S., Hirashima M., Kataoka T.;
RT   "Impaired vascular development in the yolk sac and allantois in mice
RT   lacking RA-GEF-1.";
RL   Biochem. Biophys. Res. Commun. 387:754-759(2009).
RN   [16]
RP   FUNCTION.
RX   PubMed=19652084; DOI=10.1161/HYPERTENSIONAHA.109.129973;
RA   Facemire C.S., Nixon A.B., Griffiths R., Hurwitz H., Coffman T.M.;
RT   "Vascular endothelial growth factor receptor 2 controls blood pressure
RT   by regulating nitric oxide synthase expression.";
RL   Hypertension 54:652-658(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1229; SER-1233 AND
RP   THR-1236, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Brown adipose tissue, Heart, Kidney, and Lung;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [18]
RP   FUNCTION.
RX   PubMed=20705758; DOI=10.1182/blood-2010-02-267427;
RA   Nakao S., Zandi S., Hata Y., Kawahara S., Arita R., Schering A.,
RA   Sun D., Melhorn M.I., Ito Y., Lara-Castillo N., Ishibashi T.,
RA   Hafezi-Moghadam A.;
RT   "Blood vessel endothelial VEGFR-2 delays lymphangiogenesis: an
RT   endogenous trapping mechanism links lymph- and angiogenesis.";
RL   Blood 117:1081-1090(2011).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface
CC       receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in
CC       the regulation of angiogenesis, vascular development, vascular
CC       permeability, and embryonic hematopoiesis. Promotes proliferation,
CC       survival, migration and differentiation of endothelial cells.
CC       Promotes reorganization of the actin cytoskeleton. Isoforms
CC       lacking a transmembrane domain, such as isoform 2, may function as
CC       decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an
CC       important role as a negative regulator of VEGFA- and VEGFC-
CC       mediated lymphangiogenesis by limiting the amount of free VEGFA
CC       and/or VEGFC and by preventing their binding to FLT4. Modulates
CC       FLT1 and FLT4 signaling by forming heterodimers. Binding of
CC       vascular growth factors to isoform 1 leads to the activation of
CC       several signaling cascades. Activation of PLCG1 leads to the
CC       production of the cellular signaling molecules diacylglycerol and
CC       inositol 1,4,5-trisphosphate and the activation of protein kinase
CC       C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP
CC       kinase signaling pathway, as well as of the AKT1 signaling
CC       pathway. Mediates phosphorylation of PIK3R1, the regulatory
CC       subunit of phosphatidylinositol 3-kinase, reorganization of the
CC       actin cytoskeleton and activation of PTK2/FAK1. Required for
CC       VEGFA-mediated induction of NOS2 and NOS3, leading to the
CC       production of the signaling molecule nitric oxide (NO) by
CC       endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation
CC       of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.
CC       {ECO:0000269|PubMed:12023952, ECO:0000269|PubMed:15673613,
CC       ECO:0000269|PubMed:19635461, ECO:0000269|PubMed:19652084,
CC       ECO:0000269|PubMed:19668192, ECO:0000269|PubMed:20705758,
CC       ECO:0000269|PubMed:7596435, ECO:0000269|PubMed:8356051}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:12881528}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Binding of VEGFA, VEGFC or VEGFD leads to
CC       dimerization and activation by autophosphorylation on tyrosine
CC       residues. May be regulated by hydrogen sulfide (H(2)S) levels via
CC       a sensitive intracellular disulfide bond (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer in the presence of bound dimeric VEGFA, VEGFC
CC       or VEGFD ligands; monomeric in the absence of bound ligands. Can
CC       also form heterodimers with FLT1/VEGFR1 and FLT4/VEGFR2. Interacts
CC       (tyrosine phosphorylated) with LFYN, NCK1, PLCG1. Interacts
CC       (tyrosine-phosphorylated active form preferentially) with DAB2IP
CC       (via C2 domain and active form preferentially); the interaction
CC       occurs at the late phase of VEGFA response and inhibits KDR/VEGFR2
CC       activity. Interacts with SHBSH2D2A/TSAD, GRB2, MYOF, CBL and PDCD6
CC       (PubMed:12796773, PubMed:12881528, PubMed:15026417,
CC       PubMed:15673613, PubMed:17702744, PubMed:19668192, PubMed:7681362,
CC       PubMed:8356051). Interacts (via C-terminus domain) with ERN1 (via
CC       kinase domain); the interaction is facilitated in a XBP1 isoform
CC       1- and vascular endothelial growth factor (VEGF)-dependent manner
CC       in endothelial cells (By similarity).
CC       {ECO:0000250|UniProtKB:P35968, ECO:0000269|PubMed:12796773,
CC       ECO:0000269|PubMed:12881528, ECO:0000269|PubMed:15026417,
CC       ECO:0000269|PubMed:15673613, ECO:0000269|PubMed:17702744,
CC       ECO:0000269|PubMed:19668192, ECO:0000269|PubMed:7681362,
CC       ECO:0000269|PubMed:8356051}.
CC   -!- INTERACTION:
CC       P35917:Flt4; NbExp=2; IntAct=EBI-1555005, EBI-7845747;
CC       P08581:MET (xeno); NbExp=3; IntAct=EBI-1555005, EBI-1039152;
CC       P16056:Met; NbExp=3; IntAct=EBI-1555005, EBI-1798780;
CC   -!- SUBCELLULAR LOCATION: Cell junction {ECO:0000269|PubMed:15673613,
CC       ECO:0000269|PubMed:19635461, ECO:0000269|PubMed:19668192}.
CC       Endoplasmic reticulum {ECO:0000250|UniProtKB:P35968}.
CC       Note=Colocalizes with ERN1 and XBP1 in the endoplasmic reticulum
CC       in endothelial cells in a vascular endothelial growth factor
CC       (VEGF)-dependent manner (By similarity). Localized with RAP1A at
CC       cell-cell junctions. {ECO:0000250|UniProtKB:P35968}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein. Cytoplasm {ECO:0000250}. Nucleus {ECO:0000250}.
CC       Cytoplasmic vesicle {ECO:0000250}. Early endosome {ECO:0000250}.
CC       Note=Detected on caveolae-enriched lipid rafts at the cell
CC       surface. Is recycled from the plasma membrane to endosomes and
CC       back again. Phosphorylation triggered by VEGFA binding promotes
CC       internalization and subsequent degradation. VEGFA binding triggers
CC       internalization and translocation to the nucleus (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=mbVegfr-2;
CC         IsoId=P35918-1; Sequence=Displayed;
CC       Name=2; Synonyms=sVegfr-2;
CC         IsoId=P35918-2; Sequence=VSP_041986, VSP_041987;
CC   -!- TISSUE SPECIFICITY: Expressed in endothelial cells (at protein
CC       level). Detected in embryonic endothelial cells, as well as
CC       hematopoietic stem and progenitor cells. Detected in vascular
CC       endothelium. Expressed at high levels in adult heart, lung,
CC       kidney, brain and skeletal muscle, but is also expressed at lower
CC       levels in most other adult tissues. {ECO:0000269|PubMed:1717995,
CC       ECO:0000269|PubMed:19635461, ECO:0000269|PubMed:8356051,
CC       ECO:0000269|PubMed:8423988}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in endothelial cells of
CC       allantois/umbilical vessels at 8.5 dpc (at protein level).
CC       Increases moderately during pregnancy (maximum 2.7-fold at 19
CC       days), and increases further during lactation (maximum 3.7-fold
CC       increase on day 7). {ECO:0000269|PubMed:10878616,
CC       ECO:0000269|PubMed:19635461}.
CC   -!- DOMAIN: The second and third Ig-like C2-type (immunoglobulin-like)
CC       domains are sufficient for VEGFC binding. {ECO:0000250}.
CC   -!- PTM: N-glycosylated. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. Tyrosine phosphorylation of the receptor
CC       promotes its poly-ubiquitination, leading to its degradation via
CC       the proteasome or lysosomal proteases (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding.
CC       Autophosphorylation occurs in trans, i.e. one subunit of the
CC       dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Phosphorylation at Tyr-949 is important for interaction
CC       with SH2D2A/TSAD and VEGFA-mediated reorganization of the actin
CC       cytoskeleton. Phosphorylation at Tyr-1173 is important for
CC       interaction with PLCG1 and SHB. Phosphorylation at Tyr-1212 is
CC       important for interaction with NCK1 and FYN. Dephosphorylated by
CC       PTPRJ at Tyr-799, Tyr-949, Tyr-994, Tyr-1052, Tyr-1057, Tyr-1173
CC       and Tyr-1212 (By similarity). {ECO:0000250}.
CC   -!- PTM: The inhibitory disulfide bond between Cys-1022 and Cys-1043
CC       may serve as a specific molecular switch for H(2)S-induced
CC       modification that regulates VEGFR2 function. {ECO:0000250}.
CC   -!- DISRUPTION PHENOTYPE: Embryonic lethality at 8.5 to 9.5 dpc, due
CC       to early defects in the development of hematopoietic and
CC       endothelial cells, leading to defects in vasculogenesis and
CC       endocardium development. At 7.5 dpc, there are no blood islands in
CC       the yolk sac. Organized blood vessels are absent in the yolk sac
CC       and in the embryo. {ECO:0000269|PubMed:7596435}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 7 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X70842; CAA50192.1; -; mRNA.
DR   EMBL; X59397; CAA42040.1; -; mRNA.
DR   EMBL; S53103; AAB25043.1; -; mRNA.
DR   EMBL; EU884114; ACJ66293.1; -; mRNA.
DR   EMBL; X89777; CAA61917.1; -; Genomic_DNA.
DR   PIR; A41228; A41228.
DR   UniGene; Mm.285; -.
DR   ProteinModelPortal; P35918; -.
DR   SMR; P35918; 124-327, 665-754, 757-793, 810-1166.
DR   DIP; DIP-215N; -.
DR   IntAct; P35918; 8.
DR   MINT; MINT-4996697; -.
DR   STRING; 10090.ENSMUSP00000109144; -.
DR   BindingDB; P35918; -.
DR   ChEMBL; CHEMBL3337; -.
DR   GuidetoPHARMACOLOGY; 1813; -.
DR   iPTMnet; P35918; -.
DR   PhosphoSite; P35918; -.
DR   MaxQB; P35918; -.
DR   PaxDb; P35918; -.
DR   PRIDE; P35918; -.
DR   UCSC; uc012dxk.2; mouse. [P35918-2]
DR   MGI; MGI:96683; Kdr.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   HOGENOM; HOG000037949; -.
DR   HOVERGEN; HBG053432; -.
DR   InParanoid; P35918; -.
DR   PhylomeDB; P35918; -.
DR   BRENDA; 2.7.10.1; 3474.
DR   ChiTaRS; Kdr; mouse.
DR   PRO; PR:P35918; -.
DR   Proteomes; UP000000589; Unplaced.
DR   CleanEx; MM_KDR; -.
DR   GO; GO:0030054; C:cell junction; IDA:UniProtKB.
DR   GO; GO:0071944; C:cell periphery; IDA:MGI.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0016023; C:cytoplasmic membrane-bounded vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0005769; C:early endosome; IDA:BHF-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0005768; C:endosome; ISO:MGI.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:MGI.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; ISO:MGI.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; ISO:MGI.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0097443; C:sorting endosome; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019838; F:growth factor binding; IPI:MGI.
DR   GO; GO:0005178; F:integrin binding; ISO:MGI.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; ISO:MGI.
DR   GO; GO:0038085; F:vascular endothelial growth factor binding; ISO:MGI.
DR   GO; GO:0005021; F:vascular endothelial growth factor-activated receptor activity; ISS:UniProtKB.
DR   GO; GO:0060837; P:blood vessel endothelial cell differentiation; TAS:DFLAT.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IMP:MGI.
DR   GO; GO:0055074; P:calcium ion homeostasis; IDA:MGI.
DR   GO; GO:0035584; P:calcium-mediated signaling using intracellular calcium source; ISS:UniProtKB.
DR   GO; GO:0045165; P:cell fate commitment; IMP:MGI.
DR   GO; GO:0048469; P:cell maturation; IMP:MGI.
DR   GO; GO:0016477; P:cell migration; IGI:MGI.
DR   GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; ISS:UniProtKB.
DR   GO; GO:0035162; P:embryonic hemopoiesis; IMP:UniProtKB.
DR   GO; GO:0003157; P:endocardium development; IMP:UniProtKB.
DR   GO; GO:0045446; P:endothelial cell differentiation; TAS:DFLAT.
DR   GO; GO:0003158; P:endothelium development; IMP:UniProtKB.
DR   GO; GO:0030097; P:hemopoiesis; IMP:MGI.
DR   GO; GO:0048286; P:lung alveolus development; IMP:MGI.
DR   GO; GO:0030324; P:lung development; IMP:MGI.
DR   GO; GO:0001945; P:lymph vessel development; IGI:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; ISS:UniProtKB.
DR   GO; GO:0001541; P:ovarian follicle development; IMP:MGI.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:DFLAT.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IDA:DFLAT.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; TAS:DFLAT.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IMP:MGI.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; ISO:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IMP:MGI.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; ISS:UniProtKB.
DR   GO; GO:0050927; P:positive regulation of positive chemotaxis; ISO:MGI.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; TAS:DFLAT.
DR   GO; GO:2001214; P:positive regulation of vasculogenesis; IMP:UniProtKB.
DR   GO; GO:0048597; P:post-embryonic camera-type eye morphogenesis; IGI:MGI.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; ISO:MGI.
DR   GO; GO:0045601; P:regulation of endothelial cell differentiation; IMP:MGI.
DR   GO; GO:0001936; P:regulation of endothelial cell proliferation; TAS:DFLAT.
DR   GO; GO:1901532; P:regulation of hematopoietic progenitor cell differentiation; IMP:MGI.
DR   GO; GO:0043129; P:surfactant homeostasis; IMP:MGI.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0038084; P:vascular endothelial growth factor signaling pathway; ISO:MGI.
DR   GO; GO:0001570; P:vasculogenesis; IMP:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 7.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   InterPro; IPR009136; VEGFR2_rcpt.
DR   PANTHER; PTHR24416:SF45; PTHR24416:SF45; 3.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR01834; VEGFRECEPTR2.
DR   SMART; SM00409; IG; 5.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 8.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 5.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Angiogenesis; ATP-binding; Cell junction;
KW   Cell membrane; Complete proteome; Cytoplasm; Cytoplasmic vesicle;
KW   Developmental protein; Differentiation; Disulfide bond;
KW   Endoplasmic reticulum; Endosome; Glycoprotein; Immunoglobulin domain;
KW   Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Receptor; Reference proteome; Repeat; Secreted; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   CHAIN        20   1367       Vascular endothelial growth factor
FT                                receptor 2.
FT                                /FTId=PRO_0000016772.
FT   TOPO_DOM     20    762       Extracellular. {ECO:0000255}.
FT   TRANSMEM    763    783       Helical. {ECO:0000255}.
FT   TOPO_DOM    784   1367       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       46    111       Ig-like C2-type 1.
FT   DOMAIN      143    209       Ig-like C2-type 2.
FT   DOMAIN      226    325       Ig-like C2-type 3.
FT   DOMAIN      330    416       Ig-like C2-type 4.
FT   DOMAIN      423    542       Ig-like C2-type 5.
FT   DOMAIN      549    656       Ig-like C2-type 6.
FT   DOMAIN      665    751       Ig-like C2-type 7.
FT   DOMAIN      832   1160       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     838    846       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE   1026   1026       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     866    866       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE       1173   1173       Interaction with SHB.
FT   MOD_RES     799    799       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P35968}.
FT   MOD_RES     949    949       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     980    980       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P35968}.
FT   MOD_RES     982    982       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P35968}.
FT   MOD_RES     994    994       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1052   1052       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15673613}.
FT   MOD_RES    1057   1057       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15673613}.
FT   MOD_RES    1173   1173       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1212   1212       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12023952}.
FT   MOD_RES    1229   1229       Phosphoserine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   MOD_RES    1233   1233       Phosphoserine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   MOD_RES    1236   1236       Phosphothreonine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   MOD_RES    1303   1303       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1307   1307       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1317   1317       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     46     46       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     98     98       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    145    145       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    160    160       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    247    247       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    320    320       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    376    376       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    397    397       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    509    509       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    521    521       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    578    578       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    611    611       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    617    617       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    629    629       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    673    673       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    702    702       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    719    719       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     53    105       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    152    202       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    248    309       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    447    528       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    569    640       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    686    735       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID   1022   1043       Redox-active. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00114}.
FT   VAR_SEQ     661    673       ERMAPMITGNLEN -> GMEASLGDRIAMP (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:19668192}.
FT                                /FTId=VSP_041986.
FT   VAR_SEQ     674   1367       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:19668192}.
FT                                /FTId=VSP_041987.
FT   MUTAGEN     866    866       K->R: Loss of enzyme activity. Abolishes
FT                                ubiquitination in response to VEGFA
FT                                binding. {ECO:0000269|PubMed:15673613}.
FT   MUTAGEN    1173   1173       Y->F: Loss of interaction with SHB.
FT                                {ECO:0000269|PubMed:15026417}.
FT   MUTAGEN    1188   1188       S->A: Strongly reduces internalization
FT                                and down-regulation of the activated
FT                                receptor; when associated with A-1191.
FT                                {ECO:0000269|PubMed:15673613}.
FT   MUTAGEN    1191   1191       S->A: Strongly reduces internalization
FT                                and down-regulation of the activated
FT                                receptor; when associated with A-1188.
FT                                {ECO:0000269|PubMed:15673613}.
FT   MUTAGEN    1212   1212       Y->F: Strongly reduced
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:12023952}.
FT   CONFLICT     25     25       P -> T (in Ref. 1; CAA50192).
FT                                {ECO:0000305}.
FT   CONFLICT    679    679       G -> D (in Ref. 3; AAB25043).
FT                                {ECO:0000305}.
FT   CONFLICT    783    784       LV -> VL (in Ref. 1; CAA50192).
FT                                {ECO:0000305}.
FT   CONFLICT    917    917       S -> C (in Ref. 1; CAA50192).
FT                                {ECO:0000305}.
FT   CONFLICT   1341   1367       QLTSCLNGSGPVPAPPPTPGNHERGAA -> RSPPV (in
FT                                Ref. 3; AAB25043). {ECO:0000305}.
SQ   SEQUENCE   1367 AA;  152517 MW;  EFC99704F1DCA266 CRC64;
     MESKALLAVA LWFCVETRAA SVGLPGDFLH PPKLSTQKDI LTILANTTLQ ITCRGQRDLD
     WLWPNAQRDS EERVLVTECG GGDSIFCKTL TIPRVVGNDT GAYKCSYRDV DIASTVYVYV
     RDYRSPFIAS VSDQHGIVYI TENKNKTVVI PCRGSISNLN VSLCARYPEK RFVPDGNRIS
     WDSEIGFTLP SYMISYAGMV FCEAKINDET YQSIMYIVVV VGYRIYDVIL SPPHEIELSA
     GEKLVLNCTA RTELNVGLDF TWHSPPSKSH HKKIVNRDVK PFPGTVAKMF LSTLTIESVT
     KSDQGEYTCV ASSGRMIKRN RTFVRVHTKP FIAFGSGMKS LVEATVGSQV RIPVKYLSYP
     APDIKWYRNG RPIESNYTMI VGDELTIMEV TERDAGNYTV ILTNPISMEK QSHMVSLVVN
     VPPQIGEKAL ISPMDSYQYG TMQTLTCTVY ANPPLHHIQW YWQLEEACSY RPGQTSPYAC
     KEWRHVEDFQ GGNKIEVTKN QYALIEGKNK TVSTLVIQAA NVSALYKCEA INKAGRGERV
     ISFHVIRGPE ITVQPAAQPT EQESVSLLCT ADRNTFENLT WYKLGSQATS VHMGESLTPV
     CKNLDALWKL NGTMFSNSTN DILIVAFQNA SLQDQGDYVC SAQDKKTKKR HCLVKQLIIL
     ERMAPMITGN LENQTTTIGE TIEVTCPASG NPTPHITWFK DNETLVEDSG IVLRDGNRNL
     TIRRVRKEDG GLYTCQACNV LGCARAETLF IIEGAQEKTN LEVIILVGTA VIAMFFWLLL
     VILVRTVKRA NEGELKTGYL SIVMDPDELP LDERCERLPY DASKWEFPRD RLKLGKPLGR
     GAFGQVIEAD AFGIDKTATC KTVAVKMLKE GATHSEHRAL MSELKILIHI GHHLNVVNLL
     GACTKPGGPL MVIVEFSKFG NLSTYLRGKR NEFVPYKSKG ARFRQGKDYV GELSVDLKRR
     LDSITSSQSS ASSGFVEEKS LSDVEEEEAS EELYKDFLTL EHLICYSFQV AKGMEFLASR
     KCIHRDLAAR NILLSEKNVV KICDFGLARD IYKDPDYVRK GDARLPLKWM APETIFDRVY
     TIQSDVWSFG VLLWEIFSLG ASPYPGVKID EEFCRRLKEG TRMRAPDYTT PEMYQTMLDC
     WHEDPNQRPS FSELVEHLGN LLQANAQQDG KDYIVLPMSE TLSMEEDSGL SLPTSPVSCM
     EEEEVCDPKF HYDNTAGISH YLQNSKRKSR PVSVKTFEDI PLEEPEVKVI PDDSQTDSGM
     VLASEELKTL EDRNKLSPSF GGMMPSKSRE SVASEGSNQT SGYQSGYHSD DTDTTVYSSD
     EAGLLKMVDA AVHADSGTTL QLTSCLNGSG PVPAPPPTPG NHERGAA
//
ID   NOTC1_RAT               Reviewed;        2531 AA.
AC   Q07008; F1M9E7;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   16-OCT-2013, sequence version 3.
DT   17-FEB-2016, entry version 169.
DE   RecName: Full=Neurogenic locus notch homolog protein 1;
DE            Short=Notch 1;
DE   Contains:
DE     RecName: Full=Notch 1 extracellular truncation;
DE              Short=NEXT;
DE   Contains:
DE     RecName: Full=Notch 1 intracellular domain;
DE              Short=NICD;
DE   Flags: Precursor;
GN   Name=Notch1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Schwann cell;
RX   PubMed=1764995;
RA   Weinmaster G., Roberts V.J., Lemke G.;
RT   "A homolog of Drosophila Notch expressed during mammalian
RT   development.";
RL   Development 113:199-205(1991).
RN   [2]
RP   SEQUENCE REVISION TO 1652-1653.
RA   Weinmaster G.;
RL   Submitted (APR-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T.,
RA   Smith D., Lee H.-M., Gustafson E., Cahill P., Kana A.,
RA   Doucette-Stamm L., Weinstock K., Fechtel K., Weiss R.B., Dunn D.M.,
RA   Green E.D., Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K.,
RA   Zhu B., Marra M., Schein J., Bosdet I., Fjell C., Jones S.,
RA   Krzywinski M., Mathewson C., Siddiqui A., Wye N., McPherson J.,
RA   Zhao S., Fraser C.M., Shetty J., Shatsman S., Geer K., Chen Y.,
RA   Abramzon S., Nierman W.C., Havlak P.H., Chen R., Durbin K.J., Egan A.,
RA   Ren Y., Song X.-Z., Li B., Liu Y., Qin X., Cawley S., Cooney A.J.,
RA   D'Souza L.M., Martin K., Wu J.Q., Gonzalez-Garay M.L., Jackson A.R.,
RA   Kalafus K.J., McLeod M.P., Milosavljevic A., Virk D., Volkov A.,
RA   Wheeler D.A., Zhang Z., Bailey J.A., Eichler E.E., Tuzun E.,
RA   Birney E., Mongin E., Ureta-Vidal A., Woodwark C., Zdobnov E.,
RA   Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D.,
RA   Schmidt J., Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M.,
RA   Abril J.F., Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O.,
RA   Poliakov A., Huebner N., Ganten D., Goesele C., Hummel O.,
RA   Kreitler T., Lee Y.-A., Monti J., Schulz H., Zimdahl H.,
RA   Himmelbauer H., Lehrach H., Jacob H.J., Bromberg S.,
RA   Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E., Lazar J.,
RA   Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E.,
RA   Webber C., Brandt P., Nyakatura G., Adetobi M., Chiaromonte F.,
RA   Elnitski L., Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K.,
RA   Miller W., Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S.,
RA   Zhang Y., Lindpaintner K., Andrews T.D., Caccamo M., Clamp M.,
RA   Clarke L., Curwen V., Durbin R.M., Eyras E., Searle S.M., Cooper G.M.,
RA   Batzoglou S., Brudno M., Sidow A., Stone E.A., Payseur B.A.,
RA   Bourque G., Lopez-Otin C., Puente X.S., Chakrabarti K., Chatterji S.,
RA   Dewey C., Pachter L., Bray N., Yap V.B., Caspi A., Tesler G.,
RA   Pevzner P.A., Haussler D., Roskin K.M., Baertsch R., Clawson H.,
RA   Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J., Rosenbloom K.R.,
RA   Trumbower H., Weirauch M., Cooper D.N., Stenson P.D., Ma B., Brent M.,
RA   Arumugam M., Shteynberg D., Copley R.R., Taylor M.S., Riethman H.,
RA   Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S., Mockrin S.,
RA   Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into
RT   mammalian evolution.";
RL   Nature 428:493-521(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   FUNCTION.
RX   PubMed=11182080; DOI=10.1016/S0896-6273(01)00179-9;
RA   Tanigaki K., Nogaki F., Takahashi J., Tashiro K., Kurooka H.,
RA   Honjo T.;
RT   "Notch1 and Notch3 instructively restrict bFGF-responsive multipotent
RT   neural progenitor cells to an astroglial fate.";
RL   Neuron 29:45-55(2001).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=1295745;
RA   Weinmaster G., Roberts V.J., Lemke G.;
RT   "Notch2: a second mammalian Notch gene.";
RL   Development 116:931-941(1992).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=11438922; DOI=10.1002/cne.1059.abs;
RA   Irvin D.K., Zurcher S.D., Nguyen T., Weinmaster G., Kornblum H.I.;
RT   "Expression patterns of Notch1, Notch2, and Notch3 suggest multiple
RT   functional roles for the Notch-DSL signaling system during brain
RT   development.";
RL   J. Comp. Neurol. 436:167-181(2001).
CC   -!- FUNCTION: Functions as a receptor for membrane-bound ligands
CC       Jagged1, Jagged2 and Delta1 to regulate cell-fate determination.
CC       Upon ligand activation through the released notch intracellular
CC       domain (NICD) it forms a transcriptional activator complex with
CC       RBPJ/RBPSUH and activates genes of the enhancer of split locus.
CC       Affects the implementation of differentiation, proliferation and
CC       apoptotic programs. Involved in angiogenesis; negatively regulates
CC       endothelial cell proliferation and migration and angiogenic
CC       sprouting. Involved in the maturation of both CD4+ and CD8+ cells
CC       in the thymus. Important for follicular differentiation and
CC       possibly cell fate selection within the follicle. During
CC       cerebellar development, functions as a receptor for neuronal DNER
CC       and is involved in the differentiation of Bergmann glia. Represses
CC       neuronal and myogenic differentiation. May play an essential role
CC       in postimplantation development, probably in some aspect of cell
CC       specification and/or differentiation. May be involved in mesoderm
CC       development, somite formation and neurogenesis. May enhance HIF1A
CC       function by sequestering HIF1AN away from HIF1A. Required for the
CC       THBS4 function in regulating protective astrogenesis from the
CC       subventricular zone (SVZ) niche after injury. Involved in
CC       determination of left/right symmetry by modulating the balance
CC       between motile and immotile (sensory) cilia at the left-right
CC       organiser (LRO) (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:11182080}.
CC   -!- SUBUNIT: Heterodimer of a C-terminal fragment N(TM) and an N-
CC       terminal fragment N(EC) which are probably linked by disulfide
CC       bonds. Interacts with DNER, DTX1, DTX2 and RBPJ/RBPSUH. Also
CC       interacts with MAML1, MAML2 and MAML3 which act as transcriptional
CC       coactivators for NOTCH1. Notch 1 intracellular domain interacts
CC       with SNW1; the interaction involves multimerized NOTCH1 NICD and
CC       is implicated in a formation of an intermediate preactivation
CC       complex which associates with DNA-bound CBF-1/RBPJ. The activated
CC       membrane-bound form interacts with AAK1 which promotes NOTCH1
CC       stabilization. Forms a trimeric complex with FBXW7 and SGK1.
CC       Interacts with HIF1AN. HIF1AN negatively regulates the function of
CC       notch intracellular domain (NICD), accelerating myogenic
CC       differentiation. Interacts (via NICD) with SNAI1 (via zinc
CC       fingers); the interaction induces SNAI1 degradation via MDM2-
CC       mediated ubiquitination and inhibits SNAI1-induced cell invasion.
CC       Interacts (via NICD) with MDM2A. Interacts (via NICD) with BCL6;
CC       the interaction decreases MAML1 recruitment by NOTCH1 NICD on
CC       target genes DNA and inhibits NOTCH1 transcractivation activity
CC       (By similarity). Interacts with THBS4 (By similarity). Interacts
CC       (via the EGF-like repeat region) with NOV (via CTCK domain) (By
CC       similarity). {ECO:0000250|UniProtKB:Q01705}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Single-pass
CC       type I membrane protein {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Notch 1 intracellular domain: Nucleus
CC       {ECO:0000250}. Note=Following proteolytical processing NICD is
CC       translocated to the nucleus. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in the brain, kidney and spleen.
CC       Expressed in postnatal central nervous system (CNS) germinal zones
CC       and, in early postnatal life, within numerous cells throughout the
CC       CNS. Found in both subventricular and ventricular germinal zones.
CC       {ECO:0000269|PubMed:11438922, ECO:0000269|PubMed:1295745}.
CC   -!- DEVELOPMENTAL STAGE: In the embryo, highest levels occur between
CC       days 12 and 14 and decrease rapidly to much lower levels in the
CC       adult.
CC   -!- PTM: Synthesized in the endoplasmic reticulum as an inactive form
CC       which is proteolytically cleaved by a furin-like convertase in the
CC       trans-Golgi network before it reaches the plasma membrane to yield
CC       an active, ligand-accessible form. Cleavage results in a C-
CC       terminal fragment N(TM) and a N-terminal fragment N(EC). Following
CC       ligand binding, it is cleaved by ADAM17 to yield a membrane-
CC       associated intermediate fragment called notch extracellular
CC       truncation (NEXT). Following endocytosis, this fragment is then
CC       cleaved by presenilin dependent gamma-secretase to release a
CC       notch-derived peptide containing the intracellular domain (NICD)
CC       from the membrane (By similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylated. {ECO:0000250}.
CC   -!- PTM: O-glycosylated on the EGF-like domains. Contains both O-
CC       linked fucose and O-linked glucose. O-linked glycosylation by
CC       GALNT11 is involved in determination of left/right symmetry:
CC       glycosylation promotes activation of NOTCH1, possibly by promoting
CC       cleavage by ADAM17, modulating the balance between motile and
CC       immotile (sensory) cilia at the left-right organiser (LRO) (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Ubiquitinated; undergoes 'Lys-29'-linked polyubiquitination
CC       catalyzed by ITCH. Monoubiquitination at Lys-1749 is required for
CC       activation by gamma-secretase cleavage, it promotes interaction
CC       with AAK1, which stabilizes it. Deubiquitination by EIF3F is
CC       necessary for nuclear import of activated Notch (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Hydroxylated at Asn-1945 and Asn-2012 by HIF1AN.
CC       Hydroxylation reduces affinity for HI1AN and may thus indirectly
CC       modulate negative regulation of NICD (By similarity).
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the NOTCH family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 5 ANK repeats. {ECO:0000255|PROSITE-
CC       ProRule:PRU00023}.
CC   -!- SIMILARITY: Contains 36 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 3 LNR (Lin/Notch) repeats.
CC       {ECO:0000255|PROSITE-ProRule:PRU00525}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X57405; CAA40667.1; -; mRNA.
DR   EMBL; AABR06021907; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR06021908; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH474001; EDL93491.1; -; Genomic_DNA.
DR   PIR; S18188; S18188.
DR   RefSeq; NP_001099191.1; NM_001105721.1.
DR   UniGene; Rn.25046; -.
DR   PDB; 4XL1; X-ray; 2.30 A; A/D=412-526.
DR   PDB; 4XLW; X-ray; 3.39 A; A/C/E/G=412-526.
DR   PDBsum; 4XL1; -.
DR   PDBsum; 4XLW; -.
DR   ProteinModelPortal; Q07008; -.
DR   IntAct; Q07008; 3.
DR   STRING; 10116.ENSRNOP00000026212; -.
DR   PaxDb; Q07008; -.
DR   PRIDE; Q07008; -.
DR   Ensembl; ENSRNOT00000026212; ENSRNOP00000026212; ENSRNOG00000019322.
DR   GeneID; 25496; -.
DR   KEGG; rno:25496; -.
DR   UCSC; RGD:3187; rat.
DR   CTD; 4851; -.
DR   RGD; 3187; Notch1.
DR   eggNOG; ENOG410IR7G; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   GeneTree; ENSGT00810000125346; -.
DR   HOGENOM; HOG000234369; -.
DR   HOVERGEN; HBG052650; -.
DR   InParanoid; Q07008; -.
DR   KO; K02599; -.
DR   OMA; ILDYSFV; -.
DR   OrthoDB; EOG7992RD; -.
DR   TreeFam; TF351641; -.
DR   Reactome; R-RNO-1912420; Pre-NOTCH Processing in Golgi.
DR   Reactome; R-RNO-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-RNO-2122948; Activated NOTCH1 Transmits Signal to the Nucleus.
DR   Reactome; R-RNO-350054; Notch-HLH transcription pathway.
DR   NextBio; 35582897; -.
DR   PRO; PR:Q07008; -.
DR   Proteomes; UP000002494; Chromosome 3.
DR   Genevisible; Q07008; RN.
DR   GO; GO:0001669; C:acrosomal vesicle; IDA:RGD.
DR   GO; GO:0005912; C:adherens junction; ISS:UniProtKB.
DR   GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005856; C:cytoskeleton; ISS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:RGD.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030027; C:lamellipodium; ISS:UniProtKB.
DR   GO; GO:0002193; C:MAML1-RBP-Jkappa- ICN1 complex; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IDA:RGD.
DR   GO; GO:0043235; C:receptor complex; IEA:Ensembl.
DR   GO; GO:0001726; C:ruffle; ISS:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl.
DR   GO; GO:0001047; F:core promoter binding; ISS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; ISS:UniProtKB.
DR   GO; GO:0004857; F:enzyme inhibitor activity; ISS:UniProtKB.
DR   GO; GO:0004872; F:receptor activity; IEA:InterPro.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001190; F:transcriptional activator activity, RNA polymerase II transcription factor binding; IEA:Ensembl.
DR   GO; GO:0003180; P:aortic valve morphogenesis; IEA:Ensembl.
DR   GO; GO:1902263; P:apoptotic process involved in embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:0060842; P:arterial endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0048708; P:astrocyte differentiation; IDA:RGD.
DR   GO; GO:0003162; P:atrioventricular node development; IEA:Ensembl.
DR   GO; GO:0009912; P:auditory receptor cell fate commitment; IEA:Ensembl.
DR   GO; GO:0007409; P:axonogenesis; IEA:Ensembl.
DR   GO; GO:0007420; P:brain development; IEP:RGD.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IEA:Ensembl.
DR   GO; GO:0003214; P:cardiac left ventricle morphogenesis; IEA:Ensembl.
DR   GO; GO:0060038; P:cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0003213; P:cardiac right atrium morphogenesis; IEA:Ensembl.
DR   GO; GO:0003219; P:cardiac right ventricle formation; IEA:Ensembl.
DR   GO; GO:0060948; P:cardiac vascular smooth muscle cell development; IEA:Ensembl.
DR   GO; GO:0021515; P:cell differentiation in spinal cord; IEP:RGD.
DR   GO; GO:0001708; P:cell fate specification; IEA:Ensembl.
DR   GO; GO:0003273; P:cell migration involved in endocardial cushion formation; IEA:Ensembl.
DR   GO; GO:0071372; P:cellular response to follicle-stimulating hormone stimulus; IEA:Ensembl.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; ISS:UniProtKB.
DR   GO; GO:0060271; P:cilium morphogenesis; ISS:UniProtKB.
DR   GO; GO:0072044; P:collecting duct development; IEA:Ensembl.
DR   GO; GO:0007386; P:compartment pattern specification; IEA:Ensembl.
DR   GO; GO:0060982; P:coronary artery morphogenesis; IEA:Ensembl.
DR   GO; GO:0003169; P:coronary vein morphogenesis; IEA:Ensembl.
DR   GO; GO:0072017; P:distal tubule development; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0060956; P:endocardial cell differentiation; IEA:Ensembl.
DR   GO; GO:0003160; P:endocardium morphogenesis; IEA:Ensembl.
DR   GO; GO:0007492; P:endoderm development; IEA:Ensembl.
DR   GO; GO:0003198; P:epithelial to mesenchymal transition involved in endocardial cushion formation; IEA:Ensembl.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0007440; P:foregut morphogenesis; IEA:Ensembl.
DR   GO; GO:0072144; P:glomerular mesangial cell development; IEA:Ensembl.
DR   GO; GO:0003241; P:growth involved in heart morphogenesis; IEA:Ensembl.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IEA:Ensembl.
DR   GO; GO:0001947; P:heart looping; IEA:Ensembl.
DR   GO; GO:0006959; P:humoral immune response; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0002437; P:inflammatory response to antigenic stimulus; IEA:Ensembl.
DR   GO; GO:0072602; P:interleukin-4 secretion; IEA:Ensembl.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0070986; P:left/right axis specification; IEA:Ensembl.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0003192; P:mitral valve formation; IEA:Ensembl.
DR   GO; GO:2000811; P:negative regulation of anoikis; IEA:Ensembl.
DR   GO; GO:0045608; P:negative regulation of auditory receptor cell differentiation; IEA:Ensembl.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0045955; P:negative regulation of calcium ion-dependent exocytosis; IEA:Ensembl.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0043086; P:negative regulation of catalytic activity; ISS:UniProtKB.
DR   GO; GO:0090051; P:negative regulation of cell migration involved in sprouting angiogenesis; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0010812; P:negative regulation of cell-substrate adhesion; IEA:Ensembl.
DR   GO; GO:2001027; P:negative regulation of endothelial cell chemotaxis; ISS:UniProtKB.
DR   GO; GO:0060253; P:negative regulation of glial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0045662; P:negative regulation of myoblast differentiation; IEA:Ensembl.
DR   GO; GO:0010832; P:negative regulation of myotube differentiation; ISS:UniProtKB.
DR   GO; GO:0050768; P:negative regulation of neurogenesis; ISS:UniProtKB.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IMP:RGD.
DR   GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0045668; P:negative regulation of osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0046533; P:negative regulation of photoreceptor cell differentiation; IEA:Ensembl.
DR   GO; GO:2000974; P:negative regulation of pro-B cell differentiation; ISS:UniProtKB.
DR   GO; GO:2000737; P:negative regulation of stem cell differentiation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0021915; P:neural tube development; IEA:Ensembl.
DR   GO; GO:0097150; P:neuronal stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0061314; P:Notch signaling involved in heart development; ISS:UniProtKB.
DR   GO; GO:0007219; P:Notch signaling pathway; IMP:RGD.
DR   GO; GO:0003270; P:Notch signaling pathway involved in regulation of secondary heart field cardioblast proliferation; IEA:Ensembl.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IEP:RGD.
DR   GO; GO:0031100; P:organ regeneration; IEP:RGD.
DR   GO; GO:0003344; P:pericardium morphogenesis; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0048711; P:positive regulation of astrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; ISS:UniProtKB.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0045603; P:positive regulation of endothelial cell differentiation; IMP:RGD.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IEA:Ensembl.
DR   GO; GO:0045687; P:positive regulation of glial cell differentiation; IMP:RGD.
DR   GO; GO:0046427; P:positive regulation of JAK-STAT cascade; ISS:UniProtKB.
DR   GO; GO:0045618; P:positive regulation of keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; IMP:RGD.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:RGD.
DR   GO; GO:0061419; P:positive regulation of transcription from RNA polymerase II promoter in response to hypoxia; ISS:UniProtKB.
DR   GO; GO:0007221; P:positive regulation of transcription of Notch receptor target; IMP:RGD.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0045070; P:positive regulation of viral genome replication; IEA:Ensembl.
DR   GO; GO:0050434; P:positive regulation of viral transcription; IEA:Ensembl.
DR   GO; GO:0060740; P:prostate gland epithelium morphogenesis; IEA:Ensembl.
DR   GO; GO:0003184; P:pulmonary valve morphogenesis; IEA:Ensembl.
DR   GO; GO:0003264; P:regulation of cardioblast proliferation; IMP:RGD.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:RGD.
DR   GO; GO:0060768; P:regulation of epithelial cell proliferation involved in prostate gland development; IEA:Ensembl.
DR   GO; GO:1901201; P:regulation of extracellular matrix assembly; IEA:Ensembl.
DR   GO; GO:0014807; P:regulation of somitogenesis; IEA:Ensembl.
DR   GO; GO:0003256; P:regulation of transcription from RNA polymerase II promoter involved in myocardial precursor cell differentiation; IEA:Ensembl.
DR   GO; GO:0031960; P:response to corticosteroid; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:0032495; P:response to muramyl dipeptide; IEA:Ensembl.
DR   GO; GO:0060528; P:secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development; IEA:Ensembl.
DR   GO; GO:0035914; P:skeletal muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0048103; P:somatic stem cell division; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IMP:RGD.
DR   GO; GO:0002040; P:sprouting angiogenesis; IEA:Ensembl.
DR   GO; GO:0042246; P:tissue regeneration; IEP:RGD.
DR   GO; GO:0035148; P:tube formation; ISS:UniProtKB.
DR   GO; GO:0060979; P:vasculogenesis involved in coronary vascular morphogenesis; IEA:Ensembl.
DR   GO; GO:0060843; P:venous endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0060412; P:ventricular septum morphogenesis; IEA:Ensembl.
DR   GO; GO:0003222; P:ventricular trabecula myocardium morphogenesis; IEA:Ensembl.
DR   Gene3D; 1.25.40.20; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR024600; DUF3454_notch.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR008297; Notch.
DR   InterPro; IPR022362; Notch_1.
DR   InterPro; IPR000800; Notch_dom.
DR   InterPro; IPR010660; Notch_NOD_dom.
DR   InterPro; IPR011656; Notch_NODP_dom.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF11936; DUF3454; 1.
DR   Pfam; PF00008; EGF; 22.
DR   Pfam; PF07645; EGF_CA; 5.
DR   Pfam; PF12661; hEGF; 2.
DR   Pfam; PF06816; NOD; 1.
DR   Pfam; PF07684; NODP; 1.
DR   Pfam; PF00066; Notch; 3.
DR   PIRSF; PIRSF002279; Notch; 1.
DR   PRINTS; PR01452; LNOTCHREPEAT.
DR   PRINTS; PR01984; NOTCH1.
DR   SMART; SM00248; ANK; 6.
DR   SMART; SM00181; EGF; 11.
DR   SMART; SM00179; EGF_CA; 25.
DR   SMART; SM00004; NL; 3.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF57184; SSF57184; 5.
DR   SUPFAM; SSF90193; SSF90193; 3.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 4.
DR   PROSITE; PS00010; ASX_HYDROXYL; 22.
DR   PROSITE; PS00022; EGF_1; 35.
DR   PROSITE; PS01186; EGF_2; 27.
DR   PROSITE; PS50026; EGF_3; 36.
DR   PROSITE; PS01187; EGF_CA; 21.
DR   PROSITE; PS50258; LNR; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Angiogenesis; ANK repeat; Calcium;
KW   Cell membrane; Complete proteome; Developmental protein;
KW   Differentiation; Disulfide bond; EGF-like domain; Glycoprotein;
KW   Hydroxylation; Isopeptide bond; Membrane; Metal-binding;
KW   Notch signaling pathway; Nucleus; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; Signal; Transcription;
KW   Transcription regulation; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19   2531       Neurogenic locus notch homolog protein 1.
FT                                /FTId=PRO_0000007680.
FT   CHAIN      1711   2531       Notch 1 extracellular truncation.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000007681.
FT   CHAIN      1744   2531       Notch 1 intracellular domain.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000007682.
FT   TOPO_DOM     19   1723       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1724   1746       Helical. {ECO:0000255}.
FT   TOPO_DOM   1747   2531       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       20     58       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN       59     99       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      102    139       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      140    176       EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      178    216       EGF-like 5; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      218    255       EGF-like 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      257    293       EGF-like 7; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      295    333       EGF-like 8; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      335    371       EGF-like 9; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      372    410       EGF-like 10. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      412    450       EGF-like 11; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      452    488       EGF-like 12; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      490    526       EGF-like 13; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      528    564       EGF-like 14; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      566    601       EGF-like 15; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      603    639       EGF-like 16; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      641    676       EGF-like 17; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      678    714       EGF-like 18; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      716    751       EGF-like 19; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      753    789       EGF-like 20; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      791    827       EGF-like 21; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      829    867       EGF-like 22. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      869    905       EGF-like 23; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      907    943       EGF-like 24. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      945    981       EGF-like 25; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      983   1019       EGF-like 26. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1021   1057       EGF-like 27; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1059   1095       EGF-like 28. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1097   1143       EGF-like 29. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1145   1181       EGF-like 30; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1183   1219       EGF-like 31; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1221   1265       EGF-like 32; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1267   1305       EGF-like 33. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1307   1346       EGF-like 34. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1348   1384       EGF-like 35. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1387   1426       EGF-like 36. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     1449   1489       LNR 1.
FT   REPEAT     1490   1531       LNR 2.
FT   REPEAT     1532   1571       LNR 3.
FT   REPEAT     1917   1946       ANK 1.
FT   REPEAT     1950   1980       ANK 2.
FT   REPEAT     1984   2013       ANK 3.
FT   REPEAT     2017   2046       ANK 4.
FT   REPEAT     2050   2079       ANK 5.
FT   REGION     1937   1945       HIF1AN-binding. {ECO:0000250}.
FT   REGION     2004   2012       HIF1AN-binding. {ECO:0000250}.
FT   COMPBIAS   1730   1733       Poly-Ala.
FT   COMPBIAS   1891   1894       Poly-Glu.
FT   COMPBIAS   2258   2261       Poly-Pro.
FT   COMPBIAS   2497   2500       Poly-Ser.
FT   METAL      1457   1457       Calcium; via carbonyl oxygen.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00525}.
FT   METAL      1460   1460       Calcium. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00525}.
FT   METAL      1475   1475       Calcium. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00525}.
FT   METAL      1478   1478       Calcium. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00525}.
FT   SITE       1654   1655       Cleavage; by furin-like protease.
FT                                {ECO:0000250}.
FT   SITE       1710   1711       Cleavage; by ADAM17. {ECO:0000250}.
FT   MOD_RES    1851   1851       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   MOD_RES    1945   1945       (3S)-3-hydroxyasparagine; by HIF1AN.
FT                                {ECO:0000250}.
FT   MOD_RES    2012   2012       (3S)-3-hydroxyasparagine; by HIF1AN.
FT                                {ECO:0000250}.
FT   CARBOHYD     41     41       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     65     65       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD     73     73       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD    116    116       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD    146    146       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    194    194       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD    232    232       O-linked (Fuc...); alternate.
FT                                {ECO:0000250}.
FT   CARBOHYD    232    232       O-linked (GalNAc...); alternate.
FT                                {ECO:0000250}.
FT   CARBOHYD    341    341       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    378    378       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    458    458       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    466    466       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD    496    496       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    534    534       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    609    609       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    647    647       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    722    722       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    759    759       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    767    767       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD    797    797       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    805    805       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD    888    888       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    951    951       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD    959    959       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1027   1027       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD   1035   1035       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD   1065   1065       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD   1179   1179       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1189   1189       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD   1197   1197       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD   1241   1241       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1273   1273       O-linked (Glc...). {ECO:0000250}.
FT   CARBOHYD   1362   1362       O-linked (Fuc...). {ECO:0000250}.
FT   CARBOHYD   1402   1402       O-linked (Fuc...); alternate.
FT                                {ECO:0000250}.
FT   CARBOHYD   1402   1402       O-linked (GalNAc...); alternate.
FT                                {ECO:0000250}.
FT   CARBOHYD   1489   1489       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1587   1587       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1715   1715       O-linked (GalNAc...). {ECO:0000250}.
FT   DISULFID     24     37       {ECO:0000250}.
FT   DISULFID     31     46       {ECO:0000250}.
FT   DISULFID     48     57       {ECO:0000250}.
FT   DISULFID     63     74       {ECO:0000250}.
FT   DISULFID     68     87       {ECO:0000250}.
FT   DISULFID     89     98       {ECO:0000250}.
FT   DISULFID    106    117       {ECO:0000250}.
FT   DISULFID    111    127       {ECO:0000250}.
FT   DISULFID    129    138       {ECO:0000250}.
FT   DISULFID    144    155       {ECO:0000250}.
FT   DISULFID    149    164       {ECO:0000250}.
FT   DISULFID    166    175       {ECO:0000250}.
FT   DISULFID    182    195       {ECO:0000250}.
FT   DISULFID    189    204       {ECO:0000250}.
FT   DISULFID    206    215       {ECO:0000250}.
FT   DISULFID    222    233       {ECO:0000250}.
FT   DISULFID    227    243       {ECO:0000250}.
FT   DISULFID    245    254       {ECO:0000250}.
FT   DISULFID    261    272       {ECO:0000250}.
FT   DISULFID    266    281       {ECO:0000250}.
FT   DISULFID    283    292       {ECO:0000250}.
FT   DISULFID    299    312       {ECO:0000250}.
FT   DISULFID    306    321       {ECO:0000250}.
FT   DISULFID    323    332       {ECO:0000250}.
FT   DISULFID    339    350       {ECO:0000250}.
FT   DISULFID    344    359       {ECO:0000250}.
FT   DISULFID    361    370       {ECO:0000250}.
FT   DISULFID    376    387       {ECO:0000250}.
FT   DISULFID    381    398       {ECO:0000250}.
FT   DISULFID    400    409       {ECO:0000250}.
FT   DISULFID    416    429       {ECO:0000250}.
FT   DISULFID    423    438       {ECO:0000250}.
FT   DISULFID    440    449       {ECO:0000250}.
FT   DISULFID    456    467       {ECO:0000250}.
FT   DISULFID    461    476       {ECO:0000250}.
FT   DISULFID    478    487       {ECO:0000250}.
FT   DISULFID    494    505       {ECO:0000250}.
FT   DISULFID    499    514       {ECO:0000250}.
FT   DISULFID    516    525       {ECO:0000250}.
FT   DISULFID    532    543       {ECO:0000250}.
FT   DISULFID    537    552       {ECO:0000250}.
FT   DISULFID    554    563       {ECO:0000250}.
FT   DISULFID    570    580       {ECO:0000250}.
FT   DISULFID    575    589       {ECO:0000250}.
FT   DISULFID    591    600       {ECO:0000250}.
FT   DISULFID    607    618       {ECO:0000250}.
FT   DISULFID    612    627       {ECO:0000250}.
FT   DISULFID    629    638       {ECO:0000250}.
FT   DISULFID    645    655       {ECO:0000250}.
FT   DISULFID    650    664       {ECO:0000250}.
FT   DISULFID    666    675       {ECO:0000250}.
FT   DISULFID    682    693       {ECO:0000250}.
FT   DISULFID    687    702       {ECO:0000250}.
FT   DISULFID    704    713       {ECO:0000250}.
FT   DISULFID    720    730       {ECO:0000250}.
FT   DISULFID    725    739       {ECO:0000250}.
FT   DISULFID    741    750       {ECO:0000250}.
FT   DISULFID    757    768       {ECO:0000250}.
FT   DISULFID    762    777       {ECO:0000250}.
FT   DISULFID    779    788       {ECO:0000250}.
FT   DISULFID    795    806       {ECO:0000250}.
FT   DISULFID    800    815       {ECO:0000250}.
FT   DISULFID    817    826       {ECO:0000250}.
FT   DISULFID    833    844       {ECO:0000250}.
FT   DISULFID    838    855       {ECO:0000250}.
FT   DISULFID    857    866       {ECO:0000250}.
FT   DISULFID    873    884       {ECO:0000250}.
FT   DISULFID    878    893       {ECO:0000250}.
FT   DISULFID    895    904       {ECO:0000250}.
FT   DISULFID    911    922       {ECO:0000250}.
FT   DISULFID    916    931       {ECO:0000250}.
FT   DISULFID    933    942       {ECO:0000250}.
FT   DISULFID    949    960       {ECO:0000250}.
FT   DISULFID    954    969       {ECO:0000250}.
FT   DISULFID    971    980       {ECO:0000250}.
FT   DISULFID    987    998       {ECO:0000250}.
FT   DISULFID    992   1007       {ECO:0000250}.
FT   DISULFID   1009   1018       {ECO:0000250}.
FT   DISULFID   1025   1036       {ECO:0000250}.
FT   DISULFID   1030   1045       {ECO:0000250}.
FT   DISULFID   1047   1056       {ECO:0000250}.
FT   DISULFID   1063   1074       {ECO:0000250}.
FT   DISULFID   1068   1083       {ECO:0000250}.
FT   DISULFID   1085   1094       {ECO:0000250}.
FT   DISULFID   1101   1122       {ECO:0000250}.
FT   DISULFID   1116   1131       {ECO:0000250}.
FT   DISULFID   1133   1142       {ECO:0000250}.
FT   DISULFID   1149   1160       {ECO:0000250}.
FT   DISULFID   1154   1169       {ECO:0000250}.
FT   DISULFID   1171   1180       {ECO:0000250}.
FT   DISULFID   1187   1198       {ECO:0000250}.
FT   DISULFID   1192   1207       {ECO:0000250}.
FT   DISULFID   1209   1218       {ECO:0000250}.
FT   DISULFID   1225   1244       {ECO:0000250}.
FT   DISULFID   1238   1253       {ECO:0000250}.
FT   DISULFID   1255   1264       {ECO:0000250}.
FT   DISULFID   1271   1284       {ECO:0000250}.
FT   DISULFID   1276   1293       {ECO:0000250}.
FT   DISULFID   1295   1304       {ECO:0000250}.
FT   DISULFID   1311   1322       {ECO:0000250}.
FT   DISULFID   1316   1334       {ECO:0000250}.
FT   DISULFID   1336   1345       {ECO:0000250}.
FT   DISULFID   1352   1363       {ECO:0000250}.
FT   DISULFID   1357   1372       {ECO:0000250}.
FT   DISULFID   1374   1383       {ECO:0000250}.
FT   DISULFID   1391   1403       {ECO:0000250}.
FT   DISULFID   1397   1414       {ECO:0000250}.
FT   DISULFID   1416   1425       {ECO:0000250}.
FT   DISULFID   1449   1472       {ECO:0000250}.
FT   DISULFID   1454   1467       {ECO:0000250}.
FT   DISULFID   1463   1479       {ECO:0000250}.
FT   DISULFID   1490   1514       {ECO:0000250}.
FT   DISULFID   1496   1509       {ECO:0000250}.
FT   DISULFID   1505   1521       {ECO:0000250}.
FT   DISULFID   1536   1549       {ECO:0000250}.
FT   DISULFID   1545   1561       {ECO:0000250}.
FT   CROSSLNK   1749   1749       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250}.
FT   CONFLICT    309    309       G -> A (in Ref. 1; CAA40667).
FT                                {ECO:0000305}.
FT   CONFLICT    334    334       E -> D (in Ref. 1; CAA40667).
FT                                {ECO:0000305}.
FT   CONFLICT    402    402       S -> R (in Ref. 1; CAA40667).
FT                                {ECO:0000305}.
FT   CONFLICT    577    577       Y -> I (in Ref. 1; CAA40667).
FT                                {ECO:0000305}.
FT   CONFLICT    951    951       S -> T (in Ref. 1; CAA40667).
FT                                {ECO:0000305}.
FT   CONFLICT   1339   1339       G -> R (in Ref. 1; CAA40667).
FT                                {ECO:0000305}.
FT   CONFLICT   1435   1435       G -> A (in Ref. 1; CAA40667).
FT                                {ECO:0000305}.
FT   CONFLICT   1595   1596       EL -> DV (in Ref. 1; CAA40667).
FT                                {ECO:0000305}.
FT   CONFLICT   2501   2501       P -> R (in Ref. 1; CAA40667).
FT                                {ECO:0000305}.
FT   HELIX       415    418       {ECO:0000244|PDB:4XL1}.
FT   TURN        424    426       {ECO:0000244|PDB:4XL1}.
FT   STRAND      428    432       {ECO:0000244|PDB:4XL1}.
FT   STRAND      435    439       {ECO:0000244|PDB:4XL1}.
FT   STRAND      444    446       {ECO:0000244|PDB:4XL1}.
FT   TURN        455    458       {ECO:0000244|PDB:4XL1}.
FT   STRAND      466    470       {ECO:0000244|PDB:4XL1}.
FT   STRAND      473    477       {ECO:0000244|PDB:4XL1}.
FT   STRAND      482    484       {ECO:0000244|PDB:4XL1}.
FT   TURN        493    496       {ECO:0000244|PDB:4XL1}.
FT   STRAND      504    507       {ECO:0000244|PDB:4XL1}.
FT   STRAND      512    515       {ECO:0000244|PDB:4XL1}.
FT   TURN        522    525       {ECO:0000244|PDB:4XL1}.
SQ   SEQUENCE   2531 AA;  270822 MW;  3E61AE863AA237F2 CRC64;
     MPRLLAPLLC LTLLPALAAR GLRCSQPSGT CLNGGRCEVA NGTEACVCSG AFVGQRCQDP
     SPCLSTPCKN AGTCYVVDHG GIVDYACSCP LGFSGPLCLT PLANACLANP CRNGGTCDLL
     TLTEYKCRCP PGWSGKSCQQ ADPCASNPCA NGGQCLPFES SYICGCPPGF HGPTCRQDVN
     ECSQNPGLCR HGGTCHNEIG SYRCACRATH TGPHCELPYV PCSPSPCQNG GTCRPTGDTT
     HECACLPGFA GQNCEENVDD CPGNNCKNGG ACVDGVNTYN CRCPPEWTGQ YCTEDVDECQ
     LMPNACQNGG TCHNSHGGYN CVCVNGWTGE DCSENIDDCA SAACFQGATC HDRVASFYCE
     CPHGRTGLLC HLNDACISNP CNEGSNCDTN PVNGKAICTC PSGYTGPACS QDVDECALGA
     NPCEHAGKCL NTLGSFECQC LQGYTGPRCE IDVNECISNP CQNDATCLDQ IGEFQCICMP
     GYEGVYCEIN TDECASSPCL HNGRCVDKIN EFLCQCPKGF SGHLCQYDVD ECASTPCKNG
     AKCLDGPNTY TCVCTEGYTG THCEVDIDEC DPDPCHYGLC KDGVATFTCL CQPGYTGHHC
     ETNINECHSQ PCRHGGTCQD RDNYYLCLCL KGTTGPNCEI NLDDCASNPC DSGTCLDKID
     GYECACEPGY TGSMCNVNID ECAGSPCHNG GTCEDGIAGF TCRCPEGYHD PTCLSEVNEC
     NSNPCIHGAC RDGLNGYKCD CAPGWSGTNC DINNNECESN PCVNGGTCKD MTSGYVCTCR
     EGFSGPNCQT NINECASNPC LNQGTCIDDV AGYKCNCPLP YTGATCEVVL APCATSPCKN
     SGVCKESEDY ESFSCVCPTG WQGQTCEIDI NECVKSPCRH GASCQNTNGS YRCLCQAGYT
     GRNCESDIDD CRPNPCHNGG SCTDGVNAAF CDCLPGFQGA FCEEDINECA SNPCQNGANC
     TDCVDSYTCT CPTGFNGIHC ENNTPDCTES SCFNGGTCVD GINSFTCLCP PGFTGSYCQY
     DVNECDSRPC LHGGTCQDSY GTYKCTCPQG YTGLNCQNLV RWCDSAPCKN GGKCWQTNTQ
     YHCECRSGWT GFNCDVLSVS CEVAAQKRGI DVTLLCQHGG LCVDEEDKHY CHCQAGYTGS
     YCEDEVDECS PNPCQNGATC TDYLGGFSCK CVAGYHGSNC SEEINECLSQ PCQNGGTCID
     LTNTYKCSCP RGTQGVHCEI NVDDCHPPLD PASRSPKCFN NGTCVDQVGG YTCTCPPGFV
     GERCEGDVNE CLSNPCDPRG TQNCVQRVND FHCECRAGHT GRRCESVING CRGKPCRNGG
     VCAVASNTAR GFICRCPAGF EGATCENDAR TCGSLRCLNG GTCISGPRSP TCLCLGSFTG
     PECQFPASSP CVGSNPCYNQ GTCEPTSESP FYRCLCPAKF NGLLCHILDY SFTGGAGRDI
     PPPQIEEACE LPECQEDAGN KVCNLQCNNH ACGWDGGDCS LNFNDPWKNC TQSLQCWKYF
     SDGHCDSQCN SAGCLFDGFD CQLTEGQCNP LYDQYCKDHF SDGHCDQGCN SAECEWDGLD
     CAEHVPERLA AGTLVLVVLL PPDQLRNNSF HFLRELSHVL HTNVVFKRDA QGQQMIFPYY
     GREEELRKHP IKRSAVGWAT TSLLPGTNGG RQRRELDPMD IHGSIVYLEI DNRQCVQSSS
     QCFQSATDVA AFLGALASLG SLNIPYKIEA VKSETVEPPL PSQLHLMYVA AAAFVLLFFV
     GCGVLLSRKR RRQHGQLWFP EGFKVSEASK KKRREPLGED SVGLKPLKNA SDGALMDDNQ
     NEWGDEDLET KKFRFEEPVV LPDLDDQTDH RQWTQQHLDA ADLRVSAMAP TPPQGEVDAD
     CMDVNVRGPD GFTPLMIASC SGGGLETGNS EEEEDAPAVI SDFIYQGASL HNQTDRTGET
     ALHLAARYSR SDAAKRLLEA SADANIQDNM GRTPLHAAVS ADAQGVFQIL LRNRATDLDA
     RMHDGTTPLI LAARLAVEGM LEDLINSHAD VNAVDDLGKS ALHWAAAVNN VDAAVVLLKN
     GANKDMQNNK EETPLFLAAR EGSYETAKVL LDHFANRDIT DHMDRLPRDI AQERMHHDIV
     RLLDEYNLVR SPQLHGTALG GTPTLSPTLC SPNGYLGNLK SATQGKKARK PSTKGLACSS
     KEAKDLKARR KKSQDGKGCL LDSSSMLSPV DSLESPHGYL SDVASPPLLP SPFQQSPSMP
     LSHLPGMPDT HLGISHLNVA AKPEMAALAG GSRLAFEPPP PRLSHLPVAS SASTVLSTNG
     TGAMNFTVGA PASLNGQCEW LPRLQNGMVP SQYNPLRPGV TPGTLSTQAA GLQHGMMGPI
     HSSLSTNTLS PIIYQGLPNT RLATQPHLVQ TQQVQPQNLQ IQPQNLQPPS QPHLSVSSAA
     NGHLGRSFLS GEPSQADVQP LGPSSLPVHT ILPQESQALP TSLPSSMVPP MTTTQFLTPP
     SQHSYSSSPV DNTPSHQLQV PEHPFLTPSP ESPDQWSSSS PHSNISDWSE GISSPPTSMP
     SQITHIPEAF K
//
ID   VWF_HUMAN               Reviewed;        2813 AA.
AC   P04275; Q8TCE8; Q99806;
DT   20-MAR-1987, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 4.
DT   17-FEB-2016, entry version 213.
DE   RecName: Full=von Willebrand factor;
DE            Short=vWF;
DE   Contains:
DE     RecName: Full=von Willebrand antigen 2;
DE     AltName: Full=von Willebrand antigen II;
DE   Flags: Precursor;
GN   Name=VWF; Synonyms=F8VWF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ARG-852; ALA-1381
RP   AND HIS-1472.
RX   PubMed=3489923; DOI=10.1093/nar/14.17.7125;
RA   Bonthron D., Orr E.C., Mitsock L.M., Ginsburg D., Handin R.I.,
RA   Orkin S.H.;
RT   "Nucleotide sequence of pre-pro-von Willebrand factor cDNA.";
RL   Nucleic Acids Res. 14:7125-7128(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-471; ARG-852;
RP   ALA-1381 AND HIS-1472.
RX   PubMed=2584182;
RA   Mancuso D.J., Tuley E.A., Westfield L.A., Worrall N.K.,
RA   Shelton-Inloes B.B., Sorace J.M., Alevy Y.G., Sadler J.E.;
RT   "Structure of the gene for human von Willebrand factor.";
RL   J. Biol. Chem. 264:19514-19527(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-1400 (ISOFORM 1), AND VARIANTS
RP   ARG-484; ARG-852 AND ALA-1381.
RX   PubMed=3019665;
RA   Verweij C.L., Diergaarde P.J., Hart M., Pannekoek H.;
RT   "Full-length von Willebrand factor (vWF) cDNA encodes a highly
RT   repetitive protein considerably larger than the mature vWF subunit.";
RL   EMBO J. 5:1839-1847(1986).
RN   [7]
RP   ERRATUM.
RA   Verweij C.L., Diergaarde P.J., Hart M., Pannekoek H.;
RL   EMBO J. 5:3074-3074(1986).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-178.
RX   PubMed=2828057; DOI=10.1111/j.1432-1033.1988.tb13757.x;
RA   Bonthron D., Orkin S.H.;
RT   "The human von Willebrand factor gene. Structure of the 5' region.";
RL   Eur. J. Biochem. 171:51-57(1988).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-120 (ISOFORM 1), AND PROTEIN SEQUENCE
RP   OF 23-56.
RC   TISSUE=Umbilical vein endothelial cell;
RX   PubMed=3495266; DOI=10.1016/S0006-291X(87)80016-5;
RA   Shelton-Inloes B.B., Broze G.J. Jr., Miletich J.P., Sadler J.E.;
RT   "Evolution of human von Willebrand factor: cDNA sequence
RT   polymorphisms, repeated domains, and relationship to von Willebrand
RT   antigen II.";
RL   Biochem. Biophys. Res. Commun. 144:657-665(1987).
RN   [10]
RP   PROTEIN SEQUENCE OF 764-2813, AND VARIANTS ARG-852 AND ALA-1381.
RX   PubMed=3524673; DOI=10.1021/bi00359a015;
RA   Titani K., Kumar S., Takio K., Ericsson L.H., Wade R.D., Ashida K.,
RA   Walsh K.A., Chopek M.W., Sadler J.E., Fujikawa K.;
RT   "Amino acid sequence of human von Willebrand factor.";
RL   Biochemistry 25:3171-3184(1986).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 744-873 AND 1289-2813 (ISOFORM 1), AND
RP   VARIANTS ALA-789; ARG-852 AND ALA-1381.
RX   PubMed=2864688; DOI=10.1073/pnas.82.19.6394;
RA   Sadler J.E., Shelton-Inloes B.B., Sorace J.M., Harlan J.M., Titani K.,
RA   Davie E.W.;
RT   "Cloning and characterization of two cDNAs coding for human von
RT   Willebrand factor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:6394-6398(1985).
RN   [12]
RP   PROTEIN SEQUENCE OF 764-782.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 781-1424 (ISOFORM 1), AND VARIANTS
RP   ARG-852 AND ALA-1381.
RX   PubMed=3488076; DOI=10.1021/bi00359a014;
RA   Shelton-Inloes B.B., Titani K., Sadler J.E.;
RT   "cDNA sequences for human von Willebrand factor reveal five types of
RT   repeated domains and five possible protein sequence polymorphisms.";
RL   Biochemistry 25:3164-3171(1986).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 990-1947, AND VARIANTS ALA-1381
RP   AND HIS-1472.
RX   PubMed=1988024; DOI=10.1021/bi00215a036;
RA   Mancuso D.J., Tuley E.A., Westfield L.A., Lester-Mancuso T.L.,
RA   Le Beau M.M., Sorace J.M., Sadler J.E.;
RT   "Human von Willebrand factor gene and pseudogene: structural analysis
RT   and differentiation by polymerase chain reaction.";
RL   Biochemistry 30:253-269(1991).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1236-1476 (ISOFORM 1), AND VARIANT
RP   ALA-1381.
RX   PubMed=9373253;
RA   Schulte am Esch J. II, Cruz M.A., Siegel J.B., Anrather J.,
RA   Robson S.C.;
RT   "Activation of human platelets by the membrane-expressed A1 domain of
RT   von Willebrand factor.";
RL   Blood 90:4425-4437(1997).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2621-2813 (ISOFORM 1).
RX   PubMed=3874428; DOI=10.1126/science.3874428;
RA   Ginsburg D., Handin R.I., Bonthron D.T., Donlon T.A., Bruns G.A.P.,
RA   Latt S.A., Orkin S.H.;
RT   "Human von Willebrand factor (vWF): isolation of complementary DNA
RT   (cDNA) clones and chromosomal localization.";
RL   Science 228:1401-1406(1985).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2731-2813 (ISOFORM 1).
RX   PubMed=3873280; DOI=10.1016/0092-8674(85)90060-1;
RA   Lynch D.C., Zimmerman T.S., Collins C.J., Brown M., Morin M.J.,
RA   Ling E.H., Livingston D.M.;
RT   "Molecular cloning of cDNA for human von Willebrand factor:
RT   authentication by a new method.";
RL   Cell 41:49-56(1985).
RN   [18]
RP   SEQUENCE REVISION.
RA   Lynch D.C.;
RL   Submitted (JUL-1991) to the EMBL/GenBank/DDBJ databases.
RN   [19]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2731-2813 (ISOFORM 1).
RX   PubMed=3875078; DOI=10.1093/nar/13.13.4699;
RA   Verweij C.L., de Vries C.J.M., Distel B., van Zonneveld A.-J.,
RA   Geurts van Kessel A., van Mourik J.A., Pannekoek H.;
RT   "Construction of cDNA coding for human von Willebrand factor using
RT   antibody probes for colony-screening and mapping of the chromosomal
RT   gene.";
RL   Nucleic Acids Res. 13:4699-4717(1985).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2731-2813.
RX   PubMed=3496594; DOI=10.1073/pnas.84.13.4393;
RA   Collins C.J., Underdahl J.P., Levene R.B., Ravera C.P., Morin M.J.,
RA   Dombalagian M.J., Ricca G., Livingston D.M., Lynch D.C.;
RT   "Molecular cloning of the human gene for von Willebrand factor and
RT   identification of the transcription initiation site.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:4393-4397(1987).
RN   [21]
RP   SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=10961880;
RA   Haberichter S.L., Fahs S.A., Montgomery R.R.;
RT   "von Willebrand factor storage and multimerization: 2 independent
RT   intracellular processes.";
RL   Blood 96:1808-1815(2000).
RN   [22]
RP   DISULFIDE BONDS.
RX   PubMed=3502076; DOI=10.1021/bi00399a013;
RA   Marti T., Rosselet S.J., Titani K., Walsh K.A.;
RT   "Identification of disulfide-bridged substructures within human von
RT   Willebrand factor.";
RL   Biochemistry 26:8099-8109(1987).
RN   [23]
RP   STRUCTURE OF CARBOHYDRATES.
RX   PubMed=3089784; DOI=10.1111/j.1432-1033.1986.tb09750.x;
RA   Samor B., Michalski J.C., Debray H., Mazurier C., Goudemand M.,
RA   van Halbeek H., Vliegenthart J.F.G., Montreuil J.;
RT   "Primary structure of a new tetraantennary glycan of the N-
RT   acetyllactosaminic type isolated from human factor VIII/von Willebrand
RT   factor.";
RL   Eur. J. Biochem. 158:295-298(1986).
RN   [24]
RP   INTERACTION WITH F8.
RX   PubMed=9218428; DOI=10.1074/jbc.272.29.18007;
RA   Saenko E.L., Scandella D.;
RT   "The acidic region of the factor VIII light chain and the C2 domain
RT   together form the high affinity binding site for von Willebrand
RT   factor.";
RL   J. Biol. Chem. 272:18007-18014(1997).
RN   [25]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-1515.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [26]
RP   UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-1720.
RC   TISSUE=Mammary cancer;
RX   PubMed=17370265; DOI=10.1002/pmic.200600410;
RA   Denis N.J., Vasilescu J., Lambert J.-P., Smith J.C., Figeys D.;
RT   "Tryptic digestion of ubiquitin standards reveals an improved strategy
RT   for identifying ubiquitinated proteins by mass spectrometry.";
RL   Proteomics 7:868-874(2007).
RN   [27]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-2546.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [28]
RP   GLYCOSYLATION AT ASN-1515.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1261-1468.
RX   PubMed=9553097; DOI=10.1074/jbc.273.17.10396;
RA   Emsley J., Cruz M., Handin R., Liddington R.;
RT   "Crystal structure of the von Willebrand factor A1 domain and
RT   implications for the binding of platelet glycoprotein Ib.";
RL   J. Biol. Chem. 273:10396-10401(1998).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1685-1873.
RX   PubMed=9331419; DOI=10.1016/S0969-2126(97)00266-9;
RA   Huizinga E.G., Martijn van der Plas R., Kroon J., Sixma J.J., Gros P.;
RT   "Crystal structure of the A3 domain of human von Willebrand factor:
RT   implications for collagen binding.";
RL   Structure 5:1147-1156(1997).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1686-1872.
RX   PubMed=9312128; DOI=10.1074/jbc.272.40.25162;
RA   Bienkowska J., Cruz M., Atiemo A., Handin R., Liddington R.;
RT   "The von Willebrand factor A3 domain does not contain a metal ion-
RT   dependent adhesion site motif.";
RL   J. Biol. Chem. 272:25162-25167(1997).
RN   [32]
RP   REVIEW.
RX   PubMed=12871266; DOI=10.1046/j.1538-7836.2003.00260.x;
RA   Ruggeri Z.M.;
RT   "von Willebrand factor, platelets and endothelial cell interactions.";
RL   J. Thromb. Haemost. 1:1335-1342(2003).
RN   [33]
RP   VARIANTS VWD2 TRP-1597 AND ASP-1607.
RX   PubMed=2786201; DOI=10.1073/pnas.86.10.3723;
RA   Ginsburg D., Konkle B.A., Gill J.C., Montgomery R.R.,
RA   Bockenstedt P.L., Johnson T.A., Yang A.Y.;
RT   "Molecular basis of human von Willebrand disease: analysis of platelet
RT   von Willebrand factor mRNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:3723-3727(1989).
RN   [34]
RP   VARIANT VWD2 THR-1628.
RX   PubMed=1673047;
RA   Iannuzzi M.C., Hidaka N., Boehnke M., Bruck M.E., Hanna W.T.,
RA   Collins F.S., Ginsburg D.;
RT   "Analysis of the relationship of von Willebrand disease (vWD) and
RT   hereditary hemorrhagic telangiectasia and identification of a
RT   potential type IIA vWD mutation (IIe865 to Thr).";
RL   Am. J. Hum. Genet. 48:757-763(1991).
RN   [35]
RP   VARIANTS VWD2 TRP-816 AND GLN-854.
RX   PubMed=1832934; DOI=10.1111/j.1365-2141.1991.tb04480.x;
RA   Gaucher C., Mercier B., Jorieux S., Oufkir D., Mazurier C.;
RT   "Identification of two point mutations in the von Willebrand factor
RT   gene of three families with the 'Normandy' variant of von Willebrand
RT   disease.";
RL   Br. J. Haematol. 78:506-514(1991).
RN   [36]
RP   VARIANT VWD2 CYS-1308.
RX   PubMed=1761120;
RA   Donner M., Andersson A.-M., Kristoffersson A.-C., Nilsson I.M.,
RA   Dahlback B., Holmberg L.;
RT   "An Arg545-->Cys545 substitution mutation of the von Willebrand factor
RT   in type IIB von Willebrand's disease.";
RL   Eur. J. Haematol. 47:342-345(1991).
RN   [37]
RP   VARIANTS VWD2 TRP-1306; CYS-1308 AND PRO-1613.
RX   PubMed=2010538; DOI=10.1172/JCI115122;
RA   Randi A.M., Rabinowitz I., Mancuso D.J., Mannucci P.M., Sadler J.E.;
RT   "Molecular basis of von Willebrand disease type IIB. Candidate
RT   mutations cluster in one disulfide loop between proposed platelet
RT   glycoprotein Ib binding sequences.";
RL   J. Clin. Invest. 87:1220-1226(1991).
RN   [38]
RP   VARIANTS VWD2 TRP-1306; CYS-1308; MET-1316 AND GLN-1341, AND VARIANT
RP   HIS-1399.
RX   PubMed=1672694; DOI=10.1172/JCI115123;
RA   Cooney K.A., Nichols W.C., Bruck M.E., Bahou W.F., Shapiro A.D.,
RA   Bowie E.J.W., Gralnick H.R., Ginsburg D.;
RT   "The molecular defect in type IIB von Willebrand disease.
RT   Identification of four potential missense mutations within the
RT   putative GpIb binding domain.";
RL   J. Clin. Invest. 87:1227-1233(1991).
RN   [39]
RP   VARIANT VWD2 CYS-1313.
RX   PubMed=2011604; DOI=10.1073/pnas.88.7.2946;
RA   Ware J., Dent J.A., Azuma H., Sugimoto M., Kyrle P.A., Yoshioka A.,
RA   Ruggeri Z.M.;
RT   "Identification of a point mutation in type IIB von Willebrand disease
RT   illustrating the regulation of von Willebrand factor affinity for the
RT   platelet membrane glycoprotein Ib-IX receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:2946-2950(1991).
RN   [40]
RP   VARIANT VWD2 MET-791.
RX   PubMed=1906179; DOI=10.1073/pnas.88.14.6377;
RA   Tuley E.A., Gaucher C., Jorieux S., Worrall N.K., Sadler J.E.,
RA   Mazurier C.;
RT   "Expression of von Willebrand factor 'Normandy': an autosomal mutation
RT   that mimics hemophilia A.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:6377-6381(1991).
RN   [41]
RP   VARIANT VWD2 MET-1316.
RX   PubMed=1729889;
RA   Murray E.W., Giles A.R., Lillicrap D.;
RT   "Germ-line mosaicism for a valine-to-methionine substitution at
RT   residue 553 in the glycoprotein Ib-binding domain of von Willebrand
RT   factor, causing type IIB von Willebrand disease.";
RL   Am. J. Hum. Genet. 50:199-207(1992).
RN   [42]
RP   VARIANTS VWD2 TRP-1306; MET-1316; THR-1628 AND SER-1648.
RX   PubMed=1420817;
RA   Pietu G., Ribba A.S., de Paillette L., Cherel G., Lavergne J.-M.,
RA   Bahnak B.R., Meyer D.;
RT   "Molecular study of von Willebrand disease: identification of
RT   potential mutations in patients with type IIA and type IIB.";
RL   Blood Coagul. Fibrinolysis 3:415-421(1992).
RN   [43]
RP   VARIANTS VWD2 TRP-1306; CYS-1308; LEU-1314 AND LEU-1318.
RX   PubMed=1419803; DOI=10.1111/j.1365-2141.1992.tb04594.x;
RA   Donner M., Kristoffersson A.-C., Lenk H., Scheibel E., Dahlback B.,
RA   Nilsson I.M., Holmberg L.;
RT   "Type IIB von Willebrand's disease: gene mutations and clinical
RT   presentation in nine families from Denmark, Germany and Sweden.";
RL   Br. J. Haematol. 82:58-65(1992).
RN   [44]
RP   VARIANT VWD2 ARG-1272.
RX   PubMed=1419804; DOI=10.1111/j.1365-2141.1992.tb04595.x;
RA   Lavergne J.-M., de Paillette L., Bahnak B.R., Ribba A.-S.,
RA   Fressinaud E., Meyer D., Pietu G.;
RT   "Defects in type IIA von Willebrand disease: a cysteine 509 to
RT   arginine substitution in the mature von Willebrand factor disrupts a
RT   disulphide loop involved in the interaction with platelet glycoprotein
RT   Ib-IX.";
RL   Br. J. Haematol. 82:66-72(1992).
RN   [45]
RP   VARIANT VWD2 LYS-1638.
RX   PubMed=1429668;
RA   Ribba A.S., Voorberg J., Meyer D., Pannekoek H., Pietu G.;
RT   "Characterization of recombinant von Willebrand factor corresponding
RT   to mutations in type IIA and type IIB von Willebrand disease.";
RL   J. Biol. Chem. 267:23209-23215(1992).
RN   [46]
RP   VARIANT VWD2 SER-1324.
RX   PubMed=1409710; DOI=10.1073/pnas.89.20.9846;
RA   Rabinowitz I., Tuley E.A., Mancuso D.J., Randi A.M., Firkin B.G.,
RA   Howard M.A., Sadler J.E.;
RT   "von Willebrand disease type B: a missense mutation selectively
RT   abolishes ristocetin-induced von Willebrand factor binding to platelet
RT   glycoprotein Ib.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:9846-9849(1992).
RN   [47]
RP   VARIANTS VWD2 GLN-1597; ARG-1609 AND GLU-1665.
RX   PubMed=8338947;
RA   Inbal A., Englender T., Kornbrot N., Randi A.M., Castaman G.,
RA   Mannucci P.M., Sadler J.E.;
RT   "Identification of three candidate mutations causing type IIA von
RT   Willebrand disease using a rapid, nonradioactive, allele-specific
RT   hybridization method.";
RL   Blood 82:830-836(1993).
RN   [48]
RP   VARIANT VWD2 CYS-1514.
RX   PubMed=8435341; DOI=10.1111/j.1365-2141.1993.tb04637.x;
RA   Gaucher C., Hanss M., Dechavanne M., Mazurier C.;
RT   "Substitution of cysteine for phenylalanine 751 in mature von
RT   Willebrand factor is a novel candidate mutation in a family with type
RT   IIA von Willebrand disease.";
RL   Br. J. Haematol. 83:94-99(1993).
RN   [49]
RP   VARIANTS VWD2 GLY-1597 AND ARG-1609, AND VARIANT CYS-1584.
RX   PubMed=8348943;
RA   Donner M., Kristoffersson A.C., Berntorp E., Scheibel E., Thorsen S.,
RA   Dahlback B., Nilsson I.M., Holmberg L.;
RT   "Two new candidate mutations in type IIA von Willebrand's disease
RT   (Arg834-->Gly, Gly846-->Arg) and one polymorphism (Tyr821-->Cys) in
RT   the A2 region of the von Willebrand factor.";
RL   Eur. J. Haematol. 51:38-44(1993).
RN   [50]
RP   VARIANT VWD2 ASP-1268.
RX   PubMed=8376405;
RA   Rabinowitz I., Randi A.M., Shindler K.S., Tuley E.A., Rustagi P.K.,
RA   Sadler J.E.;
RT   "Type IIB mutation His-505-->Asp implicates a new segment in the
RT   control of von Willebrand factor binding to platelet glycoprotein
RT   Ib.";
RL   J. Biol. Chem. 268:20497-20501(1993).
RN   [51]
RP   VARIANT VWD2 LEU-1266.
RX   PubMed=8486782; DOI=10.1172/JCI116443;
RA   Holmberg L., Dent J.A., Schneppenheim R., Budde U., Ware J.,
RA   Ruggeri Z.M.;
RT   "von Willebrand factor mutation enhancing interaction with platelets
RT   in patients with normal multimeric structure.";
RL   J. Clin. Invest. 91:2169-2177(1993).
RN   [52]
RP   VARIANT VWD2 VAL-1460.
RX   PubMed=8123843;
RA   Hilbert L., Gaucher C., de Romeuf C., Horellou M.H., Vink T.,
RA   Mazurier C.;
RT   "Leu 697-->Val mutation in mature von Willebrand factor is responsible
RT   for type IIB von Willebrand disease.";
RL   Blood 83:1542-1550(1994).
RN   [53]
RP   VARIANTS VWD2 PRO-1540 AND THR-1628.
RX   PubMed=8123844;
RA   Lyons S.E., Cooney K.A., Bockenstedt P., Ginsburg D.;
RT   "Characterization of Leu777Pro and Ile865Thr type IIA von Willebrand
RT   disease mutations.";
RL   Blood 83:1551-1557(1994).
RN   [54]
RP   VARIANT VWD3 TYR-2739.
RX   PubMed=8088787; DOI=10.1006/geno.1994.1241;
RA   Zhang Z.P., Blombaeck M., Egberg N., Falk G., Anvret M.;
RT   "Characterization of the von Willebrand factor gene (VWF) in von
RT   Willebrand disease type III patients from 24 families of Swedish and
RT   Finnish origin.";
RL   Genomics 21:188-193(1994).
RN   [55]
RP   VARIANT VWD3 CYS-377.
RX   PubMed=7989040; DOI=10.1007/BF00206958;
RA   Schneppenheim R., Krey S., Bergmann F., Bock D., Budde U., Lange M.,
RA   Linde R., Mittler U., Meili E., Mertes G., Olek K., Plendl H.,
RA   Simeoni E.;
RT   "Genetic heterogeneity of severe von Willebrand disease type III in
RT   the German population.";
RL   Hum. Genet. 94:640-652(1994).
RN   [56]
RP   VARIANT VWD2 SER-528.
RX   PubMed=8011991;
RA   Uno H., Nishida N., Ishizaki J., Suzuki M., Nishikubo T., Miyata S.,
RA   Takahashi Y., Yoshioka A., Tsuda K.;
RT   "Investigation of type IIC von Willebrand disease.";
RL   Int. J. Hematol. 59:219-225(1994).
RN   [57]
RP   VARIANTS VWD2 CYS-1374 AND HIS-1374.
RX   PubMed=7620154;
RA   Hilbert L., Gaucher C., Mazurier C.;
RT   "Identification of two mutations (Arg611Cys and Arg611His) in the A1
RT   loop of von Willebrand factor (vWF) responsible for type 2 von
RT   Willebrand disease with decreased platelet-dependent function of
RT   vWF.";
RL   Blood 86:1010-1018(1995).
RN   [58]
RP   VARIANT VWD2 HIS-1374.
RX   PubMed=7734373; DOI=10.1111/j.1365-2141.1995.tb08383.x;
RA   Castaman G., Eikenboom C.J.C., Rodeghiero F., Briet K., Reitsma P.H.;
RT   "A novel candidate mutation (Arg611-->His) in type I 'platelet
RT   discordant' von Willebrand's disease with desmopressin-induced
RT   thrombocytopenia.";
RL   Br. J. Haematol. 89:656-658(1995).
RN   [59]
RP   VARIANT VWD2 VAL-1461.
RX   PubMed=8547152; DOI=10.1111/j.1365-2141.1995.tb05423.x;
RA   Hilbert L., Gaucher C., Mazurier C.;
RT   "Effects of different amino-acid substitutions in the leucine 694-
RT   proline 708 segment of recombinant von Willebrand factor.";
RL   Br. J. Haematol. 91:983-990(1995).
RN   [60]
RP   VARIANT VWD2 ARG-550.
RX   PubMed=7789955; DOI=10.1007/BF00209487;
RA   Schneppenheim R., Thomas K.B., Krey S., Budde U., Jessat U.,
RA   Sutor A.H., Zeiger B.;
RT   "Identification of a candidate missense mutation in a family with von
RT   Willebrand disease type IIC.";
RL   Hum. Genet. 95:681-686(1995).
RN   [61]
RP   VARIANT VWD2 ARG-2773.
RX   PubMed=8622978; DOI=10.1073/pnas.93.8.3581;
RA   Schneppenheim R., Brassard J., Krey S., Budde U., Kunicki T.J.,
RA   Holmberg L., Ware J., Ruggeri Z.M.;
RT   "Defective dimerization of von Willebrand factor subunits due to a
RT   Cys-> Arg mutation in type IID von Willebrand disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:3581-3586(1996).
RN   [62]
RP   VARIANT VWD1 TRP-273, AND VARIANT VWD3 TRP-273.
RX   PubMed=10887119;
RA   Allen S., Abuzenadah A.M., Hinks J., Blagg J.L., Gursel T.,
RA   Ingerslev J., Goodeve A.C., Peake I.R., Daly M.E.;
RT   "A novel von Willebrand disease-causing mutation (Arg273Trp) in the
RT   von Willebrand factor propeptide that results in defective
RT   multimerization and secretion.";
RL   Blood 96:560-568(2000).
RN   [63]
RP   VARIANT VWD1 ARG-1149, AND MUTAGENESIS OF CYS-1149 AND CYS-1169.
RX   PubMed=11698279; DOI=10.1182/blood.V98.10.2973;
RA   Bodo I., Katsumi A., Tuley E.A., Eikenboom J.C., Dong Z., Sadler J.E.;
RT   "Type 1 von Willebrand disease mutation Cys1149Arg causes
RT   intracellular retention and degradation of heterodimers: a possible
RT   general mechanism for dominant mutations of oligomeric proteins.";
RL   Blood 98:2973-2979(2001).
RN   [64]
RP   VARIANT VWD2 ARG-1060.
RX   PubMed=12406074; DOI=10.1046/j.1365-2141.2002.03819.x;
RA   Mazurier C., Parquet-Gernez A., Gaucher C., Lavergne J.-M.,
RA   Goudemand J.;
RT   "Factor VIII deficiency not induced by FVIII gene mutation in a female
RT   first cousin of two brothers with haemophilia A.";
RL   Br. J. Haematol. 119:390-392(2002).
RN   [65]
RP   VARIANT CYS-1584.
RX   PubMed=15755288; DOI=10.1111/j.1365-2141.2005.05375.x;
RA   Bowen D.J., Collins P.W., Lester W., Cumming A.M., Keeney S.,
RA   Grundy P., Enayat S.M., Bolton-Maggs P.H., Keeling D.M., Khair K.,
RA   Tait R.C., Wilde J.T., Pasi K.J., Hill F.G.;
RT   "The prevalence of the cysteine1584 variant of von Willebrand factor
RT   is increased in type 1 von Willebrand disease: co-segregation with
RT   increased susceptibility to ADAMTS13 proteolysis but not clinical
RT   phenotype.";
RL   Br. J. Haematol. 128:830-836(2005).
RN   [66]
RP   VARIANT [LARGE SCALE ANALYSIS] CYS-1570.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [67]
RP   VARIANT VWD2 PHE-1272.
RX   PubMed=21592258; DOI=10.1111/j.1365-2516.2011.02569.x;
RA   Woods A.I., Sanchez-Luceros A., Kempfer A.C., Powazniak Y.,
RA   Calderazzo Pereyra J.C., Blanco A.N., Meschengieser S.S.,
RA   Lazzari M.A.;
RT   "C1272F: a novel type 2A von Willebrand's disease mutation in A1
RT   domain; its clinical significance.";
RL   Haemophilia 18:112-116(2012).
CC   -!- FUNCTION: Important in the maintenance of hemostasis, it promotes
CC       adhesion of platelets to the sites of vascular injury by forming a
CC       molecular bridge between sub-endothelial collagen matrix and
CC       platelet-surface receptor complex GPIb-IX-V. Also acts as a
CC       chaperone for coagulation factor VIII, delivering it to the site
CC       of injury, stabilizing its heterodimeric structure and protecting
CC       it from premature clearance from plasma.
CC   -!- SUBUNIT: Multimeric. Interacts with F8.
CC       {ECO:0000269|PubMed:10961880, ECO:0000269|PubMed:9218428}.
CC   -!- INTERACTION:
CC       Self; NbExp=15; IntAct=EBI-981819, EBI-981819;
CC       Q76LX8:ADAMTS13; NbExp=5; IntAct=EBI-981819, EBI-981764;
CC       P07359:GP1BA; NbExp=2; IntAct=EBI-981819, EBI-297082;
CC       Q96CV9:OPTN; NbExp=2; IntAct=EBI-981819, EBI-748974;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:10961880}.
CC       Secreted, extracellular space, extracellular matrix
CC       {ECO:0000269|PubMed:10961880}. Note=Localized to storage granules.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P04275-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P04275-2; Sequence=VSP_056527, VSP_056528, VSP_056529;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Plasma.
CC   -!- DOMAIN: The von Willebrand antigen 2 is required for
CC       multimerization of vWF and for its targeting to storage granules.
CC   -!- PTM: All cysteine residues are involved in intrachain or
CC       interchain disulfide bonds.
CC   -!- PTM: N- and O-glycosylated. {ECO:0000269|PubMed:14760718,
CC       ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:19159218}.
CC   -!- DISEASE: von Willebrand disease 1 (VWD1) [MIM:193400]: A common
CC       hemorrhagic disorder due to defects in von Willebrand factor
CC       protein and resulting in impaired platelet aggregation. Von
CC       Willebrand disease type 1 is characterized by partial quantitative
CC       deficiency of circulating von Willebrand factor, that is otherwise
CC       structurally and functionally normal. Clinical manifestations are
CC       mucocutaneous bleeding, such as epistaxis and menorrhagia, and
CC       prolonged bleeding after surgery or trauma.
CC       {ECO:0000269|PubMed:10887119, ECO:0000269|PubMed:11698279}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: von Willebrand disease 2 (VWD2) [MIM:613554]: A
CC       hemorrhagic disorder due to defects in von Willebrand factor
CC       protein and resulting in altered platelet aggregation. Von
CC       Willebrand disease type 2 is characterized by qualitative
CC       deficiency and functional anomalies of von Willebrand factor. It
CC       is divided in different subtypes including 2A, 2B, 2M and 2N
CC       (Normandy variant). The mutant VWF protein in types 2A, 2B and 2M
CC       are defective in their platelet-dependent function, whereas the
CC       mutant protein in type 2N is defective in its ability to bind
CC       factor VIII. Clinical manifestations are mucocutaneous bleeding,
CC       such as epistaxis and menorrhagia, and prolonged bleeding after
CC       surgery or trauma. {ECO:0000269|PubMed:12406074,
CC       ECO:0000269|PubMed:1409710, ECO:0000269|PubMed:1419803,
CC       ECO:0000269|PubMed:1419804, ECO:0000269|PubMed:1420817,
CC       ECO:0000269|PubMed:1429668, ECO:0000269|PubMed:1672694,
CC       ECO:0000269|PubMed:1673047, ECO:0000269|PubMed:1729889,
CC       ECO:0000269|PubMed:1761120, ECO:0000269|PubMed:1832934,
CC       ECO:0000269|PubMed:1906179, ECO:0000269|PubMed:2010538,
CC       ECO:0000269|PubMed:2011604, ECO:0000269|PubMed:21592258,
CC       ECO:0000269|PubMed:2786201, ECO:0000269|PubMed:7620154,
CC       ECO:0000269|PubMed:7734373, ECO:0000269|PubMed:7789955,
CC       ECO:0000269|PubMed:8011991, ECO:0000269|PubMed:8123843,
CC       ECO:0000269|PubMed:8123844, ECO:0000269|PubMed:8338947,
CC       ECO:0000269|PubMed:8348943, ECO:0000269|PubMed:8376405,
CC       ECO:0000269|PubMed:8435341, ECO:0000269|PubMed:8486782,
CC       ECO:0000269|PubMed:8547152, ECO:0000269|PubMed:8622978}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: von Willebrand disease 3 (VWD3) [MIM:277480]: A severe
CC       hemorrhagic disorder due to a total or near total absence of von
CC       Willebrand factor in the plasma and cellular compartments, also
CC       leading to a profound deficiency of plasmatic factor VIII.
CC       Bleeding usually starts in infancy and can include epistaxis,
CC       recurrent mucocutaneous bleeding, excessive bleeding after minor
CC       trauma, and hemarthroses. {ECO:0000269|PubMed:10887119,
CC       ECO:0000269|PubMed:7989040, ECO:0000269|PubMed:8088787}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Contains 1 CTCK (C-terminal cystine knot-like) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00039}.
CC   -!- SIMILARITY: Contains 4 TIL (trypsin inhibitory-like) domains.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 3 VWFA domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00219}.
CC   -!- SIMILARITY: Contains 3 VWFC domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00220}.
CC   -!- SIMILARITY: Contains 4 VWFD domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00580}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB59512.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=vWF; Note=von Willebrand factor (vWF) mutation
CC       db;
CC       URL="http://www.vwf.group.shef.ac.uk/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Von Willebrand factor entry;
CC       URL="https://en.wikipedia.org/wiki/Von_Willebrand_factor";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04385; CAA27972.1; -; mRNA.
DR   EMBL; M25865; AAB59458.1; -; Genomic_DNA.
DR   EMBL; M25828; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25829; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25830; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25831; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25832; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25833; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25834; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25835; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25836; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25837; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25838; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25839; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25840; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25841; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25842; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25843; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25844; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25845; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25846; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25847; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25848; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25849; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25850; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25851; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25852; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25853; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25854; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25855; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25856; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25857; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25858; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25859; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25860; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25861; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25862; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25863; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; M25864; AAB59458.1; JOINED; Genomic_DNA.
DR   EMBL; AC005845; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005846; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005904; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471116; EAW88817.1; -; Genomic_DNA.
DR   EMBL; BC022258; AAH22258.1; -; mRNA.
DR   EMBL; X04146; CAA27765.1; -; mRNA.
DR   EMBL; X06828; CAA29985.1; -; Genomic_DNA.
DR   EMBL; X06829; CAA29985.1; JOINED; Genomic_DNA.
DR   EMBL; M17588; AAA65940.1; -; mRNA.
DR   EMBL; M10321; AAB59512.1; ALT_SEQ; mRNA.
DR   EMBL; M60675; AAA61295.1; -; Genomic_DNA.
DR   EMBL; U81237; AAB39987.1; -; mRNA.
DR   EMBL; K03028; AAA61293.1; -; mRNA.
DR   EMBL; X02672; CAA26503.1; -; mRNA.
DR   EMBL; M16946; AAA61294.1; -; Genomic_DNA.
DR   EMBL; M16945; AAA61294.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS8539.1; -. [P04275-1]
DR   PIR; A34480; VWHU.
DR   RefSeq; NP_000543.2; NM_000552.3.
DR   UniGene; Hs.440848; -.
DR   PDB; 1AO3; X-ray; 2.20 A; A/B=1686-1872.
DR   PDB; 1ATZ; X-ray; 1.80 A; A/B=1685-1873.
DR   PDB; 1AUQ; X-ray; 2.30 A; A=1261-1468.
DR   PDB; 1FE8; X-ray; 2.03 A; A/B/C=1683-1874.
DR   PDB; 1FNS; X-ray; 2.00 A; A=1271-1465.
DR   PDB; 1IJB; X-ray; 1.80 A; A=1263-1464.
DR   PDB; 1IJK; X-ray; 2.60 A; A=1263-1464.
DR   PDB; 1M10; X-ray; 3.10 A; A=1261-1468.
DR   PDB; 1OAK; X-ray; 2.20 A; A=1271-1465.
DR   PDB; 1SQ0; X-ray; 2.60 A; A=1259-1471.
DR   PDB; 1U0N; X-ray; 2.95 A; A=1261-1468.
DR   PDB; 1UEX; X-ray; 2.85 A; C=1260-1468.
DR   PDB; 2ADF; X-ray; 1.90 A; A=1683-1874.
DR   PDB; 2MHP; NMR; -; A=766-864.
DR   PDB; 2MHQ; NMR; -; A=766-864.
DR   PDB; 3GXB; X-ray; 1.90 A; A/B=1495-1671.
DR   PDB; 3HXO; X-ray; 2.40 A; A=1260-1468.
DR   PDB; 3HXQ; X-ray; 2.69 A; A=1260-1468.
DR   PDB; 3PPV; X-ray; 1.90 A; A=1488-1674.
DR   PDB; 3PPW; X-ray; 1.90 A; A=1488-1674.
DR   PDB; 3PPX; X-ray; 1.91 A; A=1488-1674.
DR   PDB; 3PPY; X-ray; 2.00 A; A=1488-1674.
DR   PDB; 3ZQK; X-ray; 1.70 A; A/B/C=1478-1674.
DR   PDB; 4C29; X-ray; 2.20 A; A/B=1264-1471.
DR   PDB; 4C2A; X-ray; 2.08 A; A=1264-1471.
DR   PDB; 4C2B; X-ray; 2.80 A; A/C/E/G=1264-1471.
DR   PDB; 4DMU; X-ray; 2.80 A; B/D/F/H/J/L=1683-1874.
DR   PDB; 4NT5; X-ray; 3.28 A; A=2721-2813.
DR   PDB; 5BV8; X-ray; 1.59 A; A=1238-1461.
DR   PDBsum; 1AO3; -.
DR   PDBsum; 1ATZ; -.
DR   PDBsum; 1AUQ; -.
DR   PDBsum; 1FE8; -.
DR   PDBsum; 1FNS; -.
DR   PDBsum; 1IJB; -.
DR   PDBsum; 1IJK; -.
DR   PDBsum; 1M10; -.
DR   PDBsum; 1OAK; -.
DR   PDBsum; 1SQ0; -.
DR   PDBsum; 1U0N; -.
DR   PDBsum; 1UEX; -.
DR   PDBsum; 2ADF; -.
DR   PDBsum; 2MHP; -.
DR   PDBsum; 2MHQ; -.
DR   PDBsum; 3GXB; -.
DR   PDBsum; 3HXO; -.
DR   PDBsum; 3HXQ; -.
DR   PDBsum; 3PPV; -.
DR   PDBsum; 3PPW; -.
DR   PDBsum; 3PPX; -.
DR   PDBsum; 3PPY; -.
DR   PDBsum; 3ZQK; -.
DR   PDBsum; 4C29; -.
DR   PDBsum; 4C2A; -.
DR   PDBsum; 4C2B; -.
DR   PDBsum; 4DMU; -.
DR   PDBsum; 4NT5; -.
DR   PDBsum; 5BV8; -.
DR   ProteinModelPortal; P04275; -.
DR   SMR; P04275; 766-864, 1261-1468, 1495-1671, 1685-1873, 2721-2813.
DR   BioGrid; 113289; 14.
DR   DIP; DIP-29667N; -.
DR   IntAct; P04275; 49.
DR   MINT; MINT-244925; -.
DR   STRING; 9606.ENSP00000261405; -.
DR   ChEMBL; CHEMBL2021748; -.
DR   DrugBank; DB00025; Antihemophilic Factor (Recombinant).
DR   MEROPS; I08.950; -.
DR   iPTMnet; P04275; -.
DR   PhosphoSite; P04275; -.
DR   SwissPalm; P04275; -.
DR   UniCarbKB; P04275; -.
DR   BioMuta; VWF; -.
DR   DMDM; 317373549; -.
DR   PaxDb; P04275; -.
DR   PRIDE; P04275; -.
DR   Ensembl; ENST00000261405; ENSP00000261405; ENSG00000110799. [P04275-1]
DR   GeneID; 7450; -.
DR   KEGG; hsa:7450; -.
DR   UCSC; uc001qnn.1; human. [P04275-1]
DR   UCSC; uc001qno.1; human.
DR   CTD; 7450; -.
DR   GeneCards; VWF; -.
DR   GeneReviews; VWF; -.
DR   H-InvDB; HIX0010356; -.
DR   H-InvDB; HIX0171640; -.
DR   HGNC; HGNC:12726; VWF.
DR   HPA; CAB001694; -.
DR   HPA; HPA001815; -.
DR   HPA; HPA002082; -.
DR   MalaCards; VWF; -.
DR   MIM; 193400; phenotype.
DR   MIM; 277480; phenotype.
DR   MIM; 613160; gene.
DR   MIM; 613554; phenotype.
DR   neXtProt; NX_P04275; -.
DR   Orphanet; 166078; Von Willebrand disease type 1.
DR   Orphanet; 166084; Von Willebrand disease type 2A.
DR   Orphanet; 166087; Von Willebrand disease type 2B.
DR   Orphanet; 166090; Von Willebrand disease type 2M.
DR   Orphanet; 166093; Von Willebrand disease type 2N.
DR   Orphanet; 166096; Von Willebrand disease type 3.
DR   PharmGKB; PA37337; -.
DR   eggNOG; ENOG410IR8A; Eukaryota.
DR   eggNOG; ENOG41100RZ; LUCA.
DR   GeneTree; ENSGT00760000118896; -.
DR   HOGENOM; HOG000169747; -.
DR   HOVERGEN; HBG004380; -.
DR   InParanoid; P04275; -.
DR   KO; K03900; -.
DR   OMA; ECCGRCL; -.
DR   OrthoDB; EOG73V6J9; -.
DR   PhylomeDB; P04275; -.
DR   TreeFam; TF300299; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-140837; Intrinsic Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-354192; Integrin alphaIIb beta3 signaling.
DR   Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-HSA-372708; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; R-HSA-430116; GP1b-IX-V activation signalling.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-75892; Platelet Adhesion to exposed collagen.
DR   ChiTaRS; VWF; human.
DR   EvolutionaryTrace; P04275; -.
DR   GeneWiki; Von_Willebrand_factor; -.
DR   GenomeRNAi; 7450; -.
DR   NextBio; 29172; -.
DR   PRO; PR:P04275; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; P04275; -.
DR   CleanEx; HS_VWF; -.
DR   ExpressionAtlas; P04275; baseline and differential.
DR   Genevisible; P04275; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0031091; C:platelet alpha granule; NAS:UniProtKB.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0033093; C:Weibel-Palade body; IDA:UniProtKB.
DR   GO; GO:0051087; F:chaperone binding; IDA:UniProtKB.
DR   GO; GO:0005518; F:collagen binding; IDA:UniProtKB.
DR   GO; GO:0001948; F:glycoprotein binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019865; F:immunoglobulin binding; IDA:UniProtKB.
DR   GO; GO:0005178; F:integrin binding; IPI:UniProtKB.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; IMP:UniProtKB.
DR   GO; GO:0007597; P:blood coagulation, intrinsic pathway; TAS:Reactome.
DR   GO; GO:0007155; P:cell adhesion; IDA:UniProtKB.
DR   GO; GO:0031589; P:cell-substrate adhesion; IDA:UniProtKB.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0007599; P:hemostasis; IMP:UniProtKB.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0001890; P:placenta development; IEA:Ensembl.
DR   GO; GO:0030168; P:platelet activation; IDA:UniProtKB.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   GO; GO:0035902; P:response to immobilization stress; IEA:Ensembl.
DR   GO; GO:0009611; P:response to wounding; TAS:UniProtKB.
DR   Gene3D; 3.40.50.410; -; 3.
DR   InterPro; IPR006207; Cys_knot_C.
DR   InterPro; IPR002919; TIL_dom.
DR   InterPro; IPR014853; Unchr_dom_Cys-rich.
DR   InterPro; IPR032361; VWA_N2.
DR   InterPro; IPR012011; VWF.
DR   InterPro; IPR002035; VWF_A.
DR   InterPro; IPR001007; VWF_dom.
DR   InterPro; IPR001846; VWF_type-D.
DR   PANTHER; PTHR11339:SF259; PTHR11339:SF259; 4.
DR   Pfam; PF08742; C8; 4.
DR   Pfam; PF01826; TIL; 5.
DR   Pfam; PF00092; VWA; 3.
DR   Pfam; PF16164; VWA_N2; 1.
DR   Pfam; PF00093; VWC; 3.
DR   Pfam; PF00094; VWD; 4.
DR   SMART; SM00832; C8; 4.
DR   SMART; SM00041; CT; 1.
DR   SMART; SM00327; VWA; 3.
DR   SMART; SM00214; VWC; 5.
DR   SMART; SM00216; VWD; 4.
DR   SUPFAM; SSF53300; SSF53300; 3.
DR   SUPFAM; SSF57567; SSF57567; 5.
DR   PROSITE; PS01185; CTCK_1; 1.
DR   PROSITE; PS01225; CTCK_2; 1.
DR   PROSITE; PS50234; VWFA; 3.
DR   PROSITE; PS01208; VWFC_1; 3.
DR   PROSITE; PS50184; VWFC_2; 3.
DR   PROSITE; PS51233; VWFD; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Blood coagulation; Cell adhesion;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Extracellular matrix; Glycoprotein; Hemostasis; Isopeptide bond;
KW   Polymorphism; Reference proteome; Repeat; Secreted; Signal;
KW   Ubl conjugation; von Willebrand disease.
FT   SIGNAL        1     22       {ECO:0000269|PubMed:3495266}.
FT   CHAIN        23    763       von Willebrand antigen 2.
FT                                /FTId=PRO_0000022682.
FT   CHAIN       764   2813       von Willebrand factor.
FT                                /FTId=PRO_0000022683.
FT   DOMAIN       34    240       VWFD 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00580}.
FT   DOMAIN      295    348       TIL 1.
FT   DOMAIN      387    598       VWFD 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00580}.
FT   DOMAIN      652    707       TIL 2.
FT   DOMAIN      776    827       TIL 3.
FT   DOMAIN      866   1074       VWFD 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00580}.
FT   DOMAIN     1146   1196       TIL 4.
FT   DOMAIN     1277   1453       VWFA 1; binding site for platelet
FT                                glycoprotein Ib. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00219}.
FT   DOMAIN     1498   1665       VWFA 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00219}.
FT   DOMAIN     1691   1871       VWFA 3; main binding site for collagens
FT                                type I and III. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00219}.
FT   DOMAIN     1949   2153       VWFD 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00580}.
FT   DOMAIN     2255   2328       VWFC 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00220}.
FT   DOMAIN     2429   2495       VWFC 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00220}.
FT   DOMAIN     2580   2645       VWFC 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00220}.
FT   DOMAIN     2724   2812       CTCK. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00039}.
FT   REGION      764    787       Amino-terminal.
FT   REGION      788    833       E1.
FT   REGION      826    853       CX.
FT   REGION     2216   2261       E2.
FT   MOTIF      2507   2509       Cell attachment site.
FT   CARBOHYD     99     99       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    156    156       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    211    211       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    666    666       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    857    857       N-linked (GlcNAc...).
FT   CARBOHYD   1147   1147       N-linked (GlcNAc...); atypical.
FT   CARBOHYD   1231   1231       N-linked (GlcNAc...).
FT   CARBOHYD   1248   1248       O-linked (GalNAc...). {ECO:0000305}.
FT   CARBOHYD   1255   1255       O-linked (GalNAc...). {ECO:0000305}.
FT   CARBOHYD   1256   1256       O-linked (GalNAc...). {ECO:0000305}.
FT   CARBOHYD   1263   1263       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:3524673}.
FT   CARBOHYD   1468   1468       O-linked (GalNAc...). {ECO:0000305}.
FT   CARBOHYD   1477   1477       O-linked (GalNAc...). {ECO:0000305}.
FT   CARBOHYD   1486   1486       O-linked (GalNAc...). {ECO:0000305}.
FT   CARBOHYD   1487   1487       O-linked (GalNAc...). {ECO:0000305}.
FT   CARBOHYD   1515   1515       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:19139490}.
FT   CARBOHYD   1574   1574       N-linked (GlcNAc...).
FT   CARBOHYD   1679   1679       O-linked (GalNAc...). {ECO:0000305}.
FT   CARBOHYD   2223   2223       N-linked (GlcNAc...).
FT   CARBOHYD   2290   2290       N-linked (GlcNAc...).
FT   CARBOHYD   2298   2298       O-linked (GalNAc...). {ECO:0000305}.
FT   CARBOHYD   2357   2357       N-linked (GlcNAc...).
FT   CARBOHYD   2400   2400       N-linked (GlcNAc...).
FT   CARBOHYD   2546   2546       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   2585   2585       N-linked (GlcNAc...).
FT   CARBOHYD   2790   2790       N-linked (GlcNAc...).
FT   DISULFID    767    808       {ECO:0000269|PubMed:3502076}.
FT   DISULFID    776    804       {ECO:0000269|PubMed:3502076}.
FT   DISULFID    810    821       {ECO:0000269|PubMed:3502076}.
FT   DISULFID    867    996       {ECO:0000269|PubMed:3502076}.
FT   DISULFID    889   1031       {ECO:0000269|PubMed:3502076}.
FT   DISULFID    898    993       {ECO:0000269|PubMed:3502076}.
FT   DISULFID    914    921       {ECO:0000269|PubMed:3502076}.
FT   DISULFID   1060   1084       {ECO:0000269|PubMed:3502076}.
FT   DISULFID   1071   1111       {ECO:0000269|PubMed:3502076}.
FT   DISULFID   1089   1091       {ECO:0000269|PubMed:3502076}.
FT   DISULFID   1126   1130       {ECO:0000269|PubMed:3502076}.
FT   DISULFID   1149   1169       {ECO:0000269|PubMed:3502076}.
FT   DISULFID   1153   1165       {ECO:0000269|PubMed:3502076}.
FT   DISULFID   1196   1199       {ECO:0000269|PubMed:3502076}.
FT   DISULFID   1234   1237       {ECO:0000269|PubMed:3502076}.
FT   DISULFID   1272   1458       {ECO:0000269|PubMed:3502076}.
FT   DISULFID   1669   1670       {ECO:0000269|PubMed:3502076}.
FT   DISULFID   1686   1872       {ECO:0000269|PubMed:3502076}.
FT   DISULFID   1879   1904       {ECO:0000269|PubMed:3502076}.
FT   DISULFID   1899   1940       Or C-1899 with C-1942.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00039,
FT                                ECO:0000255|PROSITE-ProRule:PRU00580,
FT                                ECO:0000269|PubMed:3502076}.
FT   DISULFID   1927   2088       {ECO:0000269|PubMed:3502076}.
FT   DISULFID   1950   2085       {ECO:0000269|PubMed:3502076}.
FT   DISULFID   1972   2123       {ECO:0000269|PubMed:3502076}.
FT   DISULFID   1993   2001       {ECO:0000269|PubMed:3502076}.
FT   DISULFID   2724   2774       {ECO:0000250}.
FT   DISULFID   2739   2788       {ECO:0000250}.
FT   DISULFID   2750   2804       {ECO:0000250}.
FT   DISULFID   2754   2806       {ECO:0000250}.
FT   DISULFID      ?   2811       {ECO:0000250}.
FT   CROSSLNK   1720   1720       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:17370265}.
FT   VAR_SEQ       1     18       MIPARFAGVLLALALILP -> MGAQDEEEGIQDLDGLLVF
FT                                DKIVEVTLLNLPWYNEETEGQRGEMTAPKSPRAKIR (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_056527.
FT   VAR_SEQ     220    314       GLWEQCQLLKSTSVFARCHPLVDPEPFVALCEKTLCECAGG
FT                                LECACPALLEYARTCAQEGMVLYGWTDHSACSPVCPAGMEY
FT                                RQCVSPCARTCQS -> EEPECNDITARLQYVKVGSCKSEV
FT                                EVDIHYCQGKCASKAMYSIDINDVQDQCSCCSPTRTEPMQV
FT                                ALHCTNGSVVYHEVLNAMECKCSPRKCSKI (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_056528.
FT   VAR_SEQ     315   2813       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_056529.
FT   VARIANT     273    273       R -> W (in VWD1 and VWD3; defect in
FT                                secretion and formation of multimers;
FT                                dbSNP:rs61753997).
FT                                {ECO:0000269|PubMed:10887119}.
FT                                /FTId=VAR_010242.
FT   VARIANT     318    318       N -> K (in dbSNP:rs1800387).
FT                                /FTId=VAR_057023.
FT   VARIANT     377    377       W -> C (in VWD3).
FT                                {ECO:0000269|PubMed:7989040}.
FT                                /FTId=VAR_005782.
FT   VARIANT     471    471       V -> I (in dbSNP:rs1800377).
FT                                {ECO:0000269|PubMed:2584182}.
FT                                /FTId=VAR_060591.
FT   VARIANT     484    484       H -> R (in dbSNP:rs1800378).
FT                                {ECO:0000269|PubMed:3019665}.
FT                                /FTId=VAR_024553.
FT   VARIANT     528    528       N -> S (in VWD2).
FT                                {ECO:0000269|PubMed:8011991}.
FT                                /FTId=VAR_005783.
FT   VARIANT     550    550       G -> R (in VWD2).
FT                                {ECO:0000269|PubMed:7789955}.
FT                                /FTId=VAR_005784.
FT   VARIANT     740    740       M -> I (in dbSNP:rs16932374).
FT                                /FTId=VAR_057024.
FT   VARIANT     788    788       C -> Y (in VWD2).
FT                                /FTId=VAR_009141.
FT   VARIANT     789    789       T -> A (in dbSNP:rs1063856).
FT                                {ECO:0000269|PubMed:2864688}.
FT                                /FTId=VAR_005785.
FT   VARIANT     791    791       T -> M (in VWD2; Normandy type).
FT                                {ECO:0000269|PubMed:1906179}.
FT                                /FTId=VAR_005786.
FT   VARIANT     816    816       R -> W (in VWD2; Normandy type).
FT                                {ECO:0000269|PubMed:1832934}.
FT                                /FTId=VAR_005787.
FT   VARIANT     852    852       Q -> R (in dbSNP:rs216321).
FT                                {ECO:0000269|PubMed:2584182,
FT                                ECO:0000269|PubMed:2864688,
FT                                ECO:0000269|PubMed:3019665,
FT                                ECO:0000269|PubMed:3488076,
FT                                ECO:0000269|PubMed:3489923,
FT                                ECO:0000269|PubMed:3524673}.
FT                                /FTId=VAR_005788.
FT   VARIANT     854    854       R -> Q (in VWD2; Normandy type;
FT                                dbSNP:rs41276738).
FT                                {ECO:0000269|PubMed:1832934}.
FT                                /FTId=VAR_005789.
FT   VARIANT     857    857       N -> D.
FT                                /FTId=VAR_005790.
FT   VARIANT     885    885       F -> S (in dbSNP:rs11064002).
FT                                /FTId=VAR_057025.
FT   VARIANT    1060   1060       C -> R (in VWD2).
FT                                {ECO:0000269|PubMed:12406074}.
FT                                /FTId=VAR_028446.
FT   VARIANT    1149   1149       C -> R (in VWD1; reduced secretion of
FT                                homodimers and heterodimers with wild
FT                                type VWD and increased degradation by the
FT                                proteasome).
FT                                {ECO:0000269|PubMed:11698279}.
FT                                /FTId=VAR_064925.
FT   VARIANT    1266   1266       P -> L (in VWD2).
FT                                {ECO:0000269|PubMed:8486782}.
FT                                /FTId=VAR_005791.
FT   VARIANT    1268   1268       H -> D (in VWD2).
FT                                {ECO:0000269|PubMed:8376405}.
FT                                /FTId=VAR_005792.
FT   VARIANT    1272   1272       C -> F (in VWD2; subtype 2A).
FT                                {ECO:0000269|PubMed:21592258}.
FT                                /FTId=VAR_067340.
FT   VARIANT    1272   1272       C -> R (in VWD2).
FT                                {ECO:0000269|PubMed:1419804}.
FT                                /FTId=VAR_005793.
FT   VARIANT    1306   1306       R -> W (in VWD2).
FT                                {ECO:0000269|PubMed:1419803,
FT                                ECO:0000269|PubMed:1420817,
FT                                ECO:0000269|PubMed:1672694,
FT                                ECO:0000269|PubMed:2010538}.
FT                                /FTId=VAR_005794.
FT   VARIANT    1308   1308       R -> C (in VWD2).
FT                                {ECO:0000269|PubMed:1419803,
FT                                ECO:0000269|PubMed:1672694,
FT                                ECO:0000269|PubMed:1761120,
FT                                ECO:0000269|PubMed:2010538}.
FT                                /FTId=VAR_005795.
FT   VARIANT    1313   1313       W -> C (in VWD2).
FT                                {ECO:0000269|PubMed:2011604}.
FT                                /FTId=VAR_005796.
FT   VARIANT    1314   1314       V -> L (in VWD2).
FT                                {ECO:0000269|PubMed:1419803}.
FT                                /FTId=VAR_005797.
FT   VARIANT    1316   1316       V -> M (in VWD2).
FT                                {ECO:0000269|PubMed:1420817,
FT                                ECO:0000269|PubMed:1672694,
FT                                ECO:0000269|PubMed:1729889}.
FT                                /FTId=VAR_005798.
FT   VARIANT    1318   1318       V -> L (in VWD2).
FT                                {ECO:0000269|PubMed:1419803}.
FT                                /FTId=VAR_005799.
FT   VARIANT    1324   1324       G -> S (in VWD2).
FT                                {ECO:0000269|PubMed:1409710}.
FT                                /FTId=VAR_005800.
FT   VARIANT    1341   1341       R -> Q (in VWD2).
FT                                {ECO:0000269|PubMed:1672694}.
FT                                /FTId=VAR_005801.
FT   VARIANT    1374   1374       R -> C (in VWD2).
FT                                {ECO:0000269|PubMed:7620154}.
FT                                /FTId=VAR_005802.
FT   VARIANT    1374   1374       R -> H (in VWD2).
FT                                {ECO:0000269|PubMed:7620154,
FT                                ECO:0000269|PubMed:7734373}.
FT                                /FTId=VAR_005803.
FT   VARIANT    1381   1381       T -> A (in dbSNP:rs216311).
FT                                {ECO:0000269|PubMed:1988024,
FT                                ECO:0000269|PubMed:2584182,
FT                                ECO:0000269|PubMed:2864688,
FT                                ECO:0000269|PubMed:3019665,
FT                                ECO:0000269|PubMed:3488076,
FT                                ECO:0000269|PubMed:3489923,
FT                                ECO:0000269|PubMed:3524673,
FT                                ECO:0000269|PubMed:9373253}.
FT                                /FTId=VAR_005804.
FT   VARIANT    1399   1399       R -> H (in dbSNP:rs216312).
FT                                {ECO:0000269|PubMed:1672694}.
FT                                /FTId=VAR_005805.
FT   VARIANT    1460   1460       L -> V (in VWD2).
FT                                {ECO:0000269|PubMed:8123843}.
FT                                /FTId=VAR_005806.
FT   VARIANT    1461   1461       A -> V (in VWD2).
FT                                {ECO:0000269|PubMed:8547152}.
FT                                /FTId=VAR_005807.
FT   VARIANT    1472   1472       D -> H (in dbSNP:rs1800383).
FT                                {ECO:0000269|PubMed:1988024,
FT                                ECO:0000269|PubMed:2584182,
FT                                ECO:0000269|PubMed:3489923}.
FT                                /FTId=VAR_029656.
FT   VARIANT    1514   1514       F -> C (in VWD2).
FT                                {ECO:0000269|PubMed:8435341}.
FT                                /FTId=VAR_005808.
FT   VARIANT    1540   1540       L -> P (in VWD2).
FT                                {ECO:0000269|PubMed:8123844}.
FT                                /FTId=VAR_005809.
FT   VARIANT    1565   1565       V -> L (in dbSNP:rs1800385).
FT                                /FTId=VAR_014630.
FT   VARIANT    1570   1570       Y -> C (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036276.
FT   VARIANT    1584   1584       Y -> C (exhibits increased in
FT                                susceptibility to proteolysis by
FT                                ADAMTS13; dbSNP:rs1800386).
FT                                {ECO:0000269|PubMed:15755288,
FT                                ECO:0000269|PubMed:8348943}.
FT                                /FTId=VAR_005810.
FT   VARIANT    1597   1597       R -> G (in VWD2).
FT                                {ECO:0000269|PubMed:8348943}.
FT                                /FTId=VAR_005811.
FT   VARIANT    1597   1597       R -> Q (in VWD2).
FT                                {ECO:0000269|PubMed:8338947}.
FT                                /FTId=VAR_005812.
FT   VARIANT    1597   1597       R -> W (in VWD2).
FT                                {ECO:0000269|PubMed:2786201}.
FT                                /FTId=VAR_005813.
FT   VARIANT    1607   1607       V -> D (in VWD2).
FT                                {ECO:0000269|PubMed:2786201}.
FT                                /FTId=VAR_005814.
FT   VARIANT    1609   1609       G -> R (in VWD2).
FT                                {ECO:0000269|PubMed:8338947,
FT                                ECO:0000269|PubMed:8348943}.
FT                                /FTId=VAR_005815.
FT   VARIANT    1613   1613       S -> P (in VWD2).
FT                                {ECO:0000269|PubMed:2010538}.
FT                                /FTId=VAR_005816.
FT   VARIANT    1628   1628       I -> T (in VWD2).
FT                                {ECO:0000269|PubMed:1420817,
FT                                ECO:0000269|PubMed:1673047,
FT                                ECO:0000269|PubMed:8123844}.
FT                                /FTId=VAR_005817.
FT   VARIANT    1638   1638       E -> K (in VWD2).
FT                                {ECO:0000269|PubMed:1429668}.
FT                                /FTId=VAR_005818.
FT   VARIANT    1648   1648       P -> S (in VWD2).
FT                                {ECO:0000269|PubMed:1420817}.
FT                                /FTId=VAR_005819.
FT   VARIANT    1665   1665       V -> E (in VWD2).
FT                                {ECO:0000269|PubMed:8338947}.
FT                                /FTId=VAR_005820.
FT   VARIANT    2063   2063       P -> S (in VWD3; dbSNP:rs61750615).
FT                                /FTId=VAR_009142.
FT   VARIANT    2178   2178       A -> S (in dbSNP:rs34230288).
FT                                /FTId=VAR_057026.
FT   VARIANT    2185   2185       R -> Q (in dbSNP:rs2229446).
FT                                /FTId=VAR_057027.
FT   VARIANT    2362   2362       C -> F (in VWD3).
FT                                /FTId=VAR_009143.
FT   VARIANT    2546   2546       N -> Y (in VWD3).
FT                                /FTId=VAR_009144.
FT   VARIANT    2705   2705       G -> R (in dbSNP:rs7962217).
FT                                /FTId=VAR_057028.
FT   VARIANT    2739   2739       C -> Y (in VWD3).
FT                                {ECO:0000269|PubMed:8088787}.
FT                                /FTId=VAR_005821.
FT   VARIANT    2773   2773       C -> R (in VWD2).
FT                                {ECO:0000269|PubMed:8622978}.
FT                                /FTId=VAR_005822.
FT   MUTAGEN    1149   1149       C->R: Reduced secretion and increased
FT                                intracellular retention. Similar
FT                                phenotype; when associated with S-1169.
FT                                {ECO:0000269|PubMed:11698279}.
FT   MUTAGEN    1169   1169       C->S: Reduced secretion and increased
FT                                intracellular retention. Similar
FT                                phenotype; when associated with R-1149.
FT                                {ECO:0000269|PubMed:11698279}.
FT   CONFLICT    770    770       P -> H (in Ref. 11; AAB59512).
FT                                {ECO:0000305}.
FT   CONFLICT    804    804       C -> S (in Ref. 10; AA sequence and 11;
FT                                AAB59512). {ECO:0000305}.
FT   CONFLICT   1914   1914       S -> T (in Ref. 1; CAA27972).
FT                                {ECO:0000305}.
FT   CONFLICT   2168   2168       C -> S (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   STRAND      767    769       {ECO:0000244|PDB:2MHP}.
FT   STRAND      771    774       {ECO:0000244|PDB:2MHP}.
FT   TURN        781    786       {ECO:0000244|PDB:2MHP}.
FT   TURN        792    794       {ECO:0000244|PDB:2MHP}.
FT   STRAND      795    797       {ECO:0000244|PDB:2MHP}.
FT   STRAND      804    809       {ECO:0000244|PDB:2MHP}.
FT   STRAND      814    817       {ECO:0000244|PDB:2MHP}.
FT   STRAND      820    823       {ECO:0000244|PDB:2MHP}.
FT   HELIX       824    826       {ECO:0000244|PDB:2MHP}.
FT   STRAND      829    833       {ECO:0000244|PDB:2MHP}.
FT   STRAND      841    844       {ECO:0000244|PDB:2MHP}.
FT   STRAND      847    852       {ECO:0000244|PDB:2MHP}.
FT   STRAND      855    858       {ECO:0000244|PDB:2MHP}.
FT   STRAND     1267   1269       {ECO:0000244|PDB:1IJB}.
FT   TURN       1270   1273       {ECO:0000244|PDB:4C29}.
FT   STRAND     1276   1283       {ECO:0000244|PDB:1IJB}.
FT   STRAND     1285   1288       {ECO:0000244|PDB:4C2B}.
FT   HELIX      1290   1305       {ECO:0000244|PDB:1IJB}.
FT   TURN       1307   1310       {ECO:0000244|PDB:1SQ0}.
FT   STRAND     1313   1329       {ECO:0000244|PDB:1IJB}.
FT   HELIX      1337   1345       {ECO:0000244|PDB:1IJB}.
FT   HELIX      1357   1367       {ECO:0000244|PDB:1IJB}.
FT   STRAND     1369   1371       {ECO:0000244|PDB:1IJB}.
FT   STRAND     1377   1385       {ECO:0000244|PDB:1IJB}.
FT   HELIX      1391   1393       {ECO:0000244|PDB:1IJB}.
FT   HELIX      1394   1396       {ECO:0000244|PDB:1U0N}.
FT   HELIX      1397   1406       {ECO:0000244|PDB:1IJB}.
FT   STRAND     1409   1417       {ECO:0000244|PDB:1IJB}.
FT   HELIX      1422   1431       {ECO:0000244|PDB:1IJB}.
FT   HELIX      1433   1435       {ECO:0000244|PDB:4C29}.
FT   STRAND     1438   1442       {ECO:0000244|PDB:1IJB}.
FT   HELIX      1443   1445       {ECO:0000244|PDB:1IJB}.
FT   HELIX      1446   1460       {ECO:0000244|PDB:1IJB}.
FT   STRAND     1498   1504       {ECO:0000244|PDB:3ZQK}.
FT   TURN       1507   1509       {ECO:0000244|PDB:3ZQK}.
FT   HELIX      1511   1527       {ECO:0000244|PDB:3ZQK}.
FT   STRAND     1534   1550       {ECO:0000244|PDB:3ZQK}.
FT   HELIX      1558   1567       {ECO:0000244|PDB:3ZQK}.
FT   HELIX      1578   1587       {ECO:0000244|PDB:3ZQK}.
FT   TURN       1588   1590       {ECO:0000244|PDB:3ZQK}.
FT   HELIX      1592   1594       {ECO:0000244|PDB:3ZQK}.
FT   HELIX      1595   1599       {ECO:0000244|PDB:3GXB}.
FT   STRAND     1602   1608       {ECO:0000244|PDB:3ZQK}.
FT   STRAND     1623   1631       {ECO:0000244|PDB:3ZQK}.
FT   HELIX      1636   1643       {ECO:0000244|PDB:3ZQK}.
FT   STRAND     1649   1652       {ECO:0000244|PDB:3ZQK}.
FT   TURN       1654   1656       {ECO:0000244|PDB:3ZQK}.
FT   HELIX      1657   1670       {ECO:0000244|PDB:3ZQK}.
FT   STRAND     1690   1697       {ECO:0000244|PDB:1ATZ}.
FT   STRAND     1699   1702       {ECO:0000244|PDB:1ATZ}.
FT   HELIX      1704   1720       {ECO:0000244|PDB:1ATZ}.
FT   STRAND     1727   1743       {ECO:0000244|PDB:1ATZ}.
FT   STRAND     1745   1747       {ECO:0000244|PDB:4DMU}.
FT   HELIX      1751   1759       {ECO:0000244|PDB:1ATZ}.
FT   HELIX      1770   1782       {ECO:0000244|PDB:1ATZ}.
FT   HELIX      1784   1786       {ECO:0000244|PDB:2ADF}.
FT   STRAND     1792   1800       {ECO:0000244|PDB:1ATZ}.
FT   HELIX      1809   1817       {ECO:0000244|PDB:1ATZ}.
FT   STRAND     1820   1831       {ECO:0000244|PDB:1ATZ}.
FT   HELIX      1833   1839       {ECO:0000244|PDB:1ATZ}.
FT   HELIX      1841   1847       {ECO:0000244|PDB:1ATZ}.
FT   STRAND     1849   1853       {ECO:0000244|PDB:1ATZ}.
FT   HELIX      1856   1862       {ECO:0000244|PDB:1ATZ}.
FT   STRAND     1863   1865       {ECO:0000244|PDB:2ADF}.
FT   HELIX      1866   1870       {ECO:0000244|PDB:1ATZ}.
FT   STRAND     2728   2732       {ECO:0000244|PDB:4NT5}.
FT   STRAND     2739   2743       {ECO:0000244|PDB:4NT5}.
FT   STRAND     2745   2749       {ECO:0000244|PDB:4NT5}.
FT   STRAND     2756   2761       {ECO:0000244|PDB:4NT5}.
FT   TURN       2762   2765       {ECO:0000244|PDB:4NT5}.
FT   STRAND     2766   2787       {ECO:0000244|PDB:4NT5}.
FT   STRAND     2793   2801       {ECO:0000244|PDB:4NT5}.
FT   STRAND     2804   2809       {ECO:0000244|PDB:4NT5}.
SQ   SEQUENCE   2813 AA;  309265 MW;  D5C1C78360917C29 CRC64;
     MIPARFAGVL LALALILPGT LCAEGTRGRS STARCSLFGS DFVNTFDGSM YSFAGYCSYL
     LAGGCQKRSF SIIGDFQNGK RVSLSVYLGE FFDIHLFVNG TVTQGDQRVS MPYASKGLYL
     ETEAGYYKLS GEAYGFVARI DGSGNFQVLL SDRYFNKTCG LCGNFNIFAE DDFMTQEGTL
     TSDPYDFANS WALSSGEQWC ERASPPSSSC NISSGEMQKG LWEQCQLLKS TSVFARCHPL
     VDPEPFVALC EKTLCECAGG LECACPALLE YARTCAQEGM VLYGWTDHSA CSPVCPAGME
     YRQCVSPCAR TCQSLHINEM CQERCVDGCS CPEGQLLDEG LCVESTECPC VHSGKRYPPG
     TSLSRDCNTC ICRNSQWICS NEECPGECLV TGQSHFKSFD NRYFTFSGIC QYLLARDCQD
     HSFSIVIETV QCADDRDAVC TRSVTVRLPG LHNSLVKLKH GAGVAMDGQD VQLPLLKGDL
     RIQHTVTASV RLSYGEDLQM DWDGRGRLLV KLSPVYAGKT CGLCGNYNGN QGDDFLTPSG
     LAEPRVEDFG NAWKLHGDCQ DLQKQHSDPC ALNPRMTRFS EEACAVLTSP TFEACHRAVS
     PLPYLRNCRY DVCSCSDGRE CLCGALASYA AACAGRGVRV AWREPGRCEL NCPKGQVYLQ
     CGTPCNLTCR SLSYPDEECN EACLEGCFCP PGLYMDERGD CVPKAQCPCY YDGEIFQPED
     IFSDHHTMCY CEDGFMHCTM SGVPGSLLPD AVLSSPLSHR SKRSLSCRPP MVKLVCPADN
     LRAEGLECTK TCQNYDLECM SMGCVSGCLC PPGMVRHENR CVALERCPCF HQGKEYAPGE
     TVKIGCNTCV CQDRKWNCTD HVCDATCSTI GMAHYLTFDG LKYLFPGECQ YVLVQDYCGS
     NPGTFRILVG NKGCSHPSVK CKKRVTILVE GGEIELFDGE VNVKRPMKDE THFEVVESGR
     YIILLLGKAL SVVWDRHLSI SVVLKQTYQE KVCGLCGNFD GIQNNDLTSS NLQVEEDPVD
     FGNSWKVSSQ CADTRKVPLD SSPATCHNNI MKQTMVDSSC RILTSDVFQD CNKLVDPEPY
     LDVCIYDTCS CESIGDCACF CDTIAAYAHV CAQHGKVVTW RTATLCPQSC EERNLRENGY
     ECEWRYNSCA PACQVTCQHP EPLACPVQCV EGCHAHCPPG KILDELLQTC VDPEDCPVCE
     VAGRRFASGK KVTLNPSDPE HCQICHCDVV NLTCEACQEP GGLVVPPTDA PVSPTTLYVE
     DISEPPLHDF YCSRLLDLVF LLDGSSRLSE AEFEVLKAFV VDMMERLRIS QKWVRVAVVE
     YHDGSHAYIG LKDRKRPSEL RRIASQVKYA GSQVASTSEV LKYTLFQIFS KIDRPEASRI
     TLLLMASQEP QRMSRNFVRY VQGLKKKKVI VIPVGIGPHA NLKQIRLIEK QAPENKAFVL
     SSVDELEQQR DEIVSYLCDL APEAPPPTLP PDMAQVTVGP GLLGVSTLGP KRNSMVLDVA
     FVLEGSDKIG EADFNRSKEF MEEVIQRMDV GQDSIHVTVL QYSYMVTVEY PFSEAQSKGD
     ILQRVREIRY QGGNRTNTGL ALRYLSDHSF LVSQGDREQA PNLVYMVTGN PASDEIKRLP
     GDIQVVPIGV GPNANVQELE RIGWPNAPIL IQDFETLPRE APDLVLQRCC SGEGLQIPTL
     SPAPDCSQPL DVILLLDGSS SFPASYFDEM KSFAKAFISK ANIGPRLTQV SVLQYGSITT
     IDVPWNVVPE KAHLLSLVDV MQREGGPSQI GDALGFAVRY LTSEMHGARP GASKAVVILV
     TDVSVDSVDA AADAARSNRV TVFPIGIGDR YDAAQLRILA GPAGDSNVVK LQRIEDLPTM
     VTLGNSFLHK LCSGFVRICM DEDGNEKRPG DVWTLPDQCH TVTCQPDGQT LLKSHRVNCD
     RGLRPSCPNS QSPVKVEETC GCRWTCPCVC TGSSTRHIVT FDGQNFKLTG SCSYVLFQNK
     EQDLEVILHN GACSPGARQG CMKSIEVKHS ALSVELHSDM EVTVNGRLVS VPYVGGNMEV
     NVYGAIMHEV RFNHLGHIFT FTPQNNEFQL QLSPKTFASK TYGLCGICDE NGANDFMLRD
     GTVTTDWKTL VQEWTVQRPG QTCQPILEEQ CLVPDSSHCQ VLLLPLFAEC HKVLAPATFY
     AICQQDSCHQ EQVCEVIASY AHLCRTNGVC VDWRTPDFCA MSCPPSLVYN HCEHGCPRHC
     DGNVSSCGDH PSEGCFCPPD KVMLEGSCVP EEACTQCIGE DGVQHQFLEA WVPDHQPCQI
     CTCLSGRKVN CTTQPCPTAK APTCGLCEVA RLRQNADQCC PEYECVCDPV SCDLPPVPHC
     ERGLQPTLTN PGECRPNFTC ACRKEECKRV SPPSCPPHRL PTLRKTQCCD EYECACNCVN
     STVSCPLGYL ASTATNDCGC TTTTCLPDKV CVHRSTIYPV GQFWEEGCDV CTCTDMEDAV
     MGLRVAQCSQ KPCEDSCRSG FTYVLHEGEC CGRCLPSACE VVTGSPRGDS QSSWKSVGSQ
     WASPENPCLI NECVRVKEEV FIQQRNVSCP QLEVPVCPSG FQLSCKTSAC CPSCRCERME
     ACMLNGTVIG PGKTVMIDVC TTCRCMVQVG VISGFKLECR KTTCNPCPLG YKEENNTGEC
     CGRCLPTACT IQLRGGQIMT LKRDETLQDG CDTHFCKVNE RGEYFWEKRV TGCPPFDEHK
     CLAEGGKIMK IPGTCCDTCE EPECNDITAR LQYVKVGSCK SEVEVDIHYC QGKCASKAMY
     SIDINDVQDQ CSCCSPTRTE PMQVALHCTN GSVVYHEVLN AMECKCSPRK CSK
//
ID   PAR2_HUMAN              Reviewed;         397 AA.
AC   P55085; Q13317; Q13346; Q53XJ8;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   17-FEB-2016, entry version 152.
DE   RecName: Full=Proteinase-activated receptor 2;
DE            Short=PAR-2;
DE   AltName: Full=Coagulation factor II receptor-like 1;
DE   AltName: Full=G-protein coupled receptor 11;
DE   AltName: Full=Thrombin receptor-like 1;
DE   Contains:
DE     RecName: Full=Proteinase-activated receptor 2, alternate cleaved 1;
DE   Contains:
DE     RecName: Full=Proteinase-activated receptor 2, alternate cleaved 2;
DE   Flags: Precursor;
GN   Name=F2RL1; Synonyms=GPR11, PAR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7556175; DOI=10.1111/j.1432-1033.1995.tb20784.x;
RA   Nystedt S., Emilsson K., Larsson A.-K., Stroembeck B., Sundelin J.;
RT   "Molecular cloning and functional expression of the gene encoding the
RT   human proteinase-activated receptor 2.";
RL   Eur. J. Biochem. 232:84-89(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Kidney;
RX   PubMed=8615752;
RA   Boehm S.K., Kong W., Broemme D., Smeekens S.P., Anderson D.C.,
RA   Connolly A.J., Kahn M.L., Nelken N.A., Coughlin S.R., Payan D.G.,
RA   Bunnett N.W.;
RT   "Molecular cloning, expression and potential functions of the human
RT   proteinase-activated receptor-2.";
RL   Biochem. J. 314:1009-1016(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND INTERACTION WITH COPS5.
RX   PubMed=16410250; DOI=10.1074/jbc.M510784200;
RA   Luo W., Wang Y., Hanck T., Stricker R., Reiser G.;
RT   "Jab1, a novel protease-activated receptor-2 (PAR-2)-interacting
RT   protein, is involved in PAR-2-induced activation of activator protein-
RT   1.";
RL   J. Biol. Chem. 281:7927-7936(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PHE-21; GLN-270 AND
RP   ALA-291.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 29-397.
RX   PubMed=8784787;
RA   Kahn M.L., Ishii K., Kuo W.L., Piper M., Connolly A.J., Shi Y.P.,
RA   Wu R., Lin C.C., Coughlin S.R.;
RT   "Conserved structure and adjacent location of the thrombin receptor
RT   and protease-activated receptor 2 genes define a protease-activated
RT   receptor gene cluster.";
RL   Mol. Med. 2:349-357(1996).
RN   [9]
RP   ACTIVATION BY MAST CELL TRYPTASE.
RX   PubMed=9020112; DOI=10.1074/jbc.272.7.4043;
RA   Molino M., Barnathan E.S., Numerof R., Clark J., Dreyer M.,
RA   Cumashi A., Hoxie J.A., Schechter N., Woolkalis M., Brass L.F.;
RT   "Interactions of mast cell tryptase with thrombin receptors and PAR-
RT   2.";
RL   J. Biol. Chem. 272:4043-4049(1997).
RN   [10]
RP   FUNCTION IN EPITHELIAL BARRIER PROTECTION.
RX   PubMed=10086357; DOI=10.1038/18223;
RA   Cocks T.M., Fong B., Chow J.M., Anderson G.P., Frauman A.G.,
RA   Goldie R.G., Henry P.J., Carr M.J., Hamilton J.R., Moffatt J.D.;
RT   "A protective role for protease-activated receptors in the airways.";
RL   Nature 398:156-160(1999).
RN   [11]
RP   TRANSACTIVATION BY F2R.
RX   PubMed=10788464; DOI=10.1074/jbc.275.18.13502;
RA   O'Brien P.J., Prevost N., Molino M., Hollinger M.K., Woolkalis M.J.,
RA   Woulfe D.S., Brass L.F.;
RT   "Thrombin responses in human endothelial cells. Contributions from
RT   receptors other than PAR1 include the transactivation of PAR2 by
RT   thrombin-cleaved PAR1.";
RL   J. Biol. Chem. 275:13502-13509(2000).
RN   [12]
RP   FUNCTION, AND MUTAGENESIS OF SER-363 AND THR-366.
RX   PubMed=10725339; DOI=10.1083/jcb.148.6.1267;
RA   DeFea K.A., Zalevsky J., Thoma M.S., Dery O., Mullins R.D.,
RA   Bunnett N.W.;
RT   "beta-arrestin-dependent endocytosis of proteinase-activated receptor
RT   2 is required for intracellular targeting of activated ERK1/2.";
RL   J. Cell Biol. 148:1267-1281(2000).
RN   [13]
RP   ACTIVATION BY ST14.
RX   PubMed=10831593; DOI=10.1074/jbc.M002941200;
RA   Takeuchi T., Harris J.L., Huang W., Yan K.W., Coughlin S.R.,
RA   Craik C.S.;
RT   "Cellular localization of membrane-type serine protease 1 and
RT   identification of protease-activated receptor-2 and single-chain
RT   urokinase-type plasminogen activator as substrates.";
RL   J. Biol. Chem. 275:26333-26342(2000).
RN   [14]
RP   ACTIVATION BY COAGULATION FACTORS VII AND XA.
RX   PubMed=10805786; DOI=10.1073/pnas.97.10.5255;
RA   Camerer E., Huang W., Coughlin S.R.;
RT   "Tissue factor- and factor X-dependent activation of protease-
RT   activated receptor 2 by factor VIIa.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:5255-5260(2000).
RN   [15]
RP   FUNCTION, AND ACTIVATION BY GINGIPAINS.
RX   PubMed=11447194; DOI=10.1128/IAI.69.8.5121-5130.2001;
RA   Lourbakos A., Potempa J., Travis J., D'Andrea M.R., Andrade-Gordon P.,
RA   Santulli R., Mackie E.J., Pike R.N.;
RT   "Arginine-specific protease from Porphyromonas gingivalis activates
RT   protease-activated receptors on human oral epithelial cells and
RT   induces interleukin-6 secretion.";
RL   Infect. Immun. 69:5121-5130(2001).
RN   [16]
RP   FUNCTION IN JNK AND NF-KAPPA-B PATHWAYS.
RX   PubMed=11413129; DOI=10.1074/jbc.M100377200;
RA   Kanke T., Macfarlane S.R., Seatter M.J., Davenport E., Paul A.,
RA   McKenzie R.C., Plevin R.;
RT   "Proteinase-activated receptor-2-mediated activation of stress-
RT   activated protein kinases and inhibitory kappa B kinases in NCTC 2544
RT   keratinocytes.";
RL   J. Biol. Chem. 276:31657-31666(2001).
RN   [17]
RP   FUNCTION, AND ACTIVATION BY DUST MITE ALLERGENS.
RX   PubMed=11441110; DOI=10.4049/jimmunol.167.2.1014;
RA   Sun G., Stacey M.A., Schmidt M., Mori L., Mattoli S.;
RT   "Interaction of mite allergens Der p3 and Der p9 with protease-
RT   activated receptor-2 expressed by lung epithelial cells.";
RL   J. Immunol. 167:1014-1021(2001).
RN   [18]
RP   FUNCTION IN INFLAMMATORY RESPONSE.
RX   PubMed=11714832; DOI=10.4049/jimmunol.167.11.6615;
RA   Miike S., McWilliam A.S., Kita H.;
RT   "Trypsin induces activation and inflammatory mediator release from
RT   human eosinophils through protease-activated receptor-2.";
RL   J. Immunol. 167:6615-6622(2001).
RN   [19]
RP   GLYCOSYLATION AT ASN-30 AND ASN-222, AND MUTAGENESIS OF ASN-30 AND
RP   ASN-222.
RX   PubMed=12171601; DOI=10.1042/BJ20020706;
RA   Compton S.J., Sandhu S., Wijesuriya S.J., Hollenberg M.D.;
RT   "Glycosylation of human proteinase-activated receptor-2 (hPAR2): role
RT   in cell surface expression and signalling.";
RL   Biochem. J. 368:495-505(2002).
RN   [20]
RP   POSSIBLE INVOLVEMENT IN ALLERGIC DERMATITIS.
RX   PubMed=11859856; DOI=10.1254/jjp.88.77;
RA   Kawagoe J., Takizawa T., Matsumoto J., Tamiya M., Meek S.E.,
RA   Smith A.J., Hunter G.D., Plevin R., Saito N., Kanke T., Fujii M.,
RA   Wada Y.;
RT   "Effect of protease-activated receptor-2 deficiency on allergic
RT   dermatitis in the mouse ear.";
RL   Jpn. J. Pharmacol. 88:77-84(2002).
RN   [21]
RP   DEACTIVATION BY NEUTROPHIL ELASTASE AND CATHEPSIN G.
RX   PubMed=12594060; DOI=10.1165/rcmb.4908;
RA   Dulon S., Cande C., Bunnett N.W., Hollenberg M.D., Chignard M.,
RA   Pidard D.;
RT   "Proteinase-activated receptor-2 and human lung epithelial cells:
RT   disarming by neutrophil serine proteinases.";
RL   Am. J. Respir. Cell Mol. Biol. 28:339-346(2003).
RN   [22]
RP   POSSIBLE INVOLVEMENT IN SKIN DISEASES.
RX   PubMed=14519665; DOI=10.1096/fj.02-1112com;
RA   Seeliger S., Derian C.K., Vergnolle N., Bunnett N.W., Nawroth R.,
RA   Schmelz M., Von Der Weid P.Y., Buddenkotte J., Sunderkotter C.,
RA   Metze D., Andrade-Gordon P., Harms E., Vestweber D., Luger T.A.,
RA   Steinhoff M.;
RT   "Proinflammatory role of proteinase-activated receptor-2 in humans and
RT   mice during cutaneous inflammation in vivo.";
RL   FASEB J. 17:1871-1885(2003).
RN   [23]
RP   FUNCTION.
RX   PubMed=12832443; DOI=10.1189/jlb.0702351;
RA   Bolton S.J., McNulty C.A., Thomas R.J., Hewitt C.R., Wardlaw A.J.;
RT   "Expression of and functional responses to protease-activated
RT   receptors on human eosinophils.";
RL   J. Leukoc. Biol. 74:60-68(2003).
RN   [24]
RP   MUTAGENESIS OF 355-ALA--SER-363.
RX   PubMed=14607272; DOI=10.1016/S0898-6568(03)00095-0;
RA   Seatter M.J., Drummond R., Kanke T., Macfarlane S.R., Hollenberg M.D.,
RA   Plevin R.;
RT   "The role of the C-terminal tail in protease-activated receptor-2-
RT   mediated Ca2+ signalling, proline-rich tyrosine kinase-2 activation,
RT   and mitogen-activated protein kinase activity.";
RL   Cell. Signal. 16:21-29(2004).
RN   [25]
RP   FUNCTION.
RX   PubMed=15155775; DOI=10.1189/jlb.0503221;
RA   Shpacovitch V.M., Varga G., Strey A., Gunzer M., Mooren F.,
RA   Buddenkotte J., Vergnolle N., Sommerhoff C.P., Grabbe S., Gerke V.,
RA   Homey B., Hollenberg M., Luger T.A., Steinhoff M.;
RT   "Agonists of proteinase-activated receptor-2 modulate human neutrophil
RT   cytokine secretion, expression of cell adhesion molecules, and
RT   migration within 3-D collagen lattices.";
RL   J. Leukoc. Biol. 76:388-398(2004).
RN   [26]
RP   UBIQUITINATION BY CBL.
RX   PubMed=15708858; DOI=10.1074/jbc.M500109200;
RA   Jacob C., Cottrell G.S., Gehringer D., Schmidlin F., Grady E.F.,
RA   Bunnett N.W.;
RT   "c-Cbl mediates ubiquitination, degradation, and down-regulation of
RT   human protease-activated receptor 2.";
RL   J. Biol. Chem. 280:16076-16087(2005).
RN   [27]
RP   FUNCTION IN ENDOTHELIAL BARRIER PROTECTION.
RX   PubMed=16359518; DOI=10.1111/j.1538-7836.2005.01610.x;
RA   Feistritzer C., Lenta R., Riewald M.;
RT   "Protease-activated receptors-1 and -2 can mediate endothelial barrier
RT   protection: role in factor Xa signaling.";
RL   J. Thromb. Haemost. 3:2798-2805(2005).
RN   [28]
RP   POSSIBLE INVOLVEMENT IN COLITIS.
RX   PubMed=15919826; DOI=10.1073/pnas.0409535102;
RA   Hansen K.K., Sherman P.M., Cellars L., Andrade-Gordon P., Pan Z.,
RA   Baruch A., Wallace J.L., Hollenberg M.D., Vergnolle N.;
RT   "A major role for proteolytic activity and proteinase-activated
RT   receptor-2 in the pathogenesis of infectious colitis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:8363-8368(2005).
RN   [29]
RP   POSSIBLE INVOLVEMENT IN BRONCHIAL EOSINOPHILIC INFLAMMATION.
RX   PubMed=15879675; DOI=10.1254/jphs.SCZ050138;
RA   Takizawa T., Tamiya M., Hara T., Matsumoto J., Saito N., Kanke T.,
RA   Kawagoe J., Hattori Y.;
RT   "Abrogation of bronchial eosinophilic inflammation and attenuated
RT   eotaxin content in protease-activated receptor 2-deficient mice.";
RL   J. Pharmacol. Sci. 98:99-102(2005).
RN   [30]
RP   FUNCTION IN EPITHELIAL BARRIER DISRUPTION.
RX   PubMed=16714334; DOI=10.1152/ajplung.00046.2006;
RA   Winter M.C., Shasby S.S., Ries D.R., Shasby D.M.;
RT   "PAR2 activation interrupts E-cadherin adhesion and compromises the
RT   airway epithelial barrier: protective effect of beta-agonists.";
RL   Am. J. Physiol. 291:L628-L635(2006).
RN   [31]
RP   FUNCTION, AND ACTIVATION BY PRTN3.
RX   PubMed=16478888; DOI=10.1182/blood-2005-05-1875;
RA   Csernok E., Ai M., Gross W.L., Wicklein D., Petersen A., Lindner B.,
RA   Lamprecht P., Holle J.U., Hellmich B.;
RT   "Wegener autoantigen induces maturation of dendritic cells and
RT   licenses them for Th1 priming via the protease-activated receptor-2
RT   pathway.";
RL   Blood 107:4440-4448(2006).
RN   [32]
RP   POSSIBLE INVOLVEMENT IN ENCEPHALOMYELITIS AND MULTIPLE SCLEROSIS.
RX   PubMed=16476770; DOI=10.1084/jem.20052148;
RA   Noorbakhsh F., Tsutsui S., Vergnolle N., Boven L.A., Shariat N.,
RA   Vodjgani M., Warren K.G., Andrade-Gordon P., Hollenberg M.D.,
RA   Power C.;
RT   "Proteinase-activated receptor 2 modulates neuroinflammation in
RT   experimental autoimmune encephalomyelitis and multiple sclerosis.";
RL   J. Exp. Med. 203:425-435(2006).
RN   [33]
RP   FUNCTION IN ACTIN FILAMENT SEVERING.
RX   PubMed=17500066; DOI=10.1074/jbc.M701391200;
RA   Zoudilova M., Kumar P., Ge L., Wang P., Bokoch G.M., DeFea K.A.;
RT   "Beta-arrestin-dependent regulation of the cofilin pathway downstream
RT   of protease-activated receptor-2.";
RL   J. Biol. Chem. 282:20634-20646(2007).
RN   [34]
RP   INTERACTION WITH TMED2.
RX   PubMed=17693410; DOI=10.1074/jbc.M703205200;
RA   Luo W., Wang Y., Reiser G.;
RT   "p24A, a type I transmembrane protein, controls ARF1-dependent
RT   resensitization of protease-activated receptor-2 by influence on
RT   receptor trafficking.";
RL   J. Biol. Chem. 282:30246-30255(2007).
RN   [35]
RP   FUNCTION, AND ACTIVATION BY MOLD ALLERGENS.
RX   PubMed=17404307; DOI=10.4049/jimmunol.178.8.5237;
RA   Chiu L.L., Perng D.W., Yu C.H., Su S.N., Chow L.P.;
RT   "Mold allergen, pen C 13, induces IL-8 expression in human airway
RT   epithelial cells by activating protease-activated receptor 1 and 2.";
RL   J. Immunol. 178:5237-5244(2007).
RN   [36]
RP   FUNCTION, AND ACTIVATION BY BACTERIAL CHITINASE.
RX   PubMed=18474671; DOI=10.1165/rcmb.2007-0410OC;
RA   Hong J.H., Hong J.Y., Park B., Lee S.I., Seo J.T., Kim K.E.,
RA   Sohn M.H., Shin D.M.;
RT   "Chitinase activates protease-activated receptor-2 in human airway
RT   epithelial cells.";
RL   Am. J. Respir. Cell Mol. Biol. 39:530-535(2008).
RN   [37]
RP   FUNCTION.
RX   PubMed=18424071; DOI=10.1016/j.cellsig.2008.02.015;
RA   Goon Goh F., Sloss C.M., Cunningham M.R., Nilsson M., Cadalbert L.,
RA   Plevin R.;
RT   "G-protein-dependent and -independent pathways regulate proteinase-
RT   activated receptor-2 mediated p65 NFkappaB serine 536 phosphorylation
RT   in human keratinocytes.";
RL   Cell. Signal. 20:1267-1274(2008).
RN   [38]
RP   FUNCTION, AND INTERACTION WITH TLR4.
RX   PubMed=18622013; DOI=10.1074/jbc.M804800200;
RA   Rallabhandi P., Nhu Q.M., Toshchakov V.Y., Piao W., Medvedev A.E.,
RA   Hollenberg M.D., Fasano A., Vogel S.N.;
RT   "Analysis of proteinase-activated receptor 2 and TLR4 signal
RT   transduction: a novel paradigm for receptor cooperativity.";
RL   J. Biol. Chem. 283:24314-24325(2008).
RN   [39]
RP   FUNCTION IN ANTIVIRAL RESPONSE.
RX   PubMed=18453611; DOI=10.4049/jimmunol.180.10.6903;
RA   Feld M., Shpacovitch V.M., Ehrhardt C., Kerkhoff C., Hollenberg M.D.,
RA   Vergnolle N., Ludwig S., Steinhoff M.;
RT   "Agonists of proteinase-activated receptor-2 enhance IFN-gamma-
RT   inducible effects on human monocytes: role in influenza A infection.";
RL   J. Immunol. 180:6903-6910(2008).
RN   [40]
RP   DEUBIQUITINATION.
RX   PubMed=19684015; DOI=10.1074/jbc.M109.025692;
RA   Hasdemir B., Murphy J.E., Cottrell G.S., Bunnett N.W.;
RT   "Endosomal deubiquitinating enzymes control ubiquitination and down-
RT   regulation of protease-activated receptor 2.";
RL   J. Biol. Chem. 284:28453-28466(2009).
RN   [41]
RP   PHOSPHORYLATION.
RX   PubMed=19815543; DOI=10.1074/jbc.M109.048942;
RA   Ricks T.K., Trejo J.;
RT   "Phosphorylation of protease-activated receptor-2 differentially
RT   regulates desensitization and internalization.";
RL   J. Biol. Chem. 284:34444-34457(2009).
RN   [42]
RP   FUNCTION IN ANTIVIRAL RESPONSE.
RX   PubMed=19494303; DOI=10.4049/jimmunol.0803743;
RA   Khoufache K., LeBouder F., Morello E., Laurent F., Riffault S.,
RA   Andrade-Gordon P., Boullier S., Rousset P., Vergnolle N., Riteau B.;
RT   "Protective role for protease-activated receptor-2 against influenza
RT   virus pathogenesis via an IFN-gamma-dependent pathway.";
RL   J. Immunol. 182:7795-7802(2009).
RN   [43]
RP   FUNCTION, AND ACTIVATION BY TRYPSIN AND FUNGAL ASPARTATE PROTEASE.
RX   PubMed=19864598; DOI=10.4049/jimmunol.0901220;
RA   Matsuwaki Y., Wada K., White T.A., Benson L.M., Charlesworth M.C.,
RA   Checkel J.L., Inoue Y., Hotta K., Ponikau J.U., Lawrence C.B.,
RA   Kita H.;
RT   "Recognition of fungal protease activities induces cellular activation
RT   and eosinophil-derived neurotoxin release in human eosinophils.";
RL   J. Immunol. 183:6708-6716(2009).
RN   [44]
RP   POSSIBLE INVOLVEMENT IN ARTHRITIS.
RX   PubMed=20584806; DOI=10.1136/ard.2010.130336;
RA   Ferrell W.R., Kelso E.B., Lockhart J.C., Plevin R., McInnes I.B.;
RT   "Protease-activated receptor 2: a novel pathogenic pathway in a murine
RT   model of osteoarthritis.";
RL   Ann. Rheum. Dis. 69:2051-2054(2010).
RN   [45]
RP   FUNCTION IN JNK PATHWAY.
RX   PubMed=19781631; DOI=10.1016/j.cellsig.2009.09.028;
RA   McIntosh K., Cunningham M.R., Cadalbert L., Lockhart J., Boyd G.,
RA   Ferrell W.R., Plevin R.;
RT   "Proteinase-activated receptor-2 mediated inhibition of TNFalpha-
RT   stimulated JNK activation - a novel paradigm for G(q/11) linked
RT   GPCRs.";
RL   Cell. Signal. 22:265-273(2010).
RN   [46]
RP   FUNCTION IN ENDOTHELIAL BARRIER PROTECTION.
RX   PubMed=20826780; DOI=10.1074/jbc.M110.163642;
RA   Bae J.S., Yang L., Rezaie A.R.;
RT   "Factor X/Xa elicits protective signaling responses in endothelial
RT   cells directly via PAR-2 and indirectly via endothelial protein C
RT   receptor-dependent recruitment of PAR-1.";
RL   J. Biol. Chem. 285:34803-34812(2010).
RN   [47]
RP   POSSIBLE INVOLVEMENT IN PERIODONTITIS.
RX   PubMed=20530726; DOI=10.1177/0022034510373765;
RA   Holzhausen M., Cortelli J.R., da Silva V.A., Franco G.C.,
RA   Cortelli S.C., Vergnolle N.;
RT   "Protease-activated receptor-2 (PAR(2)) in human periodontitis.";
RL   J. Dent. Res. 89:948-953(2010).
RN   [48]
RP   FUNCTION.
RX   PubMed=19865078; DOI=10.1038/mi.2009.120;
RA   Nhu Q.M., Shirey K., Teijaro J.R., Farber D.L., Netzel-Arnett S.,
RA   Antalis T.M., Fasano A., Vogel S.N.;
RT   "Novel signaling interactions between proteinase-activated receptor 2
RT   and Toll-like receptors in vitro and in vivo.";
RL   Mucosal Immunol. 3:29-39(2010).
RN   [49]
RP   FUNCTION IN ANTIMICROBIAL RESPONSE.
RX   PubMed=21501162; DOI=10.1111/j.1365-2567.2011.03443.x;
RA   Shpacovitch V.M., Feld M., Holzinger D., Kido M., Hollenberg M.D.,
RA   Levi-Schaffer F., Vergnolle N., Ludwig S., Roth J., Luger T.,
RA   Steinhoff M.;
RT   "Role of proteinase-activated receptor-2 in anti-bacterial and
RT   immunomodulatory effects of interferon-gamma on human neutrophils and
RT   monocytes.";
RL   Immunology 133:329-339(2011).
RN   [50]
RP   PALMITOYLATION AT CYS-361.
RX   PubMed=21627585; DOI=10.1042/BJ20101958;
RA   Botham A., Guo X., Xiao Y.P., Morice A.H., Compton S.J.,
RA   Sadofsky L.R.;
RT   "Palmitoylation of human proteinase-activated receptor-2
RT   differentially regulates receptor triggered ERK1/2 activation, calcium
RT   signalling, and endocytosis.";
RL   Biochem. J. 438:359-367(2011).
CC   -!- FUNCTION: Receptor for trypsin and trypsin-like enzymes coupled to
CC       G proteins. Its function is mediated through the activation of
CC       several signaling pathways including phospholipase C (PLC),
CC       intracellular calcium, mitogen-activated protein kinase (MAPK), I-
CC       kappaB kinase/NF-kappaB and Rho. Can also be transactivated by
CC       cleaved F2R/PAR1. Involved in modulation of inflammatory responses
CC       and regulation of innate and adaptive immunity, and acts as a
CC       sensor for proteolytic enzymes generated during infection.
CC       Generally is promoting inflammation. Can signal synergistically
CC       with TLR4 and probably TLR2 in inflammatory responses and
CC       modulates TLR3 signaling. Has a protective role in establishing
CC       the endothelial barrier; the activity involves coagulation factor
CC       X. Proposed to have a bronchoprotective role in airway epithelium,
CC       but also shown to compromise the airway epithelial barrier by
CC       interrupting E-cadherin adhesion. Involved in the regulation of
CC       vascular tone; activation results in hypotension presumably
CC       mediated by vasodilation. Associates with a subset of G proteins
CC       alpha subunits such as G alpha-q, G alpha-11, G alpha-14, G alpha-
CC       12 and G alpha-13, but probably not with G(o) alpha, G(i) subunit
CC       alpha-1 and G(i) subunit alpha-2. However, according to
CC       PubMed:21627585 can signal through G(i) subunit alpha. Believed to
CC       be a class B receptor which internalizes as a complex with
CC       arrestin and traffic with it to endosomal vesicles, presumably as
CC       desensitized receptor, for extended periods of time. Mediates
CC       inhibition of TNF-alpha stimulated JNK phosphorylation via
CC       coupling to G alpha-q/11; the function involves dissociation of
CC       RIPK1 and TRADD from TNFR1. Mediates phosphorylation of nuclear
CC       factor NF-kappa-B RELA subunit at 'Ser-536'; the function involves
CC       IKBKB and is predominantly independent of G proteins. Involved in
CC       cellular migration. Involved in cytoskeletal rearrangement and
CC       chemotaxis through beta-arrestin-promoted scaffolds; the function
CC       is independent of G alpha-q/11 and involves promotion of cofilin
CC       dephosphoryltaion and actin filament severing. Induces
CC       redistribution of COPS5 from the plasma membrane to the cytosol
CC       and activation of the JNK cascade is mediated by COPS5. Involved
CC       in the recruitment of leukocytes to the sites of inflammation and
CC       is the major PAR receptor capable of modulating eosinophil
CC       function such as proinflammatory cytokine secretion, superoxide
CC       production and degranulation. During inflammation promotes
CC       dendritic cell maturation, trafficking to the lymph nodes and
CC       subsequent T-cell activation. Involved in antimicrobial response
CC       of innate immnune cells; activation enhances phagocytosis of Gram-
CC       positive and killing of Gram-negative bacteria. Acts
CC       synergistically with interferon-gamma in enhancing antiviral
CC       responses. Implicated in a number of acute and chronic
CC       inflammatory diseases such as of the joints, lungs, brain,
CC       gastrointestinal tract, periodontium, skin, and vascular systems,
CC       and in autoimmune disorders. {ECO:0000269|PubMed:10086357,
CC       ECO:0000269|PubMed:10725339, ECO:0000269|PubMed:11413129,
CC       ECO:0000269|PubMed:11441110, ECO:0000269|PubMed:11447194,
CC       ECO:0000269|PubMed:11714832, ECO:0000269|PubMed:12832443,
CC       ECO:0000269|PubMed:15155775, ECO:0000269|PubMed:16359518,
CC       ECO:0000269|PubMed:16410250, ECO:0000269|PubMed:16478888,
CC       ECO:0000269|PubMed:16714334, ECO:0000269|PubMed:17404307,
CC       ECO:0000269|PubMed:17500066, ECO:0000269|PubMed:18424071,
CC       ECO:0000269|PubMed:18453611, ECO:0000269|PubMed:18474671,
CC       ECO:0000269|PubMed:18622013, ECO:0000269|PubMed:19494303,
CC       ECO:0000269|PubMed:19781631, ECO:0000269|PubMed:19864598,
CC       ECO:0000269|PubMed:19865078, ECO:0000269|PubMed:20826780,
CC       ECO:0000269|PubMed:21501162}.
CC   -!- SUBUNIT: Interacts with TLR4, COPS5 and TMED2. Interacts with
CC       GNAQ, GNA11, GNA12, GNA13 and GNA14 (By similarity).
CC       {ECO:0000250}.
CC   -!- INTERACTION:
CC       P22681:CBL; NbExp=3; IntAct=EBI-4303189, EBI-518228;
CC       Q92905:COPS5; NbExp=8; IntAct=EBI-4303189, EBI-594661;
CC       Q14868:EPR-1; NbExp=4; IntAct=EBI-4303189, EBI-4309771;
CC       Q15363:TMED2; NbExp=6; IntAct=EBI-4303189, EBI-998485;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Widely expressed in tissues with especially
CC       high levels in pancreas, liver, kidney, small intestine, and
CC       colon. Moderate expression is detected in many organs, but none in
CC       brain or skeletal muscle.
CC   -!- PTM: A proteolytic cleavage generates a new N-terminus that
CC       functions as a tethered ligand. Activating serine proteases
CC       include trypsin, mast cell tryptase, coagulation factors VII and
CC       Xa, myeloblastin/PRTN3 and membrane-type serine protease 1/ST14.
CC       Proposed subsequent cleaveage by serine proteases is leading to
CC       receptor deactivation and include neutrophil elastase and
CC       cathepsin G. At least in part, implicated proteases are also shown
CC       to activate the receptor; the glycosylation status of the receptor
CC       is thought to contribute to the difference. In addition to
CC       conventional trypsin-like proteases is proposed to be activated by
CC       other proteases and glycosidases derived from bacteria, fungi and
CC       insects: serine protease allergens such as dust mite Der p3 and
CC       Der p9 and mold Pen c13, Porphyromonas gingivalis arginine-
CC       specific (trypsin-like) cysteine proteinases called gingipains,
CC       Streptomyces griseus exogenous chitinase, and an Alternaria
CC       alternata aspartate protease. Cleavage by the Alternaria alternata
CC       aspartate protease generates non-conventional processed forms.
CC       {ECO:0000269|PubMed:12171601}.
CC   -!- PTM: N-glycosylated and sialylated. {ECO:0000269|PubMed:12171601}.
CC   -!- PTM: Multiple phosphorylated on serine and threonine residues in
CC       the cytoplasmic region upon receptor activation; required for
CC       receptor desensitization and recruitment of beta-arrestin.
CC       {ECO:0000269|PubMed:19815543}.
CC   -!- PTM: Monoubiquitinated by CBL at the plasma membrane and in early
CC       endosomes; not required for receptor endocytosis but for
CC       translocation to late endosomes or lysosomes. Deubiquitination
CC       involves STAMBP and USP8; required for lysosomal trafficking and
CC       receptor degradation.
CC   -!- MISCELLANEOUS: Synthetic PAR agonist peptides (APs) that mimic the
CC       first six amino acids of the newly formed N-terminus activate the
CC       native, uncleaved receptor nonenzymatically by binding directly to
CC       the corresponding second extracellular loop to mediate signaling.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Protease-activated receptor
CC       entry;
CC       URL="https://en.wikipedia.org/wiki/Protease-activated_receptor";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/f2rl1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z49993; CAA90290.1; -; Genomic_DNA.
DR   EMBL; Z49994; CAA90290.1; JOINED; Genomic_DNA.
DR   EMBL; U34038; AAB47871.1; -; mRNA.
DR   EMBL; AY336105; AAP97012.1; -; mRNA.
DR   EMBL; AF400075; AAK77914.1; -; Genomic_DNA.
DR   EMBL; BT009856; AAP88858.1; -; mRNA.
DR   EMBL; CH471084; EAW95782.1; -; Genomic_DNA.
DR   EMBL; BC012453; AAH12453.1; -; mRNA.
DR   EMBL; BC018130; AAH18130.1; -; mRNA.
DR   EMBL; U36753; AAA90957.1; -; Genomic_DNA.
DR   CCDS; CCDS4033.1; -.
DR   PIR; S66518; S66518.
DR   RefSeq; NP_005233.3; NM_005242.4.
DR   UniGene; Hs.744181; -.
DR   ProteinModelPortal; P55085; -.
DR   SMR; P55085; 38-352.
DR   BioGrid; 108449; 12.
DR   DIP; DIP-42044N; -.
DR   IntAct; P55085; 6.
DR   MINT; MINT-1326650; -.
DR   STRING; 9606.ENSP00000296677; -.
DR   BindingDB; P55085; -.
DR   ChEMBL; CHEMBL5963; -.
DR   GuidetoPHARMACOLOGY; 348; -.
DR   TCDB; 9.A.14.13.12; the g-protein-coupled receptor (gpcr) family.
DR   iPTMnet; P55085; -.
DR   PhosphoSite; P55085; -.
DR   SwissPalm; P55085; -.
DR   BioMuta; F2RL1; -.
DR   DMDM; 1709580; -.
DR   MaxQB; P55085; -.
DR   PaxDb; P55085; -.
DR   PRIDE; P55085; -.
DR   DNASU; 2150; -.
DR   Ensembl; ENST00000296677; ENSP00000296677; ENSG00000164251.
DR   GeneID; 2150; -.
DR   KEGG; hsa:2150; -.
DR   UCSC; uc003keo.3; human.
DR   CTD; 2150; -.
DR   GeneCards; F2RL1; -.
DR   HGNC; HGNC:3538; F2RL1.
DR   HPA; CAB012989; -.
DR   MIM; 600933; gene.
DR   neXtProt; NX_P55085; -.
DR   PharmGKB; PA27947; -.
DR   eggNOG; ENOG410IGEM; Eukaryota.
DR   eggNOG; ENOG4111CWR; LUCA.
DR   HOGENOM; HOG000116291; -.
DR   HOVERGEN; HBG105658; -.
DR   InParanoid; P55085; -.
DR   KO; K04234; -.
DR   PhylomeDB; P55085; -.
DR   TreeFam; TF330775; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   GeneWiki; Protease_activated_receptor_2; -.
DR   GenomeRNAi; 2150; -.
DR   NextBio; 8689; -.
DR   PMAP-CutDB; P55085; -.
DR   PRO; PR:P55085; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; P55085; -.
DR   CleanEx; HS_F2RL1; -.
DR   ExpressionAtlas; P55085; baseline and differential.
DR   Genevisible; P55085; HS.
DR   GO; GO:0005829; C:cytosol; IDA:GOC.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; TAS:ProtInc.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031143; C:pseudopodium; ISS:UniProtKB.
DR   GO; GO:0001965; F:G-protein alpha-subunit binding; ISS:UniProtKB.
DR   GO; GO:0031681; F:G-protein beta-subunit binding; ISS:UniProtKB.
DR   GO; GO:0004930; F:G-protein coupled receptor activity; IMP:UniProtKB.
DR   GO; GO:0004872; F:receptor activity; TAS:ProtInc.
DR   GO; GO:0005102; F:receptor binding; TAS:ProtInc.
DR   GO; GO:0015057; F:thrombin receptor activity; IEA:InterPro.
DR   GO; GO:0007596; P:blood coagulation; IEA:InterPro.
DR   GO; GO:0035926; P:chemokine (C-C motif) ligand 2 secretion; IDA:UniProtKB.
DR   GO; GO:0090195; P:chemokine secretion; IDA:UniProtKB.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0061028; P:establishment of endothelial barrier; IDA:UniProtKB.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0072643; P:interferon-gamma secretion; ISS:UniProtKB.
DR   GO; GO:0050702; P:interleukin-1 beta secretion; IDA:UniProtKB.
DR   GO; GO:0072608; P:interleukin-10 secretion; IDA:UniProtKB.
DR   GO; GO:0050900; P:leukocyte migration; IDA:UniProtKB.
DR   GO; GO:0070661; P:leukocyte proliferation; ISS:UniProtKB.
DR   GO; GO:0097029; P:mature conventional dendritic cell differentiation; IDA:UniProtKB.
DR   GO; GO:0090198; P:negative regulation of chemokine secretion; IDA:UniProtKB.
DR   GO; GO:0046329; P:negative regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:0034140; P:negative regulation of toll-like receptor 3 signaling pathway; IMP:UniProtKB.
DR   GO; GO:0010804; P:negative regulation of tumor necrosis factor-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0042119; P:neutrophil activation; IDA:UniProtKB.
DR   GO; GO:0030836; P:positive regulation of actin filament depolymerization; IDA:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; ISS:UniProtKB.
DR   GO; GO:0002741; P:positive regulation of cytokine secretion involved in immune response; IDA:UniProtKB.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IDA:UniProtKB.
DR   GO; GO:0043311; P:positive regulation of eosinophil degranulation; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0003104; P:positive regulation of glomerular filtration; ISS:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:2000778; P:positive regulation of interleukin-6 secretion; IDA:UniProtKB.
DR   GO; GO:2000484; P:positive regulation of interleukin-8 secretion; IDA:UniProtKB.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:0002690; P:positive regulation of leukocyte chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0070963; P:positive regulation of neutrophil mediated killing of gram-negative bacterium; IDA:UniProtKB.
DR   GO; GO:0060100; P:positive regulation of phagocytosis, engulfment; IDA:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; ISS:UniProtKB.
DR   GO; GO:0050927; P:positive regulation of positive chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0031274; P:positive regulation of pseudopodium assembly; ISS:UniProtKB.
DR   GO; GO:1900135; P:positive regulation of renin secretion into blood stream; ISS:UniProtKB.
DR   GO; GO:0035025; P:positive regulation of Rho protein signal transduction; IMP:UniProtKB.
DR   GO; GO:0032930; P:positive regulation of superoxide anion generation; IDA:UniProtKB.
DR   GO; GO:0034137; P:positive regulation of toll-like receptor 2 signaling pathway; IMP:UniProtKB.
DR   GO; GO:0034141; P:positive regulation of toll-like receptor 3 signaling pathway; IMP:UniProtKB.
DR   GO; GO:0034145; P:positive regulation of toll-like receptor 4 signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045909; P:positive regulation of vasodilation; ISS:UniProtKB.
DR   GO; GO:0030193; P:regulation of blood coagulation; IDA:BHF-UCL.
DR   GO; GO:0043122; P:regulation of I-kappaB kinase/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:0046328; P:regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:0002286; P:T cell activation involved in immune response; ISS:UniProtKB.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR002281; Pro_rcpt_2.
DR   InterPro; IPR003912; Protea_act_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01428; PROTEASEAR.
DR   PRINTS; PR01152; PROTEASEAR2.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Immunity;
KW   Inflammatory response; Innate immunity; Lipoprotein; Membrane;
KW   Palmitate; Phosphoprotein; Polymorphism; Receptor; Reference proteome;
KW   Signal; Transducer; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   PROPEP       26     36       Removed for receptor activation.
FT                                /FTId=PRO_0000012750.
FT   CHAIN        37    397       Proteinase-activated receptor 2.
FT                                /FTId=PRO_0000412954.
FT   CHAIN        38    397       Proteinase-activated receptor 2,
FT                                alternate cleaved 1.
FT                                /FTId=PRO_0000412956.
FT   CHAIN        39    397       Proteinase-activated receptor 2,
FT                                alternate cleaved 2.
FT                                /FTId=PRO_0000012751.
FT   TOPO_DOM     37     75       Extracellular. {ECO:0000255}.
FT   TRANSMEM     76    101       Helical; Name=1. {ECO:0000255}.
FT   TOPO_DOM    102    110       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    111    130       Helical; Name=2. {ECO:0000255}.
FT   TOPO_DOM    131    149       Extracellular. {ECO:0000255}.
FT   TRANSMEM    150    171       Helical; Name=3. {ECO:0000255}.
FT   TOPO_DOM    172    190       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    191    211       Helical; Name=4. {ECO:0000255}.
FT   TOPO_DOM    212    241       Extracellular. {ECO:0000255}.
FT   TRANSMEM    242    260       Helical; Name=5. {ECO:0000255}.
FT   TOPO_DOM    261    285       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    286    308       Helical; Name=6. {ECO:0000255}.
FT   TOPO_DOM    309    323       Extracellular. {ECO:0000255}.
FT   TRANSMEM    324    347       Helical; Name=7. {ECO:0000255}.
FT   TOPO_DOM    348    397       Cytoplasmic. {ECO:0000255}.
FT   COMPBIAS    383    390       Poly-Ser.
FT   SITE         36     37       Cleavage; by trypsin.
FT   LIPID       361    361       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:21627585}.
FT   CARBOHYD     30     30       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12171601}.
FT   CARBOHYD    222    222       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12171601}.
FT   DISULFID    148    226       {ECO:0000255|PROSITE-ProRule:PRU00521}.
FT   VARIANT      21     21       S -> F (in dbSNP:rs2243072).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_012846.
FT   VARIANT      30     30       N -> S (in dbSNP:rs616235).
FT                                /FTId=VAR_049435.
FT   VARIANT     270    270       R -> Q (in dbSNP:rs2243062).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_012847.
FT   VARIANT     291    291       T -> A (in dbSNP:rs2243083).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_012848.
FT   MUTAGEN      30     30       N->A: Decreases cell surface expression;
FT                                when associate with A-222.
FT                                {ECO:0000269|PubMed:12171601}.
FT   MUTAGEN      30     30       N->A: Increase of sensitivity towards
FT                                tryptase. {ECO:0000269|PubMed:12171601}.
FT   MUTAGEN     222    222       N->A: Decreases cell surface expression;
FT                                when associate with A-30.
FT                                {ECO:0000269|PubMed:12171601}.
FT   MUTAGEN     222    222       N->A: Loss of sensitivity towards all
FT                                tested proteases.
FT                                {ECO:0000269|PubMed:12171601}.
FT   MUTAGEN     355    363       Missing: Abolishes signaling through
FT                                accumulation of intracellular calcium and
FT                                phosphoinositide; no effect in signaling
FT                                through MAPK.
FT                                {ECO:0000269|PubMed:14607272}.
FT   MUTAGEN     361    361       C->A: Loss of palmitoylation; increases
FT                                surface expression and internalization
FT                                following trypsin activation, decreases
FT                                sensitivity and intracellular calcium
FT                                signaling, increases ERK activation
FT                                through G(i) subunit alpha.
FT   MUTAGEN     363    363       S->A: Reduces receptor desensitization
FT                                and internalization, activates ERK1/2;
FT                                when associated with A-366.
FT                                {ECO:0000269|PubMed:10725339}.
FT   MUTAGEN     366    366       T->A: Reduces receptor desensitization
FT                                and internalization, activates ERK1/2;
FT                                when associated with A-363.
FT                                {ECO:0000269|PubMed:10725339}.
FT   CONFLICT    138    138       G -> A (in Ref. 2; AAB47871).
FT                                {ECO:0000305}.
FT   CONFLICT    291    291       T -> S (in Ref. 7; AAH18130).
FT                                {ECO:0000305}.
SQ   SEQUENCE   397 AA;  44126 MW;  F1A4E1D5AB9B362B CRC64;
     MRSPSAAWLL GAAILLAASL SCSGTIQGTN RSSKGRSLIG KVDGTSHVTG KGVTVETVFS
     VDEFSASVLT GKLTTVFLPI VYTIVFVVGL PSNGMALWVF LFRTKKKHPA VIYMANLALA
     DLLSVIWFPL KIAYHIHGNN WIYGEALCNV LIGFFYGNMY CSILFMTCLS VQRYWVIVNP
     MGHSRKKANI AIGISLAIWL LILLVTIPLY VVKQTIFIPA LNITTCHDVL PEQLLVGDMF
     NYFLSLAIGV FLFPAFLTAS AYVLMIRMLR SSAMDENSEK KRKRAIKLIV TVLAMYLICF
     TPSNLLLVVH YFLIKSQGQS HVYALYIVAL CLSTLNSCID PFVYYFVSHD FRDHAKNALL
     CRSVRTVKQM QVSLTSKKHS RKSSSYSSSS TTVKTSY
//
ID   ADA17_HUMAN             Reviewed;         824 AA.
AC   P78536; O60226;
DT   20-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   17-FEB-2016, entry version 185.
DE   RecName: Full=Disintegrin and metalloproteinase domain-containing protein 17;
DE            Short=ADAM 17;
DE            EC=3.4.24.86;
DE   AltName: Full=Snake venom-like protease;
DE   AltName: Full=TNF-alpha convertase;
DE   AltName: Full=TNF-alpha-converting enzyme;
DE   AltName: CD_antigen=CD156b;
DE   Flags: Precursor;
GN   Name=ADAM17; Synonyms=CSVP, TACE;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Leukocyte, and Monocyte;
RX   PubMed=9034191; DOI=10.1038/385733a0;
RA   Moss M.L., Jin S.-L.C., Milla M.E., Burkhart W., Carter H.L.,
RA   Chen W.-J., Clay W.C., Didsbury J.R., Hassler D., Hoffman C.R.,
RA   Kost T.A., Lambert M.H., Leesnitzer M.A., McCauley P., McGeehan G.,
RA   Mitchell J., Moyer M., Pahel G., Rocque W., Overton L.K., Schoenen F.,
RA   Seaton T., Su J.-L., Warner J., Willard D., Becherer J.D.;
RT   "Cloning of a disintegrin metalloproteinase that processes precursor
RT   tumour-necrosis factor-alpha.";
RL   Nature 385:733-736(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A AND B).
RX   PubMed=9034190; DOI=10.1038/385729a0;
RA   Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L.,
RA   Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S.,
RA   Nelson N., Bioani N., Schooley K.A., Gerhart M., Davis R.,
RA   Fitzner J.N., Johnson R.S., Paxton R.J., March C.J., Cerretti D.P.;
RT   "A metalloproteinase disintegrin that releases tumour-necrosis factor-
RT   alpha from cells.";
RL   Nature 385:729-733(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RC   TISSUE=Cartilage;
RX   PubMed=9574564;
RA   Patel I.R., Attur M.G., Patel R.N., Stuchin S.A., Abagyan R.A.,
RA   Abramson S.B., Amin A.R.;
RT   "TNF-alpha convertase enzyme from human arthritis-affected cartilage:
RT   isolation of cDNA by differential display, expression of the active
RT   enzyme, and regulation of TNF-alpha.";
RL   J. Immunol. 160:4570-4579(1998).
RN   [4]
RP   PHOSPHORYLATION AT THR-735.
RX   PubMed=12058067; DOI=10.1091/mbc.01-11-0561;
RA   Diaz-Rodriguez E., Montero J.C., Esparis-Ogando A., Yuste L.,
RA   Pandiella A.;
RT   "Extracellular signal-regulated kinase phosphorylates tumor necrosis
RT   factor alpha-converting enzyme at threonine 735: a potential role in
RT   regulated shedding.";
RL   Mol. Biol. Cell 13:2031-2044(2002).
RN   [5]
RP   INTERACTION WITH MUC1, AND FUNCTION.
RX   PubMed=12441351; DOI=10.1074/jbc.M208326200;
RA   Thathiah A., Blobel C.P., Carson D.D.;
RT   "Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1
RT   shedding.";
RL   J. Biol. Chem. 278:3386-3394(2003).
RN   [6]
RP   PHOSPHORYLATION AT SER-819.
RX   PubMed=12621058; DOI=10.1074/jbc.M300331200;
RA   Fan H., Turck C.W., Derynck R.;
RT   "Characterization of growth factor-induced serine phosphorylation of
RT   tumor necrosis factor-alpha converting enzyme and of an alternatively
RT   translated polypeptide.";
RL   J. Biol. Chem. 278:18617-18627(2003).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-791, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-791, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   ROLE IN PROTEOLYTICAL RELEASE OF JAM3.
RX   PubMed=20592283; DOI=10.4049/jimmunol.1000556;
RA   Rabquer B.J., Amin M.A., Teegala N., Shaheen M.K., Tsou P.S.,
RA   Ruth J.H., Lesch C.A., Imhof B.A., Koch A.E.;
RT   "Junctional adhesion molecule-C is a soluble mediator of
RT   angiogenesis.";
RL   J. Immunol. 185:1777-1785(2010).
RN   [10]
RP   PHOSPHORYLATION AT THR-735, AND INTERACTION WITH MAPK14.
RX   PubMed=20188673; DOI=10.1016/j.molcel.2010.01.034;
RA   Xu P., Derynck R.;
RT   "Direct activation of TACE-mediated ectodomain shedding by p38 MAP
RT   kinase regulates EGF receptor-dependent cell proliferation.";
RL   Mol. Cell 37:551-566(2010).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-791, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   INVOLVEMENT IN NISBD1.
RX   PubMed=22010916; DOI=10.1056/NEJMoa1100721;
RA   Blaydon D.C., Biancheri P., Di W.L., Plagnol V., Cabral R.M.,
RA   Brooke M.A., van Heel D.A., Ruschendorf F., Toynbee M., Walne A.,
RA   O'Toole E.A., Martin J.E., Lindley K., Vulliamy T., Abrams D.J.,
RA   MacDonald T.T., Harper J.I., Kelsell D.P.;
RT   "Inflammatory skin and bowel disease linked to ADAM17 deletion.";
RL   N. Engl. J. Med. 365:1502-1508(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-791, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [14]
RP   FUNCTION.
RX   PubMed=24226769; DOI=10.1038/nature12723;
RA   Boskovski M.T., Yuan S., Pedersen N.B., Goth C.K., Makova S.,
RA   Clausen H., Brueckner M., Khokha M.K.;
RT   "The heterotaxy gene GALNT11 glycosylates Notch to orchestrate cilia
RT   type and laterality.";
RL   Nature 504:456-459(2013).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-791, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   FUNCTION.
RX   PubMed=24227843; DOI=10.1128/JVI.02202-13;
RA   Heurich A., Hofmann-Winkler H., Gierer S., Liepold T., Jahn O.,
RA   Poehlmann S.;
RT   "TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by
RT   TMPRSS2 augments entry driven by the severe acute respiratory syndrome
RT   coronavirus spike protein.";
RL   J. Virol. 88:1293-1307(2014).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 219-473 IN COMPLEX WITH ZINC,
RP   COFACTOR, ACTIVE SITE, AND DISULFIDE BONDS.
RX   PubMed=9520379; DOI=10.1073/pnas.95.7.3408;
RA   Maskos K., Fernandez-Catalan C., Huber R., Bourenkov G.P.,
RA   Bartunik H., Ellestad G.A., Reddy P., Wolfson M.F., Rauch C.T.,
RA   Castner B.J., Davis R., Clarke H.R.G., Petersen M., Fitzner J.N.,
RA   Cerretti D.P., March C.J., Paxton R.J., Black R.A., Bode W.;
RT   "Crystal structure of the catalytic domain of human tumor necrosis
RT   factor-alpha-converting enzyme.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:3408-3412(1998).
CC   -!- FUNCTION: Cleaves the membrane-bound precursor of TNF-alpha to its
CC       mature soluble form. Responsible for the proteolytical release of
CC       soluble JAM3 from endothelial cells surface. Responsible for the
CC       proteolytic release of several other cell-surface proteins,
CC       including p75 TNF-receptor, interleukin 1 receptor type II, p55
CC       TNF-receptor, transforming growth factor-alpha, L-selectin, growth
CC       hormone receptor, MUC1 and the amyloid precursor protein. Acts as
CC       an activator of Notch pathway by mediating cleavage of Notch,
CC       generating the membrane-associated intermediate fragment called
CC       Notch extracellular truncation (NEXT). Plays a role in the
CC       proteolytic processing of ACE2. {ECO:0000269|PubMed:12441351,
CC       ECO:0000269|PubMed:20592283, ECO:0000269|PubMed:24226769,
CC       ECO:0000269|PubMed:24227843}.
CC   -!- CATALYTIC ACTIVITY: Narrow endopeptidase specificity. Cleaves Pro-
CC       Leu-Ala-Gln-Ala-|-Val-Arg-Ser-Ser-Ser in the membrane-bound, 26-
CC       kDa form of tumor necrosis factor alpha (TNF-alpha). Similarly
CC       cleaves other membrane-anchored, cell-surface proteins to 'shed'
CC       the extracellular domains.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:9520379};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:9520379};
CC   -!- SUBUNIT: Interacts with MAD2L1, MAPK14 and MUC1.
CC       {ECO:0000269|PubMed:12441351, ECO:0000269|PubMed:20188673}.
CC   -!- INTERACTION:
CC       Q12959:DLG1; NbExp=7; IntAct=EBI-78188, EBI-357481;
CC       Q13257:MAD2L1; NbExp=3; IntAct=EBI-78188, EBI-78203;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=A;
CC         IsoId=P78536-1; Sequence=Displayed;
CC       Name=B;
CC         IsoId=P78536-2; Sequence=VSP_005478;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Expressed at highest
CC       levels in adult heart, placenta, skeletal muscle, pancreas,
CC       spleen, thymus, prostate, testes, ovary and small intestine, and
CC       in fetal brain, lung, liver and kidney.
CC   -!- INDUCTION: In arthritis-affected cartilage.
CC   -!- DOMAIN: Must be membrane anchored to cleave the different
CC       substrates. The cytoplasmic domain is not required for the this
CC       activity. Only the catalytic domain is essential to shed TNF and
CC       p75 TNFR (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: The conserved cysteine present in the cysteine-switch
CC       motif binds the catalytic zinc ion, thus inhibiting the enzyme.
CC       The dissociation of the cysteine from the zinc ion upon the
CC       activation-peptide release activates the enzyme.
CC   -!- PTM: The precursor is cleaved by a furin endopeptidase.
CC       {ECO:0000250}.
CC   -!- PTM: Phosphorylated. Stimulation by growth factor or phorbol 12-
CC       myristate 13-acetate induces phosphorylation of Ser-819 but
CC       decreases phosphorylation of Ser-791. Phosphorylation at THR-735
CC       by MAPK14 is required for ADAM17-mediated ectodomain shedding.
CC       {ECO:0000269|PubMed:12058067, ECO:0000269|PubMed:12621058,
CC       ECO:0000269|PubMed:20188673}.
CC   -!- DISEASE: Inflammatory skin and bowel disease, neonatal, 1 (NISBD1)
CC       [MIM:614328]: A disorder characterized by inflammatory features
CC       with neonatal onset, involving the skin, hair, and gut. The skin
CC       lesions involve perioral and perianal erythema, psoriasiform
CC       erythroderma, with flares of erythema, scaling, and widespread
CC       pustules. Gastrointestinal symptoms include malabsorptive diarrhea
CC       that is exacerbated by intercurrent gastrointestinal infections.
CC       The hair is short or broken, and the eyelashes and eyebrows are
CC       wiry and disorganized. {ECO:0000269|PubMed:22010916}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Contains 1 disintegrin domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00068}.
CC   -!- SIMILARITY: Contains 1 peptidase M12B domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00276}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alpha-
CC       converting enzyme entry;
CC       URL="https://en.wikipedia.org/wiki/Tumor_Necrosis_Factor_Alpha_Converting_Enzyme";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ADAM17ID572ch2p25.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U86755; AAB51586.1; -; mRNA.
DR   EMBL; U69611; AAB51514.1; -; mRNA.
DR   EMBL; U69612; AAB53014.1; -; mRNA.
DR   EMBL; U92649; AAC39721.1; -; mRNA.
DR   CCDS; CCDS1665.1; -. [P78536-1]
DR   RefSeq; NP_003174.3; NM_003183.4. [P78536-1]
DR   UniGene; Hs.404914; -.
DR   PDB; 1BKC; X-ray; 2.00 A; A/C/E/I=219-474.
DR   PDB; 1ZXC; X-ray; 2.28 A; A/B=215-477.
DR   PDB; 2A8H; X-ray; 2.30 A; A/B=215-477.
DR   PDB; 2DDF; X-ray; 1.70 A; A/B=218-474.
DR   PDB; 2FV5; X-ray; 2.10 A; A/B=216-475.
DR   PDB; 2FV9; X-ray; 2.02 A; A/B=218-475.
DR   PDB; 2I47; X-ray; 1.90 A; A/B/C/D=212-492.
DR   PDB; 2M2F; NMR; -; A=581-642.
DR   PDB; 2OI0; X-ray; 2.00 A; A=216-477.
DR   PDB; 3B92; X-ray; 2.00 A; A=216-474.
DR   PDB; 3CKI; X-ray; 2.30 A; A=219-474.
DR   PDB; 3E8R; X-ray; 1.90 A; A/B=215-477.
DR   PDB; 3EDZ; X-ray; 1.90 A; A/B=215-477.
DR   PDB; 3EWJ; X-ray; 1.80 A; A/B=215-477.
DR   PDB; 3G42; X-ray; 2.10 A; A/B/C/D=212-492.
DR   PDB; 3KMC; X-ray; 1.80 A; A/B=215-476.
DR   PDB; 3KME; X-ray; 1.85 A; A/B=215-476.
DR   PDB; 3L0T; X-ray; 1.92 A; A/B=215-476.
DR   PDB; 3L0V; X-ray; 1.75 A; A/B=215-476.
DR   PDB; 3LE9; X-ray; 1.85 A; A/B=215-476.
DR   PDB; 3LEA; X-ray; 2.00 A; A/B=215-476.
DR   PDB; 3LGP; X-ray; 1.90 A; A/B=215-476.
DR   PDB; 3O64; X-ray; 1.88 A; A/B=215-476.
DR   PDBsum; 1BKC; -.
DR   PDBsum; 1ZXC; -.
DR   PDBsum; 2A8H; -.
DR   PDBsum; 2DDF; -.
DR   PDBsum; 2FV5; -.
DR   PDBsum; 2FV9; -.
DR   PDBsum; 2I47; -.
DR   PDBsum; 2M2F; -.
DR   PDBsum; 2OI0; -.
DR   PDBsum; 3B92; -.
DR   PDBsum; 3CKI; -.
DR   PDBsum; 3E8R; -.
DR   PDBsum; 3EDZ; -.
DR   PDBsum; 3EWJ; -.
DR   PDBsum; 3G42; -.
DR   PDBsum; 3KMC; -.
DR   PDBsum; 3KME; -.
DR   PDBsum; 3L0T; -.
DR   PDBsum; 3L0V; -.
DR   PDBsum; 3LE9; -.
DR   PDBsum; 3LEA; -.
DR   PDBsum; 3LGP; -.
DR   PDBsum; 3O64; -.
DR   ProteinModelPortal; P78536; -.
DR   SMR; P78536; 216-642.
DR   BioGrid; 112731; 16.
DR   DIP; DIP-31044N; -.
DR   IntAct; P78536; 9.
DR   MINT; MINT-108290; -.
DR   STRING; 9606.ENSP00000309968; -.
DR   BindingDB; P78536; -.
DR   ChEMBL; CHEMBL3706; -.
DR   GuidetoPHARMACOLOGY; 1662; -.
DR   MEROPS; M12.217; -.
DR   iPTMnet; P78536; -.
DR   PhosphoSite; P78536; -.
DR   SwissPalm; P78536; -.
DR   BioMuta; ADAM17; -.
DR   DMDM; 14423632; -.
DR   MaxQB; P78536; -.
DR   PaxDb; P78536; -.
DR   PRIDE; P78536; -.
DR   DNASU; 6868; -.
DR   Ensembl; ENST00000310823; ENSP00000309968; ENSG00000151694. [P78536-1]
DR   GeneID; 6868; -.
DR   KEGG; hsa:6868; -.
DR   UCSC; uc002qzu.3; human. [P78536-1]
DR   CTD; 6868; -.
DR   GeneCards; ADAM17; -.
DR   HGNC; HGNC:195; ADAM17.
DR   HPA; CAB025906; -.
DR   HPA; HPA010738; -.
DR   HPA; HPA051575; -.
DR   MalaCards; ADAM17; -.
DR   MIM; 603639; gene.
DR   MIM; 614328; phenotype.
DR   neXtProt; NX_P78536; -.
DR   Orphanet; 294023; Neonatal inflammatory skin and bowel disease.
DR   PharmGKB; PA24512; -.
DR   eggNOG; KOG3658; Eukaryota.
DR   eggNOG; ENOG410XQWB; LUCA.
DR   GeneTree; ENSGT00670000097974; -.
DR   HOGENOM; HOG000033797; -.
DR   HOVERGEN; HBG050457; -.
DR   InParanoid; P78536; -.
DR   KO; K06059; -.
DR   OMA; DQEGFKG; -.
DR   OrthoDB; EOG7S4X58; -.
DR   PhylomeDB; P78536; -.
DR   TreeFam; TF314733; -.
DR   BRENDA; 3.4.24.86; 2681.
DR   Reactome; R-HSA-1251985; Nuclear signaling by ERBB4.
DR   Reactome; R-HSA-1442490; Collagen degradation.
DR   Reactome; R-HSA-177929; Signaling by EGFR.
DR   Reactome; R-HSA-193692; Regulated proteolysis of p75NTR.
DR   Reactome; R-HSA-2122948; Activated NOTCH1 Transmits Signal to the Nucleus.
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2660826; Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant.
DR   Reactome; R-HSA-2691232; Constitutive Signaling by NOTCH1 HD Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-5362798; Release of Hh-Np from the secreting cell.
DR   Reactome; R-HSA-75893; TNF signaling.
DR   Reactome; R-HSA-982772; Growth hormone receptor signaling.
DR   SignaLink; P78536; -.
DR   ChiTaRS; ADAM17; human.
DR   EvolutionaryTrace; P78536; -.
DR   GeneWiki; ADAM17; -.
DR   GenomeRNAi; 6868; -.
DR   NextBio; 26807; -.
DR   PRO; PR:P78536; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; P78536; -.
DR   CleanEx; HS_ADAM17; -.
DR   ExpressionAtlas; P78536; baseline and differential.
DR   Genevisible; P78536; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:BHF-UCL.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005178; F:integrin binding; IPI:BHF-UCL.
DR   GO; GO:0005138; F:interleukin-6 receptor binding; IPI:BHF-UCL.
DR   GO; GO:0004222; F:metalloendopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0008237; F:metallopeptidase activity; IDA:BHF-UCL.
DR   GO; GO:0005112; F:Notch binding; IDA:UniProtKB.
DR   GO; GO:0030165; F:PDZ domain binding; IPI:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0030183; P:B cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0007155; P:cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0033627; P:cell adhesion mediated by integrin; IDA:BHF-UCL.
DR   GO; GO:0048870; P:cell motility; ISS:BHF-UCL.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0030574; P:collagen catabolic process; TAS:Reactome.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IMP:BHF-UCL.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0035625; P:epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0002467; P:germinal center formation; ISS:BHF-UCL.
DR   GO; GO:0060397; P:JAK-STAT cascade involved in growth hormone signaling pathway; TAS:Reactome.
DR   GO; GO:0006509; P:membrane protein ectodomain proteolysis; IMP:UniProtKB.
DR   GO; GO:0031293; P:membrane protein intracellular domain proteolysis; TAS:Reactome.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0002446; P:neutrophil mediated immunity; IC:BHF-UCL.
DR   GO; GO:0007220; P:Notch receptor processing; IDA:UniProtKB.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0051088; P:PMA-inducible membrane protein ectodomain proteolysis; IDA:BHF-UCL.
DR   GO; GO:0030307; P:positive regulation of cell growth; IMP:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0051272; P:positive regulation of cellular component movement; ISS:BHF-UCL.
DR   GO; GO:0032722; P:positive regulation of chemokine production; IMP:BHF-UCL.
DR   GO; GO:0031659; P:positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle; IDA:BHF-UCL.
DR   GO; GO:0045741; P:positive regulation of epidermal growth factor-activated receptor activity; IDA:BHF-UCL.
DR   GO; GO:0002690; P:positive regulation of leukocyte chemotaxis; IC:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0010820; P:positive regulation of T cell chemotaxis; IMP:BHF-UCL.
DR   GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0006508; P:proteolysis; IDA:UniProtKB.
DR   GO; GO:0033025; P:regulation of mast cell apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0042493; P:response to drug; ISS:BHF-UCL.
DR   GO; GO:0055099; P:response to high density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0001666; P:response to hypoxia; IDA:BHF-UCL.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IDA:BHF-UCL.
DR   GO; GO:0048536; P:spleen development; ISS:BHF-UCL.
DR   GO; GO:0033077; P:T cell differentiation in thymus; ISS:BHF-UCL.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0035313; P:wound healing, spreading of epidermal cells; IEP:BHF-UCL.
DR   Gene3D; 3.40.390.10; -; 1.
DR   Gene3D; 4.10.70.10; -; 1.
DR   InterPro; IPR032029; ADAM17_MPD.
DR   InterPro; IPR001762; Disintegrin_dom.
DR   InterPro; IPR024079; MetalloPept_cat_dom.
DR   InterPro; IPR001590; Peptidase_M12B.
DR   InterPro; IPR002870; Peptidase_M12B_N.
DR   Pfam; PF16698; ADAM17_MPD; 1.
DR   Pfam; PF00200; Disintegrin; 1.
DR   Pfam; PF01562; Pep_M12B_propep; 1.
DR   SMART; SM00050; DISIN; 1.
DR   SUPFAM; SSF57552; SSF57552; 1.
DR   PROSITE; PS50215; ADAM_MEPRO; 1.
DR   PROSITE; PS50214; DISINTEGRIN_2; 1.
DR   PROSITE; PS00142; ZINC_PROTEASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Hydrolase;
KW   Membrane; Metal-binding; Metalloprotease; Notch signaling pathway;
KW   Phosphoprotein; Polymorphism; Protease; Reference proteome;
KW   SH3-binding; Signal; Transmembrane; Transmembrane helix; Zinc;
KW   Zymogen.
FT   SIGNAL        1     17       {ECO:0000255}.
FT   PROPEP       18    214       {ECO:0000269|PubMed:9034191}.
FT                                /FTId=PRO_0000029088.
FT   CHAIN       215    824       Disintegrin and metalloproteinase domain-
FT                                containing protein 17.
FT                                /FTId=PRO_0000029089.
FT   TOPO_DOM    215    671       Extracellular. {ECO:0000255}.
FT   TRANSMEM    672    692       Helical. {ECO:0000255}.
FT   TOPO_DOM    693    824       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      223    474       Peptidase M12B. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00276}.
FT   DOMAIN      475    563       Disintegrin. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00068}.
FT   REGION      603    671       Crambin-like.
FT   MOTIF       182    189       Cysteine switch. {ECO:0000250}.
FT   MOTIF       731    738       SH3-binding. {ECO:0000255}.
FT   MOTIF       741    748       SH3-binding. {ECO:0000255}.
FT   COMPBIAS     96     99       Poly-Val.
FT   COMPBIAS    564    602       Cys-rich.
FT   ACT_SITE    406    406       {ECO:0000255|PROSITE-ProRule:PRU00276,
FT                                ECO:0000255|PROSITE-ProRule:PRU10095,
FT                                ECO:0000269|PubMed:9520379}.
FT   METAL       184    184       Zinc; in inhibited form. {ECO:0000250}.
FT   METAL       405    405       Zinc; catalytic.
FT                                {ECO:0000269|PubMed:9520379}.
FT   METAL       409    409       Zinc; catalytic.
FT                                {ECO:0000269|PubMed:9520379}.
FT   METAL       415    415       Zinc; catalytic.
FT                                {ECO:0000269|PubMed:9520379}.
FT   MOD_RES     735    735       Phosphothreonine; by MAPK14.
FT                                {ECO:0000269|PubMed:12058067,
FT                                ECO:0000269|PubMed:20188673}.
FT   MOD_RES     767    767       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9Z1K9}.
FT   MOD_RES     791    791       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     819    819       Phosphoserine.
FT                                {ECO:0000269|PubMed:12621058}.
FT   CARBOHYD    103    103       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    157    157       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    174    174       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    264    264       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    452    452       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    498    498       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    539    539       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    551    551       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    594    594       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    225    333       {ECO:0000269|PubMed:9520379}.
FT   DISULFID    365    469       {ECO:0000269|PubMed:9520379}.
FT   DISULFID    423    453       {ECO:0000269|PubMed:9520379}.
FT   DISULFID    534    555       {ECO:0000250}.
FT   DISULFID    573    582       {ECO:0000250}.
FT   DISULFID    578    591       {ECO:0000250}.
FT   DISULFID    593    600       {ECO:0000250}.
FT   VAR_SEQ     695    824       Missing (in isoform B).
FT                                {ECO:0000303|PubMed:9034190}.
FT                                /FTId=VSP_005478.
FT   VARIANT     162    162       K -> E (in dbSNP:rs34431503).
FT                                /FTId=VAR_051586.
FT   VARIANT     202    202       R -> G (in dbSNP:rs2230818).
FT                                /FTId=VAR_051587.
FT   CONFLICT    109    109       V -> A (in Ref. 3; AAC39721).
FT                                {ECO:0000305}.
FT   CONFLICT    563    563       D -> N (in Ref. 3; AAC39721).
FT                                {ECO:0000305}.
FT   CONFLICT    801    801       T -> A (in Ref. 3; AAC39721).
FT                                {ECO:0000305}.
FT   CONFLICT    818    818       D -> N (in Ref. 3; AAC39721).
FT                                {ECO:0000305}.
FT   HELIX       220    222       {ECO:0000244|PDB:3L0V}.
FT   STRAND      224    231       {ECO:0000244|PDB:2DDF}.
FT   HELIX       233    238       {ECO:0000244|PDB:2DDF}.
FT   TURN        239    242       {ECO:0000244|PDB:3EDZ}.
FT   HELIX       244    263       {ECO:0000244|PDB:2DDF}.
FT   STRAND      269    271       {ECO:0000244|PDB:2DDF}.
FT   STRAND      276    284       {ECO:0000244|PDB:2DDF}.
FT   STRAND      300    302       {ECO:0000244|PDB:2DDF}.
FT   STRAND      309    311       {ECO:0000244|PDB:2DDF}.
FT   HELIX       314    324       {ECO:0000244|PDB:2DDF}.
FT   HELIX       326    329       {ECO:0000244|PDB:2DDF}.
FT   STRAND      332    339       {ECO:0000244|PDB:2DDF}.
FT   HELIX       344    346       {ECO:0000244|PDB:2DDF}.
FT   STRAND      349    354       {ECO:0000244|PDB:2DDF}.
FT   STRAND      355    357       {ECO:0000244|PDB:3O64}.
FT   STRAND      363    365       {ECO:0000244|PDB:3O64}.
FT   STRAND      368    371       {ECO:0000244|PDB:2DDF}.
FT   TURN        372    375       {ECO:0000244|PDB:2DDF}.
FT   STRAND      376    379       {ECO:0000244|PDB:2DDF}.
FT   STRAND      382    389       {ECO:0000244|PDB:2DDF}.
FT   HELIX       396    410       {ECO:0000244|PDB:2DDF}.
FT   STRAND      418    420       {ECO:0000244|PDB:3CKI}.
FT   TURN        421    423       {ECO:0000244|PDB:2DDF}.
FT   HELIX       427    429       {ECO:0000244|PDB:2DDF}.
FT   STRAND      436    438       {ECO:0000244|PDB:3CKI}.
FT   STRAND      442    444       {ECO:0000244|PDB:3LGP}.
FT   TURN        445    448       {ECO:0000244|PDB:2DDF}.
FT   HELIX       452    469       {ECO:0000244|PDB:2DDF}.
FT   HELIX       583    586       {ECO:0000244|PDB:2M2F}.
FT   STRAND      589    591       {ECO:0000244|PDB:2M2F}.
FT   HELIX       597    600       {ECO:0000244|PDB:2M2F}.
FT   STRAND      603    605       {ECO:0000244|PDB:2M2F}.
FT   STRAND      611    613       {ECO:0000244|PDB:2M2F}.
FT   STRAND      631    636       {ECO:0000244|PDB:2M2F}.
FT   TURN        637    639       {ECO:0000244|PDB:2M2F}.
SQ   SEQUENCE   824 AA;  93021 MW;  5B1032F6B88A837F CRC64;
     MRQSLLFLTS VVPFVLAPRP PDDPGFGPHQ RLEKLDSLLS DYDILSLSNI QQHSVRKRDL
     QTSTHVETLL TFSALKRHFK LYLTSSTERF SQNFKVVVVD GKNESEYTVK WQDFFTGHVV
     GEPDSRVLAH IRDDDVIIRI NTDGAEYNIE PLWRFVNDTK DKRMLVYKSE DIKNVSRLQS
     PKVCGYLKVD NEELLPKGLV DREPPEELVH RVKRRADPDP MKNTCKLLVV ADHRFYRYMG
     RGEESTTTNY LIELIDRVDD IYRNTSWDNA GFKGYGIQIE QIRILKSPQE VKPGEKHYNM
     AKSYPNEEKD AWDVKMLLEQ FSFDIAEEAS KVCLAHLFTY QDFDMGTLGL AYVGSPRANS
     HGGVCPKAYY SPVGKKNIYL NSGLTSTKNY GKTILTKEAD LVTTHELGHN FGAEHDPDGL
     AECAPNEDQG GKYVMYPIAV SGDHENNKMF SNCSKQSIYK TIESKAQECF QERSNKVCGN
     SRVDEGEECD PGIMYLNNDT CCNSDCTLKE GVQCSDRNSP CCKNCQFETA QKKCQEAINA
     TCKGVSYCTG NSSECPPPGN AEDDTVCLDL GKCKDGKCIP FCEREQQLES CACNETDNSC
     KVCCRDLSGR CVPYVDAEQK NLFLRKGKPC TVGFCDMNGK CEKRVQDVIE RFWDFIDQLS
     INTFGKFLAD NIVGSVLVFS LIFWIPFSIL VHCVDKKLDK QYESLSLFHP SNVEMLSSMD
     SASVRIIKPF PAPQTPGRLQ PAPVIPSAPA APKLDHQRMD TIQEDPSTDS HMDEDGFEKD
     PFPNSSTAAK SFEDLTDHPV TRSEKAASFK LQRQNRVDSK ETEC
//
ID   CCL3_HUMAN              Reviewed;          92 AA.
AC   P10147;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   17-FEB-2016, entry version 174.
DE   RecName: Full=C-C motif chemokine 3;
DE   AltName: Full=G0/G1 switch regulatory protein 19-1;
DE   AltName: Full=Macrophage inflammatory protein 1-alpha;
DE            Short=MIP-1-alpha;
DE   AltName: Full=PAT 464.1;
DE   AltName: Full=SIS-beta;
DE   AltName: Full=Small-inducible cytokine A3;
DE   AltName: Full=Tonsillar lymphocyte LD78 alpha protein;
DE   Contains:
DE     RecName: Full=MIP-1-alpha(4-69);
DE     AltName: Full=LD78-alpha(4-69);
DE   Flags: Precursor;
GN   Name=CCL3; Synonyms=G0S19-1, MIP1A, SCYA3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RC   TISSUE=Lymphocyte;
RX   PubMed=3086300;
RA   Obaru K., Fukuda M., Maeda S., Shimada K.;
RT   "A cDNA clone used to study mRNA inducible in human tonsillar
RT   lymphocytes by a tumor promoter.";
RL   J. Biochem. 99:885-894(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=T-cell;
RX   PubMed=2521882;
RA   Zipfel P.F., Balke J., Irving S.G., Kelly K., Siebenlist U.;
RT   "Mitogenic activation of human T cells induces two closely related
RT   genes which share structural similarities with a new family of
RT   secreted factors.";
RL   J. Immunol. 142:1582-1590(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RC   TISSUE=Lymphocyte;
RX   PubMed=2271120; DOI=10.1089/dna.1990.9.589;
RA   Blum S., Forsdyke R.E., Forsdyke D.R.;
RT   "Three human homologs of a murine gene encoding an inhibitor of stem
RT   cell proliferation.";
RL   DNA Cell Biol. 9:589-602(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Lymphocyte;
RX   PubMed=1694014;
RA   Nakao M., Nomiyama H., Shimada K.;
RT   "Structures of human genes coding for cytokine LD78 and their
RT   expression.";
RL   Mol. Cell. Biol. 10:3646-3658(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Natural killer cell;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 23-92.
RC   TISSUE=Leukocyte;
RA   Jang J.S., Kim B.E.;
RL   Submitted (JAN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   PROTEIN SEQUENCE OF 24-92, AND MUTAGENESIS OF ASP-49.
RX   PubMed=8541527;
RA   Hunter M.G., Bawden L., Brotherton D., Craig S., Cribbes S.,
RA   Czaplewski L.G., Dexter T.M., Drummond A.H., Gearing A.H.,
RA   Heyworth C.M., Lord B.I., Mccourt M., Varley P.G., Wood L.M.,
RA   Edwards R.M., Lewis P.J.;
RT   "BB-10010: an active variant of human macrophage inflammatory protein-
RT   1 alpha with improved pharmaceutical properties.";
RL   Blood 86:4400-4408(1995).
RN   [8]
RP   PROTEIN SEQUENCE OF 27-40 AND 71-83, AND FUNCTION.
RX   PubMed=8525373; DOI=10.1126/science.270.5243.1811;
RA   Cocchi F., DeVico A.L., Garzino-Demo A., Arya S.K., Gallo R.C.,
RA   Lusso P.;
RT   "Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major
RT   HIV-suppressive factors produced by CD8+ T cells.";
RL   Science 270:1811-1815(1995).
RN   [9]
RP   PROTEIN SEQUENCE OF 27-51, AND IDENTIFICATION OF LD78-ALPHA(4-69).
RX   PubMed=7537510; DOI=10.1089/aid.1995.11.155;
RA   Bertini R., Luini W., Sozzani S., Bottazzi B., Ruggiero P.,
RA   Boraschi D., Saggioro D., Chieco-Bianchi L., Proost P., van Damme J.,
RA   Mantovani A.;
RT   "Identification of MIP-1 alpha/LD78 as a monocyte chemoattractant
RT   released by the HTLV-I-transformed cell line MT4.";
RL   AIDS Res. Hum. Retroviruses 11:155-160(1995).
RN   [10]
RP   GAG BINDING SITES ARG-40; ARG-68 AND ARG-70, AND MUTAGENESIS OF
RP   ARG-40; ARG-68 AND ARG-70.
RX   PubMed=9092555; DOI=10.1074/jbc.272.15.10103;
RA   Koopmann W., Krangel M.S.;
RT   "Identification of a glycosaminoglycan-binding site in chemokine
RT   macrophage inflammatory protein-1alpha.";
RL   J. Biol. Chem. 272:10103-10109(1997).
RN   [11]
RP   SUBUNIT, AND INTERACTION WITH MIP-1-BETA(3-69).
RX   PubMed=12070155; DOI=10.1074/jbc.M203077200;
RA   Guan E., Wang J., Roderiquez G., Norcross M.A.;
RT   "Natural truncation of the chemokine MIP-1beta/CCL4 affects receptor
RT   specificity but not anti-HIV-1 activity.";
RL   J. Biol. Chem. 277:32348-32352(2002).
RN   [12]
RP   REVIEW.
RX   PubMed=12401480; DOI=10.1016/S1359-6101(02)00045-X;
RA   Menten P., Wuyts A., Van Damme J.;
RT   "Macrophage inflammatory protein-1.";
RL   Cytokine Growth Factor Rev. 13:455-481(2002).
RN   [13]
RP   STRUCTURE BY NMR OF 24-92, AND MUTAGENESIS OF ASP-49 AND GLU-89.
RX   PubMed=10347159; DOI=10.1074/jbc.274.23.16077;
RA   Czaplewski L.G., McKeating J., Craven C.J., Higgins L.D., Appay V.,
RA   Brown A., Dudgeon T., Howard L.A., Meyers T., Owen J., Palan S.R.,
RA   Tan P., Wilson G., Woods N.R., Heyworth C.M., Lord B.I.,
RA   Brotherton D., Christison R., Craig S., Cribbes S., Edwards R.M.,
RA   Evans S.J., Gilbert R., Morgan P., Eliot Randle E., Schofield N.,
RA   Varley P.G., Fisher J., Jonathan P., Waltho J.P., Hunter M.G.;
RT   "Identification of amino acid residues critical for aggregation of
RT   human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-
RT   1beta, and RANTES. Characterization of active disaggregated chemokine
RT   variants.";
RL   J. Biol. Chem. 274:16077-16084(1999).
CC   -!- FUNCTION: Monokine with inflammatory and chemokinetic properties.
CC       Binds to CCR1, CCR4 and CCR5. One of the major HIV-suppressive
CC       factors produced by CD8+ T-cells. Recombinant MIP-1-alpha induces
CC       a dose-dependent inhibition of different strains of HIV-1, HIV-2,
CC       and simian immunodeficiency virus (SIV).
CC       {ECO:0000269|PubMed:8525373}.
CC   -!- SUBUNIT: Self-associates. Also heterodimer of MIP-1-alpha(4-69)
CC       and MIP-1-beta(3-69). {ECO:0000269|PubMed:12070155}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-8459634, EBI-8459634;
CC       P14735:IDE; NbExp=3; IntAct=EBI-8459634, EBI-2556886;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- INDUCTION: By TPA or PHA (TPA = 12-O-tetradecanoyl phorbol-13
CC       acetate (tumor promoter); PHA = phytohemagglutinin (T-cell
CC       mitogen)).
CC   -!- PTM: N-terminal processed form LD78-alpha(4-69) is produced by
CC       proteolytic cleavage after secretion from HTLV1-transformed T-
CC       cells.
CC   -!- SIMILARITY: Belongs to the intercrine beta (chemokine CC) family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Macrophage inflammatory protein
CC       entry;
CC       URL="https://en.wikipedia.org/wiki/Macrophage_Inflammatory_Protein";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D00044; BAA00029.1; -; mRNA.
DR   EMBL; X03754; CAA27388.1; -; mRNA.
DR   EMBL; X04018; CAA27643.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; M25315; AAA57255.1; -; mRNA.
DR   EMBL; M23452; AAA36316.1; -; mRNA.
DR   EMBL; M23178; AAA35858.1; -; Genomic_DNA.
DR   EMBL; D90144; BAA14172.1; -; Genomic_DNA.
DR   EMBL; BC071834; AAH71834.1; -; mRNA.
DR   EMBL; AF043339; AAC03539.1; -; mRNA.
DR   CCDS; CCDS11307.1; -.
DR   PIR; A35673; A30574.
DR   RefSeq; NP_002974.1; NM_002983.2.
DR   UniGene; Hs.514107; -.
DR   PDB; 1B50; NMR; -; A/B=24-92.
DR   PDB; 1B53; NMR; -; A/B=24-92.
DR   PDB; 2X69; X-ray; 2.65 A; A/B/C/D/E=23-92.
DR   PDB; 2X6G; X-ray; 2.18 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R=23-92.
DR   PDB; 3FPU; X-ray; 1.76 A; B=24-92.
DR   PDB; 3H44; X-ray; 3.00 A; C/D=23-92.
DR   PDB; 3KBX; X-ray; 2.65 A; A/B/C/D/E=23-92.
DR   PDB; 4RA8; X-ray; 2.60 A; A/B/C/D/E=23-91.
DR   PDB; 4ZKB; X-ray; 2.90 A; B=24-92.
DR   PDBsum; 1B50; -.
DR   PDBsum; 1B53; -.
DR   PDBsum; 2X69; -.
DR   PDBsum; 2X6G; -.
DR   PDBsum; 3FPU; -.
DR   PDBsum; 3H44; -.
DR   PDBsum; 3KBX; -.
DR   PDBsum; 4RA8; -.
DR   PDBsum; 4ZKB; -.
DR   ProteinModelPortal; P10147; -.
DR   SMR; P10147; 26-91.
DR   BioGrid; 112252; 5.
DR   DIP; DIP-5837N; -.
DR   IntAct; P10147; 1.
DR   MINT; MINT-103148; -.
DR   STRING; 9606.ENSP00000225245; -.
DR   BioMuta; CCL3; -.
DR   DMDM; 127078; -.
DR   PaxDb; P10147; -.
DR   PRIDE; P10147; -.
DR   Ensembl; ENST00000613396; ENSP00000480753; ENSG00000278567.
DR   Ensembl; ENST00000613922; ENSP00000477908; ENSG00000277632.
DR   Ensembl; ENST00000616221; ENSP00000483712; ENSG00000274221.
DR   GeneID; 6348; -.
DR   KEGG; hsa:6348; -.
DR   UCSC; uc002hkv.3; human.
DR   CTD; 6348; -.
DR   GeneCards; CCL3; -.
DR   HGNC; HGNC:10627; CCL3.
DR   MalaCards; CCL3; -.
DR   MIM; 182283; gene.
DR   neXtProt; NX_P10147; -.
DR   PharmGKB; PA35559; -.
DR   eggNOG; ENOG410J4I9; Eukaryota.
DR   eggNOG; ENOG410YXJU; LUCA.
DR   GeneTree; ENSGT00730000110278; -.
DR   HOGENOM; HOG000036685; -.
DR   HOVERGEN; HBG017871; -.
DR   InParanoid; P10147; -.
DR   KO; K05408; -.
DR   OMA; NTPTACC; -.
DR   OrthoDB; EOG7CVQ1F; -.
DR   PhylomeDB; P10147; -.
DR   TreeFam; TF334888; -.
DR   Reactome; R-HSA-380108; Chemokine receptors bind chemokines.
DR   EvolutionaryTrace; P10147; -.
DR   GeneWiki; CCL3; -.
DR   GenomeRNAi; 6348; -.
DR   NextBio; 24664; -.
DR   PRO; PR:P10147; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; P10147; -.
DR   CleanEx; HS_CCL3; -.
DR   Genevisible; P10147; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005622; C:intracellular; IDA:UniProtKB.
DR   GO; GO:0004698; F:calcium-dependent protein kinase C activity; IDA:UniProtKB.
DR   GO; GO:0031726; F:CCR1 chemokine receptor binding; IPI:UniProtKB.
DR   GO; GO:0031730; F:CCR5 chemokine receptor binding; IPI:UniProtKB.
DR   GO; GO:0042056; F:chemoattractant activity; IDA:UniProtKB.
DR   GO; GO:0008009; F:chemokine activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0016301; F:kinase activity; IDA:UniProtKB.
DR   GO; GO:0016004; F:phospholipase activator activity; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0043615; P:astrocyte cell migration; ISS:UniProtKB.
DR   GO; GO:0007610; P:behavior; IDA:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; IDA:UniProtKB.
DR   GO; GO:0019722; P:calcium-mediated signaling; IDA:UniProtKB.
DR   GO; GO:0001775; P:cell activation; IDA:UniProtKB.
DR   GO; GO:0007267; P:cell-cell signaling; IDA:UniProtKB.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:UniProtKB.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IEP:UniProtKB.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEP:UniProtKB.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IDA:UniProtKB.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEP:UniProtKB.
DR   GO; GO:0070098; P:chemokine-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0006935; P:chemotaxis; IDA:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0048245; P:eosinophil chemotaxis; IDA:UniProtKB.
DR   GO; GO:0043308; P:eosinophil degranulation; IDA:UniProtKB.
DR   GO; GO:0006887; P:exocytosis; IDA:UniProtKB.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0071621; P:granulocyte chemotaxis; IDA:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IDA:UniProtKB.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0048247; P:lymphocyte chemotaxis; IDA:UniProtKB.
DR   GO; GO:0048246; P:macrophage chemotaxis; ISS:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0002548; P:monocyte chemotaxis; IDA:UniProtKB.
DR   GO; GO:0043922; P:negative regulation by host of viral transcription; IDA:UniProtKB.
DR   GO; GO:0030502; P:negative regulation of bone mineralization; IDA:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0045671; P:negative regulation of osteoclast differentiation; IDA:UniProtKB.
DR   GO; GO:0030593; P:neutrophil chemotaxis; IDA:UniProtKB.
DR   GO; GO:0001649; P:osteoblast differentiation; IEP:UniProtKB.
DR   GO; GO:0050918; P:positive chemotaxis; IDA:GOC.
DR   GO; GO:0090280; P:positive regulation of calcium ion import; TAS:BHF-UCL.
DR   GO; GO:0051928; P:positive regulation of calcium ion transport; IDA:UniProtKB.
DR   GO; GO:0050850; P:positive regulation of calcium-mediated signaling; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IBA:GO_Central.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; ISS:UniProtKB.
DR   GO; GO:0050718; P:positive regulation of interleukin-1 beta secretion; ISS:UniProtKB.
DR   GO; GO:2000503; P:positive regulation of natural killer cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IEP:UniProtKB.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; ISS:UniProtKB.
DR   GO; GO:0043491; P:protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IDA:UniProtKB.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IDA:UniProtKB.
DR   GO; GO:0014808; P:release of sequestered calcium ion into cytosol by sarcoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0070723; P:response to cholesterol; IDA:UniProtKB.
DR   GO; GO:0009636; P:response to toxic substance; IDA:UniProtKB.
DR   GO; GO:0023052; P:signaling; IEP:UniProtKB.
DR   GO; GO:0010818; P:T cell chemotaxis; IDA:UniProtKB.
DR   InterPro; IPR000827; Chemokine_CC_CS.
DR   InterPro; IPR001811; Chemokine_IL8-like_dom.
DR   Pfam; PF00048; IL8; 1.
DR   SMART; SM00199; SCY; 1.
DR   SUPFAM; SSF54117; SSF54117; 1.
DR   PROSITE; PS00472; SMALL_CYTOKINES_CC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Chemotaxis; Complete proteome; Cytokine;
KW   Direct protein sequencing; Disulfide bond; Inflammatory response;
KW   Polymorphism; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     23       {ECO:0000269|PubMed:8541527}.
FT   CHAIN        24     92       C-C motif chemokine 3.
FT                                /FTId=PRO_0000005156.
FT   CHAIN        27     92       MIP-1-alpha(4-69).
FT                                /FTId=PRO_0000005157.
FT   SITE         40     40       Involved in GAG binding.
FT   SITE         68     68       Involved in GAG binding.
FT   SITE         70     70       Involved in GAG binding.
FT   DISULFID     33     57       {ECO:0000250}.
FT   DISULFID     34     73       {ECO:0000250}.
FT   VARIANT      78     78       E -> D (in dbSNP:rs34171309).
FT                                /FTId=VAR_048701.
FT   MUTAGEN      40     40       R->A: Slightly reduces heparin binding.
FT                                {ECO:0000269|PubMed:9092555}.
FT   MUTAGEN      49     49       D->A: Reduces self-association; in BB-
FT                                10010: Improved pharmaceutical
FT                                properties. {ECO:0000269|PubMed:10347159,
FT                                ECO:0000269|PubMed:8541527}.
FT   MUTAGEN      68     68       R->A: Strongly reduces heparin binding.
FT                                {ECO:0000269|PubMed:9092555}.
FT   MUTAGEN      70     70       R->A: Reduces heparin binding.
FT                                {ECO:0000269|PubMed:9092555}.
FT   MUTAGEN      89     89       E->A: Reduces self-association.
FT                                {ECO:0000269|PubMed:10347159}.
FT   HELIX        26     28       {ECO:0000244|PDB:3FPU}.
FT   STRAND       31     33       {ECO:0000244|PDB:2X6G}.
FT   HELIX        44     46       {ECO:0000244|PDB:3FPU}.
FT   STRAND       47     52       {ECO:0000244|PDB:3FPU}.
FT   STRAND       57     59       {ECO:0000244|PDB:3FPU}.
FT   STRAND       62     66       {ECO:0000244|PDB:3FPU}.
FT   STRAND       71     74       {ECO:0000244|PDB:3FPU}.
FT   STRAND       76     78       {ECO:0000244|PDB:4ZKB}.
FT   HELIX        79     87       {ECO:0000244|PDB:3FPU}.
SQ   SEQUENCE   92 AA;  10085 MW;  517865D5D6776CA8 CRC64;
     MQVSTAALAV LLCTMALCNQ FSASLAADTP TACCFSYTSR QIPQNFIADY FETSSQCSKP
     GVIFLTKRSR QVCADPSEEW VQKYVSDLEL SA
//
ID   PPBT_HUMAN              Reviewed;         524 AA.
AC   P05186; A1A4E7; B2RMP8; B7Z387; B7Z4Y6; O75090; Q2TAI7; Q59EJ7;
AC   Q5BKZ5; Q5VTG5; Q6NZI8; Q8WU32; Q9UBK0;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   21-JUN-2005, sequence version 4.
DT   20-JAN-2016, entry version 190.
DE   RecName: Full=Alkaline phosphatase, tissue-nonspecific isozyme;
DE            Short=AP-TNAP;
DE            Short=TNSALP;
DE            EC=3.1.3.1;
DE   AltName: Full=Alkaline phosphatase liver/bone/kidney isozyme;
DE   Flags: Precursor;
GN   Name=ALPL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Osteosarcoma;
RX   PubMed=3532105; DOI=10.1073/pnas.83.19.7182;
RA   Weiss M.J., Henthorn P.S., Lafferty M.A., Slaughter C., Raducha M.,
RA   Harris H.;
RT   "Isolation and characterization of a cDNA encoding a human
RT   liver/bone/kidney-type alkaline phosphatase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:7182-7186(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Osteosarcoma;
RX   PubMed=3165380;
RA   Weiss M.J., Ray K., Henthorn P.S., Lamb B., Kadesch T., Harris H.;
RT   "Structure of the human liver/bone/kidney alkaline phosphatase gene.";
RL   J. Biol. Chem. 263:12002-12010(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT HIS-263.
RC   TISSUE=Liver;
RX   PubMed=2928120; DOI=10.1093/nar/17.5.2129;
RA   Kishi F., Matsuura S., Kajii T.;
RT   "Nucleotide sequence of the human liver-type alkaline phosphatase
RT   cDNA.";
RL   Nucleic Acids Res. 17:2129-2129(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT HOPS PHE-289.
RX   PubMed=9747027; DOI=10.1007/s100380050061;
RA   Sugimoto N., Iwamoto S., Hoshino Y., Kajii E.;
RT   "A novel missense mutation of the tissue-nonspecific alkaline
RT   phosphatase gene detected in a patient with hypophosphatasia.";
RL   J. Hum. Genet. 43:160-164(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   HIS-152.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   HIS-263.
RC   TISSUE=Brain, Cerebellum, Lymphoma, and Peripheral nerve;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 18-49.
RC   TISSUE=Liver;
RX   PubMed=3954357; DOI=10.1016/0003-9861(86)90223-7;
RA   Garattini E., Hua J.-C., Pan Y.C.E., Udenfriend S.;
RT   "Human liver alkaline phosphatase, purification and partial
RT   sequencing: homology with the placental isozyme.";
RL   Arch. Biochem. Biophys. 245:331-337(1986).
RN   [11]
RP   PROTEIN SEQUENCE OF 18-32, AND GLYCOSYLATION.
RX   PubMed=1458595;
RA   Nishihara Y., Hayashi Y., Adachi T., Koyama I., Stigbrand T.,
RA   Hirano K.;
RT   "Chemical nature of intestinal-type alkaline phosphatase in human
RT   kidney.";
RL   Clin. Chem. 38:2539-2542(1992).
RN   [12]
RP   GPI-ANCHOR [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=14517339; DOI=10.1074/mcp.M300079-MCP200;
RA   Elortza F., Nuehse T.S., Foster L.J., Stensballe A., Peck S.C.,
RA   Jensen O.N.;
RT   "Proteomic analysis of glycosylphosphatidylinositol-anchored membrane
RT   proteins.";
RL   Mol. Cell. Proteomics 2:1261-1270(2003).
RN   [13]
RP   GPI-ANCHOR [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16602701; DOI=10.1021/pr050419u;
RA   Elortza F., Mohammed S., Bunkenborg J., Foster L.J., Nuehse T.S.,
RA   Brodbeck U., Peck S.C., Jensen O.N.;
RT   "Modification-specific proteomics of plasma membrane proteins:
RT   identification and characterization of glycosylphosphatidylinositol-
RT   anchored proteins released upon phospholipase D treatment.";
RL   J. Proteome Res. 5:935-943(2006).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-430.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   VARIANT HOPS THR-179.
RX   PubMed=3174660; DOI=10.1073/pnas.85.20.7666;
RA   Weiss M.J., Cole D.E.C., Ray K., Whyte M.P., Lafferty M.A.,
RA   Mulivor R.A., Harris H.;
RT   "A missense mutation in the human liver/bone/kidney alkaline
RT   phosphatase gene causing a lethal form of hypophosphatasia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:7666-7669(1988).
RN   [17]
RP   VARIANTS HOPS VAL-33; CYS-71; PRO-71; LYS-191; PRO-207; ALA-294;
RP   VAL-378 AND HIS-436, AND VARIANT HIS-263.
RX   PubMed=1409720; DOI=10.1073/pnas.89.20.9924;
RA   Henthorn P.S., Raducha M., Fedde K.N., Lafferty M.A., Whyte M.P.;
RT   "Different missense mutations at the tissue-nonspecific alkaline
RT   phosphatase gene locus in autosomal recessively inherited forms of
RT   mild and severe hypophosphatasia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:9924-9928(1992).
RN   [18]
RP   VARIANT HOPS ASP-334.
RX   PubMed=8406453; DOI=10.1006/geno.1993.1305;
RA   Greenberg C.R., Taylor C.L., Haworth J.C., Seargeant L.E.,
RA   Philipps S., Triggs-Raine B., Chodirker B.N.;
RT   "A homoallelic Gly317-->Asp mutation in ALPL causes the perinatal
RT   (lethal) form of hypophosphatasia in Canadian mennonites.";
RL   Genomics 17:215-217(1993).
RN   [19]
RP   INVOLVEMENT IN HOPSI, AND VARIANT HOPSI LYS-298.
RX   PubMed=7833929; DOI=10.1093/hmg/3.9.1683;
RA   Orimo H., Hayashi Z., Watanabe A., Hirayama T., Hirayama T.,
RA   Shimada T.;
RT   "Novel missense and frameshift mutations in the tissue-nonspecific
RT   alkaline phosphatase gene in a Japanese patient with
RT   hypophosphatasia.";
RL   Hum. Mol. Genet. 3:1683-1684(1994).
RN   [20]
RP   INVOLVEMENT IN HOPSI, AND VARIANTS HOPSI LEU-327 AND ARG-456.
RX   PubMed=8954059; DOI=10.1210/jc.81.12.4458;
RA   Ozono K., Yamagata M., Michigami T., Nakajima S., Sakai N., Cai G.,
RA   Satomura K., Yasui N., Okada S., Nakayama M.;
RT   "Identification of novel missense mutations (Phe310Leu and Gly439Arg)
RT   in a neonatal case of hypophosphatasia.";
RL   J. Clin. Endocrinol. Metab. 81:4458-4461(1996).
RN   [21]
RP   VARIANTS HOPS PHE-17; VAL-40; SER-75; ARG-120; ARG-129; ASP-170;
RP   TRP-184; LYS-191; TRP-223; LYS-291; ASP-334; PRO-445; CYS-450; SER-473
RP   AND ARG-491, AND VARIANT HIS-263.
RX   PubMed=9781036; DOI=10.1038/sj.ejhg.5200190;
RA   Mornet E., Taillandier A., Peyramaure S., Kaper F., Muller F.,
RA   Brenner R., Bussiere P., Freisinger P., Godard J., Le Merrer M.,
RA   Oury J.F., Plauchu H., Puddu R., Rival J.M., Superti-Furga A.,
RA   Touraine R.L., Serre J.L., Simon-Bouy B.;
RT   "Identification of fifteen novel mutations in the tissue-nonspecific
RT   alkaline phosphatase (TNSALP) gene in European patients with severe
RT   hypophosphatasia.";
RL   Eur. J. Hum. Genet. 6:308-314(1998).
RN   [22]
RP   VARIANTS HOPS THR-111; THR-177; GLY-191; LEU-327 AND ILE-382.
RX   PubMed=9452105;
RA   Goseki-Sone M., Orimo H., Iimura T., Takagi Y., Watanabe H.,
RA   Taketa K., Sato S., Mayanagi H., Shimada T., Oida S.;
RT   "Hypophosphatasia: identification of five novel missense mutations
RT   (G507A, G705A, A748G, T1155C, G1320A) in the tissue-nonspecific
RT   alkaline phosphatase gene among Japanese patients.";
RL   Hum. Mutat. Suppl. 1:S263-S267(1998).
RN   [23]
RP   VARIANTS HOPS VAL-40; LEU-62; SER-75; THR-111; ARG-120; ARG-129;
RP   HIS-136; VAL-162; ASP-170; TYR-171; TRP-184; LYS-191; TRP-223;
RP   VAL-249; LYS-291; VAL-306; ASP-334; CYS-391; PRO-445; CYS-450;
RP   SER-473; LYS-476 AND ARG-491, 3D-STRUCTURE MODELING, AND
RP   CHARACTERIZATION OF VARIANTS.
RX   PubMed=10332035; DOI=10.1093/hmg/8.6.1039;
RA   Zurutuza L., Muller F., Gibrat J.F., Taillandier A., Simon-Bouy B.,
RA   Serre J.L., Mornet E.;
RT   "Correlations of genotype and phenotype in hypophosphatasia.";
RL   Hum. Mol. Genet. 8:1039-1046(1999).
RN   [24]
RP   VARIANTS HOPS LEU-62; HIS-136; VAL-162; TYR-171; LYS-191; TYR-201;
RP   VAL-249; VAL-306 AND LYS-476.
RX   PubMed=10094560;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:2<171::AID-HUMU16>3.0.CO;2-T;
RA   Taillandier A., Zurutuza L., Muller F., Simon-Bouy B., Serre J.L.,
RA   Bird L., Brenner R., Boute O., Cousin J., Gaillard D., Heidemann P.H.,
RA   Steinmann B., Wallot M., Mornet E.;
RT   "Characterization of eleven novel mutations (M45L, R119H, 544delG,
RT   G145V, H154Y, C184Y, D289V, 862+5A, 1172delC, R411X, E459K) in the
RT   tissue-nonspecific alkaline phosphatase (TNSALP) gene in patients with
RT   severe hypophosphatasia.";
RL   Hum. Mutat. 13:171-172(1999).
RN   [25]
RP   VARIANTS HOPSI GLU-224 AND CYS-426.
RX   PubMed=10834525; DOI=10.1007/s004310051290;
RA   Mochizuki H., Saito M., Michigami T., Ohashi H., Koda N.,
RA   Yamaguchi S., Ozono K.;
RT   "Severe hypercalcaemia and respiratory insufficiency associated with
RT   infantile hypophosphatasia caused by two novel mutations of the
RT   tissue-nonspecific alkaline phosphatase gene.";
RL   Eur. J. Pediatr. 159:375-379(2000).
RN   [26]
RP   VARIANTS HOPS VAL-40; THR-111; ASN-134; THR-176; LYS-191; TYR-201;
RP   SER-246; THR-348; ARG-381; GLY-406; HIS-450; ILE-478 AND SER-489.
RX   PubMed=10679946;
RX   DOI=10.1002/(SICI)1098-1004(200003)15:3<293::AID-HUMU11>3.0.CO;2-Q;
RA   Taillandier A., Cozien E., Muller F., Merrien Y., Bonnin E.,
RA   Fribourg C., Simon-Bouy B., Serre J.L., Bieth E., Brenner R.,
RA   Cordier M.P., De Bie S., Fellmann F., Freisinger P., Hesse V.,
RA   Hennekam R.C.M., Josifova D., Kerzin-Storrar L., Leporrier N.,
RA   Zabot M.-T., Mornet E.;
RT   "Fifteen new mutations (-195C>T, L-12X, 298-2A>G, T117N, A159T, R229S,
RT   997+2T>A, E274X, A331T, H364R, D389G, 1256delC, R433H, N461I, C472S)
RT   in the tissue-nonspecific alkaline phosphatase (TNSALP) gene in
RT   patients with hypophosphatasia.";
RL   Hum. Mutat. 15:293-293(2000).
RN   [27]
RP   VARIANT HOPS VAL-378, AND VARIANT ALA-522.
RX   PubMed=10690885; DOI=10.1210/jc.85.2.743;
RA   Mueller H.L., Yamazaki M., Michigami T., Kageyama T., Schoenau E.,
RA   Schneider P., Ozono K.;
RT   "Asp361Val mutant of alkaline phosphatase found in patients with
RT   dominantly inherited hypophosphatasia inhibits the activity of the
RT   wild-type enzyme.";
RL   J. Clin. Endocrinol. Metab. 85:743-747(2000).
RN   [28]
RP   VARIANT HOPS SER-417.
RX   PubMed=11745997; DOI=10.1002/ajmg.1541.abs;
RA   Sergi C., Mornet E., Troeger J., Voigtlaender T.;
RT   "Perinatal hypophosphatasia: radiology, pathology and molecular
RT   biology studies in a family harboring a splicing mutation (648+1A) and
RT   a novel missense mutation (N400S) in the tissue-nonspecific alkaline
RT   phosphatase (TNSALP) gene.";
RL   Am. J. Med. Genet. 103:235-240(2001).
RN   [29]
RP   CHARACTERIZATION OF VARIANTS HOPS VAL-40; VAL-63; THR-116; LEU-181;
RP   TRP-184; TRP-223; VAL-249; VAL-378; ILE-478 AND PHE-490.
RX   PubMed=11479741; DOI=10.1007/s004390100546;
RA   Lia-Baldini A.S., Muller F., Taillandier A., Gibrat J.F., Mouchard M.,
RA   Robin B., Simon-Bouy B., Serre J.L., Aylsworth A.S., Bieth E.,
RA   Delanote S., Freisinger P., Hu J.C.-C., Krohn H.-P., Nunes M.E.,
RA   Mornet E.;
RT   "A molecular approach to dominance in hypophosphatasia.";
RL   Hum. Genet. 109:99-108(2001).
RN   [30]
RP   VARIANTS HOPSI CYS-28 AND MET-459, AND VARIANTS HOPS VAL-40; VAL-51;
RP   HIS-71; THR-116; HIS-136; HIS-152; THR-176; THR-179; LYS-191; ASP-211;
RP   VAL-220; GLY-235; TYR-294; GLY-327; SER-399 AND ALA-423.
RX   PubMed=11438998; DOI=10.1002/humu.1154;
RA   Taillandier A., Lia-Baldini A.S., Mouchard M., Robin B., Muller F.,
RA   Simon-Bouy B., Serre J.L., Bera-Louville A., Bonduelle M.,
RA   Eckhardt J., Gaillard D., Myhre A.G., Koertge-Jung S., Larget-Piet L.,
RA   Malou E., Sillence D., Temple I.K., Viot G., Mornet E.;
RT   "Twelve novel mutations in the tissue-nonspecific alkaline phosphatase
RT   gene (ALPL) in patients with various forms of hypophosphatasia.";
RL   Hum. Mutat. 18:83-84(2001).
RN   [31]
RP   INVOLVEMENT IN HOPSC, VARIANTS HOPSC MET-68; SER-71; THR-177; TRP-223;
RP   PRO-275 AND HIS-391, CHARACTERIZATION OF VARIANTS HOPSC MET-68;
RP   SER-71; THR-177; TRP-223; PRO-275 AND HIS-391, VARIANT ALA-522, AND
RP   CHARACTERIZATION OF VARIANT ALA-522.
RX   PubMed=11760847; DOI=10.1359/jbmr.2001.16.12.2313;
RA   Orimo H., Girschick H.J., Goseki-Sone M., Ito M., Oda K., Shimada T.;
RT   "Mutational analysis and functional correlation with phenotype in
RT   German patients with childhood-type hypophosphatasia.";
RL   J. Bone Miner. Res. 16:2313-2319(2001).
RN   [32]
RP   VARIANT HOPS VAL-132.
RX   PubMed=11834095; DOI=10.1034/j.1601-0825.2001.00740.x;
RA   Watanabe H., Hashimoto-Uoshima M., Goseki-Sone M., Orimo H.,
RA   Ishikawa I.;
RT   "A novel point mutation (C571T) in the tissue-non-specific alkaline
RT   phosphatase gene in a case of adult-type hypophosphatasia.";
RL   Oral Dis. 7:331-335(2001).
RN   [33]
RP   VARIANTS HOPS LYS-291 AND ARG-326.
RX   PubMed=11999978; DOI=10.1023/A:1015121414782;
RA   Litmanovitz I., Reish O., Dolfin T., Arnon S., Regev R., Grinshpan G.,
RA   Yamazaki M., Ozono K.;
RT   "Glu274Lys/Gly309Arg mutation of the tissue-nonspecific alkaline
RT   phosphatase gene in neonatal hypophosphatasia associated with
RT   convulsions.";
RL   J. Inherit. Metab. Dis. 25:35-40(2002).
RN   [34]
RP   VARIANTS HOPS SER-51; HIS-71; THR-111; MET-128; HIS-134; HIS-136;
RP   THR-176; LYS-191; GLN-223; TRP-223; SER-246; ALA-294; PRO-299; PHE-327
RP   DEL; ARG-339; THR-348; VAL-378; MET-414; ASP-426 AND LYS-476, AND
RP   VARIANTS HIS-263 AND ALA-522.
RX   PubMed=11855933; DOI=10.1006/mgme.2001.3283;
RA   Mumm S., Jones J., Finnegan P., Henthorn P.S., Podgornik M.N.,
RA   Whyte M.P.;
RT   "Denaturing gradient gel electrophoresis analysis of the tissue
RT   nonspecific alkaline phosphatase isoenzyme gene in hypophosphatasia.";
RL   Mol. Genet. Metab. 75:143-153(2002).
RN   [35]
RP   VARIANTS HOPS VAL-62; ARG-63; THR-111; ILE-148; SER-162; GLU-189;
RP   ALA-220; LEU-272; GLY-293-294-ASP DEL; LYS-311; LYS-452 AND THR-468.
RX   PubMed=12815606; DOI=10.1002/humu.9159;
RA   Spentchian M., Merrien Y., Herasse M., Dobbie Z., Glaeser D.,
RA   Holder S.E., Ivarsson S.-A., Kostiner D., Mansour S., Norman A.,
RA   Roth J., Stipoljev F., Taillemite J.-L., van der Smagt J.J.,
RA   Serre J.-L., Simon-Bouy B., Taillandier A., Mornet E.;
RT   "Severe hypophosphatasia: characterization of fifteen novel mutations
RT   in the ALPL gene.";
RL   Hum. Mutat. 22:105-106(2003).
RN   [36]
RP   VARIANTS HOPS LEU-108; THR-116 AND MET-414, AND CHARACTERIZATION OF
RP   VARIANT HOPS LEU-108.
RX   PubMed=12920074; DOI=10.1136/jmg.40.8.605;
RA   Herasse M., Spentchian M., Taillandier A., Keppler-Noreuil K.,
RA   Fliorito A.N.M., Bergoffen J., Wallerstein R., Muti C., Simon-Bouy B.,
RA   Mornet E.;
RT   "Molecular study of three cases of odontohypophosphatasia resulting
RT   from heterozygosity for mutations in the tissue non-specific alkaline
RT   phosphatase gene.";
RL   J. Med. Genet. 40:605-609(2003).
RN   [37]
RP   VARIANT HOPS GLY-114.
RX   PubMed=15135428; DOI=10.1016/j.arcped.2004.02.018;
RA   Draguet C., Gillerot Y., Mornet E.;
RT   "Childhood hypophosphatasia: a case report due to a novel mutation.";
RL   Arch. Pediatr. 11:440-443(2004).
RN   [38]
RP   VARIANTS HOPS VAL-33; HIS-136; GLN-223; TRP-223; HIS-272; THR-292;
RP   ALA-294; THR-295; ASP-297; ASP-334 AND ALA-411, AND CHARACTERIZATION
RP   OF VARIANTS HOPS VAL-33; HIS-272; THR-292; THR-295; ASP-297 AND
RP   ALA-411.
RX   PubMed=15694177; DOI=10.1016/j.ymgme.2004.11.003;
RA   Brun-Heath I., Taillandier A., Serre J.-L., Mornet E.;
RT   "Characterization of 11 novel mutations in the tissue non-specific
RT   alkaline phosphatase gene responsible for hypophosphatasia and
RT   genotype-phenotype correlations.";
RL   Mol. Genet. Metab. 84:273-277(2005).
CC   -!- FUNCTION: This isozyme may play a role in skeletal mineralization.
CC   -!- CATALYTIC ACTIVITY: A phosphate monoester + H(2)O = an alcohol +
CC       phosphate. {ECO:0000255|PROSITE-ProRule:PRU10042}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 1 Mg(2+) ion. {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 2 Zn(2+) ions. {ECO:0000250};
CC   -!- SUBUNIT: Homodimer.
CC   -!- INTERACTION:
CC       Q99558:MAP3K14; NbExp=4; IntAct=EBI-1054354, EBI-358011;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Lipid-anchor, GPI-anchor.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P05186-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P05186-2; Sequence=VSP_042711;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=P05186-3; Sequence=VSP_044228;
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:1458595,
CC       ECO:0000269|PubMed:19159218}.
CC   -!- DISEASE: Hypophosphatasia (HOPS) [MIM:146300]: A metabolic bone
CC       disease characterized by defective skeletal mineralization and
CC       biochemically by deficient activity of the tissue non-specific
CC       isoenzyme of alkaline phosphatase. Four forms are distinguished,
CC       depending on the age of onset: perinatal, infantile, childhood and
CC       adult type. The perinatal form is the most severe and is almost
CC       always fatal. The adult form is mild and characterized by
CC       recurrent fractures, osteomalacia, rickets, and loss of teeth.
CC       Some cases are asymptomatic, while some patients manifest dental
CC       features without skeletal manifestations (odontohypophosphatasia).
CC       {ECO:0000269|PubMed:10094560, ECO:0000269|PubMed:10332035,
CC       ECO:0000269|PubMed:10679946, ECO:0000269|PubMed:10690885,
CC       ECO:0000269|PubMed:10834525, ECO:0000269|PubMed:11438998,
CC       ECO:0000269|PubMed:11745997, ECO:0000269|PubMed:11760847,
CC       ECO:0000269|PubMed:11834095, ECO:0000269|PubMed:11855933,
CC       ECO:0000269|PubMed:11999978, ECO:0000269|PubMed:12815606,
CC       ECO:0000269|PubMed:12920074, ECO:0000269|PubMed:1409720,
CC       ECO:0000269|PubMed:15135428, ECO:0000269|PubMed:15694177,
CC       ECO:0000269|PubMed:3174660, ECO:0000269|PubMed:7833929,
CC       ECO:0000269|PubMed:8406453, ECO:0000269|PubMed:8954059,
CC       ECO:0000269|PubMed:9452105, ECO:0000269|PubMed:9747027,
CC       ECO:0000269|PubMed:9781036}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Hypophosphatasia childhood type (HOPSC) [MIM:241510]: A
CC       bone disease characterized by defective skeletal mineralization
CC       and biochemically by deficient activity of the tissue non-specific
CC       isoenzyme of alkaline phosphatase. {ECO:0000269|PubMed:11760847}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Hypophosphatasia infantile type (HOPSI) [MIM:241500]: A
CC       severe bone disease characterized by defective skeletal
CC       mineralization and biochemically by deficient activity of the
CC       tissue non-specific isoenzyme of alkaline phosphatase. Three more
CC       or less distinct types of infantile hypophosphatasia can be
CC       identified: (1) type 1 with onset in utero or in early postnatal
CC       life, craniostenosis, severe skeletal abnormalities,
CC       hypercalcemia, and death in the first year or so of life; (2) type
CC       2 with later, more gradual development of symptoms, moderately
CC       severe 'rachitic' skeletal changes and premature loss of teeth;
CC       (3) type 3 with no symptoms, the condition being determined on
CC       routine studies. {ECO:0000269|PubMed:10834525,
CC       ECO:0000269|PubMed:11438998, ECO:0000269|PubMed:7833929,
CC       ECO:0000269|PubMed:8954059}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the alkaline phosphatase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD93051.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=ALPL; Note=Tissue nonspecific alkaline
CC       phosphatase gene mutations database;
CC       URL="http://www.sesep.uvsq.fr/Database.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Alkaline phosphatase entry;
CC       URL="https://en.wikipedia.org/wiki/Alkaline_phosphatase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M24439; AAB59378.1; -; Genomic_DNA.
DR   EMBL; M24429; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24430; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24431; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24432; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24433; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24434; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24435; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24436; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24437; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; M24438; AAB59378.1; JOINED; Genomic_DNA.
DR   EMBL; X14174; CAA32376.1; -; mRNA.
DR   EMBL; AB011406; BAA32129.1; -; mRNA.
DR   EMBL; AK295608; BAH12123.1; -; mRNA.
DR   EMBL; AK298085; BAH12722.1; -; mRNA.
DR   EMBL; AB209814; BAD93051.1; ALT_INIT; mRNA.
DR   EMBL; AL592309; CAH72079.1; -; Genomic_DNA.
DR   EMBL; AL359815; CAH72079.1; JOINED; Genomic_DNA.
DR   EMBL; AL359815; CAI16259.1; -; Genomic_DNA.
DR   EMBL; AL592309; CAI16259.1; JOINED; Genomic_DNA.
DR   EMBL; CH471134; EAW94977.1; -; Genomic_DNA.
DR   EMBL; BC021289; AAH21289.3; -; mRNA.
DR   EMBL; BC066116; AAH66116.2; -; mRNA.
DR   EMBL; BC090861; AAH90861.2; -; mRNA.
DR   EMBL; BC110909; AAI10910.2; -; mRNA.
DR   EMBL; BC126165; AAI26166.1; -; mRNA.
DR   EMBL; BC136325; AAI36326.1; -; mRNA.
DR   CCDS; CCDS217.1; -. [P05186-1]
DR   CCDS; CCDS53274.1; -. [P05186-2]
DR   CCDS; CCDS53275.1; -. [P05186-3]
DR   PIR; S03613; PAHUH.
DR   RefSeq; NP_000469.3; NM_000478.4. [P05186-1]
DR   RefSeq; NP_001120973.2; NM_001127501.2. [P05186-3]
DR   RefSeq; NP_001170991.1; NM_001177520.1. [P05186-2]
DR   RefSeq; XP_005245875.1; XM_005245818.1. [P05186-1]
DR   RefSeq; XP_006710609.1; XM_006710546.1. [P05186-1]
DR   UniGene; Hs.75431; -.
DR   ProteinModelPortal; P05186; -.
DR   SMR; P05186; 18-490.
DR   BioGrid; 106750; 4.
DR   IntAct; P05186; 6.
DR   STRING; 9606.ENSP00000363965; -.
DR   BindingDB; P05186; -.
DR   ChEMBL; CHEMBL5979; -.
DR   DrugBank; DB01143; Amifostine.
DR   DrugBank; DB06716; Fospropofol.
DR   DEPOD; P05186; -.
DR   PhosphoSite; P05186; -.
DR   BioMuta; ALPL; -.
DR   DMDM; 68067533; -.
DR   MaxQB; P05186; -.
DR   PaxDb; P05186; -.
DR   PeptideAtlas; P05186; -.
DR   PRIDE; P05186; -.
DR   DNASU; 249; -.
DR   Ensembl; ENST00000374832; ENSP00000363965; ENSG00000162551. [P05186-1]
DR   Ensembl; ENST00000374840; ENSP00000363973; ENSG00000162551. [P05186-1]
DR   Ensembl; ENST00000539907; ENSP00000437674; ENSG00000162551. [P05186-2]
DR   Ensembl; ENST00000540617; ENSP00000442672; ENSG00000162551. [P05186-3]
DR   GeneID; 249; -.
DR   KEGG; hsa:249; -.
DR   UCSC; uc001bet.3; human. [P05186-1]
DR   UCSC; uc010odp.2; human. [P05186-2]
DR   CTD; 249; -.
DR   GeneCards; ALPL; -.
DR   GeneReviews; ALPL; -.
DR   HGNC; HGNC:438; ALPL.
DR   HPA; CAB020829; -.
DR   HPA; HPA007105; -.
DR   HPA; HPA008765; -.
DR   MalaCards; ALPL; -.
DR   MIM; 146300; phenotype.
DR   MIM; 171760; gene.
DR   MIM; 241500; phenotype.
DR   MIM; 241510; phenotype.
DR   neXtProt; NX_P05186; -.
DR   Orphanet; 247676; Adult hypophosphatasia.
DR   Orphanet; 247667; Childhood-onset hypophosphatasia.
DR   Orphanet; 247651; Infantile hypophosphatasia.
DR   Orphanet; 247685; Odontohypophosphatasia.
DR   Orphanet; 247623; Perinatal lethal hypophosphatasia.
DR   Orphanet; 247638; Prenatal benign hypophosphatasia.
DR   PharmGKB; PA24729; -.
DR   eggNOG; KOG4126; Eukaryota.
DR   eggNOG; COG1785; LUCA.
DR   GeneTree; ENSGT00390000008704; -.
DR   HOVERGEN; HBG007345; -.
DR   InParanoid; P05186; -.
DR   KO; K01077; -.
DR   OMA; YTYVTTG; -.
DR   OrthoDB; EOG7SN8CH; -.
DR   PhylomeDB; P05186; -.
DR   TreeFam; TF323513; -.
DR   BRENDA; 3.1.3.1; 2681.
DR   ChiTaRS; ALPL; human.
DR   GeneWiki; ALPL; -.
DR   GenomeRNAi; 249; -.
DR   NextBio; 997; -.
DR   PRO; PR:P05186; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; P05186; -.
DR   ExpressionAtlas; P05186; baseline and differential.
DR   Genevisible; P05186; HS.
DR   GO; GO:0031225; C:anchored component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:Ensembl.
DR   GO; GO:0004035; F:alkaline phosphatase activity; IEA:UniProtKB-EC.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0016462; F:pyrophosphatase activity; IDA:MGI.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0071529; P:cementum mineralization; IEA:Ensembl.
DR   GO; GO:0003006; P:developmental process involved in reproduction; IEA:Ensembl.
DR   GO; GO:0001958; P:endochondral ossification; IEA:Ensembl.
DR   GO; GO:0001649; P:osteoblast differentiation; IDA:UniProtKB.
DR   GO; GO:0046677; P:response to antibiotic; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0033280; P:response to vitamin D; IEP:BHF-UCL.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   Gene3D; 3.40.720.10; -; 1.
DR   InterPro; IPR017849; Alkaline_Pase-like_a/b/a.
DR   InterPro; IPR001952; Alkaline_phosphatase.
DR   InterPro; IPR018299; Alkaline_phosphatase_AS.
DR   InterPro; IPR017850; Alkaline_phosphatase_core.
DR   Pfam; PF00245; Alk_phosphatase; 1.
DR   PRINTS; PR00113; ALKPHPHTASE.
DR   SMART; SM00098; alkPPc; 1.
DR   SUPFAM; SSF53649; SSF53649; 1.
DR   PROSITE; PS00123; ALKALINE_PHOSPHATASE; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Biomineralization; Cell membrane;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glycoprotein; GPI-anchor; Hydrolase; Lipoprotein;
KW   Magnesium; Membrane; Metal-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Signal; Transmembrane; Zinc.
FT   SIGNAL        1     17       {ECO:0000269|PubMed:1458595,
FT                                ECO:0000269|PubMed:3954357}.
FT   CHAIN        18    502       Alkaline phosphatase, tissue-nonspecific
FT                                isozyme.
FT                                /FTId=PRO_0000024023.
FT   PROPEP      503    524       Removed in mature form. {ECO:0000305}.
FT                                /FTId=PRO_0000024024.
FT   ACT_SITE    110    110       Phosphoserine intermediate.
FT   METAL        60     60       Magnesium. {ECO:0000250}.
FT   METAL        60     60       Zinc 1. {ECO:0000250}.
FT   METAL       110    110       Zinc 1. {ECO:0000250}.
FT   METAL       173    173       Magnesium. {ECO:0000250}.
FT   METAL       332    332       Magnesium. {ECO:0000250}.
FT   METAL       337    337       Zinc 2. {ECO:0000250}.
FT   METAL       341    341       Zinc 2; via tele nitrogen. {ECO:0000250}.
FT   METAL       378    378       Zinc 1. {ECO:0000250}.
FT   METAL       379    379       Zinc 1; via tele nitrogen. {ECO:0000250}.
FT   METAL       454    454       Zinc 2; via tele nitrogen. {ECO:0000250}.
FT   MOD_RES     110    110       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P09242}.
FT   LIPID       502    502       GPI-anchor amidated serine.
FT                                {ECO:0000305}.
FT   CARBOHYD    140    140       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    230    230       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    271    271       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    303    303       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    430    430       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   DISULFID    139    201       {ECO:0000250}.
FT   DISULFID    489    497       {ECO:0000250}.
FT   VAR_SEQ       1     99       MISPFLVLAIGTCLTNSLVPEKEKDPKYWRDQAQETLKYAL
FT                                ELQKLNTNVAKNVIMFLGDGMGVSTVTAARILKGQLHHNPG
FT                                EETRLEMDKFPFVALSK -> MPWSFRSSTPTWLRMSSCSW
FT                                EM (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042711.
FT   VAR_SEQ       1     55       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_044228.
FT   VARIANT      17     17       S -> F (in HOPS).
FT                                {ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_025903.
FT   VARIANT      28     28       Y -> C (in HOPSI; 7% of activity).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013972.
FT   VARIANT      33     33       A -> V (in HOPS; 7.2% of wild-type
FT                                activity). {ECO:0000269|PubMed:1409720,
FT                                ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_006147.
FT   VARIANT      40     40       A -> V (in HOPS; 2% of activity).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:10679946,
FT                                ECO:0000269|PubMed:11438998,
FT                                ECO:0000269|PubMed:11479741,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_011081.
FT   VARIANT      51     51       A -> S (in HOPS).
FT                                {ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_025904.
FT   VARIANT      51     51       A -> V (in HOPS).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013973.
FT   VARIANT      62     62       M -> L (in HOPS; moderate; 27% of
FT                                activity). {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10332035}.
FT                                /FTId=VAR_006148.
FT   VARIANT      62     62       M -> V (in HOPS).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025905.
FT   VARIANT      63     63       G -> R (in HOPS).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025906.
FT   VARIANT      63     63       G -> V (in HOPS; loss of activity).
FT                                {ECO:0000269|PubMed:11479741}.
FT                                /FTId=VAR_013974.
FT   VARIANT      68     68       T -> M (in HOPSC; severe allele).
FT                                {ECO:0000269|PubMed:11760847}.
FT                                /FTId=VAR_025907.
FT   VARIANT      71     71       R -> C (in HOPS).
FT                                {ECO:0000269|PubMed:1409720}.
FT                                /FTId=VAR_006149.
FT   VARIANT      71     71       R -> H (in HOPS).
FT                                {ECO:0000269|PubMed:11438998,
FT                                ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_013975.
FT   VARIANT      71     71       R -> P (in HOPS).
FT                                {ECO:0000269|PubMed:1409720}.
FT                                /FTId=VAR_006150.
FT   VARIANT      71     71       R -> S (in HOPSC; severe allele).
FT                                {ECO:0000269|PubMed:11760847}.
FT                                /FTId=VAR_025908.
FT   VARIANT      75     75       G -> S (in HOPS; severe; 3.5% of
FT                                activity). {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013976.
FT   VARIANT      76     76       Q -> R (in HOPS).
FT                                /FTId=VAR_025909.
FT   VARIANT     108    108       P -> L (in HOPS; 0.4% of wild-type
FT                                activity; severe allele;
FT                                dbSNP:rs28933975).
FT                                {ECO:0000269|PubMed:12920074}.
FT                                /FTId=VAR_025910.
FT   VARIANT     111    111       A -> T (in HOPS; odonto).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:10679946,
FT                                ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:12815606,
FT                                ECO:0000269|PubMed:9452105}.
FT                                /FTId=VAR_006151.
FT   VARIANT     114    114       A -> G (in HOPS).
FT                                {ECO:0000269|PubMed:15135428}.
FT                                /FTId=VAR_025911.
FT   VARIANT     116    116       A -> T (in HOPS; loss of activity;
FT                                dbSNP:rs28933974).
FT                                {ECO:0000269|PubMed:11438998,
FT                                ECO:0000269|PubMed:11479741,
FT                                ECO:0000269|PubMed:12920074}.
FT                                /FTId=VAR_013977.
FT   VARIANT     120    120       G -> R (in HOPS).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013978.
FT   VARIANT     128    128       V -> M (in HOPS).
FT                                {ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_025912.
FT   VARIANT     129    129       G -> R (in HOPS).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013979.
FT   VARIANT     132    132       A -> V (in HOPS).
FT                                {ECO:0000269|PubMed:11834095}.
FT                                /FTId=VAR_013146.
FT   VARIANT     134    134       T -> H (in HOPS; requires 2 nucleotide
FT                                substitutions).
FT                                {ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_025913.
FT   VARIANT     134    134       T -> N (in HOPS; 9% of activity).
FT                                {ECO:0000269|PubMed:10679946}.
FT                                /FTId=VAR_011082.
FT   VARIANT     136    136       R -> H (in HOPS; moderate; 33% of
FT                                activity). {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:11438998,
FT                                ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_006152.
FT   VARIANT     148    148       T -> I (in HOPS).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025914.
FT   VARIANT     152    152       R -> H (in HOPS; dbSNP:rs149344982).
FT                                {ECO:0000269|PubMed:11438998,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_013980.
FT   VARIANT     162    162       G -> S (in HOPS).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025915.
FT   VARIANT     162    162       G -> V (in HOPS; severe; 1% of activity).
FT                                {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10332035}.
FT                                /FTId=VAR_006153.
FT   VARIANT     170    170       N -> D (in HOPS).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013981.
FT   VARIANT     171    171       H -> R (in HOPS).
FT                                /FTId=VAR_025916.
FT   VARIANT     171    171       H -> Y (in HOPS; severe; 2% of activity).
FT                                {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10332035}.
FT                                /FTId=VAR_006154.
FT   VARIANT     176    176       A -> T (in HOPS; dbSNP:rs121918019).
FT                                {ECO:0000269|PubMed:10679946,
FT                                ECO:0000269|PubMed:11438998,
FT                                ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_011083.
FT   VARIANT     177    177       A -> T (in HOPS and HOPSC; moderate
FT                                allele; dbSNP:rs199669988).
FT                                {ECO:0000269|PubMed:11760847,
FT                                ECO:0000269|PubMed:9452105}.
FT                                /FTId=VAR_006155.
FT   VARIANT     179    179       A -> T (in HOPS).
FT                                {ECO:0000269|PubMed:11438998,
FT                                ECO:0000269|PubMed:3174660}.
FT                                /FTId=VAR_006156.
FT   VARIANT     181    181       S -> L (in HOPS; 1% of activity).
FT                                {ECO:0000269|PubMed:11479741}.
FT                                /FTId=VAR_013982.
FT   VARIANT     184    184       R -> W (in HOPS; loss of activity).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:11479741,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013983.
FT   VARIANT     189    189       D -> E (in HOPS).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025917.
FT   VARIANT     191    191       E -> G (in HOPS; odonto).
FT                                {ECO:0000269|PubMed:9452105}.
FT                                /FTId=VAR_006157.
FT   VARIANT     191    191       E -> K (in HOPS; moderate; frequent
FT                                mutation in European countries;
FT                                dbSNP:rs121918007).
FT                                {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:10679946,
FT                                ECO:0000269|PubMed:11438998,
FT                                ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:1409720,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_006158.
FT   VARIANT     201    201       C -> Y (in HOPS).
FT                                {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10679946}.
FT                                /FTId=VAR_006159.
FT   VARIANT     207    207       Q -> P (in HOPS).
FT                                {ECO:0000269|PubMed:1409720}.
FT                                /FTId=VAR_006160.
FT   VARIANT     211    211       N -> D (in HOPS).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013984.
FT   VARIANT     212    212       I -> F (in HOPS).
FT                                /FTId=VAR_025918.
FT   VARIANT     220    220       G -> A (in HOPS).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025919.
FT   VARIANT     220    220       G -> V (in HOPS; odonto).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013985.
FT   VARIANT     223    223       R -> Q (in HOPS).
FT                                {ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_025920.
FT   VARIANT     223    223       R -> W (in HOPS and HOPSC; 3% of
FT                                activity; severe allele).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:11479741,
FT                                ECO:0000269|PubMed:11760847,
FT                                ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:15694177,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013986.
FT   VARIANT     224    224       K -> E (in HOPSI; partial loss of
FT                                activity). {ECO:0000269|PubMed:10834525}.
FT                                /FTId=VAR_011084.
FT   VARIANT     235    235       E -> G (in HOPS).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013987.
FT   VARIANT     246    246       R -> S (in HOPS; 4% of activity).
FT                                {ECO:0000269|PubMed:10679946,
FT                                ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_011085.
FT   VARIANT     249    249       G -> V (in HOPS; partial loss of
FT                                activity). {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:11479741}.
FT                                /FTId=VAR_013988.
FT   VARIANT     263    263       Y -> H (common polymorphism;
FT                                dbSNP:rs3200254).
FT                                {ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:1409720,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:2928120,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_006161.
FT   VARIANT     272    272       R -> H (in HOPS; 6.8% of wild-type
FT                                activity). {ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_025921.
FT   VARIANT     272    272       R -> L (in HOPS).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025922.
FT   VARIANT     275    275       L -> P (in HOPSC; severe allele).
FT                                {ECO:0000269|PubMed:11760847}.
FT                                /FTId=VAR_025923.
FT   VARIANT     289    289       L -> F (in HOPS).
FT                                {ECO:0000269|PubMed:9747027}.
FT                                /FTId=VAR_006162.
FT   VARIANT     291    291       E -> K (in HOPS; moderate; 8% of
FT                                activity). {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:11999978,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013989.
FT   VARIANT     292    292       P -> T (in HOPS; 4% of wild-type
FT                                activity). {ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_025924.
FT   VARIANT     293    294       Missing (in HOPS).
FT                                /FTId=VAR_025925.
FT   VARIANT     294    294       D -> A (in HOPS).
FT                                {ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:1409720,
FT                                ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_006163.
FT   VARIANT     294    294       D -> Y (in HOPS).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013990.
FT   VARIANT     295    295       M -> T (in HOPS; 8.5% of wild-type
FT                                activity). {ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_025926.
FT   VARIANT     297    297       Y -> D (in HOPS; 1.3% of wild-type
FT                                activity). {ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_025927.
FT   VARIANT     298    298       E -> K (in HOPSI).
FT                                {ECO:0000269|PubMed:7833929}.
FT                                /FTId=VAR_025928.
FT   VARIANT     299    299       L -> P (in HOPS).
FT                                {ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_025929.
FT   VARIANT     306    306       D -> V (in HOPS).
FT                                {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10332035}.
FT                                /FTId=VAR_006164.
FT   VARIANT     311    311       E -> K (in HOPS).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025930.
FT   VARIANT     326    326       G -> R (in HOPS; in a patient carrying
FT                                also K-291).
FT                                {ECO:0000269|PubMed:11999978}.
FT                                /FTId=VAR_013991.
FT   VARIANT     327    327       F -> G (in HOPS; requires 2 nucleotide
FT                                substitutions).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013992.
FT   VARIANT     327    327       F -> L (in HOPS and HOPSI).
FT                                {ECO:0000269|PubMed:8954059,
FT                                ECO:0000269|PubMed:9452105}.
FT                                /FTId=VAR_006165.
FT   VARIANT     327    327       Missing (in HOPS).
FT                                {ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_025931.
FT   VARIANT     334    334       G -> D (in HOPS).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:15694177,
FT                                ECO:0000269|PubMed:8406453,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_006166.
FT   VARIANT     339    339       G -> R (in HOPS).
FT                                {ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_025932.
FT   VARIANT     348    348       A -> T (in HOPS).
FT                                {ECO:0000269|PubMed:10679946,
FT                                ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_011086.
FT   VARIANT     354    354       E -> D (in HOPS).
FT                                /FTId=VAR_025933.
FT   VARIANT     378    378       D -> V (in HOPS; loss of activity).
FT                                {ECO:0000269|PubMed:10690885,
FT                                ECO:0000269|PubMed:11479741,
FT                                ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:1409720}.
FT                                /FTId=VAR_006167.
FT   VARIANT     381    381       H -> R (in HOPS).
FT                                {ECO:0000269|PubMed:10679946}.
FT                                /FTId=VAR_011087.
FT   VARIANT     382    382       V -> I (in HOPS).
FT                                {ECO:0000269|PubMed:9452105}.
FT                                /FTId=VAR_006168.
FT   VARIANT     391    391       R -> C (in HOPS; moderate; 10% of
FT                                activity). {ECO:0000269|PubMed:10332035}.
FT                                /FTId=VAR_013993.
FT   VARIANT     391    391       R -> H (in HOPSC; severe allele).
FT                                {ECO:0000269|PubMed:11760847}.
FT                                /FTId=VAR_025934.
FT   VARIANT     399    399       A -> S (in HOPS).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013994.
FT   VARIANT     406    406       D -> G (in HOPS; 15% of activity).
FT                                {ECO:0000269|PubMed:10679946}.
FT                                /FTId=VAR_011088.
FT   VARIANT     411    411       T -> A (in HOPS; absence of residual
FT                                enzymatic activity).
FT                                {ECO:0000269|PubMed:15694177}.
FT                                /FTId=VAR_025935.
FT   VARIANT     414    414       L -> M (in HOPS).
FT                                {ECO:0000269|PubMed:11855933,
FT                                ECO:0000269|PubMed:12920074}.
FT                                /FTId=VAR_025936.
FT   VARIANT     417    417       N -> S (in HOPS).
FT                                {ECO:0000269|PubMed:11745997}.
FT                                /FTId=VAR_025937.
FT   VARIANT     423    423       V -> A (in HOPS; 16% of activity).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013995.
FT   VARIANT     426    426       G -> C (in HOPSI; partial loss of
FT                                activity). {ECO:0000269|PubMed:10834525}.
FT                                /FTId=VAR_011089.
FT   VARIANT     426    426       G -> D (in HOPS).
FT                                {ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_025938.
FT   VARIANT     436    436       Y -> H (in HOPS).
FT                                {ECO:0000269|PubMed:1409720}.
FT                                /FTId=VAR_006169.
FT   VARIANT     445    445       S -> P (in HOPS; severe; 2% of activity).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013996.
FT   VARIANT     450    450       R -> C (in HOPS; severe; 4% of activity).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013997.
FT   VARIANT     450    450       R -> H (in HOPS).
FT                                {ECO:0000269|PubMed:10679946}.
FT                                /FTId=VAR_011090.
FT   VARIANT     452    452       E -> K (in HOPS).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025939.
FT   VARIANT     456    456       G -> R (in HOPSI; loss of activity).
FT                                {ECO:0000269|PubMed:8954059}.
FT                                /FTId=VAR_011091.
FT   VARIANT     459    459       V -> M (in HOPSI).
FT                                {ECO:0000269|PubMed:11438998}.
FT                                /FTId=VAR_013998.
FT   VARIANT     468    468       A -> T (in HOPS).
FT                                {ECO:0000269|PubMed:12815606}.
FT                                /FTId=VAR_025940.
FT   VARIANT     473    473       G -> S (in HOPS).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_013999.
FT   VARIANT     476    476       E -> K (in HOPS).
FT                                {ECO:0000269|PubMed:10094560,
FT                                ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_006170.
FT   VARIANT     478    478       N -> I (in HOPS; 9% of activity).
FT                                {ECO:0000269|PubMed:10679946,
FT                                ECO:0000269|PubMed:11479741}.
FT                                /FTId=VAR_011092.
FT   VARIANT     489    489       C -> S (in HOPS; 9% of activity).
FT                                {ECO:0000269|PubMed:10679946}.
FT                                /FTId=VAR_011093.
FT   VARIANT     490    490       I -> F (in HOPS; odonto; partial loss of
FT                                activity). {ECO:0000269|PubMed:11479741}.
FT                                /FTId=VAR_014000.
FT   VARIANT     491    491       G -> R (in HOPS).
FT                                {ECO:0000269|PubMed:10332035,
FT                                ECO:0000269|PubMed:9781036}.
FT                                /FTId=VAR_014001.
FT   VARIANT     522    522       V -> A (in dbSNP:rs34605986).
FT                                {ECO:0000269|PubMed:10690885,
FT                                ECO:0000269|PubMed:11760847,
FT                                ECO:0000269|PubMed:11855933}.
FT                                /FTId=VAR_011094.
FT   CONFLICT     29     29       W -> A (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    104    104       N -> K (in Ref. 3; CAA32376).
FT                                {ECO:0000305}.
FT   CONFLICT    361    361       Q -> H (in Ref. 1; BAA32129).
FT                                {ECO:0000305}.
FT   CONFLICT    446    446       A -> P (in Ref. 1; BAA32129).
FT                                {ECO:0000305}.
SQ   SEQUENCE   524 AA;  57305 MW;  71B45F17F6211900 CRC64;
     MISPFLVLAI GTCLTNSLVP EKEKDPKYWR DQAQETLKYA LELQKLNTNV AKNVIMFLGD
     GMGVSTVTAA RILKGQLHHN PGEETRLEMD KFPFVALSKT YNTNAQVPDS AGTATAYLCG
     VKANEGTVGV SAATERSRCN TTQGNEVTSI LRWAKDAGKS VGIVTTTRVN HATPSAAYAH
     SADRDWYSDN EMPPEALSQG CKDIAYQLMH NIRDIDVIMG GGRKYMYPKN KTDVEYESDE
     KARGTRLDGL DLVDTWKSFK PRYKHSHFIW NRTELLTLDP HNVDYLLGLF EPGDMQYELN
     RNNVTDPSLS EMVVVAIQIL RKNPKGFFLL VEGGRIDHGH HEGKAKQALH EAVEMDRAIG
     QAGSLTSSED TLTVVTADHS HVFTFGGYTP RGNSIFGLAP MLSDTDKKPF TAILYGNGPG
     YKVVGGEREN VSMVDYAHNN YQAQSAVPLR HETHGGEDVA VFSKGPMAHL LHGVHEQNYV
     PHVMAYAACI GANLGHCAPA SSAGSLAAGP LLLALALYPL SVLF
//
ID   PROS_HUMAN              Reviewed;         676 AA.
AC   P07225; A8KAC9; D3DN28; Q15518; Q7Z715; Q9UCZ8;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1988, sequence version 1.
DT   17-FEB-2016, entry version 201.
DE   RecName: Full=Vitamin K-dependent protein S;
DE   Flags: Precursor;
GN   Name=PROS1; Synonyms=PROS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND GAMMA-CARBOXYGLUTAMATION AT GLU-47;
RP   GLU-48; GLU-55; GLU-57; GLU-60; GLU-61; GLU-66; GLU-67; GLU-70; GLU-73
RP   AND GLU-77.
RX   PubMed=2820795; DOI=10.1016/0014-5793(87)80217-X;
RA   Ploos van Amstel H.K., van der Zanden A.L., Reitsma P.H.,
RA   Bertina R.M.;
RT   "Human protein S cDNA encodes Phe-16 and Tyr 222 in consensus
RT   sequences for the post-translational processing.";
RL   FEBS Lett. 222:186-190(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3467362; DOI=10.1073/pnas.84.2.349;
RA   Hoskins J., Norman D.K., Beckmann R.J., Long G.L.;
RT   "Cloning and characterization of human liver cDNA encoding a protein S
RT   precursor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:349-353(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2148110; DOI=10.1021/bi00486a010;
RA   Schmidel D.K., Tatro A.V., Phelps L.G., Tomczak J.A., Long G.L.;
RT   "Organization of the human protein S genes.";
RL   Biochemistry 29:7845-7852(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Liver;
RX   PubMed=2148111; DOI=10.1021/bi00486a011;
RA   Ploos van Amstel H.K., Reitsma P.H., der Logt C.P., Bertina R.M.;
RT   "Intron-exon organization of the active human protein S gene PS alpha
RT   and its pseudogene PS beta: duplication and silencing during primate
RT   evolution.";
RL   Biochemistry 29:7853-7861(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 27-676.
RX   PubMed=2944113; DOI=10.1073/pnas.83.18.6716;
RA   Lundwall A., Dackowski W., Cohen E., Shaffer M., Mahr A., Dahlback B.,
RA   Stenflo J., Wydro R.;
RT   "Isolation and sequence of the cDNA for human protein S, a regulator
RT   of blood coagulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:6716-6720(1986).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 500-519, AND VARIANTS THPH5
RP   VAL-381 AND GLY-508.
RX   PubMed=7482398;
RA   Gomez E., Poort S.R., Bertina R.M., Reitsma P.H.;
RT   "Identification of eight point mutations in protein S deficiency type
RT   I -- analysis of 15 pedigrees.";
RL   Thromb. Haemost. 73:750-755(1995).
RN   [11]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-530.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   STRUCTURE BY NMR OF 200-286, AND DISULFIDE BONDS.
RX   PubMed=15952784; DOI=10.1021/bi050101f;
RA   Drakenberg T., Ghasriani H., Thulin E., Thamlitz A.M., Muranyi A.,
RA   Annila A., Stenflo J.;
RT   "Solution structure of the Ca2+-binding EGF3-4 pair from vitamin K-
RT   dependent protein S: identification of an unusual fold in EGF3.";
RL   Biochemistry 44:8782-8789(2005).
RN   [14]
RP   VARIANT PRO-501.
RX   PubMed=2143091;
RA   Bertina R.M., Ploos van Amstel H.K., van Wijngaarden A., Coenen J.,
RA   Leemhuis M.P., Deutz-Terlouw P.P., van der Linden I.K., Reitsma P.H.;
RT   "Heerlen polymorphism of protein S, an immunologic polymorphism due to
RT   dimorphism of residue 460.";
RL   Blood 76:538-548(1990).
RN   [15]
RP   VARIANT THPH5 SER-258.
RA   Cooper D.N.;
RL   Unpublished observations (SEP-1993).
RN   [16]
RP   VARIANT THPH5 TOKUSHIMA GLU-196.
RX   PubMed=8298131;
RA   Hayashi T., Nishioka J., Shigekiyo T., Saito S., Suzuki K.;
RT   "Protein S Tokushima: abnormal molecule with a substitution of Glu for
RT   Lys-155 in the second epidermal growth factor-like domain of protein
RT   S.";
RL   Blood 83:683-690(1994).
RN   [17]
RP   VARIANTS THPH5 LEU-40; HIS-41; ALA-67; CYS-72; MET-78; HIS-90;
RP   ASN-144; GLY-245; LYS-249; TRP-265; ARG-265 AND ASN-376, AND VARIANTS
RP   LEU-76 AND VAL-385.
RX   PubMed=7803790;
RA   Gandrille S., Borgel D., Eschwege-Gufflet V., Aillaud M., Dreyfus M.,
RA   Matheron C., Gaussem P., Abgrall J.F., Jude B., Sie P., Toulon P.,
RA   Aiach M.;
RT   "Identification of 15 different candidate causal point mutations and
RT   three polymorphisms in 19 patients with protein S deficiency using a
RT   scanning method for the analysis of the protein S active gene.";
RL   Blood 85:130-138(1995).
RN   [18]
RP   VARIANTS THPH5 SER-258 AND THR-611.
RX   PubMed=7545463;
RA   Formstone C.J., Wacey A.I., Berg L.-P., Rahman S., Bevan D.,
RA   Rowley M., Voke J., Bernardi F., Legnani C., Simioni P., Girolami A.,
RA   Tuddenham E.G.D., Kakkar V.V., Cooper D.N.;
RT   "Detection and characterization of seven novel protein S (PROS) gene
RT   lesions: evaluation of reverse transcript-polymerase chain reaction as
RT   a mutation screening strategy.";
RL   Blood 86:2632-2641(1995).
RN   [19]
RP   VARIANTS THPH5 PRO-351; SER-552; GLN-584 AND PRO-616.
RX   PubMed=7579449;
RA   Mustafa S., Pabinger I., Mannhalter C.;
RT   "Protein S deficiency type I: identification of point mutations in 9
RT   of 10 families.";
RL   Blood 86:3444-3451(1995).
RN   [20]
RP   VARIANT THPH5 SER-644.
RX   PubMed=8977443; DOI=10.1161/01.ATV.16.12.1407;
RA   Li M., Long G.L.;
RT   "Identification of two novel point mutations in the human protein S
RT   gene associated with familial protein S deficiency and thrombosis.";
RL   Arterioscler. Thromb. Vasc. Biol. 16:1407-1415(1996).
RN   [21]
RP   VARIANT THPH5 CYS-515, CHARACTERIZATION OF VARIANT PROS1 DEFICIENCY
RP   CYS-515, AND MUTAGENESIS OF ARG-515.
RX   PubMed=8639833;
RA   Yamazaki T., Katsumi A., Kagami K., Okamoto Y., Sugiura I.,
RA   Hamaguchi M., Kojima T., Takamatsu J., Saito H.;
RT   "Molecular basis of a hereditary type I protein S deficiency caused by
RT   a substitution of Cys for Arg474.";
RL   Blood 87:4643-4650(1996).
RN   [22]
RP   VARIANTS THPH5 TYR-186; THR-611 AND LEU-665.
RX   PubMed=8781426;
RA   Beauchamp N.J., Daly M.E., Cooper P.C., Makris M., Preston F.E.,
RA   Peake I.R.;
RT   "Molecular basis of protein S deficiency in three families also
RT   showing independent inheritance of factor V Leiden.";
RL   Blood 88:1700-1707(1996).
RN   [23]
RP   VARIANTS THPH5 GLU-50; ALA-67; GLU-95; TYR-186; SER-241; PRO-324;
RP   ASP-381; SER-449 AND ARG-666, AND VARIANT PRO-501.
RX   PubMed=8943854;
RG   Protein S study group;
RA   Simmonds R.E., Ireland H., Kunz G., Lane D.A.;
RT   "Identification of 19 protein S gene mutations in patients with
RT   phenotypic protein S deficiency and thrombosis.";
RL   Blood 88:4195-4204(1996).
RN   [24]
RP   VARIANTS THPH5 SER-111; GLY-157; GLY-161; GLU-364; PRO-446; ARG-475;
RP   ALA-501; MET-508; CYS-515; PRO-525; ALA-532; TYR-568; ARG-575 AND
RP   ARG-666, AND VARIANT PRO-501.
RX   PubMed=8765219; DOI=10.1016/S0022-2143(96)90015-3;
RG   The French network on molecular abnormalities responsible for protein C and protein S deficiencies;
RA   Borgel D., Duchemin J., Alhenc-Gelas M., Matheron C., Aiach M.,
RA   Gandrille S.;
RT   "Molecular basis for protein S hereditary deficiency: genetic defects
RT   observed in 118 patients with type I and type IIa deficiencies.";
RL   J. Lab. Clin. Med. 128:218-227(1996).
RN   [25]
RP   VARIANTS THPH5 PRO-300 AND ARG-666.
RX   PubMed=8701404;
RA   Duchemin J., Borg J.-Y., Borgel D., Vasse M., Leveque H., Aiach M.,
RA   Gandrille S.;
RT   "Five novel mutations of the protein S active gene (PROS 1) in 8
RT   Norman families.";
RL   Thromb. Haemost. 75:437-444(1996).
RN   [26]
RP   VARIANT THPH5 PHE-639.
RX   PubMed=9031443;
RA   Bustorff T.C., Freire I., Gago T., Crespo F., David D.;
RT   "Identification of three novel mutations in hereditary protein S
RT   deficiency.";
RL   Thromb. Haemost. 77:21-25(1997).
RN   [27]
RP   VARIANTS THPH5 ASP-68; ARG-95 AND SER-336.
RX   PubMed=9241758;
RG   Plasma coagulation inhibitors subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis;
RA   Gandrille S., Borgel D., Ireland H., Lane D.A., Simmonds R.,
RA   Reitsma P.H., Mannhalter C., Pabinger I., Saito H., Suzuki K.,
RA   Formstone C., Cooper D.N., Espinosa Y., Sala N., Bernardi F.,
RA   Aiach M.;
RT   "Protein S deficiency: a database of mutations.";
RL   Thromb. Haemost. 77:1201-1214(1997).
RN   [28]
RP   VARIANTS THPH5 CYS-482; CYS-485 AND GLY-561, AND VARIANTS PRO-501 AND
RP   MET-559.
RX   PubMed=10447256;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:1<30::AID-HUMU4>3.0.CO;2-X;
RA   Espinosa-Parrilla Y., Morell M., Souto J.C., Tirado I.,
RA   Fontcuberta J., Estivill X., Sala N.;
RT   "Protein S gene analysis reveals the presence of a cosegregating
RT   mutation in most pedigrees with type I but not type III PS
RT   deficiency.";
RL   Hum. Mutat. 14:30-39(1999).
RN   [29]
RP   VARIANTS THPH5 ALA-67; GLY-129; PHE-175; PRO-515; LEU-562 AND ASP-638,
RP   AND VARIANTS LEU-76 AND ASP-638.
RX   PubMed=10613647;
RA   Hermida J., Faioni E.M., Mannucci P.M.;
RT   "Poor relationship between phenotypes of protein S deficiency and
RT   mutations in the protein S alpha gene.";
RL   Thromb. Haemost. 82:1634-1638(1999).
RN   [30]
RP   VARIANTS THPH5 TYR-166; GLY-247; THR-611; ARG-622 AND ARG-666.
RX   PubMed=10706858;
RA   Makris M., Leach M., Beauchamp N.J., Daly M.E., Cooper P.C.,
RA   Hampton K.K., Bayliss P., Peake I.R., Miller G.J., Preston F.E.;
RT   "Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis
RT   in families with inherited deficiencies of protein S.";
RL   Blood 95:1935-1941(2000).
RN   [31]
RP   VARIANTS THPH5 HIS-15; LYS-233; THR-640 AND LEU-667, AND VARIANTS
RP   SER-98 AND MET-559.
RX   PubMed=10790208;
RX   DOI=10.1002/(SICI)1098-1004(200005)15:5<463::AID-HUMU8>3.3.CO;2-5;
RA   Espinosa-Parrilla Y., Morell M., Borrell M., Souto J.C.,
RA   Fontcuberta J., Estivill X., Sala N.;
RT   "Optimization of a simple and rapid single-strand conformation
RT   analysis for detection of mutations in the PROS1 gene: identification
RT   of seven novel mutations and three novel, apparently neutral,
RT   variants.";
RL   Hum. Mutat. 15:463-473(2000).
RN   [32]
RP   VARIANTS THPH5 ASN-243 AND PRO-339.
RX   PubMed=11372770; DOI=10.1055/s-2001-14075;
RA   Iwaki T., Mastushita T., Kobayashi T., Yamamoto Y., Nomura Y.,
RA   Kagami K., Nakayama T., Sugiura I., Kojima T., Takamatsu J.,
RA   Kanayama N., Saito H.;
RT   "DNA sequence analysis of protein S deficiency -- identification of
RT   four point mutations in twelve Japanese subjects.";
RL   Semin. Thromb. Hemost. 27:155-160(2001).
RN   [33]
RP   VARIANTS THPH5 CYS-149; ARG-383; LYS-390 AND SER-526.
RX   PubMed=11776305;
RA   Andersen B.D., Bisgaard M.L., Lind B., Philips M., Villoutreix B.O.,
RA   Thorsen S.;
RT   "Characterization and structural impact of five novel PROS1 mutations
RT   in eleven protein S-deficient families.";
RL   Thromb. Haemost. 86:1392-1399(2001).
RN   [34]
RP   VARIANTS THPH5 ASP-52 AND MET-78, AND CHARACTERIZATION OF VARIANTS
RP   THPH5 ASP-52 AND MET-78.
RX   PubMed=12351389; DOI=10.1182/blood-2002-03-0909;
RA   Rezende S.M., Lane D.A., Mille-Baker B., Samama M.M., Conard J.,
RA   Simmonds R.E.;
RT   "Protein S Gla-domain mutations causing impaired Ca(2+)-induced
RT   phospholipid binding and severe functional protein S deficiency.";
RL   Blood 100:2812-2819(2002).
RN   [35]
RP   VARIANTS THPH5 GLU-18; CYS-90; LYS-233; SER-258; VAL-336 AND PRO-664,
RP   AND CHARACTERIZATION OF VARIANTS THPH5 GLU-18; CYS-90; LYS-233;
RP   SER-258 VAL-336 AND PRO-664.
RX   PubMed=11858485;
RA   Rezende S.M., Lane D.A., Zoeller B., Mille-Baker B., Laffan M.,
RA   Dalhbaeck B., Simmonds R.E.;
RT   "Genetic and phenotypic variability between families with hereditary
RT   protein S deficiency.";
RL   Thromb. Haemost. 87:258-265(2002).
RN   [36]
RP   VARIANTS THPH5 ARG-95; GLU-196; ILE-630 AND CYS-636, AND
RP   CHARACTERIZATION OF VARIANTS THPH5 ARG-95; GLU-196; ILE-630 AND
RP   CYS-636.
RX   PubMed=11927129; DOI=10.1016/S0049-3848(02)00015-4;
RA   Tsuda H., Urata M., Tsuda T., Wakiyama M., Iida H., Nakahara M.,
RA   Kinoshita S., Hamasaki N.;
RT   "Four missense mutations identified in the protein S gene of
RT   thrombosis patients with protein S deficiency: effects on secretion
RT   and anticoagulant activity of protein S.";
RL   Thromb. Res. 105:233-239(2002).
RN   [37]
RP   VARIANTS THPH5 CYS-101 AND ASN-144, AND VARIANT SER-168.
RX   PubMed=12632031; DOI=10.1097/00001721-200302000-00012;
RA   Boinot C., Borgel D., Kitzis A., Guicheteau M., Aiach M.,
RA   Alhenc-Gelas M.;
RT   "Familial thrombophilia is an oligogenetic disease: involvement of the
RT   prothrombin G20210A, PROC and PROS gene mutations.";
RL   Blood Coagul. Fibrinolysis 14:191-196(2003).
RN   [38]
RP   VARIANTS THPH5 LEU-87; TYR-121; GLU-196; HIS-355 AND LEU-667.
RX   PubMed=15238143; DOI=10.1111/j.1365-2141.2004.05026.x;
RA   Okada H., Takagi A., Murate T., Adachi T., Yamamoto K., Matsushita T.,
RA   Takamatsu J., Sugita K., Sugimoto M., Yoshioka A., Yamazaki T.,
RA   Saito H., Kojima T.;
RT   "Identification of protein Salpha gene mutations including four novel
RT   mutations in eight unrelated patients with protein S deficiency.";
RL   Br. J. Haematol. 126:219-225(2004).
RN   [39]
RP   VARIANTS THPH5 ALA-67; TYR-88; GLY-129; ASN-144; PHE-175; GLY-204;
RP   CYS-266; SER-267; ASP-336; ARG-357; PRO-446; PRO-515; ASP-521;
RP   LYS-611; ASP-638 AND TYR-639, VARIANTS LEU-76; PRO-501; MET-559;
RP   LEU-562 AND HIS-583, CHARACTERIZATION OF VARIANTS PROS1 DEFICIENCY
RP   ALA-67; TYR-88; GLY-129; PHE-175; GLY-204; CYS-266; SER-267; ASP-336;
RP   ARG-357; PRO-446; PRO-515; ASP-521; LYS-611; ASP-638 AND TYR-639, AND
RP   CHARACTERIZATION OF VARIANTS LEU-76; LEU-562 AND HIS-583.
RX   PubMed=15712227; DOI=10.1002/humu.20136;
RG   Protein S Italian team (PROSIT);
RA   Biguzzi E., Razzari C., Lane D.A., Castaman G., Cappellari A.,
RA   Bucciarelli P., Fontana G., Margaglione M., D'Andrea G.,
RA   Simmonds R.E., Rezende S.M., Preston R., Prisco D., Faioni E.M.;
RT   "Molecular diversity and thrombotic risk in protein S deficiency: the
RT   PROSIT study.";
RL   Hum. Mutat. 25:259-269(2005).
RN   [40]
RP   VARIANT [LARGE SCALE ANALYSIS] GLY-545.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [41]
RP   VARIANT THPH6 CYS-234.
RX   PubMed=20484936; DOI=10.1159/000298282;
RA   Fischer D., Porto L., Stoll H., Geisen C., Schloesser R.L.;
RT   "Intracerebral mass bleeding in a term neonate: manifestation of
RT   hereditary protein S deficiency with a new mutation in the PROS1
RT   gene.";
RL   Neonatology 98:337-340(2010).
CC   -!- FUNCTION: Anticoagulant plasma protein; it is a cofactor to
CC       activated protein C in the degradation of coagulation factors Va
CC       and VIIIa. It helps to prevent coagulation and stimulating
CC       fibrinolysis.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Plasma.
CC   -!- PTM: The iron and 2-oxoglutarate dependent 3-hydroxylation of
CC       aspartate and asparagine is (R) stereospecific within EGF domains.
CC       {ECO:0000250}.
CC   -!- DISEASE: Thrombophilia due to protein S deficiency, autosomal
CC       dominant (THPH5) [MIM:612336]: A hemostatic disorder characterized
CC       by impaired regulation of blood coagulation and a tendency to
CC       recurrent venous thrombosis. Based on the plasma levels of total
CC       and free PROS1 as well as the serine protease-activated protein C
CC       cofactor activity, three types of THPH5 have been described: type
CC       I, characterized by reduced total and free PROS1 levels together
CC       with reduced anticoagulant activity; type III, in which only free
CC       PROS1 antigen and PROS1 activity levels are reduced; and the rare
CC       type II which is characterized by normal concentrations of both
CC       total and free PROS1 antigen, but low cofactor activity.
CC       {ECO:0000269|PubMed:10447256, ECO:0000269|PubMed:10613647,
CC       ECO:0000269|PubMed:10706858, ECO:0000269|PubMed:10790208,
CC       ECO:0000269|PubMed:11372770, ECO:0000269|PubMed:11776305,
CC       ECO:0000269|PubMed:11858485, ECO:0000269|PubMed:11927129,
CC       ECO:0000269|PubMed:12351389, ECO:0000269|PubMed:12632031,
CC       ECO:0000269|PubMed:15238143, ECO:0000269|PubMed:15712227,
CC       ECO:0000269|PubMed:7482398, ECO:0000269|PubMed:7545463,
CC       ECO:0000269|PubMed:7579449, ECO:0000269|PubMed:7803790,
CC       ECO:0000269|PubMed:8298131, ECO:0000269|PubMed:8639833,
CC       ECO:0000269|PubMed:8701404, ECO:0000269|PubMed:8765219,
CC       ECO:0000269|PubMed:8781426, ECO:0000269|PubMed:8943854,
CC       ECO:0000269|PubMed:8977443, ECO:0000269|PubMed:9031443,
CC       ECO:0000269|PubMed:9241758, ECO:0000269|Ref.15}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Thrombophilia due to protein S deficiency, autosomal
CC       recessive (THPH6) [MIM:614514]: A very rare and severe hematologic
CC       disorder resulting in thrombosis and secondary hemorrhage usually
CC       beginning in early infancy. Some affected individuals develop
CC       neonatal purpura fulminans, multifocal thrombosis, or intracranial
CC       hemorrhage. {ECO:0000269|PubMed:20484936}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Contains 4 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 1 Gla (gamma-carboxy-glutamate) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00463}.
CC   -!- SIMILARITY: Contains 2 laminin G-like domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00122}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAP45054.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/pros1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y00692; CAA68687.1; -; mRNA.
DR   EMBL; Y00692; CAA68688.1; ALT_SEQ; mRNA.
DR   EMBL; M15036; AAA36479.1; -; mRNA.
DR   EMBL; M57853; AAA60357.1; -; Genomic_DNA.
DR   EMBL; M57840; AAA60357.1; JOINED; Genomic_DNA.
DR   EMBL; M57841; AAA60357.1; JOINED; Genomic_DNA.
DR   EMBL; M57842; AAA60357.1; JOINED; Genomic_DNA.
DR   EMBL; M57844; AAA60357.1; JOINED; Genomic_DNA.
DR   EMBL; M57845; AAA60357.1; JOINED; Genomic_DNA.
DR   EMBL; M57846; AAA60357.1; JOINED; Genomic_DNA.
DR   EMBL; M57847; AAA60357.1; JOINED; Genomic_DNA.
DR   EMBL; M57848; AAA60357.1; JOINED; Genomic_DNA.
DR   EMBL; M57849; AAA60357.1; JOINED; Genomic_DNA.
DR   EMBL; M57850; AAA60357.1; JOINED; Genomic_DNA.
DR   EMBL; M57851; AAA60357.1; JOINED; Genomic_DNA.
DR   EMBL; M57852; AAA60357.1; JOINED; Genomic_DNA.
DR   EMBL; AH002948; AAA60180.1; -; Genomic_DNA.
DR   EMBL; AK292994; BAF85683.1; -; mRNA.
DR   EMBL; AY308744; AAP45054.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471052; EAW79903.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79905.1; -; Genomic_DNA.
DR   EMBL; BC015801; AAH15801.1; -; mRNA.
DR   CCDS; CCDS2923.1; -.
DR   PIR; A35610; KXHUS.
DR   RefSeq; NP_000304.2; NM_000313.3.
DR   RefSeq; NP_001301006.1; NM_001314077.1.
DR   UniGene; Hs.64016; -.
DR   PDB; 1Z6C; NMR; -; A=200-286.
DR   PDBsum; 1Z6C; -.
DR   ProteinModelPortal; P07225; -.
DR   SMR; P07225; 46-86, 119-669.
DR   BioGrid; 111611; 12.
DR   IntAct; P07225; 3.
DR   STRING; 9606.ENSP00000377783; -.
DR   DrugBank; DB00055; Drotrecogin alfa.
DR   DrugBank; DB00170; Menadione.
DR   DrugBank; DB00464; Sodium Tetradecyl Sulfate.
DR   PhosphoSite; P07225; -.
DR   BioMuta; PROS1; -.
DR   DMDM; 131086; -.
DR   MaxQB; P07225; -.
DR   PaxDb; P07225; -.
DR   PeptideAtlas; P07225; -.
DR   PRIDE; P07225; -.
DR   DNASU; 5627; -.
DR   Ensembl; ENST00000394236; ENSP00000377783; ENSG00000184500.
DR   GeneID; 5627; -.
DR   KEGG; hsa:5627; -.
DR   UCSC; uc003dqz.4; human.
DR   CTD; 5627; -.
DR   GeneCards; PROS1; -.
DR   HGNC; HGNC:9456; PROS1.
DR   HPA; HPA007724; -.
DR   HPA; HPA023974; -.
DR   MalaCards; PROS1; -.
DR   MIM; 176880; gene.
DR   MIM; 612336; phenotype.
DR   MIM; 614514; phenotype.
DR   neXtProt; NX_P07225; -.
DR   Orphanet; 743; Hereditary thrombophilia due to congenital protein S deficiency.
DR   PharmGKB; PA33809; -.
DR   eggNOG; ENOG410IGF6; Eukaryota.
DR   eggNOG; ENOG410ZTGU; LUCA.
DR   GeneTree; ENSGT00530000063339; -.
DR   HOGENOM; HOG000065758; -.
DR   HOVERGEN; HBG051702; -.
DR   InParanoid; P07225; -.
DR   KO; K03908; -.
DR   OMA; WNMVSVE; -.
DR   OrthoDB; EOG7R2BJ0; -.
DR   PhylomeDB; P07225; -.
DR   TreeFam; TF352157; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-140875; Common Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-159740; Gamma-carboxylation of protein precursors.
DR   Reactome; R-HSA-159763; Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus.
DR   Reactome; R-HSA-159782; Removal of aminoterminal propeptides from gamma-carboxylated proteins.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-977606; Regulation of Complement cascade.
DR   ChiTaRS; PROS1; human.
DR   EvolutionaryTrace; P07225; -.
DR   GeneWiki; Protein_S; -.
DR   GenomeRNAi; 5627; -.
DR   NextBio; 21872; -.
DR   PRO; PR:P07225; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; P07225; -.
DR   CleanEx; HS_PROS1; -.
DR   ExpressionAtlas; P07225; baseline and differential.
DR   Genevisible; P07225; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0004866; F:endopeptidase inhibitor activity; TAS:ProtInc.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0042730; P:fibrinolysis; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0010951; P:negative regulation of endopeptidase activity; TAS:GOC.
DR   GO; GO:0017187; P:peptidyl-glutamic acid carboxylation; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; IEA:Ensembl.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0006508; P:proteolysis; TAS:Reactome.
DR   GO; GO:0030449; P:regulation of complement activation; TAS:Reactome.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   Gene3D; 2.60.120.200; -; 2.
DR   Gene3D; 4.10.740.10; -; 1.
DR   InterPro; IPR017857; Coagulation_fac_subgr_Gla_dom.
DR   InterPro; IPR013320; ConA-like_dom.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR000294; GLA_domain.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR001791; Laminin_G.
DR   Pfam; PF00008; EGF; 1.
DR   Pfam; PF07645; EGF_CA; 2.
DR   Pfam; PF00594; Gla; 1.
DR   Pfam; PF00054; Laminin_G_1; 1.
DR   Pfam; PF02210; Laminin_G_2; 1.
DR   PRINTS; PR00001; GLABLOOD.
DR   SMART; SM00181; EGF; 1.
DR   SMART; SM00179; EGF_CA; 3.
DR   SMART; SM00069; GLA; 1.
DR   SMART; SM00282; LamG; 2.
DR   SUPFAM; SSF49899; SSF49899; 2.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   SUPFAM; SSF57630; SSF57630; 1.
DR   PROSITE; PS00010; ASX_HYDROXYL; 4.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 3.
DR   PROSITE; PS50026; EGF_3; 4.
DR   PROSITE; PS01187; EGF_CA; 3.
DR   PROSITE; PS00011; GLA_1; 1.
DR   PROSITE; PS50998; GLA_2; 1.
DR   PROSITE; PS50025; LAM_G_DOMAIN; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Blood coagulation; Calcium;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Disease mutation; Disulfide bond; EGF-like domain; Fibrinolysis;
KW   Gamma-carboxyglutamic acid; Glycoprotein; Hemostasis; Hydroxylation;
KW   Polymorphism; Reference proteome; Repeat; Secreted; Signal;
KW   Thrombophilia; Zymogen.
FT   SIGNAL        1     24
FT   PROPEP       25     41
FT                                /FTId=PRO_0000022119.
FT   CHAIN        42    676       Vitamin K-dependent protein S.
FT                                /FTId=PRO_0000022120.
FT   DOMAIN       42     87       Gla. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463}.
FT   DOMAIN      117    155       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      157    200       EGF-like 2; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      201    242       EGF-like 3; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      243    283       EGF-like 4; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      299    475       Laminin G-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00122}.
FT   DOMAIN      484    666       Laminin G-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00122}.
FT   REGION       88    116       Thrombin-sensitive.
FT   SITE        499    499       Not glycosylated; in variant Heerlen.
FT   MOD_RES      47     47       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2820795}.
FT   MOD_RES      48     48       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2820795}.
FT   MOD_RES      55     55       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2820795}.
FT   MOD_RES      57     57       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2820795}.
FT   MOD_RES      60     60       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2820795}.
FT   MOD_RES      61     61       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2820795}.
FT   MOD_RES      66     66       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2820795}.
FT   MOD_RES      67     67       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2820795}.
FT   MOD_RES      70     70       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2820795}.
FT   MOD_RES      73     73       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2820795}.
FT   MOD_RES      77     77       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2820795}.
FT   MOD_RES     136    136       (3R)-3-hydroxyaspartate. {ECO:0000250}.
FT   CARBOHYD    499    499       N-linked (GlcNAc...).
FT   CARBOHYD    509    509       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    530    530       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952}.
FT   DISULFID     58     63       {ECO:0000250}.
FT   DISULFID    121    134       {ECO:0000250}.
FT   DISULFID    126    143       {ECO:0000250}.
FT   DISULFID    145    154       {ECO:0000250}.
FT   DISULFID    161    175       {ECO:0000250}.
FT   DISULFID    171    184       {ECO:0000250}.
FT   DISULFID    186    199       {ECO:0000250}.
FT   DISULFID    205    217       {ECO:0000269|PubMed:15952784}.
FT   DISULFID    212    226       {ECO:0000269|PubMed:15952784}.
FT   DISULFID    228    241       {ECO:0000269|PubMed:15952784}.
FT   DISULFID    247    256       {ECO:0000269|PubMed:15952784}.
FT   DISULFID    252    265       {ECO:0000269|PubMed:15952784}.
FT   DISULFID    267    282       {ECO:0000269|PubMed:15952784}.
FT   DISULFID    449    475       {ECO:0000250}.
FT   DISULFID    639    666       {ECO:0000250}.
FT   VARIANT      15     15       L -> H (in THPH5).
FT                                {ECO:0000269|PubMed:10790208}.
FT                                /FTId=VAR_046802.
FT   VARIANT      18     18       V -> E (in THPH5; expresses very low/
FT                                undetectable PROS1 levels compared to
FT                                wild-type; has impaired secretion;
FT                                intracellular degradation of unsecreted
FT                                material is found).
FT                                {ECO:0000269|PubMed:11858485}.
FT                                /FTId=VAR_046803.
FT   VARIANT      40     40       R -> L (in THPH5; dbSNP:rs7614835).
FT                                {ECO:0000269|PubMed:7803790}.
FT                                /FTId=VAR_046804.
FT   VARIANT      41     41       R -> H (in THPH5).
FT                                {ECO:0000269|PubMed:7803790}.
FT                                /FTId=VAR_046805.
FT   VARIANT      50     50       K -> E (in THPH5).
FT                                {ECO:0000269|PubMed:8943854}.
FT                                /FTId=VAR_046806.
FT   VARIANT      52     52       G -> D (in THPH5; does not affect PROS1
FT                                production but results in 15.2-fold
FT                                reduced PROS1 activity; has 5.4 fold
FT                                reduced affinity for anionic phospholipid
FT                                vesicles (P < 0.0001) and decreased
FT                                affinity for an antibody specific for the
FT                                Ca(2+)-dependent conformation of the
FT                                PROS1 Gla domain).
FT                                {ECO:0000269|PubMed:12351389}.
FT                                /FTId=VAR_046807.
FT   VARIANT      67     67       E -> A (in THPH5).
FT                                {ECO:0000269|PubMed:10613647,
FT                                ECO:0000269|PubMed:15712227,
FT                                ECO:0000269|PubMed:7803790,
FT                                ECO:0000269|PubMed:8943854}.
FT                                /FTId=VAR_046808.
FT   VARIANT      68     68       A -> D (in THPH5).
FT                                {ECO:0000269|PubMed:9241758}.
FT                                /FTId=VAR_046809.
FT   VARIANT      72     72       F -> C (in THPH5).
FT                                {ECO:0000269|PubMed:7803790}.
FT                                /FTId=VAR_046810.
FT   VARIANT      76     76       P -> L (in dbSNP:rs73846070).
FT                                {ECO:0000269|PubMed:10613647,
FT                                ECO:0000269|PubMed:15712227,
FT                                ECO:0000269|PubMed:7803790}.
FT                                /FTId=VAR_046811.
FT   VARIANT      78     78       T -> M (in THPH5; reduces expression of
FT                                PROS1 by 33.2% (P < 0.001) and activity
FT                                by 3.6-fold; has only a modest 1.5-fold
FT                                (P < 0.001) reduced affinity for
FT                                phospholipid and an antibody specific for
FT                                the Ca(2+)-dependent conformation of the
FT                                PROS1 Gla domain; dbSNP:rs6122).
FT                                {ECO:0000269|PubMed:12351389,
FT                                ECO:0000269|PubMed:7803790}.
FT                                /FTId=VAR_014666.
FT   VARIANT      87     87       V -> L (in THPH5; dbSNP:rs557733421).
FT                                {ECO:0000269|PubMed:15238143}.
FT                                /FTId=VAR_046812.
FT   VARIANT      88     88       C -> Y (in THPH5).
FT                                {ECO:0000269|PubMed:15712227}.
FT                                /FTId=VAR_046813.
FT   VARIANT      90     90       R -> C (in THPH5; produces around 50% of
FT                                PROS1 levels compared to wild-type; has
FT                                impaired secretion; intracellular
FT                                degradation of unsecreted material is
FT                                found). {ECO:0000269|PubMed:11858485}.
FT                                /FTId=VAR_046814.
FT   VARIANT      90     90       R -> H (in THPH5).
FT                                {ECO:0000269|PubMed:7803790}.
FT                                /FTId=VAR_046815.
FT   VARIANT      95     95       G -> E (in THPH5; dbSNP:rs144526169).
FT                                {ECO:0000269|PubMed:8943854}.
FT                                /FTId=VAR_046816.
FT   VARIANT      95     95       G -> R (in THPH5; the activated protein
FT                                cofactor activity is inhibited by C4BPB
FT                                with a dose dependency similar to that of
FT                                wild-type PROS1).
FT                                {ECO:0000269|PubMed:11927129,
FT                                ECO:0000269|PubMed:9241758}.
FT                                /FTId=VAR_046817.
FT   VARIANT      98     98       T -> S (in dbSNP:rs142805170).
FT                                {ECO:0000269|PubMed:10790208}.
FT                                /FTId=VAR_046818.
FT   VARIANT     101    101       R -> C (in THPH5).
FT                                {ECO:0000269|PubMed:12632031}.
FT                                /FTId=VAR_046819.
FT   VARIANT     111    111       R -> S (in THPH5).
FT                                {ECO:0000269|PubMed:8765219}.
FT                                /FTId=VAR_046820.
FT   VARIANT     121    121       C -> Y (in THPH5).
FT                                {ECO:0000269|PubMed:15238143}.
FT                                /FTId=VAR_046821.
FT   VARIANT     129    129       D -> G (in THPH5).
FT                                {ECO:0000269|PubMed:10613647,
FT                                ECO:0000269|PubMed:15712227}.
FT                                /FTId=VAR_046822.
FT   VARIANT     144    144       T -> N (in THPH5; dbSNP:rs146366248).
FT                                {ECO:0000269|PubMed:12632031,
FT                                ECO:0000269|PubMed:15712227,
FT                                ECO:0000269|PubMed:7803790}.
FT                                /FTId=VAR_046823.
FT   VARIANT     149    149       W -> C (in THPH5).
FT                                {ECO:0000269|PubMed:11776305}.
FT                                /FTId=VAR_046824.
FT   VARIANT     157    157       D -> G (in THPH5).
FT                                {ECO:0000269|PubMed:8765219}.
FT                                /FTId=VAR_046825.
FT   VARIANT     161    161       C -> G (in THPH5).
FT                                {ECO:0000269|PubMed:8765219}.
FT                                /FTId=VAR_046826.
FT   VARIANT     166    166       N -> Y (in THPH5).
FT                                {ECO:0000269|PubMed:10706858}.
FT                                /FTId=VAR_046827.
FT   VARIANT     168    168       N -> S (in dbSNP:rs144430063).
FT                                {ECO:0000269|PubMed:12632031}.
FT                                /FTId=VAR_046828.
FT   VARIANT     175    175       C -> F (in THPH5).
FT                                {ECO:0000269|PubMed:10613647,
FT                                ECO:0000269|PubMed:15712227}.
FT                                /FTId=VAR_046829.
FT   VARIANT     186    186       C -> Y (in THPH5).
FT                                {ECO:0000269|PubMed:8781426,
FT                                ECO:0000269|PubMed:8943854}.
FT                                /FTId=VAR_046830.
FT   VARIANT     196    196       K -> E (in THPH5; Tokushima; the specific
FT                                activity decreases to 58% of that of the
FT                                wild-type PROS1; the activated protein
FT                                cofactor activity is inhibited by C4BPB
FT                                with a dose dependency similar to that of
FT                                wild-type PROS1; dbSNP:rs121918474).
FT                                {ECO:0000269|PubMed:11927129,
FT                                ECO:0000269|PubMed:15238143,
FT                                ECO:0000269|PubMed:8298131}.
FT                                /FTId=VAR_005566.
FT   VARIANT     204    204       E -> G (in THPH5).
FT                                {ECO:0000269|PubMed:15712227}.
FT                                /FTId=VAR_046831.
FT   VARIANT     233    233       R -> K (in THPH5; expresses lower (p <
FT                                0.05) PROS1 levels compared to wild-type;
FT                                has impaired secretion;
FT                                dbSNP:rs41267007).
FT                                {ECO:0000269|PubMed:10790208,
FT                                ECO:0000269|PubMed:11858485}.
FT                                /FTId=VAR_046832.
FT   VARIANT     234    234       Y -> C (in THPH6).
FT                                {ECO:0000269|PubMed:20484936}.
FT                                /FTId=VAR_067302.
FT   VARIANT     241    241       C -> S (in THPH5).
FT                                {ECO:0000269|PubMed:8943854}.
FT                                /FTId=VAR_046833.
FT   VARIANT     243    243       D -> N (in THPH5).
FT                                {ECO:0000269|PubMed:11372770}.
FT                                /FTId=VAR_046834.
FT   VARIANT     245    245       D -> G (in THPH5).
FT                                {ECO:0000269|PubMed:7803790}.
FT                                /FTId=VAR_046835.
FT   VARIANT     247    247       C -> G (in THPH5).
FT                                {ECO:0000269|PubMed:10706858}.
FT                                /FTId=VAR_046836.
FT   VARIANT     249    249       E -> K (in THPH5).
FT                                {ECO:0000269|PubMed:7803790}.
FT                                /FTId=VAR_046837.
FT   VARIANT     258    258       N -> S (in THPH5; produces around 30% of
FT                                PROS1 levels compared to wild-type; has
FT                                impaired secretion; intracellular
FT                                degradation of unsecreted material is
FT                                found). {ECO:0000269|PubMed:11858485,
FT                                ECO:0000269|PubMed:7545463,
FT                                ECO:0000269|Ref.15}.
FT                                /FTId=VAR_005567.
FT   VARIANT     265    265       C -> R (in THPH5).
FT                                {ECO:0000269|PubMed:7803790}.
FT                                /FTId=VAR_046838.
FT   VARIANT     265    265       C -> W (in THPH5).
FT                                {ECO:0000269|PubMed:7803790}.
FT                                /FTId=VAR_046839.
FT   VARIANT     266    266       Y -> C (in THPH5).
FT                                {ECO:0000269|PubMed:15712227}.
FT                                /FTId=VAR_046840.
FT   VARIANT     267    267       C -> S (in THPH5).
FT                                {ECO:0000269|PubMed:15712227}.
FT                                /FTId=VAR_046841.
FT   VARIANT     300    300       L -> P (in THPH5).
FT                                {ECO:0000269|PubMed:8701404}.
FT                                /FTId=VAR_046842.
FT   VARIANT     324    324       S -> P (in THPH5).
FT                                {ECO:0000269|PubMed:8943854}.
FT                                /FTId=VAR_046843.
FT   VARIANT     336    336       G -> D (in THPH5).
FT                                {ECO:0000269|PubMed:15712227}.
FT                                /FTId=VAR_046844.
FT   VARIANT     336    336       G -> S (in THPH5).
FT                                {ECO:0000269|PubMed:9241758}.
FT                                /FTId=VAR_046845.
FT   VARIANT     336    336       G -> V (in THPH5; expresses very low/
FT                                undetectable PROS1 levels compared to
FT                                wild-type; has impaired secretion;
FT                                intracellular degradation of unsecreted
FT                                material is found).
FT                                {ECO:0000269|PubMed:11858485}.
FT                                /FTId=VAR_046846.
FT   VARIANT     339    339       L -> P (in THPH5).
FT                                {ECO:0000269|PubMed:11372770}.
FT                                /FTId=VAR_046847.
FT   VARIANT     351    351       L -> P (in THPH5).
FT                                {ECO:0000269|PubMed:7579449}.
FT                                /FTId=VAR_046848.
FT   VARIANT     355    355       R -> H (in THPH5).
FT                                {ECO:0000269|PubMed:15238143}.
FT                                /FTId=VAR_046849.
FT   VARIANT     357    357       G -> R (in THPH5).
FT                                {ECO:0000269|PubMed:15712227}.
FT                                /FTId=VAR_046850.
FT   VARIANT     364    364       K -> E (in THPH5).
FT                                {ECO:0000269|PubMed:8765219}.
FT                                /FTId=VAR_046851.
FT   VARIANT     376    376       D -> N (in THPH5).
FT                                {ECO:0000269|PubMed:7803790}.
FT                                /FTId=VAR_046852.
FT   VARIANT     381    381       G -> D (in THPH5).
FT                                {ECO:0000269|PubMed:8943854}.
FT                                /FTId=VAR_046853.
FT   VARIANT     381    381       G -> V (in THPH5).
FT                                {ECO:0000269|PubMed:7482398}.
FT                                /FTId=VAR_046854.
FT   VARIANT     383    383       W -> R (in THPH5).
FT                                {ECO:0000269|PubMed:11776305}.
FT                                /FTId=VAR_046855.
FT   VARIANT     385    385       M -> V. {ECO:0000269|PubMed:7803790}.
FT                                /FTId=VAR_046856.
FT   VARIANT     390    390       E -> K (in THPH5).
FT                                {ECO:0000269|PubMed:11776305}.
FT                                /FTId=VAR_046857.
FT   VARIANT     446    446       L -> P (in THPH5).
FT                                {ECO:0000269|PubMed:15712227,
FT                                ECO:0000269|PubMed:8765219}.
FT                                /FTId=VAR_046858.
FT   VARIANT     449    449       C -> S (in THPH5).
FT                                {ECO:0000269|PubMed:8943854}.
FT                                /FTId=VAR_046859.
FT   VARIANT     475    475       C -> R (in THPH5).
FT                                {ECO:0000269|PubMed:8765219}.
FT                                /FTId=VAR_046860.
FT   VARIANT     482    482       G -> C (in THPH5).
FT                                {ECO:0000269|PubMed:10447256}.
FT                                /FTId=VAR_014116.
FT   VARIANT     485    485       Y -> C (in THPH5).
FT                                {ECO:0000269|PubMed:10447256}.
FT                                /FTId=VAR_014117.
FT   VARIANT     495    495       I -> V (in dbSNP:rs5017712).
FT                                /FTId=VAR_046861.
FT   VARIANT     501    501       S -> A (in THPH5; dbSNP:rs121918472).
FT                                {ECO:0000269|PubMed:8765219}.
FT                                /FTId=VAR_046862.
FT   VARIANT     501    501       S -> P (variant Heerlen; could be
FT                                associated with THPH5;
FT                                dbSNP:rs121918472).
FT                                {ECO:0000269|PubMed:10447256,
FT                                ECO:0000269|PubMed:15712227,
FT                                ECO:0000269|PubMed:2143091,
FT                                ECO:0000269|PubMed:8765219,
FT                                ECO:0000269|PubMed:8943854}.
FT                                /FTId=VAR_005568.
FT   VARIANT     508    508       V -> G (in THPH5).
FT                                {ECO:0000269|PubMed:7482398}.
FT                                /FTId=VAR_046863.
FT   VARIANT     508    508       V -> M (in THPH5).
FT                                {ECO:0000269|PubMed:8765219}.
FT                                /FTId=VAR_046864.
FT   VARIANT     515    515       R -> C (in THPH5; secretion of the mutant
FT                                markedly decreased compared with that of
FT                                the wild-type; intracellular degradation
FT                                and impaired secretion of the mutant).
FT                                {ECO:0000269|PubMed:8639833,
FT                                ECO:0000269|PubMed:8765219}.
FT                                /FTId=VAR_046865.
FT   VARIANT     515    515       R -> P (in THPH5).
FT                                {ECO:0000269|PubMed:10613647,
FT                                ECO:0000269|PubMed:15712227}.
FT                                /FTId=VAR_046866.
FT   VARIANT     521    521       G -> D (in THPH5).
FT                                {ECO:0000269|PubMed:15712227}.
FT                                /FTId=VAR_046867.
FT   VARIANT     525    525       A -> P (in THPH5).
FT                                {ECO:0000269|PubMed:8765219}.
FT                                /FTId=VAR_046868.
FT   VARIANT     526    526       L -> S (in THPH5).
FT                                {ECO:0000269|PubMed:11776305}.
FT                                /FTId=VAR_046869.
FT   VARIANT     532    532       T -> A (in THPH5).
FT                                {ECO:0000269|PubMed:8765219}.
FT                                /FTId=VAR_046870.
FT   VARIANT     545    545       E -> G (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035981.
FT   VARIANT     552    552       L -> S (in THPH5).
FT                                {ECO:0000269|PubMed:7579449}.
FT                                /FTId=VAR_046871.
FT   VARIANT     559    559       I -> M (in dbSNP:rs184798444).
FT                                {ECO:0000269|PubMed:10447256,
FT                                ECO:0000269|PubMed:10790208,
FT                                ECO:0000269|PubMed:15712227}.
FT                                /FTId=VAR_014118.
FT   VARIANT     561    561       R -> G (in THPH5).
FT                                {ECO:0000269|PubMed:10447256}.
FT                                /FTId=VAR_014119.
FT   VARIANT     562    562       I -> L (in THPH5; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:10613647,
FT                                ECO:0000269|PubMed:15712227}.
FT                                /FTId=VAR_046872.
FT   VARIANT     568    568       C -> Y (in THPH5).
FT                                {ECO:0000269|PubMed:8765219}.
FT                                /FTId=VAR_046873.
FT   VARIANT     575    575       L -> R (in THPH5).
FT                                {ECO:0000269|PubMed:8765219}.
FT                                /FTId=VAR_046874.
FT   VARIANT     583    583       N -> H. {ECO:0000269|PubMed:15712227}.
FT                                /FTId=VAR_046875.
FT   VARIANT     584    584       L -> Q (in THPH5).
FT                                {ECO:0000269|PubMed:7579449}.
FT                                /FTId=VAR_046876.
FT   VARIANT     611    611       M -> K (in THPH5).
FT                                {ECO:0000269|PubMed:15712227}.
FT                                /FTId=VAR_046877.
FT   VARIANT     611    611       M -> T (in THPH5).
FT                                {ECO:0000269|PubMed:10706858,
FT                                ECO:0000269|PubMed:7545463,
FT                                ECO:0000269|PubMed:8781426}.
FT                                /FTId=VAR_046878.
FT   VARIANT     616    616       A -> P (in THPH5).
FT                                {ECO:0000269|PubMed:7579449}.
FT                                /FTId=VAR_046879.
FT   VARIANT     622    622       L -> R (in THPH5).
FT                                {ECO:0000269|PubMed:10706858}.
FT                                /FTId=VAR_046880.
FT   VARIANT     630    630       T -> I (in THPH5; the activated protein
FT                                cofactor activity is inhibited by C4BPB
FT                                with a dose dependency similar to that of
FT                                wild-type PROS1; dbSNP:rs202190731).
FT                                {ECO:0000269|PubMed:11927129}.
FT                                /FTId=VAR_046881.
FT   VARIANT     636    636       Y -> C (in THPH5; shows intracellular
FT                                degradation and decreased secretion).
FT                                {ECO:0000269|PubMed:11927129}.
FT                                /FTId=VAR_046882.
FT   VARIANT     638    638       G -> D (in THPH5).
FT                                {ECO:0000269|PubMed:10613647,
FT                                ECO:0000269|PubMed:15712227}.
FT                                /FTId=VAR_046883.
FT   VARIANT     639    639       C -> F (in THPH5).
FT                                {ECO:0000269|PubMed:9031443}.
FT                                /FTId=VAR_046884.
FT   VARIANT     639    639       C -> Y (in THPH5).
FT                                {ECO:0000269|PubMed:15712227}.
FT                                /FTId=VAR_046885.
FT   VARIANT     640    640       M -> T (in THPH5).
FT                                {ECO:0000269|PubMed:10790208}.
FT                                /FTId=VAR_046886.
FT   VARIANT     644    644       I -> S (in THPH5).
FT                                {ECO:0000269|PubMed:8977443}.
FT                                /FTId=VAR_046887.
FT   VARIANT     664    664       H -> P (in THPH5; expresses very low/
FT                                undetectable PROS1 levels compared to
FT                                wild-type; has impaired secretion;
FT                                intracellular degradation of unsecreted
FT                                material is found).
FT                                {ECO:0000269|PubMed:11858485}.
FT                                /FTId=VAR_046888.
FT   VARIANT     665    665       S -> L (in THPH5).
FT                                {ECO:0000269|PubMed:8781426}.
FT                                /FTId=VAR_046889.
FT   VARIANT     666    666       C -> R (in THPH5).
FT                                {ECO:0000269|PubMed:10706858,
FT                                ECO:0000269|PubMed:8701404,
FT                                ECO:0000269|PubMed:8765219,
FT                                ECO:0000269|PubMed:8943854}.
FT                                /FTId=VAR_046890.
FT   VARIANT     667    667       P -> L (in THPH5).
FT                                {ECO:0000269|PubMed:10790208,
FT                                ECO:0000269|PubMed:15238143}.
FT                                /FTId=VAR_046891.
FT   MUTAGEN     515    515       R->A,E: Markedly reduced secretion of the
FT                                mutant. {ECO:0000269|PubMed:8639833}.
FT   MUTAGEN     515    515       R->K: No change in secretion of the
FT                                mutant. {ECO:0000269|PubMed:8639833}.
FT   CONFLICT     11     11       L -> P (in Ref. 2; AAA36479).
FT                                {ECO:0000305}.
FT   CONFLICT     26     26       F -> L (in Ref. 2; AAA36479).
FT                                {ECO:0000305}.
FT   STRAND      204    212       {ECO:0000244|PDB:1Z6C}.
FT   STRAND      227    229       {ECO:0000244|PDB:1Z6C}.
FT   STRAND      233    235       {ECO:0000244|PDB:1Z6C}.
FT   TURN        236    239       {ECO:0000244|PDB:1Z6C}.
FT   STRAND      240    242       {ECO:0000244|PDB:1Z6C}.
FT   HELIX       246    249       {ECO:0000244|PDB:1Z6C}.
FT   STRAND      253    256       {ECO:0000244|PDB:1Z6C}.
FT   STRAND      260    262       {ECO:0000244|PDB:1Z6C}.
FT   STRAND      269    271       {ECO:0000244|PDB:1Z6C}.
FT   STRAND      279    281       {ECO:0000244|PDB:1Z6C}.
SQ   SEQUENCE   676 AA;  75123 MW;  2B88A04F85403F25 CRC64;
     MRVLGGRCGA LLACLLLVLP VSEANFLSKQ QASQVLVRKR RANSLLEETK QGNLERECIE
     ELCNKEEARE VFENDPETDY FYPKYLVCLR SFQTGLFTAA RQSTNAYPDL RSCVNAIPDQ
     CSPLPCNEDG YMSCKDGKAS FTCTCKPGWQ GEKCEFDINE CKDPSNINGG CSQICDNTPG
     SYHCSCKNGF VMLSNKKDCK DVDECSLKPS ICGTAVCKNI PGDFECECPE GYRYNLKSKS
     CEDIDECSEN MCAQLCVNYP GGYTCYCDGK KGFKLAQDQK SCEVVSVCLP LNLDTKYELL
     YLAEQFAGVV LYLKFRLPEI SRFSAEFDFR TYDSEGVILY AESIDHSAWL LIALRGGKIE
     VQLKNEHTSK ITTGGDVINN GLWNMVSVEE LEHSISIKIA KEAVMDINKP GPLFKPENGL
     LETKVYFAGF PRKVESELIK PINPRLDGCI RSWNLMKQGA SGIKEIIQEK QNKHCLVTVE
     KGSYYPGSGI AQFHIDYNNV SSAEGWHVNV TLNIRPSTGT GVMLALVSGN NTVPFAVSLV
     DSTSEKSQDI LLSVENTVIY RIQALSLCSD QQSHLEFRVN RNNLELSTPL KIETISHEDL
     QRQLAVLDKA MKAKVATYLG GLPDVPFSAT PVNAFYNGCM EVNINGVQLD LDEAISKHND
     IRAHSCPSVW KKTKNS
//
ID   PRIO_HUMAN              Reviewed;         253 AA.
AC   P04156; O60489; P78446; Q15216; Q15221; Q27H91; Q5QPB4; Q8TBG0;
AC   Q96E70; Q9UP19;
DT   01-NOV-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1986, sequence version 1.
DT   17-FEB-2016, entry version 209.
DE   RecName: Full=Major prion protein;
DE            Short=PrP;
DE   AltName: Full=ASCR;
DE   AltName: Full=PrP27-30;
DE   AltName: Full=PrP33-35C;
DE   AltName: CD_antigen=CD230;
DE   Flags: Precursor;
GN   Name=PRNP; Synonyms=ALTPRP, PRIP, PRP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3755672; DOI=10.1089/dna.1986.5.315;
RA   Kretzschmar H.A., Stowring L.E., Westaway D., Stubblebine W.H.,
RA   Prusiner S.B., Dearmond S.J.;
RT   "Molecular cloning of a human prion protein cDNA.";
RL   DNA 5:315-324(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT 56-GLY--GLY-63 DEL.
RC   TISSUE=Brain;
RX   PubMed=1678248;
RA   Puckett C., Concannon P., Casey C., Hood L.E.;
RT   "Genomic structure of the human prion protein gene.";
RL   Am. J. Hum. Genet. 49:320-329(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9799790;
RA   Lee I.Y., Westaway D., Smit A.F.A., Wang K., Seto J., Chen L.,
RA   Acharya C., Ankener M., Baskin D., Cooper C., Yao H., Prusiner S.B.,
RA   Hood L.E.;
RT   "Complete genomic sequence and analysis of the prion protein gene
RT   region from three mammalian species.";
RL   Genome Res. 8:1022-1037(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GSD ARG-187.
RC   TISSUE=Blood;
RX   PubMed=10581485;
RX   DOI=10.1002/(SICI)1096-8628(19991215)88:6<653::AID-AJMG14>3.0.CO;2-E;
RA   Cervenakova L., Buetefisch C., Lee H.S., Taller I., Stone G.,
RA   Gibbs C.J. Jr., Brown P., Hallett M., Goldfarb L.G.;
RT   "Novel PRNP sequence variant associated with familial
RT   encephalopathy.";
RL   Am. J. Med. Genet. 88:653-656(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Prostate;
RA   Hryb D.J., Reynolds T.A., Nakhla A.M., Kahn S.M., Khan S.M.,
RA   Romas N.A., Rosner W.;
RT   "Cloning of human prostate prion protein cDNA.";
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Zhang J., Liu Y., Chen H., Jiang H., Lu W., Zhu X., Xie Q., Cai X.,
RA   Liu X.;
RT   "Analysis and comparison of several mammalian prion protein genes
RT   Prnp.";
RL   Submitted (FEB-2006) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 8-253.
RX   PubMed=3014653; DOI=10.1126/science.3014653;
RA   Liao Y.-C.J., Lebo R.V., Clawson G.A., Smuckler E.A.;
RT   "Human prion protein cDNA: molecular cloning, chromosomal mapping, and
RT   biological implications.";
RL   Science 233:364-367(1986).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 9-232, AND VARIANT 56-GLY--GLY-63
RP   DEL.
RC   TISSUE=Brain;
RX   PubMed=1363802; DOI=10.1093/hmg/1.6.443;
RA   Diedrich J.F., Knopman D.S., List J.F., Olson K., Frey W.H.,
RA   Emory C.R., Sung J.H., Haase A.T.;
RT   "Deletion in the prion protein gene in a demented patient.";
RL   Hum. Mol. Genet. 1:443-444(1992).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 8-253, AND VARIANT
RP   SCHIZOAFFECTIVE DISORDER SER-171.
RX   PubMed=9384372; DOI=10.1038/36757;
RA   Samaia H.B., Mari J.J., Vallada H.P., Moura R.P., Simpson A.J.G.,
RA   Brentani R.R.;
RT   "A prion-linked psychiatric disorder.";
RL   Nature 390:241-241(1997).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 41-85, AND VARIANT 56-GLY--GLY-63
RP   DEL.
RX   PubMed=7485229; DOI=10.1002/ajmg.1320600104;
RA   Perry R.T., Go R.C., Harrell L.E., Acton R.T.;
RT   "SSCP analysis and sequencing of the human prion protein gene (PRNP)
RT   detects two different 24 bp deletions in an atypical Alzheimer's
RT   disease family.";
RL   Am. J. Med. Genet. 60:12-18(1995).
RN   [13]
RP   PROTEIN SEQUENCE OF 58-85 AND 111-150.
RX   PubMed=1672107;
RA   Tagliavini F., Prelli F., Ghiso J., Bugiani O., Serban D.,
RA   Prusiner S.B., Farlow M.R., Ghetti B., Frangione B.;
RT   "Amyloid protein of Gerstmann-Straussler-Scheinker disease (Indiana
RT   kindred) is an 11 kd fragment of prion protein with an N-terminal
RT   glycine at codon 58.";
RL   EMBO J. 10:513-519(1991).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 84-91.
RX   PubMed=1683708; DOI=10.1073/pnas.88.23.10926;
RA   Goldfarb L.G., Brown P., McCombie W.R., Goldgaber D., Swergold G.D.,
RA   Wills P.R., Cervenakova L., Baron H., Gibbs C.J. Jr., Gajdusek D.C.;
RT   "Transmissible familial Creutzfeldt-Jakob disease associated with
RT   five, seven, and eight extra octapeptide coding repeats in the PRNP
RT   gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:10926-10930(1991).
RN   [15]
RP   INVOLVEMENT IN HDL1.
RX   PubMed=9792871; DOI=10.1086/302093;
RA   Xiang F., Almqvist E.W., Huq M., Lundin A., Hayden M.R., Edstroem L.,
RA   Anvret M., Zhang Z.;
RT   "A Huntington disease-like neurodegenerative disorder maps to
RT   chromosome 20p.";
RL   Am. J. Hum. Genet. 63:1431-1438(1998).
RN   [16]
RP   COPPER-BINDING, AND FUNCTION.
RX   PubMed=12732622; DOI=10.1074/jbc.M300394200;
RA   Mani K., Cheng F., Havsmark B., Jonsson M., Belting M., Fransson L.A.;
RT   "Prion, amyloid beta-derived Cu(II) ions, or free Zn(II) ions support
RT   S-nitroso-dependent autocleavage of glypican-1 heparan sulfate.";
RL   J. Biol. Chem. 278:38956-38965(2003).
RN   [17]
RP   GLYCOSYLATION AT ASN-181, VARIANT SENF ALA-183, AND CHARACTERIZATION
RP   OF VARIANT SENF ALA-183.
RX   PubMed=12214108;
RA   Capellari S., Zaidi S.I., Long A.C., Kwon E.E., Petersen R.B.;
RT   "The Thr183Ala mutation, not the loss of the first glycosylation site,
RT   alters the physical properties of the prion protein.";
RL   J. Alzheimers Dis. 2:27-35(2000).
RN   [18]
RP   COPPER-BINDING.
RX   PubMed=16144413; DOI=10.1021/ja053254z;
RA   Chattopadhyay M., Walter E.D., Newell D.J., Jackson P.J.,
RA   Aronoff-Spencer E., Peisach J., Gerfen G.J., Bennett B.,
RA   Antholine W.E., Millhauser G.L.;
RT   "The octarepeat domain of the prion protein binds Cu(II) with three
RT   distinct coordination modes at pH 7.4.";
RL   J. Am. Chem. Soc. 127:12647-12656(2005).
RN   [19]
RP   COPPER-BINDING, AND ZINC-BINDING.
RX   PubMed=18034490; DOI=10.1021/ja077146j;
RA   Walter E.D., Stevens D.J., Visconte M.P., Millhauser G.L.;
RT   "The prion protein is a combined zinc and copper binding protein: Zn2+
RT   alters the distribution of Cu2+ coordination modes.";
RL   J. Am. Chem. Soc. 129:15440-15441(2007).
RN   [20]
RP   ALTERNATIVE INITIATION (ISOFORM 2), SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF MET-1 AND MET-8.
RX   PubMed=19059915; DOI=10.1074/jbc.M804051200;
RA   Juanes M.E., Elvira G., Garcia-Grande A., Calero M., Gasset M.;
RT   "Biosynthesis of prion protein nucleocytoplasmic isoforms by
RT   alternative initiation of translation.";
RL   J. Biol. Chem. 284:2787-2794(2009).
RN   [21]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-197.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [22]
RP   FUNCTION, SUBCELLULAR LOCATION, AND DISEASE ASSOCIATION.
RX   PubMed=19936054; DOI=10.1371/journal.ppat.1000666;
RA   Taylor D.R., Whitehouse I.J., Hooper N.M.;
RT   "Glypican-1 mediates both prion protein lipid raft association and
RT   disease isoform formation.";
RL   PLoS Pathog. 5:E1000666-E1000666(2009).
RN   [23]
RP   COPPER-BINDING.
RX   PubMed=19381258; DOI=10.1371/journal.ppat.1000390;
RA   Stevens D.J., Walter E.D., Rodriguez A., Draper D., Davies P.,
RA   Brown D.R., Millhauser G.L.;
RT   "Early onset prion disease from octarepeat expansion correlates with
RT   copper or zinc binding properties.";
RL   PLoS Pathog. 5:E1000390-E1000390(2009).
RN   [24]
RP   SUBUNIT, AND DOMAIN.
RX   PubMed=20375014; DOI=10.1074/jbc.M110.111815;
RA   Adrover M., Pauwels K., Prigent S., de Chiara C., Xu Z., Chapuis C.,
RA   Pastore A., Rezaei H.;
RT   "Prion fibrillization is mediated by a native structural element that
RT   comprises helices H2 and H3.";
RL   J. Biol. Chem. 285:21004-21012(2010).
RN   [25]
RP   COPPER-BINDING, CIRCULAR DICHROISM, DOMAIN, FUNCTION, AND SUBUNIT.
RX   PubMed=20564047; DOI=10.1002/jcb.22743;
RA   Wu D., Zhang W., Luo Q., Luo K., Huang L., Wang W., Huang T., Chen R.,
RA   Lin Y., Pang D., Xiao G.;
RT   "Copper (II) promotes the formation of soluble neurotoxic PrP
RT   oligomers in acidic environment.";
RL   J. Cell. Biochem. 111:627-633(2010).
RN   [26]
RP   BICISTRONIC GENE.
RX   PubMed=21478263; DOI=10.1096/fj.10-173815;
RA   Vanderperre B., Staskevicius A.B., Tremblay G., McCoy M.,
RA   O'Neill M.A., Cashman N.R., Roucou X.;
RT   "An overlapping reading frame in the PRNP gene encodes a novel
RT   polypeptide distinct from the prion protein.";
RL   FASEB J. 25:2373-2386(2011).
RN   [27]
RP   INTERACTION WITH KIAA1191.
RX   PubMed=21153684; DOI=10.1007/s11010-010-0690-4;
RA   Mishra M., Inoue N., Heese K.;
RT   "Characterizing the novel protein p33MONOX.";
RL   Mol. Cell. Biochem. 350:127-134(2011).
RN   [28]
RP   STRUCTURE BY NMR OF 90-231 OF MUTANT LYS-200.
RX   PubMed=10954699; DOI=10.1074/jbc.C000483200;
RA   Zhang Y., Swietnicki W., Zagorski M.G., Surewicz W.K.,
RA   Soennichsen F.D.;
RT   "Solution structure of the E200K variant of human prion protein.
RT   Implications for the mechanism of pathogenesis in familial prion
RT   diseases.";
RL   J. Biol. Chem. 275:33650-33654(2000).
RN   [29]
RP   STRUCTURE BY NMR OF 23-230.
RX   PubMed=10618385; DOI=10.1073/pnas.97.1.145;
RA   Zahn R., Liu A., Luhrs T., Riek R., von Schroetter C.,
RA   Lopez Garcia F., Billeter M., Calzolai L., Wider G., Wuethrich K.;
RT   "NMR solution structure of the human prion protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:145-150(2000).
RN   [30]
RP   STRUCTURE BY NMR OF 118-221.
RX   PubMed=10900000; DOI=10.1073/pnas.97.15.8340;
RA   Calzolai L., Lysek D.A., Guntert P., von Schroetter C., Riek R.,
RA   Zahn R., Wuethrich K.;
RT   "NMR structures of three single-residue variants of the human prion
RT   protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:8340-8345(2000).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 119-226, DOMAIN, AND SUBUNIT.
RX   PubMed=11524679; DOI=10.1038/nsb0901-770;
RA   Knaus K.J., Morillas M., Swietnicki W., Malone M., Surewicz W.K.,
RA   Yee V.C.;
RT   "Crystal structure of the human prion protein reveals a mechanism for
RT   oligomerization.";
RL   Nat. Struct. Biol. 8:770-774(2001).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (0.75 ANGSTROMS) OF 61-65 IN COMPLEX WITH COPPER
RP   ION, DOMAIN, AND SUBUNIT.
RX   PubMed=11900542; DOI=10.1021/bi011922x;
RA   Burns C.S., Aronoff-Spencer E., Dunham C.M., Lario P., Avdievich N.I.,
RA   Antholine W.E., Olmstead M.M., Vrielink A., Gerfen G.J., Peisach J.,
RA   Scott W.G., Millhauser G.L.;
RT   "Molecular features of the copper binding sites in the octarepeat
RT   domain of the prion protein.";
RL   Biochemistry 41:3991-4001(2002).
RN   [33]
RP   STRUCTURE BY NMR OF 61-68, DISULFIDE BOND, AND SUBUNIT.
RX   PubMed=14623188; DOI=10.1016/j.jmb.2003.09.048;
RA   Zahn R.;
RT   "The octapeptide repeats in mammalian prion protein constitute a pH-
RT   dependent folding and aggregation site.";
RL   J. Mol. Biol. 334:477-488(2003).
RN   [34]
RP   REVIEW ON VARIANTS.
RX   PubMed=8364585; DOI=10.1002/humu.1380020303;
RA   Palmer M.S., Collinge J.;
RT   "Mutations and polymorphisms in the prion protein gene.";
RL   Hum. Mutat. 2:168-173(1993).
RN   [35]
RP   REVIEW ON VARIANTS, AND INVOLVEMENT IN PRION DISEASES.
RX   PubMed=8105771; DOI=10.1001/archneur.1993.00540110011002;
RA   Prusiner S.B.;
RT   "Genetic and infectious prion diseases.";
RL   Arch. Neurol. 50:1129-1153(1993).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (0.85 ANGSTROMS) OF 170-175, SUBUNIT, AND
RP   DOMAIN.
RX   PubMed=17468747; DOI=10.1038/nature05695;
RA   Sawaya M.R., Sambashivan S., Nelson R., Ivanova M.I., Sievers S.A.,
RA   Apostol M.I., Thompson M.J., Balbirnie M., Wiltzius J.J.,
RA   McFarlane H.T., Madsen A.O., Riekel C., Eisenberg D.;
RT   "Atomic structures of amyloid cross-beta spines reveal varied steric
RT   zippers.";
RL   Nature 447:453-457(2007).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 119-231 IN COMPLEX WITH FAB
RP   FRAGMENT OF MONOCLONAL ANTIBODY ICSM 18, AND SUBUNIT.
RX   PubMed=19204296; DOI=10.1073/pnas.0809170106;
RA   Antonyuk S.V., Trevitt C.R., Strange R.W., Jackson G.S., Sangar D.,
RA   Batchelor M., Cooper S., Fraser C., Jones S., Georgiou T.,
RA   Khalili-Shirazi A., Clarke A.R., Hasnain S.S., Collinge J.;
RT   "Crystal structure of human prion protein bound to a therapeutic
RT   antibody.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:2554-2558(2009).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 125-227 OF VARIANT VAL-129,
RP   VARIANT VAL-129, VARIANT CJD ASN-178, VARIANT FFI ASN-178, VARIANT GSD
RP   SER-198, SUBUNIT, AND DOMAIN.
RX   PubMed=19927125; DOI=10.1038/emboj.2009.333;
RA   Lee S., Antony L., Hartmann R., Knaus K.J., Surewicz K.,
RA   Surewicz W.K., Yee V.C.;
RT   "Conformational diversity in prion protein variants influences
RT   intermolecular beta-sheet formation.";
RL   EMBO J. 29:251-262(2010).
RN   [39]
RP   VARIANT GSD LEU-102.
RX   PubMed=2564168; DOI=10.1038/338342a0;
RA   Hsiao K., Baker H.F., Crow T.J., Poulter M., Owen F.,
RA   Terwilliger J.D., Westaway D., Ott J., Pursiner S.B.;
RT   "Linkage of a prion protein missense variant to Gerstmann-Straussler
RT   syndrome.";
RL   Nature 338:342-345(1989).
RN   [40]
RP   VARIANTS LEU-102; VAL-117 AND VAL-129.
RX   PubMed=2783132; DOI=10.1016/0006-291X(89)92317-6;
RA   Doh-Ura K., Tateishi J., Sasaki H., Kitamoto T., Sakaki Y.;
RT   "Pro-->Leu change at position 102 of prion protein is the most common
RT   but not the sole mutation related to Gerstmann-Straussler syndrome.";
RL   Biochem. Biophys. Res. Commun. 163:974-979(1989).
RN   [41]
RP   VARIANT FFI ASN-178.
RX   PubMed=1347910; DOI=10.1212/WNL.42.3.669;
RA   Medori R., Montagna P., Tritschler H.J., Leblanc A., Cortelli P.,
RA   Tinuper P., Lugaresi E., Gambetti P.;
RT   "Fatal familial insomnia: a second kindred with mutation of prion
RT   protein gene at codon 178.";
RL   Neurology 42:669-670(1992).
RN   [42]
RP   VARIANT CJD ASN-178.
RX   PubMed=1671440; DOI=10.1016/0140-6736(91)91198-4;
RA   Goldfarb L.G., Haltia M., Brown P., Nieto A., Kovanen J.,
RA   McCombie W.R., Trapp S., Gajdusek D.C.;
RT   "New mutation in scrapie amyloid precursor gene (at codon 178) in
RT   Finnish Creutzfeldt-Jakob kindred.";
RL   Lancet 337:425-425(1991).
RN   [43]
RP   VARIANT CJD LYS-200.
RX   PubMed=1975028; DOI=10.1016/0140-6736(90)92073-Q;
RA   Goldfarb L., Mitrova E., Brown P., Toh B.K., Gajdusek D.C.;
RT   "Mutation in codon 200 of scrapie amyloid protein gene in two clusters
RT   of Creutzfeldt-Jakob disease in Slovakia.";
RL   Lancet 336:514-515(1990).
RN   [44]
RP   VARIANT GSD ARG-217.
RX   PubMed=1363810; DOI=10.1038/ng0492-68;
RA   Hsiao K., Dlouhy S.R., Farlow M.R., Cass C., da Costa M.,
RA   Conneally P.M., Hodes M.E., Ghetti B., Prusiner S.B.;
RT   "Mutant prion proteins in Gerstmann-Straussler-Scheinker disease with
RT   neurofibrillary tangles.";
RL   Nat. Genet. 1:68-71(1992).
RN   [45]
RP   VARIANT VAL-129, VARIANT CJD ASN-178, VARIANT FFI ASN-178,
RP   CHARACTERIZATION OF VARIANT VAL-129, CHARACTERIZATION OF VARIANT CJD
RP   ASN-178, CHARACTERIZATION OF VARIANT FFI ASN-178, AND POLYMORPHISM.
RX   PubMed=1439789; DOI=10.1126/science.1439789;
RA   Goldfarb L.G., Petersen R.B., Tabaton M., Brown P., LeBlanc A.C.,
RA   Montagna P., Cortelli P., Julien J., Vital C., Pendelbury W.W.;
RT   "Fatal familial insomnia and familial Creutzfeldt-Jakob disease:
RT   disease phenotype determined by a DNA polymorphism.";
RL   Science 258:806-808(1992).
RN   [46]
RP   VARIANTS CJD ILE-180 AND ARG-232.
RX   PubMed=8461023; DOI=10.1006/bbrc.1993.1275;
RA   Kitamoto T., Ohta M., Doh-Ura K., Hitoshi S., Terao Y., Tateishi J.;
RT   "Novel missense variants of prion protein in Creutzfeldt-Jakob disease
RT   or Gerstmann-Straussler syndrome.";
RL   Biochem. Biophys. Res. Commun. 191:709-714(1993).
RN   [47]
RP   VARIANT CJD ILE-210.
RX   PubMed=7902693; DOI=10.1002/ana.410340608;
RA   Pocchiari M., Salvatore M., Cutruzzola F., Genuardi M.,
RA   Allcatelli C.T., Masullo C., Macchi G., Alema G., Galgani S., Xi Y.G.,
RA   Petraroli R., Silvestrini M.C., Brunori M.;
RT   "A new point mutation of the prion protein gene in Creutzfeldt-Jakob
RT   disease.";
RL   Ann. Neurol. 34:802-807(1993).
RN   [48]
RP   VARIANT GSD LEU-105.
RX   PubMed=7902972; DOI=10.1212/WNL.43.12.2723-a;
RA   Yamada M., Itoh Y., Fujigasaki H., Naruse S., Kaneko K., Kitamoto T.,
RA   Tateishi J., Otomo E., Hayakawa M., Tanaka J., Matsushita M.,
RA   Miyatake T.;
RT   "A missense mutation at codon 105 with codon 129 polymorphism of the
RT   prion protein gene in a new variant of Gerstmann-Straussler-Scheinker
RT   disease.";
RL   Neurology 43:2723-2724(1993).
RN   [49]
RP   VARIANT GSD LEU-105.
RX   PubMed=7699395; DOI=10.1016/0022-510X(94)90138-4;
RA   Itoh Y., Yamada M., Hayakawa M., Shozawa T., Tanaka J., Matsushita M.,
RA   Kitamoto T., Tateishi J., Otomo E.;
RT   "A variant of Gerstmann-Straussler-Scheinker disease carrying codon
RT   105 mutation with codon 129 polymorphism of the prion protein gene: a
RT   clinicopathological study.";
RL   J. Neurol. Sci. 127:77-86(1994).
RN   [50]
RP   VARIANT CJD LYS-200.
RX   PubMed=7906019; DOI=10.1212/WNL.44.2.299;
RA   Inoue I., Kitamoto T., Doh-Ura K., Shii H., Goto I., Tateishi J.;
RT   "Japanese family with Creutzfeldt-Jakob disease with codon 200 point
RT   mutation of the prion protein gene.";
RL   Neurology 44:299-301(1994).
RN   [51]
RP   VARIANT CJD LYS-200.
RX   PubMed=7913755; DOI=10.1098/rstb.1994.0033;
RA   Gabizon R., Rosenman H., Meiner Z., Kahana I., Kahana E., Shugart Y.,
RA   Ott J., Prusiner S.B.;
RT   "Mutation in codon 200 and polymorphism in codon 129 of the prion
RT   protein gene in Libyan Jews with Creutzfeldt-Jakob disease.";
RL   Philos. Trans. R. Soc. Lond., B, Biol. Sci. 343:385-390(1994).
RN   [52]
RP   VARIANT GSD LEU-102.
RX   PubMed=7783876; DOI=10.1212/WNL.45.6.1127;
RA   Young K., Jones C.K., Piccardo P., Lazzarini A., Golbe L.I.,
RA   Zimmerman T.R., Dickson D.W., McLachlan D.C., St George-Hyslop P.H.,
RA   Lennox A.;
RT   "Gerstmann-Straussler-Scheinker disease with mutation at codon 102 and
RT   methionine at codon 129 of PRNP in previously unreported patients.";
RL   Neurology 45:1127-1134(1995).
RN   [53]
RP   VARIANT GSD LEU-102, AND VARIANT LYS-219.
RX   PubMed=8797472; DOI=10.1212/WNL.47.3.734;
RA   Barbanti P., Fabbrini G., Salvatore M., Petraroli R., Cardone F.,
RA   Maras B., Equestre M., Macchi G., Lenzi G.L., Pocchiari M.;
RT   "Polymorphism at codon 129 or codon 219 of PRNP and clinical
RT   heterogeneity in a previously unreported family with Gerstmann-
RT   Straussler-Scheinker disease (PrP-P102L mutation).";
RL   Neurology 47:734-741(1996).
RN   [54]
RP   VARIANT CJD HIS-208.
RX   PubMed=8909447; DOI=10.1212/WNL.47.5.1305;
RA   Mastrianni J.A., Iannicola C., Myers R.M., Dearmond S., Prusiner S.B.;
RT   "Mutation of the prion protein gene at codon 208 in familial
RT   Creutzfeldt-Jakob disease.";
RL   Neurology 47:1305-1312(1996).
RN   [55]
RP   VARIANT SENF ALA-183.
RX   PubMed=9266722; DOI=10.1002/ana.410420203;
RA   Nitrini R., Rosemberg S., Passos-Bueno M.R., da Silva L.S.,
RA   Iughetti P., Papadopoulos M., Carrilho P.M., Caramelli P.,
RA   Albrecht S., Zatz M., Leblanc A.;
RT   "Familial spongiform encephalopathy associated with a novel prion
RT   protein gene mutation.";
RL   Ann. Neurol. 42:138-146(1997).
RN   [56]
RP   VARIANTS GSD ASN-202 AND PRO-212.
RX   PubMed=9786248; DOI=10.1097/00005072-199810000-00010;
RA   Piccardo P., Dlouhy S.R., Lievens P.M., Young K., Bird T.D.,
RA   Nochlin D., Dickson D.W., Vinters H.V., Zimmerman T.R.,
RA   Mackenzie I.R., Kish S.J., Ang L.C., De Carli C., Pocchiari M.,
RA   Brown P., Gibbs C.J. Jr., Gajdusek D.C., Bugiani O., Ironside J.,
RA   Tagliavini F., Ghetti B.;
RT   "Phenotypic variability of Gerstmann-Straussler-Scheinker disease is
RT   associated with prion protein heterogeneity.";
RL   J. Neuropathol. Exp. Neurol. 57:979-988(1998).
RN   [57]
RP   VARIANT LYS-219, CHARACTERIZATION OF VARIANT LYS-219, AND
RP   POLYMORPHISM.
RX   PubMed=9482303; DOI=10.1016/S0140-6736(05)78358-6;
RA   Shibuya S., Higuchi J., Shin R.W., Tateishi J., Kitamoto T.;
RT   "Protective prion protein polymorphisms against sporadic Creutzfeldt-
RT   Jakob disease.";
RL   Lancet 351:419-419(1998).
RN   [58]
RP   VARIANTS ARG-188 AND SER-238.
RX   PubMed=10987652; DOI=10.1007/s004390051096;
RA   Windl O., Giese A., Schulz-Schaeffer W., Zerr I., Skworc K.,
RA   Arendt S., Oberdieck C., Bodemer M., Poser S., Kretzschmar H.A.;
RT   "Molecular genetics of human prion diseases in Germany.";
RL   Hum. Genet. 105:244-252(1999).
RN   [59]
RP   VARIANTS EARLY-ONSET DEMENTIA LEU-102; ALA-183 AND LYS-188.
RX   PubMed=10631141; DOI=10.1086/302702;
RA   Finckh U., Mueller-Thomsen T., Mann U., Eggers C., Marksteiner J.,
RA   Meins W., Binetti G., Alberici A., Hock C., Nitsch R.M., Gal A.;
RT   "High prevalence of pathogenic mutations in patients with early-onset
RT   dementia detected by sequence analyses of four different genes.";
RL   Am. J. Hum. Genet. 66:110-117(2000).
RN   [60]
RP   VARIANTS CJD LYS-196; ILE-203 AND GLN-211.
RX   PubMed=10790216;
RX   DOI=10.1002/(SICI)1098-1004(200005)15:5<482::AID-HUMU16>3.0.CO;2-1;
RA   Peoc'h K., Manivet P., Beaudry P., Attane F., Besson G., Didier H.,
RA   Delasnerie-Laupretre N., Laplanche J.-L.;
RT   "Identification of three novel mutations (E196K, V203I, E211Q) in the
RT   prion protein gene (PRNP) in inherited prion diseases with
RT   Creutzfeldt-Jakob disease phenotype.";
RL   Hum. Mutat. 15:482-482(2000).
RN   [61]
RP   VARIANT GSD VAL-131.
RX   PubMed=11709001; DOI=10.1001/archneur.58.11.1899;
RA   Panegyres P.K., Toufexis K., Kakulas B.A., Cernevakova L., Brown P.,
RA   Ghetti B., Piccardo P., Dlouhy S.R.;
RT   "A new PRNP mutation (G131V) associated with Gerstmann-Straussler-
RT   Scheinker disease.";
RL   Arch. Neurol. 58:1899-1902(2001).
RN   [62]
RP   VARIANT VAL-129, AND CHARACTERIZATION OF VARIANT VAL-129.
RX   PubMed=12690204; DOI=10.1126/science.1083320;
RA   Mead S., Stumpf M.P., Whitfield J., Beck J.A., Poulter M.,
RA   Campbell T., Uphill J.B., Goldstein D., Alpers M., Fisher E.M.,
RA   Collinge J.;
RT   "Balancing selection at the prion protein gene consistent with
RT   prehistoric kurulike epidemics.";
RL   Science 300:640-643(2003).
RN   [63]
RP   VARIANT VAL-127, AND INVOLVEMENT IN KURU.
RX   PubMed=19923577; DOI=10.1056/NEJMoa0809716;
RA   Mead S., Whitfield J., Poulter M., Shah P., Uphill J., Campbell T.,
RA   Al-Dujaily H., Hummerich H., Beck J., Mein C.A., Verzilli C.,
RA   Whittaker J., Alpers M.P., Collinge J.;
RT   "A novel protective prion protein variant that colocalizes with kuru
RT   exposure.";
RL   N. Engl. J. Med. 361:2056-2065(2009).
RN   [64]
RP   VARIANT VAL-127, CHARACTERIZATION OF VARIANT VAL-127, INVOLVEMENT IN
RP   KURU, AND POLYMORPHISM.
RX   PubMed=26061765; DOI=10.1038/nature14510;
RA   Asante E.A., Smidak M., Grimshaw A., Houghton R., Tomlinson A.,
RA   Jeelani A., Jakubcova T., Hamdan S., Richard-Londt A., Linehan J.M.,
RA   Brandner S., Alpers M., Whitfield J., Mead S., Wadsworth J.D.,
RA   Collinge J.;
RT   "A naturally occurring variant of the human prion protein completely
RT   prevents prion disease.";
RL   Nature 522:478-481(2015).
CC   -!- FUNCTION: Its primary physiological function is unclear. Has
CC       cytoprotective activity against internal or environmental
CC       stresses. May play a role in neuronal development and synaptic
CC       plasticity. May be required for neuronal myelin sheath
CC       maintenance. May play a role in iron uptake and iron homeostasis.
CC       Soluble oligomers are toxic to cultured neuroblastoma cells and
CC       induce apoptosis (in vitro) (PubMed:12732622, PubMed:19936054,
CC       PubMed:20564047). Association with GPC1 (via its heparan sulfate
CC       chains) targets PRNP to lipid rafts. Also provides Cu(2+) or
CC       ZN(2+) for the ascorbate-mediated GPC1 deaminase degradation of
CC       its heparan sulfate side chains (By similarity).
CC       {ECO:0000250|UniProtKB:P04925, ECO:0000269|PubMed:12732622,
CC       ECO:0000269|PubMed:19936054, ECO:0000269|PubMed:20564047,
CC       ECO:0000305}.
CC   -!- SUBUNIT: Monomer and homodimer. Has a tendency to aggregate into
CC       amyloid fibrils containing a cross-beta spine, formed by a steric
CC       zipper of superposed beta-strands. Soluble oligomers may represent
CC       an intermediate stage on the path to fibril formation. Copper
CC       binding may promote oligomerization (PubMed:11524679,
CC       PubMed:11900542, PubMed:14623188, PubMed:17468747,
CC       PubMed:19204296, PubMed:19927125, PubMed:20375014,
CC       PubMed:20564047). Interacts with GRB2, APP, ERI3/PRNPIP and SYN1.
CC       Mislocalized cytosolically exposed PrP interacts with MGRN1; this
CC       interaction alters MGRN1 subcellular location and causes lysosomal
CC       enlargement (By similarity). Interacts with KIAA1191
CC       (PubMed:21153684). {ECO:0000250|UniProtKB:P04925,
CC       ECO:0000269|PubMed:11524679, ECO:0000269|PubMed:11900542,
CC       ECO:0000269|PubMed:14623188, ECO:0000269|PubMed:17468747,
CC       ECO:0000269|PubMed:19204296, ECO:0000269|PubMed:19927125,
CC       ECO:0000269|PubMed:20375014, ECO:0000269|PubMed:20564047,
CC       ECO:0000269|PubMed:21153684}.
CC   -!- INTERACTION:
CC       Self; NbExp=17; IntAct=EBI-977302, EBI-977302;
CC       P05067:APP; NbExp=3; IntAct=EBI-977302, EBI-77613;
CC       P05067-4:APP; NbExp=2; IntAct=EBI-977302, EBI-302641;
CC       Q9BSJ6:FAM64A; NbExp=5; IntAct=EBI-977302, EBI-2568609;
CC       P31424-2:Grm5 (xeno); NbExp=4; IntAct=EBI-8830282, EBI-8830305;
CC       P49639:HOXA1; NbExp=4; IntAct=EBI-977302, EBI-740785;
CC       P10636:MAPT; NbExp=2; IntAct=EBI-977302, EBI-366182;
CC       P29372:MPG; NbExp=4; IntAct=EBI-977302, EBI-1043398;
CC       P52480:Pkm (xeno); NbExp=5; IntAct=EBI-8830282, EBI-647785;
CC       Q9H4B4:PLK3; NbExp=4; IntAct=EBI-977302, EBI-751877;
CC       P10279:PRNP (xeno); NbExp=5; IntAct=EBI-977302, EBI-7430632;
CC       P23907:PRNP (xeno); NbExp=3; IntAct=EBI-977302, EBI-7670302;
CC       P04925:Prnp (xeno); NbExp=3; IntAct=EBI-977302, EBI-768613;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Lipid-anchor, GPI-anchor
CC       {ECO:0000269|PubMed:19936054}. Golgi apparatus
CC       {ECO:0000250|UniProtKB:P04925}. Note=Targeted to lipid rafts via
CC       association with the heparan sulfate chains of GPC1. Colocates, in
CC       the presence of Cu(2+), to vesicles in para- and perinuclear
CC       regions, where both proteins undergo internalization. Heparin
CC       displaces PRNP from lipid rafts and promotes endocytosis.
CC       {ECO:0000269|PubMed:19936054}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm
CC       {ECO:0000269|PubMed:19059915}. Nucleus
CC       {ECO:0000269|PubMed:19059915}. Note=Accumulates outside the
CC       secretory route in the cytoplasm, from where it relocates to the
CC       nucleus. {ECO:0000269|PubMed:19059915}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=3;
CC       Name=1; Synonyms=PrP;
CC         IsoId=P04156-1; Sequence=Displayed;
CC       Name=2; Synonyms=PrP(M8);
CC         IsoId=P04156-2; Sequence=VSP_039045;
CC       Name=3; Synonyms=AltPrP;
CC         IsoId=F7VJQ1-1; Sequence=External;
CC   -!- DOMAIN: The normal, monomeric form, PRPN(C), has a mainly alpha-
CC       helical structure. Misfolding of this form produces a disease-
CC       associated, protease-resistant form, PRPN (Sc), accompanied by a
CC       large increase of the beta-sheet content and formation of amyloid
CC       fibrils. These fibrils consist of a cross-beta spine, formed by a
CC       steric zipper of superposed beta-strands. Disease mutations may
CC       favor intermolecular contacts via short beta strands, and may
CC       thereby trigger oligomerization. In addition, the heparan-sulfate
CC       proteoglycan, GPC1, promotes the association of PRPN (C) to lipid
CC       rafts and appears to facilitate the conversion to PRPN (Sc).
CC       {ECO:0000269|PubMed:17468747, ECO:0000269|PubMed:19927125,
CC       ECO:0000269|PubMed:20564047}.
CC   -!- DOMAIN: Contains an N-terminal region composed of octamer repeats.
CC       At low copper concentrations, the sidechains of His residues from
CC       three or four repeats contribute to the binding of a single copper
CC       ion. Alternatively, a copper ion can be bound by interaction with
CC       the sidechain and backbone amide nitrogen of a single His residue.
CC       The observed copper binding stoichiometry suggests that two repeat
CC       regions cooperate to stabilize the binding of a single copper ion.
CC       At higher copper concentrations, each octamer can bind one copper
CC       ion by interactions with the His sidechain and Gly backbone atoms.
CC       A mixture of binding types may occur, especially in the case of
CC       octamer repeat expansion. Copper binding may stabilize the
CC       conformation of this region and may promote oligomerization.
CC       {ECO:0000269|PubMed:11524679, ECO:0000269|PubMed:11900542,
CC       ECO:0000269|PubMed:20375014}.
CC   -!- PTM: The glycosylation pattern (the amount of mono-, di- and non-
CC       glycosylated forms or glycoforms) seems to differ in normal and
CC       CJD prion. {ECO:0000269|PubMed:12214108}.
CC   -!- PTM: Isoform 2 is sumoylated with SUMO1.
CC       {ECO:0000250|UniProtKB:P04273}.
CC   -!- POLYMORPHISM: The five tandem octapeptide repeats region is highly
CC       unstable. Insertions or deletions of octapeptide repeat units are
CC       associated to prion disease. {ECO:0000269|PubMed:1683708}.
CC   -!- POLYMORPHISM: A number of polymorphisms confer resistance to prion
CC       diseases (PubMed:1439789, PubMed:9482303, PubMed:19923577,
CC       PubMed:26061765). Val-127 has been selected for in response to the
CC       Kuru epidemic and confers resistance to prion disease by acting as
CC       a 'dominant negative' inhibitor of prion conversion
CC       (PubMed:26061765). Val-127 is not only itself resistant to
CC       conformational conversion, but also inhibits conversion of wild-
CC       type proteins. Confers protection against classical Creutzfeldt-
CC       Jakob disease (CJD) and Kuru in the heterozygous state, but can be
CC       infected with variant CJD prions, resulting from exposure to
CC       bovine spongiform encephalopathy prions. Confers complete
CC       resistance to all prion strains when homozygous (PubMed:26061765).
CC       Always associated with M-129 variant (PubMed:26061765). Val-129
CC       confers relative protection against acquired, sporadic and some
CC       inherited prion diseases in the heterozygous state, possibly by
CC       preventing homodimerization (PubMed:1439789). Lys-219 confers
CC       relative protection against sporadic Creutzfeldt-Jakob disease
CC       (CJD) in the heterozygous state (PubMed:9482303).
CC       {ECO:0000269|PubMed:1439789, ECO:0000269|PubMed:26061765,
CC       ECO:0000269|PubMed:9482303}.
CC   -!- DISEASE: Note=PrP is found in high quantity in the brain of humans
CC       and animals infected with neurodegenerative diseases known as
CC       transmissible spongiform encephalopathies or prion diseases, like:
CC       Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI),
CC       Gerstmann-Straussler disease (GSD), Huntington disease-like type 1
CC       (HDL1) and kuru in humans; scrapie in sheep and goat; bovine
CC       spongiform encephalopathy (BSE) in cattle; transmissible mink
CC       encephalopathy (TME); chronic wasting disease (CWD) of mule deer
CC       and elk; feline spongiform encephalopathy (FSE) in cats and exotic
CC       ungulate encephalopathy (EUE) in nyala and greater kudu. The prion
CC       diseases illustrate three manifestations of CNS degeneration: (1)
CC       infectious (2) sporadic and (3) dominantly inherited forms. TME,
CC       CWD, BSE, FSE, EUE are all thought to occur after consumption of
CC       prion-infected foodstuffs. {ECO:0000269|PubMed:8105771}.
CC   -!- DISEASE: Creutzfeldt-Jakob disease (CJD) [MIM:123400]: Occurs
CC       primarily as a sporadic disorder (1 per million), while 10-15% are
CC       familial. Accidental transmission of CJD to humans appears to be
CC       iatrogenic (contaminated human growth hormone (HGH), corneal
CC       transplantation, electroencephalographic electrode implantation,
CC       etc.). Epidemiologic studies have failed to implicate the
CC       ingestion of infected animal meat in the pathogenesis of CJD in
CC       human. The triad of microscopic features that characterize the
CC       prion diseases consists of (1) spongiform degeneration of neurons,
CC       (2) severe astrocytic gliosis that often appears to be out of
CC       proportion to the degree of nerve cell loss, and (3) amyloid
CC       plaque formation. CJD is characterized by progressive dementia and
CC       myoclonic seizures, affecting adults in mid-life. Some patients
CC       present sleep disorders, abnormalities of high cortical function,
CC       cerebellar and corticospinal disturbances. The disease ends in
CC       death after a 3-12 months illness. {ECO:0000269|PubMed:10790216,
CC       ECO:0000269|PubMed:1439789, ECO:0000269|PubMed:1671440,
CC       ECO:0000269|PubMed:1975028, ECO:0000269|PubMed:19927125,
CC       ECO:0000269|PubMed:7902693, ECO:0000269|PubMed:7906019,
CC       ECO:0000269|PubMed:7913755, ECO:0000269|PubMed:8461023,
CC       ECO:0000269|PubMed:8909447}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Fatal familial insomnia (FFI) [MIM:600072]: Autosomal
CC       dominant disorder and is characterized by neuronal degeneration
CC       limited to selected thalamic nuclei and progressive insomnia.
CC       {ECO:0000269|PubMed:1347910, ECO:0000269|PubMed:1439789,
CC       ECO:0000269|PubMed:19927125}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Gerstmann-Straussler disease (GSD) [MIM:137440]: A rare
CC       inherited prion disease characterized by adult onset of memory
CC       loss, dementia, ataxia, and pathologic deposition of amyloid-like
CC       plaques in the brain. GSD presents with progressive limb and
CC       truncal ataxia, dysarthria, and cognitive decline in the thirties
CC       and forties, and the average disease duration is 7 years.
CC       {ECO:0000269|PubMed:10581485, ECO:0000269|PubMed:11709001,
CC       ECO:0000269|PubMed:1363810, ECO:0000269|PubMed:1439789,
CC       ECO:0000269|PubMed:19927125, ECO:0000269|PubMed:2564168,
CC       ECO:0000269|PubMed:7699395, ECO:0000269|PubMed:7783876,
CC       ECO:0000269|PubMed:7902972, ECO:0000269|PubMed:8797472,
CC       ECO:0000269|PubMed:9786248}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Huntington disease-like 1 (HDL1) [MIM:603218]: Autosomal
CC       dominant, early-onset neurodegenerative disorder with prominent
CC       psychiatric features. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC       {ECO:0000269|PubMed:9792871}.
CC   -!- DISEASE: Kuru (KURU) [MIM:245300]: Kuru is transmitted during
CC       ritualistic cannibalism, among natives of the New Guinea
CC       highlands. Patients exhibit various movement disorders like
CC       cerebellar abnormalities, rigidity of the limbs, and clonus.
CC       Emotional lability is present, and dementia is conspicuously
CC       absent. Death usually occurs from 3 to 12 month after onset.
CC       {ECO:0000269|PubMed:19923577, ECO:0000269|PubMed:26061765}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Spongiform encephalopathy with neuropsychiatric features
CC       (SENF) [MIM:606688]: Autosomal dominant presenile dementia with a
CC       rapidly progressive and protracted clinical course. The dementia
CC       was characterized clinically by frontotemporal features, including
CC       early personality changes. Some patients had memory loss, several
CC       showed aggressiveness, hyperorality and verbal stereotypy, others
CC       had parkinsonian symptoms. {ECO:0000269|PubMed:9266722}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- MISCELLANEOUS: This protein is produced by a bicistronic gene
CC       which also produces the The alternative prion protein/AltPrP (AC
CC       F7VJQ1) from an overlapping reading frame.
CC       {ECO:0000305|PubMed:21478263}.
CC   -!- MISCELLANEOUS: The alternative prion protein/AltPrP (AC F7VJQ1)
CC       and PRNP have no apparent direct functional relation since a
CC       mutation that removes the start codon of the AltPrP has no
CC       apparent effect on the biology of PRNP. In mouse and hamster, the
CC       alternative initiation AUG codon is absent and is replaced by a
CC       GUG codon. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the prion family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=The Official Mad Cow Disease Home Page;
CC       URL="http://www.mad-cow.org/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=PRNP entry;
CC       URL="https://en.wikipedia.org/wiki/PRNP";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M13899; AAA60182.1; -; mRNA.
DR   EMBL; X83416; CAA58442.1; -; Genomic_DNA.
DR   EMBL; U29185; AAC78725.1; -; Genomic_DNA.
DR   EMBL; AF076976; AAD46098.1; -; Genomic_DNA.
DR   EMBL; AY008282; AAG21693.1; -; mRNA.
DR   EMBL; DQ408531; ABD63004.1; -; Genomic_DNA.
DR   EMBL; AL133396; CAB75503.1; -; Genomic_DNA.
DR   EMBL; AL133396; CAI19053.1; -; Genomic_DNA.
DR   EMBL; BC012844; AAH12844.1; -; mRNA.
DR   EMBL; BC022532; AAH22532.1; -; mRNA.
DR   EMBL; D00015; BAA00011.1; -; mRNA.
DR   EMBL; M13667; AAA19664.1; -; mRNA.
DR   EMBL; M81929; AAB59442.1; -; Genomic_DNA.
DR   EMBL; M81930; AAB59443.1; -; Genomic_DNA.
DR   EMBL; AF030575; AAC05365.1; -; Genomic_DNA.
DR   EMBL; S80732; AAB50648.2; -; Genomic_DNA.
DR   EMBL; S80743; AAB50649.2; -; Genomic_DNA.
DR   EMBL; S71208; AAB20521.1; -; Genomic_DNA.
DR   EMBL; S71210; AAB20522.1; -; Genomic_DNA.
DR   EMBL; S71212; AAB20523.1; -; Genomic_DNA.
DR   CCDS; CCDS13080.1; -. [P04156-1]
DR   PIR; A24173; UJHU.
DR   RefSeq; NP_000302.1; NM_000311.3. [P04156-1]
DR   RefSeq; NP_001073590.1; NM_001080121.1. [P04156-1]
DR   RefSeq; NP_001073591.1; NM_001080122.1. [P04156-1]
DR   RefSeq; NP_001073592.1; NM_001080123.1. [P04156-1]
DR   RefSeq; NP_898902.1; NM_183079.2. [P04156-1]
DR   UniGene; Hs.472010; -.
DR   UniGene; Hs.610285; -.
DR   UniGene; Hs.721670; -.
DR   PDB; 1E1G; NMR; -; A=125-228.
DR   PDB; 1E1J; NMR; -; A=125-228.
DR   PDB; 1E1P; NMR; -; A=125-228.
DR   PDB; 1E1S; NMR; -; A=125-228.
DR   PDB; 1E1U; NMR; -; A=125-228.
DR   PDB; 1E1W; NMR; -; A=125-228.
DR   PDB; 1FKC; NMR; -; A=90-231.
DR   PDB; 1FO7; NMR; -; A=90-231.
DR   PDB; 1H0L; NMR; -; A=121-230.
DR   PDB; 1HJM; NMR; -; A=125-228.
DR   PDB; 1HJN; NMR; -; A=125-228.
DR   PDB; 1I4M; X-ray; 2.00 A; A=119-226.
DR   PDB; 1OEH; NMR; -; A=77-84.
DR   PDB; 1OEI; NMR; -; A=61-84.
DR   PDB; 1QLX; NMR; -; A=23-230.
DR   PDB; 1QLZ; NMR; -; A=23-230.
DR   PDB; 1QM0; NMR; -; A=90-230.
DR   PDB; 1QM1; NMR; -; A=90-230.
DR   PDB; 1QM2; NMR; -; A=121-230.
DR   PDB; 1QM3; NMR; -; A=121-230.
DR   PDB; 2IV4; NMR; -; A=180-195.
DR   PDB; 2IV5; NMR; -; A=173-195.
DR   PDB; 2IV6; NMR; -; A=173-195.
DR   PDB; 2K1D; NMR; -; A=90-231.
DR   PDB; 2KUN; NMR; -; A=90-231.
DR   PDB; 2LBG; NMR; -; A=110-136.
DR   PDB; 2LEJ; NMR; -; A=90-231.
DR   PDB; 2LFT; NMR; -; A=90-231.
DR   PDB; 2LSB; NMR; -; A=90-231.
DR   PDB; 2LV1; NMR; -; A=90-231.
DR   PDB; 2M8T; NMR; -; A=90-231.
DR   PDB; 2OL9; X-ray; 0.85 A; A=170-175.
DR   PDB; 2W9E; X-ray; 2.90 A; A=119-231.
DR   PDB; 3HAF; X-ray; 2.26 A; A=90-231.
DR   PDB; 3HAK; X-ray; 1.80 A; A=125-227.
DR   PDB; 3HEQ; X-ray; 1.80 A; A/B=90-231.
DR   PDB; 3HER; X-ray; 1.85 A; A/B=90-231.
DR   PDB; 3HES; X-ray; 2.00 A; A/B=90-231.
DR   PDB; 3HJ5; X-ray; 3.10 A; A/B=90-231.
DR   PDB; 3HJX; X-ray; 2.00 A; A=126-231.
DR   PDB; 3MD4; X-ray; 1.15 A; A/B=127-132.
DR   PDB; 3MD5; X-ray; 1.40 A; A/B=127-132.
DR   PDB; 3NHC; X-ray; 1.57 A; A/B=127-132.
DR   PDB; 3NHD; X-ray; 1.92 A; A/B=127-132.
DR   PDB; 3NVF; X-ray; 1.80 A; A=138-143.
DR   PDB; 4DGI; X-ray; 2.40 A; A=120-230.
DR   PDB; 4E1H; X-ray; 1.40 A; A/C/E/G/I/K=177-182, B/D/F/H/J/L=211-216.
DR   PDB; 4E1I; X-ray; 2.03 A; A/C/E/G/I/K=177-182, B/D/F/H/J/L=211-216.
DR   PDB; 4KML; X-ray; 1.50 A; A=24-231.
DR   PDB; 4N9O; X-ray; 1.50 A; A=90-231.
DR   PDBsum; 1E1G; -.
DR   PDBsum; 1E1J; -.
DR   PDBsum; 1E1P; -.
DR   PDBsum; 1E1S; -.
DR   PDBsum; 1E1U; -.
DR   PDBsum; 1E1W; -.
DR   PDBsum; 1FKC; -.
DR   PDBsum; 1FO7; -.
DR   PDBsum; 1H0L; -.
DR   PDBsum; 1HJM; -.
DR   PDBsum; 1HJN; -.
DR   PDBsum; 1I4M; -.
DR   PDBsum; 1OEH; -.
DR   PDBsum; 1OEI; -.
DR   PDBsum; 1QLX; -.
DR   PDBsum; 1QLZ; -.
DR   PDBsum; 1QM0; -.
DR   PDBsum; 1QM1; -.
DR   PDBsum; 1QM2; -.
DR   PDBsum; 1QM3; -.
DR   PDBsum; 2IV4; -.
DR   PDBsum; 2IV5; -.
DR   PDBsum; 2IV6; -.
DR   PDBsum; 2K1D; -.
DR   PDBsum; 2KUN; -.
DR   PDBsum; 2LBG; -.
DR   PDBsum; 2LEJ; -.
DR   PDBsum; 2LFT; -.
DR   PDBsum; 2LSB; -.
DR   PDBsum; 2LV1; -.
DR   PDBsum; 2M8T; -.
DR   PDBsum; 2OL9; -.
DR   PDBsum; 2W9E; -.
DR   PDBsum; 3HAF; -.
DR   PDBsum; 3HAK; -.
DR   PDBsum; 3HEQ; -.
DR   PDBsum; 3HER; -.
DR   PDBsum; 3HES; -.
DR   PDBsum; 3HJ5; -.
DR   PDBsum; 3HJX; -.
DR   PDBsum; 3MD4; -.
DR   PDBsum; 3MD5; -.
DR   PDBsum; 3NHC; -.
DR   PDBsum; 3NHD; -.
DR   PDBsum; 3NVF; -.
DR   PDBsum; 4DGI; -.
DR   PDBsum; 4E1H; -.
DR   PDBsum; 4E1I; -.
DR   PDBsum; 4KML; -.
DR   PDBsum; 4N9O; -.
DR   DisProt; DP00466; -.
DR   ProteinModelPortal; P04156; -.
DR   SMR; P04156; 2-28, 90-231.
DR   BioGrid; 111606; 58.
DR   DIP; DIP-29933N; -.
DR   IntAct; P04156; 88.
DR   MINT; MINT-1420984; -.
DR   STRING; 9606.ENSP00000368752; -.
DR   BindingDB; P04156; -.
DR   ChEMBL; CHEMBL4869; -.
DR   DrugBank; DB00759; Tetracycline.
DR   iPTMnet; P04156; -.
DR   PhosphoSite; P04156; -.
DR   BioMuta; PRNP; -.
DR   DMDM; 130912; -.
DR   PaxDb; P04156; -.
DR   PRIDE; P04156; -.
DR   DNASU; 5621; -.
DR   Ensembl; ENST00000379440; ENSP00000368752; ENSG00000171867. [P04156-1]
DR   Ensembl; ENST00000430350; ENSP00000399376; ENSG00000171867. [P04156-1]
DR   GeneID; 5621; -.
DR   KEGG; hsa:5621; -.
DR   UCSC; uc002wkt.1; human. [P04156-1]
DR   CTD; 5621; -.
DR   GeneCards; PRNP; -.
DR   GeneReviews; PRNP; -.
DR   HGNC; HGNC:9449; PRNP.
DR   HPA; HPA042754; -.
DR   HPA; HPA043398; -.
DR   MalaCards; PRNP; -.
DR   MIM; 123400; phenotype.
DR   MIM; 137440; phenotype.
DR   MIM; 176640; gene.
DR   MIM; 245300; phenotype.
DR   MIM; 600072; phenotype.
DR   MIM; 603218; phenotype.
DR   MIM; 606688; phenotype.
DR   neXtProt; NX_P04156; -.
DR   Orphanet; 397606; Chronic diarrhea with hereditary sensory and autonomic neuropathy.
DR   Orphanet; 280397; Familial Alzheimer-like prion disease.
DR   Orphanet; 466; Fatal familial insomnia.
DR   Orphanet; 356; Gerstmann-Straussler-Scheinker syndrome.
DR   Orphanet; 157941; Huntington disease-like 1.
DR   Orphanet; 282166; Inherited Creutzfeldt-Jakob disease.
DR   PharmGKB; PA33796; -.
DR   eggNOG; ENOG410IJMM; Eukaryota.
DR   eggNOG; ENOG410YXUU; LUCA.
DR   HOVERGEN; HBG008260; -.
DR   InParanoid; P04156; -.
DR   KO; K05634; -.
DR   OMA; HNPGYPH; -.
DR   OrthoDB; EOG7DRJ4Q; -.
DR   PhylomeDB; P04156; -.
DR   TreeFam; TF105188; -.
DR   Reactome; R-HSA-419037; NCAM1 interactions.
DR   ChiTaRS; PRNP; human.
DR   EvolutionaryTrace; P04156; -.
DR   GenomeRNAi; 5621; -.
DR   NextBio; 21844; -.
DR   PMAP-CutDB; P04156; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; P04156; -.
DR   ExpressionAtlas; P04156; baseline and differential.
DR   Genevisible; P04156; HS.
DR   GO; GO:0031225; C:anchored component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0019898; C:extrinsic component of membrane; TAS:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005507; F:copper ion binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008017; F:microtubule binding; IDA:UniProtKB.
DR   GO; GO:0015631; F:tubulin binding; IDA:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007050; P:cell cycle arrest; IEA:UniProtKB-KW.
DR   GO; GO:0006878; P:cellular copper ion homeostasis; NAS:UniProtKB.
DR   GO; GO:0071280; P:cellular response to copper ion; IDA:MGI.
DR   GO; GO:0035690; P:cellular response to drug; IEA:Ensembl.
DR   GO; GO:0007611; P:learning or memory; IEA:Ensembl.
DR   GO; GO:0008152; P:metabolic process; TAS:ProtInc.
DR   GO; GO:0046007; P:negative regulation of activated T cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0070885; P:negative regulation of calcineurin-NFAT signaling cascade; ISS:BHF-UCL.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; ISS:BHF-UCL.
DR   GO; GO:0032700; P:negative regulation of interleukin-17 production; ISS:BHF-UCL.
DR   GO; GO:0032703; P:negative regulation of interleukin-2 production; ISS:BHF-UCL.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0043433; P:negative regulation of sequence-specific DNA binding transcription factor activity; ISS:BHF-UCL.
DR   GO; GO:0050860; P:negative regulation of T cell receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0051260; P:protein homooligomerization; IEA:InterPro.
DR   GO; GO:1901379; P:regulation of potassium ion transmembrane transport; IEA:Ensembl.
DR   GO; GO:0032880; P:regulation of protein localization; IEA:Ensembl.
DR   GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl.
DR   GO; GO:0006979; P:response to oxidative stress; ISS:UniProtKB.
DR   Gene3D; 1.10.790.10; -; 1.
DR   InterPro; IPR000817; Prion.
DR   InterPro; IPR022416; Prion/Doppel_prot_b-ribbon_dom.
DR   InterPro; IPR025860; Prion_N_dom.
DR   Pfam; PF00377; Prion; 1.
DR   Pfam; PF11587; Prion_bPrPp; 1.
DR   PRINTS; PR00341; PRION.
DR   SMART; SM00157; PRP; 1.
DR   SUPFAM; SSF54098; SSF54098; 1.
DR   PROSITE; PS00291; PRION_1; 1.
DR   PROSITE; PS00706; PRION_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Amyloid; Amyloidosis;
KW   Cell cycle; Cell membrane; Complete proteome; Copper; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Golgi apparatus; GPI-anchor; Growth arrest; Lipoprotein;
KW   Membrane; Metal-binding; Nucleus; Polymorphism; Prion;
KW   Reference proteome; Repeat; Signal; Ubl conjugation; Zinc.
FT   SIGNAL        1     22       {ECO:0000250|UniProtKB:P04925}.
FT   CHAIN        23    230       Major prion protein.
FT                                /FTId=PRO_0000025675.
FT   PROPEP      231    253       Removed in mature form.
FT                                {ECO:0000250|UniProtKB:P04273}.
FT                                /FTId=PRO_0000025676.
FT   REPEAT       51     59       1.
FT   REPEAT       60     67       2.
FT   REPEAT       68     75       3.
FT   REPEAT       76     83       4.
FT   REPEAT       84     91       5.
FT   REGION       23    230       Interaction with GRB2, ERI3 and SYN1.
FT                                {ECO:0000250|UniProtKB:P04925}.
FT   REGION       51     91       5 X 8 AA tandem repeats of P-H-G-G-G-W-G-
FT                                Q.
FT   METAL        61     61       Copper or zinc 1.
FT                                {ECO:0000269|PubMed:11900542}.
FT   METAL        62     62       Copper or zinc 1; via amide nitrogen.
FT                                {ECO:0000269|PubMed:11900542}.
FT   METAL        63     63       Copper or zinc 1; via amide nitrogen and
FT                                carbonyl oxygen.
FT                                {ECO:0000269|PubMed:11900542}.
FT   METAL        69     69       Copper or zinc 2.
FT                                {ECO:0000305|PubMed:11900542}.
FT   METAL        70     70       Copper or zinc 2; via amide nitrogen.
FT                                {ECO:0000305|PubMed:11900542}.
FT   METAL        71     71       Copper or zinc 2; via amide nitrogen and
FT                                carbonyl oxygen.
FT                                {ECO:0000305|PubMed:11900542}.
FT   METAL        77     77       Copper or zinc 3.
FT                                {ECO:0000305|PubMed:11900542}.
FT   METAL        78     78       Copper or zinc 3; via amide nitrogen.
FT                                {ECO:0000305|PubMed:11900542}.
FT   METAL        79     79       Copper or zinc 3; via amide nitrogen and
FT                                carbonyl oxygen.
FT                                {ECO:0000305|PubMed:11900542}.
FT   METAL        85     85       Copper or zinc 4.
FT                                {ECO:0000305|PubMed:11900542}.
FT   METAL        86     86       Copper or zinc 4; via amide nitrogen.
FT                                {ECO:0000305|PubMed:11900542}.
FT   METAL        87     87       Copper or zinc 4; via amide nitrogen and
FT                                carbonyl oxygen.
FT                                {ECO:0000305|PubMed:11900542}.
FT   LIPID       230    230       GPI-anchor amidated serine.
FT                                {ECO:0000250|UniProtKB:P04273}.
FT   CARBOHYD    181    181       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12214108}.
FT   CARBOHYD    197    197       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19349973}.
FT   DISULFID    179    214       {ECO:0000269|PubMed:14623188}.
FT   VAR_SEQ       1      7       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_039045.
FT   VARIANT      56     63       Missing. {ECO:0000269|PubMed:1363802,
FT                                ECO:0000269|PubMed:1678248,
FT                                ECO:0000269|PubMed:7485229}.
FT                                /FTId=VAR_013763.
FT   VARIANT     102    102       P -> L (in GSD and early-onset dementia).
FT                                {ECO:0000269|PubMed:10631141,
FT                                ECO:0000269|PubMed:2564168,
FT                                ECO:0000269|PubMed:2783132,
FT                                ECO:0000269|PubMed:7783876,
FT                                ECO:0000269|PubMed:8797472}.
FT                                /FTId=VAR_006464.
FT   VARIANT     105    105       P -> L (in GSD).
FT                                {ECO:0000269|PubMed:7699395,
FT                                ECO:0000269|PubMed:7902972}.
FT                                /FTId=VAR_006465.
FT   VARIANT     117    117       A -> V (linked to development of
FT                                dementing Gerstmann-Straussler disease).
FT                                {ECO:0000269|PubMed:2783132}.
FT                                /FTId=VAR_006466.
FT   VARIANT     127    127       G -> V (polymorphism; variant that has
FT                                been selected for in response to the Kuru
FT                                epidemic and confers resistance to prion
FT                                disease by acting as a 'dominant
FT                                negative' inhibitor of prion conversion;
FT                                is not only itself resistant to
FT                                conformational conversion, but also
FT                                inhibits conversion of wild-type
FT                                proteins; confers protection against
FT                                classical Creutzfeldt-Jakob disease (CJD)
FT                                and Kuru in the heterozygous state, but
FT                                can be infected with variant CJD prions,
FT                                resulting from exposure to bovine
FT                                spongiform encephalopathy prions; confers
FT                                complete resistance to all prion strains
FT                                when homozygous. Always associated with
FT                                M-129 variant).
FT                                {ECO:0000269|PubMed:19923577,
FT                                ECO:0000269|PubMed:26061765}.
FT                                /FTId=VAR_073722.
FT   VARIANT     129    129       M -> V (polymorphism; confers relative
FT                                protection against acquired, sporadic and
FT                                some inherited prion diseases in the
FT                                heterozygous state, possibly by
FT                                preventing homodimerization; determines
FT                                the disease phenotype in patients who
FT                                have a PrP mutation at position 178;
FT                                patients with M-129 develop FFI, those
FT                                with V-129 develop CJD; dbSNP:rs1799990).
FT                                {ECO:0000269|PubMed:12690204,
FT                                ECO:0000269|PubMed:1439789,
FT                                ECO:0000269|PubMed:19927125,
FT                                ECO:0000269|PubMed:2783132}.
FT                                /FTId=VAR_006467.
FT   VARIANT     131    131       G -> V (in GSD).
FT                                {ECO:0000269|PubMed:11709001}.
FT                                /FTId=VAR_014264.
FT   VARIANT     171    171       N -> S (in schizoaffective disorder;
FT                                dbSNP:rs16990018).
FT                                {ECO:0000269|PubMed:9384372}.
FT                                /FTId=VAR_006468.
FT   VARIANT     178    178       D -> N (in FFI and CJD).
FT                                {ECO:0000269|PubMed:1347910,
FT                                ECO:0000269|PubMed:1439789,
FT                                ECO:0000269|PubMed:1671440,
FT                                ECO:0000269|PubMed:19927125}.
FT                                /FTId=VAR_006469.
FT   VARIANT     180    180       V -> I (in CJD).
FT                                {ECO:0000269|PubMed:1439789,
FT                                ECO:0000269|PubMed:19927125,
FT                                ECO:0000269|PubMed:8461023}.
FT                                /FTId=VAR_006470.
FT   VARIANT     183    183       T -> A (in SENF and early-onset dementia;
FT                                induces loss of glycosylation at N-181).
FT                                {ECO:0000269|PubMed:10631141,
FT                                ECO:0000269|PubMed:12214108,
FT                                ECO:0000269|PubMed:9266722}.
FT                                /FTId=VAR_006471.
FT   VARIANT     187    187       H -> R (in GSD).
FT                                {ECO:0000269|PubMed:10581485}.
FT                                /FTId=VAR_008746.
FT   VARIANT     188    188       T -> K (in early-onset dementia; dementia
FT                                associated to prion diseases).
FT                                {ECO:0000269|PubMed:10631141}.
FT                                /FTId=VAR_008748.
FT   VARIANT     188    188       T -> R. {ECO:0000269|PubMed:10987652}.
FT                                /FTId=VAR_008747.
FT   VARIANT     196    196       E -> K (in CJD).
FT                                {ECO:0000269|PubMed:10790216}.
FT                                /FTId=VAR_008749.
FT   VARIANT     198    198       F -> S (in GSD; atypical form with
FT                                neurofibrillary tangles).
FT                                {ECO:0000269|PubMed:19927125}.
FT                                /FTId=VAR_006472.
FT   VARIANT     200    200       E -> K (in CJD).
FT                                {ECO:0000269|PubMed:1975028,
FT                                ECO:0000269|PubMed:7906019,
FT                                ECO:0000269|PubMed:7913755}.
FT                                /FTId=VAR_006473.
FT   VARIANT     202    202       D -> N (in GSD).
FT                                {ECO:0000269|PubMed:9786248}.
FT                                /FTId=VAR_008750.
FT   VARIANT     203    203       V -> I (in CJD; it could be an extremely
FT                                rare polymorphism).
FT                                {ECO:0000269|PubMed:10790216}.
FT                                /FTId=VAR_008751.
FT   VARIANT     208    208       R -> H (in CJD).
FT                                {ECO:0000269|PubMed:8909447}.
FT                                /FTId=VAR_006474.
FT   VARIANT     210    210       V -> I (in CJD).
FT                                {ECO:0000269|PubMed:7902693}.
FT                                /FTId=VAR_006475.
FT   VARIANT     211    211       E -> Q (in CJD).
FT                                {ECO:0000269|PubMed:10790216}.
FT                                /FTId=VAR_008752.
FT   VARIANT     212    212       Q -> P (in GSD).
FT                                {ECO:0000269|PubMed:9786248}.
FT                                /FTId=VAR_008753.
FT   VARIANT     217    217       Q -> R (in GSD; with neurofibrillary
FT                                tangles). {ECO:0000269|PubMed:1363810}.
FT                                /FTId=VAR_006476.
FT   VARIANT     219    219       E -> K (polymorphism; confers relative
FT                                protection against sporadic Creutzfeldt-
FT                                Jakob disease (CJD) in the heterozygous
FT                                state; dbSNP:rs1800014).
FT                                {ECO:0000269|PubMed:8797472,
FT                                ECO:0000269|PubMed:9482303}.
FT                                /FTId=VAR_006477.
FT   VARIANT     232    232       M -> R (in CJD).
FT                                {ECO:0000269|PubMed:8461023}.
FT                                /FTId=VAR_006478.
FT   VARIANT     238    238       P -> S. {ECO:0000269|PubMed:10987652}.
FT                                /FTId=VAR_008754.
FT   MUTAGEN       1      1       M->S: Protein detected. No protein
FT                                detected; when associated with S-8.
FT                                {ECO:0000269|PubMed:19059915}.
FT   MUTAGEN       8      8       M->S: No protein detected; when
FT                                associated with S-1.
FT                                {ECO:0000269|PubMed:19059915}.
FT   CONFLICT    118    118       Missing (in Ref. 9; AAA19664/BAA00011).
FT                                {ECO:0000305}.
FT   CONFLICT    169    169       Y -> H (in Ref. 6; ABD63004).
FT                                {ECO:0000305}.
FT   CONFLICT    227    227       Q -> K (in Ref. 8; AAH22532).
FT                                {ECO:0000305}.
FT   STRAND       63     67       {ECO:0000244|PDB:1OEI}.
FT   STRAND       70     73       {ECO:0000244|PDB:1OEI}.
FT   TURN         74     76       {ECO:0000244|PDB:1OEI}.
FT   STRAND       79     82       {ECO:0000244|PDB:1OEH}.
FT   STRAND      118    122       {ECO:0000244|PDB:4KML}.
FT   STRAND      125    127       {ECO:0000244|PDB:1H0L}.
FT   STRAND      128    131       {ECO:0000244|PDB:3MD4}.
FT   STRAND      141    143       {ECO:0000244|PDB:1E1S}.
FT   HELIX       144    153       {ECO:0000244|PDB:4KML}.
FT   HELIX       154    156       {ECO:0000244|PDB:4KML}.
FT   STRAND      159    163       {ECO:0000244|PDB:1E1U}.
FT   HELIX       166    168       {ECO:0000244|PDB:4KML}.
FT   TURN        171    173       {ECO:0000244|PDB:1QM0}.
FT   STRAND      178    181       {ECO:0000244|PDB:4E1H}.
FT   HELIX       185    187       {ECO:0000244|PDB:1E1P}.
FT   TURN        188    190       {ECO:0000244|PDB:1E1P}.
FT   TURN        193    195       {ECO:0000244|PDB:3HAK}.
FT   STRAND      212    215       {ECO:0000244|PDB:4E1H}.
FT   TURN        223    225       {ECO:0000244|PDB:3HER}.
FT   TURN        228    230       {ECO:0000244|PDB:2LFT}.
SQ   SEQUENCE   253 AA;  27661 MW;  43DB596BAAA66484 CRC64;
     MANLGCWMLV LFVATWSDLG LCKKRPKPGG WNTGGSRYPG QGSPGGNRYP PQGGGGWGQP
     HGGGWGQPHG GGWGQPHGGG WGQPHGGGWG QGGGTHSQWN KPSKPKTNMK HMAGAAAAGA
     VVGGLGGYML GSAMSRPIIH FGSDYEDRYY RENMHRYPNQ VYYRPMDEYS NQNNFVHDCV
     NITIKQHTVT TTTKGENFTE TDVKMMERVV EQMCITQYER ESQAYYQRGS SMVLFSSPPV
     ILLISFLIFL IVG
//
ID   VGFR3_HUMAN             Reviewed;        1363 AA.
AC   P35916; A8K6L4; B5A926; Q16067; Q86W07; Q86W08;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   16-NOV-2011, sequence version 3.
DT   20-JAN-2016, entry version 182.
DE   RecName: Full=Vascular endothelial growth factor receptor 3;
DE            Short=VEGFR-3;
DE            EC=2.7.10.1;
DE   AltName: Full=Fms-like tyrosine kinase 4;
DE            Short=FLT-4;
DE   AltName: Full=Tyrosine-protein kinase receptor FLT4;
DE   Flags: Precursor;
GN   Name=FLT4; Synonyms=VEGFR3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RX   PubMed=1327515;
RA   Pajusola K., Aprelikova O., Korhonen J., Kaipainen A., Pertovaara L.,
RA   Alitalo R., Alitalo K.;
RT   "FLT4 receptor tyrosine kinase contains seven immunoglobulin-like
RT   loops and is expressed in multiple human tissues and cell lines.";
RL   Cancer Res. 52:5738-5743(1992).
RN   [2]
RP   ERRATUM.
RA   Pajusola K., Aprelikova O., Korhonen J., Kaipainen A., Pertovaara L.,
RA   Alitalo R., Alitalo K.;
RL   Cancer Res. 53:3845-3845(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=1319394; DOI=10.1016/0888-7543(92)90277-Y;
RA   Galland F., Karamysheva A., Mattei M.-G., Rosnet O., Marchetto S.,
RA   Birnbaum D.;
RT   "Chromosomal localization of FLT4, a novel receptor-type tyrosine
RT   kinase gene.";
RL   Genomics 13:475-478(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANTS GLN-890 AND
RP   HIS-1146.
RC   TISSUE=Placenta;
RX   PubMed=8386825;
RA   Galland F., Karamysheva A., Pebusque M.-J., Borg J.-P., Rottapel R.,
RA   Dubreuil P., Rosnet O., Birnbaum D.;
RT   "The FLT4 gene encodes a transmembrane tyrosine kinase related to the
RT   vascular endothelial growth factor receptor.";
RL   Oncogene 8:1233-1240(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), INTERACTION WITH VEGFC,
RP   PHOSPHORYLATION, AND FUNCTION IN CELL PROLIFERATION.
RX   PubMed=8700872; DOI=10.1073/pnas.93.5.1988;
RA   Lee J., Gray A., Yuan J., Luoh S.-M., Avraham H., Wood W.I.;
RT   "Vascular endothelial growth factor-related protein: a ligand and
RT   specific activator of the tyrosine kinase receptor Flt4.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:1988-1992(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), INTERACTION WITH VEGFD, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANTS GLN-890
RP   AND HIS-1146.
RA   Lian Z., Feitelson M.;
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   GLN-890.
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 761-1190.
RX   PubMed=1310071;
RA   Aprelikova O., Pajusola K., Partanen J., Armstrong E., Alitalo R.,
RA   Bailey S.K., McMahon J., Wasmuth J., Huebner K., Alitalo K.;
RT   "FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-
RT   qter.";
RL   Cancer Res. 52:746-748(1992).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1293-1363 (ISOFORM 1), AND ALTERNATIVE
RP   SPLICING.
RX   PubMed=7692369;
RA   Pajusola K., Aprelikova O., Armstrong E., Morris S., Alitalo K.;
RT   "Two human FLT4 receptor tyrosine kinase isoforms with distinct
RT   carboxy terminal tails are produced by alternative processing of
RT   primary transcripts.";
RL   Oncogene 8:2931-2937(1993).
RN   [12]
RP   PROTEIN SEQUENCE OF 25-39.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [13]
RP   CATALYTIC ACTIVITY, GLYCOSYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=7898938;
RA   Borg J.P., deLapeyriere O., Noguchi T., Rottapel R., Dubreuil P.,
RA   Birnbaum D.;
RT   "Biochemical characterization of two isoforms of FLT4, a VEGF
RT   receptor-related tyrosine kinase.";
RL   Oncogene 10:973-984(1995).
RN   [14]
RP   FUNCTION IN CELL PROLIFERATION AND PHOSPHORYLATION OF SHC1,
RP   CHARACTERIZATION OF ISOFORM 1 AND ISOFORM 2, INTERACTION WITH SHC1 AND
RP   GRB2, AUTOPHOSPHORYLATION, MUTAGENESIS OF TYR-1333; TYR-1337 AND
RP   TYR-1363, AND TISSUE SPECIFICITY.
RX   PubMed=7675451;
RA   Fournier E., Dubreuil P., Birnbaum D., Borg J.P.;
RT   "Mutation at tyrosine residue 1337 abrogates ligand-dependent
RT   transforming capacity of the FLT4 receptor.";
RL   Oncogene 11:921-931(1995).
RN   [15]
RP   INTERACTION WITH VEGFD, FUNCTION AS VEGFD RECEPTOR, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=9435229; DOI=10.1073/pnas.95.2.548;
RA   Achen M.G., Jeltsch M., Kukk E., Maekinen T., Vitali A., Wilks A.F.,
RA   Alitalo K., Stacker S.A.;
RT   "Vascular endothelial growth factor D (VEGF-D) is a ligand for the
RT   tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:548-553(1998).
RN   [16]
RP   FUNCTION AS RECEPTOR FOR VEGFC AND VEGFD IN CELL SURVIVAL;
RP   PROLIFERATION AND MIGRATION, AND FUNCTION IN ACTIVATION OF PROTEIN
RP   KINASE C; AKT1; PIK3R1; MAPK1/ERK2 AND MAPK3/ERK1.
RX   PubMed=11532940; DOI=10.1093/emboj/20.17.4762;
RA   Makinen T., Veikkola T., Mustjoki S., Karpanen T., Catimel B.,
RA   Nice E.C., Wise L., Mercer A., Kowalski H., Kerjaschki D.,
RA   Stacker S.A., Achen M.G., Alitalo K.;
RT   "Isolated lymphatic endothelial cells transduce growth, survival and
RT   migratory signals via the VEGF-C/D receptor VEGFR-3.";
RL   EMBO J. 20:4762-4773(2001).
RN   [17]
RP   INTERACTION WITH KDR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION,
RP   CHARACTERIZATION OF VARIANT LMPH1A PRO-1041, MUTAGENESIS OF LYS-879;
RP   TYR-1230; TYR-1231; TYR-1265; TYR-1333; TYR-1337 AND TYR-1363, AND
RP   PHOSPHORYLATION AT TYR-1230; TYR-1231; TYR-1265; TYR-1333; TYR-1337
RP   AND TYR-1363.
RX   PubMed=12881528; DOI=10.1074/jbc.M304499200;
RA   Dixelius J., Makinen T., Wirzenius M., Karkkainen M.J., Wernstedt C.,
RA   Alitalo K., Claesson-Welsh L.;
RT   "Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-
RT   3) heterodimerization with VEGFR-2 in primary lymphatic endothelial
RT   cells regulates tyrosine phosphorylation sites.";
RL   J. Biol. Chem. 278:40973-40979(2003).
RN   [18]
RP   FUNCTION IN KDR SIGNALING AND IN ANGIOGENESIS, INTERACTION WITH KDR,
RP   AND PHOSPHORYLATION.
RX   PubMed=15474514; DOI=10.1016/j.bbrc.2004.08.237;
RA   Alam A., Herault J.P., Barron P., Favier B., Fons P.,
RA   Delesque-Touchard N., Senegas I., Laboudie P., Bonnin J., Cassan C.,
RA   Savi P., Ruggeri B., Carmeliet P., Bono F., Herbert J.M.;
RT   "Heterodimerization with vascular endothelial growth factor receptor-2
RT   (VEGFR-2) is necessary for VEGFR-3 activity.";
RL   Biochem. Biophys. Res. Commun. 324:909-915(2004).
RN   [19]
RP   FUNCTION IN CELL SURVIVAL, PHOSPHORYLATION IN RESPONSE TO OXIDATIVE
RP   STRESS, INTERACTION WITH PIK3R1; SHC1; GRB2; PTPN11 AND PLCG1, ENZYME
RP   REGULATION BY MAZ51, AND CHARACTERIZATION OF VARIANT LMPH1A ARG-857.
RX   PubMed=15102829; DOI=10.1074/jbc.M314015200;
RA   Wang J.F., Zhang X., Groopman J.E.;
RT   "Activation of vascular endothelial growth factor receptor-3 and its
RT   downstream signaling promote cell survival under oxidative stress.";
RL   J. Biol. Chem. 279:27088-27097(2004).
RN   [20]
RP   FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2; MAPK3/ERK1 AND MAPK8,
RP   FUNCTION IN PROMOTING CELL SURVIVAL; PROLIFERATION AND MIGRATION,
RP   CHARACTERIZATION OF ISOFORM 1 AND ISOFORM 2, INTERACTION WITH CRK AND
RP   GRB2, PHOSPHORYLATION AT TYR-1063; TYR-1068; TYR-1230; TYR-1231 AND
RP   TYR-1337, AND MUTAGENESIS OF TYR-1063; TYR-1068; TYR-1230 AND
RP   TYR-1231.
RX   PubMed=16076871; DOI=10.1182/blood-2005-04-1388;
RA   Salameh A., Galvagni F., Bardelli M., Bussolino F., Oliviero S.;
RT   "Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation,
RT   migration, and survival of endothelial cells through the activation of
RT   ERK, AKT, and JNK pathways.";
RL   Blood 106:3423-3431(2005).
RN   [21]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-527.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [22]
RP   FUNCTION IN PROMOTING CELL SURVIVAL, INTERACTION WITH PTK2/FAK1, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=16452200; DOI=10.1158/0008-5472.CAN-05-1661;
RA   Garces C.A., Kurenova E.V., Golubovskaya V.M., Cance W.G.;
RT   "Vascular endothelial growth factor receptor-3 and focal adhesion
RT   kinase bind and suppress apoptosis in breast cancer cells.";
RL   Cancer Res. 66:1446-1454(2006).
RN   [23]
RP   FUNCTION IN LYMPHANGIOGENESIS.
RX   PubMed=17210781; DOI=10.1096/fj.06-6656com;
RA   Goldman J., Rutkowski J.M., Shields J.D., Pasquier M.C., Cui Y.,
RA   Schmokel H.G., Willey S., Hicklin D.J., Pytowski B., Swartz M.A.;
RT   "Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in
RT   adult lymphangiogenesis.";
RL   FASEB J. 21:1003-1012(2007).
RN   [24]
RP   ROLE IN CANCER, FUNCTION AS VEGFC RECEPTOR IN TUMOR LYMPHANGIOGENESIS;
RP   CELL PROLIFERATION; CELL SURVIVAL; IN ACTIVATION OF PIK3R1; AKT1 AND
RP   MAP KINASES AND IN UP-REGULATION OF VEGFA AND VEGFC EXPRESSION, ENZYME
RP   REGULATION, AND AUTOPHOSPHORYLATION.
RX   PubMed=19779139; DOI=10.2353/ajpath.2009.081139;
RA   Matsuura M., Onimaru M., Yonemitsu Y., Suzuki H., Nakano T.,
RA   Ishibashi H., Shirasuna K., Sueishi K.;
RT   "Autocrine loop between vascular endothelial growth factor (VEGF)-C
RT   and VEGF receptor-3 positively regulates tumor-associated
RT   lymphangiogenesis in oral squamoid cancer cells.";
RL   Am. J. Pathol. 175:1709-1721(2009).
RN   [25]
RP   ROLE IN CANCER, AND INTERACTION WITH PTK2/FAK1.
RX   PubMed=19610651; DOI=10.1021/jm900159g;
RA   Kurenova E.V., Hunt D.L., He D., Magis A.T., Ostrov D.A., Cance W.G.;
RT   "Small molecule chloropyramine hydrochloride (C4) targets the binding
RT   site of focal adhesion kinase and vascular endothelial growth factor
RT   receptor 3 and suppresses breast cancer growth in vivo.";
RL   J. Med. Chem. 52:4716-4724(2009).
RN   [26]
RP   INTERACTION WITH PTPN14.
RX   PubMed=20826270; DOI=10.1016/j.ajhg.2010.08.008;
RA   Au A.C., Hernandez P.A., Lieber E., Nadroo A.M., Shen Y.M.,
RA   Kelley K.A., Gelb B.D., Diaz G.A.;
RT   "Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic
RT   function and choanal development in humans.";
RL   Am. J. Hum. Genet. 87:436-444(2010).
RN   [27]
RP   PHOSPHORYLATION AT TYR-830; TYR-833; TYR-853; TYR-1063; TYR-1068;
RP   TYR-1333 AND TYR-1337, IDENTIFICATION IN A COMPLEX WITH SRC AND ITGB1,
RP   MUTAGENESIS OF TYR-1063; TYR-1068 AND TYR-1337, ENZYME REGULATION BY
RP   MAZ51, INTERACTION WITH ITGB1; CRK AND SHC1, FUNCTION IN ACTIVATION OF
RP   MAPK8 AND IN REGULATION OF ANGIOGENIC SPROUTING, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=20431062; DOI=10.1161/CIRCRESAHA.109.206326;
RA   Galvagni F., Pennacchini S., Salameh A., Rocchigiani M., Neri F.,
RA   Orlandini M., Petraglia F., Gotta S., Sardone G.L., Matteucci G.,
RA   Terstappen G.C., Oliviero S.;
RT   "Endothelial cell adhesion to the extracellular matrix induces c-Src-
RT   dependent VEGFR-3 phosphorylation without the activation of the
RT   receptor intrinsic kinase activity.";
RL   Circ. Res. 106:1839-1848(2010).
RN   [28]
RP   INTERACTION WITH KDR, FUNCTION IN MODULATING KDR SIGNALING AND IN
RP   ANGIOGENESIS, AND TISSUE SPECIFICITY.
RX   PubMed=20224550; DOI=10.1038/emboj.2010.30;
RA   Nilsson I., Bahram F., Li X., Gualandi L., Koch S., Jarvius M.,
RA   Soderberg O., Anisimov A., Kholova I., Pytowski B., Baldwin M.,
RA   Yla-Herttuala S., Alitalo K., Kreuger J., Claesson-Welsh L.;
RT   "VEGF receptor 2/-3 heterodimers detected in situ by proximity
RT   ligation on angiogenic sprouts.";
RL   EMBO J. 29:1377-1388(2010).
RN   [29]
RP   FUNCTION IN ACTIVATION OF SIGNALING PATHWAYS, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=20445537; DOI=10.1038/nature09002;
RA   Wang Y., Nakayama M., Pitulescu M.E., Schmidt T.S., Bochenek M.L.,
RA   Sakakibara A., Adams S., Davy A., Deutsch U., Luthi U., Barberis A.,
RA   Benjamin L.E., Makinen T., Nobes C.D., Adams R.H.;
RT   "Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis.";
RL   Nature 465:483-486(2010).
RN   [30]
RP   FUNCTION IN LYMPHANGIOGENESIS.
RX   PubMed=21273538; DOI=10.1167/iovs.10-6408;
RA   Yuen D., Pytowski B., Chen L.;
RT   "Combined blockade of VEGFR-2 and VEGFR-3 inhibits inflammatory
RT   lymphangiogenesis in early and middle stages.";
RL   Invest. Ophthalmol. Vis. Sci. 52:2593-2597(2011).
RN   [31]
RP   REVIEW ON STRUCTURE AND FUNCTION.
RX   PubMed=18680722; DOI=10.1016/j.bbrc.2008.07.121;
RA   Roskoski R. Jr.;
RT   "VEGF receptor protein-tyrosine kinases: structure and regulation.";
RL   Biochem. Biophys. Res. Commun. 375:287-291(2008).
RN   [32]
RP   REVIEW ON ROLE IN LYMPHANGIOGENESIS AND CANCER.
RX   PubMed=19230644; DOI=10.1016/j.ceb.2008.12.012;
RA   Lohela M., Bry M., Tammela T., Alitalo K.;
RT   "VEGFs and receptors involved in angiogenesis versus
RT   lymphangiogenesis.";
RL   Curr. Opin. Cell Biol. 21:154-165(2009).
RN   [33]
RP   REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND
RP   SIGNALING.
RX   PubMed=21711246; DOI=10.1042/BJ20110301;
RA   Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L.;
RT   "Signal transduction by vascular endothelial growth factor
RT   receptors.";
RL   Biochem. J. 437:169-183(2011).
RN   [34]
RP   REVIEW ON FUNCTION IN LYMPHANGIOGENESIS AND ROLE IN CANCER.
RX   PubMed=21196198; DOI=10.2741/3715;
RA   Al-Rawi M.A., Jiang W.G.;
RT   "Lymphangiogenesis and cancer metastasis.";
RL   Front. Biosci. 16:723-739(2011).
RN   [35]
RP   VARIANT LMPH1A LEU-1114.
RX   PubMed=9817924; DOI=10.1093/hmg/7.13.2073;
RA   Ferrell R.E., Levinson K.L., Esman J.H., Kimak M.A., Lawrence E.C.,
RA   Barmada M.M., Finegold D.N.;
RT   "Hereditary lymphedema: evidence for linkage and genetic
RT   heterogeneity.";
RL   Hum. Mol. Genet. 7:2073-2078(1998).
RN   [36]
RP   INVOLVEMENT IN LMPH1A, AND CHARACTERIZATION OF VARIANT LMPH1A
RP   ARG-1035.
RX   PubMed=10856194; DOI=10.1086/303019;
RA   Irrthum A., Karkkainen M.J., Devriendt K., Alitalo K., Vikkula M.;
RT   "Congenital hereditary lymphedema caused by a mutation that
RT   inactivates VEGFR3 tyrosine kinase.";
RL   Am. J. Hum. Genet. 67:295-301(2000).
RN   [37]
RP   VARIANTS LMPH1A ARG-857; PRO-1041; PRO-1044 AND LEU-1114, VARIANT
RP   SER-641, AND CHARACTERIZATION OF VARIANTS.
RX   PubMed=10835628; DOI=10.1038/75997;
RA   Karkkainen M.J., Ferrell R.E., Lawrence E.C., Kimak M.A.,
RA   Levinson K.L., McTigue M.A., Alitalo K., Finegold D.N.;
RT   "Missense mutations interfere with VEGFR-3 signalling in primary
RT   lymphoedema.";
RL   Nat. Genet. 25:153-159(2000).
RN   [38]
RP   VARIANTS HCI SER-954 AND SER-1137, AND VARIANTS ALA-494; GLN-890 AND
RP   HIS-1146.
RX   PubMed=11807987; DOI=10.1002/gcc.10028;
RA   Walter J.W., North P.E., Waner M., Mizeracki A., Blei F.,
RA   Walker J.W.T., Reinisch J.F., Marchuk D.A.;
RT   "Somatic mutation of vascular endothelial growth factor receptors in
RT   juvenile hemangioma.";
RL   Genes Chromosomes Cancer 33:295-303(2002).
RN   [39]
RP   VARIANTS LMPH1A MET-878; THR-1086 AND PHE-1108 DEL, VARIANT GLN-1035,
RP   AND INVOLVEMENT IN LMPH1A.
RX   PubMed=16965327; DOI=10.1111/j.1399-0004.2006.00687.x;
RA   Ghalamkarpour A., Morlot S., Raas-Rothschild A., Utkus A.,
RA   Mulliken J.B., Boon L.M., Vikkula M.;
RT   "Hereditary lymphedema type I associated with VEGFR3 mutation: the
RT   first de novo case and atypical presentations.";
RL   Clin. Genet. 70:330-335(2006).
RN   [40]
RP   VARIANT LMPH1A LYS-1106, AND INVOLVEMENT IN LMPH1A.
RX   PubMed=16924388; DOI=10.1007/s10038-006-0031-3;
RA   Spiegel R., Ghalamkarpour A., Daniel-Spiegel E., Vikkula M.,
RA   Shalev S.A.;
RT   "Wide clinical spectrum in a family with hereditary lymphedema type I
RT   due to a novel missense mutation in VEGFR3.";
RL   J. Hum. Genet. 51:846-850(2006).
RN   [41]
RP   VARIANT LMPH1A LEU-1020.
RX   PubMed=17458866; DOI=10.1002/ajmg.a.31703;
RA   Butler M.G., Dagenais S.L., Rockson S.G., Glover T.W.;
RT   "A novel VEGFR3 mutation causes Milroy disease.";
RL   Am. J. Med. Genet. A 143A:1212-1217(2007).
RN   [42]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-149; CYS-378; ALA-494; SER-527;
RP   SER-641; TYR-868; ILE-1010; GLN-1031; ASN-1049; GLN-1075 AND HIS-1146.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [43]
RP   VARIANT LMPH1A THR-855, AND CHARACTERIZATION OF VARIANT LMPH1A
RP   THR-855.
RX   PubMed=19289394; DOI=10.1136/jmg.2008.064469;
RA   Ghalamkarpour A., Holnthoner W., Saharinen P., Boon L.M.,
RA   Mulliken J.B., Alitalo K., Vikkula M.;
RT   "Recessive primary congenital lymphoedema caused by a VEGFR3
RT   mutation.";
RL   J. Med. Genet. 46:399-404(2009).
RN   [44]
RP   VARIANT LMPH1A CYS-1235.
RX   PubMed=26091405; DOI=10.1089/lrb.2014.0044;
RA   Melikhan-Revzin S., Kurolap A., Dagan E., Mory A., Gershoni-Baruch R.;
RT   "A novel missense mutation in FLT4 causes autosomal recessive
RT   hereditary lymphedema.";
RL   Lymphat. Res. Biol. 13:107-111(2015).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface
CC       receptor for VEGFC and VEGFD, and plays an essential role in adult
CC       lymphangiogenesis and in the development of the vascular network
CC       and the cardiovascular system during embryonic development.
CC       Promotes proliferation, survival and migration of endothelial
CC       cells, and regulates angiogenic sprouting. Signaling by activated
CC       FLT4 leads to enhanced production of VEGFC, and to a lesser degree
CC       VEGFA, thereby creating a positive feedback loop that enhances
CC       FLT4 signaling. Modulates KDR signaling by forming heterodimers.
CC       The secreted isoform 3 may function as a decoy receptor for VEGFC
CC       and/or VEGFD and play an important role as a negative regulator of
CC       VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of
CC       vascular growth factors to isoform 1 or isoform 2 leads to the
CC       activation of several signaling cascades; isoform 2 seems to be
CC       less efficient in signal transduction, because it has a truncated
CC       C-terminus and therefore lacks several phosphorylation sites.
CC       Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling
CC       pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1
CC       signaling pathway. Phosphorylates SHC1. Mediates phosphorylation
CC       of PIK3R1, the regulatory subunit of phosphatidylinositol 3-
CC       kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-
CC       185', and of AKT1 at 'Ser-473'. {ECO:0000269|PubMed:11532940,
CC       ECO:0000269|PubMed:15102829, ECO:0000269|PubMed:15474514,
CC       ECO:0000269|PubMed:16076871, ECO:0000269|PubMed:16452200,
CC       ECO:0000269|PubMed:17210781, ECO:0000269|PubMed:19610651,
CC       ECO:0000269|PubMed:19779139, ECO:0000269|PubMed:20224550,
CC       ECO:0000269|PubMed:20431062, ECO:0000269|PubMed:20445537,
CC       ECO:0000269|PubMed:21273538, ECO:0000269|PubMed:7675451,
CC       ECO:0000269|PubMed:8700872, ECO:0000269|PubMed:9435229}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:12881528,
CC       ECO:0000269|PubMed:7898938}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Binding of VEGFC or VEGFD leads to
CC       dimerization and activation by autophosphorylation on tyrosine
CC       residues. Inhibited by MAZ51. {ECO:0000269|PubMed:15102829,
CC       ECO:0000269|PubMed:19779139, ECO:0000269|PubMed:20431062}.
CC   -!- SUBUNIT: Interacts with VEGFC and VEGFD. Monomer in the absence of
CC       bound VEGFC or VEGFD. Homodimer in the presence of bound VEGFC or
CC       VEGFD. Can also form a heterodimer with KDR. Interacts with
CC       PTPN14; the interaction is enhanced by stimulation with VEGFC.
CC       Interacts with CRK, GRB2, PTK2/FAK1, SHC1, PIK3R1 and PTPN11/SHP-
CC       2. Identified in a complex with SRC and ITGB1.
CC       {ECO:0000269|PubMed:12881528, ECO:0000269|PubMed:15102829,
CC       ECO:0000269|PubMed:15474514, ECO:0000269|PubMed:16076871,
CC       ECO:0000269|PubMed:16452200, ECO:0000269|PubMed:18593464,
CC       ECO:0000269|PubMed:19610651, ECO:0000269|PubMed:20224550,
CC       ECO:0000269|PubMed:20431062, ECO:0000269|PubMed:20826270,
CC       ECO:0000269|PubMed:7675451, ECO:0000269|PubMed:8700872,
CC       ECO:0000269|PubMed:9435229}.
CC   -!- INTERACTION:
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-1005467, EBI-352572;
CC       P35968:KDR; NbExp=5; IntAct=EBI-1005467, EBI-1005487;
CC       P49767:VEGFC; NbExp=2; IntAct=EBI-1005467, EBI-3405539;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Cytoplasm. Nucleus. Note=Ligand-mediated
CC       autophosphorylation leads to rapid internalization.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein. Note=Ligand-mediated autophosphorylation leads
CC       to rapid internalization.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Secreted. Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=Long;
CC         IsoId=P35916-2; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P35916-1; Sequence=VSP_041995;
CC       Name=3; Synonyms=sVegfr3;
CC         IsoId=P35916-3; Sequence=VSP_041993, VSP_041994;
CC   -!- TISSUE SPECIFICITY: Detected in endothelial cells (at protein
CC       level). Widely expressed. Detected in fetal spleen, lung and
CC       brain. Detected in adult liver, muscle, thymus, placenta, lung,
CC       testis, ovary, prostate, heart, and kidney.
CC       {ECO:0000269|PubMed:1327515, ECO:0000269|PubMed:20224550,
CC       ECO:0000269|PubMed:7675451}.
CC   -!- DOMAIN: The first and second Ig-like C2-type (immunoglobulin-like)
CC       domains are sufficient for VEGFC binding.
CC   -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding.
CC       Autophosphorylation occurs in trans, i.e. one subunit of the
CC       dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Phosphorylation in response to H(2)O(2) is mediated by a
CC       process that requires SRC and PRKCD activity. Phosphorylation at
CC       Tyr-1068 is required for autophosphorylation at additional
CC       tyrosine residues. Phosphorylation at Tyr-1063 and Tyr-1337 is
CC       important for interaction with CRK and subsequent activation of
CC       MAPK8. Phosphorylation at Tyr-1230, Tyr-1231 and Tyr-1337 is
CC       important for interaction with GRB2 and subsequent activation of
CC       the AKT1 and MAPK1/ERK2 and/or MAPK3/ERK1 signaling pathways. In
CC       response to endothelial cell adhesion onto collagen, can also be
CC       phosphorylated in the absence of FLT4 kinase activity by SRC at
CC       Tyr-830, Tyr-833, Tyr-853, Tyr-1063, Tyr-1333, and Tyr-1337.
CC       {ECO:0000269|PubMed:12881528, ECO:0000269|PubMed:15102829,
CC       ECO:0000269|PubMed:15474514, ECO:0000269|PubMed:16076871,
CC       ECO:0000269|PubMed:20431062, ECO:0000269|PubMed:8700872}.
CC   -!- DISEASE: Lymphedema, hereditary, 1A (LMPH1A) [MIM:153100]: A
CC       chronic disabling condition which results in swelling of the
CC       extremities due to altered lymphatic flow. Patients with
CC       lymphedema suffer from recurrent local infections and physical
CC       impairment. {ECO:0000269|PubMed:10835628,
CC       ECO:0000269|PubMed:10856194, ECO:0000269|PubMed:16924388,
CC       ECO:0000269|PubMed:16965327, ECO:0000269|PubMed:17458866,
CC       ECO:0000269|PubMed:19289394, ECO:0000269|PubMed:26091405,
CC       ECO:0000269|PubMed:9817924}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: A
CC       condition characterized by dull red, firm, dome-shaped
CC       hemangiomas, sharply demarcated from surrounding skin, usually
CC       presenting at birth or occurring within the first two or three
CC       months of life. They result from highly proliferative, localized
CC       growth of capillary endothelium and generally undergo regression
CC       and involution without scarring. {ECO:0000269|PubMed:11807987}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Plays an important role in tumor lymphangiogenesis,
CC       in cancer cell survival, migration, and formation of metastases.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 7 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA48290.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=FLT4 entry;
CC       URL="https://en.wikipedia.org/wiki/FLT4";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X69878; CAA49505.1; -; mRNA.
DR   EMBL; U43143; AAA85215.1; -; mRNA.
DR   EMBL; EU826564; ACF47600.1; -; mRNA.
DR   EMBL; AY233382; AAO89504.1; -; mRNA.
DR   EMBL; AY233383; AAO89505.1; -; mRNA.
DR   EMBL; AK291679; BAF84368.1; -; mRNA.
DR   EMBL; AC122714; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X68203; CAA48290.1; ALT_INIT; mRNA.
DR   EMBL; S66407; AAB28539.1; -; mRNA.
DR   CCDS; CCDS43412.1; -. [P35916-1]
DR   CCDS; CCDS4457.1; -. [P35916-2]
DR   PIR; A48999; A48999.
DR   RefSeq; NP_002011.2; NM_002020.4. [P35916-1]
DR   RefSeq; NP_891555.2; NM_182925.4. [P35916-2]
DR   UniGene; Hs.646917; -.
DR   PDB; 4BSJ; X-ray; 2.50 A; A=330-553.
DR   PDB; 4BSK; X-ray; 4.20 A; A=23-229.
DR   PDBsum; 4BSJ; -.
DR   PDBsum; 4BSK; -.
DR   ProteinModelPortal; P35916; -.
DR   SMR; P35916; 28-553, 567-594, 632-765, 823-1180.
DR   BioGrid; 108612; 23.
DR   DIP; DIP-5739N; -.
DR   IntAct; P35916; 7.
DR   MINT; MINT-1182429; -.
DR   STRING; 9606.ENSP00000261937; -.
DR   BindingDB; P35916; -.
DR   ChEMBL; CHEMBL2111409; -.
DR   DrugBank; DB06626; Axitinib.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   GuidetoPHARMACOLOGY; 1814; -.
DR   iPTMnet; P35916; -.
DR   PhosphoSite; P35916; -.
DR   BioMuta; FLT4; -.
DR   DMDM; 357529070; -.
DR   PaxDb; P35916; -.
DR   PRIDE; P35916; -.
DR   DNASU; 2324; -.
DR   Ensembl; ENST00000261937; ENSP00000261937; ENSG00000037280. [P35916-2]
DR   Ensembl; ENST00000393347; ENSP00000377016; ENSG00000037280. [P35916-1]
DR   GeneID; 2324; -.
DR   KEGG; hsa:2324; -.
DR   UCSC; uc003mlz.4; human. [P35916-2]
DR   UCSC; uc003mma.4; human. [P35916-1]
DR   UCSC; uc011dgy.2; human. [P35916-3]
DR   CTD; 2324; -.
DR   GeneCards; FLT4; -.
DR   GeneReviews; FLT4; -.
DR   HGNC; HGNC:3767; FLT4.
DR   MalaCards; FLT4; -.
DR   MIM; 136352; gene.
DR   MIM; 153100; phenotype.
DR   MIM; 602089; phenotype.
DR   neXtProt; NX_P35916; -.
DR   Orphanet; 79452; Milroy disease.
DR   PharmGKB; PA28183; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000037949; -.
DR   HOVERGEN; HBG053432; -.
DR   InParanoid; P35916; -.
DR   KO; K05097; -.
DR   OMA; CDTVAVK; -.
DR   OrthoDB; EOG75F4CC; -.
DR   PhylomeDB; P35916; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-195399; VEGF binds to VEGFR leading to receptor dimerization.
DR   SignaLink; P35916; -.
DR   ChiTaRS; FLT4; human.
DR   GeneWiki; FLT4; -.
DR   GenomeRNAi; 2324; -.
DR   NextBio; 9433; -.
DR   PRO; PR:P35916; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; P35916; -.
DR   CleanEx; HS_FLT4; -.
DR   ExpressionAtlas; P35916; baseline and differential.
DR   Genevisible; P35916; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019838; F:growth factor binding; IPI:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IMP:UniProtKB.
DR   GO; GO:0005021; F:vascular endothelial growth factor-activated receptor activity; IMP:UniProtKB.
DR   GO; GO:0048514; P:blood vessel morphogenesis; ISS:UniProtKB.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0001945; P:lymph vessel development; ISS:BHF-UCL.
DR   GO; GO:0001946; P:lymphangiogenesis; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IMP:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0090037; P:positive regulation of protein kinase C signaling; IMP:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0060312; P:regulation of blood vessel remodeling; ISS:UniProtKB.
DR   GO; GO:0002040; P:sprouting angiogenesis; ISS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; TAS:ProtInc.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0038084; P:vascular endothelial growth factor signaling pathway; IDA:GOC.
DR   GO; GO:0001944; P:vasculature development; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 9.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   InterPro; IPR009137; VEGFR3_rcpt.
DR   PANTHER; PTHR24416:SF49; PTHR24416:SF49; 3.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR01835; VEGFRECEPTR3.
DR   SMART; SM00409; IG; 4.
DR   SMART; SM00408; IGc2; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 6.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 6.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; ATP-binding;
KW   Cell membrane; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Membrane;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Secreted; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     24       {ECO:0000269|PubMed:15340161}.
FT   CHAIN        25   1363       Vascular endothelial growth factor
FT                                receptor 3.
FT                                /FTId=PRO_0000016776.
FT   TOPO_DOM     25    775       Extracellular. {ECO:0000255}.
FT   TRANSMEM    776    796       Helical. {ECO:0000255}.
FT   TOPO_DOM    797   1363       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       30    127       Ig-like C2-type 1.
FT   DOMAIN      151    213       Ig-like C2-type 2.
FT   DOMAIN      219    326       Ig-like C2-type 3.
FT   DOMAIN      331    415       Ig-like C2-type 4.
FT   DOMAIN      422    552       Ig-like C2-type 5.
FT   DOMAIN      555    671       Ig-like C2-type 6.
FT   DOMAIN      678    764       Ig-like C2-type 7.
FT   DOMAIN      845   1173       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     851    859       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE   1037   1037       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     879    879       ATP. {ECO:0000305}.
FT   MOD_RES     830    830       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:20431062}.
FT   MOD_RES     833    833       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:20431062}.
FT   MOD_RES     853    853       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:20431062}.
FT   MOD_RES    1063   1063       Phosphotyrosine; by autocatalysis and
FT                                SRC. {ECO:0000269|PubMed:16076871,
FT                                ECO:0000269|PubMed:20431062}.
FT   MOD_RES    1068   1068       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16076871,
FT                                ECO:0000269|PubMed:20431062}.
FT   MOD_RES    1230   1230       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:16076871}.
FT   MOD_RES    1231   1231       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:16076871}.
FT   MOD_RES    1265   1265       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12881528}.
FT   MOD_RES    1333   1333       Phosphotyrosine; by autocatalysis and
FT                                SRC. {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:20431062}.
FT   MOD_RES    1337   1337       Phosphotyrosine; by autocatalysis and
FT                                SRC. {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:16076871,
FT                                ECO:0000269|PubMed:20431062}.
FT   MOD_RES    1363   1363       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12881528}.
FT   CARBOHYD     33     33       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    104    104       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    166    166       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    251    251       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    299    299       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    411    411       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    515    515       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    527    527       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    594    594       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    683    683       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    690    690       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    758    758       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     51    111       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    158    206       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    252    310       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    445    534       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    578    653       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    699    751       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ     724    765       VDLADSNQKLSIQRVREEDAGRYLCSVCNAKGCVNSSASVA
FT                                V -> REGGPGEGQVRRPARPTIPNPGGPAPPPHPLQESTW
FT                                RTPTRS (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_041993.
FT   VAR_SEQ     766   1298       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_041994.
FT   VAR_SEQ    1298   1363       SCKGPGQNVAVTRAHPDSQGRRRRPERGARGGQVFYNSEYG
FT                                ELSEPSEEDHCSPSARVTFFTDNSY -> R (in
FT                                isoform 2). {ECO:0000303|PubMed:1319394,
FT                                ECO:0000303|PubMed:1327515,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:8386825,
FT                                ECO:0000303|PubMed:8700872,
FT                                ECO:0000303|Ref.7}.
FT                                /FTId=VSP_041995.
FT   VARIANT     149    149       N -> D (in dbSNP:rs34221241).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042062.
FT   VARIANT     378    378       R -> C (in a renal clear cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042063.
FT   VARIANT     494    494       T -> A (in dbSNP:rs307826).
FT                                {ECO:0000269|PubMed:11807987,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_018407.
FT   VARIANT     527    527       N -> S (in dbSNP:rs35874891).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_034379.
FT   VARIANT     641    641       P -> S (in dbSNP:rs55667289).
FT                                {ECO:0000269|PubMed:10835628,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_018408.
FT   VARIANT     855    855       A -> T (in LMPH1A; recessive form;
FT                                results in reduced autophosphorylation;
FT                                results in impaired ligand-induced
FT                                receptor internalisation and downstream
FT                                signaling).
FT                                {ECO:0000269|PubMed:19289394}.
FT                                /FTId=VAR_074044.
FT   VARIANT     857    857       G -> R (in LMPH1A; loss of kinase
FT                                activity). {ECO:0000269|PubMed:10835628,
FT                                ECO:0000269|PubMed:15102829}.
FT                                /FTId=VAR_018409.
FT   VARIANT     868    868       H -> Y (in dbSNP:rs35171798).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042064.
FT   VARIANT     878    878       V -> M (in LMPH1A).
FT                                {ECO:0000269|PubMed:16965327}.
FT                                /FTId=VAR_074045.
FT   VARIANT     890    890       H -> Q (in dbSNP:rs448012).
FT                                {ECO:0000269|PubMed:11807987,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:8386825,
FT                                ECO:0000269|Ref.7}.
FT                                /FTId=VAR_018410.
FT   VARIANT     954    954       P -> S (in HCI; dbSNP:rs34255532).
FT                                {ECO:0000269|PubMed:11807987}.
FT                                /FTId=VAR_018411.
FT   VARIANT    1010   1010       T -> I (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042065.
FT   VARIANT    1020   1020       Q -> L (in LMPH1A).
FT                                {ECO:0000269|PubMed:17458866}.
FT                                /FTId=VAR_074046.
FT   VARIANT    1031   1031       R -> Q (in dbSNP:rs56082504).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042066.
FT   VARIANT    1035   1035       H -> Q (probable disease-associated
FT                                mutation found in sporadic congenital
FT                                lymphedema; de novo mutation).
FT                                {ECO:0000269|PubMed:16965327}.
FT                                /FTId=VAR_074047.
FT   VARIANT    1035   1035       H -> R (in LMPH1A; loss of kinase
FT                                activity). {ECO:0000269|PubMed:10856194}.
FT                                /FTId=VAR_018412.
FT   VARIANT    1041   1041       R -> P (in LMPH1A; loss of kinase
FT                                activity). {ECO:0000269|PubMed:10835628,
FT                                ECO:0000269|PubMed:12881528}.
FT                                /FTId=VAR_018413.
FT   VARIANT    1044   1044       L -> P (in LMPH1A; loss of kinase
FT                                activity). {ECO:0000269|PubMed:10835628}.
FT                                /FTId=VAR_018414.
FT   VARIANT    1049   1049       D -> N (in dbSNP:rs56310180).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042067.
FT   VARIANT    1075   1075       R -> Q. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042068.
FT   VARIANT    1086   1086       I -> T (in LMPH1A).
FT                                {ECO:0000269|PubMed:16965327}.
FT                                /FTId=VAR_074048.
FT   VARIANT    1106   1106       E -> K (in LMPH1A).
FT                                {ECO:0000269|PubMed:16924388}.
FT                                /FTId=VAR_074049.
FT   VARIANT    1108   1108       Missing (in LMPH1A).
FT                                {ECO:0000269|PubMed:16965327}.
FT                                /FTId=VAR_074050.
FT   VARIANT    1114   1114       P -> L (in LMPH1A; loss of kinase
FT                                activity). {ECO:0000269|PubMed:10835628,
FT                                ECO:0000269|PubMed:9817924}.
FT                                /FTId=VAR_018415.
FT   VARIANT    1137   1137       P -> S (in HCI).
FT                                {ECO:0000269|PubMed:11807987}.
FT                                /FTId=VAR_018416.
FT   VARIANT    1146   1146       R -> H (in dbSNP:rs1130379).
FT                                {ECO:0000269|PubMed:11807987,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8386825,
FT                                ECO:0000269|Ref.7}.
FT                                /FTId=VAR_018417.
FT   VARIANT    1235   1235       S -> C (in LMPH1A; recessive form).
FT                                {ECO:0000269|PubMed:26091405}.
FT                                /FTId=VAR_074051.
FT   MUTAGEN     879    879       K->G: Abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:12881528}.
FT   MUTAGEN    1063   1063       Y->F: Loss of phosphorylation site. No
FT                                effect on stimulation of cell
FT                                proliferation and cell migration.
FT                                {ECO:0000269|PubMed:16076871,
FT                                ECO:0000269|PubMed:20431062}.
FT   MUTAGEN    1068   1068       Y->F: Global loss of autophosphorylation.
FT                                Abolishes stimulation of cell
FT                                proliferation and cell migration.
FT                                {ECO:0000269|PubMed:16076871,
FT                                ECO:0000269|PubMed:20431062}.
FT   MUTAGEN    1230   1230       Y->F: Loss of phosphorylation site.
FT                                Strongly reduces stimulation of cell
FT                                proliferation and cell migration.
FT                                {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:16076871}.
FT   MUTAGEN    1231   1231       Y->F: Loss of phosphorylation site.
FT                                Strongly reduces stimulation of cell
FT                                proliferation and cell migration.
FT                                {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:16076871}.
FT   MUTAGEN    1265   1265       Y->F: Loss of phosphorylation site. No
FT                                effect on stimulation of cell
FT                                proliferation and cell migration.
FT                                {ECO:0000269|PubMed:12881528}.
FT   MUTAGEN    1333   1333       Y->F: Loss of phosphorylation site.
FT                                Reduced autophosphorylation.
FT                                {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:7675451}.
FT   MUTAGEN    1337   1337       Y->F: Reduced autophosphorylation.
FT                                Strongly reduces stimulation of cell
FT                                proliferation and cell migration.
FT                                {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:20431062,
FT                                ECO:0000269|PubMed:7675451}.
FT   MUTAGEN    1363   1363       Y->F: Loss of phosphorylation site.
FT                                Slighly reduced autophosphorylation.
FT                                {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:7675451}.
FT   CONFLICT     24     24       G -> D (in Ref. 3; CAA49505 and 7;
FT                                AAO89504/AAO89505). {ECO:0000305}.
FT   CONFLICT    538    538       N -> D (in Ref. 8; BAF84368).
FT                                {ECO:0000305}.
FT   CONFLICT    745    745       R -> P (in Ref. 3; CAA49505 and 7;
FT                                AAO89504/AAO89505). {ECO:0000305}.
FT   CONFLICT    752    753       NA -> RP (in Ref. 3; CAA49505 and 7;
FT                                AAO89504/AAO89505). {ECO:0000305}.
FT   CONFLICT   1128   1128       L -> V (in Ref. 3; CAA49505 and 7;
FT                                AAO89504/AAO89505). {ECO:0000305}.
FT   CONFLICT   1164   1164       E -> D (in Ref. 3; CAA49505).
FT                                {ECO:0000305}.
FT   STRAND      332    339       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      341    346       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      350    362       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      365    370       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      381    388       {ECO:0000244|PDB:4BSJ}.
FT   HELIX       391    393       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      395    403       {ECO:0000244|PDB:4BSJ}.
FT   TURN        404    407       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      408    424       {ECO:0000244|PDB:4BSJ}.
FT   HELIX       425    428       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      441    451       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      457    464       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      501    511       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      514    524       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      530    538       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      541    549       {ECO:0000244|PDB:4BSJ}.
SQ   SEQUENCE   1363 AA;  152757 MW;  B1473AAAC95E7E93 CRC64;
     MQRGAALCLR LWLCLGLLDG LVSGYSMTPP TLNITEESHV IDTGDSLSIS CRGQHPLEWA
     WPGAQEAPAT GDKDSEDTGV VRDCEGTDAR PYCKVLLLHE VHANDTGSYV CYYKYIKARI
     EGTTAASSYV FVRDFEQPFI NKPDTLLVNR KDAMWVPCLV SIPGLNVTLR SQSSVLWPDG
     QEVVWDDRRG MLVSTPLLHD ALYLQCETTW GDQDFLSNPF LVHITGNELY DIQLLPRKSL
     ELLVGEKLVL NCTVWAEFNS GVTFDWDYPG KQAERGKWVP ERRSQQTHTE LSSILTIHNV
     SQHDLGSYVC KANNGIQRFR ESTEVIVHEN PFISVEWLKG PILEATAGDE LVKLPVKLAA
     YPPPEFQWYK DGKALSGRHS PHALVLKEVT EASTGTYTLA LWNSAAGLRR NISLELVVNV
     PPQIHEKEAS SPSIYSRHSR QALTCTAYGV PLPLSIQWHW RPWTPCKMFA QRSLRRRQQQ
     DLMPQCRDWR AVTTQDAVNP IESLDTWTEF VEGKNKTVSK LVIQNANVSA MYKCVVSNKV
     GQDERLIYFY VTTIPDGFTI ESKPSEELLE GQPVLLSCQA DSYKYEHLRW YRLNLSTLHD
     AHGNPLLLDC KNVHLFATPL AASLEEVAPG ARHATLSLSI PRVAPEHEGH YVCEVQDRRS
     HDKHCHKKYL SVQALEAPRL TQNLTDLLVN VSDSLEMQCL VAGAHAPSIV WYKDERLLEE
     KSGVDLADSN QKLSIQRVRE EDAGRYLCSV CNAKGCVNSS ASVAVEGSED KGSMEIVILV
     GTGVIAVFFW VLLLLIFCNM RRPAHADIKT GYLSIIMDPG EVPLEEQCEY LSYDASQWEF
     PRERLHLGRV LGYGAFGKVV EASAFGIHKG SSCDTVAVKM LKEGATASEH RALMSELKIL
     IHIGNHLNVV NLLGACTKPQ GPLMVIVEFC KYGNLSNFLR AKRDAFSPCA EKSPEQRGRF
     RAMVELARLD RRRPGSSDRV LFARFSKTEG GARRASPDQE AEDLWLSPLT MEDLVCYSFQ
     VARGMEFLAS RKCIHRDLAA RNILLSESDV VKICDFGLAR DIYKDPDYVR KGSARLPLKW
     MAPESIFDKV YTTQSDVWSF GVLLWEIFSL GASPYPGVQI NEEFCQRLRD GTRMRAPELA
     TPAIRRIMLN CWSGDPKARP AFSELVEILG DLLQGRGLQE EEEVCMAPRS SQSSEEGSFS
     QVSTMALHIA QADAEDSPPS LQRHSLAARY YNWVSFPGCL ARGAETRGSS RMKTFEEFPM
     TPTTYKGSVD NQTDSGMVLA SEEFEQIESR HRQESGFSCK GPGQNVAVTR AHPDSQGRRR
     RPERGARGGQ VFYNSEYGEL SEPSEEDHCS PSARVTFFTD NSY
//
ID   RELN_MOUSE              Reviewed;        3461 AA.
AC   Q60841; E9PZ78; Q9CUA6;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 3.
DT   20-JAN-2016, entry version 149.
DE   RecName: Full=Reelin;
DE            EC=3.4.21.-;
DE   AltName: Full=Reeler protein;
DE   Flags: Precursor;
GN   Name=Reln; Synonyms=Rl;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INVOLVEMENT IN RL.
RC   TISSUE=Cerebellum;
RX   PubMed=7715726; DOI=10.1038/374719a0;
RA   D'Arcangelo G., Miao G.G., Chen S.-C., Soares H.D., Morgan J.I.,
RA   Curran T.;
RT   "A protein related to extracellular matrix proteins deleted in the
RT   mouse mutant reeler.";
RL   Nature 374:719-723(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING.
RX   PubMed=9417911; DOI=10.1006/geno.1997.4983;
RA   Royaux I., Lambert de Rouvroit C., D'Arcangelo G., Demirov D.,
RA   Goffinet A.M.;
RT   "Genomic organization of the mouse reelin gene.";
RL   Genomics 46:240-250(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2152-3461 (ISOFORM 1).
RC   STRAIN=BALB/cJ; TISSUE=Brain;
RX   PubMed=7647795; DOI=10.1038/ng0595-77;
RA   Hirotsune S., Takahara T., Sasaki N., Hirose K., Yoshiki A.,
RA   Ohashi T., Kusakabe M., Murakami Y., Muramatsu M., Watanabe S.,
RA   Nakao K., Katsuki M., Hayashizaki Y.;
RT   "The reeler gene encodes a protein with an EGF-like motif expressed by
RT   pioneer neurons.";
RL   Nat. Genet. 10:77-83(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3044-3461 (ISOFORM 2).
RC   STRAIN=C57BL/6J; TISSUE=Testis;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [6]
RP   CHARACTERIZATION.
RX   PubMed=8987733;
RA   D'Arcangelo G., Nakajima K., Miyata T., Ogawa M., Mikoshiba K.,
RA   Curran T.;
RT   "Reelin is a secreted glycoprotein recognized by the CR-50 monoclonal
RT   antibody.";
RL   J. Neurosci. 17:23-31(1997).
RN   [7]
RP   CHARACTERIZATION.
RX   PubMed=11689558; DOI=10.1074/jbc.M106996200;
RA   Quattrocchi C.C., Wannenes F., Persico A.M., Ciafre S.A.,
RA   D'Arcangelo G., Farace M.G., Keller F.;
RT   "Reelin is a serine protease of the extracellular matrix.";
RL   J. Biol. Chem. 277:303-309(2002).
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=9182958; DOI=10.1111/j.1460-9568.1997.tb01456.x;
RA   Schiffmann S.N., Bernier B., Goffinet A.M.;
RT   "Reelin mRNA expression during mouse brain development.";
RL   Eur. J. Neurosci. 9:1055-1071(1997).
RN   [9]
RP   ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RX   PubMed=10328932; DOI=10.1006/exnr.1999.7019;
RA   Lambert de Rouvroit C., Bernier B., Royaux I., de Bergeyck V.,
RA   Goffinet A.M.;
RT   "Evolutionarily conserved, alternative splicing of reelin during brain
RT   development.";
RL   Exp. Neurol. 156:229-238(1999).
RN   [10]
RP   INTERACTION WITH VLDLR AND APOER2.
RX   PubMed=10571241; DOI=10.1016/S0896-6273(00)80861-2;
RA   Hiesberger T., Trommsdorff M., Howell B.W., Goffinet A.M., Mumby M.C.,
RA   Cooper J.A., Herz J.;
RT   "Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces
RT   tyrosine phosphorylation of disabled-1 and modulates tau
RT   phosphorylation.";
RL   Neuron 24:481-489(1999).
RN   [11]
RP   FUNCTION.
RX   PubMed=10880573; DOI=10.1073/pnas.150040497;
RA   Yip J.W., Yip Y.P.L., Nakajima K., Capriotti C.;
RT   "Reelin controls position of autonomic neurons in the spinal cord.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:8612-8616(2000).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [13]
RP   SUBUNIT, INTERCHAIN DISULFIDE BOND, AND MUTAGENESIS OF CYS-2101.
RX   PubMed=21844191; DOI=10.1074/jbc.M111.242719;
RA   Yasui N., Kitago Y., Beppu A., Kohno T., Morishita S., Gomi H.,
RA   Nagae M., Hattori M., Takagi J.;
RT   "Functional importance of covalent homodimer of reelin protein linked
RT   via its central region.";
RL   J. Biol. Chem. 286:35247-35256(2011).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 1222-1597, DISULFIDE BONDS,
RP   AND CALCIUM-BINDING.
RX   PubMed=16858396; DOI=10.1038/sj.emboj.7601240;
RA   Nogi T., Yasui N., Hattori M., Iwasaki K., Takagi J.;
RT   "Structure of a signaling-competent reelin fragment revealed by X-ray
RT   crystallography and electron tomography.";
RL   EMBO J. 25:3675-3683(2006).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1948-2662, DISULFIDE BONDS,
RP   GLYCOSYLATION AT ASN-2145; ASN-2269; ASN-2317 AND ASN-2569,
RP   CALCIUM-BINDING, ZINC-BINDING SITES, AND MUTAGENESIS OF LYS-2360 AND
RP   LYS-2467.
RX   PubMed=17548821; DOI=10.1073/pnas.0700438104;
RA   Yasui N., Nogi T., Kitao T., Nakano Y., Hattori M., Takagi J.;
RT   "Structure of a receptor-binding fragment of reelin and mutational
RT   analysis reveal a recognition mechanism similar to endocytic
RT   receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:9988-9993(2007).
CC   -!- FUNCTION: Extracellular matrix serine protease that plays a role
CC       in layering of neurons in the cerebral cortex and cerebellum.
CC       Regulates microtubule function in neurons and neuronal migration.
CC       Affects migration of sympathetic preganglionic neurons in the
CC       spinal cord, where it seems to act as a barrier to neuronal
CC       migration. Enzymatic activity is important for the modulation of
CC       cell adhesion. Binding to the extracellular domains of lipoprotein
CC       receptors VLDLR and LRP8/APOER2 induces tyrosine phosphorylation
CC       of DAB1 and modulation of TAU phosphorylation.
CC       {ECO:0000269|PubMed:10880573}.
CC   -!- SUBUNIT: Oligomer of disulfide-linked homodimers. Binds to the
CC       ectodomains of VLDLR and LRP8/APOER2.
CC       {ECO:0000269|PubMed:16858396, ECO:0000269|PubMed:17548821,
CC       ECO:0000269|PubMed:21844191}.
CC   -!- INTERACTION:
CC       Q924X6:Lrp8; NbExp=4; IntAct=EBI-9248666, EBI-432319;
CC       P98155:VLDLR (xeno); NbExp=4; IntAct=EBI-9248666, EBI-9004309;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q60841-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q60841-2; Sequence=VSP_005577;
CC       Name=3;
CC         IsoId=Q60841-3; Sequence=VSP_005578;
CC   -!- TISSUE SPECIFICITY: The major isoform 1 is neuron-specific. It is
CC       abundantly produced during brain ontogenesis by the Cajal-Retzius
CC       cells and other pioneer neurons located in the telencephalic
CC       marginal zone and by granule cells of the external granular layer
CC       of the cerebellum. Expression is located in deeper layers in the
CC       developing hippocampus and olfactory bulb, low levels of
CC       expression are also detected in the immature striatum. At early
CC       developmental stages, expressed also in hypothalamic
CC       differentiation fields, tectum and spinal cord. A moderate to low
CC       level of expression occurs in the septal area, striatal fields,
CC       habenular nuclei, some thalamic nuclei, particularly the lateral
CC       geniculate, the retina and some nuclei of the reticular formation
CC       in the central field of the medulla. Very low levels found in
CC       liver and kidney. No expression in radial glial cells, cortical
CC       plate, Purkinje cells and inferior olivary neurons. The minor
CC       isoform 2 is only expressed in non neuronal cells. The minor
CC       isoform 3 is found in the same cells as isoform 1, but is almost
CC       undetectable in retina and brain stem.
CC       {ECO:0000269|PubMed:10328932, ECO:0000269|PubMed:9182958}.
CC   -!- DEVELOPMENTAL STAGE: First detected at embryonic day 11.5.
CC       Expression increases up to birth and remains high from postnatal
CC       day 2 to 11 in both cerebellum and fore/midbrain. Expression
CC       declines thereafter and is largely brain specific in the adult.
CC   -!- DOMAIN: The basic C-terminal region is essential for secretion.
CC   -!- PTM: N-glycosylated and to a lesser extent also O-glycosylated.
CC       {ECO:0000269|PubMed:17548821}.
CC   -!- DISEASE: Note=Defects in Reln are the cause of the autosomal
CC       recessive reeler (rl) phenotype which is characterized by impaired
CC       motor coordination, tremors and ataxia. Neurons in affected mice
CC       fail to reach their correct locations in the developing brain,
CC       disrupting the organization of the cerebellar and cerebral
CC       cortices and other laminated regions.
CC       {ECO:0000269|PubMed:7715726}.
CC   -!- SIMILARITY: Belongs to the reelin family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 16 BNR repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 8 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 1 reelin domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00363}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA09788.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U24703; AAB91599.1; -; mRNA.
DR   EMBL; AC113028; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC116404; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC119906; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC121878; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; D63520; BAA09788.1; ALT_INIT; mRNA.
DR   EMBL; AK017094; BAB30592.1; -; mRNA.
DR   CCDS; CCDS39023.1; -. [Q60841-1]
DR   CCDS; CCDS80217.1; -. [Q60841-2]
DR   PIR; S58870; S58870.
DR   RefSeq; NP_001297393.1; NM_001310464.1. [Q60841-2]
DR   RefSeq; NP_035391.2; NM_011261.2. [Q60841-1]
DR   UniGene; Mm.425236; -.
DR   PDB; 2DDU; X-ray; 2.05 A; A=1222-1597.
DR   PDB; 2E26; X-ray; 2.00 A; A=1948-2661.
DR   PDB; 3A7Q; X-ray; 2.60 A; A=1948-2661.
DR   PDBsum; 2DDU; -.
DR   PDBsum; 2E26; -.
DR   PDBsum; 3A7Q; -.
DR   ProteinModelPortal; Q60841; -.
DR   SMR; Q60841; 1294-1597, 1956-2662.
DR   DIP; DIP-40924N; -.
DR   IntAct; Q60841; 2.
DR   MINT; MINT-111528; -.
DR   STRING; 10090.ENSMUSP00000124052; -.
DR   iPTMnet; Q60841; -.
DR   PhosphoSite; Q60841; -.
DR   MaxQB; Q60841; -.
DR   PaxDb; Q60841; -.
DR   PRIDE; Q60841; -.
DR   Ensembl; ENSMUST00000062372; ENSMUSP00000058025; ENSMUSG00000042453. [Q60841-2]
DR   Ensembl; ENSMUST00000161356; ENSMUSP00000124052; ENSMUSG00000042453. [Q60841-1]
DR   GeneID; 19699; -.
DR   KEGG; mmu:19699; -.
DR   UCSC; uc008wpi.1; mouse. [Q60841-1]
DR   CTD; 5649; -.
DR   MGI; MGI:103022; Reln.
DR   eggNOG; ENOG410IEXI; Eukaryota.
DR   eggNOG; ENOG410XQKB; LUCA.
DR   GeneTree; ENSGT00580000081623; -.
DR   HOGENOM; HOG000252908; -.
DR   HOVERGEN; HBG023117; -.
DR   InParanoid; Q60841; -.
DR   KO; K06249; -.
DR   OMA; NWFFYPG; -.
DR   OrthoDB; EOG7P2XR4; -.
DR   TreeFam; TF106479; -.
DR   ChiTaRS; Reln; mouse.
DR   EvolutionaryTrace; Q60841; -.
DR   NextBio; 297056; -.
DR   PRO; PR:Q60841; -.
DR   Proteomes; UP000000589; Chromosome 5.
DR   Bgee; Q60841; -.
DR   CleanEx; MM_RELN; -.
DR   ExpressionAtlas; Q60841; baseline and differential.
DR   Genevisible; Q60841; MM.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0030425; C:dendrite; IDA:MGI.
DR   GO; GO:0005615; C:extracellular space; IDA:MGI.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IDA:MGI.
DR   GO; GO:0070325; F:lipoprotein particle receptor binding; IPI:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008236; F:serine-type peptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0070326; F:very-low-density lipoprotein particle receptor binding; IPI:BHF-UCL.
DR   GO; GO:0008306; P:associative learning; IDA:BHF-UCL.
DR   GO; GO:0007411; P:axon guidance; IMP:MGI.
DR   GO; GO:0007420; P:brain development; IMP:MGI.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0016477; P:cell migration; IMP:MGI.
DR   GO; GO:0000904; P:cell morphogenesis involved in differentiation; IMP:MGI.
DR   GO; GO:0007417; P:central nervous system development; IMP:MGI.
DR   GO; GO:0021987; P:cerebral cortex development; IMP:MGI.
DR   GO; GO:0021800; P:cerebral cortex tangential migration; IMP:MGI.
DR   GO; GO:0016358; P:dendrite development; IMP:MGI.
DR   GO; GO:0030900; P:forebrain development; IMP:MGI.
DR   GO; GO:0010001; P:glial cell differentiation; IMP:MGI.
DR   GO; GO:0021766; P:hippocampus development; IDA:BHF-UCL.
DR   GO; GO:0097477; P:lateral motor column neuron migration; IMP:UniProtKB.
DR   GO; GO:0021819; P:layer formation in cerebral cortex; IMP:MGI.
DR   GO; GO:0007612; P:learning; IMP:CACAO.
DR   GO; GO:0007616; P:long-term memory; IDA:BHF-UCL.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IMP:CACAO.
DR   GO; GO:0050804; P:modulation of synaptic transmission; IMP:BHF-UCL.
DR   GO; GO:0001764; P:neuron migration; IMP:MGI.
DR   GO; GO:0097114; P:NMDA glutamate receptor clustering; IMP:BHF-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:MGI.
DR   GO; GO:2000969; P:positive regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activity; IDA:BHF-UCL.
DR   GO; GO:0032793; P:positive regulation of CREB transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0061003; P:positive regulation of dendritic spine morphogenesis; IDA:BHF-UCL.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; IDA:BHF-UCL.
DR   GO; GO:1902078; P:positive regulation of lateral motor column neuron migration; IMP:BHF-UCL.
DR   GO; GO:1900273; P:positive regulation of long-term synaptic potentiation; IDA:BHF-UCL.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IDA:BHF-UCL.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IDA:MGI.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0051057; P:positive regulation of small GTPase mediated signal transduction; IDA:MGI.
DR   GO; GO:0090129; P:positive regulation of synapse maturation; IDA:BHF-UCL.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IDA:BHF-UCL.
DR   GO; GO:0032008; P:positive regulation of TOR signaling; IDA:BHF-UCL.
DR   GO; GO:0097107; P:postsynaptic density assembly; IC:BHF-UCL.
DR   GO; GO:0097119; P:postsynaptic density protein 95 clustering; IMP:BHF-UCL.
DR   GO; GO:0035418; P:protein localization to synapse; IMP:BHF-UCL.
DR   GO; GO:0097120; P:receptor localization to synapse; IMP:BHF-UCL.
DR   GO; GO:0038026; P:reelin-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0050795; P:regulation of behavior; IMP:BHF-UCL.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:MGI.
DR   GO; GO:2000310; P:regulation of N-methyl-D-aspartate selective glutamate receptor activity; IMP:BHF-UCL.
DR   GO; GO:0048265; P:response to pain; IMP:MGI.
DR   GO; GO:0021511; P:spinal cord patterning; IMP:MGI.
DR   GO; GO:0021517; P:ventral spinal cord development; IEP:UniProtKB.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR002861; Reeler_dom.
DR   InterPro; IPR011040; Sialidases.
DR   Pfam; PF02014; Reeler; 1.
DR   SMART; SM00181; EGF; 5.
DR   SUPFAM; SSF50939; SSF50939; 14.
DR   PROSITE; PS00022; EGF_1; 7.
DR   PROSITE; PS01186; EGF_2; 6.
DR   PROSITE; PS50026; EGF_3; 5.
DR   PROSITE; PS51019; REELIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell adhesion;
KW   Complete proteome; Developmental protein; Disulfide bond;
KW   EGF-like domain; Extracellular matrix; Glycoprotein; Hydrolase;
KW   Metal-binding; Protease; Reference proteome; Repeat; Secreted;
KW   Serine protease; Signal; Zinc.
FT   SIGNAL        1     26       {ECO:0000255}.
FT   CHAIN        27   3461       Reelin.
FT                                /FTId=PRO_0000030305.
FT   DOMAIN       27    191       Reelin. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00363}.
FT   REPEAT      593    604       BNR 1.
FT   DOMAIN      671    702       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT      799    810       BNR 2.
FT   REPEAT      952    963       BNR 3.
FT   DOMAIN     1030   1061       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     1157   1168       BNR 4.
FT   REPEAT     1323   1334       BNR 5.
FT   DOMAIN     1409   1442       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     1535   1546       BNR 6.
FT   REPEAT     1686   1697       BNR 7.
FT   DOMAIN     1765   1796       EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     1884   1895       BNR 8.
FT   REPEAT     2043   2054       BNR 9.
FT   DOMAIN     2129   2161       EGF-like 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     2250   2261       BNR 10.
FT   REPEAT     2399   2410       BNR 11.
FT   DOMAIN     2478   2509       EGF-like 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     2598   2609       BNR 12.
FT   REPEAT     2778   2789       BNR 13.
FT   DOMAIN     2853   2884       EGF-like 7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     2979   2990       BNR 14.
FT   REPEAT     3143   3155       BNR 15.
FT   DOMAIN     3228   3260       EGF-like 8. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     3363   3374       BNR 16.
FT   COMPBIAS   3432   3461       Arg-rich (basic).
FT   METAL      2061   2061       Zinc 1.
FT   METAL      2074   2074       Zinc 1.
FT   METAL      2179   2179       Zinc 1.
FT   METAL      2264   2264       Zinc 1.
FT   METAL      2397   2397       Zinc 2.
FT   METAL      2399   2399       Zinc 2.
FT   METAL      2460   2460       Zinc 2.
FT   CARBOHYD    141    141       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    258    258       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    290    290       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    306    306       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    629    629       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1267   1267       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1447   1447       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1600   1600       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1750   1750       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1921   1921       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2145   2145       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17548821}.
FT   CARBOHYD   2269   2269       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17548821}.
FT   CARBOHYD   2317   2317       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17548821}.
FT   CARBOHYD   2569   2569       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17548821}.
FT   CARBOHYD   2962   2962       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3016   3016       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3073   3073       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3185   3185       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3412   3412       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3439   3439       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     41    127       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    155    179       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    540    581       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    609    614       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    675    685       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    692    701       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    895    937       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    968    975       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1034   1044       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1051   1060       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1271   1310
FT   DISULFID   1339   1348
FT   DISULFID   1633   1673       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1702   1709       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1983   2030
FT   DISULFID   2059   2070
FT   DISULFID   2101   2101       Interchain.
FT   DISULFID   2133   2143
FT   DISULFID   2137   2149
FT   DISULFID   2151   2160
FT   DISULFID   2195   2235
FT   DISULFID   2348   2387
FT   DISULFID   2393   2559
FT   DISULFID   2482   2492
FT   DISULFID   2486   2497
FT   DISULFID   2499   2508
FT   DISULFID   2544   2584
FT   DISULFID   2794   2801       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2919   2966       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   3160   3170       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   3232   3242       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   3236   3248       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   3250   3259       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   3296   3346       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   VAR_SEQ    3429   3461       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_005578.
FT   VAR_SEQ    3429   3430       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:16141072}.
FT                                /FTId=VSP_005577.
FT   MUTAGEN    2101   2101       C->A: Fails to assemble into disulfide-
FT                                bonded multimers, while still exhibiting
FT                                non-covalently associated high molecular
FT                                weight oligomeric states in solution;
FT                                retains binding to LRP8 and VLDR
FT                                receptors but fails to show signaling
FT                                activity. {ECO:0000269|PubMed:21844191}.
FT   MUTAGEN    2360   2360       K->A: Abolishes ApoER2-binding.
FT                                {ECO:0000269|PubMed:17548821}.
FT   MUTAGEN    2467   2467       K->A: Abolishes ApoER2-binding.
FT                                {ECO:0000269|PubMed:17548821}.
FT   CONFLICT   1191   1191       A -> G (in Ref. 1; AAB91599).
FT                                {ECO:0000305}.
FT   CONFLICT   1202   1202       Q -> K (in Ref. 1; AAB91599).
FT                                {ECO:0000305}.
FT   CONFLICT   1335   1335       V -> L (in Ref. 1; AAB91599).
FT                                {ECO:0000305}.
FT   CONFLICT   1345   1345       G -> A (in Ref. 1; AAB91599).
FT                                {ECO:0000305}.
FT   CONFLICT   1505   1505       R -> S (in Ref. 1; AAB91599).
FT                                {ECO:0000305}.
FT   CONFLICT   1522   1524       CIK -> YIT (in Ref. 1; AAB91599).
FT                                {ECO:0000305}.
FT   CONFLICT   1529   1529       N -> Y (in Ref. 1; AAB91599).
FT                                {ECO:0000305}.
FT   CONFLICT   1593   1593       D -> G (in Ref. 1; AAB91599).
FT                                {ECO:0000305}.
FT   CONFLICT   1611   1611       F -> L (in Ref. 1; AAB91599).
FT                                {ECO:0000305}.
FT   CONFLICT   1648   1648       K -> N (in Ref. 1; AAB91599).
FT                                {ECO:0000305}.
FT   CONFLICT   1661   1661       A -> E (in Ref. 1; AAB91599).
FT                                {ECO:0000305}.
FT   CONFLICT   1667   1667       F -> W (in Ref. 1; AAB91599).
FT                                {ECO:0000305}.
FT   CONFLICT   3066   3066       Missing (in Ref. 5; BAB30592).
FT                                {ECO:0000305}.
FT   STRAND     1301   1310       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1320   1327       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1333   1335       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1345   1348       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1359   1361       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1370   1375       {ECO:0000244|PDB:2DDU}.
FT   HELIX      1378   1380       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1386   1390       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1408   1411       {ECO:0000244|PDB:2DDU}.
FT   HELIX      1414   1419       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1420   1424       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1427   1430       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1434   1437       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1440   1445       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1451   1453       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1456   1458       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1463   1472       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1478   1481       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1483   1486       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1493   1496       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1506   1513       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1516   1518       {ECO:0000244|PDB:2DDU}.
FT   HELIX      1528   1530       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1531   1539       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1545   1550       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1559   1564       {ECO:0000244|PDB:2DDU}.
FT   HELIX      1567   1569       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1571   1579       {ECO:0000244|PDB:2DDU}.
FT   HELIX      1584   1586       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1590   1597       {ECO:0000244|PDB:2DDU}.
FT   STRAND     1958   1960       {ECO:0000244|PDB:2E26}.
FT   STRAND     1963   1965       {ECO:0000244|PDB:2E26}.
FT   HELIX      1968   1970       {ECO:0000244|PDB:2E26}.
FT   STRAND     1971   1973       {ECO:0000244|PDB:2E26}.
FT   STRAND     1978   1980       {ECO:0000244|PDB:2E26}.
FT   STRAND     1996   1999       {ECO:0000244|PDB:2E26}.
FT   STRAND     2005   2011       {ECO:0000244|PDB:2E26}.
FT   STRAND     2014   2016       {ECO:0000244|PDB:2E26}.
FT   STRAND     2020   2032       {ECO:0000244|PDB:2E26}.
FT   STRAND     2040   2047       {ECO:0000244|PDB:2E26}.
FT   STRAND     2053   2056       {ECO:0000244|PDB:2E26}.
FT   STRAND     2059   2061       {ECO:0000244|PDB:2E26}.
FT   STRAND     2078   2080       {ECO:0000244|PDB:2E26}.
FT   STRAND     2089   2095       {ECO:0000244|PDB:2E26}.
FT   TURN       2096   2099       {ECO:0000244|PDB:2E26}.
FT   STRAND     2102   2113       {ECO:0000244|PDB:2E26}.
FT   STRAND     2122   2131       {ECO:0000244|PDB:2E26}.
FT   HELIX      2134   2139       {ECO:0000244|PDB:2E26}.
FT   STRAND     2140   2144       {ECO:0000244|PDB:2E26}.
FT   TURN       2145   2147       {ECO:0000244|PDB:2E26}.
FT   STRAND     2148   2151       {ECO:0000244|PDB:2E26}.
FT   STRAND     2155   2157       {ECO:0000244|PDB:2E26}.
FT   STRAND     2170   2172       {ECO:0000244|PDB:2E26}.
FT   STRAND     2174   2176       {ECO:0000244|PDB:2E26}.
FT   STRAND     2178   2187       {ECO:0000244|PDB:2E26}.
FT   STRAND     2189   2193       {ECO:0000244|PDB:2E26}.
FT   STRAND     2197   2201       {ECO:0000244|PDB:2E26}.
FT   STRAND     2203   2206       {ECO:0000244|PDB:2E26}.
FT   STRAND     2208   2210       {ECO:0000244|PDB:3A7Q}.
FT   STRAND     2212   2216       {ECO:0000244|PDB:2E26}.
FT   STRAND     2226   2233       {ECO:0000244|PDB:2E26}.
FT   STRAND     2236   2238       {ECO:0000244|PDB:2E26}.
FT   STRAND     2247   2254       {ECO:0000244|PDB:2E26}.
FT   STRAND     2260   2265       {ECO:0000244|PDB:2E26}.
FT   TURN       2269   2272       {ECO:0000244|PDB:2E26}.
FT   STRAND     2275   2280       {ECO:0000244|PDB:2E26}.
FT   HELIX      2283   2285       {ECO:0000244|PDB:2E26}.
FT   STRAND     2287   2296       {ECO:0000244|PDB:2E26}.
FT   STRAND     2299   2301       {ECO:0000244|PDB:2E26}.
FT   STRAND     2307   2315       {ECO:0000244|PDB:2E26}.
FT   STRAND     2324   2326       {ECO:0000244|PDB:2E26}.
FT   STRAND     2328   2330       {ECO:0000244|PDB:2E26}.
FT   TURN       2333   2335       {ECO:0000244|PDB:2E26}.
FT   STRAND     2336   2338       {ECO:0000244|PDB:2E26}.
FT   STRAND     2343   2345       {ECO:0000244|PDB:2E26}.
FT   STRAND     2354   2357       {ECO:0000244|PDB:2E26}.
FT   STRAND     2364   2368       {ECO:0000244|PDB:2E26}.
FT   STRAND     2371   2373       {ECO:0000244|PDB:2E26}.
FT   STRAND     2378   2384       {ECO:0000244|PDB:2E26}.
FT   STRAND     2387   2389       {ECO:0000244|PDB:3A7Q}.
FT   STRAND     2395   2403       {ECO:0000244|PDB:2E26}.
FT   STRAND     2409   2412       {ECO:0000244|PDB:2E26}.
FT   STRAND     2419   2422       {ECO:0000244|PDB:2E26}.
FT   TURN       2433   2436       {ECO:0000244|PDB:2E26}.
FT   STRAND     2440   2445       {ECO:0000244|PDB:2E26}.
FT   HELIX      2448   2450       {ECO:0000244|PDB:2E26}.
FT   STRAND     2452   2461       {ECO:0000244|PDB:2E26}.
FT   STRAND     2471   2480       {ECO:0000244|PDB:2E26}.
FT   HELIX      2484   2488       {ECO:0000244|PDB:2E26}.
FT   STRAND     2489   2493       {ECO:0000244|PDB:2E26}.
FT   STRAND     2496   2499       {ECO:0000244|PDB:2E26}.
FT   STRAND     2503   2505       {ECO:0000244|PDB:2E26}.
FT   STRAND     2510   2513       {ECO:0000244|PDB:2E26}.
FT   STRAND     2519   2521       {ECO:0000244|PDB:2E26}.
FT   TURN       2529   2531       {ECO:0000244|PDB:2E26}.
FT   STRAND     2532   2542       {ECO:0000244|PDB:2E26}.
FT   STRAND     2547   2550       {ECO:0000244|PDB:2E26}.
FT   STRAND     2552   2555       {ECO:0000244|PDB:2E26}.
FT   STRAND     2562   2565       {ECO:0000244|PDB:2E26}.
FT   STRAND     2575   2582       {ECO:0000244|PDB:2E26}.
FT   STRAND     2584   2586       {ECO:0000244|PDB:2E26}.
FT   HELIX      2591   2593       {ECO:0000244|PDB:2E26}.
FT   STRAND     2594   2602       {ECO:0000244|PDB:2E26}.
FT   STRAND     2608   2613       {ECO:0000244|PDB:2E26}.
FT   STRAND     2615   2617       {ECO:0000244|PDB:3A7Q}.
FT   STRAND     2622   2627       {ECO:0000244|PDB:2E26}.
FT   HELIX      2630   2632       {ECO:0000244|PDB:2E26}.
FT   STRAND     2634   2642       {ECO:0000244|PDB:2E26}.
FT   STRAND     2654   2661       {ECO:0000244|PDB:2E26}.
SQ   SEQUENCE   3461 AA;  387495 MW;  1CCE64C845160F2E CRC64;
     MERGCWAPRA LVLAVLLLLA TLRARAATGY YPRFSPFFFL CTHHGELEGD GEQGEVLISL
     HIAGNPTYYV PGQEYHVTIS TSTFFDGLLV TGLYTSTSIQ SSQSIGGSSA FGFGIMSDHQ
     FGNQFMCSVV ASHVSHLPTT NLSFVWIAPP AGTGCVNFMA TATHRGQVIF KDALAQQLCE
     QGAPTEATAY SHLAEIHSDS VILRDDFDSY QQLELNPNIW VECSNCEMGE QCGTIMHGNA
     VTFCEPYGPR ELTTTCLNTT TASVLQFSIG SGSCRFSYSD PSITVSYAKN NTADWIQLEK
     IRAPSNVSTV IHILYLPEEA KGESVQFQWK QDSLRVGEVY EACWALDNIL VINSAHREVV
     LEDNLDPVDT GNWLFFPGAT VKHSCQSDGN SIYFHGNEGS EFNFATTRDV DLSTEDIQEQ
     WSEEFESQPT GWDILGAVVG ADCGTVESGL SLVFLKDGER KLCTPYMDTT GYGNLRFYFV
     MGGICDPGVS HENDIILYAK IEGRKEHIAL DTLTYSSYKV PSLVSVVINP ELQTPATKFC
     LRQKSHQGYN RNVWAVDFFH VLPVLPSTMS HMIQFSINLG CGTHQPGNSV SLEFSTNHGR
     SWSLLHTECL PEICAGPHLP HSTVYSSENY SGWNRITIPL PNAALTRDTR IRWRQTGPIL
     GNMWAIDNVY IGPSCLKFCS GRGQCTRHGC KCDPGFSGPA CEMASQTFPM FISESFGSAR
     LSSYHNFYSI RGAEVSFGCG VLASGKALVF NKDGRRQLIT SFLDSSQSRF LQFTLRLGSK
     SVLSTCRAPD QPGEGVLLHY SYDNGITWKL LEHYSYVNYH EPRIISVELP DDARQFGIQF
     RWWQPYHSSQ GEDVWAIDEI VMTSVLFNSI SLDFTNLVEV TQSLGFYLGN VQPYCGHDWT
     LCFTGDSKLA SSMRYVETQS MQIGASYMIQ FSLVMGCGQK YTPHMDNQVK LEYSANHGLT
     WHLVQEECLP SMPSCQEFTS ASIYHASEFT QWRRVTVVLP QKTWSGATRF RWSQSYYTAQ
     DEWALDNIYI GQQCPNMCSG HGSCDHGVCR CDQGYQGTEC HPEAALPSTI MSDFENPSSW
     ESDWQEVIGG EVVKPEQGCG VVSSGSSLYF SKAGKRQLVS WDLDTSWVDF VQFYIQIGGE
     SAACNKPDSR EEGILLQYSN NGGIQWHLLA EMYFSDFSKP RFVYLELPAA AKTPCTRFRW
     WQPVFSGEDY DQWAVDDIII LSEKQKQVIP VVNPTLPQNF YEKPAFDYPM NQMSVWLMLA
     NEGMAKNDSF CATTPSAMVF GKSDGDRFAV TRDLTLKPGY VLQFKLNIGC TSQFSSTAPV
     LLQYSHDAGM SWFLVKEGCF PASAGKGCEG NSRELSEPTV YYTGDFEEWT RITIAIPRSL
     ASSKTRFRWI QESSSQKNVP PFGLDGVYIS EPCPSYCSGH GDCISGVCFC DLGYTAAQGT
     CVSNTPNHSE MFDRFEGKLS PLWYKITGGQ VGTGCGTLND GRSLYFNGLG KREARTVPLD
     TRNIRLVQFY IQIGSKTSGI TCIKPRARNE GLVVQYSNDN GILWHLLREL DFMSFLEPQI
     ISIDLPREAK TPATAFRWWQ PQHGKHSAQW ALDDVLIGVN DSSQTGFQDK FDGSIDLQAN
     WYRIQGGQVD IDCLSMDTAL IFTENIGKPR YAETWDFHVS ASSFLQFEMN MGCSKPFSGA
     HGIQLQYSLN NGKDWQLVTE ECVPPTIGCV HYTESSTYTS ERFQNWRRVT VYLPLATNSP
     RTRFRWIQTN YTVGADSWAI DNVILASGCP WMCSGRGICD SGRCVCDRGF GGPFCVPVVP
     LPSILKDDFN GNLHPDLWPE VYGAERGNLN GETIKSGTCL IFKGEGLRML ISRDLDCTNT
     MYVQFSLRFI AKGTPERSHS ILLQFSVSGG VTWHLMDEFY FPQTTSILFI NVPLPYGAQT
     NATRFRLWQP YNNGKKEEIW IIDDFIIDGN NLNNPVLLLD TFDFGPREDN WFFYPGGNIG
     LYCPYSSKGA PEEDSAMVFV SNEVGEHSIT TRDLSVNENT IIQFEINVGC STDSSSADPV
     RLEFSRDFGA TWHLLLPLCY HSSSLVSSLC STEHHPSSTY YAGTTQGWRR EVVHFGKLHL
     CGSVRFRWYQ GFYPAGSQPV TWAIDNVYIG PQCEEMCYGH GSCINGTKCI CDPGYSGPTC
     KISTKNPDFL KDDFEGQLES DRFLLMSGGK PSRKCGILSS GNNLFFNEDG LRMLVTRDLD
     LSHARFVQFF MRLGCGKGVP DPRSQPVLLQ YSLNGGLSWS LLQEFLFSNS SNVGRYIALE
     MPLKARSGST RLRWWQPSEN GHFYSPWVID QILIGGNISG NTVLEDDFST LDSRKWLLHP
     GGTKMPVCGS TGDALVFIEK ASTRYVVTTD IAVNEDSFLQ IDFAASCSVT DSCYAIELEY
     SVDLGLSWHP LVRDCLPTNV ECSRYHLQRI LVSDTFNKWT RITLPLPSYT RSQATRFRWH
     QPAPFDKQQT WAIDNVYIGD GCLDMCSGHG RCVQGSCVCD EQWGGLYCDE PETSLPTQLK
     DNFNRAPSNQ NWLTVSGGKL STVCGAVASG LALHFSGGCS RLLVTVDLNL TNAEFIQFYF
     MYGCLITPSN RNQGVLLEYS VNGGITWNLL MEIFYDQYSK PGFVNILLPP DAKEIATRFR
     WWQPRHDGLD QNDWAIDNVL ISGSADQRTV MLDTFSSAPV PQHERSPADA GPVGRIAFEM
     FLEDKTSVNE NWLFHDDCTV ERFCDSPDGV MLCGSHDGRE VYAVTHDLTP TENWIMQFKI
     SVGCKVPEKI AQNQIHVQFS TDFGVSWSYL VPQCLPADPK CSGSVSQPSV FFPTEGWKRI
     TYPLPESLTG NPVRFRFYQK YSDVQWAIDN FYLGPGCLDN CGGHGDCLKE QCICDPGYSG
     PNCYLTHSLK TFLKERFDSE EIKPDLWMSL EGGSTCTECG VLAENTALYF GGSTVRQAIT
     QDLDLRGAKF LQYWGRIGSE NNMTSCHRPV CRKEGVLLDF STDGGITWTL LHEMDFQKYI
     SVRHDYILLP EGALTNTTRL RWWQPFVISN GLVVSGVERA QWALDNILIG GAEINPSQLV
     DTFDDEGSSH EENWSFYPNA VRTAGFCGNP SFHLYWPNKK KDKTHNALSS RELIIQPGYM
     MQFKIVVGCE ATSCGDLHSV MLEYTKDARS DSWQLVQTQC LPSSSNSIGC SPFQFHEATI
     YNAVNSSSWK RITIQLPDHV SSSATQFRWI QKGEETEKQS WAIDHVYIGE ACPKLCSGHG
     YCTTGAVCIC DESFQGDDCS VFSHELPSYI KDNFESARVT EANWETIQGG VIGSGCGQLA
     PYAHGDSLYF NGCQIRQAAT KPLDLTRASK IMFVLQIGSP AQTDSCNSDL SGPHTVDKAV
     LLQYSVNNGI TWHVIAQHQP KDFTQAQRVS YNVPLEARMK GVLLRWWQPR HNGTGHDQWA
     LDHVEVVLVS TRKQNYMMNF SRQHGLRHFY NRRRRSLRRY P
//
ID   ANGI_HUMAN              Reviewed;         147 AA.
AC   P03950; Q05CV1; Q53X86; Q6P5T2; Q8WXE7;
DT   23-OCT-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-OCT-1986, sequence version 1.
DT   20-JAN-2016, entry version 188.
DE   RecName: Full=Angiogenin;
DE            EC=3.1.27.-;
DE   AltName: Full=Ribonuclease 5;
DE            Short=RNase 5;
DE   Flags: Precursor;
GN   Name=ANG; Synonyms=RNASE5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2866795; DOI=10.1021/bi00341a032;
RA   Kurachi K., Davie E.W., Strydom D.J., Riordan J.F., Vallee B.L.;
RT   "Sequence of the cDNA and gene for angiogenin, a human angiogenesis
RT   factor.";
RL   Biochemistry 24:5494-5499(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLU-84.
RX   PubMed=11919285; DOI=10.1093/oxfordjournals.molbev.a004099;
RA   Zhang J., Rosenberg H.F.;
RT   "Diversifying selection of the tumor-growth promoter angiogenin in
RT   primate evolution.";
RL   Mol. Biol. Evol. 19:438-445(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Li J., Wang H.;
RL   Submitted (SEP-2008) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Small intestine;
RA   Wakamatsu A., Yamamoto J., Kimura K., Kaida T., Tsuchiya K., Iida Y.,
RA   Takayama Y., Murakawa K., Kanehori K., Andoh T., Kagawa N., Sato R.,
RA   Kawamura Y., Tanaka S., Kisu Y., Sugano S., Goshima N., Nomura N.,
RA   Isogai T.;
RT   "NEDO functional analysis of protein and research application
RT   project.";
RL   Submitted (JAN-2008) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 25-147, PYROGLUTAMATE FORMATION AT GLN-25, AND
RP   DISULFIDE BONDS.
RX   PubMed=2866794; DOI=10.1021/bi00341a031;
RA   Strydom D.J., Fett J.W., Lobb R.R., Alderman E.M., Bethune J.L.,
RA   Riordan J.F., Vallee B.L.;
RT   "Amino acid sequence of human tumor derived angiogenin.";
RL   Biochemistry 24:5486-5494(1985).
RN   [9]
RP   TISSUE SPECIFICITY.
RX   PubMed=2440105; DOI=10.1126/science.2440105;
RA   Weiner H.L., Weiner L.H., Swain J.L.;
RT   "Tissue distribution and developmental expression of the messenger RNA
RT   encoding angiogenin.";
RL   Science 237:280-282(1987).
RN   [10]
RP   FUNCTION.
RX   PubMed=1400510;
RA   Saxena S.K., Rybak S.M., Davey R.T. Jr., Youle R.J., Ackerman E.J.;
RT   "Angiogenin is a cytotoxic, tRNA-specific ribonuclease in the RNase A
RT   superfamily.";
RL   J. Biol. Chem. 267:21982-21986(1992).
RN   [11]
RP   SUBCELLULAR LOCATION, AND NUCLEOLAR LOCALIZATION SIGNAL.
RX   PubMed=7945327; DOI=10.1006/bbrc.1994.2391;
RA   Moroianu J., Riordan J.F.;
RT   "Identification of the nucleolar targeting signal of human
RT   angiogenin.";
RL   Biochem. Biophys. Res. Commun. 203:1765-1772(1994).
RN   [12]
RP   MUTAGENESIS OF HIS-32; GLN-36; LYS-64; ASN-92 AND GLU-132.
RX   PubMed=9050852; DOI=10.1073/pnas.94.5.1761;
RA   Chen C.Z., Shapiro R.;
RT   "Site-specific mutagenesis reveals differences in the structural bases
RT   for tight binding of RNase inhibitor to angiogenin and RNase A.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:1761-1766(1997).
RN   [13]
RP   INTERACTION WITH RNH1, AND MUTAGENESIS OF ARG-29 AND LYS-64.
RX   PubMed=10413501; DOI=10.1021/bi990762a;
RA   Chen C.Z., Shapiro R.;
RT   "Superadditive and subadditive effects of 'hot spot' mutations within
RT   the interfaces of placental ribonuclease inhibitor with angiogenin and
RT   ribonuclease A.";
RL   Biochemistry 38:9273-9285(1999).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, AND DNA-BINDING.
RX   PubMed=12051708; DOI=10.1016/S0006-291X(02)00479-5;
RA   Xu Z.P., Tsuji T., Riordan J.F., Hu G.F.;
RT   "The nuclear function of angiogenin in endothelial cells is related to
RT   rRNA production.";
RL   Biochem. Biophys. Res. Commun. 294:287-292(2002).
RN   [15]
RP   FUNCTION, INTERACTION WITH RNH1, AND MUTAGENESIS OF 109-GLY-GLY-110.
RX   PubMed=19354288; DOI=10.1021/bi9005094;
RA   Dickson K.A., Kang D.K., Kwon Y.S., Kim J.C., Leland P.A., Kim B.M.,
RA   Chang S.I., Raines R.T.;
RT   "Ribonuclease inhibitor regulates neovascularization by human
RT   angiogenin.";
RL   Biochemistry 48:3804-3806(2009).
RN   [16]
RP   FUNCTION.
RX   PubMed=21855800; DOI=10.1016/j.molcel.2011.06.022;
RA   Ivanov P., Emara M.M., Villen J., Gygi S.P., Anderson P.;
RT   "Angiogenin-induced tRNA fragments inhibit translation initiation.";
RL   Mol. Cell 43:613-623(2011).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 25-147.
RX   PubMed=8159679; DOI=10.1073/pnas.91.8.2915;
RA   Acharya K.R., Shapiro R., Allen S.C., Riordan J.F., Vallee B.L.;
RT   "Crystal structure of human angiogenin reveals the structural basis
RT   for its functional divergence from ribonuclease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:2915-2919(1994).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 25-147 IN COMPLEX WITH RNH1
RP   AND SUBUNIT.
RX   PubMed=9311977; DOI=10.1093/emboj/16.17.5162;
RA   Papageorgiou A.C., Shapiro R., Acharya K.R.;
RT   "Molecular recognition of human angiogenin by placental ribonuclease
RT   inhibitor -- an X-ray crystallographic study at 2.0-A resolution.";
RL   EMBO J. 16:5162-5177(1997).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 26-147.
RX   PubMed=9918722; DOI=10.1006/jmbi.1998.2378;
RA   Leonidas D.D., Shapiro R., Allen S.C., Subbarao G.V., Veluraja K.,
RA   Acharya K.R.;
RT   "Refined crystal structures of native human angiogenin and two active
RT   site variants: implications for the unique functional properties of an
RT   enzyme involved in neovascularisation during tumour growth.";
RL   J. Mol. Biol. 285:1209-1233(1999).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 26-147 OF MUTANT GLY-141 IN
RP   COMPLEX WITH PHOSPHATE AND PYROPHOSPHATE.
RX   PubMed=11468363; DOI=10.1110/ps.13601;
RA   Leonidas D.D., Chavali G.B., Jardine A.M., Li S., Shapiro R.,
RA   Acharya K.R.;
RT   "Binding of phosphate and pyrophosphate ions at the active site of
RT   human angiogenin as revealed by X-ray crystallography.";
RL   Protein Sci. 10:1669-1676(2001).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 26-147, AND MUTAGENESIS OF
RP   ASP-140; GLN-141 AND 143-ILE-PHE-144.
RX   PubMed=11851402; DOI=10.1021/bi015768q;
RA   Leonidas D.D., Shapiro R., Subbarao G.V., Russo A., Acharya K.R.;
RT   "Crystallographic studies on the role of the C-terminal segment of
RT   human angiogenin in defining enzymatic potency.";
RL   Biochemistry 41:2552-2562(2002).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 26-147.
RX   PubMed=12842050; DOI=10.1016/S0969-2126(03)00131-X;
RA   Chavali G.B., Papageorgiou A.C., Olson K.A., Fett J.W., Hu G.,
RA   Shapiro R., Acharya K.R.;
RT   "The crystal structure of human angiogenin in complex with an
RT   antitumor neutralizing antibody.";
RL   Structure 11:875-885(2003).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF MUTANTS ASP-68 AND ALA-104.
RX   PubMed=14756559; DOI=10.1021/bi035654+;
RA   Holloway D.E., Chavali G.B., Hares M.C., Baker M.D., Subbarao G.V.,
RA   Shapiro R., Acharya K.R.;
RT   "Crystallographic studies on structural features that determine the
RT   enzymatic specificity and potency of human angiogenin: Thr44, Thr80,
RT   and residues 38-41.";
RL   Biochemistry 43:1230-1241(2004).
RN   [24]
RP   STRUCTURE BY NMR.
RX   PubMed=9461294; DOI=10.1111/j.1432-1033.1997.00712.x;
RA   Lequin O., Thuering H., Robin M., Lallemand J.-Y.;
RT   "Three-dimensional solution structure of human angiogenin determined
RT   by 1H,15N-NMR spectroscopy -- characterization of histidine
RT   protonation states and pKa values.";
RL   Eur. J. Biochem. 250:712-726(1997).
RN   [25]
RP   3D-STRUCTURE MODELING.
RX   PubMed=22384259; DOI=10.1371/journal.pone.0032479;
RA   Padhi A.K., Kumar H., Vasaikar S.V., Jayaram B., Gomes J.;
RT   "Mechanisms of loss of functions of human angiogenin variants
RT   implicated in amyotrophic lateral sclerosis.";
RL   PLoS ONE 7:E32479-E32479(2012).
RN   [26]
RP   VARIANT ALS9 ILE-64.
RX   PubMed=15557516; DOI=10.1212/01.WNL.0000144344.39103.F6;
RA   Greenway M.J., Alexander M.D., Ennis S., Traynor B.J., Corr B.,
RA   Frost E., Green A., Hardiman O.;
RT   "A novel candidate region for ALS on chromosome 14q11.2.";
RL   Neurology 63:1936-1938(2004).
RN   [27]
RP   VARIANTS ALS9 LEU-36; ILE-41; GLU-41; LYS-55; TRP-63 AND ILE-64, AND
RP   VARIANT VAL-70.
RX   PubMed=16501576; DOI=10.1038/ng1742;
RA   Greenway M.J., Andersen P.M., Russ C., Ennis S., Cashman S.,
RA   Donaghy C., Patterson V., Swingler R., Kieran D., Prehn J.,
RA   Morrison K.E., Green A., Acharya K.R., Brown R.H. Jr., Hardiman O.;
RT   "ANG mutations segregate with familial and 'sporadic' amyotrophic
RT   lateral sclerosis.";
RL   Nat. Genet. 38:411-413(2006).
RN   [28]
RP   VARIANTS ALS9 SER-20; ILE-41; ASN-52 AND LEU-136, CHARACTERIZATION OF
RP   VARIANTS ALS9 ILE-41; ASN-52 AND LEU-136, AND TISSUE SPECIFICITY.
RX   PubMed=17886298; DOI=10.1002/ana.21221;
RA   Wu D., Yu W., Kishikawa H., Folkerth R.D., Iafrate A.J., Shen Y.,
RA   Xin W., Sims K., Hu G.-F.;
RT   "Angiogenin loss-of-function mutations in amyotrophic lateral
RT   sclerosis.";
RL   Ann. Neurol. 62:609-617(2007).
RN   [29]
RP   CHARACTERIZATION OF VARIANTS ALS9 LEU-36; ILE-41; GLU-41; LYS-55;
RP   TRP-63 AND ILE-64, AND CHARACTERIZATION OF VARIANT VAL-70.
RX   PubMed=17900154; DOI=10.1021/bi701333h;
RA   Crabtree B., Thiyagarajan N., Prior S.H., Wilson P., Iyer S.,
RA   Ferns T., Shapiro R., Brew K., Subramanian V., Acharya K.R.;
RT   "Characterization of human angiogenin variants implicated in
RT   amyotrophic lateral sclerosis.";
RL   Biochemistry 46:11810-11818(2007).
RN   [30]
RP   VARIANTS ALS9 SER-12; SER-20; ILE-137 AND ARG-138, AND VARIANT VAL-70.
RX   PubMed=18087731; DOI=10.1007/s10048-007-0111-3;
RA   Gellera C., Colombrita C., Ticozzi N., Castellotti B., Bragato C.,
RA   Ratti A., Taroni F., Silani V.;
RT   "Identification of new ANG gene mutations in a large cohort of Italian
RT   patients with amyotrophic lateral sclerosis.";
RL   Neurogenetics 9:33-40(2008).
RN   [31]
RP   INVOLVEMENT IN ALS9.
RX   PubMed=17703939; DOI=10.1016/j.nmd.2007.07.003;
RA   Conforti F.L., Sprovieri T., Mazzei R., Ungaro C., La Bella V.,
RA   Tessitore A., Patitucci A., Magariello A., Gabriele A.L., Tedeschi G.,
RA   Simone I.L., Majorana G., Valentino P., Condino F., Bono F.,
RA   Monsurro M.R., Muglia M., Quattrone A.;
RT   "A novel angiogenin gene mutation in a sporadic patient with
RT   amyotrophic lateral sclerosis from southern Italy.";
RL   Neuromuscul. Disord. 18:68-70(2008).
RN   [32]
RP   VARIANTS ALS9 HIS-38; ILE-41 AND GLY-46.
RX   PubMed=22292843; DOI=10.3109/17482968.2011.643899;
RA   Brown J.A., Min J., Staropoli J.F., Collin E., Bi S., Feng X.,
RA   Barone R., Cao Y., O'Malley L., Xin W., Mullen T.E., Sims K.B.;
RT   "SOD1, ANG, TARDBP and FUS mutations in amyotrophic lateral sclerosis:
RT   a United States clinical testing lab experience.";
RL   Amyotroph. Lateral Scler. 13:217-222(2012).
RN   [33]
RP   VARIANT ALS9 GLY-46, CHARACTERIZATION OF VARIANT ALS9 GLY-46,
RP   MUTAGENESIS OF LEU-59, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=25372031; DOI=10.1371/journal.pone.0111963;
RA   Padhi A.K., Banerjee K., Gomes J., Banerjee M.;
RT   "Computational and functional characterization of Angiogenin
RT   mutations, and correlation with amyotrophic lateral sclerosis.";
RL   PLoS ONE 9:E111963-E111963(2014).
CC   -!- FUNCTION: Binds to actin on the surface of endothelial cells; once
CC       bound, angiogenin is endocytosed and translocated to the nucleus.
CC       Stimulates ribosomal RNA synthesis including that containing the
CC       initiation site sequences of 45S rRNA. Cleaves tRNA within
CC       anticodon loops to produce tRNA-derived stress-induced fragments
CC       (tiRNAs) which inhibit protein synthesis and triggers the assembly
CC       of stress granules (SGs). Angiogenin induces vascularization of
CC       normal and malignant tissues. Angiogenic activity is regulated by
CC       interaction with RNH1 in vivo. {ECO:0000269|PubMed:12051708,
CC       ECO:0000269|PubMed:1400510, ECO:0000269|PubMed:19354288,
CC       ECO:0000269|PubMed:21855800}.
CC   -!- SUBUNIT: Homodimer (PubMed:25372031). Interacts with and forms a
CC       tight 1:1 complex with RNH1. Dimerization of two such complexes
CC       may occur. {ECO:0000269|PubMed:10413501,
CC       ECO:0000269|PubMed:11468363, ECO:0000269|PubMed:19354288,
CC       ECO:0000269|PubMed:25372031, ECO:0000269|PubMed:9311977}.
CC   -!- INTERACTION:
CC       P35609:ACTN2; NbExp=4; IntAct=EBI-525291, EBI-77797;
CC       P19883:FST; NbExp=3; IntAct=EBI-525291, EBI-1571188;
CC       P13489:RNH1; NbExp=2; IntAct=EBI-525291, EBI-1237106;
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle, secretory vesicle lumen
CC       {ECO:0000250|UniProtKB:Q3TMQ6}. Secreted
CC       {ECO:0000250|UniProtKB:P10152}. Nucleus
CC       {ECO:0000269|PubMed:12051708, ECO:0000269|PubMed:25372031}.
CC       Nucleus, nucleolus {ECO:0000269|PubMed:7945327}. Note=Rapidly
CC       endocytosed by target cells and translocated to the nucleus where
CC       it accumulates in the nucleolus and binds to DNA
CC       (PubMed:12051708). {ECO:0000269|PubMed:12051708}.
CC   -!- TISSUE SPECIFICITY: Expressed predominantly in the liver. Also
CC       detected in endothelial cells and spinal cord neurons.
CC       {ECO:0000269|PubMed:17886298, ECO:0000269|PubMed:2440105}.
CC   -!- DEVELOPMENTAL STAGE: Low level expression in the developing fetus,
CC       increased in the neonate, and maximal in the adult.
CC   -!- DISEASE: Amyotrophic lateral sclerosis 9 (ALS9) [MIM:611895]: A
CC       neurodegenerative disorder affecting upper motor neurons in the
CC       brain and lower motor neurons in the brain stem and spinal cord,
CC       resulting in fatal paralysis. Sensory abnormalities are absent.
CC       The pathologic hallmarks of the disease include pallor of the
CC       corticospinal tract due to loss of motor neurons, presence of
CC       ubiquitin-positive inclusions within surviving motor neurons, and
CC       deposition of pathologic aggregates. The etiology of amyotrophic
CC       lateral sclerosis is likely to be multifactorial, involving both
CC       genetic and environmental factors. The disease is inherited in 5-
CC       10% of the cases. {ECO:0000269|PubMed:15557516,
CC       ECO:0000269|PubMed:16501576, ECO:0000269|PubMed:17703939,
CC       ECO:0000269|PubMed:17886298, ECO:0000269|PubMed:18087731,
CC       ECO:0000269|PubMed:22292843, ECO:0000269|PubMed:25372031}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the pancreatic ribonuclease family.
CC       {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-3 is the initiator.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH20704.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=R&D Systems' cytokine mini-reviews: Angiogenin;
CC       URL="http://www.rndsystems.com/molecule_detail.aspx?m=1054";
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;
CC       Note=Angiogenin;
CC       URL="http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_other_803";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ANGID635ch14q11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M11567; AAA51678.1; -; Genomic_DNA.
DR   EMBL; AF449647; AAL67710.1; -; Genomic_DNA.
DR   EMBL; AF449648; AAL67711.1; -; Genomic_DNA.
DR   EMBL; AF449649; AAL67712.1; -; Genomic_DNA.
DR   EMBL; AF449650; AAL67713.1; -; Genomic_DNA.
DR   EMBL; AF449651; AAL67714.1; -; Genomic_DNA.
DR   EMBL; FJ236304; ACI45236.1; -; mRNA.
DR   EMBL; CR407633; CAG28561.1; -; mRNA.
DR   EMBL; AK313989; BAG36701.1; -; mRNA.
DR   EMBL; CH471078; EAW66450.1; -; Genomic_DNA.
DR   EMBL; CH471078; EAW66451.1; -; Genomic_DNA.
DR   EMBL; BC020704; AAH20704.1; ALT_INIT; mRNA.
DR   EMBL; BC054880; AAH54880.1; -; mRNA.
DR   EMBL; BC062698; AAH62698.1; -; mRNA.
DR   CCDS; CCDS9554.1; -.
DR   PIR; A90498; NRHUAG.
DR   RefSeq; NP_001091046.1; NM_001097577.2.
DR   RefSeq; NP_001136.1; NM_001145.4.
DR   UniGene; Hs.283749; -.
DR   PDB; 1A4Y; X-ray; 2.00 A; B/E=25-147.
DR   PDB; 1ANG; X-ray; 2.40 A; A=25-147.
DR   PDB; 1AWZ; NMR; -; A=25-147.
DR   PDB; 1B1E; X-ray; 2.00 A; A=25-147.
DR   PDB; 1B1I; X-ray; 1.80 A; A=26-147.
DR   PDB; 1B1J; X-ray; 2.00 A; A=25-147.
DR   PDB; 1GV7; X-ray; 2.10 A; A=26-145.
DR   PDB; 1H0D; X-ray; 2.00 A; C=26-147.
DR   PDB; 1H52; X-ray; 2.00 A; A=25-147.
DR   PDB; 1H53; X-ray; 2.00 A; A=26-147.
DR   PDB; 1HBY; X-ray; 2.00 A; A=25-147.
DR   PDB; 1K58; X-ray; 2.70 A; A=25-147.
DR   PDB; 1K59; X-ray; 1.80 A; A=25-147.
DR   PDB; 1K5A; X-ray; 2.33 A; A=25-147.
DR   PDB; 1K5B; X-ray; 1.80 A; A=25-144.
DR   PDB; 1UN3; X-ray; 1.70 A; A=26-147.
DR   PDB; 1UN4; X-ray; 2.10 A; A=26-147.
DR   PDB; 1UN5; X-ray; 2.60 A; A=25-147.
DR   PDB; 2ANG; X-ray; 2.00 A; A=25-147.
DR   PDB; 4AHD; X-ray; 2.47 A; A/B=25-147.
DR   PDB; 4AHE; X-ray; 2.08 A; A=25-147.
DR   PDB; 4AHF; X-ray; 2.12 A; A=25-147.
DR   PDB; 4AHG; X-ray; 2.45 A; A=25-147.
DR   PDB; 4AHH; X-ray; 2.50 A; A=25-147.
DR   PDB; 4AHI; X-ray; 2.80 A; A=25-147.
DR   PDB; 4AHJ; X-ray; 2.03 A; A=25-147.
DR   PDB; 4AHK; X-ray; 1.97 A; A/B=25-147.
DR   PDB; 4AHL; X-ray; 2.05 A; A=25-147.
DR   PDB; 4AHM; X-ray; 1.96 A; A=25-147.
DR   PDB; 4AHN; X-ray; 2.98 A; A=25-147.
DR   PDB; 4AOH; X-ray; 1.04 A; A=24-147.
DR   PDB; 4B36; X-ray; 1.76 A; A/B=25-107, A/B=116-147.
DR   PDBsum; 1A4Y; -.
DR   PDBsum; 1ANG; -.
DR   PDBsum; 1AWZ; -.
DR   PDBsum; 1B1E; -.
DR   PDBsum; 1B1I; -.
DR   PDBsum; 1B1J; -.
DR   PDBsum; 1GV7; -.
DR   PDBsum; 1H0D; -.
DR   PDBsum; 1H52; -.
DR   PDBsum; 1H53; -.
DR   PDBsum; 1HBY; -.
DR   PDBsum; 1K58; -.
DR   PDBsum; 1K59; -.
DR   PDBsum; 1K5A; -.
DR   PDBsum; 1K5B; -.
DR   PDBsum; 1UN3; -.
DR   PDBsum; 1UN4; -.
DR   PDBsum; 1UN5; -.
DR   PDBsum; 2ANG; -.
DR   PDBsum; 4AHD; -.
DR   PDBsum; 4AHE; -.
DR   PDBsum; 4AHF; -.
DR   PDBsum; 4AHG; -.
DR   PDBsum; 4AHH; -.
DR   PDBsum; 4AHI; -.
DR   PDBsum; 4AHJ; -.
DR   PDBsum; 4AHK; -.
DR   PDBsum; 4AHL; -.
DR   PDBsum; 4AHM; -.
DR   PDBsum; 4AHN; -.
DR   PDBsum; 4AOH; -.
DR   PDBsum; 4B36; -.
DR   ProteinModelPortal; P03950; -.
DR   SMR; P03950; 24-145.
DR   BioGrid; 106780; 7.
DR   IntAct; P03950; 7.
DR   STRING; 9606.ENSP00000336762; -.
DR   BindingDB; P03950; -.
DR   ChEMBL; CHEMBL5829; -.
DR   PhosphoSite; P03950; -.
DR   BioMuta; ANG; -.
DR   DMDM; 113873; -.
DR   PaxDb; P03950; -.
DR   PeptideAtlas; P03950; -.
DR   PRIDE; P03950; -.
DR   DNASU; 283; -.
DR   Ensembl; ENST00000336811; ENSP00000336762; ENSG00000214274.
DR   Ensembl; ENST00000397990; ENSP00000381077; ENSG00000214274.
DR   GeneID; 283; -.
DR   KEGG; hsa:283; -.
DR   UCSC; uc001vxw.4; human.
DR   CTD; 283; -.
DR   GeneCards; ANG; -.
DR   GeneReviews; ANG; -.
DR   HGNC; HGNC:483; ANG.
DR   MalaCards; ANG; -.
DR   MIM; 105850; gene.
DR   MIM; 611895; phenotype.
DR   neXtProt; NX_P03950; -.
DR   Orphanet; 803; Amyotrophic lateral sclerosis.
DR   PharmGKB; PA24790; -.
DR   eggNOG; ENOG410J3ET; Eukaryota.
DR   eggNOG; ENOG410Y4FD; LUCA.
DR   HOGENOM; HOG000276883; -.
DR   HOVERGEN; HBG008396; -.
DR   InParanoid; P03950; -.
DR   KO; K16631; -.
DR   OMA; CESMMER; -.
DR   OrthoDB; EOG7J1826; -.
DR   PhylomeDB; P03950; -.
DR   TreeFam; TF333393; -.
DR   Reactome; R-HSA-418990; Adherens junctions interactions.
DR   EvolutionaryTrace; P03950; -.
DR   GeneWiki; Angiogenin; -.
DR   GenomeRNAi; 283; -.
DR   NextBio; 1141; -.
DR   PRO; PR:P03950; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; P03950; -.
DR   CleanEx; HS_ANG; -.
DR   ExpressionAtlas; P03950; baseline and differential.
DR   Genevisible; P03950; HS.
DR   GO; GO:0032311; C:angiogenin-PRI complex; IPI:UniProtKB.
DR   GO; GO:0005605; C:basal lamina; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0030426; C:growth cone; ISS:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; ISS:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003779; F:actin binding; IDA:UniProtKB.
DR   GO; GO:0005507; F:copper ion binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IC:UniProtKB.
DR   GO; GO:0004519; F:endonuclease activity; TAS:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IDA:UniProtKB.
DR   GO; GO:0042277; F:peptide binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IDA:UniProtKB.
DR   GO; GO:0004540; F:ribonuclease activity; IDA:UniProtKB.
DR   GO; GO:0019843; F:rRNA binding; TAS:UniProtKB.
DR   GO; GO:0030041; P:actin filament polymerization; ISS:UniProtKB.
DR   GO; GO:0032431; P:activation of phospholipase A2 activity; IMP:UniProtKB.
DR   GO; GO:0007202; P:activation of phospholipase C activity; IMP:UniProtKB.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IMP:UniProtKB.
DR   GO; GO:0034332; P:adherens junction organization; TAS:Reactome.
DR   GO; GO:0001525; P:angiogenesis; IMP:UniProtKB.
DR   GO; GO:0019731; P:antibacterial humoral response; IDA:UniProtKB.
DR   GO; GO:0019732; P:antifungal humoral response; IDA:UniProtKB.
DR   GO; GO:0007154; P:cell communication; NAS:UniProtKB.
DR   GO; GO:0034329; P:cell junction assembly; TAS:Reactome.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0045216; P:cell-cell junction organization; TAS:Reactome.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IDA:UniProtKB.
DR   GO; GO:0006651; P:diacylglycerol biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0042592; P:homeostatic process; NAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IDA:UniProtKB.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IDA:UniProtKB.
DR   GO; GO:0017148; P:negative regulation of translation; IEA:UniProtKB-KW.
DR   GO; GO:0090305; P:nucleic acid phosphodiester bond hydrolysis; TAS:GOC.
DR   GO; GO:0001556; P:oocyte maturation; NAS:UniProtKB.
DR   GO; GO:0001541; P:ovarian follicle development; NAS:UniProtKB.
DR   GO; GO:0001890; P:placenta development; NAS:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0042327; P:positive regulation of phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050714; P:positive regulation of protein secretion; IDA:UniProtKB.
DR   GO; GO:0009725; P:response to hormone; IDA:UniProtKB.
DR   GO; GO:0001666; P:response to hypoxia; IDA:UniProtKB.
DR   GO; GO:0001878; P:response to yeast; IDA:UniProtKB.
DR   GO; GO:0090501; P:RNA phosphodiester bond hydrolysis; IDA:GOC.
DR   GO; GO:0009303; P:rRNA transcription; IMP:UniProtKB.
DR   Gene3D; 3.10.130.10; -; 1.
DR   InterPro; IPR001427; RNaseA.
DR   InterPro; IPR023411; RNaseA_AS.
DR   InterPro; IPR023412; RNaseA_domain.
DR   PANTHER; PTHR11437; PTHR11437; 1.
DR   Pfam; PF00074; RnaseA; 1.
DR   PRINTS; PR00794; RIBONUCLEASE.
DR   ProDom; PD000535; RNaseA; 1.
DR   SMART; SM00092; RNAse_Pc; 1.
DR   SUPFAM; SSF54076; SSF54076; 1.
DR   PROSITE; PS00127; RNASE_PANCREATIC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Amyotrophic lateral sclerosis; Angiogenesis;
KW   Complete proteome; Cytoplasmic vesicle; Developmental protein;
KW   Differentiation; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; DNA-binding; Endonuclease; Hydrolase;
KW   Neurodegeneration; Nuclease; Nucleus; Polymorphism;
KW   Protein synthesis inhibitor; Pyrrolidone carboxylic acid;
KW   Reference proteome; Secreted; Signal; Stress response.
FT   SIGNAL        1     24       {ECO:0000269|PubMed:2866794}.
FT   CHAIN        25    147       Angiogenin. {ECO:0000269|PubMed:2866794,
FT                                ECO:0000269|PubMed:2866795}.
FT                                /FTId=PRO_0000030843.
FT   REGION       64     68       Substrate binding.
FT   MOTIF        55     59       Nucleolar localization signal.
FT   ACT_SITE     37     37       Proton acceptor.
FT   ACT_SITE    138    138       Proton donor.
FT   MOD_RES      25     25       Pyrrolidone carboxylic acid.
FT                                {ECO:0000269|PubMed:2866794}.
FT   DISULFID     50    105       {ECO:0000269|PubMed:2866794}.
FT   DISULFID     63    116       {ECO:0000269|PubMed:2866794}.
FT   DISULFID     81    131       {ECO:0000269|PubMed:2866794}.
FT   VARIANT      12     12       F -> S (in ALS9).
FT                                {ECO:0000269|PubMed:18087731}.
FT                                /FTId=VAR_044145.
FT   VARIANT      20     20       P -> S (in ALS9).
FT                                {ECO:0000269|PubMed:17886298,
FT                                ECO:0000269|PubMed:18087731}.
FT                                /FTId=VAR_044146.
FT   VARIANT      36     36       Q -> L (in ALS9; reduced ribonucleolytic
FT                                activity; low angiogenic activity;
FT                                reduced mitogenic activity; wild type
FT                                far-UV CD spectra).
FT                                {ECO:0000269|PubMed:16501576,
FT                                ECO:0000269|PubMed:17900154}.
FT                                /FTId=VAR_044147.
FT   VARIANT      38     38       Y -> H (in ALS9).
FT                                {ECO:0000269|PubMed:22292843}.
FT                                /FTId=VAR_073021.
FT   VARIANT      41     41       K -> E (in ALS9; reduced ribonucleolytic
FT                                activity). {ECO:0000269|PubMed:16501576,
FT                                ECO:0000269|PubMed:17900154}.
FT                                /FTId=VAR_044148.
FT   VARIANT      41     41       K -> I (in ALS9; loss of angiogenic
FT                                activity; reduced ribonucleolytic
FT                                activity; retains nuclear translocation).
FT                                {ECO:0000269|PubMed:16501576,
FT                                ECO:0000269|PubMed:17886298,
FT                                ECO:0000269|PubMed:17900154,
FT                                ECO:0000269|PubMed:22292843}.
FT                                /FTId=VAR_044149.
FT   VARIANT      46     46       D -> G (in ALS9; homodimerization is
FT                                similar to wild-type; localization in the
FT                                nucleus is similar to the wild-type;
FT                                reduces strongly ribonucleolytic
FT                                activity). {ECO:0000269|PubMed:22292843,
FT                                ECO:0000269|PubMed:25372031}.
FT                                /FTId=VAR_073022.
FT   VARIANT      52     52       S -> N (in ALS9; loss of angiogenic
FT                                activity; reduced ribonucleolytic
FT                                activity; unable to translocate to the
FT                                nucleus). {ECO:0000269|PubMed:17886298}.
FT                                /FTId=VAR_044150.
FT   VARIANT      55     55       R -> K (in ALS9; marginally reduced
FT                                ribonucleolytic activity; wild type far-
FT                                UV CD spectra).
FT                                {ECO:0000269|PubMed:16501576,
FT                                ECO:0000269|PubMed:17900154}.
FT                                /FTId=VAR_044151.
FT   VARIANT      63     63       C -> W (in ALS9; reduced ribonucleolytic
FT                                activity; low angiogenic activity;
FT                                reduced mitogenic activity; reduced
FT                                thermal stability).
FT                                {ECO:0000269|PubMed:16501576,
FT                                ECO:0000269|PubMed:17900154}.
FT                                /FTId=VAR_044152.
FT   VARIANT      64     64       K -> I (in ALS9; reduced ribonucleolytic
FT                                activity; low angiogenic activity;
FT                                reduced mitogenic activity; moderate
FT                                reduction of thermal stability).
FT                                {ECO:0000269|PubMed:15557516,
FT                                ECO:0000269|PubMed:16501576,
FT                                ECO:0000269|PubMed:17900154}.
FT                                /FTId=VAR_044153.
FT   VARIANT      70     70       I -> V (in some ALS9 patients;
FT                                pathogenicity uncertain; reduced
FT                                ribonucleolytic activity; moderate
FT                                reduction of thermal stability).
FT                                {ECO:0000269|PubMed:16501576,
FT                                ECO:0000269|PubMed:17900154,
FT                                ECO:0000269|PubMed:18087731}.
FT                                /FTId=VAR_044154.
FT   VARIANT      84     84       K -> E (in dbSNP:rs17560).
FT                                {ECO:0000269|PubMed:11919285}.
FT                                /FTId=VAR_013148.
FT   VARIANT     136    136       P -> L (in ALS9; loss of angiogenic
FT                                activity; reduced ribonucleolytic
FT                                activity; unable to translocate to the
FT                                nucleus). {ECO:0000269|PubMed:17886298}.
FT                                /FTId=VAR_044155.
FT   VARIANT     137    137       V -> I (in ALS9).
FT                                {ECO:0000269|PubMed:18087731}.
FT                                /FTId=VAR_044156.
FT   VARIANT     138    138       H -> R (in ALS9).
FT                                {ECO:0000269|PubMed:18087731}.
FT                                /FTId=VAR_044157.
FT   MUTAGEN      29     29       R->A: Significantly decreases binding
FT                                affinity for RNH1.
FT                                {ECO:0000269|PubMed:10413501}.
FT   MUTAGEN      32     32       H->A: Significantly decreases binding
FT                                affinity for RNH1.
FT                                {ECO:0000269|PubMed:9050852}.
FT   MUTAGEN      36     36       Q->A: Slightly decreases binding affinity
FT                                for RNH1. {ECO:0000269|PubMed:9050852}.
FT   MUTAGEN      59     59       L->P: Homodimerization is similar to
FT                                wild-type; causes mislocalization in the
FT                                cytoplasm; reduces strongly
FT                                ribonucleolytic activity.
FT                                {ECO:0000269|PubMed:25372031}.
FT   MUTAGEN      64     64       K->Q: Significantly decreases binding
FT                                affinity for RNH1.
FT                                {ECO:0000269|PubMed:10413501,
FT                                ECO:0000269|PubMed:9050852}.
FT   MUTAGEN      92     92       N->A: Slightly decreases binding affinity
FT                                for RNH1. {ECO:0000269|PubMed:9050852}.
FT   MUTAGEN     109    110       GG->RR: Significantly decreases binding
FT                                affinity for RNH1.
FT                                {ECO:0000269|PubMed:19354288}.
FT   MUTAGEN     132    132       E->A: Slightly decreases binding affinity
FT                                for RNH1. {ECO:0000269|PubMed:9050852}.
FT   MUTAGEN     140    140       D->H,S,A: 15- to 18-fold increase in
FT                                RNase activity.
FT                                {ECO:0000269|PubMed:11851402}.
FT   MUTAGEN     141    141       Q->G: Over 18-fold increase in RNase
FT                                activity. {ECO:0000269|PubMed:11851402}.
FT   MUTAGEN     143    144       IF->AA: 3- to 5-fold increase in RNase
FT                                activity. {ECO:0000269|PubMed:11851402}.
FT   CONFLICT     59     59       L -> P (in Ref. 7; AAH62698).
FT                                {ECO:0000305}.
FT   HELIX        28     37       {ECO:0000244|PDB:4AOH}.
FT   HELIX        47     56       {ECO:0000244|PDB:4AOH}.
FT   TURN         60     63       {ECO:0000244|PDB:4AOH}.
FT   STRAND       65     70       {ECO:0000244|PDB:4AOH}.
FT   HELIX        74     78       {ECO:0000244|PDB:4AOH}.
FT   HELIX        79     81       {ECO:0000244|PDB:4AOH}.
FT   TURN         83     85       {ECO:0000244|PDB:4AOH}.
FT   STRAND       86     89       {ECO:0000244|PDB:4AOH}.
FT   TURN         90     92       {ECO:0000244|PDB:4AOH}.
FT   STRAND       93     98       {ECO:0000244|PDB:4AOH}.
FT   STRAND      100    110       {ECO:0000244|PDB:4AOH}.
FT   STRAND      112    115       {ECO:0000244|PDB:4AOH}.
FT   STRAND      117    125       {ECO:0000244|PDB:4AOH}.
FT   STRAND      128    132       {ECO:0000244|PDB:4AOH}.
FT   STRAND      135    139       {ECO:0000244|PDB:4AOH}.
FT   HELIX       141    144       {ECO:0000244|PDB:4AOH}.
SQ   SEQUENCE   147 AA;  16550 MW;  9C462DA3C8D39ACC CRC64;
     MVMGLGVLLL VFVLGLGLTP PTLAQDNSRY THFLTQHYDA KPQGRDDRYC ESIMRRRGLT
     SPCKDINTFI HGNKRSIKAI CENKNGNPHR ENLRISKSSF QVTTCKLHGG SPWPPCQYRA
     TAGFRNVVVA CENGLPVHLD QSIFRRP
//
ID   ATS13_HUMAN             Reviewed;        1427 AA.
AC   Q76LX8; Q6UY16; Q710F6; Q711T8; Q96L37; Q9H0G3; Q9UGQ1;
DT   25-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2004, sequence version 1.
DT   17-FEB-2016, entry version 128.
DE   RecName: Full=A disintegrin and metalloproteinase with thrombospondin motifs 13;
DE            Short=ADAM-TS 13;
DE            Short=ADAM-TS13;
DE            Short=ADAMTS-13;
DE            EC=3.4.24.87;
DE   AltName: Full=von Willebrand factor-cleaving protease;
DE            Short=vWF-CP;
DE            Short=vWF-cleaving protease;
DE   Flags: Precursor;
GN   Name=ADAMTS13; Synonyms=C9orf8; ORFNames=UNQ6102/PRO20085;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 75-103,
RP   AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=11574066; DOI=10.1093/oxfordjournals.jbchem.a003009;
RA   Soejima K., Mimura N., Hirashima M., Maeda H., Hamamoto T.,
RA   Nakagaki T., Nozaki C.;
RT   "A novel human metalloprotease synthesized in the liver and secreted
RT   into the blood: possibly, the von Willebrand factor-cleaving
RT   protease?";
RL   J. Biochem. 130:475-480(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), GLYCOSYLATION, AND VARIANT
RP   VAL-900.
RC   TISSUE=Liver;
RX   PubMed=11557746; DOI=10.1074/jbc.C100515200;
RA   Zheng X., Chung D., Takayama T.K., Majerus E.M., Sadler J.E.,
RA   Fujikawa K.;
RT   "Structure of von Willebrand factor-cleaving protease (ADAMTS13), a
RT   metalloprotease involved in thrombotic thrombocytopenic purpura.";
RL   J. Biol. Chem. 276:41059-41063(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INVOLVEMENT IN THROMBOTIC
RP   THROMBOCYTOPENIC PURPURA, VARIANTS TTP ASP-96; CYS-102; ILE-196;
RP   HIS-398; GLY-528; CYS-692; GLY-951; GLY-1024 AND TYR-1213, AND
RP   VARIANTS TRP-7; GLU-448; ALA-618; HIS-625; VAL-732; VAL-900 AND
RP   THR-1033.
RC   TISSUE=Liver;
RX   PubMed=11586351; DOI=10.1038/35097008;
RA   Levy G.G., Nichols W.C., Lian E.C., Foroud T., McClintick J.N.,
RA   McGee B.M., Yang A.Y., Siemieniak D.R., Stark K.R., Gruppo R.,
RA   Sarode R., Shurin S.B., Chandrasekaran V., Stabler S.P., Sabio H.,
RA   Bouhassira E.E., Upshaw J.D. Jr., Ginsburg D., Tsai H.-M.;
RT   "Mutations in a member of the ADAMTS gene family cause thrombotic
RT   thrombocytopenic purpura.";
RL   Nature 413:488-494(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Liver;
RX   PubMed=11867212; DOI=10.1016/S0378-1119(01)00861-7;
RA   Cal S., Obaya A.J., Llamazares M., Garabaya C., Quesada V.,
RA   Lopez-Otin C.;
RT   "Cloning, expression analysis, and structural characterization of
RT   seven novel human ADAMTSs, a family of metalloproteinases with
RT   disintegrin and thrombospondin-1 domains.";
RL   Gene 283:49-62(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RC   TISSUE=Brain;
RA   Young J.M., Woodward K.J., Aziz S., Burley M., Kwiatkowski D.J.,
RA   Povey S.;
RT   "Cloning of a sugar transporter gene, a G-beta subunit like gene and
RT   three novel genes in human chromosome 9q34.";
RL   Submitted (SEP-1998) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS TRP-7; GLU-448;
RP   HIS-456; LEU-457; ALA-618; HIS-625; LYS-740; VAL-900; ARG-982;
RP   THR-1033 AND ILE-1226.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAR-2006) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 275-1427, AND VARIANT
RP   GLU-448.
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1191-1427.
RC   TISSUE=Testis;
RX   PubMed=11230166; DOI=10.1101/gr.GR1547R;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H.,
RA   Lauber J., Duesterhoeft A., Beyer A., Koehrer K., Strack N.,
RA   Mewes H.-W., Ottenwaelder B., Obermaier B., Tampe J., Heubner D.,
RA   Wambutt R., Korn B., Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and
RT   analysis of 500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [11]
RP   PROTEIN SEQUENCE OF 75-89.
RX   PubMed=11535494; DOI=10.1182/blood.V98.6.1654;
RA   Gerritsen H.E., Robles R., Laemmle B., Furlan M.;
RT   "Partial amino acid sequence of purified von Willebrand factor-
RT   cleaving protease.";
RL   Blood 98:1654-1661(2001).
RN   [12]
RP   PROTEIN SEQUENCE OF 75-94.
RX   PubMed=11535495; DOI=10.1182/blood.V98.6.1662;
RA   Fujikawa K., Suzuki H., McMullen B., Chung D.;
RT   "Purification of human von Willebrand factor-cleaving protease and its
RT   identification as a new member of the metalloproteinase family.";
RL   Blood 98:1662-1666(2001).
RN   [13]
RP   CHARACTERIZATION, AND SUBCELLULAR LOCATION.
RX   PubMed=12791682; DOI=10.1074/jbc.M305331200;
RA   Zheng X., Nishio K., Majerus E.M., Sadler J.E.;
RT   "Cleavage of von Willebrand factor requires the spacer domain of the
RT   metalloprotease ADAMTS13.";
RL   J. Biol. Chem. 278:30136-30141(2003).
RN   [14]
RP   ENZYME REGULATION, AND MUTAGENESIS OF ARG-71 AND ARG-73.
RX   PubMed=12975358; DOI=10.1074/jbc.M309872200;
RA   Majerus E.M., Zheng X., Tuley E.A., Sadler J.E.;
RT   "Cleavage of the ADAMTS13 propeptide is not required for protease
RT   activity.";
RL   J. Biol. Chem. 278:46643-46648(2003).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-614; ASN-667 AND ASN-1354.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [16]
RP   ENZYME REGULATION.
RX   PubMed=16286459; DOI=10.1074/jbc.M504540200;
RA   Anderson P.J., Kokame K., Sadler J.E.;
RT   "Zinc and calcium ions cooperatively modulate ADAMTS13 activity.";
RL   J. Biol. Chem. 281:850-857(2006).
RN   [17]
RP   GLYCOSYLATION AT SER-698; SER-757; SER-907; SER-965; SER-1027 AND
RP   SER-1087, IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF
RP   SER-399; SER-698; SER-757; SER-907; SER-965; SER-1027 AND SER-1087.
RX   PubMed=17395589; DOI=10.1074/jbc.M700317200;
RA   Ricketts L.M., Dlugosz M., Luther K.B., Haltiwanger R.S.,
RA   Majerus E.M.;
RT   "O-fucosylation is required for ADAMTS13 secretion.";
RL   J. Biol. Chem. 282:17014-17023(2007).
RN   [18]
RP   ENZYME REGULATION, CALCIUM-BINDING SITES, AND MUTAGENESIS OF GLU-83;
RP   ASP-173; GLU-184; ASP-187 AND GLU-212.
RX   PubMed=19047683; DOI=10.1182/blood-2008-03-144683;
RA   Gardner M.D., Chion C.K., de Groot R., Shah A., Crawley J.T.,
RA   Lane D.A.;
RT   "A functional calcium-binding site in the metalloprotease domain of
RT   ADAMTS13.";
RL   Blood 113:1149-1157(2009).
RN   [19]
RP   GLYCOSYLATION AT ASN-667 AND ASN-707.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [20]
RP   REVIEW ON VARIANTS.
RX   PubMed=19847791; DOI=10.1002/humu.21143;
RA   Lotta L.A., Garagiola I., Palla R., Cairo A., Peyvandi F.;
RT   "ADAMTS13 mutations and polymorphisms in congenital thrombotic
RT   thrombocytopenic purpura.";
RL   Hum. Mutat. 31:11-19(2010).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 287-685, FUNCTION,
RP   GLYCOSYLATION AT TRP-387; SER-399; ASN-552 AND ASN-614, SPACER DOMAIN,
RP   AND DISULFIDE BONDS.
RX   PubMed=19880749; DOI=10.1073/pnas.0909755106;
RA   Akiyama M., Takeda S., Kokame K., Takagi J., Miyata T.;
RT   "Crystal structures of the noncatalytic domains of ADAMTS13 reveal
RT   multiple discontinuous exosites for von Willebrand factor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:19274-19279(2009).
RN   [22]
RP   VARIANTS TTP PRO-268 AND TYR-508, VARIANTS GLU-448 AND SER-475,
RP   CHARACTERIZATION OF VARIANTS TTP PRO-268 AND TYR-508, AND
RP   CHARACTERIZATION OF VARIANTS GLU-448 AND SER-475.
RX   PubMed=12181489; DOI=10.1073/pnas.172277399;
RA   Kokame K., Matsumoto M., Soejima K., Yagi H., Ishizashi H., Funato M.,
RA   Tamai H., Konno M., Kamide K., Kawano Y., Miyata T., Fujimura Y.;
RT   "Mutations and common polymorphisms in ADAMTS13 gene responsible for
RT   von Willebrand factor-cleaving protease activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:11902-11907(2002).
RN   [23]
RP   VARIANTS TTP GLN-232; CYS-263 AND LEU-353.
RX   PubMed=12393505; DOI=10.1182/blood-2002-08-2399;
RA   Schneppenheim R., Budde U., Oyen F., Angerhaus D., Aumann V.,
RA   Drewke E., Hassenpflug W., Haberle J., Kentouche K., Kohne E.,
RA   Kurnik K., Mueller-Wiefel D., Obser T., Santer R., Sykora K.W.;
RT   "von Willebrand factor cleaving protease and ADAMTS13 mutations in
RT   childhood TTP.";
RL   Blood 101:1845-1850(2003).
RN   [24]
RP   VARIANT TTP TRP-1336, AND VARIANT VAL-732.
RX   PubMed=12614216; DOI=10.1046/j.1365-2141.2003.04183.x;
RA   Antoine G., Zimmermann K., Plaimauer B., Grillowitzer M., Studt J.D.,
RA   Lammle B., Scheiflinger F.;
RT   "ADAMTS13 gene defects in two brothers with constitutional thrombotic
RT   thrombocytopenic purpura and normalization of von Willebrand factor-
RT   cleaving protease activity by recombinant human ADAMTS13.";
RL   Br. J. Haematol. 120:821-824(2003).
RN   [25]
RP   VARIANTS TTP HIS-235; TYR-311 AND LEU-353, AND VARIANT LEU-457.
RX   PubMed=12753286; DOI=10.1046/j.1523-1755.63.6s.1.x;
RA   Assink K., Schiphorst R., Allford S., Karpman D., Etzioni A.,
RA   Brichard B., van de Kar N., Monnens L., van den Heuvel L.;
RT   "Mutation analysis and clinical implications of von Willebrand factor-
RT   cleaving protease deficiency.";
RL   Kidney Int. 63:1995-1999(2003).
RN   [26]
RP   VARIANT TTP ILE-196, AND VARIANT GLU-448.
RX   PubMed=14512317; DOI=10.1182/blood-2003-04-1346;
RA   Pimanda J.E., Maekawa A., Wind T., Paxton J., Chesterman C.N.,
RA   Hogg P.J.;
RT   "Congenital thrombotic thrombocytopenic purpura in association with a
RT   mutation in the second CUB domain of ADAMTS13.";
RL   Blood 103:627-629(2004).
RN   [27]
RP   VARIANTS TTP TRP-193; PHE-673; TYR-908 AND CYS-1123, VARIANT GLU-448,
RP   AND CHARACTERIZATION OF VARIANTS TTP TRP-193; PHE-673; TYR-908 AND
RP   CYS-1123.
RX   PubMed=14563640; DOI=10.1182/blood-2003-06-1796;
RA   Matsumoto M., Kokame K., Soejima K., Miura M., Hayashi S., Fujii Y.,
RA   Iwai A., Ito E., Tsuji Y., Takeda-Shitaka M., Iwadate M., Umeyama H.,
RA   Yagi H., Ishizashi H., Banno F., Nakagaki T., Miyata T., Fujimura Y.;
RT   "Molecular characterization of ADAMTS13 gene mutations in Japanese
RT   patients with Upshaw-Schulman syndrome.";
RL   Blood 103:1305-1310(2004).
RN   [28]
RP   VARIANT TTP VAL-250, AND CHARACTERIZATION OF VARIANT TTP VAL-250.
RX   PubMed=15126318; DOI=10.1182/blood-2004-02-0715;
RA   Uchida T., Wada H., Mizutani M., Iwashita M., Ishihara H., Shibano T.,
RA   Suzuki M., Matsubara Y., Soejima K., Matsumoto M., Fujimura Y.,
RA   Ikeda Y., Murata M.;
RT   "Identification of novel mutations in ADAMTS13 in an adult patient
RT   with congenital thrombotic thrombocytopenic purpura.";
RL   Blood 104:2081-2083(2004).
RN   [29]
RP   VARIANTS TTP MET-79; PRO-203; PRO-268; GLN-507; VAL-596; ARG-758 AND
RP   SER-908.
RX   PubMed=15009458; DOI=10.1111/j.1538-7933.2004.00623.x;
RA   Veyradier A., Lavergne J.M., Ribba A.S., Obert B., Loirat C.,
RA   Meyer D., Girma J.P.;
RT   "Ten candidate ADAMTS13 mutations in six French families with
RT   congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman
RT   syndrome).";
RL   J. Thromb. Haemost. 2:424-429(2004).
RN   [30]
RP   VARIANT TTP CYS-390.
RX   PubMed=15327386; DOI=10.1111/j.1523-1755.2004.00841.x;
RA   Licht C., Stapenhorst L., Simon T., Budde U., Schneppenheim R.,
RA   Hoppe B.;
RT   "Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic
RT   purpura/hemolytic-uremic syndrome (TTP/HUS).";
RL   Kidney Int. 66:955-958(2004).
RN   [31]
RP   VARIANTS LEU-903 AND TRP-1095.
RX   PubMed=16468327;
RA   Liu F., Jin J., Dong N.Z., Wang Y.G., Ruan C.G.;
RT   "Identification of two novel mutations in ADAMTS13 gene in a patient
RT   with hereditary thrombotic thrombocytopenic purpura.";
RL   Zhonghua Xue Ye Xue Za Zhi 26:521-524(2005).
RN   [32]
RP   CHARACTERIZATION OF VARIANTS TRP-7; GLU-448; ALA-618 AND VAL-732,
RP   CHARACTERIZATION OF VARIANT TTP TRP-1336, AND DISCUSSION OF MUTUAL
RP   MODULATORY EFFECTS OF POLYMORPHISMS.
RX   PubMed=16160007; DOI=10.1182/blood-2005-06-2482;
RA   Plaimauer B., Fuhrmann J., Mohr G., Wernhart W., Bruno K., Ferrari S.,
RA   Konetschny C., Antoine G., Rieger M., Scheiflinger F.;
RT   "Modulation of ADAMTS13 secretion and specific activity by a
RT   combination of common amino acid polymorphisms and a missense
RT   mutation.";
RL   Blood 107:118-125(2006).
RN   [33]
RP   VARIANTS TTP MET-88 AND VAL-1239, AND CHARACTERIZATION OF VARIANTS TTP
RP   MET-88 AND VAL-1239.
RX   PubMed=16453338; DOI=10.1002/humu.20267;
RA   Peyvandi F., Lavoretano S., Palla R., Valsecchi C., Merati G.,
RA   De Cristofaro R., Rossi E., Mannuccio Mannucci P.;
RT   "Mechanisms of the interaction between two ADAMTS13 gene mutations
RT   leading to severe deficiency of enzymatic activity.";
RL   Hum. Mutat. 27:330-336(2006).
RN   [34]
RP   VARIANT TTP TRP-1060, AND CHARACTERIZATION OF VARIANTS TTP TRP-1060.
RX   PubMed=16796708; DOI=10.1111/j.1538-7836.2006.02098.x;
RA   Tao Z., Anthony K., Peng Y., Choi H., Nolasco L., Rice L., Moake J.L.,
RA   Dong J.F.;
RT   "Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic
RT   thrombocytopenic purpura.";
RL   J. Thromb. Haemost. 4:1931-1935(2006).
RN   [35]
RP   VARIANT TTP GLN-234, AND VARIANT LEU-903.
RX   PubMed=16449289; DOI=10.1093/ndt/gfk072;
RA   Shibagaki Y., Matsumoto M., Kokame K., Ohba S., Miyata T.,
RA   Fujimura Y., Fujita T.;
RT   "Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13
RT   gene in an adult patient with Upshaw-Schulman syndrome showing
RT   predominant episodes of repeated acute renal failure.";
RL   Nephrol. Dial. Transplant. 21:1289-1292(2006).
RN   [36]
RP   VARIANTS TTP ILE-196; CYS-263; SER-347; LEU-353; GLN-507; LEU-671 AND
RP   TRP-1060.
RX   PubMed=16807643; DOI=10.1160/TH05-12-0817;
RA   Schneppenheim R., Kremer Hovinga J.A., Becker T., Budde U.,
RA   Karpman D., Brockhaus W., Hrachovinova I., Korczowski B., Oyen F.,
RA   Rittich S., von Rosen J., Tjonnfjord G.E., Pimanda J.E., Wienker T.F.,
RA   Lammle B.;
RT   "A common origin of the 4143insA ADAMTS13 mutation.";
RL   Thromb. Haemost. 96:3-6(2006).
RN   [37]
RP   VARIANTS TTP TRP-1060; CYS-1123 AND TRP-1219, CHARACTERIZATION OF
RP   VARIANTS TTP TRP-1060; CYS-1123 AND TRP-1219, AND VARIANT GLU-448.
RX   PubMed=17003922;
RA   Donadelli R., Banterla F., Galbusera M., Capoferri C., Bucchioni S.,
RA   Gastoldi S., Nosari S., Monteferrante G., Ruggeri Z.M., Bresin E.,
RA   Scheiflinger F., Rossi E., Martinez C., Coppo R., Remuzzi G.,
RA   Noris M.;
RT   "In-vitro and in-vivo consequences of mutations in the von Willebrand
RT   factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic
RT   purpura.";
RL   Thromb. Haemost. 96:454-464(2006).
RN   [38]
RP   VARIANT TTP PHE-119.
RX   PubMed=18443791; DOI=10.1007/s00277-008-0496-6;
RA   Meyer S.C., Jeddi R., Meddeb B., Gouider E., Lammle B.,
RA   Kremer Hovinga J.A.;
RT   "A first case of congenital TTP on the African continent due to a new
RT   homozygous mutation in the catalytic domain of ADAMTS13.";
RL   Ann. Hematol. 87:663-666(2008).
RN   [39]
RP   VARIANTS TTP THR-178; TRP-193; CYS-304; CYS-349; ASP-525 AND PRO-606,
RP   AND VARIANTS ARG-339; GLU-448 AND ALA-618.
RX   PubMed=19055667; DOI=10.1111/j.1365-2141.2008.07515.x;
RA   Fujimura Y., Matsumoto M., Kokame K., Isonishi A., Soejima K.,
RA   Akiyama N., Tomiyama J., Natori K., Kuranishi Y., Imamura Y.,
RA   Inoue N., Higasa S., Seike M., Kozuka T., Hara M., Wada H., Murata M.,
RA   Ikeda Y., Miyata T., George J.N.;
RT   "Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal
RT   death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9
RT   genotyped patients.";
RL   Br. J. Haematol. 144:742-754(2009).
RN   [40]
RP   VARIANT TTP 977-CYS--ARG-979 DELINS TRP.
RX   PubMed=19116307; DOI=10.3324/haematol.13524;
RA   Palla R., Lavoretano S., Lombardi R., Garagiola I., Karimi M.,
RA   Afrasiabi A., Ramzi M., De Cristofaro R., Peyvandi F.;
RT   "The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13
RT   in a family with inherited thrombotic thrombocytopenic purpura.";
RL   Haematologica 94:289-293(2009).
RN   [41]
RP   VARIANT TTP CYS-658.
RX   PubMed=22075512;
RA   Lee S.H., Park J.H., Park S.K., Lee E.H., Choi J.I., Visentin G.P.,
RA   Park T.S., Oh S.H., Kim S.R.;
RT   "A novel homozygous missense ADAMTS13 mutation Y658C in a patient with
RT   recurrent thrombotic thrombocytopenic purpura.";
RL   Ann. Clin. Lab. Sci. 41:273-276(2011).
RN   [42]
RP   VARIANT LEU-1314.
RX   PubMed=21488199; DOI=10.3349/ymj.2011.52.3.530;
RA   Choi H.S., Cheong H.I., Kim N.K., Oh D., Park H.W.;
RT   "ADAMTS13 gene mutations in children with hemolytic uremic syndrome.";
RL   Yonsei Med. J. 52:530-534(2011).
CC   -!- FUNCTION: Cleaves the vWF multimers in plasma into smaller forms
CC       thereby controlling vWF-mediated platelet thrombus formation.
CC       {ECO:0000269|PubMed:19880749}.
CC   -!- CATALYTIC ACTIVITY: Cleaves the vWF at the 842-Tyr-|-Met-843 in
CC       the A2 domain of the vWF subunit.
CC   -!- CATALYTIC ACTIVITY: The enzyme cleaves the von Willebrand factor
CC       at bond Tyr(842)-|-Met(843) within the A2 domain.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000250|UniProtKB:Q9UNA0};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250|UniProtKB:Q9UNA0};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:19047683};
CC       Note=Binds 4 Ca(2+) ions. {ECO:0000269|PubMed:19047683};
CC   -!- ENZYME REGULATION: Zinc and calcium ions cooperatively modulate
CC       enzyme activity. The cleavage of the pro-domain is not required
CC       for protease activity. Dependence on calcium for proteolytic
CC       activity is mediated by the high affinity site.
CC       {ECO:0000269|PubMed:12975358, ECO:0000269|PubMed:16286459,
CC       ECO:0000269|PubMed:19047683}.
CC   -!- INTERACTION:
CC       P04275:VWF; NbExp=5; IntAct=EBI-981764, EBI-981819;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:12791682}.
CC       Note=Secretion enhanced by O-fucosylation of TSP type-1 repeats.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q76LX8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q76LX8-2; Sequence=VSP_020003;
CC       Name=3;
CC         IsoId=Q76LX8-3; Sequence=VSP_020002, VSP_020003;
CC       Name=4;
CC         IsoId=Q76LX8-4; Sequence=VSP_055537, VSP_055538, VSP_055539;
CC   -!- TISSUE SPECIFICITY: Plasma. Expressed primarily in liver.
CC       {ECO:0000269|PubMed:11574066}.
CC   -!- DOMAIN: The pro-domain is not required for folding or secretion
CC       and does not perform the common function of maintening enzyme
CC       latency.
CC   -!- DOMAIN: The globular cysteineless spacer domain adopts a jelly-
CC       roll topology, and is necessary to recognize and cleave vWF. The
CC       C-terminal TSP type-1 and CUB domains may modulate this
CC       interaction.
CC   -!- PTM: Glycosylated. O-fucosylated by POFUT2 on a serine or a
CC       threonine residue found within the consensus sequence C1-X(2)-
CC       (S/T)-C2-G of the TSP type-1 repeat domains where C1 and C2 are
CC       the first and second cysteine residue of the repeat, respectively.
CC       Fucosylated repeats can then be further glycosylated by the
CC       addition of a beta-1,3-glucose residue by the glucosyltransferase,
CC       B3GALTL. Fucosylation mediates the efficient secretion of
CC       ADAMTS13. May also be C-glycosylated on tryptophan residues within
CC       the consensus sequence W-X-X-W of the TPRs, and also N-
CC       glycosylated. These other glycosylations can also facilitate
CC       secretion. {ECO:0000269|PubMed:11557746,
CC       ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:17395589,
CC       ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:19880749}.
CC   -!- PTM: The precursor is processed by a furin endopeptidase which
CC       cleaves off the pro-domain.
CC   -!- POLYMORPHISM: Genetic variations in ADAMTS13 coding region
CC       influence plasmatic ADAMTS13 activity levels. Dependent on the
CC       sequence context, the same polymorphisms might be either positive
CC       or negative modifiers of gene expression, thereby altering the
CC       phenotype of ADAMTS13 deficiency. {ECO:0000305|PubMed:16160007}.
CC   -!- DISEASE: Thrombotic thrombocytopenic purpura congenital (TTP)
CC       [MIM:274150]: A hematologic disease characterized by hemolytic
CC       anemia with fragmentation of erythrocytes, thrombocytopenia,
CC       diffuse and non-focal neurologic findings, decreased renal
CC       function and fever. recessive. {ECO:0000269|PubMed:11586351,
CC       ECO:0000269|PubMed:12181489, ECO:0000269|PubMed:12393505,
CC       ECO:0000269|PubMed:12614216, ECO:0000269|PubMed:12753286,
CC       ECO:0000269|PubMed:14512317, ECO:0000269|PubMed:14563640,
CC       ECO:0000269|PubMed:15009458, ECO:0000269|PubMed:15126318,
CC       ECO:0000269|PubMed:15327386, ECO:0000269|PubMed:16449289,
CC       ECO:0000269|PubMed:16453338, ECO:0000269|PubMed:16796708,
CC       ECO:0000269|PubMed:16807643, ECO:0000269|PubMed:17003922,
CC       ECO:0000269|PubMed:18443791, ECO:0000269|PubMed:19055667,
CC       ECO:0000269|PubMed:19116307, ECO:0000269|PubMed:22075512}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Contains 2 CUB domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 disintegrin domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 peptidase M12B domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00276}.
CC   -!- SIMILARITY: Contains 8 TSP type-1 domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00210}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAQ88485.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=CAB66743.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=ADAMTS13 entry;
CC       URL="https://en.wikipedia.org/wiki/ADAMTS13";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/adamts13/";
CC   -!- WEB RESOURCE: Name=Mendelian genes ADAM metallopeptidase with
CC       thrombospondin type 1 motif, 13 (ADAMTS13); Note=Leiden Open
CC       Variation Database (LOVD);
CC       URL="http://www.lovd.nl/ADAMTS13";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB069698; BAB69487.2; -; mRNA.
DR   EMBL; AY055376; AAL17652.1; -; mRNA.
DR   EMBL; AF414401; AAL11095.1; -; mRNA.
DR   EMBL; AJ305314; CAC83682.1; -; mRNA.
DR   EMBL; AJ420810; CAD12729.1; -; mRNA.
DR   EMBL; AJ011374; CAB66157.1; -; mRNA.
DR   EMBL; DQ422807; ABD72606.1; -; Genomic_DNA.
DR   EMBL; AL158826; CAI12850.1; -; Genomic_DNA.
DR   EMBL; AL593848; CAI12850.1; JOINED; Genomic_DNA.
DR   EMBL; AL158826; CAI12851.1; -; Genomic_DNA.
DR   EMBL; AL593848; CAI12851.1; JOINED; Genomic_DNA.
DR   EMBL; AL158826; CAI12852.1; -; Genomic_DNA.
DR   EMBL; AL593848; CAI12852.1; JOINED; Genomic_DNA.
DR   EMBL; CH471090; EAW88086.1; -; Genomic_DNA.
DR   EMBL; AY358118; AAQ88485.1; ALT_INIT; mRNA.
DR   EMBL; AL136809; CAB66743.1; ALT_INIT; mRNA.
DR   CCDS; CCDS6970.1; -. [Q76LX8-1]
DR   CCDS; CCDS6971.1; -. [Q76LX8-3]
DR   CCDS; CCDS6972.1; -. [Q76LX8-2]
DR   RefSeq; NP_620594.1; NM_139025.4. [Q76LX8-1]
DR   RefSeq; NP_620595.1; NM_139026.4. [Q76LX8-3]
DR   RefSeq; NP_620596.2; NM_139027.4. [Q76LX8-2]
DR   UniGene; Hs.131433; -.
DR   PDB; 3GHM; X-ray; 2.60 A; A=287-685.
DR   PDB; 3GHN; X-ray; 2.80 A; A=287-685.
DR   PDB; 3VN4; X-ray; 2.80 A; A=287-685.
DR   PDBsum; 3GHM; -.
DR   PDBsum; 3GHN; -.
DR   PDBsum; 3VN4; -.
DR   ProteinModelPortal; Q76LX8; -.
DR   SMR; Q76LX8; 298-682.
DR   DIP; DIP-36050N; -.
DR   IntAct; Q76LX8; 1.
DR   MINT; MINT-4713142; -.
DR   STRING; 9606.ENSP00000360997; -.
DR   BindingDB; Q76LX8; -.
DR   ChEMBL; CHEMBL2346492; -.
DR   MEROPS; M12.241; -.
DR   PhosphoSite; Q76LX8; -.
DR   BioMuta; ADAMTS13; -.
DR   DMDM; 74749836; -.
DR   PaxDb; Q76LX8; -.
DR   PRIDE; Q76LX8; -.
DR   DNASU; 11093; -.
DR   Ensembl; ENST00000355699; ENSP00000347927; ENSG00000160323. [Q76LX8-2]
DR   Ensembl; ENST00000356589; ENSP00000348997; ENSG00000160323. [Q76LX8-3]
DR   Ensembl; ENST00000371929; ENSP00000360997; ENSG00000160323. [Q76LX8-1]
DR   GeneID; 11093; -.
DR   KEGG; hsa:11093; -.
DR   UCSC; uc004cdt.1; human. [Q76LX8-2]
DR   UCSC; uc004cdu.1; human. [Q76LX8-3]
DR   UCSC; uc004cdv.4; human. [Q76LX8-1]
DR   CTD; 11093; -.
DR   GeneCards; ADAMTS13; -.
DR   HGNC; HGNC:1366; ADAMTS13.
DR   HPA; HPA042014; -.
DR   HPA; HPA042844; -.
DR   MalaCards; ADAMTS13; -.
DR   MIM; 274150; phenotype.
DR   MIM; 604134; gene.
DR   neXtProt; NX_Q76LX8; -.
DR   Orphanet; 93583; Congenital thrombotic thrombocytopenic purpura due to ADAMTS-13 deficiency.
DR   PharmGKB; PA24539; -.
DR   eggNOG; KOG3538; Eukaryota.
DR   eggNOG; ENOG410XPKZ; LUCA.
DR   GeneTree; ENSGT00760000118885; -.
DR   HOGENOM; HOG000231627; -.
DR   HOVERGEN; HBG080358; -.
DR   InParanoid; Q76LX8; -.
DR   KO; K08627; -.
DR   OMA; QCRVAFG; -.
DR   PhylomeDB; Q76LX8; -.
DR   TreeFam; TF313537; -.
DR   BRENDA; 3.4.24.87; 2681.
DR   Reactome; R-HSA-5173214; O-glycosylation of TSR domain-containing proteins.
DR   EvolutionaryTrace; Q76LX8; -.
DR   GeneWiki; ADAMTS13; -.
DR   GenomeRNAi; 11093; -.
DR   NextBio; 42166; -.
DR   PRO; PR:Q76LX8; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Proteomes; UP000005640; Unplaced.
DR   Bgee; Q76LX8; -.
DR   CleanEx; HS_ADAMTS13; -.
DR   ExpressionAtlas; Q76LX8; baseline and differential.
DR   Genevisible; Q76LX8; HS.
DR   GO; GO:0009986; C:cell surface; NAS:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IEA:Ensembl.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; TAS:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; TAS:UniProtKB.
DR   GO; GO:0005178; F:integrin binding; TAS:UniProtKB.
DR   GO; GO:0004222; F:metalloendopeptidase activity; IEA:InterPro.
DR   GO; GO:0008237; F:metallopeptidase activity; TAS:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; TAS:UniProtKB.
DR   GO; GO:0007160; P:cell-matrix adhesion; NAS:UniProtKB.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0009100; P:glycoprotein metabolic process; NAS:UniProtKB.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; NAS:UniProtKB.
DR   GO; GO:0043171; P:peptide catabolic process; IDA:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; NAS:UniProtKB.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0036066; P:protein O-linked fucosylation; TAS:Reactome.
DR   GO; GO:0006493; P:protein O-linked glycosylation; TAS:Reactome.
DR   GO; GO:0016485; P:protein processing; TAS:UniProtKB.
DR   GO; GO:0006508; P:proteolysis; IDA:UniProtKB.
DR   GO; GO:0034341; P:response to interferon-gamma; IEA:Ensembl.
DR   GO; GO:0070670; P:response to interleukin-4; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IEA:Ensembl.
DR   Gene3D; 3.40.390.10; -; 1.
DR   InterPro; IPR000859; CUB_dom.
DR   InterPro; IPR024079; MetalloPept_cat_dom.
DR   InterPro; IPR001590; Peptidase_M12B.
DR   InterPro; IPR013273; Peptidase_M12B_ADAM-TS.
DR   InterPro; IPR000884; TSP1_rpt.
DR   Pfam; PF01421; Reprolysin; 1.
DR   Pfam; PF00090; TSP_1; 4.
DR   PRINTS; PR01857; ADAMTSFAMILY.
DR   SMART; SM00209; TSP1; 7.
DR   SUPFAM; SSF49854; SSF49854; 2.
DR   SUPFAM; SSF82895; SSF82895; 5.
DR   PROSITE; PS50215; ADAM_MEPRO; 1.
DR   PROSITE; PS50092; TSP1; 4.
DR   PROSITE; PS00142; ZINC_PROTEASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Blood coagulation; Calcium;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Hemostasis; Hydrolase; Metal-binding; Metalloprotease;
KW   Polymorphism; Protease; Reference proteome; Repeat; Secreted; Signal;
KW   Zinc; Zymogen.
FT   SIGNAL        1     29       {ECO:0000255}.
FT   PROPEP       30     74       {ECO:0000269|PubMed:11535494,
FT                                ECO:0000269|PubMed:11535495,
FT                                ECO:0000269|PubMed:11574066}.
FT                                /FTId=PRO_0000247510.
FT   CHAIN        75   1427       A disintegrin and metalloproteinase with
FT                                thrombospondin motifs 13.
FT                                /FTId=PRO_0000247511.
FT   DOMAIN       80    286       Peptidase M12B. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00276}.
FT   DOMAIN      287    383       Disintegrin.
FT   DOMAIN      384    439       TSP type-1 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      682    730       TSP type-1 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      742    805       TSP type-1 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      808    859       TSP type-1 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      896    950       TSP type-1 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      951   1011       TSP type-1 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN     1012   1068       TSP type-1 7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN     1072   1131       TSP type-1 8. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN     1192   1298       CUB 1.
FT   DOMAIN     1299   1427       CUB 2.
FT   REGION      440    556       Cysteine-rich.
FT   REGION      556    685       Spacer.
FT   MOTIF       498    500       Cell attachment site. {ECO:0000255}.
FT   ACT_SITE    225    225       {ECO:0000255|PROSITE-ProRule:PRU00276,
FT                                ECO:0000255|PROSITE-ProRule:PRU10095}.
FT   METAL        83     83       Calcium. {ECO:0000255}.
FT   METAL       173    173       Calcium. {ECO:0000255}.
FT   METAL       182    182       Calcium; high affinity.
FT                                {ECO:0000269|PubMed:19047683}.
FT   METAL       184    184       Calcium; high affinity.
FT                                {ECO:0000269|PubMed:19047683}.
FT   METAL       187    187       Calcium; high affinity.
FT                                {ECO:0000269|PubMed:19047683}.
FT   METAL       212    212       Calcium; high affinity.
FT                                {ECO:0000269|PubMed:19047683}.
FT   METAL       224    224       Zinc; catalytic.
FT                                {ECO:0000250|UniProtKB:Q9UNA0}.
FT   METAL       228    228       Zinc; catalytic.
FT                                {ECO:0000250|UniProtKB:Q9UNA0}.
FT   METAL       234    234       Zinc; catalytic.
FT                                {ECO:0000250|UniProtKB:Q9UNA0}.
FT   METAL       281    281       Calcium. {ECO:0000255}.
FT   METAL       284    284       Calcium. {ECO:0000255}.
FT   CARBOHYD    142    142       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    146    146       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    387    387       C-linked (Man). {ECO:0000244|PDB:3VN4}.
FT   CARBOHYD    399    399       O-linked (Fuc...). {ECO:0000244|PDB:3GHM,
FT                                ECO:0000244|PDB:3GHN,
FT                                ECO:0000244|PDB:3VN4}.
FT   CARBOHYD    552    552       N-linked (GlcNAc...).
FT                                {ECO:0000244|PDB:3GHM,
FT                                ECO:0000244|PDB:3VN4,
FT                                ECO:0000269|PubMed:19880749}.
FT   CARBOHYD    579    579       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    614    614       N-linked (GlcNAc...).
FT                                {ECO:0000244|PDB:3GHM,
FT                                ECO:0000244|PDB:3GHN,
FT                                ECO:0000244|PDB:3VN4,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19880749}.
FT   CARBOHYD    667    667       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19139490}.
FT   CARBOHYD    698    698       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:17395589}.
FT   CARBOHYD    707    707       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:19139490}.
FT   CARBOHYD    757    757       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:17395589}.
FT   CARBOHYD    828    828       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    907    907       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:17395589}.
FT   CARBOHYD    965    965       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:17395589}.
FT   CARBOHYD   1027   1027       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:17395589}.
FT   CARBOHYD   1087   1087       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:17395589}.
FT   CARBOHYD   1235   1235       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1354   1354       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952}.
FT   DISULFID    155    208       {ECO:0000250}.
FT   DISULFID    202    281       {ECO:0000250}.
FT   DISULFID    242    265       {ECO:0000250}.
FT   DISULFID    311    337       {ECO:0000244|PDB:3GHM,
FT                                ECO:0000244|PDB:3GHN,
FT                                ECO:0000244|PDB:3VN4,
FT                                ECO:0000269|PubMed:19880749}.
FT   DISULFID    322    347       {ECO:0000244|PDB:3GHM,
FT                                ECO:0000244|PDB:3GHN,
FT                                ECO:0000244|PDB:3VN4,
FT                                ECO:0000269|PubMed:19880749}.
FT   DISULFID    332    366       {ECO:0000244|PDB:3GHM,
FT                                ECO:0000244|PDB:3GHN,
FT                                ECO:0000244|PDB:3VN4,
FT                                ECO:0000269|PubMed:19880749}.
FT   DISULFID    360    371       {ECO:0000244|PDB:3GHM,
FT                                ECO:0000244|PDB:3GHN,
FT                                ECO:0000244|PDB:3VN4,
FT                                ECO:0000269|PubMed:19880749}.
FT   DISULFID    396    433       {ECO:0000244|PDB:3GHM,
FT                                ECO:0000244|PDB:3GHN,
FT                                ECO:0000244|PDB:3VN4,
FT                                ECO:0000269|PubMed:19880749}.
FT   DISULFID    400    438       {ECO:0000244|PDB:3GHM,
FT                                ECO:0000244|PDB:3GHN,
FT                                ECO:0000244|PDB:3VN4,
FT                                ECO:0000269|PubMed:19880749}.
FT   DISULFID    411    423       {ECO:0000244|PDB:3GHM,
FT                                ECO:0000244|PDB:3GHN,
FT                                ECO:0000244|PDB:3VN4,
FT                                ECO:0000269|PubMed:19880749}.
FT   DISULFID    450    487       {ECO:0000244|PDB:3GHM,
FT                                ECO:0000244|PDB:3GHN,
FT                                ECO:0000244|PDB:3VN4}.
FT   DISULFID    483    522       {ECO:0000244|PDB:3GHM,
FT                                ECO:0000244|PDB:3GHN,
FT                                ECO:0000244|PDB:3VN4,
FT                                ECO:0000269|PubMed:19880749}.
FT   DISULFID    508    527       {ECO:0000244|PDB:3GHM,
FT                                ECO:0000244|PDB:3GHN,
FT                                ECO:0000244|PDB:3VN4,
FT                                ECO:0000269|PubMed:19880749}.
FT   DISULFID    532    548       {ECO:0000244|PDB:3GHM,
FT                                ECO:0000244|PDB:3GHN,
FT                                ECO:0000244|PDB:3VN4,
FT                                ECO:0000269|PubMed:19880749}.
FT   DISULFID    545    555       {ECO:0000244|PDB:3GHM,
FT                                ECO:0000244|PDB:3GHN,
FT                                ECO:0000244|PDB:3VN4,
FT                                ECO:0000269|PubMed:19880749}.
FT   VAR_SEQ       2    329       Missing (in isoform 4).
FT                                {ECO:0000303|Ref.5}.
FT                                /FTId=VSP_055537.
FT   VAR_SEQ     275    305       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:11867212}.
FT                                /FTId=VSP_020002.
FT   VAR_SEQ     658    692       YRRYGEEYGNLTRPDITFTYFQPKPRQAWVWAAVR -> GG
FT                                VRAQLMHISWWSRPGLGERDLCARGRWPGGSSD (in
FT                                isoform 4). {ECO:0000303|Ref.5}.
FT                                /FTId=VSP_055538.
FT   VAR_SEQ     693   1427       Missing (in isoform 4).
FT                                {ECO:0000303|Ref.5}.
FT                                /FTId=VSP_055539.
FT   VAR_SEQ    1135   1190       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:11867212}.
FT                                /FTId=VSP_020003.
FT   VARIANT       7      7       R -> W (does not affect protein
FT                                secretion; dbSNP:rs34024143).
FT                                {ECO:0000269|PubMed:11586351,
FT                                ECO:0000269|PubMed:16160007,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_027109.
FT   VARIANT      79     79       I -> M (in TTP; dbSNP:rs281875297).
FT                                {ECO:0000269|PubMed:15009458}.
FT                                /FTId=VAR_067770.
FT   VARIANT      88     88       V -> M (in TTP; reduces protein secretion
FT                                and proteolytic activity;
FT                                dbSNP:rs281875302).
FT                                {ECO:0000269|PubMed:16453338}.
FT                                /FTId=VAR_027110.
FT   VARIANT      96     96       H -> D (in TTP; dbSNP:rs121908467).
FT                                {ECO:0000269|PubMed:11586351}.
FT                                /FTId=VAR_027111.
FT   VARIANT     102    102       R -> C (in TTP; dbSNP:rs121908469).
FT                                {ECO:0000269|PubMed:11586351}.
FT                                /FTId=VAR_027112.
FT   VARIANT     119    119       S -> F (in TTP; dbSNP:rs281875291).
FT                                {ECO:0000269|PubMed:18443791}.
FT                                /FTId=VAR_067771.
FT   VARIANT     178    178       I -> T (in TTP; dbSNP:rs281875289).
FT                                {ECO:0000269|PubMed:19055667}.
FT                                /FTId=VAR_067772.
FT   VARIANT     193    193       R -> W (in TTP; low activity;
FT                                dbSNP:rs281875287).
FT                                {ECO:0000269|PubMed:14563640,
FT                                ECO:0000269|PubMed:19055667}.
FT                                /FTId=VAR_027113.
FT   VARIANT     196    196       T -> I (in TTP; dbSNP:rs121908470).
FT                                {ECO:0000269|PubMed:11586351,
FT                                ECO:0000269|PubMed:14512317,
FT                                ECO:0000269|PubMed:16807643}.
FT                                /FTId=VAR_027114.
FT   VARIANT     203    203       S -> P (in TTP; dbSNP:rs281875298).
FT                                {ECO:0000269|PubMed:15009458}.
FT                                /FTId=VAR_067773.
FT   VARIANT     232    232       L -> Q (in TTP; dbSNP:rs281875292).
FT                                {ECO:0000269|PubMed:12393505}.
FT                                /FTId=VAR_067774.
FT   VARIANT     234    234       H -> Q (in TTP; dbSNP:rs281875304).
FT                                {ECO:0000269|PubMed:16449289}.
FT                                /FTId=VAR_027115.
FT   VARIANT     235    235       D -> H (in TTP; dbSNP:rs281875337).
FT                                {ECO:0000269|PubMed:12753286}.
FT                                /FTId=VAR_067775.
FT   VARIANT     250    250       A -> V (in TTP; mild effect on protein
FT                                secretion; strong reduction of
FT                                proteolytic activity; dbSNP:rs121908478).
FT                                {ECO:0000269|PubMed:15126318}.
FT                                /FTId=VAR_027116.
FT   VARIANT     263    263       S -> C (in TTP; dbSNP:rs281875293).
FT                                {ECO:0000269|PubMed:12393505,
FT                                ECO:0000269|PubMed:16807643}.
FT                                /FTId=VAR_067776.
FT   VARIANT     268    268       R -> P (in TTP; affects protein
FT                                secretion; dbSNP:rs121908477).
FT                                {ECO:0000269|PubMed:12181489,
FT                                ECO:0000269|PubMed:15009458}.
FT                                /FTId=VAR_027117.
FT   VARIANT     304    304       Y -> C (in TTP; dbSNP:rs281875285).
FT                                {ECO:0000269|PubMed:19055667}.
FT                                /FTId=VAR_067777.
FT   VARIANT     311    311       C -> Y (in TTP; dbSNP:rs281875336).
FT                                {ECO:0000269|PubMed:12753286}.
FT                                /FTId=VAR_067778.
FT   VARIANT     339    339       T -> R (in dbSNP:rs149517360).
FT                                {ECO:0000269|PubMed:19055667}.
FT                                /FTId=VAR_067779.
FT   VARIANT     347    347       C -> S (in TTP; dbSNP:rs281875294).
FT                                {ECO:0000269|PubMed:16807643}.
FT                                /FTId=VAR_067780.
FT   VARIANT     349    349       R -> C (in TTP; dbSNP:rs281875288).
FT                                {ECO:0000269|PubMed:19055667}.
FT                                /FTId=VAR_067781.
FT   VARIANT     353    353       P -> L (in TTP; dbSNP:rs281875338).
FT                                {ECO:0000269|PubMed:12393505,
FT                                ECO:0000269|PubMed:12753286,
FT                                ECO:0000269|PubMed:16807643}.
FT                                /FTId=VAR_067782.
FT   VARIANT     390    390       W -> C (in TTP; dbSNP:rs281875306).
FT                                {ECO:0000269|PubMed:15327386}.
FT                                /FTId=VAR_027118.
FT   VARIANT     398    398       R -> H (in TTP; dbSNP:rs121908471).
FT                                {ECO:0000269|PubMed:11586351}.
FT                                /FTId=VAR_027119.
FT   VARIANT     448    448       Q -> E (does not affect protein
FT                                secretion; normal proteolytic activity;
FT                                dbSNP:rs2301612).
FT                                {ECO:0000269|PubMed:11586351,
FT                                ECO:0000269|PubMed:12181489,
FT                                ECO:0000269|PubMed:12975309,
FT                                ECO:0000269|PubMed:14512317,
FT                                ECO:0000269|PubMed:14563640,
FT                                ECO:0000269|PubMed:16160007,
FT                                ECO:0000269|PubMed:17003922,
FT                                ECO:0000269|PubMed:19055667,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_027120.
FT   VARIANT     456    456       Q -> H (in dbSNP:rs36220239).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_027162.
FT   VARIANT     457    457       P -> L (in dbSNP:rs36220240).
FT                                {ECO:0000269|PubMed:12753286,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_027163.
FT   VARIANT     475    475       P -> S (in dbSNP:rs11575933).
FT                                {ECO:0000269|PubMed:12181489}.
FT                                /FTId=VAR_027121.
FT   VARIANT     507    507       R -> Q (in TTP; dbSNP:rs281875296).
FT                                {ECO:0000269|PubMed:15009458,
FT                                ECO:0000269|PubMed:16807643}.
FT                                /FTId=VAR_067783.
FT   VARIANT     508    508       C -> Y (in TTP; impairs protein
FT                                secretion; dbSNP:rs281875305).
FT                                {ECO:0000269|PubMed:12181489}.
FT                                /FTId=VAR_027122.
FT   VARIANT     525    525       G -> D (in TTP; dbSNP:rs281875286).
FT                                {ECO:0000269|PubMed:19055667}.
FT                                /FTId=VAR_067784.
FT   VARIANT     528    528       R -> G (in TTP; dbSNP:rs121908473).
FT                                {ECO:0000269|PubMed:11586351}.
FT                                /FTId=VAR_027123.
FT   VARIANT     596    596       A -> V (in TTP; dbSNP:rs281875299).
FT                                {ECO:0000269|PubMed:15009458}.
FT                                /FTId=VAR_067785.
FT   VARIANT     606    606       A -> P (in TTP; dbSNP:rs281875290).
FT                                {ECO:0000269|PubMed:19055667}.
FT                                /FTId=VAR_067786.
FT   VARIANT     618    618       P -> A (in dbSNP:rs28647808).
FT                                {ECO:0000269|PubMed:11586351,
FT                                ECO:0000269|PubMed:16160007,
FT                                ECO:0000269|PubMed:19055667,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_027124.
FT   VARIANT     625    625       R -> H (in dbSNP:rs36090624).
FT                                {ECO:0000269|PubMed:11586351,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_027125.
FT   VARIANT     658    658       Y -> C (in TTP; dbSNP:rs281875335).
FT                                {ECO:0000269|PubMed:22075512}.
FT                                /FTId=VAR_067787.
FT   VARIANT     671    671       P -> L (in TTP; dbSNP:rs281875295).
FT                                {ECO:0000269|PubMed:16807643}.
FT                                /FTId=VAR_067788.
FT   VARIANT     673    673       I -> F (in TTP; impairs protein
FT                                secretion; dbSNP:rs281875307).
FT                                {ECO:0000269|PubMed:14563640}.
FT                                /FTId=VAR_027126.
FT   VARIANT     692    692       R -> C (in TTP; dbSNP:rs121908475).
FT                                {ECO:0000269|PubMed:11586351}.
FT                                /FTId=VAR_027127.
FT   VARIANT     732    732       A -> V (in dbSNP:rs41314453).
FT                                {ECO:0000269|PubMed:11586351,
FT                                ECO:0000269|PubMed:12614216,
FT                                ECO:0000269|PubMed:16160007}.
FT                                /FTId=VAR_027128.
FT   VARIANT     740    740       E -> K (in dbSNP:rs36221451).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_027164.
FT   VARIANT     758    758       C -> R (in TTP; dbSNP:rs281875300).
FT                                {ECO:0000269|PubMed:15009458}.
FT                                /FTId=VAR_067789.
FT   VARIANT     900    900       A -> V (in dbSNP:rs685523).
FT                                {ECO:0000269|PubMed:11557746,
FT                                ECO:0000269|PubMed:11586351,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_027129.
FT   VARIANT     903    903       S -> L (in dbSNP:rs78977446).
FT                                {ECO:0000269|PubMed:16449289,
FT                                ECO:0000269|PubMed:16468327}.
FT                                /FTId=VAR_027130.
FT   VARIANT     908    908       C -> S (in TTP; dbSNP:rs281875301).
FT                                {ECO:0000269|PubMed:15009458}.
FT                                /FTId=VAR_067790.
FT   VARIANT     908    908       C -> Y (in TTP; impairs protein
FT                                secretion; dbSNP:rs281875301).
FT                                {ECO:0000269|PubMed:14563640}.
FT                                /FTId=VAR_027131.
FT   VARIANT     951    951       C -> G (in TTP; dbSNP:rs121908468).
FT                                {ECO:0000269|PubMed:11586351}.
FT                                /FTId=VAR_027132.
FT   VARIANT     977    979       CAR -> W (in TTP).
FT                                {ECO:0000269|PubMed:19116307}.
FT                                /FTId=VAR_067791.
FT   VARIANT     982    982       G -> R (in dbSNP:rs36222275).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_027165.
FT   VARIANT    1024   1024       C -> G (in TTP; dbSNP:rs121908472).
FT                                {ECO:0000269|PubMed:11586351}.
FT                                /FTId=VAR_027133.
FT   VARIANT    1033   1033       A -> T (in dbSNP:rs28503257).
FT                                {ECO:0000269|PubMed:11586351,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_027134.
FT   VARIANT    1060   1060       R -> W (in TTP; affects protein
FT                                secretion; the mutant protein has reduced
FT                                protease activity; dbSNP:rs142572218).
FT                                {ECO:0000269|PubMed:16796708,
FT                                ECO:0000269|PubMed:16807643,
FT                                ECO:0000269|PubMed:17003922}.
FT                                /FTId=VAR_067792.
FT   VARIANT    1095   1095       R -> W (in a patient with thrombotic
FT                                thrombocytopenic purpura).
FT                                {ECO:0000269|PubMed:16468327}.
FT                                /FTId=VAR_027135.
FT   VARIANT    1123   1123       R -> C (in TTP; impairs protein
FT                                secretion; the mutant protein has reduced
FT                                protease activity; dbSNP:rs281875340).
FT                                {ECO:0000269|PubMed:14563640,
FT                                ECO:0000269|PubMed:17003922}.
FT                                /FTId=VAR_027136.
FT   VARIANT    1213   1213       C -> Y (in TTP; dbSNP:rs121908474).
FT                                {ECO:0000269|PubMed:11586351}.
FT                                /FTId=VAR_027137.
FT   VARIANT    1219   1219       R -> W (in TTP; affects protein
FT                                secretion; the mutant protein has reduced
FT                                protease activity; dbSNP:rs281875339).
FT                                {ECO:0000269|PubMed:17003922}.
FT                                /FTId=VAR_067793.
FT   VARIANT    1226   1226       T -> I (in dbSNP:rs36222894).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_027166.
FT   VARIANT    1239   1239       G -> V (in TTP; impairs protein
FT                                secretion; dbSNP:rs281875303).
FT                                {ECO:0000269|PubMed:16453338}.
FT                                /FTId=VAR_027138.
FT   VARIANT    1314   1314       S -> L (found in a patient with hemolytic
FT                                uremic syndrome; dbSNP:rs142060916).
FT                                {ECO:0000269|PubMed:21488199}.
FT                                /FTId=VAR_067794.
FT   VARIANT    1336   1336       R -> W (in TTP; impairs protein secretion
FT                                and proteolytic activity;
FT                                dbSNP:rs281875308).
FT                                {ECO:0000269|PubMed:12614216,
FT                                ECO:0000269|PubMed:16160007}.
FT                                /FTId=VAR_027139.
FT   MUTAGEN      71     71       R->K: Abolishes pro-domain removal but no
FT                                loss of proteolytic activity; when
FT                                associated with D-73.
FT                                {ECO:0000269|PubMed:12975358}.
FT   MUTAGEN      73     73       R->D: Abolishes pro-domain removal but no
FT                                loss of proteolytic activity; when
FT                                associated with K-71.
FT                                {ECO:0000269|PubMed:12975358}.
FT   MUTAGEN      83     83       E->A: No change in calcium dependence for
FT                                proteolysis.
FT                                {ECO:0000269|PubMed:19047683}.
FT   MUTAGEN     173    173       D->A: No change in calcium dependence for
FT                                proteolysis.
FT                                {ECO:0000269|PubMed:19047683}.
FT   MUTAGEN     184    184       E->A: Dramatically reduced affinity for
FT                                calcium. {ECO:0000269|PubMed:19047683}.
FT   MUTAGEN     187    187       D->A: Dramatically reduced affinity for
FT                                calcium. {ECO:0000269|PubMed:19047683}.
FT   MUTAGEN     212    212       E->A: Dramatically reduced affinity for
FT                                calcium. {ECO:0000269|PubMed:19047683}.
FT   MUTAGEN     399    399       S->A: No effect on cleavage of VWF and
FT                                little change in secretion of ADAMTS13.
FT                                Abolishes secretion of ADAMTS13; when
FT                                associated with A-698.
FT                                {ECO:0000269|PubMed:17395589}.
FT   MUTAGEN     698    698       S->A: No effect on cleavage of VWF and
FT                                greatly reduced secretion of ADAMTS13.
FT                                Abolishes secretion of ADAMTS13; when
FT                                associated with A-399.
FT                                {ECO:0000269|PubMed:17395589}.
FT   MUTAGEN     757    757       S->A: No effect on cleavage of VWF and
FT                                little change in secretion of ADAMTS13.
FT                                {ECO:0000269|PubMed:17395589}.
FT   MUTAGEN     907    907       S->A: No effect on cleavage of VWF and
FT                                greatly reduced secretion of ADAMTS13.
FT                                Abolishes most of the secretion of
FT                                ADAMTS13; when associated with A-965.
FT                                {ECO:0000269|PubMed:17395589}.
FT   MUTAGEN     965    965       S->A: No effect on cleavage of VWF and
FT                                little change in secretion of ADAMTS13.
FT                                Abolishes most of the secretion of
FT                                ADAMTS13; when associated with A-907.
FT                                {ECO:0000269|PubMed:17395589}.
FT   MUTAGEN    1027   1027       S->A: No effect on cleavage of VWF and
FT                                little change in secretion of ADAMTS13.
FT                                Abolishes most of the secretion of
FT                                ADAMTS13; when associated with A-1087.
FT                                {ECO:0000269|PubMed:17395589}.
FT   MUTAGEN    1087   1087       S->A: No effect on cleavage of VWF and
FT                                little change in secretion of ADAMTS13.
FT                                Abolishes most of the secretion of
FT                                ADAMTS13; when associated with A-1027.
FT                                {ECO:0000269|PubMed:17395589}.
FT   CONFLICT    101    101       E -> R (in Ref. 1; AA sequence).
FT                                {ECO:0000305}.
FT   HELIX       301    303       {ECO:0000244|PDB:3GHM}.
FT   HELIX       307    314       {ECO:0000244|PDB:3GHM}.
FT   HELIX       331    334       {ECO:0000244|PDB:3GHN}.
FT   STRAND      337    340       {ECO:0000244|PDB:3GHM}.
FT   STRAND      348    351       {ECO:0000244|PDB:3VN4}.
FT   STRAND      359    361       {ECO:0000244|PDB:3GHM}.
FT   STRAND      364    367       {ECO:0000244|PDB:3GHM}.
FT   STRAND      370    373       {ECO:0000244|PDB:3GHM}.
FT   HELIX       374    377       {ECO:0000244|PDB:3GHM}.
FT   STRAND      399    401       {ECO:0000244|PDB:3GHM}.
FT   STRAND      403    406       {ECO:0000244|PDB:3GHM}.
FT   STRAND      417    419       {ECO:0000244|PDB:3GHM}.
FT   STRAND      430    433       {ECO:0000244|PDB:3GHM}.
FT   HELIX       442    451       {ECO:0000244|PDB:3GHM}.
FT   TURN        452    455       {ECO:0000244|PDB:3GHM}.
FT   STRAND      470    472       {ECO:0000244|PDB:3GHM}.
FT   TURN        474    476       {ECO:0000244|PDB:3GHM}.
FT   HELIX       479    483       {ECO:0000244|PDB:3GHM}.
FT   STRAND      486    489       {ECO:0000244|PDB:3GHM}.
FT   STRAND      495    497       {ECO:0000244|PDB:3GHM}.
FT   STRAND      519    523       {ECO:0000244|PDB:3GHM}.
FT   STRAND      526    530       {ECO:0000244|PDB:3GHM}.
FT   STRAND      534    536       {ECO:0000244|PDB:3GHM}.
FT   STRAND      554    562       {ECO:0000244|PDB:3GHM}.
FT   STRAND      569    576       {ECO:0000244|PDB:3GHM}.
FT   STRAND      581    588       {ECO:0000244|PDB:3GHM}.
FT   STRAND      592    599       {ECO:0000244|PDB:3GHM}.
FT   STRAND      602    605       {ECO:0000244|PDB:3GHM}.
FT   STRAND      608    610       {ECO:0000244|PDB:3GHM}.
FT   STRAND      614    618       {ECO:0000244|PDB:3GHM}.
FT   STRAND      623    632       {ECO:0000244|PDB:3GHM}.
FT   STRAND      634    636       {ECO:0000244|PDB:3GHM}.
FT   STRAND      638    647       {ECO:0000244|PDB:3GHM}.
FT   STRAND      653    661       {ECO:0000244|PDB:3GHM}.
FT   HELIX       663    665       {ECO:0000244|PDB:3GHM}.
FT   HELIX       667    669       {ECO:0000244|PDB:3GHN}.
FT   STRAND      673    680       {ECO:0000244|PDB:3GHM}.
SQ   SEQUENCE   1427 AA;  153604 MW;  A2103AFABC1A4445 CRC64;
     MHQRHPRARC PPLCVAGILA CGFLLGCWGP SHFQQSCLQA LEPQAVSSYL SPGAPLKGRP
     PSPGFQRQRQ RQRRAAGGIL HLELLVAVGP DVFQAHQEDT ERYVLTNLNI GAELLRDPSL
     GAQFRVHLVK MVILTEPEGA PNITANLTSS LLSVCGWSQT INPEDDTDPG HADLVLYITR
     FDLELPDGNR QVRGVTQLGG ACSPTWSCLI TEDTGFDLGV TIAHEIGHSF GLEHDGAPGS
     GCGPSGHVMA SDGAAPRAGL AWSPCSRRQL LSLLSAGRAR CVWDPPRPQP GSAGHPPDAQ
     PGLYYSANEQ CRVAFGPKAV ACTFAREHLD MCQALSCHTD PLDQSSCSRL LVPLLDGTEC
     GVEKWCSKGR CRSLVELTPI AAVHGRWSSW GPRSPCSRSC GGGVVTRRRQ CNNPRPAFGG
     RACVGADLQA EMCNTQACEK TQLEFMSQQC ARTDGQPLRS SPGGASFYHW GAAVPHSQGD
     ALCRHMCRAI GESFIMKRGD SFLDGTRCMP SGPREDGTLS LCVSGSCRTF GCDGRMDSQQ
     VWDRCQVCGG DNSTCSPRKG SFTAGRAREY VTFLTVTPNL TSVYIANHRP LFTHLAVRIG
     GRYVVAGKMS ISPNTTYPSL LEDGRVEYRV ALTEDRLPRL EEIRIWGPLQ EDADIQVYRR
     YGEEYGNLTR PDITFTYFQP KPRQAWVWAA VRGPCSVSCG AGLRWVNYSC LDQARKELVE
     TVQCQGSQQP PAWPEACVLE PCPPYWAVGD FGPCSASCGG GLRERPVRCV EAQGSLLKTL
     PPARCRAGAQ QPAVALETCN PQPCPARWEV SEPSSCTSAG GAGLALENET CVPGADGLEA
     PVTEGPGSVD EKLPAPEPCV GMSCPPGWGH LDATSAGEKA PSPWGSIRTG AQAAHVWTPA
     AGSCSVSCGR GLMELRFLCM DSALRVPVQE ELCGLASKPG SRREVCQAVP CPARWQYKLA
     ACSVSCGRGV VRRILYCARA HGEDDGEEIL LDTQCQGLPR PEPQEACSLE PCPPRWKVMS
     LGPCSASCGL GTARRSVACV QLDQGQDVEV DEAACAALVR PEASVPCLIA DCTYRWHVGT
     WMECSVSCGD GIQRRRDTCL GPQAQAPVPA DFCQHLPKPV TVRGCWAGPC VGQGTPSLVP
     HEEAAAPGRT TATPAGASLE WSQARGLLFS PAPQPRRLLP GPQENSVQSS ACGRQHLEPT
     GTIDMRGPGQ ADCAVAIGRP LGEVVTLRVL ESSLNCSAGD MLLLWGRLTW RKMCRKLLDM
     TFSSKTNTLV VRQRCGRPGG GVLLRYGSQL APETFYRECD MQLFGPWGEI VSPSLSPATS
     NAGGCRLFIN VAPHARIAIH ALATNMGAGT EGANASYILI RDTHSLRTTA FHGQQVLYWE
     SESSQAEMEF SEGFLKAQAS LRGQYWTLQS WVPEMQDPQS WKGKEGT
//
ID   IDS_HUMAN               Reviewed;         550 AA.
AC   P22304; D3DWT4; Q14604; Q9BRM3;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 1.
DT   20-JAN-2016, entry version 167.
DE   RecName: Full=Iduronate 2-sulfatase;
DE            EC=3.1.6.13;
DE   AltName: Full=Alpha-L-iduronate sulfate sulfatase;
DE            Short=Idursulfase;
DE   Contains:
DE     RecName: Full=Iduronate 2-sulfatase 42 kDa chain;
DE   Contains:
DE     RecName: Full=Iduronate 2-sulfatase 14 kDa chain;
DE   Flags: Precursor;
GN   Name=IDS; Synonyms=SIDS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEIN SEQUENCE OF 34-58
RP   AND 456-473.
RC   TISSUE=Endothelial cell;
RX   PubMed=2122463; DOI=10.1073/pnas.87.21.8531;
RA   Wilson P.J., Morris C.P., Anson D.S., Occhiodoro T., Bielicki J.,
RA   Clements P.R., Hopwood J.J.;
RT   "Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and
RT   analysis of patient DNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8531-8535(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8244397; DOI=10.1006/geno.1993.1406;
RA   Wilson P.J., Meaney C.A., Hopwood J.J., Morris C.P.;
RT   "Sequence of the human iduronate 2-sulfatase (IDS) gene.";
RL   Genomics 17:773-775(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8717057; DOI=10.1101/gr.5.1.71;
RA   Timms K.M., Lu F., Shen Y., Pierson C.A., Muzny D.M., Gu Y.,
RA   Nelson D.L., Gibbs R.A.;
RT   "130 kb of DNA sequence reveals two new genes and a regional
RT   duplication distal to the human iduronate-2-sulfate sulfatase locus.";
RL   Genome Res. 5:71-78(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Lymphocyte;
RX   PubMed=8530090; DOI=10.1006/geno.1995.1249;
RA   Malmgren H., Carlberg B.M., Pettersson U., Bondeson M.L.;
RT   "Identification of an alternative transcript from the human iduronate-
RT   2-sulfatase (IDS) gene.";
RL   Genomics 29:291-293(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-398.
RX   PubMed=8490623; DOI=10.1093/hmg/2.1.5;
RA   Flomen R.H., Green E.P., Green P.M., Bentley D.R., Giannelli F.;
RT   "Determination of the organisation of coding sequences within the
RT   iduronate sulphate sulphatase (IDS) gene.";
RL   Hum. Mol. Genet. 2:5-10(1993).
RN   [9]
RP   REVIEW ON MPS2 VARIANTS.
RX   PubMed=8111411; DOI=10.1002/humu.1380020603;
RA   Hopwood J.J., Bunge S., Morris C.P., Wilson P.J., Steglich C.,
RA   Beck M., Schwinger E., Gal A.;
RT   "Molecular basis of mucopolysaccharidosis type II: mutations in the
RT   iduronate-2-sulphatase gene.";
RL   Hum. Mutat. 2:435-442(1993).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-115.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [11]
RP   VARIANTS MPS2 ARG-135 AND GLY-422.
RX   PubMed=1303211; DOI=10.1093/hmg/1.5.335;
RA   Bunge S., Steglich C., Beck M., Rosenkranz W., Schwinger E.,
RA   Hopwood J.J., Gal A.;
RT   "Mutation analysis of the iduronate-2-sulfatase gene in patients with
RT   mucopolysaccharidosis type II (Hunter syndrome).";
RL   Hum. Mol. Genet. 1:335-339(1992).
RN   [12]
RP   VARIANT MPS2 TRP-468.
RX   PubMed=1284597; DOI=10.1093/hmg/1.9.755;
RA   Crotti P.L., Bunge S., Anderson R.A., Whitley C.B.;
RT   "Mutation R468W of the iduronate-2-sulfatase gene in mild Hunter
RT   syndrome (mucopolysaccharidosis type II) confirmed by in vitro
RT   mutagenesis and expression.";
RL   Hum. Mol. Genet. 1:755-757(1992).
RN   [13]
RP   VARIANTS MPS2 ARG-86; ASP-94; ARG-120; PRO-221 AND GLY-422.
RX   PubMed=8281149; DOI=10.1093/hmg/2.11.1871;
RA   Bunge S., Steglich C., Zuther C., Beck M., Morris C.P., Schwinger E.,
RA   Schinzel A., Hopwood J.J., Gal A.;
RT   "Iduronate-2-sulfatase gene mutations in 16 patients with
RT   mucopolysaccharidosis type II (Hunter syndrome).";
RL   Hum. Mol. Genet. 2:1871-1875(1993).
RN   [14]
RP   VARIANTS MPS2 GLU-68; HIS-293; GLY-478 AND ARG-485.
RX   PubMed=7981716; DOI=10.1002/humu.1380040206;
RA   Schroeder W., Wulff K., Wehnert M., Seidlitz G., Herrmann F.H.;
RT   "Mutations of the iduronate-2-sulfatase (IDS) gene in patients with
RT   Hunter syndrome (mucopolysaccharidosis II).";
RL   Hum. Mutat. 4:128-131(1994).
RN   [15]
RP   VARIANT MPS2 PRO-410.
RX   PubMed=7866405; DOI=10.1002/humu.1380040406;
RA   Ben-Simon-Schiff E., Bach G., Hopwood J.J., Abeliovich D.;
RT   "Mutation analysis of Jewish Hunter patients in Israel.";
RL   Hum. Mutat. 4:263-270(1994).
RN   [16]
RP   VARIANTS MPS2 TRP-132; TYR-229; ARG-358; HIS-469 AND CYS-523.
RX   PubMed=7887413;
RA   Jonsson J.J., Aronovich E.L., Braun S.E., Whitley C.B.;
RT   "Molecular diagnosis of mucopolysaccharidosis type II (Hunter
RT   syndrome) by automated sequencing and computer-assisted
RT   interpretation: toward mutation mapping of the iduronate-2-sulfatase
RT   gene.";
RL   Am. J. Hum. Genet. 56:597-607(1995).
RN   [17]
RP   VARIANTS MPS2 LEU-86; ASN-87; PRO-92; ASN-135; CYS-345 AND TRP-468.
RX   PubMed=7728156; DOI=10.1002/humu.1380050114;
RA   Popowska E., Rathmann M., Tylki-Szymanska A., Bunge S., Steglich C.,
RA   Schwinger E., Gal A.;
RT   "Mutations of the iduronate-2-sulfatase gene in 12 Polish patients
RT   with mucopolysaccharidosis type II (Hunter syndrome).";
RL   Hum. Mutat. 5:97-100(1995).
RN   [18]
RP   VARIANTS MPS2 PRO-48; SER-117 DEL; LEU-333; ARG-337; LEU-468 AND
RP   GLN-468.
RX   PubMed=7581397; DOI=10.1002/humu.1380060206;
RA   Sukegawa K., Tomatsu S., Fukao T., Iwata H., Song X.-Q., Yamada Y.,
RA   Fukuda S., Isogai K., Orii T.;
RT   "Mucopolysaccharidosis type II (Hunter disease): identification and
RT   characterization of eight point mutations in the iduronate-2-sulfatase
RT   gene in Japanese patients.";
RL   Hum. Mutat. 6:136-143(1995).
RN   [19]
RP   VARIANT MPS2 VAL-346.
RX   PubMed=7599640; DOI=10.1002/humu.1380050314;
RA   Li P., Huffman P., Thompson J.N.;
RT   "Mutations of the iduronate-2-sulfatase gene on a T146T background in
RT   three patients with Hunter syndrome.";
RL   Hum. Mutat. 5:272-274(1995).
RN   [20]
RP   VARIANTS MPS2 ASP-63; THR-85; GLN-86; CYS-88; HIS-88; CYS-108; SER-117
RP   DEL; VAL-125; ARG-134; PHE-184; ASN-252; LEU-333; ILE-347; ARG-403 AND
RP   GLN-468.
RX   PubMed=8940265;
RA   Rathmann M., Bunge S., Beck M., Kresse H., Tylki-Szymanska A., Gal A.;
RT   "Mucopolysaccharidosis type II (Hunter syndrome): mutation 'hot spots'
RT   in the iduronate-2-sulfatase gene.";
RL   Am. J. Hum. Genet. 59:1202-1209(1996).
RN   [21]
RP   VARIANTS MPS2 LEU-333 AND ASP-346.
RX   PubMed=8566953; DOI=10.1007/BF02265265;
RA   Olsen T.C., Eiken H.G., Knappskog P.M., Kase B.F., Mansson J.-E.,
RA   Boman H., Apold J.;
RT   "Mutations in the iduronate-2-sulfatase gene in five Norwegians with
RT   Hunter syndrome.";
RL   Hum. Genet. 97:198-203(1996).
RN   [22]
RP   VARIANTS MPS2 ASP-63; ARG-86; GLY-95; PRO-205; TRP-468 AND GLN-468.
RX   PubMed=8664909;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:1<76::AID-HUMU14>3.0.CO;2-P;
RA   Goldenfum S.L., Young E., Michelakakis H., Tsagarakis S.,
RA   Winchester B.;
RT   "Mutation analysis in 20 patients with Hunter disease.";
RL   Hum. Mutat. 7:76-78(1996).
RN   [23]
RP   VARIANTS MPS2 LEU-333 AND GLY-334.
RX   PubMed=8830188; DOI=10.1007/BF01799358;
RA   Li P., Thompson J.N.;
RT   "Detection of four novel mutations in the iduronate-2-sulphatase gene
RT   by single-strand conformation polymorphism analysis of genomic
RT   amplicons.";
RL   J. Inherit. Metab. Dis. 19:93-94(1996).
RN   [24]
RP   VARIANTS MPS2 ASP-63; THR-347; GLN-468 AND LEU-468.
RX   PubMed=9222763;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:1<71::AID-HUMU10>3.0.CO;2-X;
RA   Villani G.R.D., Balzano N., Grosso M., Salvadore F., Izzo P.,
RA   di Natale P.;
RT   "Mucopolysaccharidosis type II: identification of six novel mutations
RT   in Italian patients.";
RL   Hum. Mutat. 10:71-75(1997).
RN   [25]
RP   VARIANT MPS2 GLN-468.
RX   PubMed=9375851;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:5<361::AID-HUMU5>3.3.CO;2-I;
RA   Sukegawa K., Song X.-Q., Masuno M., Fukao T., Shimozawa N., Fukuda S.,
RA   Isogai K., Nishio H., Matsuo M., Tomatsu S., Kondo N., Orii T.;
RT   "Hunter disease in a girl caused by R468Q mutation in the iduronate-2-
RT   sulfatase gene and skewed inactivation of the X chromosome carrying
RT   the normal allele.";
RL   Hum. Mutat. 10:361-367(1997).
RN   [26]
RP   VARIANTS MPS2 PHE-73; THR-118 DEL; HIS-121; TRP-132; ARG-336; LYS-341;
RP   GLN-347; TRP-468; GLN-468; LYS-521 AND VAL-521.
RX   PubMed=9266380; DOI=10.1023/A:1005335624386;
RA   Lissens W., Seneca S., Liebaers I.;
RT   "Molecular analysis in 23 Hunter disease families.";
RL   J. Inherit. Metab. Dis. 20:453-456(1997).
RN   [27]
RP   VARIANTS MPS2 ASN-45; TYR-115; LEU-228; ARG-266; LYS-434; LYS-485 AND
RP   CYS-502.
RX   PubMed=9875019; DOI=10.1136/adc.79.3.237;
RA   Vafiadaki E., Cooper A., Heptinstall L.E., Hatton C.E., Thornley M.,
RA   Wraith J.E.;
RT   "Mutation analysis in 57 unrelated patients with MPS II.";
RL   Arch. Dis. Child. 79:237-241(1998).
RN   [28]
RP   VARIANTS MPS2 ASN-71; SER-85; THR-85; LEU-86; GLY-88; HIS-88; PHE-89;
RP   SER-108; SER-117 DEL; ILE-118; ARG-121; ASP-138; HIS-148; ARG-229;
RP   LEU-333; ASN-334; ARG-335; GLU-336; ARG-339; ARG-403; LEU-467;
RP   GLN-468; TRP-468; ARG-480; GLN-480; LEU-480 AND SER-490.
RX   PubMed=9660053;
RA   Froissart R., Maire I., Millat G., Cudry S., Birot A.-M., Bonnet V.,
RA   Bouton O., Bozon D.;
RT   "Identification of iduronate sulfatase gene alterations in 70
RT   unrelated Hunter patients.";
RL   Clin. Genet. 53:362-368(1998).
RN   [29]
RP   VARIANTS MPS2 ASP-54; ASP-63; GLU-79; CYS-88; LEU-88; HIS-88; ARG-102;
RP   PRO-159; SER-196; GLY-198; GLU-224; LEU-333; ASP-340; TYR-432;
RP   GLN-468; TYR-478 AND ARG-485.
RX   PubMed=9921913; DOI=10.1007/s004390050901;
RA   Karsten S., Voskoboeva E., Tishkanina S., Pettersson U.,
RA   Krasnopolskaya X., Bondeson M.-L.;
RT   "Mutational spectrum of the iduronate-2-sulfatase (IDS) gene in 36
RT   unrelated Russian MPS II patients.";
RL   Hum. Genet. 103:732-735(1998).
RN   [30]
RP   VARIANTS MPS2 LEU-86; HIS-88; PRO-88; ILE-118 AND HIS-266.
RX   PubMed=10215411;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:4<333::AID-HUMU18>3.0.CO;2-G;
RA   Balzano N., Villani G.R.D., Grosso M., Izzo P., di Natale P.;
RT   "Detection of four novel mutations in the iduronate-2-sulfatase
RT   gene.";
RL   Hum. Mutat. 11:333-333(1998).
RN   [31]
RP   VARIANTS MPS2 THR-85; HIS-88; ILE-349 AND VAL-521.
RX   PubMed=9452044;
RA   Gort L., Coll M.J., Chabas A.;
RT   "Mutations in the iduronate-2-sulfatase gene in 12 Spanish patients
RT   with Hunter disease.";
RL   Hum. Mutat. Suppl. 1:S66-S68(1998).
RN   [32]
RP   VARIANTS MPS2 PHE-143; TRP-184; VAL-269 AND HIS-348.
RX   PubMed=10671065;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:6<433::AID-HUMU12>3.0.CO;2-M;
RA   Karsten S.L., Voskoboeva E., Carlberg B.-M., Kleijer W.J.,
RA   Toennesen T., Pettersson U., Bondeson M.-L.;
RT   "Identification of 9 novel gene mutations in 19 unrelated Hunter
RT   syndrome (Mucopolysaccharidosis type II) patients.";
RL   Hum. Mutat. 12:433-433(1998).
RN   [33]
RP   VARIANTS MPS2 PRO-48; THR-85; LEU-86; PRO-182; SER-196; ASP-225;
RP   MET-227; ASN-308; PRO-314; LEU-333; ARG-337; ILE-349; GLN-468; LEU-468
RP   AND TRP-468.
RX   PubMed=9501270; DOI=10.1023/A:1005363414792;
RA   Isogai K., Sukegawa K., Tomatsu S., Fukao T., Song X.-Q., Yamada Y.,
RA   Fukuda S., Orii T., Kondo N.;
RT   "Mutation analysis in the iduronate-2-sulphatase gene in 43 Japanese
RT   patients with mucopolysaccharidosis type II (Hunter disease).";
RL   J. Inherit. Metab. Dis. 21:60-70(1998).
RN   [34]
RP   VARIANTS MPS2 THR-228; ARG-229; LEU-231; GLU-308; ALA-309 AND CYS-313.
RX   PubMed=9762601; DOI=10.1023/A:1005432600871;
RA   Gort L., Chabas A., Coll M.J.;
RT   "Hunter disease in the Spanish population: molecular analysis in 31
RT   families.";
RL   J. Inherit. Metab. Dis. 21:655-661(1998).
RN   [35]
RP   VARIANTS MPS2 PHE-143; LYS-341; TYR-342 AND PHE-491.
RX   PubMed=10220152;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:4<338::AID-HUMU15>3.0.CO;2-3;
RA   Vallance H.D., Bernard L., Rashed M., Chiu D., Le G., Toone J.,
RA   Applegarth D.A., Coulter-Mackie M.;
RT   "Identification of 6 new mutations in the iduronate sulfatase gene.";
RL   Hum. Mutat. 13:338-338(1999).
RN   [36]
RP   VARIANTS MPS2 ASN-264; PRO-465 AND TRP-468.
RX   PubMed=10447264;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:1<87::AID-HUMU14>3.0.CO;2-N;
RA   Hartog C., Fryer A., Upadhyaya M.;
RT   "Mutation analysis of iduronate-2-sulphatase gene in 24 patients with
RT   Hunter syndrome: characterisation of 6 novel mutations.";
RL   Hum. Mutat. 14:87-87(1999).
RN   [37]
RP   VARIANTS MPS2 ARG-71; GLU-82; THR-85; CYS-88; ARG-95 DEL; GLN-468;
RP   TRP-468 AND VAL-521.
RX   PubMed=9950361;
RA   Li P., Bellows A.B., Thompson J.N.;
RT   "Molecular basis of iduronate-2-sulphatase gene mutations in patients
RT   with mucopolysaccharidosis type II (Hunter syndrome).";
RL   J. Med. Genet. 36:21-27(1999).
RN   [38]
RP   CHARACTERIZATION OF VARIANTS MPS2 HIS-88; PRO-88; ILE-118 AND GLN-468.
RX   PubMed=10838181; DOI=10.1016/S0925-4439(00)00006-5;
RA   Villani G.R.D., Daniele A., Balzano N., Di Natale P.;
RT   "Expression of five iduronate-2-sulfatase site-directed mutations.";
RL   Biochim. Biophys. Acta 1501:71-80(2000).
RN   [39]
RP   VARIANT MPS2 PRO-41, AND CHARACTERIZATION OF VARIANT MPS2 PRO-41.
RX   PubMed=11015461; DOI=10.1136/jmg.37.10.e29;
RA   Cudry S., Tigaud I., Froissart R., Bonnet V., Maire I., Bozon D.;
RT   "MPS II in females: molecular basis of two different cases.";
RL   J. Med. Genet. 37:E29-E29(2000).
RN   [40]
RP   VARIANTS MPS2 SER-117 DEL; ILE-265 AND THR-347, AND CHARACTERIZATION
RP   OF VARIANTS MPS2 SER-117 DEL; ILE-265 AND THR-347.
RX   PubMed=11731225; DOI=10.1016/S0925-4439(01)00075-8;
RA   Bonuccelli G., Di Natale P., Corsolini F., Villani G., Regis S.,
RA   Filocamo M.;
RT   "The effect of four mutations on the expression of iduronate-2-
RT   sulfatase in mucopolysaccharidosis type II.";
RL   Biochim. Biophys. Acta 1537:233-238(2001).
RN   [41]
RP   VARIANTS MPS2 CYS-88; THR-95; ILE-181; ARG-422; LEU-467; GLN-468 AND
RP   TRP-468.
RX   PubMed=11683780; DOI=10.1034/j.1399-0004.2001.600412.x;
RA   Moreira da Silva I., Froissart R., Marques dos Santos H., Caseiro C.,
RA   Maire I., Bozon D.;
RT   "Molecular basis of mucopolysaccharidosis type II in Portugal:
RT   identification of four novel mutations.";
RL   Clin. Genet. 60:316-318(2001).
RN   [42]
RP   VARIANT MPS2 488-ILE-ALA-489, AND CHARACTERIZATION OF VARIANT MPS2
RP   488-ILE-ALA-489.
RX   PubMed=12794697; DOI=10.1002/ajmg.a.10215;
RA   Ricci V., Filocamo M., Regis S., Corsolini F., Stroppiano M.,
RA   Di Duca M., Gatti R.;
RT   "Expression studies of two novel in CIS-mutations identified in an
RT   intermediate case of Hunter syndrome.";
RL   Am. J. Med. Genet. A 120:84-87(2003).
RN   [43]
RP   VARIANTS MPS2 LEU-41 DEL; TYR-117; PRO-259 AND ILE-299.
RX   PubMed=12655569; DOI=10.1002/humu.9128;
RA   Kim C.H., Hwang H.Z., Song S.M., Paik K.H., Kwon E.K., Moon K.B.,
RA   Yoon J.H., Han C.K., Jin D.-K.;
RT   "Mutational spectrum of the iduronate 2 sulfatase gene in 25 unrelated
RT   Korean Hunter syndrome patients: identification of 13 novel
RT   mutations.";
RL   Hum. Mutat. 21:449-450(2003).
RN   [44]
RP   VARIANTS MPS2 VAL-82 AND VAL-140, AND CHARACTERIZATION OF VARIANTS
RP   MPS2 VAL-82 AND VAL-140.
RX   PubMed=16699754; DOI=10.1007/s00109-006-0057-1;
RA   Lualdi S., Pittis M.G., Regis S., Parini R., Allegri A.E., Furlan F.,
RA   Bembi B., Filocamo M.;
RT   "Multiple cryptic splice sites can be activated by IDS point mutations
RT   generating misspliced transcripts.";
RL   J. Mol. Med. 84:692-700(2006).
CC   -!- FUNCTION: Required for the lysosomal degradation of heparan
CC       sulfate and dermatan sulfate.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of the 2-sulfate groups of the L-
CC       iduronate 2-sulfate units of dermatan sulfate, heparan sulfate and
CC       heparin.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000250};
CC       Note=Binds 1 Ca(2+) ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Liver iduronate 2-sulfatase is composed of two major
CC       forms (A and B) which contain both a 42 kDa and a 14 kDa
CC       polypeptides.
CC   -!- SUBCELLULAR LOCATION: Lysosome.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=Long;
CC         IsoId=P22304-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P22304-2; Sequence=VSP_006301, VSP_006302;
CC       Name=3;
CC         IsoId=P22304-3; Sequence=VSP_039116, VSP_039117;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Liver, kidney, lung, and placenta.
CC   -!- PTM: The conversion to 3-oxoalanine (also known as C-
CC       formylglycine, FGly), of a serine or cysteine residue in
CC       prokaryotes and of a cysteine residue in eukaryotes, is critical
CC       for catalytic activity. {ECO:0000250}.
CC   -!- DISEASE: Mucopolysaccharidosis 2 (MPS2) [MIM:309900]: An X-linked
CC       lysosomal storage disease characterized by intracellular
CC       accumulation of heparan sulfate and dermatan sulfate and their
CC       excretion in urine. Most children with MPS2 have a severe form
CC       with early somatic abnormalities including skeletal deformities,
CC       hepatosplenomegaly, and progressive cardiopulmonary deterioration.
CC       A prominent feature is neurological damage that presents as
CC       developmental delay and hyperactivity but progresses to mental
CC       retardation and dementia. They die before 15 years of age, usually
CC       as a result of obstructive airway disease or cardiac failure. In
CC       contrast, those with a mild form of MPS2 may survive into
CC       adulthood, with attenuated somatic complications and often without
CC       mental retardation. {ECO:0000269|PubMed:10215411,
CC       ECO:0000269|PubMed:10220152, ECO:0000269|PubMed:10447264,
CC       ECO:0000269|PubMed:10671065, ECO:0000269|PubMed:11015461,
CC       ECO:0000269|PubMed:11683780, ECO:0000269|PubMed:11731225,
CC       ECO:0000269|PubMed:12655569, ECO:0000269|PubMed:12794697,
CC       ECO:0000269|PubMed:1284597, ECO:0000269|PubMed:1303211,
CC       ECO:0000269|PubMed:16699754, ECO:0000269|PubMed:7581397,
CC       ECO:0000269|PubMed:7599640, ECO:0000269|PubMed:7728156,
CC       ECO:0000269|PubMed:7866405, ECO:0000269|PubMed:7887413,
CC       ECO:0000269|PubMed:7981716, ECO:0000269|PubMed:8281149,
CC       ECO:0000269|PubMed:8566953, ECO:0000269|PubMed:8664909,
CC       ECO:0000269|PubMed:8830188, ECO:0000269|PubMed:8940265,
CC       ECO:0000269|PubMed:9222763, ECO:0000269|PubMed:9266380,
CC       ECO:0000269|PubMed:9375851, ECO:0000269|PubMed:9452044,
CC       ECO:0000269|PubMed:9501270, ECO:0000269|PubMed:9660053,
CC       ECO:0000269|PubMed:9762601, ECO:0000269|PubMed:9875019,
CC       ECO:0000269|PubMed:9921913, ECO:0000269|PubMed:9950361}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the sulfatase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M58342; AAA63197.1; -; mRNA.
DR   EMBL; L13329; AAA16877.1; -; Genomic_DNA.
DR   EMBL; L13321; AAA16877.1; JOINED; Genomic_DNA.
DR   EMBL; L13322; AAA16877.1; JOINED; Genomic_DNA.
DR   EMBL; L13323; AAA16877.1; JOINED; Genomic_DNA.
DR   EMBL; L13324; AAA16877.1; JOINED; Genomic_DNA.
DR   EMBL; L13325; AAA16877.1; JOINED; Genomic_DNA.
DR   EMBL; L13326; AAA16877.1; JOINED; Genomic_DNA.
DR   EMBL; L13327; AAA16877.1; JOINED; Genomic_DNA.
DR   EMBL; L13328; AAA16877.1; JOINED; Genomic_DNA.
DR   EMBL; L04586; AAA59192.1; -; Genomic_DNA.
DR   EMBL; L04578; AAA59192.1; JOINED; Genomic_DNA.
DR   EMBL; L04579; AAA59192.1; JOINED; Genomic_DNA.
DR   EMBL; L04580; AAA59192.1; JOINED; Genomic_DNA.
DR   EMBL; L04581; AAA59192.1; JOINED; Genomic_DNA.
DR   EMBL; L04583; AAA59192.1; JOINED; Genomic_DNA.
DR   EMBL; L04582; AAA59192.1; JOINED; Genomic_DNA.
DR   EMBL; L04584; AAA59192.1; JOINED; Genomic_DNA.
DR   EMBL; L04585; AAA59192.1; JOINED; Genomic_DNA.
DR   EMBL; L40586; AAA92014.1; -; mRNA.
DR   EMBL; AC233288; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471171; EAW61282.1; -; Genomic_DNA.
DR   EMBL; CH471171; EAW61281.1; -; Genomic_DNA.
DR   EMBL; CH471171; EAW61283.1; -; Genomic_DNA.
DR   EMBL; BC006170; AAH06170.1; -; mRNA.
DR   EMBL; AF011889; AAC77828.1; -; Genomic_DNA.
DR   CCDS; CCDS14685.1; -. [P22304-1]
DR   CCDS; CCDS14686.1; -. [P22304-2]
DR   PIR; A47535; KJHUID.
DR   RefSeq; NP_000193.1; NM_000202.6. [P22304-1]
DR   RefSeq; NP_001160022.1; NM_001166550.2.
DR   RefSeq; NP_006114.1; NM_006123.4. [P22304-2]
DR   UniGene; Hs.460960; -.
DR   ProteinModelPortal; P22304; -.
DR   SMR; P22304; 34-450.
DR   BioGrid; 109649; 42.
DR   IntAct; P22304; 2.
DR   MINT; MINT-4722325; -.
DR   STRING; 9606.ENSP00000339801; -.
DR   Allergome; 9623; Hom s Idursulfase.
DR   PhosphoSite; P22304; -.
DR   BioMuta; IDS; -.
DR   DMDM; 124174; -.
DR   MaxQB; P22304; -.
DR   PaxDb; P22304; -.
DR   PRIDE; P22304; -.
DR   Ensembl; ENST00000340855; ENSP00000339801; ENSG00000010404. [P22304-1]
DR   Ensembl; ENST00000370441; ENSP00000359470; ENSG00000010404. [P22304-2]
DR   Ensembl; ENST00000466323; ENSP00000418264; ENSG00000010404. [P22304-3]
DR   GeneID; 3423; -.
DR   KEGG; hsa:3423; -.
DR   UCSC; uc004fcw.4; human. [P22304-1]
DR   UCSC; uc011mxh.2; human. [P22304-2]
DR   CTD; 3423; -.
DR   GeneCards; IDS; -.
DR   HGNC; HGNC:5389; IDS.
DR   MalaCards; IDS; -.
DR   MIM; 300823; gene.
DR   MIM; 309900; phenotype.
DR   neXtProt; NX_P22304; -.
DR   Orphanet; 217093; Mucopolysaccharidosis type 2, attenuated form.
DR   Orphanet; 217085; Mucopolysaccharidosis type 2, severe form.
DR   PharmGKB; PA29636; -.
DR   eggNOG; KOG3867; Eukaryota.
DR   eggNOG; COG3119; LUCA.
DR   GeneTree; ENSGT00730000110906; -.
DR   HOGENOM; HOG000014304; -.
DR   HOVERGEN; HBG006120; -.
DR   InParanoid; P22304; -.
DR   KO; K01136; -.
DR   OMA; DHNMYND; -.
DR   PhylomeDB; P22304; -.
DR   TreeFam; TF323156; -.
DR   BioCyc; MetaCyc:HS00286-MONOMER; -.
DR   BRENDA; 3.1.6.13; 2681.
DR   Reactome; R-HSA-2024096; HS-GAG degradation.
DR   Reactome; R-HSA-2024101; CS/DS degradation.
DR   Reactome; R-HSA-2206296; MPS II - Hunter syndrome.
DR   SABIO-RK; P22304; -.
DR   ChiTaRS; IDS; human.
DR   GeneWiki; Iduronate-2-sulfatase; -.
DR   GenomeRNAi; 3423; -.
DR   NextBio; 13500; -.
DR   PMAP-CutDB; P22304; -.
DR   PRO; PR:P22304; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; P22304; -.
DR   CleanEx; HS_IDS; -.
DR   ExpressionAtlas; P22304; baseline and differential.
DR   Genevisible; P22304; HS.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0004423; F:iduronate-2-sulfatase activity; TAS:Reactome.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005975; P:carbohydrate metabolic process; TAS:Reactome.
DR   GO; GO:0030207; P:chondroitin sulfate catabolic process; TAS:Reactome.
DR   GO; GO:0030204; P:chondroitin sulfate metabolic process; TAS:Reactome.
DR   GO; GO:0006027; P:glycosaminoglycan catabolic process; TAS:Reactome.
DR   GO; GO:0030203; P:glycosaminoglycan metabolic process; TAS:Reactome.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   Gene3D; 3.40.720.10; -; 1.
DR   InterPro; IPR017849; Alkaline_Pase-like_a/b/a.
DR   InterPro; IPR017850; Alkaline_phosphatase_core.
DR   InterPro; IPR024607; Sulfatase_CS.
DR   InterPro; IPR000917; Sulfatase_N.
DR   Pfam; PF00884; Sulfatase; 1.
DR   SUPFAM; SSF53649; SSF53649; 2.
DR   PROSITE; PS00523; SULFATASE_1; 1.
DR   PROSITE; PS00149; SULFATASE_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Calcium; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Glycoprotein; Hydrolase;
KW   Lysosome; Metal-binding; Mucopolysaccharidosis; Reference proteome;
KW   Signal; Zymogen.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   PROPEP       26     33       {ECO:0000269|PubMed:2122463}.
FT                                /FTId=PRO_0000033428.
FT   CHAIN        34    455       Iduronate 2-sulfatase 42 kDa chain.
FT                                /FTId=PRO_0000033429.
FT   CHAIN       456    550       Iduronate 2-sulfatase 14 kDa chain.
FT                                /FTId=PRO_0000033430.
FT   METAL        45     45       Calcium. {ECO:0000250}.
FT   METAL        46     46       Calcium. {ECO:0000250}.
FT   METAL        84     84       Calcium; via 3-oxoalanine. {ECO:0000250}.
FT   METAL       334    334       Calcium. {ECO:0000250}.
FT   METAL       335    335       Calcium. {ECO:0000250}.
FT   MOD_RES      84     84       3-oxoalanine (Cys). {ECO:0000250}.
FT   CARBOHYD    115    115       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    144    144       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    246    246       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    280    280       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    325    325       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    513    513       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    537    537       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ     294    312       RKIRQSYFASVSYLDTQVG -> EDQSSTGFRLKTSSTRKY
FT                                K (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_039116.
FT   VAR_SEQ     313    550       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_039117.
FT   VAR_SEQ     337    343       WALGEHG -> FLMRTNT (in isoform 2).
FT                                {ECO:0000303|PubMed:8530090}.
FT                                /FTId=VSP_006301.
FT   VAR_SEQ     344    550       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8530090}.
FT                                /FTId=VSP_006302.
FT   VARIANT      41     41       L -> P (in MPS2; mild form; increase in
FT                                enzyme activity observed in transfected
FT                                cells). {ECO:0000269|PubMed:11015461}.
FT                                /FTId=VAR_026915.
FT   VARIANT      41     41       Missing (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:12655569}.
FT                                /FTId=VAR_026914.
FT   VARIANT      45     45       D -> N (in MPS2).
FT                                {ECO:0000269|PubMed:9875019}.
FT                                /FTId=VAR_007313.
FT   VARIANT      48     48       R -> P (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:7581397,
FT                                ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_007314.
FT   VARIANT      54     54       Y -> D (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007315.
FT   VARIANT      63     63       N -> D (in MPS2; mild/intermediate form).
FT                                {ECO:0000269|PubMed:8664909,
FT                                ECO:0000269|PubMed:8940265,
FT                                ECO:0000269|PubMed:9222763,
FT                                ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007316.
FT   VARIANT      68     68       A -> E (in MPS2; severe).
FT                                {ECO:0000269|PubMed:7981716}.
FT                                /FTId=VAR_007317.
FT   VARIANT      71     71       S -> N (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026916.
FT   VARIANT      71     71       S -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9950361}.
FT                                /FTId=VAR_008998.
FT   VARIANT      73     73       L -> F (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9266380}.
FT                                /FTId=VAR_026917.
FT   VARIANT      79     79       A -> E (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007318.
FT   VARIANT      82     82       A -> E (in MPS2).
FT                                {ECO:0000269|PubMed:9950361}.
FT                                /FTId=VAR_008999.
FT   VARIANT      82     82       A -> V (in MPS2; no significant enzyme
FT                                activity). {ECO:0000269|PubMed:16699754}.
FT                                /FTId=VAR_026918.
FT   VARIANT      85     85       A -> S (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026919.
FT   VARIANT      85     85       A -> T (in MPS2; mild to severe forms).
FT                                {ECO:0000269|PubMed:8940265,
FT                                ECO:0000269|PubMed:9452044,
FT                                ECO:0000269|PubMed:9501270,
FT                                ECO:0000269|PubMed:9660053,
FT                                ECO:0000269|PubMed:9950361}.
FT                                /FTId=VAR_007319.
FT   VARIANT      86     86       P -> L (in MPS2; intermediate to severe
FT                                forms). {ECO:0000269|PubMed:10215411,
FT                                ECO:0000269|PubMed:7728156,
FT                                ECO:0000269|PubMed:9501270,
FT                                ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_007320.
FT   VARIANT      86     86       P -> Q (in MPS2).
FT                                {ECO:0000269|PubMed:8940265}.
FT                                /FTId=VAR_007321.
FT   VARIANT      86     86       P -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:8281149,
FT                                ECO:0000269|PubMed:8664909}.
FT                                /FTId=VAR_007322.
FT   VARIANT      87     87       S -> N (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:7728156}.
FT                                /FTId=VAR_007323.
FT   VARIANT      88     88       R -> C (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:11683780,
FT                                ECO:0000269|PubMed:8940265,
FT                                ECO:0000269|PubMed:9921913,
FT                                ECO:0000269|PubMed:9950361}.
FT                                /FTId=VAR_007324.
FT   VARIANT      88     88       R -> G (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026920.
FT   VARIANT      88     88       R -> H (in MPS2; intermediate/severe
FT                                form; higher affinity for the artificial
FT                                substrate; poor transport to lysosomes).
FT                                {ECO:0000269|PubMed:10215411,
FT                                ECO:0000269|PubMed:10838181,
FT                                ECO:0000269|PubMed:8940265,
FT                                ECO:0000269|PubMed:9452044,
FT                                ECO:0000269|PubMed:9660053,
FT                                ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007325.
FT   VARIANT      88     88       R -> L (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007326.
FT   VARIANT      88     88       R -> P (in MPS2; severe form; total
FT                                absence of residual activity; poor
FT                                transport to lysosomes).
FT                                {ECO:0000269|PubMed:10215411,
FT                                ECO:0000269|PubMed:10838181}.
FT                                /FTId=VAR_007327.
FT   VARIANT      89     89       V -> F (in MPS2).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026921.
FT   VARIANT      92     92       L -> P (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:7728156}.
FT                                /FTId=VAR_007328.
FT   VARIANT      94     94       G -> D (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:8281149}.
FT                                /FTId=VAR_007329.
FT   VARIANT      95     95       R -> G (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:8664909}.
FT                                /FTId=VAR_026922.
FT   VARIANT      95     95       R -> T (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:11683780}.
FT                                /FTId=VAR_026923.
FT   VARIANT      95     95       Missing (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9950361}.
FT                                /FTId=VAR_009000.
FT   VARIANT     102    102       L -> R (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007330.
FT   VARIANT     108    108       Y -> C (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:8940265}.
FT                                /FTId=VAR_007331.
FT   VARIANT     108    108       Y -> S (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026924.
FT   VARIANT     115    115       N -> Y (in MPS2).
FT                                {ECO:0000269|PubMed:9875019}.
FT                                /FTId=VAR_007332.
FT   VARIANT     117    117       S -> Y (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:12655569}.
FT                                /FTId=VAR_026926.
FT   VARIANT     117    117       Missing (in MPS2; severe form;
FT                                deleterious mutation; results in an
FT                                inactive enzyme).
FT                                {ECO:0000269|PubMed:11731225,
FT                                ECO:0000269|PubMed:7581397,
FT                                ECO:0000269|PubMed:8940265,
FT                                ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026925.
FT   VARIANT     118    118       T -> I (in MPS2; mild to severe forms;
FT                                greatly reduced activity; poor transport
FT                                to lysosomes).
FT                                {ECO:0000269|PubMed:10215411,
FT                                ECO:0000269|PubMed:10838181,
FT                                ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_007333.
FT   VARIANT     118    118       Missing (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9266380}.
FT                                /FTId=VAR_026927.
FT   VARIANT     120    120       P -> H (in MPS2; mild form).
FT                                /FTId=VAR_007334.
FT   VARIANT     120    120       P -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:8281149}.
FT                                /FTId=VAR_007335.
FT   VARIANT     121    121       Q -> H (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9266380}.
FT                                /FTId=VAR_026928.
FT   VARIANT     121    121       Q -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026929.
FT   VARIANT     125    125       E -> V (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:8940265}.
FT                                /FTId=VAR_007336.
FT   VARIANT     132    132       S -> W (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:7887413,
FT                                ECO:0000269|PubMed:9266380}.
FT                                /FTId=VAR_007337.
FT   VARIANT     134    134       G -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:8940265}.
FT                                /FTId=VAR_007338.
FT   VARIANT     135    135       K -> N (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:7728156}.
FT                                /FTId=VAR_007339.
FT   VARIANT     135    135       K -> R (in MPS2; intermediate form;
FT                                dbSNP:rs28937311).
FT                                {ECO:0000269|PubMed:1303211}.
FT                                /FTId=VAR_007340.
FT   VARIANT     138    138       H -> D (in MPS2; mild/intermediate form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026930.
FT   VARIANT     140    140       G -> V (in MPS2; no significant enzyme
FT                                activity). {ECO:0000269|PubMed:16699754}.
FT                                /FTId=VAR_026931.
FT   VARIANT     143    143       S -> F (in MPS2).
FT                                {ECO:0000269|PubMed:10220152,
FT                                ECO:0000269|PubMed:10671065}.
FT                                /FTId=VAR_007341.
FT   VARIANT     148    148       D -> H (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026932.
FT   VARIANT     159    159       H -> P (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007342.
FT   VARIANT     159    159       Missing (in MPS2; intermediate form).
FT                                /FTId=VAR_007343.
FT   VARIANT     160    160       P -> R (in MPS2).
FT                                /FTId=VAR_007344.
FT   VARIANT     181    181       N -> I (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:11683780}.
FT                                /FTId=VAR_026933.
FT   VARIANT     182    182       L -> P (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_026934.
FT   VARIANT     184    184       C -> F (in MPS2; mild/intermediate form).
FT                                {ECO:0000269|PubMed:8940265}.
FT                                /FTId=VAR_007345.
FT   VARIANT     184    184       C -> W (in MPS2).
FT                                {ECO:0000269|PubMed:10671065}.
FT                                /FTId=VAR_007346.
FT   VARIANT     196    196       L -> S (in MPS2; mild/intermediate form).
FT                                {ECO:0000269|PubMed:9501270,
FT                                ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007347.
FT   VARIANT     198    198       D -> G (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007348.
FT   VARIANT     205    205       A -> P (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:8664909}.
FT                                /FTId=VAR_026935.
FT   VARIANT     221    221       L -> P (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:8281149}.
FT                                /FTId=VAR_007349.
FT   VARIANT     224    224       G -> E (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007350.
FT   VARIANT     225    225       Y -> D (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_007351.
FT   VARIANT     227    227       K -> M (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_026936.
FT   VARIANT     227    227       K -> Q (in MPS2; severe form).
FT                                /FTId=VAR_007352.
FT   VARIANT     228    228       P -> L (in MPS2).
FT                                {ECO:0000269|PubMed:9875019}.
FT                                /FTId=VAR_007353.
FT   VARIANT     228    228       P -> T (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9762601}.
FT                                /FTId=VAR_026937.
FT   VARIANT     229    229       H -> R (in MPS2; intermediate/severe
FT                                form). {ECO:0000269|PubMed:9660053,
FT                                ECO:0000269|PubMed:9762601}.
FT                                /FTId=VAR_026938.
FT   VARIANT     229    229       H -> Y (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:7887413}.
FT                                /FTId=VAR_007354.
FT   VARIANT     231    231       P -> L (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9762601}.
FT                                /FTId=VAR_026939.
FT   VARIANT     252    252       D -> N (in MPS2; dbSNP:rs146458524).
FT                                {ECO:0000269|PubMed:8940265}.
FT                                /FTId=VAR_007355.
FT   VARIANT     259    259       L -> P (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:12655569}.
FT                                /FTId=VAR_026940.
FT   VARIANT     264    264       Y -> N (in MPS2).
FT                                {ECO:0000269|PubMed:10447264}.
FT                                /FTId=VAR_009001.
FT   VARIANT     265    265       N -> I (in MPS2; intermediate form;
FT                                deleterious mutation; residual activity
FT                                of 7.5% of the wild-type).
FT                                {ECO:0000269|PubMed:11731225}.
FT                                /FTId=VAR_026941.
FT   VARIANT     266    266       P -> H (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:10215411}.
FT                                /FTId=VAR_007356.
FT   VARIANT     266    266       P -> R (in MPS2).
FT                                {ECO:0000269|PubMed:9875019}.
FT                                /FTId=VAR_007357.
FT   VARIANT     269    269       D -> V (in MPS2).
FT                                {ECO:0000269|PubMed:10671065}.
FT                                /FTId=VAR_007358.
FT   VARIANT     293    293       Q -> H (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:7981716}.
FT                                /FTId=VAR_007359.
FT   VARIANT     299    299       S -> I (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:12655569}.
FT                                /FTId=VAR_026942.
FT   VARIANT     308    308       D -> E (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9762601}.
FT                                /FTId=VAR_026943.
FT   VARIANT     308    308       D -> N (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_026944.
FT   VARIANT     309    309       T -> A (in MPS2; severe form;
FT                                dbSNP:rs145807417).
FT                                {ECO:0000269|PubMed:9762601}.
FT                                /FTId=VAR_026945.
FT   VARIANT     313    313       R -> C (in MPS2; unknown pathological
FT                                significance; dbSNP:rs201048643).
FT                                {ECO:0000269|PubMed:9762601}.
FT                                /FTId=VAR_026946.
FT   VARIANT     314    314       L -> P (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_026947.
FT   VARIANT     333    333       S -> L (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:7581397,
FT                                ECO:0000269|PubMed:8566953,
FT                                ECO:0000269|PubMed:8830188,
FT                                ECO:0000269|PubMed:8940265,
FT                                ECO:0000269|PubMed:9501270,
FT                                ECO:0000269|PubMed:9660053,
FT                                ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007360.
FT   VARIANT     334    334       D -> G (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:8830188}.
FT                                /FTId=VAR_009002.
FT   VARIANT     334    334       D -> N (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026948.
FT   VARIANT     335    335       H -> R (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026949.
FT   VARIANT     336    336       G -> E (in MPS2; severe from).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026950.
FT   VARIANT     336    336       G -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9266380}.
FT                                /FTId=VAR_026951.
FT   VARIANT     337    337       W -> R (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:7581397,
FT                                ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_007361.
FT   VARIANT     339    339       L -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026952.
FT   VARIANT     340    340       G -> D (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007362.
FT   VARIANT     341    341       E -> K (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:10220152,
FT                                ECO:0000269|PubMed:9266380}.
FT                                /FTId=VAR_008134.
FT   VARIANT     342    342       H -> Y (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:10220152}.
FT                                /FTId=VAR_008135.
FT   VARIANT     345    345       W -> C (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:7728156}.
FT                                /FTId=VAR_007363.
FT   VARIANT     346    346       A -> D (in MPS2; mild/severe form).
FT                                {ECO:0000269|PubMed:8566953}.
FT                                /FTId=VAR_007364.
FT   VARIANT     346    346       A -> V (in MPS2; mild/severe form).
FT                                {ECO:0000269|PubMed:7599640}.
FT                                /FTId=VAR_007365.
FT   VARIANT     347    347       K -> I (in MPS2).
FT                                {ECO:0000269|PubMed:8940265}.
FT                                /FTId=VAR_007366.
FT   VARIANT     347    347       K -> Q (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9266380}.
FT                                /FTId=VAR_026953.
FT   VARIANT     347    347       K -> T (in MPS2; severe form; deleterious
FT                                mutation confirmed).
FT                                {ECO:0000269|PubMed:11731225,
FT                                ECO:0000269|PubMed:9222763}.
FT                                /FTId=VAR_007367.
FT   VARIANT     348    348       Y -> H (in MPS2).
FT                                {ECO:0000269|PubMed:10671065}.
FT                                /FTId=VAR_007368.
FT   VARIANT     349    349       S -> I (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9452044,
FT                                ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_007369.
FT   VARIANT     358    358       P -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:7887413}.
FT                                /FTId=VAR_007370.
FT   VARIANT     403    403       L -> R (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:8940265,
FT                                ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_007371.
FT   VARIANT     410    410       L -> P (in MPS2).
FT                                {ECO:0000269|PubMed:7866405}.
FT                                /FTId=VAR_026954.
FT   VARIANT     422    422       C -> G (in MPS2; mild form;
FT                                dbSNP:rs28937310).
FT                                {ECO:0000269|PubMed:1303211,
FT                                ECO:0000269|PubMed:8281149}.
FT                                /FTId=VAR_007372.
FT   VARIANT     422    422       C -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:11683780}.
FT                                /FTId=VAR_026955.
FT   VARIANT     432    432       C -> Y (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007373.
FT   VARIANT     434    434       E -> K (in MPS2).
FT                                {ECO:0000269|PubMed:9875019}.
FT                                /FTId=VAR_007374.
FT   VARIANT     465    465       Q -> P (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:10447264}.
FT                                /FTId=VAR_009003.
FT   VARIANT     467    467       P -> L (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:11683780,
FT                                ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026956.
FT   VARIANT     468    468       R -> G (in MPS2; mild to severe forms).
FT                                /FTId=VAR_007375.
FT   VARIANT     468    468       R -> L (in MPS2; mild to severe forms).
FT                                {ECO:0000269|PubMed:7581397,
FT                                ECO:0000269|PubMed:9222763,
FT                                ECO:0000269|PubMed:9501270}.
FT                                /FTId=VAR_007376.
FT   VARIANT     468    468       R -> Q (in MPS2; severe/intermediate
FT                                form; greatly reduced activity; poor
FT                                transport to lysosomes).
FT                                {ECO:0000269|PubMed:10838181,
FT                                ECO:0000269|PubMed:11683780,
FT                                ECO:0000269|PubMed:7581397,
FT                                ECO:0000269|PubMed:8664909,
FT                                ECO:0000269|PubMed:8940265,
FT                                ECO:0000269|PubMed:9222763,
FT                                ECO:0000269|PubMed:9266380,
FT                                ECO:0000269|PubMed:9375851,
FT                                ECO:0000269|PubMed:9501270,
FT                                ECO:0000269|PubMed:9660053,
FT                                ECO:0000269|PubMed:9921913,
FT                                ECO:0000269|PubMed:9950361}.
FT                                /FTId=VAR_007377.
FT   VARIANT     468    468       R -> W (in MPS2; mild to severe forms).
FT                                {ECO:0000269|PubMed:10447264,
FT                                ECO:0000269|PubMed:11683780,
FT                                ECO:0000269|PubMed:1284597,
FT                                ECO:0000269|PubMed:7728156,
FT                                ECO:0000269|PubMed:8664909,
FT                                ECO:0000269|PubMed:9266380,
FT                                ECO:0000269|PubMed:9501270,
FT                                ECO:0000269|PubMed:9660053,
FT                                ECO:0000269|PubMed:9950361}.
FT                                /FTId=VAR_007378.
FT   VARIANT     469    469       P -> H (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:7887413}.
FT                                /FTId=VAR_007379.
FT   VARIANT     478    478       D -> G (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:7981716}.
FT                                /FTId=VAR_007380.
FT   VARIANT     478    478       D -> Y (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007381.
FT   VARIANT     480    480       P -> L (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026957.
FT   VARIANT     480    480       P -> Q (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026958.
FT   VARIANT     480    480       P -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026959.
FT   VARIANT     485    485       I -> K (in MPS2).
FT                                {ECO:0000269|PubMed:9875019}.
FT                                /FTId=VAR_007382.
FT   VARIANT     485    485       I -> R (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:7981716,
FT                                ECO:0000269|PubMed:9921913}.
FT                                /FTId=VAR_007383.
FT   VARIANT     488    489       MG -> IA (in MPS2; intermediate form;
FT                                mutation A-489 confirmed as causative of
FT                                MPS2).
FT                                /FTId=VAR_026960.
FT   VARIANT     490    490       Y -> S (in MPS2; intermediate form).
FT                                {ECO:0000269|PubMed:9660053}.
FT                                /FTId=VAR_026961.
FT   VARIANT     491    491       S -> F (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:10220152}.
FT                                /FTId=VAR_008136.
FT   VARIANT     502    502       W -> C (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9875019}.
FT                                /FTId=VAR_007384.
FT   VARIANT     502    502       W -> S (in MPS2).
FT                                /FTId=VAR_007385.
FT   VARIANT     521    521       E -> K (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9266380}.
FT                                /FTId=VAR_026962.
FT   VARIANT     521    521       E -> V (in MPS2; severe form).
FT                                {ECO:0000269|PubMed:9266380,
FT                                ECO:0000269|PubMed:9452044,
FT                                ECO:0000269|PubMed:9950361}.
FT                                /FTId=VAR_007386.
FT   VARIANT     523    523       Y -> C (in MPS2; mild form).
FT                                {ECO:0000269|PubMed:7887413}.
FT                                /FTId=VAR_007387.
SQ   SEQUENCE   550 AA;  61873 MW;  EA1B713417280413 CRC64;
     MPPPRTGRGL LWLGLVLSSV CVALGSETQA NSTTDALNVL LIIVDDLRPS LGCYGDKLVR
     SPNIDQLASH SLLFQNAFAQ QAVCAPSRVS FLTGRRPDTT RLYDFNSYWR VHAGNFSTIP
     QYFKENGYVT MSVGKVFHPG ISSNHTDDSP YSWSFPPYHP SSEKYENTKT CRGPDGELHA
     NLLCPVDVLD VPEGTLPDKQ STEQAIQLLE KMKTSASPFF LAVGYHKPHI PFRYPKEFQK
     LYPLENITLA PDPEVPDGLP PVAYNPWMDI RQREDVQALN ISVPYGPIPV DFQRKIRQSY
     FASVSYLDTQ VGRLLSALDD LQLANSTIIA FTSDHGWALG EHGEWAKYSN FDVATHVPLI
     FYVPGRTASL PEAGEKLFPY LDPFDSASQL MEPGRQSMDL VELVSLFPTL AGLAGLQVPP
     RCPVPSFHVE LCREGKNLLK HFRFRDLEED PYLPGNPREL IAYSQYPRPS DIPQWNSDKP
     SLKDIKIMGY SIRTIDYRYT VWVGFNPDEF LANFSDIHAG ELYFVDSDPL QDHNMYNDSQ
     GGDLFQLLMP
//
ID   THRB_HUMAN              Reviewed;         622 AA.
AC   P00734; B2R7F7; B4E1A7; Q4QZ40; Q53H04; Q53H06; Q69EZ7; Q7Z7P3;
AC   Q9UCA1;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1990, sequence version 2.
DT   20-JAN-2016, entry version 216.
DE   RecName: Full=Prothrombin;
DE            EC=3.4.21.5;
DE   AltName: Full=Coagulation factor II;
DE   Contains:
DE     RecName: Full=Activation peptide fragment 1;
DE   Contains:
DE     RecName: Full=Activation peptide fragment 2;
DE   Contains:
DE     RecName: Full=Thrombin light chain;
DE   Contains:
DE     RecName: Full=Thrombin heavy chain;
DE   Flags: Precursor;
GN   Name=F2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2825773; DOI=10.1021/bi00393a033;
RA   Degen S.J.F., Davie E.W.;
RT   "Nucleotide sequence of the gene for human prothrombin.";
RL   Biochemistry 26:6165-6177(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT FA2D GLY-72.
RC   TISSUE=Blood;
RX   PubMed=14962227; DOI=10.1046/j.1365-2516.2003.00838.x;
RA   Wang W., Fu Q., Zhou R., Wu W., Ding Q., Hu Y., Wang X., Wang H.,
RA   Wang Z.;
RT   "Prothrombin Shanghai: hypoprothrombinaemia caused by substitution of
RT   Gla29 by Gly.";
RL   Haemophilia 10:94-97(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT MET-165.
RC   TISSUE=Liver, and Mammary gland;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT MET-165.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 8-622, AND GAMMA-CARBOXYGLUTAMATION AT
RP   GLU-49; GLU-50; GLU-57; GLU-59; GLU-62; GLU-63; GLU-68; GLU-69; GLU-72
RP   AND GLU-75.
RX   PubMed=6305407; DOI=10.1021/bi00278a008;
RA   Degen S.J.F., McGillivray R.T.A., Davie E.W.;
RT   "Characterization of the complementary deoxyribonucleic acid and gene
RT   coding for human prothrombin.";
RL   Biochemistry 22:2087-2097(1983).
RN   [8]
RP   PROTEIN SEQUENCE OF 44-64.
RC   TISSUE=Urine;
RX   PubMed=8073540; DOI=10.1007/BF00431548;
RA   Suzuki K., Moriyama M., Nakajima C., Kawamura K., Miyazawa K.,
RA   Tsugawa R., Kikuchi N., Nagata K.;
RT   "Isolation and partial characterization of crystal matrix protein as a
RT   potent inhibitor of calcium oxalate crystal aggregation: evidence of
RT   activation peptide of human prothrombin.";
RL   Urol. Res. 22:45-50(1994).
RN   [9]
RP   PROTEIN SEQUENCE OF 44-314.
RX   PubMed=266717; DOI=10.1073/pnas.74.5.1969;
RA   Walz D.A., Hewett-Emmett D., Seegers W.H.;
RT   "Amino acid sequence of human prothrombin fragments 1 and 2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 74:1969-1972(1977).
RN   [10]
RP   PROTEIN SEQUENCE OF 315-622, GLYCOSYLATION AT ASN-416, AND VARIANT
RP   GLN-532.
RX   PubMed=873923;
RA   Butkowski R.J., Elion J., Downing M.R., Mann K.G.;
RT   "Primary structure of human prethrombin 2 and alpha-thrombin.";
RL   J. Biol. Chem. 252:4942-4957(1977).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 364-622.
RA   Gruber A., Hanson S.R., DiCera E.;
RT   "Antithrombotic thrombin variants.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   ENZYME REGULATION, AND HETERODIMER WITH SERPINA5.
RX   PubMed=6323392;
RA   Suzuki K., Nishioka J., Kusumoto H., Hashimoto S.;
RT   "Mechanism of inhibition of activated protein C by protein C
RT   inhibitor.";
RL   J. Biochem. 95:187-195(1984).
RN   [13]
RP   PROTEOLYTIC PROCESSING, AND GAMMA-CARBOXYGLUTAMATION AT GLU-49 AND
RP   GLU-50.
RX   PubMed=3759958;
RA   Rabiet M.J., Blashill A., Furie B., Furie B.C.;
RT   "Prothrombin fragment 1 X 2 X 3, a major product of prothrombin
RT   activation in human plasma.";
RL   J. Biol. Chem. 261:13210-13215(1986).
RN   [14]
RP   FUNCTION, AND CHARACTERIZATION.
RX   PubMed=2856554;
RA   Glenn K.C., Frost G.H., Bergmann J.S., Carney D.H.;
RT   "Synthetic peptides bind to high-affinity thrombin receptors and
RT   modulate thrombin mitogenesis.";
RL   Pept. Res. 1:65-73(1988).
RN   [15]
RP   INVOLVEMENT IN RPRGL2 SUSCEPTIBILITY.
RX   PubMed=11506076; DOI=10.1111/j.8755-8920.2001.460202.x;
RA   Pihusch R., Buchholz T., Lohse P., Rubsamen H., Rogenhofer N.,
RA   Hasbargen U., Hiller E., Thaler C.J.;
RT   "Thrombophilic gene mutations and recurrent spontaneous abortion:
RT   prothrombin mutation increases the risk in the first trimester.";
RL   Am. J. Reprod. Immunol. 46:124-131(2001).
RN   [16]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO ISCHSTR.
RX   PubMed=15534175; DOI=10.1001/archneur.61.11.1652;
RA   Casas J.P., Hingorani A.D., Bautista L.E., Sharma P.;
RT   "Meta-analysis of genetic studies in ischemic stroke: thirty-two genes
RT   involving approximately 18,000 cases and 58,000 controls.";
RL   Arch. Neurol. 61:1652-1661(2004).
RN   [17]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-121 AND ASN-143.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [18]
RP   CHARACTERIZATION OF THE TP508 PEPTIDE.
RX   PubMed=15885491; DOI=10.1016/j.orthres.2004.12.005;
RA   Li G., Cui Y., McIlmurray L., Allen W.E., Wang H.;
RT   "rhBMP-2, rhVEGF(165), rhPTN and thrombin-related peptide, TP508
RT   induce chemotaxis of human osteoblasts and microvascular endothelial
RT   cells.";
RL   J. Orthop. Res. 23:680-685(2005).
RN   [19]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-121; ASN-143 AND ASN-416.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [20]
RP   THERAPEUTIC USAGE OF THE TP508 PEPTIDE.
RX   PubMed=17244316; DOI=10.1111/j.1524-475X.2006.00181.x;
RA   Fife C., Mader J.T., Stone J., Brill L., Satterfield K., Norfleet A.,
RA   Zwernemann A., Ryaby J.T., Carney D.H.;
RT   "Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers
RT   in a placebo-controlled phase I/II study.";
RL   Wound Repair Regen. 15:23-34(2007).
RN   [21]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-416.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [22]
RP   GLYCOSYLATION AT ASN-416.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [23]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-416, AND STRUCTURE OF
RP   CARBOHYDRATE.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=19838169; DOI=10.1038/nmeth.1392;
RA   Nilsson J., Rueetschi U., Halim A., Hesse C., Carlsohn E.,
RA   Brinkmalm G., Larson G.;
RT   "Enrichment of glycopeptides for glycan structure and attachment site
RT   identification.";
RL   Nat. Methods 6:809-811(2009).
RN   [24]
RP   GLYCOSYLATION AT ASN-121 AND ASN-143, STRUCTURE OF CARBOHYDRATES, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22171320; DOI=10.1074/mcp.M111.013649;
RA   Halim A., Nilsson J., Ruetschi U., Hesse C., Larson G.;
RT   "Human urinary glycoproteomics; attachment site specific analysis of
RT   N-and O-linked glycosylations by CID and ECD.";
RL   Mol. Cell. Proteomics 0:0-0(2011).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS).
RX   PubMed=2583108;
RA   Bode W., Mayr I., Baumann U., Huber R., Stone S.R., Hofsteenge J.;
RT   "The refined 1.9 A crystal structure of human alpha-thrombin:
RT   interaction with D-Phe-Pro-Arg chloromethylketone and significance of
RT   the Tyr-Pro-Pro-Trp insertion segment.";
RL   EMBO J. 8:3467-3475(1989).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.95 ANGSTROMS) IN COMPLEX WITH HIRUDIN.
RX   PubMed=2369893;
RA   Gruetter M.G., Priestle J.P., Rahuel J., Grossenbacher H., Bode W.,
RA   Hofsteenge J., Stone S.R.;
RT   "Crystal structure of the thrombin-hirudin complex: a novel mode of
RT   serine protease inhibition.";
RL   EMBO J. 9:2361-2365(1990).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) IN COMPLEX WITH HIRUDIN.
RX   PubMed=2374926; DOI=10.1126/science.2374926;
RA   Rydel T.J., Ravichandran K.G., Tulinsky A., Bode W., Huber R.,
RA   Roitsch C., Fenton J.W. II;
RT   "The structure of a complex of recombinant hirudin and human alpha-
RT   thrombin.";
RL   Science 249:277-280(1990).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 328-622 IN COMPLEXES WITH
RP   HIRUDIN AND SYNTHETIC INHIBITOR.
RX   PubMed=8251938; DOI=10.1002/pro.5560021009;
RA   Priestle J.P., Rahuel J., Rink H., Tones M., Gruetter M.G.;
RT   "Changes in interactions in complexes of hirudin derivatives and human
RT   alpha-thrombin due to different crystal forms.";
RL   Protein Sci. 2:1630-1642(1993).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS).
RX   PubMed=8071320;
RA   Rydel T.J., Yin M., Padmanabhan K.P., Blankenship D.T., Cardin A.D.,
RA   Correa P.E., Fenton J.W. II, Tulinsky A.;
RT   "Crystallographic structure of human gamma-thrombin.";
RL   J. Biol. Chem. 269:22000-22006(1994).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS).
RX   PubMed=9214615; DOI=10.1093/emboj/16.11.2977;
RA   van de Locht A., Bode W., Huber R., le Bonniec B.F., Stone S.R.,
RA   Esmon C.T., Stubbs M.T.;
RT   "The thrombin E192Q-BPTI complex reveals gross structural
RT   rearrangements: implications for the interaction with antithrombin and
RT   thrombomodulin.";
RL   EMBO J. 16:2977-2984(1997).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 328-601.
RX   PubMed=10051558; DOI=10.1073/pnas.96.5.1852;
RA   Guinto E.R., Caccia S., Rose T., Fuetterer K., Waksman G., di Cera E.;
RT   "Unexpected crucial role of residue 225 in serine proteases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:1852-1857(1999).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 333-621 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR.
RX   PubMed=11493008; DOI=10.1006/jmbi.2001.4872;
RA   Skordalakes E., Dodson G.G., Green D.S., Goodwin C.A., Scully M.F.,
RA   Hudson H.R., Kakkar V.V., Deadman J.J.;
RT   "Inhibition of human alpha-thrombin by a phosphonate tripeptide
RT   proceeds via a metastable pentacoordinated phosphorus intermediate.";
RL   J. Mol. Biol. 311:549-555(2001).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) OF 334-620 IN COMPLEX WITH
RP   HIRUDIN AND SYNTHETIC INHIBITOR.
RX   PubMed=16763681; DOI=10.1039/b602585d;
RA   Schweizer E., Hoffmann-Roeder A., Olsen J.A., Seiler P.,
RA   Obst-Sander U., Wagner B., Kansy M., Banner D.W., Diederich F.;
RT   "Multipolar interactions in the D pocket of thrombin: large
RT   differences between tricyclic imide and lactam inhibitors.";
RL   Org. Biomol. Chem. 4:2364-2375(2006).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (1.84 ANGSTROMS) OF 334-621 IN COMPLEX WITH
RP   HIRUDIN.
RX   PubMed=17685615; DOI=10.1021/ja0735002;
RA   Liu C.C., Brustad E., Liu W., Schultz P.G.;
RT   "Crystal structure of a biosynthetic sulfo-hirudin complexed to
RT   thrombin.";
RL   J. Am. Chem. Soc. 129:10648-10649(2007).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (1.84 ANGSTROMS) OF 335-621 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR.
RX   PubMed=18291642; DOI=10.1016/j.bmcl.2008.01.098;
RA   Isaacs R.C.A., Solinsky M.G., Cutrona K.J., Newton C.L.,
RA   Naylor-Olsen A.M., McMasters D.R., Krueger J.A., Lewis S.D.,
RA   Lucas B.J., Kuo L.C., Yan Y., Lynch J.J., Lyle E.A.;
RT   "Structure-based design of novel groups for use in the P1 position of
RT   thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.";
RL   Bioorg. Med. Chem. Lett. 18:2062-2066(2008).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 315-622 IN COMPLEX WITH
RP   SERPINA5 AND HEPARIN.
RX   PubMed=18362344; DOI=10.1073/pnas.0711055105;
RA   Li W., Adams T.E., Nangalia J., Esmon C.T., Huntington J.A.;
RT   "Molecular basis of thrombin recognition by protein C inhibitor
RT   revealed by the 1.6-A structure of the heparin-bridged complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:4661-4666(2008).
RN   [38]
RP   VARIANT FA2D LYS-200, AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=6405779; DOI=10.1111/j.1365-2141.1983.tb02092.x;
RA   Board P.G., Shaw D.C.;
RT   "Determination of the amino acid substitution in human prothrombin
RT   type 3 (157 Glu leads to Lys) and the localization of a third thrombin
RT   cleavage site.";
RL   Br. J. Haematol. 54:245-254(1983).
RN   [39]
RP   VARIANT FA2D CYS-314, AND PROTEIN SEQUENCE OF 310-327.
RX   PubMed=3771562;
RA   Rabiet M.-J., Furie B.C., Furie B.;
RT   "Molecular defect of prothrombin Barcelona. Substitution of cysteine
RT   for arginine at residue 273.";
RL   J. Biol. Chem. 261:15045-15048(1986).
RN   [40]
RP   VARIANT FA2D TRP-461, AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=3567158; DOI=10.1021/bi00378a020;
RA   Miyata T., Morita T., Inomoto T., Kawauchi S., Shirakami A.,
RA   Iwanaga S.;
RT   "Prothrombin Tokushima, a replacement of arginine-418 by tryptophan
RT   that impairs the fibrinogen clotting activity of derived thrombin
RT   Tokushima.";
RL   Biochemistry 26:1117-1122(1987).
RN   [41]
RP   VARIANT FA2D TRP-461.
RX   PubMed=3801671;
RA   Inomoto T., Shirakami A., Kawauchi S., Shigekiyo T., Saito S.,
RA   Miyoshi K., Morita T., Iwanaga S.;
RT   "Prothrombin Tokushima: characterization of dysfunctional thrombin
RT   derived from a variant of human prothrombin.";
RL   Blood 69:565-569(1987).
RN   [42]
RP   VARIANT FA2D CYS-425, AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=3242619; DOI=10.1021/bi00426a013;
RA   Henriksen R.A., Mann K.G.;
RT   "Identification of the primary structural defect in the dysthrombin
RT   thrombin Quick I: substitution of cysteine for arginine-382.";
RL   Biochemistry 27:9160-9165(1988).
RN   [43]
RP   VARIANT FA2D VAL-601, AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=2719946; DOI=10.1021/bi00431a017;
RA   Henriksen R.A., Mann K.G.;
RT   "Substitution of valine for glycine-558 in the congenital dysthrombin
RT   thrombin Quick II alters primary substrate specificity.";
RL   Biochemistry 28:2078-2082(1989).
RN   [44]
RP   VARIANT FA2D ALA-509, AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=1354985; DOI=10.1021/bi00148a005;
RA   Miyata T., Aruga R., Umeyama H., Bezeaud A., Guillin M.-C.,
RA   Iwanaga S.;
RT   "Prothrombin Salakta: substitution of glutamic acid-466 by alanine
RT   reduces the fibrinogen clotting activity and the esterase activity.";
RL   Biochemistry 31:7457-7462(1992).
RN   [45]
RP   VARIANTS FA2D THR-380 AND HIS-431.
RX   PubMed=1421398;
RA   Morishita E., Saito M., Kumabashiri I., Asakura H., Matsuda T.,
RA   Yamaguchi K.;
RT   "Prothrombin Himi: a compound heterozygote for two dysfunctional
RT   prothrombin molecules (Met-337-->Thr and Arg-388-->His).";
RL   Blood 80:2275-2280(1992).
RN   [46]
RP   VARIANT FA2D TRP-461.
RX   PubMed=1349838;
RA   Iwahana H., Yoshimoto K., Shigekiyo T., Shirakami A., Saito S.,
RA   Itakura M.;
RT   "Detection of a single base substitution of the gene for prothrombin
RT   Tokushima. The application of PCR-SSCP for the genetic and molecular
RT   analysis of dysprothrombinemia.";
RL   Int. J. Hematol. 55:93-100(1992).
RN   [47]
RP   VARIANT FA2D HIS-314.
RX   PubMed=7865694;
RA   James H.L., Kim D.J., Zheng D.-Q., Girolami A.;
RT   "Prothrombin Padua I: incomplete activation due to an amino acid
RT   substitution at a factor Xa cleavage site.";
RL   Blood Coagul. Fibrinolysis 5:841-844(1994).
RN   [48]
RP   VARIANT FA2D ALA-509.
RX   PubMed=7792730;
RA   Degen S.J.F., McDowell S.A., Sparks L.M., Scharrer I.;
RT   "Prothrombin Frankfurt: a dysfunctional prothrombin characterized by
RT   substitution of Glu-466 by Ala.";
RL   Thromb. Haemost. 73:203-209(1995).
RN   [49]
RP   VARIANTS MET-165 AND THR-386.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [50]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [51]
RP   VARIANTS MET-165; LYS-200; THR-386 AND GLN-532, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=22028381; DOI=10.1093/jmcb/mjr024;
RA   Su Z.D., Sun L., Yu D.X., Li R.X., Li H.X., Yu Z.J., Sheng Q.H.,
RA   Lin X., Zeng R., Wu J.R.;
RT   "Quantitative detection of single amino acid polymorphisms by targeted
RT   proteomics.";
RL   J. Mol. Cell Biol. 3:309-315(2011).
CC   -!- FUNCTION: Thrombin, which cleaves bonds after Arg and Lys,
CC       converts fibrinogen to fibrin and activates factors V, VII, VIII,
CC       XIII, and, in complex with thrombomodulin, protein C. Functions in
CC       blood homeostasis, inflammation and wound healing.
CC       {ECO:0000269|PubMed:2856554}.
CC   -!- CATALYTIC ACTIVITY: Selective cleavage of Arg-|-Gly bonds in
CC       fibrinogen to form fibrin and release fibrinopeptides A and B.
CC   -!- ENZYME REGULATION: Inhibited by SERPINA5.
CC       {ECO:0000269|PubMed:6323392}.
CC   -!- SUBUNIT: Heterodimer (named alpha-thrombin) of a light and a heavy
CC       chain; disulfide-linked. Forms a heterodimer with SERPINA5.
CC       {ECO:0000269|PubMed:11493008, ECO:0000269|PubMed:16763681,
CC       ECO:0000269|PubMed:17685615, ECO:0000269|PubMed:18291642,
CC       ECO:0000269|PubMed:18362344, ECO:0000269|PubMed:2369893,
CC       ECO:0000269|PubMed:2374926}.
CC   -!- INTERACTION:
CC       Q846V4:- (xeno); NbExp=5; IntAct=EBI-297094, EBI-989571;
CC       P07204:THBD; NbExp=4; IntAct=EBI-297094, EBI-941422;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space.
CC   -!- TISSUE SPECIFICITY: Expressed by the liver and secreted in plasma.
CC   -!- PTM: The gamma-carboxyglutamyl residues, which bind calcium ions,
CC       result from the carboxylation of glutamyl residues by a microsomal
CC       enzyme, the vitamin K-dependent carboxylase. The modified residues
CC       are necessary for the calcium-dependent interaction with a
CC       negatively charged phospholipid surface, which is essential for
CC       the conversion of prothrombin to thrombin.
CC       {ECO:0000269|PubMed:3759958, ECO:0000269|PubMed:6305407}.
CC   -!- PTM: N-glycosylated. N-glycan heterogeneity at Asn-121:
CC       Hex3HexNAc3 (minor), Hex4HexNAc3 (minor) and Hex5HexNAc4 (major).
CC       At Asn-143: Hex4HexNAc3 (minor) and Hex5HexNAc4 (major).
CC       {ECO:0000269|PubMed:14760718, ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:19838169, ECO:0000269|PubMed:22171320,
CC       ECO:0000269|PubMed:873923}.
CC   -!- DISEASE: Factor II deficiency (FA2D) [MIM:613679]: A very rare
CC       blood coagulation disorder characterized by mucocutaneous bleeding
CC       symptoms. The severity of the bleeding manifestations correlates
CC       with blood factor II levels. {ECO:0000269|PubMed:1349838,
CC       ECO:0000269|PubMed:1354985, ECO:0000269|PubMed:1421398,
CC       ECO:0000269|PubMed:14962227, ECO:0000269|PubMed:2719946,
CC       ECO:0000269|PubMed:3242619, ECO:0000269|PubMed:3567158,
CC       ECO:0000269|PubMed:3771562, ECO:0000269|PubMed:3801671,
CC       ECO:0000269|PubMed:6405779, ECO:0000269|PubMed:7792730,
CC       ECO:0000269|PubMed:7865694}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Ischemic stroke (ISCHSTR) [MIM:601367]: A stroke is an
CC       acute neurologic event leading to death of neural tissue of the
CC       brain and resulting in loss of motor, sensory and/or cognitive
CC       function. Ischemic strokes, resulting from vascular occlusion, is
CC       considered to be a highly complex disease consisting of a group of
CC       heterogeneous disorders with multiple genetic and environmental
CC       risk factors. {ECO:0000269|PubMed:15534175}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Thrombophilia due to thrombin defect (THPH1)
CC       [MIM:188050]: A multifactorial disorder of hemostasis
CC       characterized by abnormal platelet aggregation in response to
CC       various agents and recurrent thrombi formation.
CC       {ECO:0000269|PubMed:2825773}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. A common
CC       genetic variation in the 3-prime untranslated region of the
CC       prothrombin gene is associated with elevated plasma prothrombin
CC       levels and an increased risk of venous thrombosis.
CC   -!- DISEASE: Pregnancy loss, recurrent, 2 (RPRGL2) [MIM:614390]: A
CC       common complication of pregnancy, resulting in spontaneous
CC       abortion before the fetus has reached viability. The term includes
CC       all miscarriages from the time of conception until 24 weeks of
CC       gestation. Recurrent pregnancy loss is defined as 3 or more
CC       consecutive spontaneous abortions. {ECO:0000269|PubMed:11506076}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- PHARMACEUTICAL: The peptide TP508 also known as Chrysalin
CC       (Orthologic) could be used to accelerate repair of both soft and
CC       hard tissues.
CC   -!- MISCELLANEOUS: Prothrombin is activated on the surface of a
CC       phospholipid membrane that binds the amino end of prothrombin and
CC       factors Va and Xa in Ca-dependent interactions; factor Xa removes
CC       the activation peptide and cleaves the remaining part into light
CC       and heavy chains. The activation process starts slowly because
CC       factor V itself has to be activated by the initial, small amounts
CC       of thrombin.
CC   -!- MISCELLANEOUS: It is not known whether 1 or 2 smaller activation
CC       peptides, with additional cleavage after Arg-314, are released in
CC       natural blood clotting.
CC   -!- MISCELLANEOUS: Thrombin can itself cleave the N-terminal fragment
CC       (fragment 1) of the prothrombin, prior to its activation by factor
CC       Xa.
CC   -!- MISCELLANEOUS: The cleavage after Arg-198, observed in vitro, does
CC       not occur in plasma.
CC   -!- SIMILARITY: Belongs to the peptidase S1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00274}.
CC   -!- SIMILARITY: Contains 1 Gla (gamma-carboxy-glutamate) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00463}.
CC   -!- SIMILARITY: Contains 2 kringle domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00121}.
CC   -!- SIMILARITY: Contains 1 peptidase S1 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00274}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Thrombin entry;
CC       URL="https://en.wikipedia.org/wiki/Thrombin";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/f2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M17262; AAC63054.1; -; Genomic_DNA.
DR   EMBL; AJ972449; CAJ01369.1; -; mRNA.
DR   EMBL; AK303747; BAG64719.1; -; mRNA.
DR   EMBL; AK312965; BAG35804.1; -; mRNA.
DR   EMBL; AK222775; BAD96495.1; -; mRNA.
DR   EMBL; AK222777; BAD96497.1; -; mRNA.
DR   EMBL; AF478696; AAL77436.1; -; Genomic_DNA.
DR   EMBL; BC051332; AAH51332.1; -; mRNA.
DR   EMBL; V00595; CAA23842.1; -; mRNA.
DR   EMBL; AY344794; AAR08143.1; -; mRNA.
DR   CCDS; CCDS31476.1; -.
DR   PIR; A29351; TBHU.
DR   RefSeq; NP_000497.1; NM_000506.4.
DR   RefSeq; NP_001298186.1; NM_001311257.1.
DR   UniGene; Hs.655207; -.
DR   PDB; 1A2C; X-ray; 2.10 A; H=364-622, L=328-363.
DR   PDB; 1A3B; X-ray; 1.80 A; H=364-622, L=328-363.
DR   PDB; 1A3E; X-ray; 1.85 A; H=364-622, L=328-363.
DR   PDB; 1A46; X-ray; 2.12 A; H=364-622, L=328-363.
DR   PDB; 1A4W; X-ray; 1.80 A; H=364-622, L=328-363.
DR   PDB; 1A5G; X-ray; 2.06 A; H=364-622, L=328-363.
DR   PDB; 1A61; X-ray; 2.20 A; H=364-622, L=328-363.
DR   PDB; 1ABI; X-ray; 2.30 A; H=364-622, L=328-363.
DR   PDB; 1ABJ; X-ray; 2.40 A; H=364-622, L=328-363.
DR   PDB; 1AD8; X-ray; 2.00 A; H=364-622, L=328-363.
DR   PDB; 1AE8; X-ray; 2.00 A; H=364-622, L=328-363.
DR   PDB; 1AFE; X-ray; 2.00 A; H=364-622, L=328-363.
DR   PDB; 1AHT; X-ray; 1.60 A; H=364-622, L=328-363.
DR   PDB; 1AI8; X-ray; 1.85 A; H=364-622, L=328-363.
DR   PDB; 1AIX; X-ray; 2.10 A; H=364-622, L=328-363.
DR   PDB; 1AWF; X-ray; 2.20 A; H=364-622, L=328-363.
DR   PDB; 1AWH; X-ray; 3.00 A; A/C=328-363, B/D=364-622.
DR   PDB; 1AY6; X-ray; 1.80 A; H=364-622, L=328-363.
DR   PDB; 1B5G; X-ray; 2.07 A; H=364-622, L=328-363.
DR   PDB; 1B7X; X-ray; 2.10 A; A=328-363, B=364-622.
DR   PDB; 1BA8; X-ray; 1.80 A; A=328-363, B=364-622.
DR   PDB; 1BB0; X-ray; 2.10 A; A=328-363, B=364-622.
DR   PDB; 1BCU; X-ray; 2.00 A; H=364-622, L=328-363.
DR   PDB; 1BHX; X-ray; 2.30 A; A=331-349, B=364-510, F=518-622.
DR   PDB; 1BMM; X-ray; 2.60 A; H=364-622, L=328-363.
DR   PDB; 1BMN; X-ray; 2.80 A; H=364-622, L=328-363.
DR   PDB; 1BTH; X-ray; 2.30 A; H/K=364-622, J/L=328-363.
DR   PDB; 1C1U; X-ray; 1.75 A; H=364-616, L=328-363.
DR   PDB; 1C1V; X-ray; 1.98 A; H=364-616, L=328-363.
DR   PDB; 1C1W; X-ray; 1.90 A; H=364-616, L=328-363.
DR   PDB; 1C4U; X-ray; 2.10 A; 1=328-363, 2=364-622.
DR   PDB; 1C4V; X-ray; 2.10 A; 1=328-363, 2=364-622.
DR   PDB; 1C4Y; X-ray; 2.70 A; 1=328-363, 2=364-622.
DR   PDB; 1C5L; X-ray; 1.47 A; H=364-622, L=328-363.
DR   PDB; 1C5N; X-ray; 1.50 A; H=364-622, L=328-363.
DR   PDB; 1C5O; X-ray; 1.90 A; H=364-622, L=328-363.
DR   PDB; 1CA8; X-ray; 2.10 A; A=328-363, B=364-622.
DR   PDB; 1D3D; X-ray; 2.04 A; A=333-360, B=364-620.
DR   PDB; 1D3P; X-ray; 2.10 A; A=328-363, B=364-622.
DR   PDB; 1D3Q; X-ray; 2.90 A; A=328-363, B=364-622.
DR   PDB; 1D3T; X-ray; 3.00 A; A=328-363, B=364-622.
DR   PDB; 1D4P; X-ray; 2.07 A; A=328-363, B=364-622.
DR   PDB; 1D6W; X-ray; 2.00 A; A=334-620.
DR   PDB; 1D9I; X-ray; 2.30 A; A=334-621.
DR   PDB; 1DE7; X-ray; 2.00 A; H/K=364-619, J/L=328-360.
DR   PDB; 1DIT; X-ray; 2.30 A; H=364-622, L=328-363.
DR   PDB; 1DM4; X-ray; 2.50 A; A=328-362, B=363-622.
DR   PDB; 1DOJ; X-ray; 1.70 A; A=328-622.
DR   PDB; 1DWB; X-ray; 3.16 A; H=364-622, L=328-363.
DR   PDB; 1DWC; X-ray; 3.00 A; H=364-622, L=328-363.
DR   PDB; 1DWD; X-ray; 3.00 A; H=364-622, L=328-363.
DR   PDB; 1DWE; X-ray; 3.00 A; H=364-622, L=328-363.
DR   PDB; 1DX5; X-ray; 2.30 A; A/B/C/D=328-363, M/N/O/P=364-622.
DR   PDB; 1E0F; X-ray; 3.10 A; A/B/C=328-363, D/E/F=364-622.
DR   PDB; 1EB1; X-ray; 1.80 A; H=364-620, L=334-360.
DR   PDB; 1EOJ; X-ray; 2.10 A; A=332-620.
DR   PDB; 1EOL; X-ray; 2.10 A; A=332-620.
DR   PDB; 1FPC; X-ray; 2.30 A; H=364-622, L=328-363.
DR   PDB; 1FPH; X-ray; 2.50 A; H=364-622, L=328-363.
DR   PDB; 1G30; X-ray; 2.00 A; A=328-363, B=364-622.
DR   PDB; 1G32; X-ray; 1.90 A; A=328-363, B=364-622.
DR   PDB; 1G37; X-ray; 2.00 A; A=334-620.
DR   PDB; 1GHV; X-ray; 1.85 A; H=364-620, L=328-363.
DR   PDB; 1GHW; X-ray; 1.75 A; H=364-620, L=328-363.
DR   PDB; 1GHX; X-ray; 1.65 A; H=364-620, L=328-363.
DR   PDB; 1GHY; X-ray; 1.85 A; H=364-620, L=328-363.
DR   PDB; 1GJ4; X-ray; 1.81 A; H=364-621, L=328-363.
DR   PDB; 1GJ5; X-ray; 1.73 A; H=364-621, L=328-363.
DR   PDB; 1H8D; X-ray; 1.40 A; H=364-621, L=333-360.
DR   PDB; 1H8I; X-ray; 1.75 A; H=364-622, L=334-360.
DR   PDB; 1HAG; X-ray; 2.00 A; E=328-622.
DR   PDB; 1HAH; X-ray; 2.30 A; H=364-622, L=328-363.
DR   PDB; 1HAI; X-ray; 2.40 A; H=364-622, L=328-363.
DR   PDB; 1HAO; X-ray; 2.80 A; H=364-622, L=328-363.
DR   PDB; 1HAP; X-ray; 2.80 A; H=364-622, L=328-360.
DR   PDB; 1HBT; X-ray; 2.00 A; H=364-622, L=328-363.
DR   PDB; 1HDT; X-ray; 2.60 A; H=364-622, L=331-363.
DR   PDB; 1HGT; X-ray; 2.20 A; H=364-622, L=328-363.
DR   PDB; 1HLT; X-ray; 3.00 A; H/K=364-622, J/L=334-349.
DR   PDB; 1HUT; X-ray; 2.90 A; H=364-622, L=328-363.
DR   PDB; 1HXE; X-ray; 2.10 A; H=364-622, L=328-363.
DR   PDB; 1HXF; X-ray; 2.10 A; H=364-622, L=328-363.
DR   PDB; 1IHS; X-ray; 2.00 A; H=364-622, L=328-363.
DR   PDB; 1IHT; X-ray; 2.10 A; H=364-622, L=328-363.
DR   PDB; 1JMO; X-ray; 2.20 A; H=363-622, L=315-362.
DR   PDB; 1JOU; X-ray; 1.80 A; A/C/E=315-363, B/D/F=364-622.
DR   PDB; 1JWT; X-ray; 2.50 A; A=328-622.
DR   PDB; 1K21; X-ray; 1.86 A; H=364-622, L=328-363.
DR   PDB; 1K22; X-ray; 1.93 A; H=364-622, L=328-363.
DR   PDB; 1KTS; X-ray; 2.40 A; A=328-363, B=364-622.
DR   PDB; 1KTT; X-ray; 2.10 A; A=328-363, B=364-622.
DR   PDB; 1LHC; X-ray; 1.95 A; H=364-622, L=328-363.
DR   PDB; 1LHD; X-ray; 2.35 A; H=364-622, L=328-363.
DR   PDB; 1LHE; X-ray; 2.25 A; H=364-622, L=328-363.
DR   PDB; 1LHF; X-ray; 2.40 A; H=364-622, L=328-363.
DR   PDB; 1LHG; X-ray; 2.25 A; H=364-622, L=328-363.
DR   PDB; 1MH0; X-ray; 2.80 A; A/B=334-620.
DR   PDB; 1MU6; X-ray; 1.99 A; A=328-363, B=364-622.
DR   PDB; 1MU8; X-ray; 2.00 A; A=328-363, B=364-622.
DR   PDB; 1MUE; X-ray; 2.00 A; A=328-363, B=364-622.
DR   PDB; 1NM6; X-ray; 1.80 A; A=335-621.
DR   PDB; 1NO9; X-ray; 1.90 A; H=364-622, L=328-363.
DR   PDB; 1NRN; X-ray; 3.10 A; H=364-622, L=328-363.
DR   PDB; 1NRO; X-ray; 3.10 A; H=364-622, L=328-363.
DR   PDB; 1NRP; X-ray; 3.00 A; H=364-622, L=328-363.
DR   PDB; 1NRQ; X-ray; 3.50 A; H=364-622, L=328-363.
DR   PDB; 1NRR; X-ray; 2.40 A; H=364-622, L=328-363.
DR   PDB; 1NRS; X-ray; 2.40 A; H=364-622, L=328-349.
DR   PDB; 1NT1; X-ray; 2.00 A; A=335-621.
DR   PDB; 1NU7; X-ray; 2.20 A; A/E=332-359, B/F=364-622.
DR   PDB; 1NU9; X-ray; 2.20 A; A/D=332-622.
DR   PDB; 1NY2; X-ray; 2.30 A; 1=328-363, 2=364-622.
DR   PDB; 1NZQ; X-ray; 2.18 A; H=364-620, L=328-361.
DR   PDB; 1O0D; X-ray; 2.44 A; H=364-622, L=328-363.
DR   PDB; 1O2G; X-ray; 1.58 A; H=364-622, L=328-363.
DR   PDB; 1O5G; X-ray; 1.75 A; H=364-622, L=328-363.
DR   PDB; 1OOK; X-ray; 2.30 A; A=328-363, B=364-622.
DR   PDB; 1OYT; X-ray; 1.67 A; H=364-622, L=328-363.
DR   PDB; 1P8V; X-ray; 2.60 A; B=333-361, C=364-621.
DR   PDB; 1PPB; X-ray; 1.92 A; H=364-622, L=328-363.
DR   PDB; 1QBV; X-ray; 1.80 A; H=364-622, L=328-359.
DR   PDB; 1QHR; X-ray; 2.20 A; A=328-363, B=364-622.
DR   PDB; 1QJ1; X-ray; 2.00 A; A=328-363, B=364-622.
DR   PDB; 1QJ6; X-ray; 2.20 A; A=328-363, B=364-622.
DR   PDB; 1QJ7; X-ray; 2.20 A; A=328-363, B=364-622.
DR   PDB; 1QUR; X-ray; 2.00 A; H=364-620, L=334-360.
DR   PDB; 1RD3; X-ray; 2.50 A; A/C=328-363, B/D=364-622.
DR   PDB; 1RIW; X-ray; 2.04 A; A=328-363, B=364-510, C=518-622.
DR   PDB; 1SB1; X-ray; 1.90 A; H=364-621, L=333-361.
DR   PDB; 1SFQ; X-ray; 1.91 A; A/D=328-363, B/E=364-622.
DR   PDB; 1SG8; X-ray; 2.30 A; A/D=328-363, B/E=364-622.
DR   PDB; 1SGI; X-ray; 2.30 A; A/D=328-363, B/E=364-622.
DR   PDB; 1SHH; X-ray; 1.55 A; A/D=328-363, B/E=364-622.
DR   PDB; 1SL3; X-ray; 1.81 A; A=335-621.
DR   PDB; 1SR5; X-ray; 3.10 A; B=328-363, C=364-622.
DR   PDB; 1T4U; X-ray; 2.00 A; H=364-622, L=334-359.
DR   PDB; 1T4V; X-ray; 2.00 A; H=364-622, L=334-359.
DR   PDB; 1TA2; X-ray; 2.30 A; A=335-621.
DR   PDB; 1TA6; X-ray; 1.90 A; A=335-621.
DR   PDB; 1TB6; X-ray; 2.50 A; H=364-622, L=315-363.
DR   PDB; 1TBZ; X-ray; 2.30 A; H=364-622, L=328-363.
DR   PDB; 1THP; X-ray; 2.10 A; A=328-362, B=364-620.
DR   PDB; 1THR; X-ray; 2.30 A; H=364-622, L=328-349.
DR   PDB; 1THS; X-ray; 2.20 A; H=364-622, L=328-363.
DR   PDB; 1TMB; X-ray; 2.30 A; H=364-622, L=328-363.
DR   PDB; 1TMT; X-ray; 2.20 A; H=364-622, L=328-363.
DR   PDB; 1TMU; X-ray; 2.50 A; H=364-620, L=333-349.
DR   PDB; 1TOM; X-ray; 1.80 A; H=364-622, L=328-363.
DR   PDB; 1TQ0; X-ray; 2.80 A; A/C=333-363, B/D=364-620.
DR   PDB; 1TQ7; X-ray; 2.40 A; A=320-363, B=364-620.
DR   PDB; 1TWX; X-ray; 2.40 A; A=334-349, B=364-622.
DR   PDB; 1UMA; X-ray; 2.00 A; H=364-622, L=328-363.
DR   PDB; 1UVS; X-ray; 2.80 A; H=364-622, L=328-363.
DR   PDB; 1VR1; X-ray; 1.90 A; H=364-620, L=334-360.
DR   PDB; 1VZQ; X-ray; 1.54 A; H=364-620, L=334-360.
DR   PDB; 1W7G; X-ray; 1.65 A; H=364-622, L=328-363.
DR   PDB; 1WAY; X-ray; 2.02 A; A=328-363, B=364-622.
DR   PDB; 1WBG; X-ray; 2.20 A; B=364-622.
DR   PDB; 1XM1; X-ray; 2.30 A; A=328-622.
DR   PDB; 1XMN; X-ray; 1.85 A; A/C/E/G=328-363, B/D/F/H=364-622.
DR   PDB; 1YPE; X-ray; 1.81 A; H=364-620, L=334-360.
DR   PDB; 1YPG; X-ray; 1.80 A; H=364-620, L=334-360.
DR   PDB; 1YPJ; X-ray; 1.78 A; H=364-620, L=334-360.
DR   PDB; 1YPK; X-ray; 1.78 A; H=364-620, L=334-360.
DR   PDB; 1YPL; X-ray; 1.85 A; H=364-620, L=334-360.
DR   PDB; 1YPM; X-ray; 1.85 A; H=364-620, L=334-360.
DR   PDB; 1Z71; X-ray; 1.80 A; A=335-621.
DR   PDB; 1Z8I; X-ray; 2.00 A; A=324-361, B=364-622.
DR   PDB; 1Z8J; X-ray; 2.00 A; A=322-361, B=364-622.
DR   PDB; 1ZGI; X-ray; 2.20 A; A=335-621.
DR   PDB; 1ZGV; X-ray; 2.20 A; A=335-621.
DR   PDB; 1ZRB; X-ray; 1.90 A; A=335-621.
DR   PDB; 2A0Q; X-ray; 1.90 A; A/C=334-349, B/D=364-620.
DR   PDB; 2A2X; X-ray; 2.44 A; H=364-622, L=330-363.
DR   PDB; 2A45; X-ray; 3.65 A; A/D=328-363, B/E=364-622.
DR   PDB; 2AFQ; X-ray; 1.93 A; A/C=332-360, B/D=364-622.
DR   PDB; 2ANK; X-ray; 2.46 A; H=364-622, L=330-363.
DR   PDB; 2ANM; X-ray; 2.40 A; H=364-620, L=328-363.
DR   PDB; 2B5T; X-ray; 2.10 A; A/C=315-363, B/D=364-622.
DR   PDB; 2BDY; X-ray; 1.61 A; A=334-622.
DR   PDB; 2BVR; X-ray; 1.25 A; H=364-622, L=328-363.
DR   PDB; 2BVS; X-ray; 1.40 A; H=364-622, L=328-363.
DR   PDB; 2BVX; X-ray; 3.20 A; H=364-622, L=328-363.
DR   PDB; 2BXT; X-ray; 1.83 A; H=364-622, L=328-363.
DR   PDB; 2BXU; X-ray; 2.80 A; H=364-622, L=328-363.
DR   PDB; 2C8W; X-ray; 1.96 A; A=328-363, B=364-622.
DR   PDB; 2C8X; X-ray; 2.17 A; A=328-363, B=364-622.
DR   PDB; 2C8Y; X-ray; 2.20 A; A=328-363, B=364-622.
DR   PDB; 2C8Z; X-ray; 2.14 A; A=328-363, B=364-622.
DR   PDB; 2C90; X-ray; 2.25 A; A=328-363, B=364-622.
DR   PDB; 2C93; X-ray; 2.20 A; A=328-363, B=364-622.
DR   PDB; 2CF8; X-ray; 1.30 A; H=364-620, L=334-361.
DR   PDB; 2CF9; X-ray; 1.79 A; H=364-620, L=334-361.
DR   PDB; 2CN0; X-ray; 1.30 A; H=364-620, L=334-361.
DR   PDB; 2FEQ; X-ray; 2.44 A; H=364-622, L=328-363.
DR   PDB; 2FES; X-ray; 2.42 A; H=364-622, L=328-363.
DR   PDB; 2GDE; X-ray; 2.00 A; H=364-622, L=328-363.
DR   PDB; 2GP9; X-ray; 1.87 A; A=328-362, B=364-620.
DR   PDB; 2H9T; X-ray; 2.40 A; H=364-622, L=328-363.
DR   PDB; 2HGT; X-ray; 2.20 A; H=364-622, L=328-363.
DR   PDB; 2HNT; X-ray; 2.50 A; C=364-433, E=437-517, F=518-622, L=328-363.
DR   PDB; 2HPP; X-ray; 3.30 A; H=364-622.
DR   PDB; 2HPQ; X-ray; 3.30 A; H=364-622, L=328-363, P=213-291.
DR   PDB; 2HWL; X-ray; 2.40 A; A/C=328-363, B/D=364-622.
DR   PDB; 2JH0; X-ray; 1.70 A; C=328-361, D=364-622.
DR   PDB; 2JH5; X-ray; 2.50 A; C=328-363, D=364-622.
DR   PDB; 2JH6; X-ray; 2.21 A; C=328-361, D=364-622.
DR   PDB; 2OD3; X-ray; 1.75 A; A=328-363, B=364-622.
DR   PDB; 2PGB; X-ray; 1.54 A; A=328-363, B=364-622.
DR   PDB; 2PGQ; X-ray; 1.80 A; A=319-363, B=364-622.
DR   PDB; 2PKS; X-ray; 2.50 A; A=334-360, B=364-510, C=518-619.
DR   PDB; 2PW8; X-ray; 1.84 A; H=364-621, L=334-360.
DR   PDB; 2R2M; X-ray; 2.10 A; A=334-359, B=364-622.
DR   PDB; 2THF; X-ray; 2.10 A; A=328-363, B=364-622.
DR   PDB; 2UUF; X-ray; 1.26 A; A=328-363, B=364-622.
DR   PDB; 2UUJ; X-ray; 1.32 A; A=328-363, B=364-622.
DR   PDB; 2UUK; X-ray; 1.39 A; A=328-363, B=364-622.
DR   PDB; 2V3H; X-ray; 1.79 A; H=364-620, L=334-361.
DR   PDB; 2V3O; X-ray; 1.79 A; H=364-620, L=334-361.
DR   PDB; 2ZC9; X-ray; 1.58 A; H=364-622, L=328-363.
DR   PDB; 2ZDA; X-ray; 1.73 A; H=364-622, L=328-363.
DR   PDB; 2ZDV; X-ray; 1.72 A; H=364-622, L=328-363.
DR   PDB; 2ZF0; X-ray; 2.20 A; H=364-622, L=328-363.
DR   PDB; 2ZFF; X-ray; 1.47 A; H=364-622, L=328-363.
DR   PDB; 2ZFP; X-ray; 2.25 A; H=364-622, L=328-363.
DR   PDB; 2ZFQ; X-ray; 1.80 A; H=364-622, L=328-363.
DR   PDB; 2ZFR; X-ray; 1.85 A; H=364-622, L=328-363.
DR   PDB; 2ZG0; X-ray; 1.75 A; H=364-622, L=328-363.
DR   PDB; 2ZGB; X-ray; 1.60 A; H=364-622, L=328-363.
DR   PDB; 2ZGX; X-ray; 1.80 A; H=364-622, L=328-363.
DR   PDB; 2ZHE; X-ray; 2.10 A; H=364-622, L=328-363.
DR   PDB; 2ZHF; X-ray; 1.98 A; H=364-622, L=328-363.
DR   PDB; 2ZHQ; X-ray; 1.96 A; H=364-622, L=328-363.
DR   PDB; 2ZHW; X-ray; 2.02 A; H=364-622, L=328-363.
DR   PDB; 2ZI2; X-ray; 1.65 A; H=364-622, L=328-363.
DR   PDB; 2ZIQ; X-ray; 1.65 A; H=364-622, L=328-363.
DR   PDB; 2ZNK; X-ray; 1.80 A; H=364-622, L=328-363.
DR   PDB; 2ZO3; X-ray; 1.70 A; H=364-622, L=328-363.
DR   PDB; 3B23; X-ray; 2.40 A; A=328-363, B=364-622.
DR   PDB; 3B9F; X-ray; 1.60 A; H=364-622, L=315-363.
DR   PDB; 3BEF; X-ray; 2.20 A; A/D=320-363, B/E=364-622.
DR   PDB; 3BEI; X-ray; 1.55 A; A=320-363, B=364-622.
DR   PDB; 3BF6; X-ray; 2.50 A; H=364-622, L=328-363.
DR   PDB; 3BIU; X-ray; 2.30 A; H=364-620, L=333-361.
DR   PDB; 3BIV; X-ray; 1.80 A; H=364-620, L=333-361.
DR   PDB; 3BV9; X-ray; 1.80 A; A=333-363, B=364-622.
DR   PDB; 3C1K; X-ray; 1.84 A; A=335-621.
DR   PDB; 3C27; X-ray; 2.18 A; A=334-359, B=364-622.
DR   PDB; 3D49; X-ray; 1.50 A; H=364-622, L=328-363.
DR   PDB; 3DA9; X-ray; 1.80 A; A=328-363, B=364-622.
DR   PDB; 3DD2; X-ray; 1.90 A; H=364-621, L=332-361.
DR   PDB; 3DHK; X-ray; 1.73 A; H=364-622, L=328-363.
DR   PDB; 3DT0; X-ray; 2.40 A; H=364-622, L=328-363.
DR   PDB; 3DUX; X-ray; 1.60 A; H=364-622, L=328-363.
DR   PDB; 3E6P; X-ray; 2.10 A; H=364-622, L=206-363.
DR   PDB; 3EE0; X-ray; 2.75 A; A=328-363, B=364-622.
DR   PDB; 3EGK; X-ray; 2.20 A; H=364-622, L=328-363.
DR   PDB; 3EQ0; X-ray; 1.53 A; H=364-622, L=328-363.
DR   PDB; 3F68; X-ray; 1.75 A; H=364-622, L=328-363.
DR   PDB; 3GIC; X-ray; 1.55 A; A=328-363, B=364-622.
DR   PDB; 3GIS; X-ray; 2.40 A; A/C/E=315-363, B/D/F=364-622.
DR   PDB; 3HAT; X-ray; 2.50 A; H=364-622, L=328-363.
DR   PDB; 3HKJ; X-ray; 2.60 A; A/D=333-363, B/E=364-622.
DR   PDB; 3HTC; X-ray; 2.30 A; H=364-622, L=328-363.
DR   PDB; 3JZ1; X-ray; 1.60 A; A=328-363, B=364-622.
DR   PDB; 3JZ2; X-ray; 2.40 A; A=328-363, B=364-622.
DR   PDB; 3K65; X-ray; 1.85 A; A=199-314, B=315-622.
DR   PDB; 3LDX; X-ray; 2.25 A; H=364-622, L=328-363.
DR   PDB; 3LU9; X-ray; 1.80 A; A/D=318-363, B/E=364-622.
DR   PDB; 3NXP; X-ray; 2.20 A; A=199-622.
DR   PDB; 3P17; X-ray; 1.43 A; H=364-622, L=328-363.
DR   PDB; 3P6Z; X-ray; 1.70 A; A/G=328-363, B/H=364-622.
DR   PDB; 3P70; X-ray; 2.55 A; A/C/E/G=328-363, B/D/F/H=364-622.
DR   PDB; 3PMH; X-ray; 3.20 A; A=328-363, B=364-622.
DR   PDB; 3PO1; X-ray; 1.65 A; A=334-360, B=364-510, C=518-619.
DR   PDB; 3QDZ; X-ray; 2.80 A; A/C=333-363, B/D=364-622.
DR   PDB; 3QGN; X-ray; 2.10 A; A=333-363, B=364-622.
DR   PDB; 3QLP; X-ray; 2.14 A; H=364-622, L=328-363.
DR   PDB; 3QTO; X-ray; 1.52 A; H=364-622, L=328-363.
DR   PDB; 3QTV; X-ray; 1.63 A; H=364-622, L=328-363.
DR   PDB; 3QWC; X-ray; 1.75 A; H=364-622, L=328-363.
DR   PDB; 3QX5; X-ray; 1.35 A; H=364-622, L=328-363.
DR   PDB; 3R3G; X-ray; 1.75 A; A=333-363, B=364-622.
DR   PDB; 3RLW; X-ray; 1.69 A; H=364-622, L=328-363.
DR   PDB; 3RLY; X-ray; 1.51 A; H=364-622, L=328-363.
DR   PDB; 3RM0; X-ray; 1.34 A; H=364-622, L=328-363.
DR   PDB; 3RM2; X-ray; 1.23 A; H=364-622, L=328-363.
DR   PDB; 3RML; X-ray; 1.53 A; H=364-622, L=328-363.
DR   PDB; 3RMM; X-ray; 1.58 A; H=364-622, L=328-363.
DR   PDB; 3RMN; X-ray; 1.78 A; H=364-622, L=328-363.
DR   PDB; 3RMO; X-ray; 1.40 A; H=364-622, L=328-363.
DR   PDB; 3S7H; X-ray; 1.90 A; A=329-363, B=364-622.
DR   PDB; 3S7K; X-ray; 1.90 A; A/C=329-363, B/D=364-622.
DR   PDB; 3SHA; X-ray; 1.52 A; H=364-622, L=328-363.
DR   PDB; 3SHC; X-ray; 1.90 A; H=364-622, L=328-363.
DR   PDB; 3SI3; X-ray; 1.55 A; H=364-622, L=328-363.
DR   PDB; 3SI4; X-ray; 1.27 A; H=364-622, L=328-363.
DR   PDB; 3SQE; X-ray; 1.90 A; E=333-622.
DR   PDB; 3SQH; X-ray; 2.20 A; E=333-622.
DR   PDB; 3SV2; X-ray; 1.30 A; H=364-622, L=328-363.
DR   PDB; 3T5F; X-ray; 1.45 A; H=364-622, L=328-363.
DR   PDB; 3TU7; X-ray; 2.49 A; H=364-622, L=328-363.
DR   PDB; 3U69; X-ray; 1.55 A; H=364-622, L=334-363.
DR   PDB; 3U8O; X-ray; 1.28 A; H=364-622, L=334-363.
DR   PDB; 3U8R; X-ray; 1.47 A; H=364-622, L=334-363.
DR   PDB; 3U8T; X-ray; 1.86 A; H=364-620, L=334-360.
DR   PDB; 3U98; X-ray; 1.45 A; H=364-622, L=328-363.
DR   PDB; 3U9A; X-ray; 1.58 A; H=364-622, L=328-363.
DR   PDB; 3UTU; X-ray; 1.55 A; H=364-622, L=328-363.
DR   PDB; 3UWJ; X-ray; 1.50 A; H=364-622, L=328-363.
DR   PDB; 3VXE; X-ray; 1.25 A; H=364-622, L=328-363.
DR   PDB; 3VXF; Other; 1.60 A; H=364-622, L=328-363.
DR   PDB; 4AX9; X-ray; 1.90 A; H=364-620, L=334-361.
DR   PDB; 4AYV; X-ray; 2.80 A; A=332-361, B=364-620.
DR   PDB; 4AYY; X-ray; 2.60 A; A=332-361, B=364-620.
DR   PDB; 4AZ2; X-ray; 2.60 A; A=332-361, B=364-620.
DR   PDB; 4BAH; X-ray; 1.94 A; A=328-363, B=364-622.
DR   PDB; 4BAK; X-ray; 1.94 A; A=328-363, B=364-622.
DR   PDB; 4BAM; X-ray; 1.88 A; A=328-363, B=364-622.
DR   PDB; 4BAN; X-ray; 1.87 A; A=328-363, B=364-622.
DR   PDB; 4BAO; X-ray; 1.87 A; A=328-363, B=364-622.
DR   PDB; 4BAQ; X-ray; 1.89 A; A=328-363, B=364-622.
DR   PDB; 4BOH; X-ray; 2.60 A; A/H=364-622, B/L=328-363.
DR   PDB; 4CH2; X-ray; 1.60 A; A/C=328-363, B/D=364-622.
DR   PDB; 4CH8; X-ray; 1.75 A; A/C/E/G=328-363, B/D/F/H=364-622.
DR   PDB; 4DIH; X-ray; 1.80 A; H=364-622, L=328-363.
DR   PDB; 4DII; X-ray; 2.05 A; H=364-622, L=328-363.
DR   PDB; 4DT7; X-ray; 1.90 A; A/C=332-363, B/D=364-622.
DR   PDB; 4DY7; X-ray; 2.80 A; A/D=315-363, B/E=364-622.
DR   PDB; 4E05; X-ray; 2.30 A; H=364-622, L=328-363.
DR   PDB; 4E06; X-ray; 3.20 A; H=364-622, L=328-363.
DR   PDB; 4E7R; X-ray; 2.25 A; G/H=364-622, L/M=328-363.
DR   PDB; 4H6S; X-ray; 2.19 A; A=333-363, B=364-622.
DR   PDB; 4H6T; X-ray; 2.40 A; A=317-622.
DR   PDB; 4HFP; X-ray; 2.40 A; A/C=333-363, B/D=364-622.
DR   PDB; 4HTC; X-ray; 2.30 A; H=364-622, L=328-363.
DR   PDB; 4HZH; X-ray; 3.30 A; A/B=90-622.
DR   PDB; 4I7Y; X-ray; 2.40 A; H=364-622, L=328-363.
DR   PDB; 4LOY; X-ray; 1.77 A; H=364-620, L=334-360.
DR   PDB; 4LXB; X-ray; 1.61 A; H=364-622, L=328-363.
DR   PDB; 4LZ1; X-ray; 1.65 A; H=364-622, L=328-363.
DR   PDB; 4LZ4; X-ray; 2.56 A; A/C=328-363, B/D=364-622.
DR   PDB; 4MLF; X-ray; 2.20 A; A=331-363, B=364-622.
DR   PDB; 4N3L; X-ray; 1.94 A; H=364-622, L=328-363.
DR   PDB; 4NZE; X-ray; 1.98 A; H=364-622, L=328-363.
DR   PDB; 4NZQ; X-ray; 2.81 A; A=44-622.
DR   PDB; 4O03; X-ray; 3.38 A; A=44-622.
DR   PDB; 4RKJ; X-ray; 1.70 A; A=330-363, B=364-622.
DR   PDB; 4RKO; X-ray; 1.84 A; A=322-363, B=364-622.
DR   PDB; 4RN6; X-ray; 3.00 A; A/B=333-622.
DR   PDB; 4THN; X-ray; 2.50 A; H=364-622, L=328-363.
DR   PDB; 4UD9; X-ray; 1.12 A; H=364-622, L=333-360.
DR   PDB; 4UDW; X-ray; 1.16 A; H=364-621, L=333-360.
DR   PDB; 4UE7; X-ray; 1.13 A; H=364-621, L=333-360.
DR   PDB; 4UEH; X-ray; 1.16 A; H=364-621, L=333-361.
DR   PDB; 4YES; X-ray; 1.50 A; A=328-363, B=364-622.
DR   PDB; 5AF9; X-ray; 1.18 A; H=364-621, L=333-361.
DR   PDB; 5AFY; X-ray; 1.12 A; H=364-621, L=333-361.
DR   PDB; 5AFZ; X-ray; 1.53 A; H=364-621, L=333-361.
DR   PDB; 5AHG; X-ray; 1.24 A; H=364-621, L=333-361.
DR   PDB; 5E8E; X-ray; 1.90 A; H=364-622, L=328-363.
DR   PDB; 5GDS; X-ray; 2.10 A; H=364-622, L=328-363.
DR   PDB; 7KME; X-ray; 2.10 A; H=364-622, L=328-363.
DR   PDB; 8KME; X-ray; 2.10 A; 1=328-359, 2=364-620.
DR   PDBsum; 1A2C; -.
DR   PDBsum; 1A3B; -.
DR   PDBsum; 1A3E; -.
DR   PDBsum; 1A46; -.
DR   PDBsum; 1A4W; -.
DR   PDBsum; 1A5G; -.
DR   PDBsum; 1A61; -.
DR   PDBsum; 1ABI; -.
DR   PDBsum; 1ABJ; -.
DR   PDBsum; 1AD8; -.
DR   PDBsum; 1AE8; -.
DR   PDBsum; 1AFE; -.
DR   PDBsum; 1AHT; -.
DR   PDBsum; 1AI8; -.
DR   PDBsum; 1AIX; -.
DR   PDBsum; 1AWF; -.
DR   PDBsum; 1AWH; -.
DR   PDBsum; 1AY6; -.
DR   PDBsum; 1B5G; -.
DR   PDBsum; 1B7X; -.
DR   PDBsum; 1BA8; -.
DR   PDBsum; 1BB0; -.
DR   PDBsum; 1BCU; -.
DR   PDBsum; 1BHX; -.
DR   PDBsum; 1BMM; -.
DR   PDBsum; 1BMN; -.
DR   PDBsum; 1BTH; -.
DR   PDBsum; 1C1U; -.
DR   PDBsum; 1C1V; -.
DR   PDBsum; 1C1W; -.
DR   PDBsum; 1C4U; -.
DR   PDBsum; 1C4V; -.
DR   PDBsum; 1C4Y; -.
DR   PDBsum; 1C5L; -.
DR   PDBsum; 1C5N; -.
DR   PDBsum; 1C5O; -.
DR   PDBsum; 1CA8; -.
DR   PDBsum; 1D3D; -.
DR   PDBsum; 1D3P; -.
DR   PDBsum; 1D3Q; -.
DR   PDBsum; 1D3T; -.
DR   PDBsum; 1D4P; -.
DR   PDBsum; 1D6W; -.
DR   PDBsum; 1D9I; -.
DR   PDBsum; 1DE7; -.
DR   PDBsum; 1DIT; -.
DR   PDBsum; 1DM4; -.
DR   PDBsum; 1DOJ; -.
DR   PDBsum; 1DWB; -.
DR   PDBsum; 1DWC; -.
DR   PDBsum; 1DWD; -.
DR   PDBsum; 1DWE; -.
DR   PDBsum; 1DX5; -.
DR   PDBsum; 1E0F; -.
DR   PDBsum; 1EB1; -.
DR   PDBsum; 1EOJ; -.
DR   PDBsum; 1EOL; -.
DR   PDBsum; 1FPC; -.
DR   PDBsum; 1FPH; -.
DR   PDBsum; 1G30; -.
DR   PDBsum; 1G32; -.
DR   PDBsum; 1G37; -.
DR   PDBsum; 1GHV; -.
DR   PDBsum; 1GHW; -.
DR   PDBsum; 1GHX; -.
DR   PDBsum; 1GHY; -.
DR   PDBsum; 1GJ4; -.
DR   PDBsum; 1GJ5; -.
DR   PDBsum; 1H8D; -.
DR   PDBsum; 1H8I; -.
DR   PDBsum; 1HAG; -.
DR   PDBsum; 1HAH; -.
DR   PDBsum; 1HAI; -.
DR   PDBsum; 1HAO; -.
DR   PDBsum; 1HAP; -.
DR   PDBsum; 1HBT; -.
DR   PDBsum; 1HDT; -.
DR   PDBsum; 1HGT; -.
DR   PDBsum; 1HLT; -.
DR   PDBsum; 1HUT; -.
DR   PDBsum; 1HXE; -.
DR   PDBsum; 1HXF; -.
DR   PDBsum; 1IHS; -.
DR   PDBsum; 1IHT; -.
DR   PDBsum; 1JMO; -.
DR   PDBsum; 1JOU; -.
DR   PDBsum; 1JWT; -.
DR   PDBsum; 1K21; -.
DR   PDBsum; 1K22; -.
DR   PDBsum; 1KTS; -.
DR   PDBsum; 1KTT; -.
DR   PDBsum; 1LHC; -.
DR   PDBsum; 1LHD; -.
DR   PDBsum; 1LHE; -.
DR   PDBsum; 1LHF; -.
DR   PDBsum; 1LHG; -.
DR   PDBsum; 1MH0; -.
DR   PDBsum; 1MU6; -.
DR   PDBsum; 1MU8; -.
DR   PDBsum; 1MUE; -.
DR   PDBsum; 1NM6; -.
DR   PDBsum; 1NO9; -.
DR   PDBsum; 1NRN; -.
DR   PDBsum; 1NRO; -.
DR   PDBsum; 1NRP; -.
DR   PDBsum; 1NRQ; -.
DR   PDBsum; 1NRR; -.
DR   PDBsum; 1NRS; -.
DR   PDBsum; 1NT1; -.
DR   PDBsum; 1NU7; -.
DR   PDBsum; 1NU9; -.
DR   PDBsum; 1NY2; -.
DR   PDBsum; 1NZQ; -.
DR   PDBsum; 1O0D; -.
DR   PDBsum; 1O2G; -.
DR   PDBsum; 1O5G; -.
DR   PDBsum; 1OOK; -.
DR   PDBsum; 1OYT; -.
DR   PDBsum; 1P8V; -.
DR   PDBsum; 1PPB; -.
DR   PDBsum; 1QBV; -.
DR   PDBsum; 1QHR; -.
DR   PDBsum; 1QJ1; -.
DR   PDBsum; 1QJ6; -.
DR   PDBsum; 1QJ7; -.
DR   PDBsum; 1QUR; -.
DR   PDBsum; 1RD3; -.
DR   PDBsum; 1RIW; -.
DR   PDBsum; 1SB1; -.
DR   PDBsum; 1SFQ; -.
DR   PDBsum; 1SG8; -.
DR   PDBsum; 1SGI; -.
DR   PDBsum; 1SHH; -.
DR   PDBsum; 1SL3; -.
DR   PDBsum; 1SR5; -.
DR   PDBsum; 1T4U; -.
DR   PDBsum; 1T4V; -.
DR   PDBsum; 1TA2; -.
DR   PDBsum; 1TA6; -.
DR   PDBsum; 1TB6; -.
DR   PDBsum; 1TBZ; -.
DR   PDBsum; 1THP; -.
DR   PDBsum; 1THR; -.
DR   PDBsum; 1THS; -.
DR   PDBsum; 1TMB; -.
DR   PDBsum; 1TMT; -.
DR   PDBsum; 1TMU; -.
DR   PDBsum; 1TOM; -.
DR   PDBsum; 1TQ0; -.
DR   PDBsum; 1TQ7; -.
DR   PDBsum; 1TWX; -.
DR   PDBsum; 1UMA; -.
DR   PDBsum; 1UVS; -.
DR   PDBsum; 1VR1; -.
DR   PDBsum; 1VZQ; -.
DR   PDBsum; 1W7G; -.
DR   PDBsum; 1WAY; -.
DR   PDBsum; 1WBG; -.
DR   PDBsum; 1XM1; -.
DR   PDBsum; 1XMN; -.
DR   PDBsum; 1YPE; -.
DR   PDBsum; 1YPG; -.
DR   PDBsum; 1YPJ; -.
DR   PDBsum; 1YPK; -.
DR   PDBsum; 1YPL; -.
DR   PDBsum; 1YPM; -.
DR   PDBsum; 1Z71; -.
DR   PDBsum; 1Z8I; -.
DR   PDBsum; 1Z8J; -.
DR   PDBsum; 1ZGI; -.
DR   PDBsum; 1ZGV; -.
DR   PDBsum; 1ZRB; -.
DR   PDBsum; 2A0Q; -.
DR   PDBsum; 2A2X; -.
DR   PDBsum; 2A45; -.
DR   PDBsum; 2AFQ; -.
DR   PDBsum; 2ANK; -.
DR   PDBsum; 2ANM; -.
DR   PDBsum; 2B5T; -.
DR   PDBsum; 2BDY; -.
DR   PDBsum; 2BVR; -.
DR   PDBsum; 2BVS; -.
DR   PDBsum; 2BVX; -.
DR   PDBsum; 2BXT; -.
DR   PDBsum; 2BXU; -.
DR   PDBsum; 2C8W; -.
DR   PDBsum; 2C8X; -.
DR   PDBsum; 2C8Y; -.
DR   PDBsum; 2C8Z; -.
DR   PDBsum; 2C90; -.
DR   PDBsum; 2C93; -.
DR   PDBsum; 2CF8; -.
DR   PDBsum; 2CF9; -.
DR   PDBsum; 2CN0; -.
DR   PDBsum; 2FEQ; -.
DR   PDBsum; 2FES; -.
DR   PDBsum; 2GDE; -.
DR   PDBsum; 2GP9; -.
DR   PDBsum; 2H9T; -.
DR   PDBsum; 2HGT; -.
DR   PDBsum; 2HNT; -.
DR   PDBsum; 2HPP; -.
DR   PDBsum; 2HPQ; -.
DR   PDBsum; 2HWL; -.
DR   PDBsum; 2JH0; -.
DR   PDBsum; 2JH5; -.
DR   PDBsum; 2JH6; -.
DR   PDBsum; 2OD3; -.
DR   PDBsum; 2PGB; -.
DR   PDBsum; 2PGQ; -.
DR   PDBsum; 2PKS; -.
DR   PDBsum; 2PW8; -.
DR   PDBsum; 2R2M; -.
DR   PDBsum; 2THF; -.
DR   PDBsum; 2UUF; -.
DR   PDBsum; 2UUJ; -.
DR   PDBsum; 2UUK; -.
DR   PDBsum; 2V3H; -.
DR   PDBsum; 2V3O; -.
DR   PDBsum; 2ZC9; -.
DR   PDBsum; 2ZDA; -.
DR   PDBsum; 2ZDV; -.
DR   PDBsum; 2ZF0; -.
DR   PDBsum; 2ZFF; -.
DR   PDBsum; 2ZFP; -.
DR   PDBsum; 2ZFQ; -.
DR   PDBsum; 2ZFR; -.
DR   PDBsum; 2ZG0; -.
DR   PDBsum; 2ZGB; -.
DR   PDBsum; 2ZGX; -.
DR   PDBsum; 2ZHE; -.
DR   PDBsum; 2ZHF; -.
DR   PDBsum; 2ZHQ; -.
DR   PDBsum; 2ZHW; -.
DR   PDBsum; 2ZI2; -.
DR   PDBsum; 2ZIQ; -.
DR   PDBsum; 2ZNK; -.
DR   PDBsum; 2ZO3; -.
DR   PDBsum; 3B23; -.
DR   PDBsum; 3B9F; -.
DR   PDBsum; 3BEF; -.
DR   PDBsum; 3BEI; -.
DR   PDBsum; 3BF6; -.
DR   PDBsum; 3BIU; -.
DR   PDBsum; 3BIV; -.
DR   PDBsum; 3BV9; -.
DR   PDBsum; 3C1K; -.
DR   PDBsum; 3C27; -.
DR   PDBsum; 3D49; -.
DR   PDBsum; 3DA9; -.
DR   PDBsum; 3DD2; -.
DR   PDBsum; 3DHK; -.
DR   PDBsum; 3DT0; -.
DR   PDBsum; 3DUX; -.
DR   PDBsum; 3E6P; -.
DR   PDBsum; 3EE0; -.
DR   PDBsum; 3EGK; -.
DR   PDBsum; 3EQ0; -.
DR   PDBsum; 3F68; -.
DR   PDBsum; 3GIC; -.
DR   PDBsum; 3GIS; -.
DR   PDBsum; 3HAT; -.
DR   PDBsum; 3HKJ; -.
DR   PDBsum; 3HTC; -.
DR   PDBsum; 3JZ1; -.
DR   PDBsum; 3JZ2; -.
DR   PDBsum; 3K65; -.
DR   PDBsum; 3LDX; -.
DR   PDBsum; 3LU9; -.
DR   PDBsum; 3NXP; -.
DR   PDBsum; 3P17; -.
DR   PDBsum; 3P6Z; -.
DR   PDBsum; 3P70; -.
DR   PDBsum; 3PMH; -.
DR   PDBsum; 3PO1; -.
DR   PDBsum; 3QDZ; -.
DR   PDBsum; 3QGN; -.
DR   PDBsum; 3QLP; -.
DR   PDBsum; 3QTO; -.
DR   PDBsum; 3QTV; -.
DR   PDBsum; 3QWC; -.
DR   PDBsum; 3QX5; -.
DR   PDBsum; 3R3G; -.
DR   PDBsum; 3RLW; -.
DR   PDBsum; 3RLY; -.
DR   PDBsum; 3RM0; -.
DR   PDBsum; 3RM2; -.
DR   PDBsum; 3RML; -.
DR   PDBsum; 3RMM; -.
DR   PDBsum; 3RMN; -.
DR   PDBsum; 3RMO; -.
DR   PDBsum; 3S7H; -.
DR   PDBsum; 3S7K; -.
DR   PDBsum; 3SHA; -.
DR   PDBsum; 3SHC; -.
DR   PDBsum; 3SI3; -.
DR   PDBsum; 3SI4; -.
DR   PDBsum; 3SQE; -.
DR   PDBsum; 3SQH; -.
DR   PDBsum; 3SV2; -.
DR   PDBsum; 3T5F; -.
DR   PDBsum; 3TU7; -.
DR   PDBsum; 3U69; -.
DR   PDBsum; 3U8O; -.
DR   PDBsum; 3U8R; -.
DR   PDBsum; 3U8T; -.
DR   PDBsum; 3U98; -.
DR   PDBsum; 3U9A; -.
DR   PDBsum; 3UTU; -.
DR   PDBsum; 3UWJ; -.
DR   PDBsum; 3VXE; -.
DR   PDBsum; 3VXF; -.
DR   PDBsum; 4AX9; -.
DR   PDBsum; 4AYV; -.
DR   PDBsum; 4AYY; -.
DR   PDBsum; 4AZ2; -.
DR   PDBsum; 4BAH; -.
DR   PDBsum; 4BAK; -.
DR   PDBsum; 4BAM; -.
DR   PDBsum; 4BAN; -.
DR   PDBsum; 4BAO; -.
DR   PDBsum; 4BAQ; -.
DR   PDBsum; 4BOH; -.
DR   PDBsum; 4CH2; -.
DR   PDBsum; 4CH8; -.
DR   PDBsum; 4DIH; -.
DR   PDBsum; 4DII; -.
DR   PDBsum; 4DT7; -.
DR   PDBsum; 4DY7; -.
DR   PDBsum; 4E05; -.
DR   PDBsum; 4E06; -.
DR   PDBsum; 4E7R; -.
DR   PDBsum; 4H6S; -.
DR   PDBsum; 4H6T; -.
DR   PDBsum; 4HFP; -.
DR   PDBsum; 4HTC; -.
DR   PDBsum; 4HZH; -.
DR   PDBsum; 4I7Y; -.
DR   PDBsum; 4LOY; -.
DR   PDBsum; 4LXB; -.
DR   PDBsum; 4LZ1; -.
DR   PDBsum; 4LZ4; -.
DR   PDBsum; 4MLF; -.
DR   PDBsum; 4N3L; -.
DR   PDBsum; 4NZE; -.
DR   PDBsum; 4NZQ; -.
DR   PDBsum; 4O03; -.
DR   PDBsum; 4RKJ; -.
DR   PDBsum; 4RKO; -.
DR   PDBsum; 4RN6; -.
DR   PDBsum; 4THN; -.
DR   PDBsum; 4UD9; -.
DR   PDBsum; 4UDW; -.
DR   PDBsum; 4UE7; -.
DR   PDBsum; 4UEH; -.
DR   PDBsum; 4YES; -.
DR   PDBsum; 5AF9; -.
DR   PDBsum; 5AFY; -.
DR   PDBsum; 5AFZ; -.
DR   PDBsum; 5AHG; -.
DR   PDBsum; 5E8E; -.
DR   PDBsum; 5GDS; -.
DR   PDBsum; 7KME; -.
DR   PDBsum; 8KME; -.
DR   ProteinModelPortal; P00734; -.
DR   SMR; P00734; 44-622.
DR   BioGrid; 108447; 15.
DR   DIP; DIP-6115N; -.
DR   IntAct; P00734; 10.
DR   MINT; MINT-147273; -.
DR   STRING; 9606.ENSP00000308541; -.
DR   BindingDB; P00734; -.
DR   ChEMBL; CHEMBL2111379; -.
DR   DrugBank; DB00025; Antihemophilic Factor (Recombinant).
DR   DrugBank; DB00278; Argatroban.
DR   DrugBank; DB05777; ART-123.
DR   DrugBank; DB00006; Bivalirudin.
DR   DrugBank; DB00100; Coagulation Factor IX.
DR   DrugBank; DB06695; Dabigatran etexilate.
DR   DrugBank; DB00055; Drotrecogin alfa.
DR   DrugBank; DB00001; Lepirudin.
DR   DrugBank; DB00170; Menadione.
DR   DrugBank; DB01123; Proflavine.
DR   DrugBank; DB04786; Suramin.
DR   DrugBank; DB04898; Ximelagatran.
DR   GuidetoPHARMACOLOGY; 2362; -.
DR   MEROPS; S01.217; -.
DR   iPTMnet; P00734; -.
DR   PhosphoSite; P00734; -.
DR   UniCarbKB; P00734; -.
DR   BioMuta; F2; -.
DR   DMDM; 135807; -.
DR   SWISS-2DPAGE; P00734; -.
DR   MaxQB; P00734; -.
DR   PaxDb; P00734; -.
DR   PeptideAtlas; P00734; -.
DR   PRIDE; P00734; -.
DR   DNASU; 2147; -.
DR   Ensembl; ENST00000311907; ENSP00000308541; ENSG00000180210.
DR   GeneID; 2147; -.
DR   KEGG; hsa:2147; -.
DR   UCSC; uc001ndf.4; human.
DR   CTD; 2147; -.
DR   GeneCards; F2; -.
DR   GeneReviews; F2; -.
DR   H-InvDB; HIX0026188; -.
DR   HGNC; HGNC:3535; F2.
DR   HPA; CAB016780; -.
DR   HPA; CAB018650; -.
DR   HPA; HPA051476; -.
DR   HPA; HPA054698; -.
DR   MalaCards; F2; -.
DR   MIM; 176930; gene.
DR   MIM; 188050; phenotype.
DR   MIM; 601367; phenotype.
DR   MIM; 613679; phenotype.
DR   MIM; 614390; phenotype.
DR   neXtProt; NX_P00734; -.
DR   Orphanet; 329217; Cerebral sinovenous thrombosis.
DR   Orphanet; 325; Congenital factor II deficiency.
DR   Orphanet; 64738; Non rare thrombophilia.
DR   PharmGKB; PA157; -.
DR   eggNOG; ENOG410IKPN; Eukaryota.
DR   eggNOG; COG5640; LUCA.
DR   GeneTree; ENSGT00760000118890; -.
DR   HOVERGEN; HBG108381; -.
DR   InParanoid; P00734; -.
DR   KO; K01313; -.
DR   OMA; GIECQLW; -.
DR   PhylomeDB; P00734; -.
DR   TreeFam; TF327329; -.
DR   BRENDA; 3.4.21.5; 2681.
DR   Reactome; R-HSA-140837; Intrinsic Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-140875; Common Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-159740; Gamma-carboxylation of protein precursors.
DR   Reactome; R-HSA-159763; Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus.
DR   Reactome; R-HSA-159782; Removal of aminoterminal propeptides from gamma-carboxylated proteins.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-456926; Thrombin signalling through proteinase activated receptors (PARs).
DR   Reactome; R-HSA-76009; Platelet Aggregation (Plug Formation).
DR   SABIO-RK; P00734; -.
DR   EvolutionaryTrace; P00734; -.
DR   GeneWiki; Thrombin; -.
DR   GenomeRNAi; 2147; -.
DR   NextBio; 8681; -.
DR   PMAP-CutDB; P00734; -.
DR   PRO; PR:P00734; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; P00734; -.
DR   CleanEx; HS_F2; -.
DR   ExpressionAtlas; P00734; baseline and differential.
DR   Genevisible; P00734; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:GOC.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0008083; F:growth factor activity; TAS:BHF-UCL.
DR   GO; GO:0005102; F:receptor binding; IPI:UniProtKB.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0070053; F:thrombospondin receptor activity; IDA:BHF-UCL.
DR   GO; GO:0006953; P:acute-phase response; IEA:UniProtKB-KW.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0007597; P:blood coagulation, intrinsic pathway; TAS:Reactome.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0051480; P:cytosolic calcium ion homeostasis; IDA:BHF-UCL.
DR   GO; GO:0042730; P:fibrinolysis; IDA:UniProtKB.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0007275; P:multicellular organismal development; TAS:ProtInc.
DR   GO; GO:0048712; P:negative regulation of astrocyte differentiation; IDA:BHF-UCL.
DR   GO; GO:0051918; P:negative regulation of fibrinolysis; TAS:BHF-UCL.
DR   GO; GO:0010544; P:negative regulation of platelet activation; TAS:BHF-UCL.
DR   GO; GO:0045861; P:negative regulation of proteolysis; IDA:BHF-UCL.
DR   GO; GO:0017187; P:peptidyl-glutamic acid carboxylation; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; IDA:BHF-UCL.
DR   GO; GO:0030194; P:positive regulation of blood coagulation; IDA:BHF-UCL.
DR   GO; GO:0030307; P:positive regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IEA:Ensembl.
DR   GO; GO:1900738; P:positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IDA:UniProtKB.
DR   GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IDA:BHF-UCL.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0006508; P:proteolysis; TAS:Reactome.
DR   GO; GO:0030193; P:regulation of blood coagulation; TAS:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IEA:Ensembl.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0014854; P:response to inactivity; IEA:Ensembl.
DR   GO; GO:0009611; P:response to wounding; IDA:BHF-UCL.
DR   Gene3D; 4.10.140.10; -; 1.
DR   Gene3D; 4.10.740.10; -; 1.
DR   InterPro; IPR017857; Coagulation_fac_subgr_Gla_dom.
DR   InterPro; IPR000294; GLA_domain.
DR   InterPro; IPR000001; Kringle.
DR   InterPro; IPR013806; Kringle-like.
DR   InterPro; IPR018056; Kringle_CS.
DR   InterPro; IPR018114; Peptidase_S1_AS.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR001314; Peptidase_S1A.
DR   InterPro; IPR003966; Prothrombin/thrombin.
DR   InterPro; IPR018992; Thrombin_light_chain.
DR   InterPro; IPR001254; Trypsin_dom.
DR   Pfam; PF00594; Gla; 1.
DR   Pfam; PF00051; Kringle; 2.
DR   Pfam; PF09396; Thrombin_light; 1.
DR   Pfam; PF00089; Trypsin; 1.
DR   PIRSF; PIRSF001149; Thrombin; 1.
DR   PRINTS; PR00722; CHYMOTRYPSIN.
DR   PRINTS; PR00001; GLABLOOD.
DR   PRINTS; PR01505; PROTHROMBIN.
DR   SMART; SM00069; GLA; 1.
DR   SMART; SM00130; KR; 2.
DR   SMART; SM00020; Tryp_SPc; 1.
DR   SUPFAM; SSF50494; SSF50494; 1.
DR   SUPFAM; SSF57440; SSF57440; 2.
DR   SUPFAM; SSF57630; SSF57630; 1.
DR   PROSITE; PS00011; GLA_1; 1.
DR   PROSITE; PS50998; GLA_2; 1.
DR   PROSITE; PS00021; KRINGLE_1; 2.
DR   PROSITE; PS50070; KRINGLE_2; 2.
DR   PROSITE; PS50240; TRYPSIN_DOM; 1.
DR   PROSITE; PS00134; TRYPSIN_HIS; 1.
DR   PROSITE; PS00135; TRYPSIN_SER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Blood coagulation; Calcium;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Gamma-carboxyglutamic acid; Glycoprotein; Hemostasis; Hydrolase;
KW   Kringle; Pharmaceutical; Polymorphism; Protease; Reference proteome;
KW   Repeat; Secreted; Serine protease; Signal; Thrombophilia; Zymogen.
FT   SIGNAL        1     24       {ECO:0000255}.
FT   PROPEP       25     43       {ECO:0000269|PubMed:266717,
FT                                ECO:0000269|PubMed:8073540}.
FT                                /FTId=PRO_0000028159.
FT   CHAIN        44    622       Prothrombin.
FT                                /FTId=PRO_0000028160.
FT   PEPTIDE      44    198       Activation peptide fragment 1.
FT                                /FTId=PRO_0000028161.
FT   PEPTIDE     199    327       Activation peptide fragment 2.
FT                                /FTId=PRO_0000028162.
FT   CHAIN       328    363       Thrombin light chain.
FT                                /FTId=PRO_0000028163.
FT   CHAIN       364    622       Thrombin heavy chain.
FT                                /FTId=PRO_0000028164.
FT   DOMAIN       44     89       Gla. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463}.
FT   DOMAIN      108    186       Kringle 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00121}.
FT   DOMAIN      213    291       Kringle 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00121}.
FT   DOMAIN      364    618       Peptidase S1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00274}.
FT   REGION      551    573       High affinity receptor-binding region
FT                                which is also known as the TP508 peptide.
FT   ACT_SITE    406    406       Charge relay system.
FT   ACT_SITE    462    462       Charge relay system.
FT   ACT_SITE    568    568       Charge relay system.
FT   SITE        198    199       Cleavage; by thrombin.
FT   SITE        327    328       Cleavage; by factor Xa.
FT   SITE        363    364       Cleavage; by factor Xa.
FT   MOD_RES      49     49       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:3759958,
FT                                ECO:0000269|PubMed:6305407}.
FT   MOD_RES      50     50       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:3759958,
FT                                ECO:0000269|PubMed:6305407}.
FT   MOD_RES      57     57       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:6305407}.
FT   MOD_RES      59     59       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:6305407}.
FT   MOD_RES      62     62       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:6305407}.
FT   MOD_RES      63     63       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:6305407}.
FT   MOD_RES      68     68       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:6305407}.
FT   MOD_RES      69     69       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:6305407}.
FT   MOD_RES      72     72       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:6305407}.
FT   MOD_RES      75     75       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:6305407}.
FT   CARBOHYD    121    121       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:22171320}.
FT   CARBOHYD    143    143       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:22171320}.
FT   CARBOHYD    416    416       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19139490,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19838169,
FT                                ECO:0000269|PubMed:873923}.
FT   DISULFID     60     65
FT   DISULFID     90    103
FT   DISULFID    108    186
FT   DISULFID    129    169
FT   DISULFID    157    181
FT   DISULFID    213    291
FT   DISULFID    234    274
FT   DISULFID    262    286
FT   DISULFID    336    482       Interchain (between light and heavy
FT                                chains).
FT   DISULFID    391    407
FT   DISULFID    536    550       {ECO:0000250}.
FT   DISULFID    564    594       {ECO:0000250}.
FT   VARIANT      72     72       E -> G (in FA2D; Shanghai).
FT                                {ECO:0000269|PubMed:14962227}.
FT                                /FTId=VAR_055232.
FT   VARIANT     165    165       T -> M (polymorphism; confirmed at
FT                                protein level; dbSNP:rs5896).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:22028381,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_011781.
FT   VARIANT     200    200       E -> K (in FA2D; prothrombin type 3;
FT                                variant confirmed at protein level;
FT                                dbSNP:rs62623459).
FT                                {ECO:0000269|PubMed:22028381,
FT                                ECO:0000269|PubMed:6405779}.
FT                                /FTId=VAR_006711.
FT   VARIANT     314    314       R -> C (in FA2D; Barcelona/Madrid).
FT                                {ECO:0000269|PubMed:3771562}.
FT                                /FTId=VAR_006712.
FT   VARIANT     314    314       R -> H (in FA2D; Padua-1).
FT                                {ECO:0000269|PubMed:7865694}.
FT                                /FTId=VAR_006713.
FT   VARIANT     380    380       M -> T (in FA2D; Himi-1).
FT                                {ECO:0000269|PubMed:1421398}.
FT                                /FTId=VAR_006714.
FT   VARIANT     386    386       P -> T (polymorphism; confirmed at
FT                                protein level; dbSNP:rs5897).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:22028381}.
FT                                /FTId=VAR_011782.
FT   VARIANT     425    425       R -> C (in FA2D; Quick-1).
FT                                {ECO:0000269|PubMed:3242619}.
FT                                /FTId=VAR_006715.
FT   VARIANT     431    431       R -> H (in FA2D; Himi-2).
FT                                {ECO:0000269|PubMed:1421398}.
FT                                /FTId=VAR_006716.
FT   VARIANT     461    461       R -> W (in FA2D; Tokushima).
FT                                {ECO:0000269|PubMed:1349838,
FT                                ECO:0000269|PubMed:3567158,
FT                                ECO:0000269|PubMed:3801671}.
FT                                /FTId=VAR_006717.
FT   VARIANT     509    509       E -> A (in FA2D; Salakta/Frankfurt).
FT                                {ECO:0000269|PubMed:1354985,
FT                                ECO:0000269|PubMed:7792730}.
FT                                /FTId=VAR_006718.
FT   VARIANT     532    532       E -> Q (polymorphism; confirmed at
FT                                protein level).
FT                                {ECO:0000269|PubMed:22028381,
FT                                ECO:0000269|PubMed:873923}.
FT                                /FTId=VAR_068913.
FT   VARIANT     601    601       G -> V (in FA2D; Quick-2).
FT                                {ECO:0000269|PubMed:2719946}.
FT                                /FTId=VAR_006719.
FT   CONFLICT      9     25       Missing (in Ref. 3; BAG64719).
FT                                {ECO:0000305}.
FT   CONFLICT     66     66       S -> N (in Ref. 4; BAD96497).
FT                                {ECO:0000305}.
FT   CONFLICT    119    119       H -> N (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    121    121       N -> S (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    164    164       T -> I (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    164    164       T -> N (in Ref. 7; CAA23842).
FT                                {ECO:0000305}.
FT   CONFLICT    176    176       V -> A (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    183    183       I -> T (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    194    195       AM -> MV (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    308    308       D -> DEE (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    335    335       D -> N (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    337    337       G -> R (in Ref. 4; BAD96495).
FT                                {ECO:0000305}.
FT   CONFLICT    349    349       D -> N (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    369    369       D -> N (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    398    398       D -> N (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    414    414       D -> N (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    485    485       D -> N (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    494    494       Q -> G (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    504    504       W -> Y (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    509    509       E -> S (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    511    511       W -> V (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    514    514       N -> D (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    529    530       PI -> AL (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    590    592       WGE -> AGA (in Ref. 11; AAR08143).
FT                                {ECO:0000305}.
FT   HELIX        56     60       {ECO:0000244|PDB:4O03}.
FT   HELIX        67     73       {ECO:0000244|PDB:4O03}.
FT   STRAND       74     76       {ECO:0000244|PDB:4O03}.
FT   HELIX        78     89       {ECO:0000244|PDB:4NZQ}.
FT   TURN         90     92       {ECO:0000244|PDB:4NZQ}.
FT   HELIX        97    104       {ECO:0000244|PDB:4NZQ}.
FT   STRAND      107    109       {ECO:0000244|PDB:4NZQ}.
FT   TURN        112    115       {ECO:0000244|PDB:4HZH}.
FT   TURN        144    146       {ECO:0000244|PDB:4NZQ}.
FT   STRAND      148    150       {ECO:0000244|PDB:4NZQ}.
FT   STRAND      167    173       {ECO:0000244|PDB:4NZQ}.
FT   STRAND      177    180       {ECO:0000244|PDB:4NZQ}.
FT   TURN        186    188       {ECO:0000244|PDB:4NZQ}.
FT   HELIX       216    218       {ECO:0000244|PDB:3K65}.
FT   STRAND      229    231       {ECO:0000244|PDB:4HZH}.
FT   STRAND      233    235       {ECO:0000244|PDB:4HZH}.
FT   STRAND      237    239       {ECO:0000244|PDB:4NZQ}.
FT   HELIX       240    246       {ECO:0000244|PDB:3K65}.
FT   STRAND      273    275       {ECO:0000244|PDB:3K65}.
FT   STRAND      277    279       {ECO:0000244|PDB:3K65}.
FT   STRAND      283    285       {ECO:0000244|PDB:3K65}.
FT   HELIX       295    297       {ECO:0000244|PDB:4NZQ}.
FT   STRAND      322    324       {ECO:0000244|PDB:3BEI}.
FT   HELIX       326    329       {ECO:0000244|PDB:3BEI}.
FT   STRAND      330    332       {ECO:0000244|PDB:1QJ1}.
FT   TURN        334    337       {ECO:0000244|PDB:5AFY}.
FT   TURN        340    342       {ECO:0000244|PDB:5AFY}.
FT   HELIX       343    345       {ECO:0000244|PDB:5AFY}.
FT   HELIX       352    358       {ECO:0000244|PDB:5AFY}.
FT   TURN        360    362       {ECO:0000244|PDB:1NO9}.
FT   STRAND      367    369       {ECO:0000244|PDB:3SQH}.
FT   STRAND      372    375       {ECO:0000244|PDB:3QDZ}.
FT   STRAND      378    383       {ECO:0000244|PDB:5AFY}.
FT   TURN        384    387       {ECO:0000244|PDB:5AFY}.
FT   STRAND      388    395       {ECO:0000244|PDB:5AFY}.
FT   STRAND      397    403       {ECO:0000244|PDB:5AFY}.
FT   HELIX       405    407       {ECO:0000244|PDB:5AFY}.
FT   STRAND      408    410       {ECO:0000244|PDB:4DY7}.
FT   HELIX       411    413       {ECO:0000244|PDB:5AFY}.
FT   HELIX       419    421       {ECO:0000244|PDB:5AFY}.
FT   STRAND      422    427       {ECO:0000244|PDB:5AFY}.
FT   STRAND      430    433       {ECO:0000244|PDB:5AFY}.
FT   TURN        436    438       {ECO:0000244|PDB:5AFY}.
FT   STRAND      440    449       {ECO:0000244|PDB:5AFY}.
FT   TURN        455    458       {ECO:0000244|PDB:5AFY}.
FT   STRAND      464    470       {ECO:0000244|PDB:5AFY}.
FT   STRAND      475    477       {ECO:0000244|PDB:4O03}.
FT   HELIX       486    492       {ECO:0000244|PDB:5AFY}.
FT   STRAND      498    504       {ECO:0000244|PDB:5AFY}.
FT   STRAND      507    510       {ECO:0000244|PDB:4UD9}.
FT   TURN        513    515       {ECO:0000244|PDB:4CH2}.
FT   STRAND      516    518       {ECO:0000244|PDB:4CH2}.
FT   STRAND      524    530       {ECO:0000244|PDB:5AFY}.
FT   HELIX       533    538       {ECO:0000244|PDB:5AFY}.
FT   STRAND      540    542       {ECO:0000244|PDB:1MH0}.
FT   STRAND      548    551       {ECO:0000244|PDB:5AFY}.
FT   HELIX       555    557       {ECO:0000244|PDB:5AFY}.
FT   TURN        565    569       {ECO:0000244|PDB:3U8O}.
FT   STRAND      571    575       {ECO:0000244|PDB:5AFY}.
FT   TURN        577    579       {ECO:0000244|PDB:5AFY}.
FT   STRAND      582    590       {ECO:0000244|PDB:5AFY}.
FT   STRAND      592    595       {ECO:0000244|PDB:5AFY}.
FT   STRAND      596    598       {ECO:0000244|PDB:3K65}.
FT   STRAND      601    605       {ECO:0000244|PDB:5AFY}.
FT   HELIX       607    609       {ECO:0000244|PDB:5AFY}.
FT   HELIX       610    619       {ECO:0000244|PDB:5AFY}.
SQ   SEQUENCE   622 AA;  70037 MW;  8A25E1DA88208FCF CRC64;
     MAHVRGLQLP GCLALAALCS LVHSQHVFLA PQQARSLLQR VRRANTFLEE VRKGNLEREC
     VEETCSYEEA FEALESSTAT DVFWAKYTAC ETARTPRDKL AACLEGNCAE GLGTNYRGHV
     NITRSGIECQ LWRSRYPHKP EINSTTHPGA DLQENFCRNP DSSTTGPWCY TTDPTVRRQE
     CSIPVCGQDQ VTVAMTPRSE GSSVNLSPPL EQCVPDRGQQ YQGRLAVTTH GLPCLAWASA
     QAKALSKHQD FNSAVQLVEN FCRNPDGDEE GVWCYVAGKP GDFGYCDLNY CEEAVEEETG
     DGLDEDSDRA IEGRTATSEY QTFFNPRTFG SGEADCGLRP LFEKKSLEDK TERELLESYI
     DGRIVEGSDA EIGMSPWQVM LFRKSPQELL CGASLISDRW VLTAAHCLLY PPWDKNFTEN
     DLLVRIGKHS RTRYERNIEK ISMLEKIYIH PRYNWRENLD RDIALMKLKK PVAFSDYIHP
     VCLPDRETAA SLLQAGYKGR VTGWGNLKET WTANVGKGQP SVLQVVNLPI VERPVCKDST
     RIRITDNMFC AGYKPDEGKR GDACEGDSGG PFVMKSPFNN RWYQMGIVSW GEGCDRDGKY
     GFYTHVFRLK KWIQKVIDQF GE
//
ID   NMDE1_HUMAN             Reviewed;        1464 AA.
AC   Q12879; O00669; Q17RZ6;
DT   01-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   17-FEB-2016, entry version 166.
DE   RecName: Full=Glutamate receptor ionotropic, NMDA 2A;
DE            Short=GluN2A;
DE   AltName: Full=Glutamate [NMDA] receptor subunit epsilon-1;
DE   AltName: Full=N-methyl D-aspartate receptor subtype 2A;
DE            Short=NMDAR2A;
DE            Short=NR2A;
DE            Short=hNR2A;
DE   Flags: Precursor;
GN   Name=GRIN2A; Synonyms=NMDAR2A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLU-270.
RX   PubMed=8061049; DOI=10.1016/0167-4889(94)90086-8;
RA   Foldes R.L., Adams S.L., Fantaske R.P., Kamboj R.K.;
RT   "Human N-methyl-D-aspartate receptor modulatory subunit hNR2A: cloning
RT   and sequencing of the cDNA and primary structure of the protein.";
RL   Biochim. Biophys. Acta 1223:155-159(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Cerebellum;
RX   PubMed=8768735;
RA   Hess S.D., Daggett L.P., Crona J., Deal C., Lu C.-C., Urrutia A.,
RA   Chavez-Noriega L., Ellis S.B., Johnson E.C., Velicelebi G.;
RT   "Cloning and functional characterization of human heteromeric N-
RT   methyl-D-aspartate receptors.";
RL   J. Pharmacol. Exp. Ther. 278:808-816(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   CHROMOSOMAL TRANSLOCATION, VARIANT FESD LYS-615, AND CHARACTERIZATION
RP   OF VARIANT FESD LYS-615.
RX   PubMed=20890276; DOI=10.1038/ng.677;
RA   Endele S., Rosenberger G., Geider K., Popp B., Tamer C., Stefanova I.,
RA   Milh M., Kortum F., Fritsch A., Pientka F.K., Hellenbroich Y.,
RA   Kalscheuer V.M., Kohlhase J., Moog U., Rappold G., Rauch A.,
RA   Ropers H.H., von Spiczak S., Tonnies H., Villeneuve N., Villard L.,
RA   Zabel B., Zenker M., Laube B., Reis A., Wieczorek D.,
RA   Van Maldergem L., Kutsche K.;
RT   "Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA
RT   receptors cause variable neurodevelopmental phenotypes.";
RL   Nat. Genet. 42:1021-1026(2010).
RN   [6]
RP   PROBABLE INVOLVEMENT IN MELANOMA, AND VARIANTS LEU-57; ILE-183;
RP   ASN-252; PHE-278; LYS-371; LYS-373; GLU-449; SER-459; ARG-595;
RP   PHE-598; ILE-653; GLU-712; TRP-740; GLU-889; LYS-920; PHE-929;
RP   LYS-962; LYS-1073; LEU-1074; ASN-1153; LYS-1175; GLY-1276; LYS-1285;
RP   TRP-1318; LEU-1366; ASN-1421; LEU-1425; LYS-1426 AND CYS-1462.
RX   PubMed=21499247; DOI=10.1038/ng.810;
RA   Wei X., Walia V., Lin J.C., Teer J.K., Prickett T.D., Gartner J.,
RA   Davis S., Stemke-Hale K., Davies M.A., Gershenwald J.E., Robinson W.,
RA   Robinson S., Rosenberg S.A., Samuels Y.;
RT   "Exome sequencing identifies GRIN2A as frequently mutated in
RT   melanoma.";
RL   Nat. Genet. 43:442-446(2011).
RN   [7]
RP   VARIANTS FESD ARG-552 AND VAL-649.
RX   PubMed=23033978; DOI=10.1056/NEJMoa1206524;
RA   de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G.,
RA   Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P.,
RA   Gilissen C., del Rosario M., Hoischen A., Scheffer H., de Vries B.B.,
RA   Brunner H.G., Veltman J.A., Vissers L.E.;
RT   "Diagnostic exome sequencing in persons with severe intellectual
RT   disability.";
RL   N. Engl. J. Med. 367:1921-1929(2012).
RN   [8]
RP   VARIANTS FESD SER-184; SER-295; ARG-483; TRP-504; HIS-518; THR-548;
RP   VAL-652; ASN-669; THR-694; THR-716; ASN-731; ASN-933 AND ASN-1251,
RP   VARIANT GLY-1276, AND CHARACTERIZATION OF VARIANTS FESD HIS-518 AND
RP   VAL-652.
RX   PubMed=23933820; DOI=10.1038/ng.2726;
RA   Lesca G., Rudolf G., Bruneau N., Lozovaya N., Labalme A.,
RA   Boutry-Kryza N., Salmi M., Tsintsadze T., Addis L., Motte J.,
RA   Wright S., Tsintsadze V., Michel A., Doummar D., Lascelles K.,
RA   Strug L., Waters P., de Bellescize J., Vrielynck P.,
RA   de Saint Martin A., Ville D., Ryvlin P., Arzimanoglou A., Hirsch E.,
RA   Vincent A., Pal D., Burnashev N., Sanlaville D., Szepetowski P.;
RT   "GRIN2A mutations in acquired epileptic aphasia and related childhood
RT   focal epilepsies and encephalopathies with speech and language
RT   dysfunction.";
RL   Nat. Genet. 45:1061-1066(2013).
RN   [9]
RP   VARIANTS FESD ARG-79; TYR-231; VAL-243; VAL-290; TRP-370; ARG-436;
RP   SER-547 DEL; SER-699; VAL-705; LYS-714; THR-727; LEU-734; GLU-772;
RP   THR-814; PHE-904 AND SER-976, VARIANT ILE-183, AND CHARACTERIZATION OF
RP   VARIANT FESD VAL-243.
RX   PubMed=23933819; DOI=10.1038/ng.2728;
RA   Lemke J.R., Lal D., Reinthaler E.M., Steiner I., Nothnagel M.,
RA   Alber M., Geider K., Laube B., Schwake M., Finsterwalder K.,
RA   Franke A., Schilhabel M., Jahn J.A., Muhle H., Boor R.,
RA   Van Paesschen W., Caraballo R., Fejerman N., Weckhuysen S.,
RA   De Jonghe P., Larsen J., Moller R.S., Hjalgrim H., Addis L., Tang S.,
RA   Hughes E., Pal D.K., Veri K., Vaher U., Talvik T., Dimova P.,
RA   Guerrero Lopez R., Serratosa J.M., Linnankivi T., Lehesjoki A.E.,
RA   Ruf S., Wolff M., Buerki S., Wohlrab G., Kroell J., Datta A.N.,
RA   Fiedler B., Kurlemann G., Kluger G., Hahn A., Haberlandt D.E.,
RA   Kutzer C., Sperner J., Becker F., Weber Y.G., Feucht M., Steinbock H.,
RA   Neophythou B., Ronen G.M., Gruber-Sedlmayr U., Geldner J.,
RA   Harvey R.J., Hoffmann P., Herms S., Altmuller J., Toliat M.R.,
RA   Thiele H., Nurnberg P., Wilhelm C., Stephani U., Helbig I., Lerche H.,
RA   Zimprich F., Neubauer B.A., Biskup S., von Spiczak S.;
RT   "Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic
RT   spikes.";
RL   Nat. Genet. 45:1067-1072(2013).
RN   [10]
RP   VARIANT FESD MET-531, AND CHARACTERIZATION OF VARIANT FESD MET-531.
RX   PubMed=23933818; DOI=10.1038/ng.2727;
RA   Carvill G.L., Regan B.M., Yendle S.C., O'Roak B.J., Lozovaya N.,
RA   Bruneau N., Burnashev N., Khan A., Cook J., Geraghty E., Sadleir L.G.,
RA   Turner S.J., Tsai M.H., Webster R., Ouvrier R., Damiano J.A.,
RA   Berkovic S.F., Shendure J., Hildebrand M.S., Szepetowski P.,
RA   Scheffer I.E., Mefford H.C.;
RT   "GRIN2A mutations cause epilepsy-aphasia spectrum disorders.";
RL   Nat. Genet. 45:1073-1076(2013).
RN   [11]
RP   PROBABLE INVOLVEMENT IN MELANOMA, AND VARIANTS PHE-349; ALA-762;
RP   GLU-889; LEU-1132 AND SER-1133.
RX   PubMed=24455489; DOI=10.3389/fonc.2013.00333;
RA   D'mello S.A., Flanagan J.U., Green T.N., Leung E.Y.,
RA   Askarian-Amiri M.E., Joseph W.R., McCrystal M.R., Isaacs R.J.,
RA   Shaw J.H., Furneaux C.E., During M.J., Finlay G.J., Baguley B.C.,
RA   Kalev-Zylinska M.L.;
RT   "Evidence that GRIN2A mutations in melanoma correlate with decreased
RT   survival.";
RL   Front. Oncol. 3:333-333(2014).
RN   [12]
RP   VARIANT FESD VAL-817.
RX   PubMed=24903190; DOI=10.1111/epi.12663;
RG   FORGE Canada Consortium;
RA   Venkateswaran S., Myers K.A., Smith A.C., Beaulieu C.L.,
RA   Schwartzentruber J.A., Majewski J., Bulman D., Boycott K.M.,
RA   Dyment D.A.;
RT   "Whole-exome sequencing in an individual with severe global
RT   developmental delay and intractable epilepsy identifies a novel, de
RT   novo GRIN2A mutation.";
RL   Epilepsia 55:E75-E79(2014).
RN   [13]
RP   VARIANT FESD MET-812, AND CHARACTERIZATION OF VARIANT FESD MET-812.
RX   PubMed=24504326; DOI=10.1038/ncomms4251;
RA   Yuan H., Hansen K.B., Zhang J., Pierson T.M., Markello T.C.,
RA   Fajardo K.V., Holloman C.M., Golas G., Adams D.R., Boerkoel C.F.,
RA   Gahl W.A., Traynelis S.F.;
RT   "Functional analysis of a de novo GRIN2A missense mutation associated
RT   with early-onset epileptic encephalopathy.";
RL   Nat. Commun. 5:3251-3251(2014).
CC   -!- FUNCTION: NMDA receptor subtype of glutamate-gated ion channels
CC       possesses high calcium permeability and voltage-dependent
CC       sensitivity to magnesium. Activation requires binding of agonist
CC       to both types of subunits.
CC   -!- SUBUNIT: Forms heteromeric channel of a zeta subunit (GRIN1), a
CC       epsilon subunit (GRIN2A, GRIN2B, GRIN2C or GRIN2D) and a third
CC       subunit (GRIN3A or GRIN3B). Found in a complex with GRIN1 and
CC       GRIN3B. Found in a complex with GRIN1, GRIN3A and PPP2CB.
CC       Interacts with PDZ domains of AIP1, INADL and DLG4. Interacts with
CC       HIP1 and NETO1 (By similarity). Interacts with LRFN2. Interacts
CC       with SNX27 (via PDZ domain); the interaction is required for
CC       recycling to the plasma membrane when endocytosed and prevent
CC       degradation in lysosomes (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q62936:Dlg3 (xeno); NbExp=5; IntAct=EBI-7249937, EBI-349596;
CC       P78352:DLG4; NbExp=3; IntAct=EBI-7249937, EBI-80389;
CC       P31016:Dlg4 (xeno); NbExp=2; IntAct=EBI-7249937, EBI-375655;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Cell junction, synapse, postsynaptic cell membrane; Multi-pass
CC       membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q12879-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q12879-2; Sequence=VSP_044300;
CC   -!- DISEASE: Epilepsy, focal, with speech disorder and with or without
CC       mental retardation (FESD) [MIM:245570]: A highly variable
CC       neurologic disorder with features ranging from severe early-onset
CC       seizures associated with delayed psychomotor development,
CC       persistent speech difficulties, and mental retardation to a more
CC       benign entity characterized by childhood onset of mild or
CC       asymptomatic seizures associated with transient speech
CC       difficulties followed by remission of seizures in adolescence and
CC       normal psychomotor development. The disorder encompasses several
CC       clinical entities, including Landau-Kleffner syndrome, epileptic
CC       encephalopathy with continuous spike and wave during slow-wave
CC       sleep, autosomal dominant rolandic epilepsy, mental retardation
CC       and speech dyspraxia, and benign epilepsy with centrotemporal
CC       spikes. {ECO:0000269|PubMed:20890276, ECO:0000269|PubMed:23033978,
CC       ECO:0000269|PubMed:23933818, ECO:0000269|PubMed:23933819,
CC       ECO:0000269|PubMed:23933820, ECO:0000269|PubMed:24504326,
CC       ECO:0000269|PubMed:24903190}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A chromosomal aberration involving GRIN2A has been
CC       found in a family with epilepsy and neurodevelopmental defects.
CC       Translocation t(16;17)(p13.2;q11.2).
CC   -!- DISEASE: Note=GRIN2A somatic mutations have been frequently found
CC       in cutaneous malignant melanoma, suggesting that the glutamate
CC       signaling pathway may play a role in the pathogenesis of melanoma.
CC       {ECO:0000269|PubMed:21499247, ECO:0000269|PubMed:24455489}.
CC   -!- SIMILARITY: Belongs to the glutamate-gated ion channel
CC       (TC 1.A.10.1) family. NR2A/GRIN2A subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U09002; AAB60343.1; -; mRNA.
DR   EMBL; U90277; AAB49992.1; -; mRNA.
DR   EMBL; AC006531; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC007218; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC022168; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC026423; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC133565; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC117131; AAI17132.1; -; mRNA.
DR   EMBL; BC143273; AAI43274.1; -; mRNA.
DR   CCDS; CCDS10539.1; -. [Q12879-1]
DR   CCDS; CCDS45407.1; -. [Q12879-2]
DR   PIR; S47555; S47555.
DR   RefSeq; NP_000824.1; NM_000833.4. [Q12879-1]
DR   RefSeq; NP_001127879.1; NM_001134407.2. [Q12879-1]
DR   RefSeq; NP_001127880.1; NM_001134408.2. [Q12879-2]
DR   RefSeq; XP_011520763.1; XM_011522461.1. [Q12879-2]
DR   UniGene; Hs.411472; -.
DR   PDB; 3NFL; X-ray; 1.91 A; E/F/G/H=1449-1464.
DR   PDBsum; 3NFL; -.
DR   ProteinModelPortal; Q12879; -.
DR   SMR; Q12879; 32-842.
DR   BioGrid; 109160; 16.
DR   DIP; DIP-40798N; -.
DR   IntAct; Q12879; 4.
DR   MINT; MINT-414776; -.
DR   STRING; 9606.ENSP00000332549; -.
DR   BindingDB; Q12879; -.
DR   ChEMBL; CHEMBL1972; -.
DR   DrugBank; DB00659; Acamprosate.
DR   DrugBank; DB06151; Acetylcysteine.
DR   DrugBank; DB00289; Atomoxetine.
DR   DrugBank; DB00949; Felbamate.
DR   DrugBank; DB00996; Gabapentin.
DR   DrugBank; DB00145; Glycine.
DR   DrugBank; DB01159; Halothane.
DR   DrugBank; DB06738; Ketobemidone.
DR   DrugBank; DB01043; Memantine.
DR   DrugBank; DB04896; Milnacipran.
DR   DrugBank; DB00312; Pentobarbital.
DR   DrugBank; DB00454; Pethidine.
DR   DrugBank; DB01174; Phenobarbital.
DR   DrugBank; DB00418; Secobarbital.
DR   GuidetoPHARMACOLOGY; 456; -.
DR   iPTMnet; Q12879; -.
DR   PhosphoSite; Q12879; -.
DR   BioMuta; GRIN2A; -.
DR   DMDM; 14285603; -.
DR   PaxDb; Q12879; -.
DR   PRIDE; Q12879; -.
DR   DNASU; 2903; -.
DR   Ensembl; ENST00000330684; ENSP00000332549; ENSG00000183454. [Q12879-1]
DR   Ensembl; ENST00000396573; ENSP00000379818; ENSG00000183454. [Q12879-1]
DR   Ensembl; ENST00000562109; ENSP00000454998; ENSG00000183454. [Q12879-2]
DR   GeneID; 2903; -.
DR   KEGG; hsa:2903; -.
DR   UCSC; uc002czo.4; human. [Q12879-1]
DR   UCSC; uc002czr.4; human. [Q12879-2]
DR   CTD; 2903; -.
DR   GeneCards; GRIN2A; -.
DR   HGNC; HGNC:4585; GRIN2A.
DR   HPA; CAB022725; -.
DR   MalaCards; GRIN2A; -.
DR   MIM; 138253; gene.
DR   MIM; 245570; phenotype.
DR   neXtProt; NX_Q12879; -.
DR   Orphanet; 725; Continuous spikes and waves during sleep.
DR   Orphanet; 289266; Early-onset epileptic encephalopathy and intellectual disability due to GRIN2A mutation.
DR   Orphanet; 98818; Landau-Kleffner syndrome.
DR   Orphanet; 1945; Rolandic epilepsy.
DR   Orphanet; 163721; Rolandic epilepsy - speech dyspraxia.
DR   PharmGKB; PA28979; -.
DR   eggNOG; KOG1053; Eukaryota.
DR   eggNOG; ENOG410XNUR; LUCA.
DR   GeneTree; ENSGT00760000119186; -.
DR   HOGENOM; HOG000113802; -.
DR   HOVERGEN; HBG052635; -.
DR   InParanoid; Q12879; -.
DR   KO; K05209; -.
DR   OMA; WEYPLET; -.
DR   OrthoDB; EOG72ZCD1; -.
DR   PhylomeDB; Q12879; -.
DR   TreeFam; TF314731; -.
DR   Reactome; R-HSA-438066; Unblocking of NMDA receptor, glutamate binding and activation.
DR   Reactome; R-HSA-442729; CREB phosphorylation through the activation of CaMKII.
DR   Reactome; R-HSA-442982; Ras activation uopn Ca2+ infux through NMDA receptor.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; Q12879; -.
DR   ChiTaRS; GRIN2A; human.
DR   EvolutionaryTrace; Q12879; -.
DR   GeneWiki; GRIN2A; -.
DR   GenomeRNAi; 2903; -.
DR   NextBio; 11495; -.
DR   PRO; PR:Q12879; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; Q12879; -.
DR   CleanEx; HS_GRIN2A; -.
DR   ExpressionAtlas; Q12879; baseline and differential.
DR   Genevisible; Q12879; HS.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0009986; C:cell surface; ISS:BHF-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0097481; C:neuronal postsynaptic density; IEA:Ensembl.
DR   GO; GO:0017146; C:NMDA selective glutamate receptor complex; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl.
DR   GO; GO:0008021; C:synaptic vesicle; IEA:Ensembl.
DR   GO; GO:0005262; F:calcium channel activity; IEA:Ensembl.
DR   GO; GO:0005234; F:extracellular-glutamate-gated ion channel activity; IEA:InterPro.
DR   GO; GO:0004972; F:NMDA glutamate receptor activity; TAS:ProtInc.
DR   GO; GO:0008270; F:zinc ion binding; ISS:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0033058; P:directional locomotion; IEA:Ensembl.
DR   GO; GO:0042417; P:dopamine metabolic process; IEA:Ensembl.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007215; P:glutamate receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; TAS:GOC.
DR   GO; GO:0007611; P:learning or memory; TAS:ProtInc.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IEA:Ensembl.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0008104; P:protein localization; IEA:Ensembl.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0001975; P:response to amphetamine; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IDA:UniProtKB.
DR   GO; GO:0009611; P:response to wounding; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0042428; P:serotonin metabolic process; IEA:Ensembl.
DR   GO; GO:0030431; P:sleep; IEA:Ensembl.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0001964; P:startle response; IEA:Ensembl.
DR   GO; GO:0007268; P:synaptic transmission; TAS:Reactome.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008542; P:visual learning; IEA:Ensembl.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR019594; Glu/Gly-bd.
DR   InterPro; IPR001508; Iono_rcpt_met.
DR   InterPro; IPR001320; Iontro_rcpt.
DR   InterPro; IPR018884; NMDAR2_C.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF00060; Lig_chan; 1.
DR   Pfam; PF10613; Lig_chan-Glu_bd; 1.
DR   Pfam; PF10565; NMDAR2_C; 1.
DR   PRINTS; PR00177; NMDARECEPTOR.
DR   SMART; SM00918; Lig_chan-Glu_bd; 1.
DR   SMART; SM00079; PBPe; 1.
DR   SUPFAM; SSF53822; SSF53822; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell junction;
KW   Cell membrane; Chromosomal rearrangement; Complete proteome;
KW   Disease mutation; Disulfide bond; Epilepsy; Glycoprotein; Ion channel;
KW   Ion transport; Ligand-gated ion channel; Magnesium; Membrane;
KW   Metal-binding; Phosphoprotein; Polymorphism;
KW   Postsynaptic cell membrane; Receptor; Reference proteome; Signal;
KW   Synapse; Transmembrane; Transmembrane helix; Transport; Zinc.
FT   SIGNAL        1     22       {ECO:0000255}.
FT   CHAIN        23   1464       Glutamate receptor ionotropic, NMDA 2A.
FT                                /FTId=PRO_0000011573.
FT   TOPO_DOM     23    555       Extracellular. {ECO:0000255}.
FT   TRANSMEM    556    576       Helical. {ECO:0000255}.
FT   TOPO_DOM    577    633       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    634    654       Helical. {ECO:0000255}.
FT   TOPO_DOM    655    816       Extracellular. {ECO:0000255}.
FT   TRANSMEM    817    837       Helical. {ECO:0000255}.
FT   TOPO_DOM    838   1464       Cytoplasmic. {ECO:0000255}.
FT   REGION      511    513       Glutamate binding. {ECO:0000250}.
FT   REGION      689    690       Glutamate binding. {ECO:0000250}.
FT   MOTIF      1462   1464       PDZ-binding.
FT   METAL       128    128       Zinc. {ECO:0000250}.
FT   METAL       283    283       Zinc. {ECO:0000250}.
FT   BINDING     518    518       Glutamate. {ECO:0000250}.
FT   BINDING     731    731       Glutamate; via amide nitrogen.
FT                                {ECO:0000250}.
FT   SITE        614    614       Functional determinant of NMDA receptors.
FT                                {ECO:0000250}.
FT   MOD_RES     882    882       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P35436}.
FT   MOD_RES     890    890       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P35436}.
FT   MOD_RES     929    929       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P35436}.
FT   MOD_RES    1025   1025       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q00959}.
FT   MOD_RES    1059   1059       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P35436}.
FT   MOD_RES    1062   1062       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q00959}.
FT   MOD_RES    1198   1198       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q00959}.
FT   CARBOHYD     75     75       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    340    340       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    380    380       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    443    443       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    444    444       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    541    541       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     87    320       {ECO:0000250}.
FT   VAR_SEQ    1259   1464       NPATGEQVYQQDWAQNNALQLQKNKLRISRQHSYDNIVDKP
FT                                RELDLSRPSRSISLKDRERLLEGNFYGSLFSVPSSKLSGKK
FT                                SSLFPQGLEDSKRSKSLLPDHTSDNPFLHSHRDDQRLVIGR
FT                                CPSDPYKHSLPSQAVNDSYLRSSLRSTASYCSRDSRGHNDV
FT                                YISEHVMPYAANKNNMYSTPRVLNSCSNRRVYKKMPSIESD
FT                                V -> MTNAWLLGDAPRTLTNTRCHPRR (in isoform
FT                                2). {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_044300.
FT   VARIANT      57     57       P -> L (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067725.
FT   VARIANT      79     79       P -> R (in FESD).
FT                                {ECO:0000269|PubMed:23933819}.
FT                                /FTId=VAR_070345.
FT   VARIANT     183    183       F -> I (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation; also
FT                                found in a patient with benign epilepsy
FT                                with centrotemporal spike).
FT                                {ECO:0000269|PubMed:21499247,
FT                                ECO:0000269|PubMed:23933819}.
FT                                /FTId=VAR_067726.
FT   VARIANT     184    184       I -> S (in FESD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23933820}.
FT                                /FTId=VAR_070346.
FT   VARIANT     231    231       C -> Y (in FESD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23933819}.
FT                                /FTId=VAR_070347.
FT   VARIANT     243    243       A -> V (in FESD; results in reduced high-
FT                                affinity zinc mediated inhibition).
FT                                {ECO:0000269|PubMed:23933819}.
FT                                /FTId=VAR_070348.
FT   VARIANT     252    252       D -> N (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067727.
FT   VARIANT     270    270       K -> E. {ECO:0000269|PubMed:8061049}.
FT                                /FTId=VAR_010938.
FT   VARIANT     278    278       S -> F (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067728.
FT   VARIANT     290    290       A -> V (in FESD).
FT                                {ECO:0000269|PubMed:23933819}.
FT                                /FTId=VAR_070349.
FT   VARIANT     295    295       G -> S (in FESD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23933820}.
FT                                /FTId=VAR_070350.
FT   VARIANT     349    349       S -> F (found in a cutaneous malignant
FT                                melanoma sample).
FT                                {ECO:0000269|PubMed:24455489}.
FT                                /FTId=VAR_071624.
FT   VARIANT     370    370       R -> W (in FESD).
FT                                {ECO:0000269|PubMed:23933819}.
FT                                /FTId=VAR_070351.
FT   VARIANT     371    371       E -> K (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067729.
FT   VARIANT     373    373       E -> K (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067730.
FT   VARIANT     436    436       C -> R (in FESD).
FT                                {ECO:0000269|PubMed:23933819}.
FT                                /FTId=VAR_070352.
FT   VARIANT     449    449       G -> E (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067731.
FT   VARIANT     459    459       F -> S (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067732.
FT   VARIANT     483    483       G -> R (in FESD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23933820}.
FT                                /FTId=VAR_070353.
FT   VARIANT     504    504       R -> W (in FESD).
FT                                {ECO:0000269|PubMed:23933820}.
FT                                /FTId=VAR_070354.
FT   VARIANT     518    518       R -> H (in FESD; affects receptor
FT                                kinetics). {ECO:0000269|PubMed:23933820}.
FT                                /FTId=VAR_070355.
FT   VARIANT     531    531       T -> M (in FESD; affects receptor
FT                                kinetics). {ECO:0000269|PubMed:23933818}.
FT                                /FTId=VAR_070356.
FT   VARIANT     547    547       Missing (in FESD).
FT                                {ECO:0000269|PubMed:23933819}.
FT                                /FTId=VAR_070357.
FT   VARIANT     548    548       A -> T (in FESD).
FT                                {ECO:0000269|PubMed:23933820}.
FT                                /FTId=VAR_070358.
FT   VARIANT     552    552       P -> R (in FESD).
FT                                {ECO:0000269|PubMed:23033978}.
FT                                /FTId=VAR_069382.
FT   VARIANT     595    595       H -> R (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067733.
FT   VARIANT     598    598       S -> F (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067734.
FT   VARIANT     615    615       N -> K (in FESD; the mutant receptor has
FT                                decreased calcium permeability; shows a
FT                                dominant-negative effect).
FT                                {ECO:0000269|PubMed:20890276}.
FT                                /FTId=VAR_065899.
FT   VARIANT     649    649       L -> V (in FESD).
FT                                {ECO:0000269|PubMed:23033978}.
FT                                /FTId=VAR_069383.
FT   VARIANT     652    652       F -> V (in FESD; affects receptor
FT                                kinetics). {ECO:0000269|PubMed:23933820}.
FT                                /FTId=VAR_070359.
FT   VARIANT     653    653       M -> I (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067735.
FT   VARIANT     669    669       K -> N (in FESD).
FT                                {ECO:0000269|PubMed:23933820}.
FT                                /FTId=VAR_070360.
FT   VARIANT     694    694       I -> T (in FESD).
FT                                {ECO:0000269|PubMed:23933820}.
FT                                /FTId=VAR_070361.
FT   VARIANT     699    699       P -> S (in FESD).
FT                                {ECO:0000269|PubMed:23933819}.
FT                                /FTId=VAR_070362.
FT   VARIANT     705    705       M -> V (in FESD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23933819}.
FT                                /FTId=VAR_070363.
FT   VARIANT     712    712       G -> E (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067736.
FT   VARIANT     714    714       E -> K (in FESD).
FT                                {ECO:0000269|PubMed:23933819}.
FT                                /FTId=VAR_070364.
FT   VARIANT     716    716       A -> T (in FESD).
FT                                {ECO:0000269|PubMed:23933820}.
FT                                /FTId=VAR_070365.
FT   VARIANT     727    727       A -> T (in FESD).
FT                                {ECO:0000269|PubMed:23933819}.
FT                                /FTId=VAR_070366.
FT   VARIANT     731    731       D -> N (in FESD).
FT                                {ECO:0000269|PubMed:23933820}.
FT                                /FTId=VAR_070367.
FT   VARIANT     734    734       V -> L (in FESD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23933819}.
FT                                /FTId=VAR_070368.
FT   VARIANT     740    740       G -> W (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067737.
FT   VARIANT     762    762       G -> A (found in a cutaneous malignant
FT                                melanoma sample).
FT                                {ECO:0000269|PubMed:24455489}.
FT                                /FTId=VAR_071625.
FT   VARIANT     772    772       K -> E (in FESD).
FT                                {ECO:0000269|PubMed:23933819}.
FT                                /FTId=VAR_070369.
FT   VARIANT     812    812       L -> M (in FESD; increase in receptor
FT                                response to agonists; decrease in the
FT                                actions of endogenous negative
FT                                modulators; increase in channel open
FT                                probability; prolonged deactivation time
FT                                course). {ECO:0000269|PubMed:24504326}.
FT                                /FTId=VAR_072750.
FT   VARIANT     814    814       I -> T (in FESD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23933819}.
FT                                /FTId=VAR_070370.
FT   VARIANT     817    817       M -> V (in FESD).
FT                                {ECO:0000269|PubMed:24903190}.
FT                                /FTId=VAR_071626.
FT   VARIANT     889    889       G -> E (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247,
FT                                ECO:0000269|PubMed:24455489}.
FT                                /FTId=VAR_067738.
FT   VARIANT     904    904       I -> F (in FESD).
FT                                {ECO:0000269|PubMed:23933819}.
FT                                /FTId=VAR_070371.
FT   VARIANT     920    920       R -> K (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067739.
FT   VARIANT     929    929       S -> F (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067740.
FT   VARIANT     933    933       D -> N (in FESD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23933820}.
FT                                /FTId=VAR_070372.
FT   VARIANT     962    962       E -> K (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067741.
FT   VARIANT     976    976       N -> S (in FESD).
FT                                {ECO:0000269|PubMed:23933819}.
FT                                /FTId=VAR_070373.
FT   VARIANT    1073   1073       E -> K (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067742.
FT   VARIANT    1074   1074       P -> L (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067743.
FT   VARIANT    1132   1132       P -> L (found in a cutaneous malignant
FT                                melanoma sample).
FT                                {ECO:0000269|PubMed:24455489}.
FT                                /FTId=VAR_071627.
FT   VARIANT    1133   1133       P -> S (found in a cutaneous malignant
FT                                melanoma sample).
FT                                {ECO:0000269|PubMed:24455489}.
FT                                /FTId=VAR_071628.
FT   VARIANT    1153   1153       D -> N (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067744.
FT   VARIANT    1175   1175       E -> K (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067745.
FT   VARIANT    1251   1251       D -> N (in FESD).
FT                                {ECO:0000269|PubMed:23933820}.
FT                                /FTId=VAR_070374.
FT   VARIANT    1276   1276       A -> G (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation; also
FT                                found in a patient with continuous spike-
FT                                wave discharges during slow-wave sleep;
FT                                dbSNP:rs145063086).
FT                                {ECO:0000269|PubMed:21499247,
FT                                ECO:0000269|PubMed:23933820}.
FT                                /FTId=VAR_067746.
FT   VARIANT    1285   1285       R -> K (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067747.
FT   VARIANT    1318   1318       R -> W (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067748.
FT   VARIANT    1366   1366       P -> L (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067749.
FT   VARIANT    1421   1421       D -> N (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067750.
FT   VARIANT    1425   1425       S -> L (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067751.
FT   VARIANT    1426   1426       E -> K (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067752.
FT   VARIANT    1462   1462       S -> C (found in a cutaneous malignant
FT                                melanoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21499247}.
FT                                /FTId=VAR_067753.
FT   STRAND     1461   1464       {ECO:0000244|PDB:3NFL}.
SQ   SEQUENCE   1464 AA;  165283 MW;  AF5EDD599EC0B1E3 CRC64;
     MGRVGYWTLL VLPALLVWRG PAPSAAAEKG PPALNIAVML GHSHDVTERE LRTLWGPEQA
     AGLPLDVNVV ALLMNRTDPK SLITHVCDLM SGARIHGLVF GDDTDQEAVA QMLDFISSHT
     FVPILGIHGG ASMIMADKDP TSTFFQFGAS IQQQATVMLK IMQDYDWHVF SLVTTIFPGY
     REFISFVKTT VDNSFVGWDM QNVITLDTSF EDAKTQVQLK KIHSSVILLY CSKDEAVLIL
     SEARSLGLTG YDFFWIVPSL VSGNTELIPK EFPSGLISVS YDDWDYSLEA RVRDGIGILT
     TAASSMLEKF SYIPEAKASC YGQMERPEVP MHTLHPFMVN VTWDGKDLSF TEEGYQVHPR
     LVVIVLNKDR EWEKVGKWEN HTLSLRHAVW PRYKSFSDCE PDDNHLSIVT LEEAPFVIVE
     DIDPLTETCV RNTVPCRKFV KINNSTNEGM NVKKCCKGFC IDILKKLSRT VKFTYDLYLV
     TNGKHGKKVN NVWNGMIGEV VYQRAVMAVG SLTINEERSE VVDFSVPFVE TGISVMVSRS
     NGTVSPSAFL EPFSASVWVM MFVMLLIVSA IAVFVFEYFS PVGYNRNLAK GKAPHGPSFT
     IGKAIWLLWG LVFNNSVPVQ NPKGTTSKIM VSVWAFFAVI FLASYTANLA AFMIQEEFVD
     QVTGLSDKKF QRPHDYSPPF RFGTVPNGST ERNIRNNYPY MHQYMTKFNQ KGVEDALVSL
     KTGKLDAFIY DAAVLNYKAG RDEGCKLVTI GSGYIFATTG YGIALQKGSP WKRQIDLALL
     QFVGDGEMEE LETLWLTGIC HNEKNEVMSS QLDIDNMAGV FYMLAAAMAL SLITFIWEHL
     FYWKLRFCFT GVCSDRPGLL FSISRGIYSC IHGVHIEEKK KSPDFNLTGS QSNMLKLLRS
     AKNISSMSNM NSSRMDSPKR AADFIQRGSL IMDMVSDKGN LMYSDNRSFQ GKESIFGDNM
     NELQTFVANR QKDNLNNYVF QGQHPLTLNE SNPNTVEVAV STESKANSRP RQLWKKSVDS
     IRQDSLSQNP VSQRDEATAE NRTHSLKSPR YLPEEMAHSD ISETSNRATC HREPDNSKNH
     KTKDNFKRSV ASKYPKDCSE VERTYLKTKS SSPRDKIYTI DGEKEPGFHL DPPQFVENVT
     LPENVDFPDP YQDPSENFRK GDSTLPMNRN PLHNEEGLSN NDQYKLYSKH FTLKDKGSPH
     SETSERYRQN STHCRSCLSN MPTYSGHFTM RSPFKCDACL RMGNLYDIDE DQMLQETGNP
     ATGEQVYQQD WAQNNALQLQ KNKLRISRQH SYDNIVDKPR ELDLSRPSRS ISLKDRERLL
     EGNFYGSLFS VPSSKLSGKK SSLFPQGLED SKRSKSLLPD HTSDNPFLHS HRDDQRLVIG
     RCPSDPYKHS LPSQAVNDSY LRSSLRSTAS YCSRDSRGHN DVYISEHVMP YAANKNNMYS
     TPRVLNSCSN RRVYKKMPSI ESDV
//
ID   TLR3_HUMAN              Reviewed;         904 AA.
AC   O15455; B2RAI7; B7Z7K0; E6Y0F0; E6Y0F1; E9PGH4; Q4VAL2; Q504W0;
DT   31-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   17-FEB-2016, entry version 162.
DE   RecName: Full=Toll-like receptor 3;
DE   AltName: CD_antigen=CD283;
DE   Flags: Precursor;
GN   Name=TLR3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9435236; DOI=10.1073/pnas.95.2.588;
RA   Rock F.L., Hardiman G., Timans J.C., Kastelein R.A., Bazan J.F.;
RT   "A family of human receptors structurally related to Drosophila
RT   Toll.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:588-593(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Neuron;
RX   PubMed=17085778; DOI=10.1385/JMN:29:3:185;
RA   Lafon M., Megret F., Lafage M., Prehaud C.;
RT   "The innate immune facet of brain: human neurons express TLR-3 and
RT   sense viral dsRNA.";
RL   J. Mol. Neurosci. 29:185-194(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=18810425; DOI=10.1007/s00251-008-0332-0;
RA   Nakajima T., Ohtani H., Satta Y., Uno Y., Akari H., Ishida T.,
RA   Kimura A.;
RT   "Natural selection in the TLR-related genes in the course of primate
RT   evolution.";
RL   Immunogenetics 60:727-735(2008).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PHE-412.
RA   Macquin C., Bahram S.;
RT   "TLR polymorphism.";
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   PHE-412.
RC   TISSUE=Testis, and Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 24-38.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH TICAM1.
RX   PubMed=12471095; DOI=10.4049/jimmunol.169.12.6668;
RA   Yamamoto M., Sato S., Mori K., Hoshino K., Takeuchi O., Takeda K.,
RA   Akira S.;
RT   "A novel Toll/IL-1 receptor domain-containing adapter that
RT   preferentially activates the IFN-beta promoter in the Toll-like
RT   receptor signaling.";
RL   J. Immunol. 169:6668-6672(2002).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH TICAM1.
RC   TISSUE=Lung;
RX   PubMed=12539043; DOI=10.1038/ni886;
RA   Oshiumi H., Matsumoto M., Funami K., Akazawa T., Seya T.;
RT   "TICAM-1, an adapter molecule that participates in Toll-like receptor
RT   3 mediated interferon-beta induction.";
RL   Nat. Immunol. 4:161-167(2003).
RN   [12]
RP   FUNCTION, SUBUNIT, AND MUTAGENESIS OF CYS-95; CYS-122; ASN-196 AND
RP   ASN-247.
RX   PubMed=16144834; DOI=10.1074/jbc.M507163200;
RA   de Bouteiller O., Merck E., Hasan U.A., Hubac S., Benguigui B.,
RA   Trinchieri G., Bates E.E., Caux C.;
RT   "Recognition of double-stranded RNA by human toll-like receptor 3 and
RT   downstream receptor signaling requires multimerization and an acidic
RT   pH.";
RL   J. Biol. Chem. 280:38133-38145(2005).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH SRC.
RX   PubMed=16858407; DOI=10.1038/sj.emboj.7601222;
RA   Johnsen I.B., Nguyen T.T., Ringdal M., Tryggestad A.M., Bakke O.,
RA   Lien E., Espevik T., Anthonsen M.W.;
RT   "Toll-like receptor 3 associates with c-Src tyrosine kinase on
RT   endosomes to initiate antiviral signaling.";
RL   EMBO J. 25:3335-3346(2006).
RN   [14]
RP   FUNCTION, AND MUTAGENESIS OF HIS-539 AND ASN-541.
RX   PubMed=16720699; DOI=10.1073/pnas.0603245103;
RA   Bell J.K., Askins J., Hall P.R., Davies D.R., Segal D.M.;
RT   "The dsRNA binding site of human Toll-like receptor 3.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:8792-8797(2006).
RN   [15]
RP   PHOSPHORYLATION AT TYR-759 AND TYR-858, FUNCTION, AND MUTAGENESIS OF
RP   TYR-759.
RX   PubMed=17178723; DOI=10.1074/jbc.C600226200;
RA   Sarkar S.N., Elco C.P., Peters K.L., Chattopadhyay S., Sen G.C.;
RT   "Two tyrosine residues of Toll-like receptor 3 trigger different steps
RT   of NF-kappa B activation.";
RL   J. Biol. Chem. 282:3423-3427(2007).
RN   [16]
RP   FUNCTION, DOUBLE-STRANDED RNA-BINDING, AND HOMODIMERIZATION.
RX   PubMed=18172197; DOI=10.1073/pnas.0710779105;
RA   Leonard J.N., Ghirlando R., Askins J., Bell J.K., Margulies D.H.,
RA   Davies D.R., Segal D.M.;
RT   "The TLR3 signaling complex forms by cooperative receptor
RT   dimerization.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:258-263(2008).
RN   [17]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-52 AND ASN-57.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [18]
RP   FUNCTION, PROTEOLYTIC PROCESSING, SUBCELLULAR LOCATION, AND
RP   INTERACTION WITH UNC93B1.
RX   PubMed=22611194; DOI=10.1073/pnas.1115091109;
RA   Garcia-Cattaneo A., Gobert F.X., Muller M., Toscano F., Flores M.,
RA   Lescure A., Del Nery E., Benaroch P.;
RT   "Cleavage of Toll-like receptor 3 by cathepsins B and H is essential
RT   for signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:9053-9058(2012).
RN   [19]
RP   INTERACTION WITH WDFY1 AND TICAM1, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF TYR-759 AND TYR-858.
RX   PubMed=25736436; DOI=10.15252/embr.201439637;
RA   Hu Y.H., Zhang Y., Jiang L.Q., Wang S., Lei C.Q., Sun M.S., Shu H.B.,
RA   Liu Y.;
RT   "WDFY1 mediates TLR3/4 signaling by recruiting TRIF.";
RL   EMBO Rep. 16:447-455(2015).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 22-703, FUNCTION, DISULFIDE
RP   BONDS, SUBUNIT, GLYCOSYLATION AT ASN-52; ASN-70; ASN-196; ASN-252;
RP   ASN-265; ASN-275; ASN-291; ASN-398; ASN-413; ASN-507 AND ASN-636, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16043704; DOI=10.1073/pnas.0505077102;
RA   Bell J.K., Botos I., Hall P.R., Askins J., Shiloach J., Segal D.M.,
RA   Davies D.R.;
RT   "The molecular structure of the Toll-like receptor 3 ligand-binding
RT   domain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:10976-10980(2005).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 27-700, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-124; ASN-252; ASN-275; ASN-291; ASN-398; ASN-413
RP   AND ASN-507.
RX   PubMed=15961631; DOI=10.1126/science.1115253;
RA   Choe J., Kelker M.S., Wilson I.A.;
RT   "Crystal structure of human toll-like receptor 3 (TLR3) ectodomain.";
RL   Science 309:581-585(2005).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (3.52 ANGSTROMS) OF 22-702 IN COMPLEX WITH
RP   ANTIBODY, DISULFIDE BONDS, SUBUNIT, DS-RNA BINDING REGIONS, AND
RP   GLYCOSYLATION AT ASN-52; ASN-70; ASN-124; ASN-247; ASN-252; ASN-265;
RP   ASN-275; ASN-291; ASN-398; ASN-413 AND ASN-507.
RX   PubMed=22579623; DOI=10.1016/j.jmb.2012.05.006;
RA   Luo J., Obmolova G., Malia T.J., Wu S.J., Duffy K.E., Marion J.D.,
RA   Bell J.K., Ge P., Zhou Z.H., Teplyakov A., Zhao Y., Lamb R.J.,
RA   Jordan J.L., San Mateo L.R., Sweet R.W., Gilliland G.L.;
RT   "Lateral clustering of TLR3:dsRNA signaling units revealed by
RT   TLR3ecd:3Fabs quaternary structure.";
RL   J. Mol. Biol. 421:112-124(2012).
RN   [23]
RP   VARIANT HSE2 SER-554.
RX   PubMed=17872438; DOI=10.1126/science.1139522;
RA   Zhang S.-Y., Jouanguy E., Ugolini S., Smahi A., Elain G., Romero P.,
RA   Segal D., Sancho-Shimizu V., Lorenzo L., Puel A., Picard C.,
RA   Chapgier A., Plancoulaine S., Titeux M., Cognet C., von Bernuth H.,
RA   Ku C.-L., Casrouge A., Zhang X.-X., Barreiro L., Leonard J.,
RA   Hamilton C., Lebon P., Heron B., Vallee L., Quintana-Murci L.,
RA   Hovnanian A., Rozenberg F., Vivier E., Geissmann F., Tardieu M.,
RA   Abel L., Casanova J.-L.;
RT   "TLR3 deficiency in patients with herpes simplex encephalitis.";
RL   Science 317:1522-1527(2007).
RN   [24]
RP   VARIANT PHE-412.
RX   PubMed=18753640; DOI=10.1056/NEJMoa0802437;
RA   Yang Z., Stratton C., Francis P.J., Kleinman M.E., Tan P.L., Gibbs D.,
RA   Tong Z., Chen H., Constantine R., Yang X., Chen Y., Zeng J., Davey L.,
RA   Ma X., Hau V.S., Wang C., Harmon J., Buehler J., Pearson E., Patel S.,
RA   Kaminoh Y., Watkins S., Luo L., Zabriskie N.A., Bernstein P.S.,
RA   Cho W., Schwager A., Hinton D.R., Klein M.L., Hamon S.C., Simmons E.,
RA   Yu B., Campochiaro B., Sunness J.S., Campochiaro P., Jorde L.,
RA   Parmigiani G., Zack D.J., Katsanis N., Ambati J., Zhang K.;
RT   "Toll-like receptor 3 and geographic atrophy in age-related macular
RT   degeneration.";
RL   N. Engl. J. Med. 359:1456-1463(2008).
RN   [25]
RP   ERRATUM.
RA   Yang Z., Stratton C., Francis P.J., Kleinman M.E., Tan P.L., Gibbs D.,
RA   Tong Z., Chen H., Constantine R., Yang X., Chen Y., Zeng J., Davey L.,
RA   Ma X., Hau V.S., Wang C., Harmon J., Buehler J., Pearson E., Patel S.,
RA   Kaminoh Y., Watkins S., Luo L., Zabriskie N.A., Bernstein P.S.,
RA   Cho W., Schwager A., Hinton D.R., Klein M.L., Hamon S.C., Simmons E.,
RA   Yu B., Campochiaro B., Sunness J.S., Campochiaro P., Jorde L.,
RA   Parmigiani G., Zack D.J., Katsanis N., Ambati J., Zhang K.;
RL   N. Engl. J. Med. 359:1859-1859(2008).
RN   [26]
RP   VARIANT PHE-412.
RX   PubMed=22174453; DOI=10.4049/jimmunol.1102179;
RA   Sironi M., Biasin M., Cagliani R., Forni D., De Luca M., Saulle I.,
RA   Lo Caputo S., Mazzotta F., Macias J., Pineda J.A., Caruz A.,
RA   Clerici M.;
RT   "A common polymorphism in TLR3 confers natural resistance to HIV-1
RT   infection.";
RL   J. Immunol. 188:818-823(2012).
CC   -!- FUNCTION: Key component of innate and adaptive immunity. TLRs
CC       (Toll-like receptors) control host immune response against
CC       pathogens through recognition of molecular patterns specific to
CC       microorganisms. TLR3 is a nucleotide-sensing TLR which is
CC       activated by double-stranded RNA, a sign of viral infection. Acts
CC       via the adapter TRIF/TICAM1, leading to NF-kappa-B activation,
CC       IRF3 nuclear translocation, cytokine secretion and the
CC       inflammatory response. {ECO:0000269|PubMed:12471095,
CC       ECO:0000269|PubMed:12539043, ECO:0000269|PubMed:16043704,
CC       ECO:0000269|PubMed:16144834, ECO:0000269|PubMed:16720699,
CC       ECO:0000269|PubMed:16858407, ECO:0000269|PubMed:17178723,
CC       ECO:0000269|PubMed:18172197, ECO:0000269|PubMed:22611194}.
CC   -!- SUBUNIT: Monomer and homodimer; dimerization is triggered by
CC       ligand-binding, the signaling unit is composed of one ds-RNA of
CC       around 40 bp and two TLR3 molecules, and lateral clustering of
CC       signaling units along the length of the ds-RNA ligand is required
CC       for TLR3 signal transduction. Interacts (via transmembrane domain)
CC       with UNC93B1; the interaction is required for transport from the
CC       ER to the endosomes. Interacts with SRC; upon binding of double-
CC       stranded RNA. Interacts with TICAM1 (via the TIR domain) in
CC       response to poly(I:C) and this interaction is enhanced in the
CC       presence of WDFY1 (PubMed:25736436). The tyrosine-phosphorylated
CC       form (via TIR domain) interacts with WDFY1 (via WD repeat 2) in
CC       response to poly(I:C) (PubMed:25736436).
CC       {ECO:0000269|PubMed:12471095, ECO:0000269|PubMed:12539043,
CC       ECO:0000269|PubMed:16043704, ECO:0000269|PubMed:16144834,
CC       ECO:0000269|PubMed:16858407, ECO:0000269|PubMed:22579623,
CC       ECO:0000269|PubMed:22611194, ECO:0000269|PubMed:25736436}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-6116630, EBI-6116630;
CC       P27986:PIK3R1; NbExp=2; IntAct=EBI-6116630, EBI-79464;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Single-pass
CC       type I membrane protein. Endosome membrane. Early endosome
CC       {ECO:0000269|PubMed:25736436}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O15455-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15455-2; Sequence=VSP_054188;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed at high level in placenta and
CC       pancreas. Also detected in CD11c+ immature dendritic cells. Only
CC       expressed in dendritic cells and not in other leukocytes,
CC       including monocyte precursors. TLR3 is the TLR that is expressed
CC       most strongly in the brain, especially in astrocytes, glia, and
CC       neurons. {ECO:0000269|PubMed:17085778}.
CC   -!- DOMAIN: ds-RNA binding is mediated by LRR 1 to 3, and LRR 17 to
CC       18.
CC   -!- PTM: Heavily N-glycosylated, except on that part of the surface of
CC       the ectodomain that is involved in ligand binding.
CC       {ECO:0000269|PubMed:15961631, ECO:0000269|PubMed:16043704,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:22579623}.
CC   -!- PTM: TLR3 signaling requires a proteolytic cleavage mediated by
CC       cathepsins CTSB and CTSH, the cleavage occurs between amino acids
CC       252 and 346. The cleaved form of TLR3 is the predominant form
CC       found in endosomes. {ECO:0000269|PubMed:22611194}.
CC   -!- POLYMORPHISM: The Phe-412 allele (dbSNP:rs3775291) occurs with a
CC       frequency of 30% in populations with European and Asian ancestry,
CC       and confers some natural resistance to HIV-1 infection.
CC   -!- DISEASE: Herpes simplex encephalitis 2 (HSE2) [MIM:613002]: A rare
CC       complication of human herpesvirus 1 (HHV-1) infection, occurring
CC       in only a small minority of HHV-1 infected individuals. HSE is
CC       characterized by hemorrhagic necrosis of parts of the temporal and
CC       frontal lobes. Onset is over several days and involves fever,
CC       headache, seizures, stupor, and often coma, frequently with a
CC       fatal outcome. {ECO:0000269|PubMed:17872438}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry. TLR3 mutations predispose otherwise
CC       healthy individuals to isolated herpes simplex encephalitis
CC       through a mechanism that involves impaired IFNs production and
CC       reduced immune defense against viral infection in the central
CC       nervous system.
CC   -!- SIMILARITY: Belongs to the Toll-like receptor family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 22 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 LRRCT domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 LRRNT domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 TIR domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00204}.
CC   -!- WEB RESOURCE: Name=TLR3base; Note=TLR3 mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/TLR3base/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U88879; AAC34134.1; -; mRNA.
DR   EMBL; DQ445682; ABE01399.1; -; mRNA.
DR   EMBL; AB445631; BAG55028.1; -; mRNA.
DR   EMBL; DQ360814; ABC86908.1; -; Genomic_DNA.
DR   EMBL; DQ360815; ABC86909.1; -; Genomic_DNA.
DR   EMBL; DQ360816; ABC86910.1; -; Genomic_DNA.
DR   EMBL; AK302143; BAH13636.1; -; mRNA.
DR   EMBL; AK314208; BAG36884.1; -; mRNA.
DR   EMBL; AC104070; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471056; EAX04628.1; -; Genomic_DNA.
DR   EMBL; BC094737; AAH94737.1; -; mRNA.
DR   EMBL; BC096333; AAH96333.1; -; mRNA.
DR   EMBL; BC096334; AAH96334.1; -; mRNA.
DR   EMBL; BC096335; AAH96335.1; -; mRNA.
DR   CCDS; CCDS3846.1; -. [O15455-1]
DR   RefSeq; NP_003256.1; NM_003265.2. [O15455-1]
DR   UniGene; Hs.657724; -.
DR   PDB; 1ZIW; X-ray; 2.10 A; A=27-700.
DR   PDB; 2A0Z; X-ray; 2.40 A; A=22-703.
DR   PDB; 2MK9; NMR; -; A/B=698-730.
DR   PDB; 2MKA; NMR; -; A/B/C=698-730.
DR   PDB; 3ULU; X-ray; 3.52 A; A=22-702.
DR   PDB; 3ULV; X-ray; 3.52 A; A=22-702.
DR   PDBsum; 1ZIW; -.
DR   PDBsum; 2A0Z; -.
DR   PDBsum; 2MK9; -.
DR   PDBsum; 2MKA; -.
DR   PDBsum; 3ULU; -.
DR   PDBsum; 3ULV; -.
DR   ProteinModelPortal; O15455; -.
DR   SMR; O15455; 26-897.
DR   BioGrid; 112953; 15.
DR   DIP; DIP-29660N; -.
DR   IntAct; O15455; 7.
DR   MINT; MINT-2840066; -.
DR   STRING; 9606.ENSP00000296795; -.
DR   ChEMBL; CHEMBL1075113; -.
DR   iPTMnet; O15455; -.
DR   PhosphoSite; O15455; -.
DR   BioMuta; TLR3; -.
DR   MaxQB; O15455; -.
DR   PaxDb; O15455; -.
DR   PRIDE; O15455; -.
DR   Ensembl; ENST00000296795; ENSP00000296795; ENSG00000164342. [O15455-1]
DR   Ensembl; ENST00000504367; ENSP00000423684; ENSG00000164342. [O15455-2]
DR   GeneID; 7098; -.
DR   KEGG; hsa:7098; -.
DR   UCSC; uc003iyq.3; human. [O15455-1]
DR   CTD; 7098; -.
DR   GeneCards; TLR3; -.
DR   HGNC; HGNC:11849; TLR3.
DR   HPA; CAB025658; -.
DR   MalaCards; TLR3; -.
DR   MIM; 603029; gene.
DR   MIM; 613002; phenotype.
DR   neXtProt; NX_O15455; -.
DR   Orphanet; 1930; Herpetic encephalitis.
DR   PharmGKB; PA36551; -.
DR   eggNOG; KOG4641; Eukaryota.
DR   eggNOG; COG4886; LUCA.
DR   GeneTree; ENSGT00760000119006; -.
DR   HOGENOM; HOG000251618; -.
DR   HOVERGEN; HBG023181; -.
DR   InParanoid; O15455; -.
DR   KO; K05401; -.
DR   OMA; THEVADC; -.
DR   OrthoDB; EOG79SDZG; -.
DR   PhylomeDB; O15455; -.
DR   TreeFam; TF325595; -.
DR   Reactome; R-HSA-140534; Ligand-dependent caspase activation.
DR   Reactome; R-HSA-166166; MyD88-independent TLR3/TLR4 cascade.
DR   Reactome; R-HSA-1679131; Trafficking and processing of endosomal TLR.
DR   Reactome; R-HSA-168164; Toll Like Receptor 3 (TLR3) Cascade.
DR   Reactome; R-HSA-1810476; RIP-mediated NFkB activation via ZBP1.
DR   Reactome; R-HSA-2562578; TRIF-mediated programmed cell death.
DR   Reactome; R-HSA-5602410; TLR3 deficiency - HSE.
DR   Reactome; R-HSA-5602415; UNC93B1 deficiency - HSE.
DR   Reactome; R-HSA-5602566; TICAM1 deficiency - HSE.
DR   Reactome; R-HSA-5602571; TRAF3 deficiency - HSE.
DR   Reactome; R-HSA-936964; Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon.
DR   Reactome; R-HSA-937041; IKK complex recruitment mediated by RIP1.
DR   Reactome; R-HSA-937072; TRAF6 mediated induction of TAK1 complex.
DR   SignaLink; O15455; -.
DR   EvolutionaryTrace; O15455; -.
DR   GeneWiki; TLR_3; -.
DR   GenomeRNAi; 7098; -.
DR   NextBio; 27769; -.
DR   PRO; PR:O15455; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; O15455; -.
DR   CleanEx; HS_TLR3; -.
DR   ExpressionAtlas; O15455; baseline and differential.
DR   Genevisible; O15455; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005769; C:early endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0036020; C:endolysosome membrane; TAS:Reactome.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005622; C:intracellular; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; NAS:UniProtKB.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004872; F:receptor activity; TAS:ProtInc.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; NAS:UniProtKB.
DR   GO; GO:0097296; P:activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0007250; P:activation of NF-kappaB-inducing kinase activity; NAS:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:Reactome.
DR   GO; GO:0035690; P:cellular response to drug; IEA:Ensembl.
DR   GO; GO:0071360; P:cellular response to exogenous dsRNA; IEA:Ensembl.
DR   GO; GO:0035458; P:cellular response to interferon-beta; IEA:Ensembl.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IEA:Ensembl.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0042742; P:defense response to bacterium; TAS:ProtInc.
DR   GO; GO:0051607; P:defense response to virus; TAS:BHF-UCL.
DR   GO; GO:0009597; P:detection of virus; NAS:UniProtKB.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006972; P:hyperosmotic response; NAS:UniProtKB.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; TAS:Reactome.
DR   GO; GO:0007252; P:I-kappaB phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; TAS:BHF-UCL.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0002282; P:microglial cell activation involved in immune response; IEA:Ensembl.
DR   GO; GO:0002756; P:MyD88-independent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0097527; P:necroptotic signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045671; P:negative regulation of osteoclast differentiation; NAS:UniProtKB.
DR   GO; GO:0045080; P:positive regulation of chemokine biosynthetic process; IEA:Ensembl.
DR   GO; GO:0032722; P:positive regulation of chemokine production; IDA:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0045356; P:positive regulation of interferon-alpha biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045359; P:positive regulation of interferon-beta biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; ISS:BHF-UCL.
DR   GO; GO:0045078; P:positive regulation of interferon-gamma biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; ISS:BHF-UCL.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:BHF-UCL.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; IDA:BHF-UCL.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IEA:Ensembl.
DR   GO; GO:0042346; P:positive regulation of NF-kappaB import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IEA:Ensembl.
DR   GO; GO:0034123; P:positive regulation of toll-like receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:BHF-UCL.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; ISS:BHF-UCL.
DR   GO; GO:0034346; P:positive regulation of type III interferon production; IEA:Ensembl.
DR   GO; GO:0012501; P:programmed cell death; TAS:Reactome.
DR   GO; GO:0002730; P:regulation of dendritic cell cytokine production; IEA:Ensembl.
DR   GO; GO:0043330; P:response to exogenous dsRNA; IDA:MGI.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0034138; P:toll-like receptor 3 signaling pathway; TAS:Reactome.
DR   GO; GO:0034142; P:toll-like receptor 4 signaling pathway; TAS:Reactome.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0035666; P:TRIF-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 3.40.50.10140; -; 1.
DR   Gene3D; 3.80.10.10; -; 5.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR000372; LRRNT.
DR   InterPro; IPR000157; TIR_dom.
DR   InterPro; IPR027173; TLR3.
DR   PANTHER; PTHR24365:SF5; PTHR24365:SF5; 2.
DR   Pfam; PF00560; LRR_1; 1.
DR   Pfam; PF13855; LRR_8; 5.
DR   Pfam; PF01582; TIR; 1.
DR   SMART; SM00369; LRR_TYP; 2.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00013; LRRNT; 1.
DR   SMART; SM00255; TIR; 1.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF52200; SSF52200; 1.
DR   PROSITE; PS51450; LRR; 19.
DR   PROSITE; PS50104; TIR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Endoplasmic reticulum; Endosome; Glycoprotein; Immunity;
KW   Inflammatory response; Innate immunity; Leucine-rich repeat; Membrane;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   RNA-binding; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     23       {ECO:0000269|PubMed:15340161}.
FT   CHAIN        24    904       Toll-like receptor 3.
FT                                /FTId=PRO_0000034715.
FT   TOPO_DOM     24    704       Lumenal. {ECO:0000255}.
FT   TRANSMEM    705    725       Helical. {ECO:0000255}.
FT   TOPO_DOM    726    904       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       24     51       LRRNT.
FT   REPEAT       52     73       LRR 1.
FT   REPEAT       76     97       LRR 2.
FT   REPEAT      100    121       LRR 3.
FT   REPEAT      124    145       LRR 4.
FT   REPEAT      148    168       LRR 5.
FT   REPEAT      172    193       LRR 6.
FT   REPEAT      198    219       LRR 7.
FT   REPEAT      222    244       LRR 8.
FT   REPEAT      249    270       LRR 9.
FT   REPEAT      275    296       LRR 10.
FT   REPEAT      299    320       LRR 11.
FT   REPEAT      323    344       LRR 12.
FT   REPEAT      356    377       LRR 13.
FT   REPEAT      380    400       LRR 14.
FT   REPEAT      408    429       LRR 15.
FT   REPEAT      432    454       LRR 16.
FT   REPEAT      465    486       LRR 17.
FT   REPEAT      507    528       LRR 18.
FT   REPEAT      531    552       LRR 19.
FT   REPEAT      563    584       LRR 20.
FT   REPEAT      587    608       LRR 21.
FT   REPEAT      611    632       LRR 22.
FT   DOMAIN      645    698       LRRCT.
FT   DOMAIN      754    896       TIR. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00204}.
FT   MOD_RES     759    759       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:17178723}.
FT   MOD_RES     858    858       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:17178723}.
FT   CARBOHYD     52     52       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16043704,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:22579623}.
FT   CARBOHYD     57     57       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD     70     70       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16043704,
FT                                ECO:0000269|PubMed:22579623}.
FT   CARBOHYD    124    124       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15961631,
FT                                ECO:0000269|PubMed:22579623}.
FT   CARBOHYD    196    196       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16043704}.
FT   CARBOHYD    247    247       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:22579623}.
FT   CARBOHYD    252    252       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15961631,
FT                                ECO:0000269|PubMed:16043704,
FT                                ECO:0000269|PubMed:22579623}.
FT   CARBOHYD    265    265       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16043704,
FT                                ECO:0000269|PubMed:22579623}.
FT   CARBOHYD    275    275       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15961631,
FT                                ECO:0000269|PubMed:16043704,
FT                                ECO:0000269|PubMed:22579623}.
FT   CARBOHYD    291    291       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15961631,
FT                                ECO:0000269|PubMed:16043704,
FT                                ECO:0000269|PubMed:22579623}.
FT   CARBOHYD    398    398       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15961631,
FT                                ECO:0000269|PubMed:16043704,
FT                                ECO:0000269|PubMed:22579623}.
FT   CARBOHYD    413    413       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15961631,
FT                                ECO:0000269|PubMed:16043704,
FT                                ECO:0000269|PubMed:22579623}.
FT   CARBOHYD    507    507       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15961631,
FT                                ECO:0000269|PubMed:16043704,
FT                                ECO:0000269|PubMed:22579623}.
FT   CARBOHYD    636    636       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16043704}.
FT   CARBOHYD    662    662       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     28     37
FT   DISULFID     95    122
FT   DISULFID    649    677
FT   DISULFID    651    696
FT   VAR_SEQ       1    277       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_054188.
FT   VARIANT     284    284       N -> I (in dbSNP:rs5743316).
FT                                /FTId=VAR_052361.
FT   VARIANT     307    307       Y -> D (in dbSNP:rs5743317).
FT                                /FTId=VAR_052362.
FT   VARIANT     412    412       L -> F (in dbSNP:rs3775291).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:18753640,
FT                                ECO:0000269|PubMed:22174453,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021976.
FT   VARIANT     554    554       P -> S (in HSE2; causes TLR3 deficiency
FT                                and predisposition to herpes simplex
FT                                encephalitis).
FT                                {ECO:0000269|PubMed:17872438}.
FT                                /FTId=VAR_054887.
FT   VARIANT     737    737       S -> T (in dbSNP:rs5743318).
FT                                /FTId=VAR_024664.
FT   MUTAGEN      95     95       C->A: Reduced response to ds-RNA.
FT                                {ECO:0000269|PubMed:16144834}.
FT   MUTAGEN     122    122       C->A: Reduced response to ds-RNA.
FT                                {ECO:0000269|PubMed:16144834}.
FT   MUTAGEN     196    196       N->G: Reduced expression levels; when
FT                                associated with R-247.
FT                                {ECO:0000269|PubMed:16144834}.
FT   MUTAGEN     247    247       N->R: Reduced response to ds-RNA. Reduced
FT                                expression levels; when associated with
FT                                G-196. {ECO:0000269|PubMed:16144834}.
FT   MUTAGEN     539    539       H->A: No effect.
FT                                {ECO:0000269|PubMed:16720699}.
FT   MUTAGEN     539    539       H->E: Loss of RNA binding. Constitutive
FT                                activation of NF-kappa-B.
FT                                {ECO:0000269|PubMed:16720699}.
FT   MUTAGEN     541    541       N->A: Loss of RNA binding. Abolishes
FT                                activation of NF-kappa-B.
FT                                {ECO:0000269|PubMed:16720699}.
FT   MUTAGEN     759    759       Y->F: Reduced activation of NF-kappa-B in
FT                                response to ds-RNA. Reduced induction of
FT                                IL-8 in response to ds-RNA. Loss of
FT                                interaction with WDFY1.
FT                                {ECO:0000269|PubMed:17178723,
FT                                ECO:0000269|PubMed:25736436}.
FT   MUTAGEN     858    858       Y->F: Loss of interaction with WDFY1.
FT                                {ECO:0000269|PubMed:25736436}.
FT   CONFLICT    290    290       G -> R (in Ref. 5; BAG36884).
FT                                {ECO:0000305}.
FT   CONFLICT    575    575       D -> N (in Ref. 8; AAH94737).
FT                                {ECO:0000305}.
FT   CONFLICT    605    605       V -> A (in Ref. 5; BAG36884).
FT                                {ECO:0000305}.
FT   CONFLICT    663    663       E -> G (in Ref. 5; BAG36884).
FT                                {ECO:0000305}.
FT   STRAND       31     36       {ECO:0000244|PDB:1ZIW}.
FT   STRAND       47     49       {ECO:0000244|PDB:2A0Z}.
FT   STRAND       54     57       {ECO:0000244|PDB:1ZIW}.
FT   HELIX        68     74       {ECO:0000244|PDB:1ZIW}.
FT   STRAND       78     81       {ECO:0000244|PDB:1ZIW}.
FT   HELIX        94     97       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      103    105       {ECO:0000244|PDB:1ZIW}.
FT   TURN        118    121       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      126    129       {ECO:0000244|PDB:1ZIW}.
FT   TURN        142    145       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      151    153       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      166    168       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      175    177       {ECO:0000244|PDB:1ZIW}.
FT   HELIX       188    191       {ECO:0000244|PDB:1ZIW}.
FT   HELIX       192    194       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      198    203       {ECO:0000244|PDB:1ZIW}.
FT   HELIX       216    219       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      220    223       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      225    227       {ECO:0000244|PDB:1ZIW}.
FT   HELIX       234    245       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      252    254       {ECO:0000244|PDB:1ZIW}.
FT   TURN        265    268       {ECO:0000244|PDB:1ZIW}.
FT   HELIX       269    273       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      278    280       {ECO:0000244|PDB:1ZIW}.
FT   TURN        291    296       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      302    304       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      310    313       {ECO:0000244|PDB:1ZIW}.
FT   TURN        315    320       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      326    328       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      338    340       {ECO:0000244|PDB:2A0Z}.
FT   TURN        348    353       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      359    361       {ECO:0000244|PDB:1ZIW}.
FT   TURN        372    377       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      383    385       {ECO:0000244|PDB:1ZIW}.
FT   TURN        398    401       {ECO:0000244|PDB:1ZIW}.
FT   HELIX       402    404       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      411    413       {ECO:0000244|PDB:1ZIW}.
FT   TURN        424    429       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      435    437       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      444    446       {ECO:0000244|PDB:1ZIW}.
FT   HELIX       450    452       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      460    462       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      467    470       {ECO:0000244|PDB:1ZIW}.
FT   TURN        473    478       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      484    486       {ECO:0000244|PDB:1ZIW}.
FT   TURN        501    504       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      510    512       {ECO:0000244|PDB:1ZIW}.
FT   TURN        523    528       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      534    536       {ECO:0000244|PDB:1ZIW}.
FT   HELIX       543    546       {ECO:0000244|PDB:1ZIW}.
FT   TURN        557    560       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      566    568       {ECO:0000244|PDB:1ZIW}.
FT   TURN        579    584       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      590    592       {ECO:0000244|PDB:1ZIW}.
FT   TURN        603    608       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      614    616       {ECO:0000244|PDB:1ZIW}.
FT   HELIX       627    634       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      638    641       {ECO:0000244|PDB:1ZIW}.
FT   STRAND      655    658       {ECO:0000244|PDB:1ZIW}.
FT   HELIX       671    674       {ECO:0000244|PDB:2A0Z}.
FT   STRAND      676    680       {ECO:0000244|PDB:2A0Z}.
FT   HELIX       688    690       {ECO:0000244|PDB:2A0Z}.
FT   HELIX       700    727       {ECO:0000244|PDB:2MK9}.
SQ   SEQUENCE   904 AA;  103829 MW;  034E05ECA7A4D2F7 CRC64;
     MRQTLPCIYF WGGLLPFGML CASSTTKCTV SHEVADCSHL KLTQVPDDLP TNITVLNLTH
     NQLRRLPAAN FTRYSQLTSL DVGFNTISKL EPELCQKLPM LKVLNLQHNE LSQLSDKTFA
     FCTNLTELHL MSNSIQKIKN NPFVKQKNLI TLDLSHNGLS STKLGTQVQL ENLQELLLSN
     NKIQALKSEE LDIFANSSLK KLELSSNQIK EFSPGCFHAI GRLFGLFLNN VQLGPSLTEK
     LCLELANTSI RNLSLSNSQL STTSNTTFLG LKWTNLTMLD LSYNNLNVVG NDSFAWLPQL
     EYFFLEYNNI QHLFSHSLHG LFNVRYLNLK RSFTKQSISL ASLPKIDDFS FQWLKCLEHL
     NMEDNDIPGI KSNMFTGLIN LKYLSLSNSF TSLRTLTNET FVSLAHSPLH ILNLTKNKIS
     KIESDAFSWL GHLEVLDLGL NEIGQELTGQ EWRGLENIFE IYLSYNKYLQ LTRNSFALVP
     SLQRLMLRRV ALKNVDSSPS PFQPLRNLTI LDLSNNNIAN INDDMLEGLE KLEILDLQHN
     NLARLWKHAN PGGPIYFLKG LSHLHILNLE SNGFDEIPVE VFKDLFELKI IDLGLNNLNT
     LPASVFNNQV SLKSLNLQKN LITSVEKKVF GPAFRNLTEL DMRFNPFDCT CESIAWFVNW
     INETHTNIPE LSSHYLCNTP PHYHGFPVRL FDTSSCKDSA PFELFFMINT SILLIFIFIV
     LLIHFEGWRI SFYWNVSVHR VLGFKEIDRQ TEQFEYAAYI IHAYKDKDWV WEHFSSMEKE
     DQSLKFCLEE RDFEAGVFEL EAIVNSIKRS RKIIFVITHH LLKDPLCKRF KVHHAVQQAI
     EQNLDSIILV FLEEIPDYKL NHALCLRRGM FKSHCILNWP VQKERIGAFR HKLQVALGSK
     NSVH
//
ID   ACE2_HUMAN              Reviewed;         805 AA.
AC   Q9BYF1; C7ECU1; Q6UWP0; Q86WT0; Q9NRA7; Q9UFZ6;
DT   02-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   02-AUG-2005, sequence version 2.
DT   20-JAN-2016, entry version 145.
DE   RecName: Full=Angiotensin-converting enzyme 2;
DE            EC=3.4.17.23;
DE   AltName: Full=ACE-related carboxypeptidase;
DE   AltName: Full=Angiotensin-converting enzyme homolog;
DE            Short=ACEH;
DE   AltName: Full=Metalloprotease MPROT15;
DE   Contains:
DE     RecName: Full=Processed angiotensin-converting enzyme 2;
DE   Flags: Precursor;
GN   Name=ACE2; ORFNames=UNQ868/PRO1885;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, FUNCTION,
RP   AND ENZYME REGULATION.
RC   TISSUE=Heart;
RX   PubMed=10969042; DOI=10.1161/01.RES.87.5.e1;
RA   Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M.,
RA   Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R.,
RA   Breitbart R.E., Acton S.;
RT   "A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2)
RT   converts angiotensin I to angiotensin 1-9.";
RL   Circ. Res. 87:E1-E9(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY,
RP   GLYCOSYLATION, FUNCTION, AND ENZYME REGULATION.
RC   TISSUE=Lymphoma;
RX   PubMed=10924499; DOI=10.1074/jbc.M002615200;
RA   Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G.,
RA   Turner A.J.;
RT   "A human homolog of angiotensin-converting enzyme. Cloning and
RT   functional expression as a captopril-insensitive carboxypeptidase.";
RL   J. Biol. Chem. 275:33238-33243(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY,
RP   SUBCELLULAR LOCATION, AND ENZYME REGULATION.
RC   TISSUE=Testis;
RX   PubMed=15231706; DOI=10.1210/en.2004-0443;
RA   Douglas G.C., O'Bryan M.K., Hedger M.P., Lee D.K.L., Yarski M.A.,
RA   Smith A.I., Lew R.A.;
RT   "The novel angiotensin-converting enzyme (ACE) homolog, ACE2, is
RT   selectively expressed by adult Leydig cells of the testis.";
RL   Endocrinology 145:4703-4711(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT SER-638.
RC   TISSUE=Lung, and Testis;
RX   PubMed=15937940; DOI=10.1002/ajmg.a.30779;
RA   Itoyama S., Keicho N., Hijikata M., Quy T., Phi N.C., Long H.T.,
RA   Ha L.D., Ban V.V., Matsushita I., Yanai H., Kirikae F., Kirikae T.,
RA   Kuratsuji T., Sasazuki T.;
RT   "Identification of an alternative 5'-untranslated exon and new
RT   polymorphisms of angiotensin-converting enzyme 2 gene: lack of
RT   association with SARS in the Vietnamese population.";
RL   Am. J. Med. Genet. A 136:52-57(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Suzuki Y., Watanabe M., Sugano S.;
RT   "Cloning, expression analysis and chromosomal localization of a novel
RT   ACE like enzyme.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Southan C., Burgess N.;
RT   "MPROT15 polypeptide and MPROT15 polynucleotide.";
RL   Patent number JP11318472, 24-NOV-1999.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Li K.K.B., Yip C.W., Hon C.C., Lam C.Y., Leung F.C.C.;
RT   "Comparative susceptibility to SARS-CoV mediated by ACE2 protein of 15
RT   different species.";
RL   Submitted (JUN-2009) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ARG-26.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2-805 (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [13]
RP   PROTEIN SEQUENCE OF 679-689, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   INTERACTION WITH ITGB1.
RX   PubMed=15276642; DOI=10.1016/j.bbadis.2004.05.005;
RA   Lin Q., Keller R.S., Weaver B., Zisman L.S.;
RT   "Interaction of ACE2 and integrin beta1 in failing human heart.";
RL   Biochim. Biophys. Acta 1689:175-178(2004).
RN   [14]
RP   TISSUE SPECIFICITY.
RX   PubMed=12459472; DOI=10.1016/S0014-5793(02)03640-2;
RA   Harmer D., Gilbert M., Borman R., Clark K.L.;
RT   "Quantitative mRNA expression profiling of ACE 2, a novel homologue of
RT   angiotensin converting enzyme.";
RL   FEBS Lett. 532:107-110(2002).
RN   [15]
RP   BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION, AND COFACTOR.
RX   PubMed=11815627; DOI=10.1074/jbc.M200581200;
RA   Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J.,
RA   Godbout K., Parsons T., Baronas E., Hsieh F., Acton S., Patane M.A.,
RA   Nichols A., Tummino P.;
RT   "Hydrolysis of biological peptides by human angiotensin-converting
RT   enzyme-related carboxypeptidase.";
RL   J. Biol. Chem. 277:14838-14843(2002).
RN   [16]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH SARS-COV SPIKE
RP   GLYCOPROTEIN, GLYCOSYLATION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=14647384; DOI=10.1038/nature02145;
RA   Li W., Moore M.J., Vasilieva N., Sui J., Wong S.-K., Berne M.A.,
RA   Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H.,
RA   Farzan M.;
RT   "Angiotensin-converting enzyme 2 is a functional receptor for the SARS
RT   coronavirus.";
RL   Nature 426:450-454(2003).
RN   [17]
RP   INDUCTION.
RX   PubMed=15151696; DOI=10.1186/1741-7015-2-19;
RA   Goulter A.B., Goddard M.J., Allen J.C., Clark K.L.;
RT   "ACE2 gene expression is up-regulated in the human failing heart.";
RL   BMC Med. 2:19-19(2004).
RN   [18]
RP   TISSUE SPECIFICITY.
RX   PubMed=15141377; DOI=10.1002/path.1570;
RA   Hamming I., Timens W., Bulthuis M.L.C., Lely A.T., Navis G.J.,
RA   van Goor H.;
RT   "Tissue distribution of ACE2 protein, the functional receptor for SARS
RT   coronavirus. A first step in understanding SARS pathogenesis.";
RL   J. Pathol. 203:631-637(2004).
RN   [19]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH SARS-COV SPIKE
RP   GLYCOPROTEIN.
RX   PubMed=15452268; DOI=10.1128/JVI.78.20.11429-11433.2004;
RA   Li W., Greenough T.C., Moore M.J., Vasilieva N., Somasundaran M.,
RA   Sullivan J.L., Farzan M., Choe H.;
RT   "Efficient replication of severe acute respiratory syndrome
RT   coronavirus in mouse cells is limited by murine angiotensin-converting
RT   enzyme 2.";
RL   J. Virol. 78:11429-11433(2004).
RN   [20]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-90.
RC   TISSUE=Bile;
RX   PubMed=15084671; DOI=10.1074/mcp.M400015-MCP200;
RA   Kristiansen T.Z., Bunkenborg J., Gronborg M., Molina H.,
RA   Thuluvath P.J., Argani P., Goggins M.G., Maitra A., Pandey A.;
RT   "A proteomic analysis of human bile.";
RL   Mol. Cell. Proteomics 3:715-728(2004).
RN   [21]
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=15671045; DOI=10.1093/eurheartj/ehi114;
RA   Burrell L.M., Risvanis J., Kubota E., Dean R.G., MacDonald P.S.,
RA   Lu S., Tikellis C., Grant S.L., Lew R.A., Smith A.I., Cooper M.E.,
RA   Johnston C.I.;
RT   "Myocardial infarction increases ACE2 expression in rat and humans.";
RL   Eur. Heart J. 26:369-375(2005).
RN   [22]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH SARS-COV SPIKE
RP   GLYCOPROTEIN, AND MUTAGENESIS.
RX   PubMed=15791205; DOI=10.1038/sj.emboj.7600640;
RA   Li W., Zhang C., Sui J., Kuhn J.H., Moore M.J., Luo S., Wong S.-K.,
RA   Huang I.-C., Xu K., Vasilieva N., Murakami A., He Y., Marasco W.A.,
RA   Guan Y., Choe H., Farzan M.;
RT   "Receptor and viral determinants of SARS-coronavirus adaptation to
RT   human ACE2.";
RL   EMBO J. 24:1634-1643(2005).
RN   [23]
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=15983030; DOI=10.1074/jbc.M505111200;
RA   Lambert D.W., Yarski M., Warner F.J., Thornhill P., Parkin E.T.,
RA   Smith A.I., Hooper N.M., Turner A.J.;
RT   "Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated
RT   ectodomain shedding of the severe-acute respiratory syndrome-
RT   coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2
RT   (ACE2).";
RL   J. Biol. Chem. 280:30113-30119(2005).
RN   [24]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HCOV-NL63 SPIKE
RP   GLYCOPROTEIN.
RX   PubMed=15897467; DOI=10.1073/pnas.0409465102;
RA   Hofmann H., Pyrc K., van der Hoek L., Geier M., Berkhout B.,
RA   Poehlmann S.;
RT   "Human coronavirus NL63 employs the severe acute respiratory syndrome
RT   coronavirus receptor for cellular entry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:7988-7993(2005).
RN   [25]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-546.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [26]
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=21563828; DOI=10.1021/bi200525y;
RA   Lai Z.W., Hanchapola I., Steer D.L., Smith A.I.;
RT   "Angiotensin-converting enzyme 2 ectodomain shedding cleavage-site
RT   identification: determinants and constraints.";
RL   Biochemistry 50:5182-5194(2011).
RN   [27]
RP   SUBCELLULAR LOCATION, PROTEOLYTIC CLEAVAGE, AND INTERACTION WITH
RP   TMPRSS2.
RX   PubMed=21068237; DOI=10.1128/JVI.02062-10;
RA   Shulla A., Heald-Sargent T., Subramanya G., Zhao J., Perlman S.,
RA   Gallagher T.;
RT   "A transmembrane serine protease is linked to the severe acute
RT   respiratory syndrome coronavirus receptor and activates virus entry.";
RL   J. Virol. 85:873-882(2011).
RN   [28]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PROTEOLYTIC CLEAVAGE.
RX   PubMed=24227843; DOI=10.1128/JVI.02202-13;
RA   Heurich A., Hofmann-Winkler H., Gierer S., Liepold T., Jahn O.,
RA   Poehlmann S.;
RT   "TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by
RT   TMPRSS2 augments entry driven by the severe acute respiratory syndrome
RT   coronavirus spike protein.";
RL   J. Virol. 88:1293-1307(2014).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 19-615, X-RAY CRYSTALLOGRAPHY
RP   (3.0 ANGSTROMS) OF 19-615 IN COMPLEX WITH MLN-4760, DISULFIDE BONDS,
RP   AND GLYCOSYLATION AT ASN-53; ASN-90; ASN-103; ASN-322; ASN-432 AND
RP   ASN-546.
RX   PubMed=14754895; DOI=10.1074/jbc.M311191200;
RA   Towler P., Staker B., Prasad S.G., Menon S., Tang J., Parsons T.,
RA   Ryan D., Fisher M., Williams D., Dales N.A., Patane M.A.,
RA   Pantoliano M.W.;
RT   "ACE2 X-ray structures reveal a large hinge-bending motion important
RT   for inhibitor binding and catalysis.";
RL   J. Biol. Chem. 279:17996-18007(2004).
CC   -!- FUNCTION: Carboxypeptidase which converts angiotensin I to
CC       angiotensin 1-9, a peptide of unknown function, and angiotensin II
CC       to angiotensin 1-7, a vasodilator. Also able to hydrolyze apelin-
CC       13 and dynorphin-13 with high efficiency. May be an important
CC       regulator of heart function. {ECO:0000269|PubMed:10924499,
CC       ECO:0000269|PubMed:10969042, ECO:0000269|PubMed:14647384,
CC       ECO:0000269|PubMed:24227843}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for SARS
CC       coronavirus/SARS-CoV and human coronavirus NL63/HCoV-NL63.
CC       {ECO:0000269|PubMed:14647384, ECO:0000269|PubMed:15452268,
CC       ECO:0000269|PubMed:15791205, ECO:0000269|PubMed:15897467}.
CC   -!- CATALYTIC ACTIVITY: Angiotensin II + H(2)O = angiotensin-(1-7) +
CC       L-phenylalanine.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:11815627};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:11815627};
CC   -!- COFACTOR:
CC       Name=chloride; Xref=ChEBI:CHEBI:17996;
CC         Evidence={ECO:0000269|PubMed:11815627};
CC       Note=Binds 1 Cl(-) ion per subunit. {ECO:0000269|PubMed:11815627};
CC   -!- ENZYME REGULATION: Activated by chloride and fluoride, but not
CC       bromide. Inhibited by MLN-4760, cFP_Leu, and EDTA, but not by the
CC       ACE inhibitors linosipril, captopril and enalaprilat.
CC       {ECO:0000269|PubMed:10924499, ECO:0000269|PubMed:10969042,
CC       ECO:0000269|PubMed:11815627, ECO:0000269|PubMed:15231706}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=6.9 uM for angiotensin I {ECO:0000269|PubMed:11815627};
CC         KM=2 uM for angiotensin II {ECO:0000269|PubMed:11815627};
CC         KM=6.8 uM for apelin-13 {ECO:0000269|PubMed:11815627};
CC         KM=5.5 uM for dynorphin-13 {ECO:0000269|PubMed:11815627};
CC       pH dependence:
CC         Optimum pH is 6.5 in the presence of 1 M NaCl. Active from pH 6
CC         to 9. {ECO:0000269|PubMed:11815627};
CC   -!- SUBUNIT: Interacts with ITGB1. Interacts with the catalytically
CC       active form of TMPRSS2. (Microbial infection) Interacts with SARS
CC       coronavirus/SARS-CoV and human coronavirus NL63/HCoV-NL63 spike
CC       glycoprotein (PubMed:14647384, PubMed:15452268, PubMed:15791205,
CC       PubMed:15897467). {ECO:0000269|PubMed:14647384,
CC       ECO:0000269|PubMed:14754895, ECO:0000269|PubMed:15276642,
CC       ECO:0000269|PubMed:15452268, ECO:0000269|PubMed:15791205,
CC       ECO:0000269|PubMed:15897467, ECO:0000269|PubMed:21068237}.
CC   -!- SUBCELLULAR LOCATION: Processed angiotensin-converting enzyme 2:
CC       Secreted.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Cytoplasm {ECO:0000250}. Note=Detected in both cell
CC       membrane and cytoplasm in neurons. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9BYF1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BYF1-2; Sequence=VSP_014901, VSP_014902;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in endothelial cells from small and
CC       large arteries, and in arterial smooth muscle cells. Expressed in
CC       lung alveolar epithelial cells, enterocytes of the small
CC       intestine, Leydig cells and Sertoli cells (at protein level).
CC       Expressed in heart, kidney, testis, and gastrointestinal system.
CC       {ECO:0000269|PubMed:10924499, ECO:0000269|PubMed:10969042,
CC       ECO:0000269|PubMed:12459472, ECO:0000269|PubMed:15141377,
CC       ECO:0000269|PubMed:15231706, ECO:0000269|PubMed:15671045}.
CC   -!- INDUCTION: Up-regulated in failing heart.
CC       {ECO:0000269|PubMed:15151696, ECO:0000269|PubMed:15671045}.
CC   -!- PTM: N-glycosylation on Asn-90 may limit SARS infectivity.
CC       {ECO:0000269|PubMed:10924499, ECO:0000269|PubMed:14647384,
CC       ECO:0000269|PubMed:14754895, ECO:0000269|PubMed:15084671,
CC       ECO:0000269|PubMed:19159218}.
CC   -!- PTM: Proteolytic cleavage by ADAM17 generates a secreted form.
CC       Also cleaved by serine proteases: TMPRSS2, TMPRSS11D and
CC       HPN/TMPRSS1. {ECO:0000269|PubMed:15983030,
CC       ECO:0000269|PubMed:21068237, ECO:0000269|PubMed:21563828,
CC       ECO:0000269|PubMed:24227843}.
CC   -!- SIMILARITY: Belongs to the peptidase M2 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/ace2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF291820; AAF99721.1; -; mRNA.
DR   EMBL; AF241254; AAF78220.1; -; mRNA.
DR   EMBL; AY623811; AAT45083.1; -; mRNA.
DR   EMBL; AB193259; BAD99266.1; -; mRNA.
DR   EMBL; AB193260; BAD99267.1; -; mRNA.
DR   EMBL; AB046569; BAB40370.1; -; mRNA.
DR   EMBL; E39033; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; GQ262784; ACT66268.1; -; mRNA.
DR   EMBL; AY358714; AAQ89076.1; -; mRNA.
DR   EMBL; AY217547; AAO25651.1; -; Genomic_DNA.
DR   EMBL; CH471074; EAW98892.1; -; Genomic_DNA.
DR   EMBL; BC039902; AAH39902.1; -; mRNA.
DR   EMBL; BC048094; AAH48094.2; -; mRNA.
DR   EMBL; AL110224; CAB53682.1; -; mRNA.
DR   CCDS; CCDS14169.1; -. [Q9BYF1-1]
DR   PIR; T14762; T14762.
DR   RefSeq; NP_068576.1; NM_021804.2. [Q9BYF1-1]
DR   UniGene; Hs.178098; -.
DR   PDB; 1R42; X-ray; 2.20 A; A=1-615.
DR   PDB; 1R4L; X-ray; 3.00 A; A=1-615.
DR   PDB; 1XJP; Model; -; B=19-615.
DR   PDB; 2AJF; X-ray; 2.90 A; A/B=19-615.
DR   PDB; 3D0G; X-ray; 2.80 A; A/B=56-615.
DR   PDB; 3D0H; X-ray; 3.10 A; A/B=56-615.
DR   PDB; 3D0I; X-ray; 2.90 A; A/B=56-615.
DR   PDB; 3KBH; X-ray; 3.31 A; A/B/C/D=19-615.
DR   PDB; 3SCI; X-ray; 2.90 A; A/B=19-615.
DR   PDB; 3SCJ; X-ray; 3.00 A; A/B=19-615.
DR   PDB; 3SCK; X-ray; 3.00 A; A/B=83-615.
DR   PDB; 3SCL; X-ray; 3.00 A; A/B=83-615.
DR   PDBsum; 1R42; -.
DR   PDBsum; 1R4L; -.
DR   PDBsum; 1XJP; -.
DR   PDBsum; 2AJF; -.
DR   PDBsum; 3D0G; -.
DR   PDBsum; 3D0H; -.
DR   PDBsum; 3D0I; -.
DR   PDBsum; 3KBH; -.
DR   PDBsum; 3SCI; -.
DR   PDBsum; 3SCJ; -.
DR   PDBsum; 3SCK; -.
DR   PDBsum; 3SCL; -.
DR   ProteinModelPortal; Q9BYF1; -.
DR   SMR; Q9BYF1; 19-615.
DR   BioGrid; 121864; 6.
DR   DIP; DIP-44689N; -.
DR   IntAct; Q9BYF1; 1.
DR   MINT; MINT-4538816; -.
DR   STRING; 9606.ENSP00000252519; -.
DR   BindingDB; Q9BYF1; -.
DR   ChEMBL; CHEMBL2096989; -.
DR   DrugBank; DB00722; Lisinopril.
DR   DrugBank; DB00691; Moexipril.
DR   GuidetoPHARMACOLOGY; 1614; -.
DR   MEROPS; M02.006; -.
DR   iPTMnet; Q9BYF1; -.
DR   PhosphoSite; Q9BYF1; -.
DR   BioMuta; ACE2; -.
DR   DMDM; 71658783; -.
DR   PaxDb; Q9BYF1; -.
DR   PRIDE; Q9BYF1; -.
DR   Ensembl; ENST00000252519; ENSP00000252519; ENSG00000130234. [Q9BYF1-1]
DR   Ensembl; ENST00000427411; ENSP00000389326; ENSG00000130234. [Q9BYF1-1]
DR   GeneID; 59272; -.
DR   KEGG; hsa:59272; -.
DR   UCSC; uc004cxa.1; human. [Q9BYF1-1]
DR   CTD; 59272; -.
DR   GeneCards; ACE2; -.
DR   HGNC; HGNC:13557; ACE2.
DR   HPA; CAB026174; -.
DR   HPA; HPA000288; -.
DR   MIM; 300335; gene.
DR   neXtProt; NX_Q9BYF1; -.
DR   PharmGKB; PA425; -.
DR   eggNOG; KOG3690; Eukaryota.
DR   eggNOG; ENOG410XPJ3; LUCA.
DR   GeneTree; ENSGT00520000055576; -.
DR   HOGENOM; HOG000292210; -.
DR   HOVERGEN; HBG000265; -.
DR   InParanoid; Q9BYF1; -.
DR   KO; K09708; -.
DR   OMA; CNPNNPQ; -.
DR   OrthoDB; EOG76HQ13; -.
DR   PhylomeDB; Q9BYF1; -.
DR   TreeFam; TF312861; -.
DR   BRENDA; 3.4.15.1; 2681.
DR   BRENDA; 3.4.17.23; 2681.
DR   Reactome; R-HSA-2022377; Metabolism of Angiotensinogen to Angiotensins.
DR   SABIO-RK; Q9BYF1; -.
DR   ChiTaRS; ACE2; human.
DR   EvolutionaryTrace; Q9BYF1; -.
DR   GeneWiki; Angiotensin-converting_enzyme_2; -.
DR   GenomeRNAi; 59272; -.
DR   NextBio; 65154; -.
DR   PMAP-CutDB; Q9BYF1; -.
DR   PRO; PR:Q9BYF1; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; Q9BYF1; -.
DR   CleanEx; HS_ACE2; -.
DR   Genevisible; Q9BYF1; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0045121; C:membrane raft; TAS:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0004180; F:carboxypeptidase activity; IDA:UniProtKB.
DR   GO; GO:0004175; F:endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0001618; F:virus receptor activity; IMP:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; TAS:BHF-UCL.
DR   GO; GO:0002005; P:angiotensin catabolic process in blood; IC:BHF-UCL.
DR   GO; GO:0002003; P:angiotensin maturation; TAS:Reactome.
DR   GO; GO:0003051; P:angiotensin-mediated drinking behavior; IMP:BHF-UCL.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0060452; P:positive regulation of cardiac muscle contraction; IEA:Ensembl.
DR   GO; GO:1903598; P:positive regulation of gap junction assembly; IMP:BHF-UCL.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IC:BHF-UCL.
DR   GO; GO:0032800; P:receptor biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0046813; P:receptor-mediated virion attachment to host cell; IDA:BHF-UCL.
DR   GO; GO:1903779; P:regulation of cardiac conduction; IMP:BHF-UCL.
DR   GO; GO:0042127; P:regulation of cell proliferation; TAS:BHF-UCL.
DR   GO; GO:0001817; P:regulation of cytokine production; IC:BHF-UCL.
DR   GO; GO:0050727; P:regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0003081; P:regulation of systemic arterial blood pressure by renin-angiotensin; IMP:BHF-UCL.
DR   GO; GO:0019229; P:regulation of vasoconstriction; IC:BHF-UCL.
DR   GO; GO:0042312; P:regulation of vasodilation; IC:BHF-UCL.
DR   GO; GO:0015827; P:tryptophan transport; IEA:Ensembl.
DR   GO; GO:0046718; P:viral entry into host cell; TAS:UniProtKB.
DR   InterPro; IPR031588; Collectrin_dom.
DR   InterPro; IPR001548; Peptidase_M2.
DR   PANTHER; PTHR10514; PTHR10514; 2.
DR   Pfam; PF16959; Collectrin; 1.
DR   Pfam; PF01401; Peptidase_M2; 1.
DR   PRINTS; PR00791; PEPDIPTASEA.
DR   PROSITE; PS00142; ZINC_PROTEASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Carboxypeptidase; Cell membrane;
KW   Chloride; Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Host cell receptor for virus entry;
KW   Host-virus interaction; Hydrolase; Membrane; Metal-binding;
KW   Metalloprotease; Polymorphism; Protease; Receptor; Reference proteome;
KW   Secreted; Signal; Transmembrane; Transmembrane helix; Zinc.
FT   SIGNAL        1     17       {ECO:0000255}.
FT   CHAIN        18    805       Angiotensin-converting enzyme 2.
FT                                /FTId=PRO_0000028570.
FT   CHAIN        18    708       Processed angiotensin-converting enzyme
FT                                2.
FT                                /FTId=PRO_0000292268.
FT   TOPO_DOM     18    740       Extracellular. {ECO:0000255}.
FT   TRANSMEM    741    761       Helical. {ECO:0000255}.
FT   TOPO_DOM    762    805       Cytoplasmic. {ECO:0000255}.
FT   REGION       30     41       Interaction with SARS-CoV spike
FT                                glycoprotein.
FT   REGION       82     84       Interaction with SARS-CoV spike
FT                                glycoprotein.
FT   REGION      353    357       Interaction with SARS-CoV spike
FT                                glycoprotein.
FT   REGION      652    659       Essential for cleavage by ADAM17.
FT   REGION      697    716       Essential for cleavage by TMPRSS11D and
FT                                TMPRSS2.
FT   ACT_SITE    375    375
FT   ACT_SITE    505    505
FT   METAL       374    374       Zinc; catalytic.
FT   METAL       378    378       Zinc; catalytic.
FT   METAL       402    402       Zinc; catalytic.
FT   BINDING     169    169       Chloride.
FT   BINDING     273    273       Substrate.
FT   BINDING     345    345       Substrate.
FT   BINDING     346    346       Substrate; via carbonyl oxygen.
FT   BINDING     371    371       Substrate.
FT   BINDING     477    477       Chloride.
FT   BINDING     481    481       Chloride.
FT   BINDING     515    515       Substrate.
FT   CARBOHYD     53     53       N-linked (GlcNAc...).
FT                                {ECO:0000305|PubMed:14754895}.
FT   CARBOHYD     90     90       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:14754895,
FT                                ECO:0000269|PubMed:15084671}.
FT   CARBOHYD    103    103       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:14754895}.
FT   CARBOHYD    322    322       N-linked (GlcNAc...).
FT                                {ECO:0000305|PubMed:14754895}.
FT   CARBOHYD    432    432       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:14754895}.
FT   CARBOHYD    546    546       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:14754895,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    690    690       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    133    141       {ECO:0000269|PubMed:14754895}.
FT   DISULFID    344    361       {ECO:0000269|PubMed:14754895}.
FT   DISULFID    530    542       {ECO:0000269|PubMed:14754895}.
FT   VAR_SEQ     555    555       F -> L (in isoform 2).
FT                                {ECO:0000303|PubMed:12975309}.
FT                                /FTId=VSP_014901.
FT   VAR_SEQ     556    805       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:12975309}.
FT                                /FTId=VSP_014902.
FT   VARIANT      26     26       K -> R (in dbSNP:rs4646116).
FT                                {ECO:0000269|Ref.9}.
FT                                /FTId=VAR_023082.
FT   VARIANT     638    638       N -> S (in dbSNP:rs183135788).
FT                                {ECO:0000269|PubMed:15937940}.
FT                                /FTId=VAR_023083.
FT   MUTAGEN      24     26       QAK->KAE: Slightly inhibits interaction
FT                                with SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN      31     31       K->D: Abolishes interaction with SARS-CoV
FT                                spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN      37     37       E->A: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN      38     38       D->A: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN      41     41       Y->A: Strongly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN      68     68       K->D: Slightly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN      82     84       MYP->NFS: Inhibits interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     110    110       E->P: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     135    136       PD->SM: No effect on interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     160    160       E->R: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     192    192       R->D: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     219    219       R->D: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     239    239       H->Q: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     309    309       K->D: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     312    312       E->A: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     324    324       T->A: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     338    340       NVQ->DDR: No effect on interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     350    350       D->A: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     353    353       K->H,A,D: Abolishes interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     355    355       D->A: Strongly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     357    357       R->A: Strongly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     359    359       L->K,A: No effect on interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     383    383       M->A: Slightly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     389    389       P->A: Slightly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     393    393       R->A: Slightly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     425    427       SPD->PSN: Slightly inhibits interaction
FT                                with SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     465    467       KGE->QDK: No effect on interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     559    559       R->S: Slightly inhibits interaction with
FT                                SARS-CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   MUTAGEN     603    603       F->T: No effect on interaction with SARS-
FT                                CoV spike glycoprotein.
FT                                {ECO:0000269|PubMed:15791205}.
FT   CONFLICT     18     18       Q -> H (in Ref. 12; CAB53682).
FT                                {ECO:0000305}.
FT   CONFLICT    508    508       N -> D (in Ref. 8; AAQ89076).
FT                                {ECO:0000305}.
FT   CONFLICT    631    631       K -> R (in Ref. 5; BAB40370).
FT                                {ECO:0000305}.
FT   HELIX        23     52       {ECO:0000244|PDB:1R42}.
FT   HELIX        56     77       {ECO:0000244|PDB:1R42}.
FT   TURN         78     82       {ECO:0000244|PDB:1R42}.
FT   HELIX        85     87       {ECO:0000244|PDB:3D0G}.
FT   HELIX        91    100       {ECO:0000244|PDB:1R42}.
FT   HELIX       104    107       {ECO:0000244|PDB:1R42}.
FT   HELIX       110    129       {ECO:0000244|PDB:1R42}.
FT   STRAND      131    134       {ECO:0000244|PDB:1R42}.
FT   STRAND      137    143       {ECO:0000244|PDB:1R42}.
FT   TURN        144    146       {ECO:0000244|PDB:1R42}.
FT   HELIX       148    154       {ECO:0000244|PDB:1R42}.
FT   HELIX       158    171       {ECO:0000244|PDB:1R42}.
FT   HELIX       173    193       {ECO:0000244|PDB:1R42}.
FT   STRAND      196    198       {ECO:0000244|PDB:1R4L}.
FT   HELIX       199    204       {ECO:0000244|PDB:1R42}.
FT   TURN        205    207       {ECO:0000244|PDB:1R42}.
FT   TURN        213    215       {ECO:0000244|PDB:1R42}.
FT   HELIX       220    251       {ECO:0000244|PDB:1R42}.
FT   TURN        253    255       {ECO:0000244|PDB:1R42}.
FT   STRAND      258    260       {ECO:0000244|PDB:3SCJ}.
FT   HELIX       264    266       {ECO:0000244|PDB:1R42}.
FT   STRAND      267    271       {ECO:0000244|PDB:1R42}.
FT   HELIX       276    278       {ECO:0000244|PDB:1R42}.
FT   HELIX       279    282       {ECO:0000244|PDB:1R42}.
FT   TURN        284    287       {ECO:0000244|PDB:1R42}.
FT   TURN        294    297       {ECO:0000244|PDB:1R42}.
FT   HELIX       298    300       {ECO:0000244|PDB:1R42}.
FT   HELIX       304    316       {ECO:0000244|PDB:1R42}.
FT   TURN        317    319       {ECO:0000244|PDB:1R42}.
FT   HELIX       327    330       {ECO:0000244|PDB:1R42}.
FT   STRAND      338    340       {ECO:0000244|PDB:3D0G}.
FT   STRAND      347    352       {ECO:0000244|PDB:1R42}.
FT   STRAND      355    359       {ECO:0000244|PDB:1R42}.
FT   HELIX       366    384       {ECO:0000244|PDB:1R42}.
FT   TURN        385    387       {ECO:0000244|PDB:1R42}.
FT   HELIX       390    392       {ECO:0000244|PDB:1R42}.
FT   HELIX       400    413       {ECO:0000244|PDB:1R42}.
FT   HELIX       415    420       {ECO:0000244|PDB:1R42}.
FT   TURN        422    426       {ECO:0000244|PDB:1R4L}.
FT   HELIX       432    446       {ECO:0000244|PDB:1R42}.
FT   HELIX       449    465       {ECO:0000244|PDB:1R42}.
FT   STRAND      466    468       {ECO:0000244|PDB:1R4L}.
FT   HELIX       470    472       {ECO:0000244|PDB:1R42}.
FT   HELIX       473    483       {ECO:0000244|PDB:1R42}.
FT   STRAND      486    488       {ECO:0000244|PDB:3D0G}.
FT   HELIX       499    502       {ECO:0000244|PDB:1R42}.
FT   HELIX       504    507       {ECO:0000244|PDB:1R42}.
FT   HELIX       514    531       {ECO:0000244|PDB:1R42}.
FT   TURN        532    534       {ECO:0000244|PDB:1R42}.
FT   HELIX       539    541       {ECO:0000244|PDB:1R42}.
FT   HELIX       548    558       {ECO:0000244|PDB:1R42}.
FT   TURN        559    562       {ECO:0000244|PDB:1R42}.
FT   HELIX       566    574       {ECO:0000244|PDB:1R42}.
FT   STRAND      575    578       {ECO:0000244|PDB:1R42}.
FT   HELIX       582    598       {ECO:0000244|PDB:1R42}.
FT   STRAND      600    602       {ECO:0000244|PDB:1R42}.
FT   STRAND      607    609       {ECO:0000244|PDB:1R42}.
SQ   SEQUENCE   805 AA;  92463 MW;  8EE6EB0A931550E8 CRC64;
     MSSSSWLLLS LVAVTAAQST IEEQAKTFLD KFNHEAEDLF YQSSLASWNY NTNITEENVQ
     NMNNAGDKWS AFLKEQSTLA QMYPLQEIQN LTVKLQLQAL QQNGSSVLSE DKSKRLNTIL
     NTMSTIYSTG KVCNPDNPQE CLLLEPGLNE IMANSLDYNE RLWAWESWRS EVGKQLRPLY
     EEYVVLKNEM ARANHYEDYG DYWRGDYEVN GVDGYDYSRG QLIEDVEHTF EEIKPLYEHL
     HAYVRAKLMN AYPSYISPIG CLPAHLLGDM WGRFWTNLYS LTVPFGQKPN IDVTDAMVDQ
     AWDAQRIFKE AEKFFVSVGL PNMTQGFWEN SMLTDPGNVQ KAVCHPTAWD LGKGDFRILM
     CTKVTMDDFL TAHHEMGHIQ YDMAYAAQPF LLRNGANEGF HEAVGEIMSL SAATPKHLKS
     IGLLSPDFQE DNETEINFLL KQALTIVGTL PFTYMLEKWR WMVFKGEIPK DQWMKKWWEM
     KREIVGVVEP VPHDETYCDP ASLFHVSNDY SFIRYYTRTL YQFQFQEALC QAAKHEGPLH
     KCDISNSTEA GQKLFNMLRL GKSEPWTLAL ENVVGAKNMN VRPLLNYFEP LFTWLKDQNK
     NSFVGWSTDW SPYADQSIKV RISLKSALGD KAYEWNDNEM YLFRSSVAYA MRQYFLKVKN
     QMILFGEEDV RVANLKPRIS FNFFVTAPKN VSDIIPRTEV EKAIRMSRSR INDAFRLNDN
     SLEFLGIQPT LGPPNQPPVS IWLIVFGVVM GVIVVGIVIL IFTGIRDRKK KNKARSGENP
     YASIDISKGE NNPGFQNTDD VQTSF
//
ID   HFE_HUMAN               Reviewed;         348 AA.
AC   Q30201; B2CKL0; O75929; O75930; O75931; Q17RT0; Q96KU5; Q96KU6;
AC   Q96KU7; Q96KU8; Q9HC64; Q9HC68; Q9HC70; Q9HC83;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 1.
DT   20-JAN-2016, entry version 175.
DE   RecName: Full=Hereditary hemochromatosis protein;
DE   AltName: Full=HLA-H;
DE   Flags: Precursor;
GN   Name=HFE; Synonyms=HLAH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT HFE1 TYR-282, AND
RP   VARIANT ASP-63.
RX   PubMed=8696333; DOI=10.1038/ng0896-399;
RA   Feder J.N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D.A.,
RA   Basava A., Dormishian F., Domingo R. Jr., Ellis M.C. Jr., Fullan A.,
RA   Hinton L.M., Jones N.L., Kimmel B.E., Kronmal G.S., Lauer P.,
RA   Lee V.K., Loeb D.B., Mapa F.A., McClelland E., Meyer N.C.,
RA   Mintier G.A., Moeller N., Moore T., Morikang E., Prass C.E.,
RA   Quintana L., Starnes S.M., Schatzman R.C., Brunke K.J., Drayna D.T.,
RA   Risch N.J., Bacon B.R., Wolff R.K.;
RT   "A novel MHC class I-like gene is mutated in patients with hereditary
RT   haemochromatosis.";
RL   Nat. Genet. 13:399-409(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RX   PubMed=9149941;
RA   Ruddy D.A., Kronmal G.S., Lee V.K., Mintier G.A., Quintana L.,
RA   Domingo R. Jr., Meyer N.C., Irrinki A., McClelland E.E., Fullan A.,
RA   Mapa F.A., Moore T., Thomas W., Loeb D.B., Harmon C., Tsuchihashi Z.,
RA   Wolff R.K., Schatzman R.C., Feder J.N.;
RT   "A 1.1-Mb transcript map of the hereditary hemochromatosis locus.";
RL   Genome Res. 7:441-456(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=9548560;
RX   DOI=10.1002/(SICI)1097-4644(19980501)69:2<117::AID-JCB3>3.0.CO;2-V;
RA   Albig W., Drabent B., Burmester N., Bode C., Doenecke D.;
RT   "The haemochromatosis candidate gene HFE (HLA-H) of man and mouse is
RT   located in syntenic regions within the histone gene.";
RL   J. Cell. Biochem. 69:117-126(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RA   Gasparini P.;
RT   "Hereditary hemochromatosis genomic structure and organization of HLA-
RT   H gene.";
RL   Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4).
RX   PubMed=10079302; DOI=10.1007/s002510050505;
RA   Rhodes D.A., Trowsdale J.;
RT   "Alternate splice variants of the hemochromatosis gene Hfe.";
RL   Immunogenetics 49:357-359(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 7; 8; 9 AND 10).
RX   PubMed=11001625; DOI=10.1006/bcmd.2000.0291;
RA   Thenie A., Orhant M., Gicquel I., Fergelot P., Le Gall J.-Y.,
RA   David V., Mosser J.;
RT   "The HFE gene undergoes alternate splicing processes.";
RL   Blood Cells Mol. Dis. 26:155-162(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 5; 6; 7 AND 11).
RX   PubMed=11358357; DOI=10.1006/bcmd.2000.0346;
RA   Sanchez M., Bruguera M., Rodos J., Oliva R.;
RT   "Complete characterization of the 3' region of the human and mouse
RT   hereditary hemochromatosis HFE gene and detection of novel splicing
RT   forms.";
RL   Blood Cells Mol. Dis. 27:35-43(2001).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-53; ASP-63;
RP   GLN-224 AND TYR-282.
RG   NIEHS SNPs program;
RL   Submitted (FEB-2008) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=9465039; DOI=10.1073/pnas.95.4.1472;
RA   Feder J.N., Penny D.M., Irrinki A., Lee V.K., Lebron J.A., Watson N.,
RA   Tsuchihashi Z., Sigal E., Bjorkman P.J., Schatzman R.C.;
RT   "The hemochromatosis gene product complexes with the transferrin
RT   receptor and lowers its affinity for ligand binding.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:1472-1477(1998).
RN   [12]
RP   INVOLVEMENT IN TFQTL2.
RX   PubMed=19084217; DOI=10.1016/j.ajhg.2008.11.011;
RA   Benyamin B., McRae A.F., Zhu G., Gordon S., Henders A.K., Palotie A.,
RA   Peltonen L., Martin N.G., Montgomery G.W., Whitfield J.B.,
RA   Visscher P.M.;
RT   "Variants in TF and HFE explain approximately 40% of genetic variation
RT   in serum-transferrin levels.";
RL   Am. J. Hum. Genet. 84:60-65(2009).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 23-297 IN COMPLEX WITH TFR.
RX   PubMed=9546397; DOI=10.1016/S0092-8674(00)81151-4;
RA   Lebron J.A., Bennett M.J., Vaughn D.E., Chirino A.J., Snow P.M.,
RA   Mintier G.A., Feder J.N., Bjorkman P.J.;
RT   "Crystal structure of the hemochromatosis protein HFE and
RT   characterization of its interaction with transferrin receptor.";
RL   Cell 93:111-123(1998).
RN   [14]
RP   3D-STRUCTURE MODELING OF 26-293 IN COMPLEX WITH B2MG.
RX   PubMed=11018711; DOI=10.1016/S0167-4838(00)00126-6;
RA   Dupradeau F., Altenberg-Greulich B., Warin R., Fuentes V., Monti J.,
RA   Rochette J.;
RT   "A 3-dimensional model building by homology of the HFE protein:
RT   molecular consequences and application to antibody development.";
RL   Biochim. Biophys. Acta 1481:213-221(2000).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 26-297 IN COMPLEX WITH TFR.
RX   PubMed=10638746; DOI=10.1038/47417;
RA   Bennett M.J., Lebron J.A., Bjorkman P.J.;
RT   "Crystal structure of the hereditary haemochromatosis protein HFE
RT   complexed with transferrin receptor.";
RL   Nature 403:46-53(2000).
RN   [16]
RP   SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX   PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA   Hillman R.T., Green R.E., Brenner S.E.;
RT   "An unappreciated role for RNA surveillance.";
RL   Genome Biol. 5:R8.1-R8.16(2004).
RN   [17]
RP   VARIANT HFE1 TYR-282, AND VARIANT ASP-63.
RX   PubMed=9106528;
RA   Carella M., D'Ambrosio L., Totaro A., Grifa A., Valentino M.A.,
RA   Piperno A., Girelli D., Roetto A., Franco B., Gasparini P.,
RA   Camaschella C.;
RT   "Mutation analysis of the HLA-H gene in Italian hemochromatosis
RT   patients.";
RL   Am. J. Hum. Genet. 60:828-832(1997).
RN   [18]
RP   VARIANT HFE1 TYR-282, AND ASSOCIATION WITH PORPHYRIA CUTANEA TARDA.
RX   PubMed=9024376; DOI=10.1016/S0140-6736(96)09436-6;
RA   Roberts A.G., Whatley S.D., Morgan R.R., Worwood M., Elder G.H.;
RT   "Increased frequency of the haemochromatosis Cys282Tyr mutation in
RT   sporadic porphyria cutanea tarda.";
RL   Lancet 349:321-323(1997).
RN   [19]
RP   VARIANT ASP-63.
RX   PubMed=9425935; DOI=10.1002/hep.510270128;
RA   Sampietro M., Piperno A., Lupica L., Arosio C., Vergani A.,
RA   Corbetta N., Malosio I., Mattioli M., Fracanzani A.L.,
RA   Cappellini M.D., Fiorelli G., Fargion S.;
RT   "High prevalence of the His63Asp HFE mutation in Italian patients with
RT   porphyria cutanea tarda.";
RL   Hepatology 27:181-184(1998).
RN   [20]
RP   VARIANT HFE1 TYR-282, AND VARIANT ASP-63.
RX   PubMed=9620340; DOI=10.1002/hep.510270627;
RA   Bonkovsky H.L., Poh-Fitzpatrick M., Pimstone N., Obando J.,
RA   Di Bisceglie A., Tattrie C., Tortorelli K., LeClair P., Mercurio M.G.,
RA   Lambrecht R.W.;
RT   "Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North
RT   America.";
RL   Hepatology 27:1661-1669(1998).
RN   [21]
RP   VARIANTS HFE1 CYS-65 AND TYR-282, AND VARIANT ASP-63.
RX   PubMed=10194428;
RA   Mura C., Raguenes O., Ferec C.;
RT   "HFE mutations analysis in 711 hemochromatosis probands: evidence for
RT   S65C implication in mild form of hemochromatosis.";
RL   Blood 93:2502-2505(1999).
RN   [22]
RP   VARIANTS HFE1 CYS-65; ARG-93 AND THR-105.
RX   PubMed=10575540; DOI=10.1006/bcmd.1999.0240;
RA   Barton J.C., Sawada-Hirai R., Rothenberg B.E., Acton R.T.;
RT   "Two novel missense mutations of the HFE gene (I105T and G93R) and
RT   identification of the S65C mutation in Alabama hemochromatosis
RT   probands.";
RL   Blood Cells Mol. Dis. 25:147-155(1999).
RN   [23]
RP   VARIANTS HFE1 HIS-127 AND MET-330, AND VARIANTS MET-53; MET-59 AND
RP   ASP-63.
RX   PubMed=10401000; DOI=10.1093/hmg/8.8.1517;
RA   de Villiers J.N.P., Hillermann R., Loubser L., Kotze M.J.;
RT   "Spectrum of mutations in the HFE gene implicated in haemochromatosis
RT   and porphyria.";
RL   Hum. Mol. Genet. 8:1517-1522(1999).
RN   [24]
RP   VARIANT HFE1 TYR-282, AND VARIANT ASP-63.
RX   PubMed=10094552;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:2<154::AID-HUMU8>3.0.CO;2-E;
RA   Merryweather-Clarke A.T., Simonsen H., Shearman J.D., Pointon J.J.,
RA   Norgaard-Pedersen B., Robson K.J.H.;
RT   "A retrospective anonymous pilot study in screening newborns for HFE
RT   mutations in Scandinavian populations.";
RL   Hum. Mutat. 13:154-159(1999).
RN   [25]
RP   VARIANT HFE1 CYS-65.
RA   Fagan E., Payne S.J.;
RT   "A novel missense mutation S65C in the HFE gene with a possible role
RT   in hereditary haemochromatosis.";
RL   Hum. Mutat. 13:507-508(1999).
RN   [26]
RP   VARIANT LYS-277.
RX   PubMed=10612845;
RX   DOI=10.1002/(SICI)1098-1004(200001)15:1<120::AID-HUMU32>3.0.CO;2-B;
RA   Bradbury R., Fagan E., Payne S.J.;
RT   "Two novel polymorphisms (E277K and V212V) in the haemochromatosis
RT   gene HFE.";
RL   Hum. Mutat. 15:120-120(2000).
RN   [27]
RP   VARIANTS ASP-63 AND TYR-282.
RX   PubMed=11069625; DOI=10.1046/j.1523-1747.2000.00148.x;
RA   Brady J.J., Jackson H.A., Roberts A.G., Morgan R.R., Whatley S.D.,
RA   Rowlands G.L., Darby C., Shudell E., Watson R., Paiker J.,
RA   Worwood M.W., Elder G.H.;
RT   "Co-inheritance of mutations in the uroporphyrinogen decarboxylase and
RT   hemochromatosis genes accelerates the onset of porphyria cutanea
RT   tarda.";
RL   J. Invest. Dermatol. 115:868-874(2000).
RN   [28]
RP   VARIANT HFE1 TYR-282, VARIANT ASP-63, AND ASSOCIATION WITH DIABETIC
RP   NEPHROPATHY SUSCEPTIBILITY.
RX   PubMed=11423500; DOI=10.2337/diacare.24.7.1187;
RA   Moczulski D.K., Grzeszczak W., Gawlik B.;
RT   "Role of hemochromatosis C282Y and H63D mutations in HFE gene in
RT   development of type 2 diabetes and diabetic nephropathy.";
RL   Diabetes Care 24:1187-1191(2001).
RN   [29]
RP   VARIANT HFE1 VAL-176.
RX   PubMed=11446670;
RA   Imanishi H., Liu W., Cheng J., Ikeda N., Amuro Y., Hada T.;
RT   "Idiopathic hemochromatosis with the mutation of Ala176Val
RT   heterozygous for HFE gene.";
RL   Intern. Med. 40:479-483(2001).
RN   [30]
RP   VARIANTS HFE1 CYS-65; TYR-282 AND ALA-295.
RX   PubMed=12542741; DOI=10.1034/j.1399-0039.2002.600603.x;
RA   Jones D.C., Young N.T., Pigott C., Fuggle S.V., Barnardo M.C.N.M.,
RA   Marshall S.E., Bunce M.;
RT   "Comprehensive hereditary hemochromatosis genotyping.";
RL   Tissue Antigens 60:481-488(2002).
RN   [31]
RP   VARIANT HFE1 PRO-283, AND CHARACTERIZATION OF VARIANT HFE1 PRO-283.
RX   PubMed=12737937; DOI=10.1016/S1079-9796(03)00036-6;
RA   Le Gac G., Dupradeau F.-Y., Mura C., Jacolot S., Scotet V.,
RA   Esnault G., Mercier A.-Y., Rochette J., Ferec C.;
RT   "Phenotypic expression of the C282Y/Q283P compound heterozygosity in
RT   HFE and molecular modeling of the Q283P mutation effect.";
RL   Blood Cells Mol. Dis. 30:231-237(2003).
RN   [32]
RP   VARIANTS HFE1 CYS-65; CYS-66; GLY-224 AND TYR-282.
RX   PubMed=14633868; DOI=10.1373/clinchem.2003.023440;
RA   Biasiotto G., Belloli S., Ruggeri G., Zanella I., Gerardi G.,
RA   Corrado M., Gobbi E., Albertini A., Arosio P.;
RT   "Identification of new mutations of the HFE, hepcidin, and transferrin
RT   receptor 2 genes by denaturing HPLC analysis of individuals with
RT   biochemical indications of iron overload.";
RL   Clin. Chem. 49:1981-1988(2003).
RN   [33]
RP   VARIANT HFE1 SER-6.
RX   PubMed=12584229; DOI=10.1136/gut.52.3.433;
RA   Wigg A.J., Harley H., Casey G.;
RT   "Heterozygous recipient and donor HFE mutations associated with a
RT   hereditary haemochromatosis phenotype after liver transplantation.";
RL   Gut 52:433-435(2003).
RN   [34]
RP   VARIANT HFE1 ALA-295.
RX   PubMed=15046077;
RA   Bento M.C., Ribeiro M.L., Relvas L.;
RT   "Gene symbol: HFE. Disease: haemochromatosis.";
RL   Hum. Genet. 114:405-405(2004).
RN   [35]
RP   CHARACTERIZATION OF VARIANT HFE1 PRO-283.
RX   PubMed=15965644; DOI=10.1007/s00439-005-1307-y;
RA   Ka C., Le Gac G., Dupradeau F.-Y., Rochette J., Ferec C.;
RT   "The Q283P amino-acid change in HFE leads to structural and functional
RT   consequences similar to those described for the mutated 282Y HFE
RT   protein.";
RL   Hum. Genet. 117:467-475(2005).
RN   [36]
RP   VARIANTS HFE1 ASP-43 AND TYR-282, AND VARIANT ASP-63.
RX   PubMed=18157833; DOI=10.1002/humu.9517;
RA   Dupradeau F.-Y., Pissard S., Coulhon M.-P., Cadet E., Foulon K.,
RA   Fourcade C., Goossens M., Case D.A., Rochette J.;
RT   "An unusual case of hemochromatosis due to a new compound
RT   heterozygosity in HFE (p.[Gly43Asp;His63Asp]+[Cys282Tyr]): structural
RT   implications with respect to binding with transferrin receptor 1.";
RL   Hum. Mutat. 29:206-206(2008).
CC   -!- FUNCTION: Binds to transferrin receptor (TFR) and reduces its
CC       affinity for iron-loaded transferrin.
CC       {ECO:0000269|PubMed:9465039}.
CC   -!- SUBUNIT: Binds TFR through the extracellular domain in a pH-
CC       dependent manner. {ECO:0000269|PubMed:10638746,
CC       ECO:0000269|PubMed:9546397}.
CC   -!- INTERACTION:
CC       P61769:B2M; NbExp=5; IntAct=EBI-1028850, EBI-714718;
CC       P02786:TFRC; NbExp=3; IntAct=EBI-1028850, EBI-355727;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:9465039};
CC       Single-pass type I membrane protein {ECO:0000305|PubMed:8696333}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1;
CC         IsoId=Q30201-1; Sequence=Displayed;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC       Name=2; Synonyms=delE2;
CC         IsoId=Q30201-2; Sequence=VSP_003218;
CC       Name=3; Synonyms=del14E4;
CC         IsoId=Q30201-3; Sequence=VSP_003225;
CC       Name=4; Synonyms=delE214E4;
CC         IsoId=Q30201-4; Sequence=VSP_003218, VSP_003225;
CC       Name=5;
CC         IsoId=Q30201-5; Sequence=VSP_003219;
CC       Name=6;
CC         IsoId=Q30201-6; Sequence=VSP_047336, VSP_003220;
CC       Name=7; Synonyms=delE3;
CC         IsoId=Q30201-7; Sequence=VSP_003221;
CC       Name=8; Synonyms=1043-2283del,intron6ins;
CC         IsoId=Q30201-8; Sequence=VSP_003226, VSP_003227;
CC       Name=9; Synonyms=delE3-7;
CC         IsoId=Q30201-9; Sequence=VSP_003223, VSP_003224;
CC       Name=10; Synonyms=562-878del;
CC         IsoId=Q30201-10; Sequence=VSP_003222;
CC       Name=11;
CC         IsoId=Q30201-11; Sequence=VSP_043477, VSP_043478;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues tested except brain.
CC   -!- POLYMORPHISM: Genetic variations in HFE define the transferrin
CC       serum level quantitative trait locus 2 (TFQTL2) [MIM:614193]. Iron
CC       is essential for biochemical functions such as oxygen transport
CC       and oxidative phosphorylation. Excessive iron can cause iron-
CC       overload-related liver diseases, whereas iron deficiency can lead
CC       to anemia. Iron status can be assessed by measuring the levels of
CC       serum iron, serum transferrin, transferrin saturation with iron,
CC       and serum ferritin.
CC   -!- DISEASE: Hemochromatosis 1 (HFE1) [MIM:235200]: A disorder of iron
CC       metabolism characterized by iron overload. Excess iron is
CC       deposited in a variety of organs leading to their failure, and
CC       resulting in serious illnesses including cirrhosis, hepatomas,
CC       diabetes, cardiomyopathy, arthritis, and hypogonadotropic
CC       hypogonadism. Severe effects of the disease usually do not appear
CC       until after decades of progressive iron loading.
CC       {ECO:0000269|PubMed:10094552, ECO:0000269|PubMed:10194428,
CC       ECO:0000269|PubMed:10401000, ECO:0000269|PubMed:10575540,
CC       ECO:0000269|PubMed:11423500, ECO:0000269|PubMed:11446670,
CC       ECO:0000269|PubMed:12542741, ECO:0000269|PubMed:12584229,
CC       ECO:0000269|PubMed:12737937, ECO:0000269|PubMed:14633868,
CC       ECO:0000269|PubMed:15046077, ECO:0000269|PubMed:18157833,
CC       ECO:0000269|PubMed:8696333, ECO:0000269|PubMed:9024376,
CC       ECO:0000269|PubMed:9106528, ECO:0000269|PubMed:9620340,
CC       ECO:0000269|Ref.25}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Variegate porphyria (VP) [MIM:176200]: A form of
CC       porphyria. Porphyrias are inherited defects in the biosynthesis of
CC       heme, resulting in the accumulation and increased excretion of
CC       porphyrins or porphyrin precursors. They are classified as
CC       erythropoietic or hepatic, depending on whether the enzyme
CC       deficiency occurs in red blood cells or in the liver. Variegate
CC       porphyria is the most common form of porphyria in South Africa. It
CC       is characterized by skin hyperpigmentation and hypertrichosis,
CC       abdominal pain, tachycardia, hypertension and neuromuscular
CC       disturbances. High fecal levels of protoporphyrin and
CC       coproporphyrin, increased urine uroporphyrins and iron overload
CC       are typical markers of the disease. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry. Iron overload due to HFE variants is a precipitating or
CC       exacerbating factor in variegate porphyria.
CC   -!- DISEASE: Microvascular complications of diabetes 7 (MVCD7)
CC       [MIM:612635]: Pathological conditions that develop in numerous
CC       tissues and organs as a consequence of diabetes mellitus. They
CC       include diabetic retinopathy, diabetic nephropathy leading to end-
CC       stage renal disease, and diabetic neuropathy. Diabetic retinopathy
CC       remains the major cause of new-onset blindness among diabetic
CC       adults. It is characterized by vascular permeability and increased
CC       tissue ischemia and angiogenesis. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the MHC class I family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/HFEID44099ch6p22.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/hfe/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U60319; AAC51823.1; -; mRNA.
DR   EMBL; U91328; AAB82083.1; -; Genomic_DNA.
DR   EMBL; Z92910; CAB07442.1; -; Genomic_DNA.
DR   EMBL; Y09801; CAA70934.1; -; Genomic_DNA.
DR   EMBL; Y09800; CAA70934.1; JOINED; Genomic_DNA.
DR   EMBL; Y09803; CAA70934.1; JOINED; Genomic_DNA.
DR   EMBL; Y09799; CAA70934.1; JOINED; Genomic_DNA.
DR   EMBL; AF079407; AAC62646.1; -; mRNA.
DR   EMBL; AF079408; AAC62647.1; -; mRNA.
DR   EMBL; AF079409; AAC62648.1; -; mRNA.
DR   EMBL; AF115264; AAG29571.1; -; mRNA.
DR   EMBL; AF115265; AAG29572.1; -; mRNA.
DR   EMBL; AF144240; AAG29575.1; -; mRNA.
DR   EMBL; AF144242; AAG29577.1; -; mRNA.
DR   EMBL; AF149804; AAG29342.1; -; mRNA.
DR   EMBL; AJ249335; CAC67792.1; -; mRNA.
DR   EMBL; AJ249336; CAC67793.1; -; mRNA.
DR   EMBL; AJ249337; CAC67794.1; -; mRNA.
DR   EMBL; AJ249338; CAC67795.1; -; mRNA.
DR   EMBL; AJ250635; CAC80805.1; -; mRNA.
DR   EMBL; EU523119; ACB21042.1; -; Genomic_DNA.
DR   EMBL; CH471087; EAW55524.1; -; Genomic_DNA.
DR   EMBL; CH471087; EAW55526.1; -; Genomic_DNA.
DR   EMBL; BC117201; AAI17202.1; -; mRNA.
DR   EMBL; BC117203; AAI17204.1; -; mRNA.
DR   CCDS; CCDS4578.1; -. [Q30201-1]
DR   CCDS; CCDS4579.1; -. [Q30201-7]
DR   CCDS; CCDS4580.1; -. [Q30201-2]
DR   CCDS; CCDS4581.1; -. [Q30201-6]
DR   CCDS; CCDS4582.1; -. [Q30201-11]
DR   CCDS; CCDS47386.1; -. [Q30201-10]
DR   CCDS; CCDS47387.1; -. [Q30201-5]
DR   CCDS; CCDS54974.1; -. [Q30201-3]
DR   CCDS; CCDS54975.1; -. [Q30201-4]
DR   RefSeq; NP_000401.1; NM_000410.3. [Q30201-1]
DR   RefSeq; NP_001287678.1; NM_001300749.1.
DR   RefSeq; NP_620572.1; NM_139003.2. [Q30201-10]
DR   RefSeq; NP_620573.1; NM_139004.2. [Q30201-7]
DR   RefSeq; NP_620575.1; NM_139006.2. [Q30201-3]
DR   RefSeq; NP_620576.1; NM_139007.2. [Q30201-2]
DR   RefSeq; NP_620577.1; NM_139008.2. [Q30201-4]
DR   RefSeq; NP_620578.1; NM_139009.2. [Q30201-5]
DR   RefSeq; NP_620579.1; NM_139010.2. [Q30201-6]
DR   RefSeq; NP_620580.1; NM_139011.2. [Q30201-11]
DR   UniGene; Hs.233325; -.
DR   PDB; 1A6Z; X-ray; 2.60 A; A/C=23-297.
DR   PDB; 1C42; Model; -; A=26-293.
DR   PDB; 1DE4; X-ray; 2.80 A; A/D/G=23-297.
DR   PDBsum; 1A6Z; -.
DR   PDBsum; 1C42; -.
DR   PDBsum; 1DE4; -.
DR   ProteinModelPortal; Q30201; -.
DR   SMR; Q30201; 26-297.
DR   BioGrid; 109325; 4.
DR   DIP; DIP-2737N; -.
DR   IntAct; Q30201; 8.
DR   MINT; MINT-7896047; -.
DR   STRING; 9606.ENSP00000417404; -.
DR   PhosphoSite; Q30201; -.
DR   BioMuta; HFE; -.
DR   DMDM; 2497915; -.
DR   MaxQB; Q30201; -.
DR   PaxDb; Q30201; -.
DR   PRIDE; Q30201; -.
DR   DNASU; 3077; -.
DR   Ensembl; ENST00000317896; ENSP00000313776; ENSG00000010704. [Q30201-7]
DR   Ensembl; ENST00000336625; ENSP00000337819; ENSG00000010704. [Q30201-10]
DR   Ensembl; ENST00000349999; ENSP00000259699; ENSG00000010704. [Q30201-2]
DR   Ensembl; ENST00000352392; ENSP00000315936; ENSG00000010704. [Q30201-11]
DR   Ensembl; ENST00000353147; ENSP00000312342; ENSG00000010704. [Q30201-6]
DR   Ensembl; ENST00000357618; ENSP00000417404; ENSG00000010704. [Q30201-1]
DR   Ensembl; ENST00000397022; ENSP00000380217; ENSG00000010704. [Q30201-5]
DR   Ensembl; ENST00000461397; ENSP00000420802; ENSG00000010704. [Q30201-3]
DR   Ensembl; ENST00000488199; ENSP00000420559; ENSG00000010704. [Q30201-4]
DR   GeneID; 3077; -.
DR   KEGG; hsa:3077; -.
DR   UCSC; uc003nfx.1; human. [Q30201-1]
DR   UCSC; uc003nfy.1; human. [Q30201-5]
DR   UCSC; uc003nfz.1; human. [Q30201-2]
DR   UCSC; uc003nga.1; human. [Q30201-3]
DR   UCSC; uc003ngb.1; human. [Q30201-10]
DR   UCSC; uc003ngc.1; human. [Q30201-7]
DR   UCSC; uc003ngd.1; human. [Q30201-4]
DR   UCSC; uc003nge.1; human. [Q30201-6]
DR   UCSC; uc003ngf.1; human. [Q30201-11]
DR   CTD; 3077; -.
DR   GeneCards; HFE; -.
DR   GeneReviews; HFE; -.
DR   H-InvDB; HIX0025100; -.
DR   HGNC; HGNC:4886; HFE.
DR   HPA; HPA017276; -.
DR   HPA; HPA053470; -.
DR   MalaCards; HFE; -.
DR   MIM; 176200; phenotype.
DR   MIM; 235200; phenotype.
DR   MIM; 612635; phenotype.
DR   MIM; 613609; gene.
DR   MIM; 614193; phenotype.
DR   neXtProt; NX_Q30201; -.
DR   Orphanet; 139498; Hemochromatosis type 1.
DR   Orphanet; 101330; Porphyria cutanea tarda.
DR   Orphanet; 79473; Porphyria variegata.
DR   PharmGKB; PA29263; -.
DR   eggNOG; ENOG410IFNV; Eukaryota.
DR   eggNOG; ENOG4111CQR; LUCA.
DR   GeneTree; ENSGT00760000118960; -.
DR   HOGENOM; HOG000151270; -.
DR   HOVERGEN; HBG016709; -.
DR   InParanoid; Q30201; -.
DR   OMA; CEMQEDN; -.
DR   OrthoDB; EOG7JT6WQ; -.
DR   PhylomeDB; Q30201; -.
DR   TreeFam; TF336617; -.
DR   EvolutionaryTrace; Q30201; -.
DR   GeneWiki; HFE_(gene); -.
DR   GenomeRNAi; 3077; -.
DR   NextBio; 12169; -.
DR   PRO; PR:Q30201; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; Q30201; -.
DR   ExpressionAtlas; Q30201; baseline and differential.
DR   Genevisible; Q30201; HS.
DR   GO; GO:0045177; C:apical part of cell; IDA:UniProtKB.
DR   GO; GO:0045178; C:basal part of cell; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:UniProtKB.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:1990712; C:HFE-transferrin receptor complex; IDA:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:ProtInc.
DR   GO; GO:0055037; C:recycling endosome; IDA:UniProtKB.
DR   GO; GO:1990357; C:terminal web; IEA:Ensembl.
DR   GO; GO:0030881; F:beta-2-microglobulin binding; IPI:BHF-UCL.
DR   GO; GO:0039706; F:co-receptor binding; IPI:BHF-UCL.
DR   GO; GO:0005102; F:receptor binding; IPI:UniProtKB.
DR   GO; GO:1990459; F:transferrin receptor binding; IPI:BHF-UCL.
DR   GO; GO:0006953; P:acute-phase response; IEA:Ensembl.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0006879; P:cellular iron ion homeostasis; TAS:ProtInc.
DR   GO; GO:0071281; P:cellular response to iron ion; IGI:BHF-UCL.
DR   GO; GO:0010106; P:cellular response to iron ion starvation; IEA:Ensembl.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0042446; P:hormone biosynthetic process; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; IEA:InterPro.
DR   GO; GO:0055072; P:iron ion homeostasis; IMP:BHF-UCL.
DR   GO; GO:0097459; P:iron ion import into cell; IDA:UniProtKB.
DR   GO; GO:0097421; P:liver regeneration; IEA:Ensembl.
DR   GO; GO:0060586; P:multicellular organismal iron ion homeostasis; IEA:Ensembl.
DR   GO; GO:1904283; P:negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I; IGI:BHF-UCL.
DR   GO; GO:2001186; P:negative regulation of CD8-positive, alpha-beta T cell activation; IGI:BHF-UCL.
DR   GO; GO:0032435; P:negative regulation of proteasomal ubiquitin-dependent protein catabolic process; IC:BHF-UCL.
DR   GO; GO:2000059; P:negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:2000272; P:negative regulation of receptor activity; IDA:BHF-UCL.
DR   GO; GO:1900121; P:negative regulation of receptor binding; IDA:BHF-UCL.
DR   GO; GO:0002626; P:negative regulation of T cell antigen processing and presentation; IEA:InterPro.
DR   GO; GO:0002725; P:negative regulation of T cell cytokine production; IGI:BHF-UCL.
DR   GO; GO:1904434; P:positive regulation of ferrous iron binding; IGI:BHF-UCL.
DR   GO; GO:1903991; P:positive regulation of ferrous iron import into cell; IGI:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:BHF-UCL.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0090277; P:positive regulation of peptide hormone secretion; IMP:BHF-UCL.
DR   GO; GO:0032092; P:positive regulation of protein binding; IGI:BHF-UCL.
DR   GO; GO:2000273; P:positive regulation of receptor activity; IGI:BHF-UCL.
DR   GO; GO:1900122; P:positive regulation of receptor binding; IGI:BHF-UCL.
DR   GO; GO:0048260; P:positive regulation of receptor-mediated endocytosis; IGI:BHF-UCL.
DR   GO; GO:1904437; P:positive regulation of transferrin receptor binding; IGI:BHF-UCL.
DR   GO; GO:0006461; P:protein complex assembly; TAS:ProtInc.
DR   GO; GO:0010039; P:response to iron ion; IMP:BHF-UCL.
DR   GO; GO:1990641; P:response to iron ion starvation; IEA:Ensembl.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.30.500.10; -; 1.
DR   InterPro; IPR031092; HFE.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011161; MHC_I-like_Ag-recog.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR027648; MHC_I_a.
DR   InterPro; IPR001039; MHC_I_a_a1/a2.
DR   PANTHER; PTHR16675:SF172; PTHR16675:SF172; 1.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00129; MHC_I; 1.
DR   PRINTS; PR01638; MHCCLASSI.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Complete proteome;
KW   Disease mutation; Disulfide bond; Glycoprotein; Ion transport; Iron;
KW   Iron transport; Membrane; Polymorphism; Reference proteome; Signal;
KW   Transmembrane; Transmembrane helix; Transport.
FT   SIGNAL        1     22
FT   CHAIN        23    348       Hereditary hemochromatosis protein.
FT                                /FTId=PRO_0000018892.
FT   TOPO_DOM     23    306       Extracellular.
FT                                {ECO:0000305|PubMed:9465039}.
FT   TRANSMEM    307    330       Helical. {ECO:0000255}.
FT   TOPO_DOM    331    348       Cytoplasmic.
FT                                {ECO:0000305|PubMed:9465039}.
FT   DOMAIN      207    298       Ig-like C1-type.
FT   REGION       23    114       Alpha-1.
FT   REGION      115    205       Alpha-2.
FT   REGION      206    297       Alpha-3.
FT   REGION      298    306       Connecting peptide.
FT   CARBOHYD    110    110       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    130    130       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    234    234       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    124    187
FT   DISULFID    225    282
FT   VAR_SEQ      26    114       RSHSLHYLFMGASEQDLGLSLFEALGYVDDQLFVFYDHESR
FT                                RVEPRTPWVSSRISSQMWLQLSQSLKGWDHMFTVDFWTIME
FT                                NHNHSKE -> Q (in isoform 2 and isoform
FT                                4). {ECO:0000303|PubMed:10079302,
FT                                ECO:0000303|PubMed:11358357}.
FT                                /FTId=VSP_003218.
FT   VAR_SEQ      26     49       RSHSLHYLFMGASEQDLGLSLFEA -> P (in isoform
FT                                5). {ECO:0000303|PubMed:11358357}.
FT                                /FTId=VSP_003219.
FT   VAR_SEQ      26     26       R -> Q (in isoform 11).
FT                                {ECO:0000303|PubMed:11358357}.
FT                                /FTId=VSP_043477.
FT   VAR_SEQ      26     26       R -> L (in isoform 6).
FT                                {ECO:0000303|PubMed:11358357}.
FT                                /FTId=VSP_047336.
FT   VAR_SEQ      27    298       Missing (in isoform 11).
FT                                {ECO:0000303|PubMed:11358357}.
FT                                /FTId=VSP_043478.
FT   VAR_SEQ      27    206       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:11358357}.
FT                                /FTId=VSP_003220.
FT   VAR_SEQ     114    219       Missing (in isoform 10).
FT                                {ECO:0000303|PubMed:11001625}.
FT                                /FTId=VSP_003222.
FT   VAR_SEQ     114    205       Missing (in isoform 7).
FT                                {ECO:0000303|PubMed:11001625,
FT                                ECO:0000303|PubMed:11358357}.
FT                                /FTId=VSP_003221.
FT   VAR_SEQ     144    161       DHLEFCPDTLDWRAAEPR -> VLQDTIYSSEVSSLGIKF
FT                                (in isoform 9).
FT                                {ECO:0000303|PubMed:11001625}.
FT                                /FTId=VSP_003223.
FT   VAR_SEQ     162    348       Missing (in isoform 9).
FT                                {ECO:0000303|PubMed:11001625}.
FT                                /FTId=VSP_003224.
FT   VAR_SEQ     207    220       Missing (in isoform 3 and isoform 4).
FT                                {ECO:0000303|PubMed:10079302}.
FT                                /FTId=VSP_003225.
FT   VAR_SEQ     275    276       GE -> KY (in isoform 8).
FT                                {ECO:0000303|PubMed:11001625}.
FT                                /FTId=VSP_003226.
FT   VAR_SEQ     277    348       Missing (in isoform 8).
FT                                {ECO:0000303|PubMed:11001625}.
FT                                /FTId=VSP_003227.
FT   VARIANT       6      6       R -> S (in HFE1).
FT                                {ECO:0000269|PubMed:12584229}.
FT                                /FTId=VAR_042506.
FT   VARIANT      43     43       G -> D (in HFE1; associated with D-63 in
FT                                one patient).
FT                                {ECO:0000269|PubMed:18157833}.
FT                                /FTId=VAR_042507.
FT   VARIANT      53     53       V -> M (in dbSNP:rs28934889).
FT                                {ECO:0000269|PubMed:10401000,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_008111.
FT   VARIANT      59     59       V -> M (in dbSNP:rs28934890).
FT                                {ECO:0000269|PubMed:10401000}.
FT                                /FTId=VAR_008112.
FT   VARIANT      63     63       H -> D (polymorphism associated with
FT                                hemochromatosis and variegate porphyria;
FT                                increased frequency among patients with
FT                                diabetic nephropathy; dbSNP:rs1799945).
FT                                {ECO:0000269|PubMed:10094552,
FT                                ECO:0000269|PubMed:10194428,
FT                                ECO:0000269|PubMed:10401000,
FT                                ECO:0000269|PubMed:11069625,
FT                                ECO:0000269|PubMed:11423500,
FT                                ECO:0000269|PubMed:18157833,
FT                                ECO:0000269|PubMed:8696333,
FT                                ECO:0000269|PubMed:9106528,
FT                                ECO:0000269|PubMed:9425935,
FT                                ECO:0000269|PubMed:9620340,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_004396.
FT   VARIANT      65     65       S -> C (in HFE1; mild form;
FT                                dbSNP:rs1800730).
FT                                {ECO:0000269|PubMed:10194428,
FT                                ECO:0000269|PubMed:10575540,
FT                                ECO:0000269|PubMed:12542741,
FT                                ECO:0000269|PubMed:14633868,
FT                                ECO:0000269|Ref.25}.
FT                                /FTId=VAR_004397.
FT   VARIANT      66     66       R -> C (in HFE1).
FT                                {ECO:0000269|PubMed:14633868}.
FT                                /FTId=VAR_042508.
FT   VARIANT      93     93       G -> R (in HFE1; dbSNP:rs28934597).
FT                                {ECO:0000269|PubMed:10575540}.
FT                                /FTId=VAR_008729.
FT   VARIANT     105    105       I -> T (in HFE1; dbSNP:rs28934596).
FT                                {ECO:0000269|PubMed:10575540}.
FT                                /FTId=VAR_008730.
FT   VARIANT     127    127       Q -> H (in HFE1; dbSNP:rs28934595).
FT                                {ECO:0000269|PubMed:10401000}.
FT                                /FTId=VAR_008113.
FT   VARIANT     176    176       A -> V (in HFE1; uncertain pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:11446670}.
FT                                /FTId=VAR_042509.
FT   VARIANT     217    217       T -> I (in dbSNP:rs4986950).
FT                                /FTId=VAR_020270.
FT   VARIANT     224    224       R -> G (in HFE1).
FT                                {ECO:0000269|PubMed:14633868}.
FT                                /FTId=VAR_042510.
FT   VARIANT     224    224       R -> Q (in dbSNP:rs62625346).
FT                                {ECO:0000269|Ref.8}.
FT                                /FTId=VAR_062279.
FT   VARIANT     277    277       E -> K (rare polymorphism;
FT                                dbSNP:rs140080192).
FT                                {ECO:0000269|PubMed:10612845}.
FT                                /FTId=VAR_008731.
FT   VARIANT     282    282       C -> Y (in HFE1; associated with
FT                                susceptibility to porphyria cutanea
FT                                tarda; associated with increased serum
FT                                transferrin levels; higher frequency in
FT                                patients with type 2 diabetes than in
FT                                controls; dbSNP:rs1800562).
FT                                {ECO:0000269|PubMed:10094552,
FT                                ECO:0000269|PubMed:10194428,
FT                                ECO:0000269|PubMed:11069625,
FT                                ECO:0000269|PubMed:11423500,
FT                                ECO:0000269|PubMed:12542741,
FT                                ECO:0000269|PubMed:14633868,
FT                                ECO:0000269|PubMed:18157833,
FT                                ECO:0000269|PubMed:8696333,
FT                                ECO:0000269|PubMed:9024376,
FT                                ECO:0000269|PubMed:9106528,
FT                                ECO:0000269|PubMed:9620340,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_004398.
FT   VARIANT     283    283       Q -> P (in HFE1; destabilizing effect on
FT                                the tertiary structure of the protein;
FT                                prevents the normal interaction between
FT                                HFE and B2M and between HFE and TFRC;
FT                                decreases the capacity of HFE to reduce
FT                                transferrin-mediated iron uptake).
FT                                {ECO:0000269|PubMed:12737937,
FT                                ECO:0000269|PubMed:15965644}.
FT                                /FTId=VAR_037304.
FT   VARIANT     295    295       V -> A (in HFE1; dbSNP:rs143175221).
FT                                {ECO:0000269|PubMed:12542741,
FT                                ECO:0000269|PubMed:15046077}.
FT                                /FTId=VAR_042511.
FT   VARIANT     330    330       R -> M (in HFE1).
FT                                {ECO:0000269|PubMed:10401000}.
FT                                /FTId=VAR_008114.
FT   CONFLICT    230    230       Y -> H (in Ref. 7; AAG29342).
FT                                {ECO:0000305}.
FT   CONFLICT    248    248       A -> T (in Ref. 7; AAG29575).
FT                                {ECO:0000305}.
FT   CONFLICT    256    256       V -> A (in Ref. 7; AAG29577).
FT                                {ECO:0000305}.
FT   CONFLICT    275    275       G -> E (in Ref. 7; AAG29342).
FT                                {ECO:0000305}.
FT   CONFLICT    311    311       S -> R (in Ref. 7; AAG29342).
FT                                {ECO:0000305}.
FT   CONFLICT    339    339       M -> V (in Ref. 7; AAG29577).
FT                                {ECO:0000305}.
FT   STRAND       28     38       {ECO:0000244|PDB:1A6Z}.
FT   STRAND       43     45       {ECO:0000244|PDB:1A6Z}.
FT   STRAND       48     53       {ECO:0000244|PDB:1A6Z}.
FT   STRAND       56     65       {ECO:0000244|PDB:1A6Z}.
FT   STRAND       68     70       {ECO:0000244|PDB:1A6Z}.
FT   HELIX        75     78       {ECO:0000244|PDB:1DE4}.
FT   TURN         79     82       {ECO:0000244|PDB:1A6Z}.
FT   HELIX        83    107       {ECO:0000244|PDB:1A6Z}.
FT   TURN        108    110       {ECO:0000244|PDB:1A6Z}.
FT   STRAND      112    114       {ECO:0000244|PDB:1A6Z}.
FT   STRAND      117    126       {ECO:0000244|PDB:1A6Z}.
FT   STRAND      132    140       {ECO:0000244|PDB:1A6Z}.
FT   STRAND      143    149       {ECO:0000244|PDB:1A6Z}.
FT   HELIX       150    152       {ECO:0000244|PDB:1A6Z}.
FT   STRAND      154    159       {ECO:0000244|PDB:1A6Z}.
FT   HELIX       160    162       {ECO:0000244|PDB:1A6Z}.
FT   HELIX       163    170       {ECO:0000244|PDB:1A6Z}.
FT   HELIX       174    184       {ECO:0000244|PDB:1A6Z}.
FT   HELIX       186    198       {ECO:0000244|PDB:1A6Z}.
FT   TURN        199    201       {ECO:0000244|PDB:1A6Z}.
FT   STRAND      209    216       {ECO:0000244|PDB:1A6Z}.
FT   STRAND      221    233       {ECO:0000244|PDB:1A6Z}.
FT   STRAND      236    241       {ECO:0000244|PDB:1A6Z}.
FT   HELIX       248    250       {ECO:0000244|PDB:1A6Z}.
FT   STRAND      255    258       {ECO:0000244|PDB:1A6Z}.
FT   STRAND      264    272       {ECO:0000244|PDB:1A6Z}.
FT   HELIX       276    279       {ECO:0000244|PDB:1A6Z}.
FT   STRAND      280    285       {ECO:0000244|PDB:1A6Z}.
FT   STRAND      289    291       {ECO:0000244|PDB:1A6Z}.
FT   STRAND      293    296       {ECO:0000244|PDB:1A6Z}.
SQ   SEQUENCE   348 AA;  40108 MW;  432EB9A314A55BEA CRC64;
     MGPRARPALL LLMLLQTAVL QGRLLRSHSL HYLFMGASEQ DLGLSLFEAL GYVDDQLFVF
     YDHESRRVEP RTPWVSSRIS SQMWLQLSQS LKGWDHMFTV DFWTIMENHN HSKESHTLQV
     ILGCEMQEDN STEGYWKYGY DGQDHLEFCP DTLDWRAAEP RAWPTKLEWE RHKIRARQNR
     AYLERDCPAQ LQQLLELGRG VLDQQVPPLV KVTHHVTSSV TTLRCRALNY YPQNITMKWL
     KDKQPMDAKE FEPKDVLPNG DGTYQGWITL AVPPGEEQRY TCQVEHPGLD QPLIVIWEPS
     PSGTLVIGVI SGIAVFVVIL FIGILFIILR KRQGSRGAMG HYVLAERE
//
ID   CSF1R_HUMAN             Reviewed;         972 AA.
AC   P07333; B5A955; D3DQG2; Q6LDW5; Q6LDY4; Q86VW7;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 2.
DT   20-JAN-2016, entry version 189.
DE   RecName: Full=Macrophage colony-stimulating factor 1 receptor;
DE   AltName: Full=CSF-1 receptor;
DE            Short=CSF-1-R;
DE            Short=CSF-1R;
DE            Short=M-CSF-R;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene c-Fms;
DE   AltName: CD_antigen=CD115;
DE   Flags: Precursor;
GN   Name=CSF1R; Synonyms=FMS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2524025;
RA   Hampe A., Shamoon B.M., Gobet M., Sherr C.J., Galibert F.;
RT   "Nucleotide sequence and structural organization of the human FMS
RT   proto-oncogene.";
RL   Oncogene Res. 4:9-17(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2421165; DOI=10.1038/320277a0;
RA   Coussens L., van Beveren C., Smith D., Chen E., Mitchell R.L.,
RA   Isacke C.M., Verma I.M., Ullrich A.;
RT   "Structural alteration of viral homologue of receptor proto-oncogene
RT   fms at carboxyl terminus.";
RL   Nature 320:277-280(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=9027509; DOI=10.1006/geno.1996.4482;
RA   Andre C., Hampe A., Lachaume P., Martin E., Wang X.P., Manus V.,
RA   Hu W.X., Galibert F.;
RT   "Sequence analysis of two genomic regions containing the KIT and the
RT   FMS receptor tyrosine kinase genes.";
RL   Genomics 39:216-226(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16.
RX   PubMed=2524648;
RA   Visvader J., Verma I.M.;
RT   "Differential transcription of exon 1 of the human c-fms gene in
RT   placental trophoblasts and monocytes.";
RL   Mol. Cell. Biol. 9:1336-1341(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16.
RX   PubMed=3525854;
RA   Wheeler E.F., Roussel M.F., Hampe A., Walker M.H., Fried V.A.,
RA   Look A.T., Rettenmier C.W., Sherr C.J.;
RT   "The amino-terminal domain of the v-fms oncogene product includes a
RT   functional signal peptide that directs synthesis of a transforming
RT   glycoprotein in the absence of feline leukemia virus gag sequences.";
RL   J. Virol. 59:224-233(1986).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16.
RC   TISSUE=Placenta;
RA   Flick M.B., Sapi E., Kacinski B.M.;
RT   "Expression of a novel exon in the 5' UTR of human c-fms
RT   transcripts.";
RL   Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 244-295.
RX   PubMed=4028159; DOI=10.1016/0092-8674(85)90099-6;
RA   Nienhuis A.W., Bunn H.F., Turner P.H., Gopal T.V., Nash W.G.,
RA   O'Brien S.J., Sherr C.J.;
RT   "Expression of the human c-fms proto-oncogene in hematopoietic cells
RT   and its deletion in the 5q- syndrome.";
RL   Cell 42:421-428(1985).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 874-972 (ISOFORM 1).
RX   PubMed=3532121; DOI=10.1073/pnas.83.20.7800;
RA   Browning P.J., Bunn H.F., Cline A., Shuman M., Nienhuis A.W.;
RT   "'Replacement' of COOH-terminal truncation of v-fms with c-fms
RT   sequences markedly reduces transformation potential.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:7800-7804(1986).
RN   [13]
RP   FUNCTION IN CELL PROLIFERATION.
RX   PubMed=7683918;
RA   Bourette R.P., Mouchiroud G., Ouazana R., Morle F., Godet J.,
RA   Blanchet J.P.;
RT   "Expression of human colony-stimulating factor-1 (CSF-1) receptor in
RT   murine pluripotent hematopoietic NFS-60 cells induces long-term
RT   proliferation in response to CSF-1 without loss of erythroid
RT   differentiation potential.";
RL   Blood 81:2511-2520(1993).
RN   [14]
RP   INTERACTION WITH SRC; FYN AND YES1, AND MUTAGENESIS OF TYR-809.
RX   PubMed=7681396;
RA   Courtneidge S.A., Dhand R., Pilat D., Twamley G.M., Waterfield M.D.,
RA   Roussel M.F.;
RT   "Activation of Src family kinases by colony stimulating factor-1, and
RT   their association with its receptor.";
RL   EMBO J. 12:943-950(1993).
RN   [15]
RP   INDUCTION BY GLUCOCORTICOIDS.
RX   PubMed=7845678;
RA   Sapi E., Flick M.B., Gilmore-Hebert M., Rodov S., Kacinski B.M.;
RT   "Transcriptional regulation of the c-fms (CSF-1R) proto-oncogene in
RT   human breast carcinoma cells by glucocorticoids.";
RL   Oncogene 10:529-542(1995).
RN   [16]
RP   MUTAGENESIS OF TYR-708 AND ASP-802.
RX   PubMed=10340379; DOI=10.1038/sj.onc.1202646;
RA   Morley G.M., Uden M., Gullick W.J., Dibb N.J.;
RT   "Cell specific transformation by c-fms activating loop mutations is
RT   attributable to constitutive receptor degradation.";
RL   Oncogene 18:3076-3084(1999).
RN   [17]
RP   FUNCTION IN CELLULAR SIGNALING; PHOSPHORYLATION OF INPP5D AND
RP   ACTIVATION OF AKT1.
RX   PubMed=12882960; DOI=10.1074/jbc.M305021200;
RA   Baran C.P., Tridandapani S., Helgason C.D., Humphries R.K.,
RA   Krystal G., Marsh C.B.;
RT   "The inositol 5'-phosphatase SHIP-1 and the Src kinase Lyn negatively
RT   regulate macrophage colony-stimulating factor-induced Akt activity.";
RL   J. Biol. Chem. 278:38628-38636(2003).
RN   [18]
RP   FUNCTION IN REGULATION OF CELL PROLIFERATION; CELL ADHESION; CELL
RP   SHAPE AND INTEGRITY OF CELL JUNCTIONS, MUTAGENESIS OF LEU-301 AND
RP   TYR-969, AND ROLE IN DISEASE.
RX   PubMed=15117969; DOI=10.1083/jcb.200309102;
RA   Wrobel C.N., Debnath J., Lin E., Beausoleil S., Roussel M.F.,
RA   Brugge J.S.;
RT   "Autocrine CSF-1R activation promotes Src-dependent disruption of
RT   mammary epithelial architecture.";
RL   J. Cell Biol. 165:263-273(2004).
RN   [19]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-302 AND ASN-353.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [20]
RP   FUNCTION AS CSF1 RECEPTOR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION,
RP   ROLE IN DISEASE, AND ENZYME REGULATION.
RX   PubMed=16648572; DOI=10.1158/1535-7163.MCT-05-0359;
RA   Guo J., Marcotte P.A., McCall J.O., Dai Y., Pease L.J.,
RA   Michaelides M.R., Davidsen S.K., Glaser K.B.;
RT   "Inhibition of phosphorylation of the colony-stimulating factor-1
RT   receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and
RT   other tyrosine kinase inhibitors.";
RL   Mol. Cancer Ther. 5:1007-1013(2006).
RN   [21]
RP   FUNCTION IN CELL PROLIFERATION, CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, ROLE IN DISEASE, AND ENZYME REGULATION.
RX   PubMed=17121910; DOI=10.1158/1535-7163.MCT-05-0313;
RA   Ohno H., Kubo K., Murooka H., Kobayashi Y., Nishitoba T., Shibuya M.,
RA   Yoneda T., Isoe T.;
RT   "A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast
RT   differentiation and osteolytic bone destruction in a bone metastasis
RT   model.";
RL   Mol. Cancer Ther. 5:2634-2643(2006).
RN   [22]
RP   FUNCTION IN REGULATION OF CELL PROLIFERATION AND CELL SHAPE, CATALYTIC
RP   ACTIVITY, UBIQUITINATION, ENZYME REGULATION, AND MUTAGENESIS OF
RP   ASP-802.
RX   PubMed=16170366; DOI=10.1038/sj.onc.1209007;
RA   Taylor J.R., Brownlow N., Domin J., Dibb N.J.;
RT   "FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor
RT   imatinib and mutation of Asp-802 to Val confers resistance.";
RL   Oncogene 25:147-151(2006).
RN   [23]
RP   FUNCTION AS IL34 RECEPTOR.
RX   PubMed=18467591; DOI=10.1126/science.1154370;
RA   Lin H., Lee E., Hestir K., Leo C., Huang M., Bosch E., Halenbeck R.,
RA   Wu G., Zhou A., Behrens D., Hollenbaugh D., Linnemann T., Qin M.,
RA   Wong J., Chu K., Doberstein S.K., Williams L.T.;
RT   "Discovery of a cytokine and its receptor by functional screening of
RT   the extracellular proteome.";
RL   Science 320:807-811(2008).
RN   [24]
RP   ROLE IN DISEASE, AND ENZYME REGULATION.
RX   PubMed=18814279; DOI=10.1002/ijc.23903;
RA   Hiraga T., Nakamura H.;
RT   "Imatinib mesylate suppresses bone metastases of breast cancer by
RT   inhibiting osteoclasts through the blockade of c-Fms signals.";
RL   Int. J. Cancer 124:215-222(2009).
RN   [25]
RP   ROLE IN DISEASE.
RX   PubMed=19934330; DOI=10.1158/0008-5472.CAN-09-1868;
RA   Patsialou A., Wyckoff J., Wang Y., Goswami S., Stanley E.R.,
RA   Condeelis J.S.;
RT   "Invasion of human breast cancer cells in vivo requires both paracrine
RT   and autocrine loops involving the colony-stimulating factor-1
RT   receptor.";
RL   Cancer Res. 69:9498-9506(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-699 AND SER-713, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [27]
RP   AUTOPHOSPHORYLATION, AND ENZYME REGULATION.
RX   PubMed=20156689; DOI=10.1016/j.bmc.2010.01.056;
RA   Mashkani B., Griffith R., Ashman L.K.;
RT   "Colony stimulating factor-1 receptor as a target for small molecule
RT   inhibitors.";
RL   Bioorg. Med. Chem. 18:1789-1797(2010).
RN   [28]
RP   FUNCTION AS RECEPTOR FOR IL34 AND CSF1, PHOSPHORYLATION AT TYR-546;
RP   TYR-699; TYR-708; TYR-723 AND TYR-809, AUTOPHOSPHORYLATION, ENZYME
RP   REGULATION, AND INTERACTION WITH IL34 AND CSF1.
RX   PubMed=20489731; DOI=10.1038/cdd.2010.60;
RA   Chihara T., Suzu S., Hassan R., Chutiwitoonchai N., Hiyoshi M.,
RA   Motoyoshi K., Kimura F., Okada S.;
RT   "IL-34 and M-CSF share the receptor Fms but are not identical in
RT   biological activity and signal activation.";
RL   Cell Death Differ. 17:1917-1927(2010).
RN   [29]
RP   FUNCTION IN RELEASE OF PROINFLAMMATORY CHEMOKINES.
RX   PubMed=20829061; DOI=10.1016/j.cyto.2010.08.005;
RA   Eda H., Zhang J., Keith R.H., Michener M., Beidler D.R., Monahan J.B.;
RT   "Macrophage-colony stimulating factor and interleukin-34 induce
RT   chemokines in human whole blood.";
RL   Cytokine 52:215-220(2010).
RN   [30]
RP   FUNCTION AS IL34 AND CSF1 RECEPTOR; ACTIVATION OF MAPK1/ERK2;
RP   MAPK3/ERK1; PHOSPHORYLATION AT TYR-723, AND AUTOPHOSPHORYLATION.
RX   PubMed=20504948; DOI=10.1189/jlb.1209822;
RA   Wei S., Nandi S., Chitu V., Yeung Y.G., Yu W., Huang M.,
RA   Williams L.T., Lin H., Stanley E.R.;
RT   "Functional overlap but differential expression of CSF-1 and IL-34 in
RT   their CSF-1 receptor-mediated regulation of myeloid cells.";
RL   J. Leukoc. Biol. 88:495-505(2010).
RN   [31]
RP   REVIEW ON FUNCTION; SIGNALING PATHWAYS AND PHOSPHORYLATION.
RX   PubMed=15519852; DOI=10.1016/j.tcb.2004.09.016;
RA   Pixley F.J., Stanley E.R.;
RT   "CSF-1 regulation of the wandering macrophage: complexity in action.";
RL   Trends Cell Biol. 14:628-638(2004).
RN   [32]
RP   REVIEW ON FUNCTION IN IMMUNITY AND INFLAMMATION, AND ROLE IN DISEASE.
RX   PubMed=16337366; DOI=10.1016/j.coi.2005.11.006;
RA   Chitu V., Stanley E.R.;
RT   "Colony-stimulating factor-1 in immunity and inflammation.";
RL   Curr. Opin. Immunol. 18:39-48(2006).
RN   [33]
RP   REVIEW ON FUNCTION; SIGNALING PATHWAYS AND PHOSPHORYLATION.
RX   PubMed=18687298; DOI=10.1016/j.intimp.2008.04.016;
RA   Douglass T.G., Driggers L., Zhang J.G., Hoa N., Delgado C.,
RA   Williams C.C., Dan Q., Sanchez R., Jeffes E.W., Wepsic H.T.,
RA   Myers M.P., Koths K., Jadus M.R.;
RT   "Macrophage colony stimulating factor: not just for macrophages
RT   anymore! A gateway into complex biologies.";
RL   Int. Immunopharmacol. 8:1354-1376(2008).
RN   [34]
RP   REVIEW.
RX   PubMed=19132917; DOI=10.1146/annurev.immunol.021908.132557;
RA   Auffray C., Sieweke M.H., Geissmann F.;
RT   "Blood monocytes: development, heterogeneity, and relationship with
RT   dendritic cells.";
RL   Annu. Rev. Immunol. 27:669-692(2009).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 538-922 IN COMPLEXES WITH
RP   ARYLAMIDE AND QUINOLONE INHIBITORS, AND DOMAIN.
RX   PubMed=17132624; DOI=10.1074/jbc.M608183200;
RA   Schubert C., Schalk-Hihi C., Struble G.T., Ma H.C., Petrounia I.P.,
RA   Brandt B., Deckman I.C., Patch R.J., Player M.R., Spurlino J.C.,
RA   Springer B.A.;
RT   "Crystal structure of the tyrosine kinase domain of colony-stimulating
RT   factor-1 receptor (cFMS) in complex with two inhibitors.";
RL   J. Biol. Chem. 282:4094-4101(2007).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 543-918 IN AUTOINHIBITED
RP   CONFORMATION, AND DOMAIN.
RX   PubMed=17292918; DOI=10.1016/j.jmb.2007.01.036;
RA   Walter M., Lucet I.S., Patel O., Broughton S.E., Bamert R.,
RA   Williams N.K., Fantino E., Wilks A.F., Rossjohn J.;
RT   "The 2.7 A crystal structure of the autoinhibited human c-Fms kinase
RT   domain.";
RL   J. Mol. Biol. 367:839-847(2007).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.02 ANGSTROMS) OF 538-922 IN COMPLEX WITH
RP   PYRIMIDINOPYRIDONE INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=18342505; DOI=10.1016/j.bmcl.2008.02.070;
RA   Huang H., Hutta D.A., Hu H., DesJarlais R.L., Schubert C.,
RA   Petrounia I.P., Chaikin M.A., Manthey C.L., Player M.R.;
RT   "Design and synthesis of a pyrido[2,3-d]pyrimidin-5-one class of anti-
RT   inflammatory FMS inhibitors.";
RL   Bioorg. Med. Chem. Lett. 18:2355-2361(2008).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 538-922 IN COMPLEX WITH
RP   INHIBITOR, CATALYTIC ACTIVITY, AND FUNCTION IN INFLAMMATION AND
RP   DISEASE.
RX   PubMed=19193011; DOI=10.1021/jm801406h;
RA   Huang H., Hutta D.A., Rinker J.M., Hu H., Parsons W.H., Schubert C.,
RA   DesJarlais R.L., Crysler C.S., Chaikin M.A., Donatelli R.R., Chen Y.,
RA   Cheng D., Zhou Z., Yurkow E., Manthey C.L., Player M.R.;
RT   "Pyrido[2,3-d]pyrimidin-5-ones: a novel class of antiinflammatory
RT   macrophage colony-stimulating factor-1 receptor inhibitors.";
RL   J. Med. Chem. 52:1081-1099(2009).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 538-922 IN COMPLEXES WITH
RP   INHIBITORS, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=20137931; DOI=10.1016/j.bmcl.2010.01.078;
RA   Meyers M.J., Pelc M., Kamtekar S., Day J., Poda G.I., Hall M.K.,
RA   Michener M.L., Reitz B.A., Mathis K.J., Pierce B.S., Parikh M.D.,
RA   Mischke D.A., Long S.A., Parlow J.J., Anderson D.R., Thorarensen A.;
RT   "Structure-based drug design enables conversion of a DFG-in binding
RT   CSF-1R kinase inhibitor to a DFG-out binding mode.";
RL   Bioorg. Med. Chem. Lett. 20:1543-1547(2010).
RN   [41]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-32; ARG-362; SER-413; VAL-536;
RP   HIS-693; ASP-920 AND GLN-921.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [42]
RP   VARIANTS HDLS 774-CYS--ASN-814 DEL; 585-GLY--LYS-619 DELINS ALA;
RP   GLU-589; LYS-633; THR-766; PRO-770; ASN-775; THR-794; TYR-837;
RP   SER-849; PHE-849 DEL; PRO-868; THR-875 AND THR-878, VARIANTS HIS-710;
RP   ARG-747 AND ASP-920, AND CHARACTERIZATION OF VARIANTS HDLS LYS-633;
RP   THR-766 AND THR-875.
RX   PubMed=22197934; DOI=10.1038/ng.1027;
RA   Rademakers R., Baker M., Nicholson A.M., Rutherford N.J., Finch N.,
RA   Soto-Ortolaza A., Lash J., Wider C., Wojtas A., DeJesus-Hernandez M.,
RA   Adamson J., Kouri N., Sundal C., Shuster E.A., Aasly J., MacKenzie J.,
RA   Roeber S., Kretzschmar H.A., Boeve B.F., Knopman D.S., Petersen R.C.,
RA   Cairns N.J., Ghetti B., Spina S., Garbern J., Tselis A.C., Uitti R.,
RA   Das P., Van Gerpen J.A., Meschia J.F., Levy S., Broderick D.F.,
RA   Graff-Radford N., Ross O.A., Miller B.B., Swerdlow R.H., Dickson D.W.,
RA   Wszolek Z.K.;
RT   "Mutations in the colony stimulating factor 1 receptor (CSF1R) gene
RT   cause hereditary diffuse leukoencephalopathy with spheroids.";
RL   Nat. Genet. 44:200-205(2012).
RN   [43]
RP   VARIANTS HDLS ARG-653; PHE-843 AND THR-906.
RX   PubMed=24532199; DOI=10.1007/s00415-014-7257-3;
RA   Battisti C., Di Donato I., Bianchi S., Monti L., Formichi P., Rufa A.,
RA   Taglia I., Cerase A., Dotti M.T., Federico A.;
RT   "Hereditary diffuse leukoencephalopathy with axonal spheroids: three
RT   patients with stroke-like presentation carrying new mutations in the
RT   CSF1R gene.";
RL   J. Neurol. 261:768-772(2014).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for CSF1 and IL34 and plays an essential role in the
CC       regulation of survival, proliferation and differentiation of
CC       hematopoietic precursor cells, especially mononuclear phagocytes,
CC       such as macrophages and monocytes. Promotes the release of
CC       proinflammatory chemokines in response to IL34 and CSF1, and
CC       thereby plays an important role in innate immunity and in
CC       inflammatory processes. Plays an important role in the regulation
CC       of osteoclast proliferation and differentiation, the regulation of
CC       bone resorption, and is required for normal bone and tooth
CC       development. Required for normal male and female fertility, and
CC       for normal development of milk ducts and acinar structures in the
CC       mammary gland during pregnancy. Promotes reorganization of the
CC       actin cytoskeleton, regulates formation of membrane ruffles, cell
CC       adhesion and cell migration, and promotes cancer cell invasion.
CC       Activates several signaling pathways in response to ligand
CC       binding. Phosphorylates PIK3R1, PLCG2, GRB2, SLA2 and CBL.
CC       Activation of PLCG2 leads to the production of the cellular
CC       signaling molecules diacylglycerol and inositol 1,4,5-
CC       trisphosphate, that then lead to the activation of protein kinase
CC       C family members, especially PRKCD. Phosphorylation of PIK3R1, the
CC       regulatory subunit of phosphatidylinositol 3-kinase, leads to
CC       activation of the AKT1 signaling pathway. Activated CSF1R also
CC       mediates activation of the MAP kinases MAPK1/ERK2 and/or
CC       MAPK3/ERK1, and of the SRC family kinases SRC, FYN and YES1.
CC       Activated CSF1R transmits signals both via proteins that directly
CC       interact with phosphorylated tyrosine residues in its
CC       intracellular domain, or via adapter proteins, such as GRB2.
CC       Promotes activation of STAT family members STAT3, STAT5A and/or
CC       STAT5B. Promotes tyrosine phosphorylation of SHC1 and INPP5D/SHIP-
CC       1. Receptor signaling is down-regulated by protein phosphatases,
CC       such as INPP5D/SHIP-1, that dephosphorylate the receptor and its
CC       downstream effectors, and by rapid internalization of the
CC       activated receptor. {ECO:0000269|PubMed:12882960,
CC       ECO:0000269|PubMed:15117969, ECO:0000269|PubMed:16170366,
CC       ECO:0000269|PubMed:16337366, ECO:0000269|PubMed:16648572,
CC       ECO:0000269|PubMed:17121910, ECO:0000269|PubMed:18467591,
CC       ECO:0000269|PubMed:18814279, ECO:0000269|PubMed:19193011,
CC       ECO:0000269|PubMed:19934330, ECO:0000269|PubMed:20489731,
CC       ECO:0000269|PubMed:20504948, ECO:0000269|PubMed:20829061,
CC       ECO:0000269|PubMed:7683918}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:16170366,
CC       ECO:0000269|PubMed:16648572, ECO:0000269|PubMed:17121910,
CC       ECO:0000269|PubMed:18342505, ECO:0000269|PubMed:19193011,
CC       ECO:0000269|PubMed:20137931}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. CSF1 or IL34 binding leads to
CC       dimerization and activation by autophosphorylation on tyrosine
CC       residues. Inhibited by imatinib/STI-571 (Gleevec), dasatinib,
CC       sunitinib/SU11248, lestaurtinib/CEP-701, midostaurin/PKC-412,
CC       Ki20227, linifanib/ABT-869, Axitinib/AG013736, sorafenib/BAY 43-
CC       9006 and GW2580. {ECO:0000269|PubMed:16170366,
CC       ECO:0000269|PubMed:16648572, ECO:0000269|PubMed:17121910,
CC       ECO:0000269|PubMed:18814279, ECO:0000269|PubMed:20137931,
CC       ECO:0000269|PubMed:20156689, ECO:0000269|PubMed:20489731}.
CC   -!- SUBUNIT: Interacts with INPPL1/SHIP2 and THOC5 (By similarity).
CC       Monomer. Homodimer. Interacts with CSF1 and IL34. Interaction with
CC       dimeric CSF1 or IL34 leads to receptor homodimerization. Interacts
CC       (tyrosine phosphorylated) with PLCG2 (via SH2 domain). Interacts
CC       (tyrosine phosphorylated) with PIK3R1 (via SH2 domain). Interacts
CC       (tyrosine phosphorylated) with FYN, YES1 and SRC (via SH2 domain).
CC       Interacts (tyrosine phosphorylated) with CBL, GRB2 and SLA2.
CC       {ECO:0000250, ECO:0000269|PubMed:18342505,
CC       ECO:0000269|PubMed:19193011, ECO:0000269|PubMed:20489731,
CC       ECO:0000269|PubMed:7681396}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P07333-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P07333-2; Sequence=VSP_047757, VSP_047758;
CC   -!- TISSUE SPECIFICITY: Expressed in bone marrow and in differentiated
CC       blood mononuclear cells.
CC   -!- INDUCTION: Up-regulated by glucocorticoids.
CC       {ECO:0000269|PubMed:7845678}.
CC   -!- DOMAIN: The juxtamembrane domain functions as autoinhibitory
CC       region. Phosphorylation of tyrosine residues in this region leads
CC       to a conformation change and activation of the kinase.
CC   -!- DOMAIN: The activation loop plays an important role in the
CC       regulation of kinase activity. Phosphorylation of tyrosine
CC       residues in this region leads to a conformation change and
CC       activation of the kinase.
CC   -!- PTM: Autophosphorylated in response to CSF1 or IL34 binding.
CC       Phosphorylation at Tyr-561 is important for normal down-regulation
CC       of signaling by ubiquitination, internalization and degradation.
CC       Phosphorylation at Tyr-561 and Tyr-809 is important for
CC       interaction with SRC family members, including FYN, YES1 and SRC,
CC       and for subsequent activation of these protein kinases.
CC       Phosphorylation at Tyr-699 and Tyr-923 is important for
CC       interaction with GRB2. Phosphorylation at Tyr-723 is important for
CC       interaction with PIK3R1. Phosphorylation at Tyr-708 is important
CC       for normal receptor degradation. Phosphorylation at Tyr-723 and
CC       Tyr-809 is important for interaction with PLCG2. Phosphorylation
CC       at Tyr-969 is important for interaction with CBL.
CC       Dephosphorylation by PTPN2 negatively regulates downstream
CC       signaling and macrophage differentiation.
CC       {ECO:0000269|PubMed:16170366, ECO:0000269|PubMed:20489731}.
CC   -!- PTM: Ubiquitinated. Becomes rapidly polyubiquitinated after
CC       autophosphorylation, leading to its degradation.
CC       {ECO:0000269|PubMed:16170366}.
CC   -!- DISEASE: Note=Aberrant expression of CSF1 or CSF1R can promote
CC       cancer cell proliferation, invasion and formation of metastases.
CC       Overexpression of CSF1 or CSF1R is observed in a significant
CC       percentage of breast, ovarian, prostate, and endometrial cancers.
CC   -!- DISEASE: Note=Aberrant expression of CSF1 or CSF1R may play a role
CC       in inflammatory diseases, such as rheumatoid arthritis,
CC       glomerulonephritis, atherosclerosis, and allograft rejection.
CC   -!- DISEASE: Leukoencephalopathy, diffuse hereditary, with spheroids
CC       (HDLS) [MIM:221820]: An autosomal dominant adult-onset rapidly
CC       progressive neurodegenerative disorder characterized by variable
CC       behavioral, cognitive, and motor changes. Patients often die of
CC       dementia within 6 years of onset. Brain imaging shows patchy
CC       abnormalities in the cerebral white matter, predominantly
CC       affecting the frontal and parietal lobes.
CC       {ECO:0000269|PubMed:22197934, ECO:0000269|PubMed:24532199}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 5 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CSF1RID40161ch5q32.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X03663; CAA27300.1; -; mRNA.
DR   EMBL; U63963; AAB51696.1; -; Genomic_DNA.
DR   EMBL; M25786; AAA58421.1; -; mRNA.
DR   EMBL; EU826593; ACF47629.1; -; mRNA.
DR   EMBL; AC011382; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471062; EAW61749.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW61750.1; -; Genomic_DNA.
DR   EMBL; BC047521; AAH47521.1; -; mRNA.
DR   EMBL; M14002; AAA35849.1; -; Genomic_DNA.
DR   EMBL; U78096; AAB51235.1; -; Genomic_DNA.
DR   EMBL; M11067; AAA35848.1; -; Genomic_DNA.
DR   EMBL; M14193; AAA35834.1; -; mRNA.
DR   CCDS; CCDS4302.1; -. [P07333-1]
DR   PIR; S08123; TVHUMD.
DR   RefSeq; NP_001275634.1; NM_001288705.1. [P07333-1]
DR   RefSeq; NP_005202.2; NM_005211.3. [P07333-1]
DR   UniGene; Hs.586219; -.
DR   PDB; 2I0V; X-ray; 2.80 A; A=538-678, A=753-922.
DR   PDB; 2I0Y; X-ray; 1.90 A; A=538-678, A=753-922.
DR   PDB; 2I1M; X-ray; 1.80 A; A=538-678, A=753-922.
DR   PDB; 2OGV; X-ray; 2.70 A; A=543-918.
DR   PDB; 3BEA; X-ray; 2.02 A; A=538-678, A=753-922.
DR   PDB; 3DPK; X-ray; 1.95 A; A=538-678, A=771-922.
DR   PDB; 3KRJ; X-ray; 2.10 A; A=538-678, A=753-922.
DR   PDB; 3KRL; X-ray; 2.40 A; A=538-678, A=753-922.
DR   PDB; 3LCD; X-ray; 2.50 A; A=538-919.
DR   PDB; 3LCO; X-ray; 3.40 A; A=550-919.
DR   PDB; 4DKD; X-ray; 3.00 A; C=20-299.
DR   PDB; 4HW7; X-ray; 2.90 A; A=542-919.
DR   PDB; 4LIQ; X-ray; 2.60 A; E=2-512.
DR   PDB; 4R7H; X-ray; 2.80 A; A=542-919.
DR   PDB; 4R7I; X-ray; 2.75 A; A=542-919.
DR   PDB; 4WRL; X-ray; 2.80 A; A/C=20-296.
DR   PDB; 4WRM; X-ray; 6.85 A; A=20-504.
DR   PDBsum; 2I0V; -.
DR   PDBsum; 2I0Y; -.
DR   PDBsum; 2I1M; -.
DR   PDBsum; 2OGV; -.
DR   PDBsum; 3BEA; -.
DR   PDBsum; 3DPK; -.
DR   PDBsum; 3KRJ; -.
DR   PDBsum; 3KRL; -.
DR   PDBsum; 3LCD; -.
DR   PDBsum; 3LCO; -.
DR   PDBsum; 4DKD; -.
DR   PDBsum; 4HW7; -.
DR   PDBsum; 4LIQ; -.
DR   PDBsum; 4R7H; -.
DR   PDBsum; 4R7I; -.
DR   PDBsum; 4WRL; -.
DR   PDBsum; 4WRM; -.
DR   ProteinModelPortal; P07333; -.
DR   SMR; P07333; 20-500, 544-945.
DR   BioGrid; 107823; 17.
DR   DIP; DIP-59421N; -.
DR   IntAct; P07333; 12.
DR   MINT; MINT-8019993; -.
DR   STRING; 9606.ENSP00000286301; -.
DR   BindingDB; P07333; -.
DR   ChEMBL; CHEMBL1844; -.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB01268; Sunitinib.
DR   GuidetoPHARMACOLOGY; 1806; -.
DR   iPTMnet; P07333; -.
DR   PhosphoSite; P07333; -.
DR   BioMuta; CSF1R; -.
DR   DMDM; 547770; -.
DR   PaxDb; P07333; -.
DR   PeptideAtlas; P07333; -.
DR   PRIDE; P07333; -.
DR   DNASU; 1436; -.
DR   Ensembl; ENST00000286301; ENSP00000286301; ENSG00000182578. [P07333-1]
DR   Ensembl; ENST00000543093; ENSP00000445282; ENSG00000182578. [P07333-2]
DR   GeneID; 1436; -.
DR   KEGG; hsa:1436; -.
DR   UCSC; uc003lrl.3; human. [P07333-1]
DR   UCSC; uc011dce.1; human.
DR   CTD; 1436; -.
DR   GeneCards; CSF1R; -.
DR   GeneReviews; CSF1R; -.
DR   HGNC; HGNC:2433; CSF1R.
DR   HPA; CAB008970; -.
DR   HPA; HPA012323; -.
DR   MalaCards; CSF1R; -.
DR   MIM; 164770; gene.
DR   MIM; 221820; phenotype.
DR   neXtProt; NX_P07333; -.
DR   Orphanet; 313808; Hereditary diffuse leukoencephalopathy with axonal spheroids and pigmented glia.
DR   PharmGKB; PA26936; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000112008; -.
DR   HOVERGEN; HBG004335; -.
DR   InParanoid; P07333; -.
DR   KO; K05090; -.
DR   OMA; WKIIESY; -.
DR   PhylomeDB; P07333; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   SignaLink; P07333; -.
DR   ChiTaRS; CSF1R; human.
DR   EvolutionaryTrace; P07333; -.
DR   GeneWiki; Colony_stimulating_factor_1_receptor; -.
DR   GenomeRNAi; 1436; -.
DR   NextBio; 35477774; -.
DR   PRO; PR:P07333; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; P07333; -.
DR   CleanEx; HS_CSF1R; -.
DR   ExpressionAtlas; P07333; baseline and differential.
DR   Genevisible; P07333; HS.
DR   GO; GO:0009986; C:cell surface; ISS:UniProtKB.
DR   GO; GO:1990682; C:CSF1-CSF1R complex; ISS:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005622; C:intracellular; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019955; F:cytokine binding; IDA:UniProtKB.
DR   GO; GO:0005011; F:macrophage colony-stimulating factor receptor activity; IMP:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:BHF-UCL.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0008283; P:cell proliferation; IMP:UniProtKB.
DR   GO; GO:0045217; P:cell-cell junction maintenance; IMP:UniProtKB.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; ISS:UniProtKB.
DR   GO; GO:0036006; P:cellular response to macrophage colony-stimulating factor stimulus; IMP:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0021879; P:forebrain neuron differentiation; IEA:Ensembl.
DR   GO; GO:0030097; P:hemopoiesis; IMP:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; TAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0038145; P:macrophage colony-stimulating factor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0030225; P:macrophage differentiation; TAS:UniProtKB.
DR   GO; GO:0060603; P:mammary gland duct morphogenesis; TAS:UniProtKB.
DR   GO; GO:0030224; P:monocyte differentiation; TAS:UniProtKB.
DR   GO; GO:0007275; P:multicellular organismal development; TAS:ProtInc.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0021772; P:olfactory bulb development; IEA:Ensembl.
DR   GO; GO:0030316; P:osteoclast differentiation; ISS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0046488; P:phosphatidylinositol metabolic process; ISS:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; ISS:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:2000147; P:positive regulation of cell motility; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0090197; P:positive regulation of chemokine secretion; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0045672; P:positive regulation of osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; IMP:UniProtKB.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphorylation of Stat3 protein; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; ISS:UniProtKB.
DR   GO; GO:0045124; P:regulation of bone resorption; ISS:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0031529; P:ruffle organization; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 5.
DR   InterPro; IPR030658; CSF-1_receptor.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016243; Tyr_kinase_CSF1/PDGF_rcpt.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   PANTHER; PTHR24416:SF47; PTHR24416:SF47; 3.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF500947; CSF-1_receptor; 1.
DR   PIRSF; PIRSF000615; TyrPK_CSF1-R; 1.
DR   SMART; SM00409; IG; 3.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 5.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Disease mutation; Disulfide bond; Glycoprotein;
KW   Immunity; Immunoglobulin domain; Inflammatory response;
KW   Innate immunity; Kinase; Membrane; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   CHAIN        20    972       Macrophage colony-stimulating factor 1
FT                                receptor.
FT                                /FTId=PRO_0000016765.
FT   TOPO_DOM     20    517       Extracellular. {ECO:0000255}.
FT   TRANSMEM    518    538       Helical. {ECO:0000255}.
FT   TOPO_DOM    539    972       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       21    104       Ig-like C2-type 1.
FT   DOMAIN      107    197       Ig-like C2-type 2.
FT   DOMAIN      203    290       Ig-like C2-type 3.
FT   DOMAIN      299    399       Ig-like C2-type 4.
FT   DOMAIN      402    502       Ig-like C2-type 5.
FT   DOMAIN      582    910       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     588    596       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      542    574       Regulatory juxtamembrane domain.
FT   REGION      796    818       Activation loop.
FT   ACT_SITE    778    778       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     616    616       ATP. {ECO:0000305}.
FT   MOD_RES     546    546       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:20489731}.
FT   MOD_RES     561    561       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     699    699       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:20489731}.
FT   MOD_RES     708    708       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:20489731}.
FT   MOD_RES     713    713       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     723    723       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:20489731}.
FT   MOD_RES     809    809       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:20489731}.
FT   MOD_RES     923    923       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     969    969       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     45     45       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     73     73       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    153    153       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    240    240       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    275    275       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    302    302       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    335    335       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    353    353       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    412    412       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    428    428       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    480    480       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     42     84       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    127    177       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    224    278       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    419    485       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ     297    306       ESAYLNLSSE -> GTPSPSLCPA (in isoform 2).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_047757.
FT   VAR_SEQ     307    972       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_047758.
FT   VARIANT      32     32       V -> G (in dbSNP:rs56048668).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042038.
FT   VARIANT     245    245       A -> S (in dbSNP:rs41338945).
FT                                /FTId=VAR_061290.
FT   VARIANT     279    279       V -> M (in dbSNP:rs3829986).
FT                                /FTId=VAR_049718.
FT   VARIANT     362    362       H -> R (in dbSNP:rs10079250).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042039.
FT   VARIANT     413    413       G -> S (in dbSNP:rs34951517).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042040.
FT   VARIANT     536    536       L -> V (in dbSNP:rs55942044).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042041.
FT   VARIANT     585    619       GKTLGAGAFGKVVEATAFGLGKEDAVLKVAVKMLK -> A
FT                                (in HDLS). {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067396.
FT   VARIANT     589    589       G -> E (in HDLS).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067397.
FT   VARIANT     633    633       E -> K (in HDLS; impairs
FT                                autophosphorylation upon stimulation with
FT                                CSF1). {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067398.
FT   VARIANT     653    653       C -> R (in HDLS).
FT                                {ECO:0000269|PubMed:24532199}.
FT                                /FTId=VAR_072081.
FT   VARIANT     693    693       P -> H (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042042.
FT   VARIANT     710    710       R -> H. {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067399.
FT   VARIANT     747    747       G -> R (in dbSNP:rs41355444).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067400.
FT   VARIANT     766    766       M -> T (in HDLS; impairs
FT                                autophosphorylation upon stimulation with
FT                                CSF1). {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067401.
FT   VARIANT     770    770       A -> P (in HDLS).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067402.
FT   VARIANT     774    814       Missing (in HDLS).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067403.
FT   VARIANT     775    775       I -> N (in HDLS; impairs
FT                                autophosphorylation upon stimulation with
FT                                CSF1). {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067404.
FT   VARIANT     794    794       I -> T (in HDLS).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067405.
FT   VARIANT     837    837       D -> Y (in HDLS).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067406.
FT   VARIANT     843    843       I -> F (in HDLS).
FT                                {ECO:0000269|PubMed:24532199}.
FT                                /FTId=VAR_072082.
FT   VARIANT     849    849       F -> S (in HDLS).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067407.
FT   VARIANT     849    849       Missing (in HDLS).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067408.
FT   VARIANT     868    868       L -> P (in HDLS).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067409.
FT   VARIANT     875    875       M -> T (in HDLS).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067410.
FT   VARIANT     878    878       P -> T (in HDLS).
FT                                {ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_067411.
FT   VARIANT     906    906       I -> T (in HDLS).
FT                                {ECO:0000269|PubMed:24532199}.
FT                                /FTId=VAR_072083.
FT   VARIANT     920    920       E -> D (in dbSNP:rs34030164).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:22197934}.
FT                                /FTId=VAR_042043.
FT   VARIANT     921    921       R -> Q (in dbSNP:rs56059682).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042044.
FT   VARIANT     969    969       Y -> C (in dbSNP:rs1801271).
FT                                /FTId=VAR_011953.
FT   MUTAGEN     301    301       L->S: Constitutive kinase activity.
FT                                {ECO:0000269|PubMed:15117969}.
FT   MUTAGEN     708    708       Y->F: Impairs degradation of activated
FT                                CSF1R. {ECO:0000269|PubMed:10340379}.
FT   MUTAGEN     802    802       D->V: Constitutive kinase activity. Loss
FT                                of inhibition by imatinib.
FT                                {ECO:0000269|PubMed:10340379,
FT                                ECO:0000269|PubMed:16170366}.
FT   MUTAGEN     809    809       Y->F: Reduced kinase activity. Reduced
FT                                interaction with SRC, FYN and YES1.
FT                                {ECO:0000269|PubMed:7681396}.
FT   MUTAGEN     969    969       Y->F: Abolishes down-regulation of
FT                                activated CSF1R.
FT                                {ECO:0000269|PubMed:15117969}.
FT   CONFLICT     54     54       P -> A (in Ref. 2; CAA27300).
FT                                {ECO:0000305}.
FT   CONFLICT    247    247       P -> H (in Ref. 7; AAH47521).
FT                                {ECO:0000305}.
FT   CONFLICT    354    354       A -> V (in Ref. 7; AAH47521).
FT                                {ECO:0000305}.
FT   CONFLICT    629    629       A -> S (in Ref. 7; AAH47521).
FT                                {ECO:0000305}.
FT   STRAND       22     25       {ECO:0000244|PDB:4LIQ}.
FT   STRAND       27     32       {ECO:0000244|PDB:4LIQ}.
FT   STRAND       38     43       {ECO:0000244|PDB:4LIQ}.
FT   STRAND       49     51       {ECO:0000244|PDB:4LIQ}.
FT   TURN         55     57       {ECO:0000244|PDB:4LIQ}.
FT   STRAND       58     62       {ECO:0000244|PDB:4LIQ}.
FT   STRAND       64     73       {ECO:0000244|PDB:4LIQ}.
FT   HELIX        76     78       {ECO:0000244|PDB:4LIQ}.
FT   STRAND       80     85       {ECO:0000244|PDB:4LIQ}.
FT   STRAND       95    101       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      108    111       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      113    118       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      123    125       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      127    130       {ECO:0000244|PDB:4LIQ}.
FT   HELIX       132    137       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      139    142       {ECO:0000244|PDB:4LIQ}.
FT   HELIX       143    145       {ECO:0000244|PDB:4WRL}.
FT   STRAND      154    157       {ECO:0000244|PDB:4LIQ}.
FT   TURN        158    160       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      161    166       {ECO:0000244|PDB:4LIQ}.
FT   HELIX       169    171       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      173    181       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      184    187       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      191    196       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      204    208       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      210    215       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      216    218       {ECO:0000244|PDB:4DKD}.
FT   STRAND      220    231       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      234    239       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      248    252       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      257    267       {ECO:0000244|PDB:4LIQ}.
FT   TURN        270    272       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      274    282       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      285    298       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      300    304       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      309    314       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      319    329       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      332    338       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      340    342       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      351    354       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      361    368       {ECO:0000244|PDB:4LIQ}.
FT   HELIX       373    375       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      377    385       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      388    411       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      414    425       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      428    437       {ECO:0000244|PDB:4LIQ}.
FT   TURN        443    445       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      446    454       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      456    459       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      466    473       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      479    488       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      493    498       {ECO:0000244|PDB:4LIQ}.
FT   STRAND      551    553       {ECO:0000244|PDB:4R7H}.
FT   STRAND      556    560       {ECO:0000244|PDB:3BEA}.
FT   HELIX       566    568       {ECO:0000244|PDB:3KRJ}.
FT   HELIX       573    575       {ECO:0000244|PDB:2I1M}.
FT   STRAND      581    590       {ECO:0000244|PDB:2I1M}.
FT   STRAND      592    601       {ECO:0000244|PDB:2I1M}.
FT   STRAND      605    607       {ECO:0000244|PDB:2I1M}.
FT   STRAND      612    618       {ECO:0000244|PDB:2I1M}.
FT   HELIX       624    640       {ECO:0000244|PDB:2I1M}.
FT   STRAND      649    653       {ECO:0000244|PDB:2I1M}.
FT   STRAND      655    658       {ECO:0000244|PDB:2I1M}.
FT   STRAND      660    664       {ECO:0000244|PDB:2I1M}.
FT   HELIX       671    678       {ECO:0000244|PDB:2I1M}.
FT   TURN        684    686       {ECO:0000244|PDB:4R7I}.
FT   TURN        742    744       {ECO:0000244|PDB:2OGV}.
FT   HELIX       753    771       {ECO:0000244|PDB:2I1M}.
FT   HELIX       781    783       {ECO:0000244|PDB:2I1M}.
FT   STRAND      785    787       {ECO:0000244|PDB:2I1M}.
FT   HELIX       788    790       {ECO:0000244|PDB:2I1M}.
FT   STRAND      791    794       {ECO:0000244|PDB:2I1M}.
FT   HELIX       798    800       {ECO:0000244|PDB:2I1M}.
FT   HELIX       803    805       {ECO:0000244|PDB:2I1M}.
FT   TURN        806    808       {ECO:0000244|PDB:3LCO}.
FT   STRAND      809    811       {ECO:0000244|PDB:2I1M}.
FT   STRAND      815    817       {ECO:0000244|PDB:3BEA}.
FT   HELIX       819    821       {ECO:0000244|PDB:2I1M}.
FT   HELIX       824    829       {ECO:0000244|PDB:2I1M}.
FT   HELIX       834    848       {ECO:0000244|PDB:2I1M}.
FT   TURN        849    851       {ECO:0000244|PDB:2I1M}.
FT   HELIX       863    871       {ECO:0000244|PDB:2I1M}.
FT   HELIX       883    892       {ECO:0000244|PDB:2I1M}.
FT   HELIX       897    899       {ECO:0000244|PDB:2I1M}.
FT   HELIX       903    920       {ECO:0000244|PDB:2I1M}.
SQ   SEQUENCE   972 AA;  107984 MW;  A8D99BE237573FE8 CRC64;
     MGPGVLLLLL VATAWHGQGI PVIEPSVPEL VVKPGATVTL RCVGNGSVEW DGPPSPHWTL
     YSDGSSSILS TNNATFQNTG TYRCTEPGDP LGGSAAIHLY VKDPARPWNV LAQEVVVFED
     QDALLPCLLT DPVLEAGVSL VRVRGRPLMR HTNYSFSPWH GFTIHRAKFI QSQDYQCSAL
     MGGRKVMSIS IRLKVQKVIP GPPALTLVPA ELVRIRGEAA QIVCSASSVD VNFDVFLQHN
     NTKLAIPQQS DFHNNRYQKV LTLNLDQVDF QHAGNYSCVA SNVQGKHSTS MFFRVVESAY
     LNLSSEQNLI QEVTVGEGLN LKVMVEAYPG LQGFNWTYLG PFSDHQPEPK LANATTKDTY
     RHTFTLSLPR LKPSEAGRYS FLARNPGGWR ALTFELTLRY PPEVSVIWTF INGSGTLLCA
     ASGYPQPNVT WLQCSGHTDR CDEAQVLQVW DDPYPEVLSQ EPFHKVTVQS LLTVETLEHN
     QTYECRAHNS VGSGSWAFIP ISAGAHTHPP DEFLFTPVVV ACMSIMALLL LLLLLLLYKY
     KQKPKYQVRW KIIESYEGNS YTFIDPTQLP YNEKWEFPRN NLQFGKTLGA GAFGKVVEAT
     AFGLGKEDAV LKVAVKMLKS TAHADEKEAL MSELKIMSHL GQHENIVNLL GACTHGGPVL
     VITEYCCYGD LLNFLRRKAE AMLGPSLSPG QDPEGGVDYK NIHLEKKYVR RDSGFSSQGV
     DTYVEMRPVS TSSNDSFSEQ DLDKEDGRPL ELRDLLHFSS QVAQGMAFLA SKNCIHRDVA
     ARNVLLTNGH VAKIGDFGLA RDIMNDSNYI VKGNARLPVK WMAPESIFDC VYTVQSDVWS
     YGILLWEIFS LGLNPYPGIL VNSKFYKLVK DGYQMAQPAF APKNIYSIMQ ACWALEPTHR
     PTFQQICSFL QEQAQEDRRE RDYTNLPSSS RSGGSGSSSS ELEEESSSEH LTCCEQGDIA
     QPLLQPNNYQ FC
//
ID   BMP2_MOUSE              Reviewed;         394 AA.
AC   P21274; Q497W8;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 3.
DT   09-DEC-2015, entry version 149.
DE   RecName: Full=Bone morphogenetic protein 2;
DE            Short=BMP-2;
DE   AltName: Full=Bone morphogenetic protein 2A;
DE            Short=BMP-2A;
DE   Flags: Precursor;
GN   Name=Bmp2; Synonyms=Bmp-2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8018727; DOI=10.1016/0167-4781(94)90017-5;
RA   Feng J.Q., Harris M.A., Ghosh-Choudhury N., Feng M., Mundy G.R.,
RA   Harris S.E.;
RT   "Structure and sequence of mouse bone morphogenetic protein-2 gene
RT   (BMP-2): comparison of the structures and promoter regions of BMP-2
RT   and BMP-4 genes.";
RL   Biochim. Biophys. Acta 1218:221-224(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Embryo, and Medulla oblongata;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Thyroid;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-351.
RX   PubMed=1970330; DOI=10.1016/0888-7543(90)90480-I;
RA   Dickinson M.E., Kobrin M.S., Silan C.M., Kingsley D.M., Justice M.J.,
RA   Miller D.A., Ceci J.D., Lock L.F., Lee A., Buchberg A.M.,
RA   Siracusa L.D., Lyons K.M., Derynck R., Hogan B.L.M., Copeland N.G.,
RA   Jenkins N.A.;
RT   "Chromosomal localization of seven members of the murine TGF-beta
RT   superfamily suggests close linkage to several morphogenetic mutant
RT   loci.";
RL   Genomics 6:505-520(1990).
RN   [7]
RP   INTERACTION WITH SOSTDC1.
RX   PubMed=14623234; DOI=10.1016/j.ydbio.2003.08.011;
RA   Laurikkala J., Kassai Y., Pakkasjaervi L., Thesleff I., Itoh N.;
RT   "Identification of a secreted BMP antagonist, ectodin, integrating
RT   BMP, FGF, and SHH signals from the tooth enamel knot.";
RL   Dev. Biol. 264:91-105(2003).
RN   [8]
RP   INTERACTION WITH GREM2.
RX   PubMed=15039429; DOI=10.1074/jbc.M402376200;
RA   Sudo S., Avsian-Kretchmer O., Wang L.S., Hsueh A.J.;
RT   "Protein related to DAN and cerberus is a bone morphogenetic protein
RT   antagonist that participates in ovarian paracrine regulation.";
RL   J. Biol. Chem. 279:23134-23141(2004).
RN   [9]
RP   INTERACTION WITH RGMB.
RX   PubMed=15671031; DOI=10.1074/jbc.M410034200;
RA   Samad T.A., Rebbapragada A., Bell E., Zhang Y., Sidis Y., Jeong S.-J.,
RA   Campagna J.A., Perusini S., Fabrizio D.A., Schneyer A.L., Lin H.Y.,
RA   Brivanlou A.H., Attisano L., Woolf C.J.;
RT   "DRAGON, a bone morphogenetic protein co-receptor.";
RL   J. Biol. Chem. 280:14122-14129(2005).
RN   [10]
RP   INTERACTION WITH RGMA.
RX   PubMed=15975920; DOI=10.1074/jbc.M503511200;
RA   Babitt J.L., Zhang Y., Samad T.A., Xia Y., Tang J., Campagna J.A.,
RA   Schneyer A.L., Woolf C.J., Lin H.Y.;
RT   "Repulsive guidance molecule (RGMa), a DRAGON homologue, is a bone
RT   morphogenetic protein co-receptor.";
RL   J. Biol. Chem. 280:29820-29827(2005).
RN   [11]
RP   INTERACTION WITH RGMC.
RX   PubMed=16604073; DOI=10.1038/ng1777;
RA   Babitt J.L., Huang F.W., Wrighting D.M., Xia Y., Sidis Y., Samad T.A.,
RA   Campagna J.A., Chung R.T., Schneyer A.L., Woolf C.J., Andrews N.C.,
RA   Lin H.Y.;
RT   "Bone morphogenetic protein signaling by hemojuvelin regulates
RT   hepcidin expression.";
RL   Nat. Genet. 38:531-539(2006).
RN   [12]
RP   INTERACTION WITH RGMA.
RX   PubMed=17472960; DOI=10.1074/jbc.M701679200;
RA   Xia Y., Yu P.B., Sidis Y., Beppu H., Bloch K.D., Schneyer A.L.,
RA   Lin H.Y.;
RT   "Repulsive guidance molecule RGMa alters utilization of bone
RT   morphogenetic protein (BMP) type II receptors by BMP2 and BMP4.";
RL   J. Biol. Chem. 282:18129-18140(2007).
RN   [13]
RP   INTERACTION WITH ASPN.
RX   PubMed=17522060; DOI=10.1074/jbc.M611181200;
RA   Yamada S., Tomoeda M., Ozawa Y., Yoneda S., Terashima Y., Ikezawa K.,
RA   Ikegawa S., Saito M., Toyosawa S., Murakami S.;
RT   "PLAP-1/asporin, a novel negative regulator of periodontal ligament
RT   mineralization.";
RL   J. Biol. Chem. 282:23070-23080(2007).
RN   [14]
RP   INTERACTION WITH MFAP5.
RX   PubMed=23963447; DOI=10.1074/jbc.M113.497727;
RA   Combs M.D., Knutsen R.H., Broekelmann T.J., Toennies H.M., Brett T.J.,
RA   Miller C.A., Kober D.L., Craft C.S., Atkinson J.J., Shipley J.M.,
RA   Trask B.C., Mecham R.P.;
RT   "Microfibril-associated glycoprotein 2 (MAGP2) loss of function has
RT   pleiotropic effects in vivo.";
RL   J. Biol. Chem. 288:28869-28880(2013).
CC   -!- FUNCTION: Induces cartilage and bone formation. Stimulates the
CC       differentiation of myoblasts into osteoblasts via the EIF2AK3-
CC       EIF2A- ATF4 pathway. BMP2 activation of EIF2AK3 stimulates
CC       phosphorylation of EIF2A which leads to increased expression of
CC       ATF4 which plays a central role in osteoblast differentiation. In
CC       addition stimulates TMEM119, which upregulates the expression of
CC       ATF4. {ECO:0000250|UniProtKB:P12643}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked (By similarity). Interacts
CC       with SOSTDC1, GREM2, RGMA, RGMB and RGMC. Interacts with ASPN.
CC       Interacts with MFAP5. {ECO:0000250|UniProtKB:P12643,
CC       ECO:0000269|PubMed:14623234, ECO:0000269|PubMed:15039429,
CC       ECO:0000269|PubMed:15671031, ECO:0000269|PubMed:15975920,
CC       ECO:0000269|PubMed:16604073, ECO:0000269|PubMed:17472960,
CC       ECO:0000269|PubMed:17522060, ECO:0000269|PubMed:23963447}.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- SIMILARITY: Belongs to the TGF-beta family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L25602; AAB05665.1; -; Genomic_DNA.
DR   EMBL; AK133923; BAE21928.1; -; mRNA.
DR   EMBL; AK161862; BAE36612.1; -; mRNA.
DR   EMBL; AL831753; CAM22737.1; -; Genomic_DNA.
DR   EMBL; CH466519; EDL28371.1; -; Genomic_DNA.
DR   EMBL; BC100344; AAI00345.1; -; mRNA.
DR   CCDS; CCDS16782.1; -.
DR   PIR; A34201; A34201.
DR   PIR; S45355; S45355.
DR   RefSeq; NP_031579.2; NM_007553.3.
DR   UniGene; Mm.103205; -.
DR   ProteinModelPortal; P21274; -.
DR   SMR; P21274; 291-394.
DR   BioGrid; 198363; 1.
DR   STRING; 10090.ENSMUSP00000028836; -.
DR   PhosphoSite; P21274; -.
DR   MaxQB; P21274; -.
DR   PaxDb; P21274; -.
DR   PRIDE; P21274; -.
DR   Ensembl; ENSMUST00000028836; ENSMUSP00000028836; ENSMUSG00000027358.
DR   GeneID; 12156; -.
DR   KEGG; mmu:12156; -.
DR   UCSC; uc008mnr.2; mouse.
DR   CTD; 650; -.
DR   MGI; MGI:88177; Bmp2.
DR   eggNOG; KOG3900; Eukaryota.
DR   eggNOG; ENOG410XT8Z; LUCA.
DR   GeneTree; ENSGT00760000118883; -.
DR   HOGENOM; HOG000249478; -.
DR   HOVERGEN; HBG004860; -.
DR   InParanoid; P21274; -.
DR   KO; K04662; -.
DR   OMA; DEHSWSQ; -.
DR   OrthoDB; EOG7WHH9D; -.
DR   TreeFam; TF351789; -.
DR   Reactome; R-MMU-201451; Signaling by BMP.
DR   Reactome; R-MMU-2129379; Molecules associated with elastic fibres.
DR   NextBio; 280499; -.
DR   PRO; PR:P21274; -.
DR   Proteomes; UP000000589; Chromosome 2.
DR   Bgee; P21274; -.
DR   CleanEx; MM_BMP2; -.
DR   Genevisible; P21274; MM.
DR   GO; GO:0070724; C:BMP receptor complex; ISO:MGI.
DR   GO; GO:0009986; C:cell surface; ISO:MGI.
DR   GO; GO:0005615; C:extracellular space; IDA:MGI.
DR   GO; GO:0070700; F:BMP receptor binding; ISO:MGI.
DR   GO; GO:0039706; F:co-receptor binding; ISO:MGI.
DR   GO; GO:0005125; F:cytokine activity; TAS:MGI.
DR   GO; GO:0019211; F:phosphatase activator activity; ISO:MGI.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISO:MGI.
DR   GO; GO:0004745; F:retinol dehydrogenase activity; IDA:MGI.
DR   GO; GO:0046332; F:SMAD binding; ISO:MGI.
DR   GO; GO:0005160; F:transforming growth factor beta receptor binding; IBA:GO_Central.
DR   GO; GO:0000187; P:activation of MAPK activity; ISO:MGI.
DR   GO; GO:0003181; P:atrioventricular valve morphogenesis; IMP:MGI.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:MGI.
DR   GO; GO:0003130; P:BMP signaling pathway involved in heart induction; ISO:MGI.
DR   GO; GO:0030282; P:bone mineralization; IDA:MGI.
DR   GO; GO:0035630; P:bone mineralization involved in bone maturation; ISO:MGI.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IGI:MGI.
DR   GO; GO:0060317; P:cardiac epithelial to mesenchymal transition; ISO:MGI.
DR   GO; GO:0055007; P:cardiac muscle cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0055008; P:cardiac muscle tissue morphogenesis; IMP:MGI.
DR   GO; GO:0035051; P:cardiocyte differentiation; ISO:MGI.
DR   GO; GO:0048468; P:cell development; IBA:GO_Central.
DR   GO; GO:0045165; P:cell fate commitment; IMP:MGI.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; ISO:MGI.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:MGI.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IDA:MGI.
DR   GO; GO:0002062; P:chondrocyte differentiation; ISO:MGI.
DR   GO; GO:0060128; P:corticotropin hormone secreting cell differentiation; IDA:MGI.
DR   GO; GO:0035054; P:embryonic heart tube anterior/posterior pattern specification; IMP:MGI.
DR   GO; GO:0003203; P:endocardial cushion morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; ISO:MGI.
DR   GO; GO:0040007; P:growth; IEA:InterPro.
DR   GO; GO:0007507; P:heart development; IMP:MGI.
DR   GO; GO:0001701; P:in utero embryonic development; IMP:MGI.
DR   GO; GO:0006954; P:inflammatory response; IEP:UniProtKB.
DR   GO; GO:0048839; P:inner ear development; IDA:MGI.
DR   GO; GO:0048762; P:mesenchymal cell differentiation; ISS:UniProtKB.
DR   GO; GO:0072138; P:mesenchymal cell proliferation involved in ureteric bud development; IMP:UniProtKB.
DR   GO; GO:0060485; P:mesenchyme development; ISS:BHF-UCL.
DR   GO; GO:0032348; P:negative regulation of aldosterone biosynthetic process; ISO:MGI.
DR   GO; GO:0051042; P:negative regulation of calcium-independent cell-cell adhesion; ISO:MGI.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:2000726; P:negative regulation of cardiac muscle cell differentiation; ISO:MGI.
DR   GO; GO:0045786; P:negative regulation of cell cycle; ISO:MGI.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IGI:MGI.
DR   GO; GO:2000065; P:negative regulation of cortisol biosynthetic process; ISO:MGI.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:MGI.
DR   GO; GO:0043569; P:negative regulation of insulin-like growth factor receptor signaling pathway; ISO:MGI.
DR   GO; GO:0010894; P:negative regulation of steroid biosynthetic process; ISO:MGI.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISO:MGI.
DR   GO; GO:0003308; P:negative regulation of Wnt signaling pathway involved in heart development; ISO:MGI.
DR   GO; GO:0007219; P:Notch signaling pathway; IMP:MGI.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IDA:MGI.
DR   GO; GO:0009887; P:organ morphogenesis; IMP:MGI.
DR   GO; GO:0001649; P:osteoblast differentiation; IDA:MGI.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:GOC.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; ISO:MGI.
DR   GO; GO:0060039; P:pericardium development; IMP:MGI.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0048711; P:positive regulation of astrocyte differentiation; IDA:MGI.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; ISO:MGI.
DR   GO; GO:0061036; P:positive regulation of cartilage development; IDA:MGI.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; IDA:MGI.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; ISO:MGI.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:MGI.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:BHF-UCL.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; IDA:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISO:MGI.
DR   GO; GO:0050769; P:positive regulation of neurogenesis; ISO:MGI.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IDA:MGI.
DR   GO; GO:0042482; P:positive regulation of odontogenesis; IDA:MGI.
DR   GO; GO:0045778; P:positive regulation of ossification; IDA:MGI.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL.
DR   GO; GO:0033690; P:positive regulation of osteoblast proliferation; IMP:BHF-UCL.
DR   GO; GO:1900745; P:positive regulation of p38MAPK cascade; ISO:MGI.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0010922; P:positive regulation of phosphatase activity; ISO:MGI.
DR   GO; GO:0032092; P:positive regulation of protein binding; ISO:MGI.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISO:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:1901522; P:positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus; ISO:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISO:MGI.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IDA:MGI.
DR   GO; GO:0060804; P:positive regulation of Wnt signaling pathway by BMP signaling pathway; IDA:MGI.
DR   GO; GO:0031648; P:protein destabilization; IDA:MGI.
DR   GO; GO:0006468; P:protein phosphorylation; ISO:MGI.
DR   GO; GO:0006029; P:proteoglycan metabolic process; IGI:MGI.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0042487; P:regulation of odontogenesis of dentin-containing tooth; IGI:MGI.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; ISO:MGI.
DR   GO; GO:0001666; P:response to hypoxia; IMP:MGI.
DR   GO; GO:0060395; P:SMAD protein signal transduction; ISS:UniProtKB.
DR   GO; GO:0021537; P:telencephalon development; ISO:MGI.
DR   GO; GO:0021978; P:telencephalon regionalization; IGI:MGI.
DR   GO; GO:0060129; P:thyroid-stimulating hormone-secreting cell differentiation; IDA:MGI.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; TAS:MGI.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR001839; TGF-b_C.
DR   InterPro; IPR001111; TGF-b_N.
DR   InterPro; IPR015615; TGF-beta-rel.
DR   InterPro; IPR017948; TGFb_CS.
DR   PANTHER; PTHR11848; PTHR11848; 1.
DR   Pfam; PF00019; TGF_beta; 1.
DR   Pfam; PF00688; TGFb_propeptide; 1.
DR   SMART; SM00204; TGFB; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS00250; TGF_BETA_1; 1.
DR   PROSITE; PS51362; TGF_BETA_2; 1.
PE   1: Evidence at protein level;
KW   Chondrogenesis; Cleavage on pair of basic residues; Complete proteome;
KW   Cytokine; Developmental protein; Differentiation; Disulfide bond;
KW   Glycoprotein; Growth factor; Osteogenesis; Phosphoprotein;
KW   Reference proteome; Secreted; Signal.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   PROPEP       20    280       Cleaved by PCSK5. {ECO:0000305}.
FT                                /FTId=PRO_0000033826.
FT   CHAIN       281    394       Bone morphogenetic protein 2.
FT                                /FTId=PRO_0000033827.
FT   MOD_RES      86     86       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P12644}.
FT   CARBOHYD    134    134       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    162    162       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    198    198       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    336    336       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    294    359       {ECO:0000250}.
FT   DISULFID    323    391       {ECO:0000250}.
FT   DISULFID    327    393       {ECO:0000250}.
FT   DISULFID    358    358       Interchain. {ECO:0000250}.
FT   CONFLICT    110    110       S -> T (in Ref. 1; AAB05665).
FT                                {ECO:0000305}.
FT   CONFLICT    113    114       HE -> QL (in Ref. 1; AAB05665).
FT                                {ECO:0000305}.
FT   CONFLICT    271    271       G -> R (in Ref. 6; no nucleotide entry).
FT                                {ECO:0000305}.
SQ   SEQUENCE   394 AA;  44525 MW;  D0C03B63B1D5C4E2 CRC64;
     MVAGTRCLLV LLLPQVLLGG AAGLIPELGR KKFAAASSRP LSRPSEDVLS EFELRLLSMF
     GLKQRPTPSK DVVVPPYMLD LYRRHSGQPG APAPDHRLER AASRANTVRS FHHEEAVEEL
     PEMSGKTARR FFFNLSSVPS DEFLTSAELQ IFREQIQEAL GNSSFQHRIN IYEIIKPAAA
     NLKFPVTRLL DTRLVNQNTS QWESFDVTPA VMRWTTQGHT NHGFVVEVAH LEENPGVSKR
     HVRISRSLHQ DEHSWSQIRP LLVTFGHDGK GHPLHKREKR QAKHKQRKRL KSSCKRHPLY
     VDFSDVGWND WIVAPPGYHA FYCHGECPFP LADHLNSTNH AIVQTLVNSV NSKIPKACCV
     PTELSAISML YLDENEKVVL KNYQDMVVEG CGCR
//
ID   VGP_EBOZM               Reviewed;         676 AA.
AC   Q05320; Q66818; Q77LU5; Q8B9S1; Q8JS62;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 1.
DT   20-JAN-2016, entry version 115.
DE   RecName: Full=Envelope glycoprotein;
DE   AltName: Full=GP1,2;
DE            Short=GP;
DE   Contains:
DE     RecName: Full=GP1;
DE   Contains:
DE     RecName: Full=GP2;
DE   Contains:
DE     RecName: Full=GP2-delta;
DE   Flags: Precursor;
GN   Name=GP;
OS   Zaire ebolavirus (strain Mayinga-76) (ZEBOV) (Zaire Ebola virus).
OC   Viruses; ssRNA viruses; ssRNA negative-strand viruses;
OC   Mononegavirales; Filoviridae; Ebolavirus.
OX   NCBI_TaxID=128952;
OH   NCBI_TaxID=77231; Epomops franqueti (Franquet's epauleted fruit bat).
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=77243; Myonycteris torquata (Little collared fruit bat).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=8237108; DOI=10.1016/0168-1702(93)90063-S;
RA   Sanchez A., Kiley M.P., Holloway B.P., Auperin D.D.;
RT   "Sequence analysis of the Ebola virus genome: organization, genetic
RT   elements, and comparison with the genome of Marburg virus.";
RL   Virus Res. 29:215-240(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA / MRNA], AND RNA EDITING.
RX   PubMed=8553543; DOI=10.1006/viro.1995.0052;
RA   Volchkov V.E., Becker S., Volchkova V.A., Ternovoj V.A., Kotov A.N.,
RA   Netesov S.V., Klenk H.-D.;
RT   "GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by
RT   T7 and vaccinia virus polymerases.";
RL   Virology 214:421-430(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA], AND RNA EDITING.
RX   PubMed=8622982; DOI=10.1073/pnas.93.8.3602;
RA   Sanchez A., Trappier S.G., Mahy B.W.J., Peters C.J., Nichol S.T.;
RT   "The virion glycoproteins of Ebola viruses are encoded in two reading
RT   frames and are expressed through transcriptional editing.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:3602-3607(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate guinea pig-adapted;
RX   PubMed=11062045; DOI=10.1006/viro.2000.0572;
RA   Volchkov V.E., Chepurnov A.A., Volchkova V.A., Ternovoj V.A.,
RA   Klenk H.D.;
RT   "Molecular characterization of guinea pig-adapted variants of Ebola
RT   virus.";
RL   Virology 277:147-155(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RA   Volchkov V.E.;
RL   Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate mouse-adapted;
RA   Wilson J.A., Kondig J.P., Kuehne A.I., Hart M.K.;
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 359-676.
RX   PubMed=1299611; DOI=10.1016/0014-5793(92)80662-Z;
RA   Volchkov V.E., Blinov V.M., Netesov S.V.;
RT   "The envelope glycoprotein of Ebola virus contains an
RT   immunosuppressive-like domain similar to oncogenic retroviruses.";
RL   FEBS Lett. 305:181-184(1992).
RN   [8]
RP   PROTEOLYTIC PROCESSING OF ENVELOPE GLYCOPROTEIN, AND TOPOLOGY.
RX   PubMed=9576958; DOI=10.1073/pnas.95.10.5762;
RA   Volchkov V.E., Feldmann H., Volchkova V.A., Klenk H.-D.;
RT   "Processing of the Ebola virus glycoprotein by the proprotein
RT   convertase furin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:5762-5767(1998).
RN   [9]
RP   PROTEOLYTIC PROCESSING OF ENVELOPE GLYCOPROTEIN.
RX   PubMed=9614872; DOI=10.1006/viro.1998.9143;
RA   Volchkov V.E., Volchkova V.A., Slenczka W., Klenk H.-D., Feldmann H.;
RT   "Release of viral glycoproteins during Ebola virus infection.";
RL   Virology 245:110-119(1998).
RN   [10]
RP   DOMAIN FUSION PEPTIDE.
RX   PubMed=9499027;
RA   Ruiz-Arguello M.B., Goni F.M., Pereira F.B., Nieva J.L.;
RT   "Phosphatidylinositol-dependent membrane fusion induced by a putative
RT   fusogenic sequence of Ebola virus.";
RL   J. Virol. 72:1775-1781(1998).
RN   [11]
RP   DOMAIN FUSION PEPTIDE, AND MUTAGENESIS OF GLY-528; LEU-529; ILE-532;
RP   PHE-535; GLY-536 AND PRO-537.
RX   PubMed=10482652;
RA   Ito H., Watanabe S., Sanchez A., Whitt M.A., Kawaoka Y.;
RT   "Mutational analysis of the putative fusion domain of Ebola virus
RT   glycoprotein.";
RL   J. Virol. 73:8907-8912(1999).
RN   [12]
RP   PROTEOLYTIC PROCESSING OF ENVELOPE GLYCOPROTEIN, AND MUTAGENESIS OF
RP   498-ARG--ARG-501.
RX   PubMed=9882347;
RA   Wool-Lewis R.J., Bates P.;
RT   "Endoproteolytic processing of the ebola virus envelope glycoprotein:
RT   cleavage is not required for function.";
RL   J. Virol. 73:1419-1426(1999).
RN   [13]
RP   FUNCTION, AND DOMAIN MUCIN/LIKE REGION.
RX   PubMed=10932225; DOI=10.1038/78645;
RA   Yang Z.-Y., Duckers H.J., Sullivan N.J., Sanchez A., Nabel E.G.,
RA   Nabel G.J.;
RT   "Identification of the Ebola virus glycoprotein as the main viral
RT   determinant of vascular cell cytotoxicity and injury.";
RL   Nat. Med. 6:886-889(2000).
RN   [14]
RP   DOWN-MODULATION OF HOST ITGB1/BETA-1 INTEGRIN.
RX   PubMed=11112476; DOI=10.1006/viro.2000.0601;
RA   Takada A., Watanabe S., Ito H., Okazaki K., Kida H., Kawaoka Y.;
RT   "Downregulation of beta1 integrins by Ebola virus glycoprotein:
RT   implication for virus entry.";
RL   Virology 278:20-26(2000).
RN   [15]
RP   PROTEOLYTIC PROCESSING OF ENVELOPE GLYCOPROTEIN, PALMITOYLATION, AND
RP   MUTAGENESIS OF 497-ARG--ARG-501; CYS-670 AND CYS-672.
RX   PubMed=11152533; DOI=10.1128/JVI.75.3.1576-1580.2001;
RA   Ito H., Watanabe S., Takada A., Kawaoka Y.;
RT   "Ebola virus glycoprotein: proteolytic processing, acylation, cell
RT   tropism, and detection of neutralizing antibodies.";
RL   J. Virol. 75:1576-1580(2001).
RN   [16]
RP   COILED-COIL DOMAIN.
RX   PubMed=11024148; DOI=10.1128/JVI.74.21.10194-10201.2000;
RA   Watanabe S., Takada A., Watanabe T., Ito H., Kida H., Kawaoka Y.;
RT   "Functional importance of the coiled-coil of the Ebola virus
RT   glycoprotein.";
RL   J. Virol. 74:10194-10201(2000).
RN   [17]
RP   INTERACTION WITH HUMAN FOLR1.
RX   PubMed=11461707; DOI=10.1016/S0092-8674(01)00418-4;
RA   Chan S.Y., Empig C.J., Welte F.J., Speck R.F., Schmaljohn A.,
RA   Kreisberg J.F., Goldsmith M.A.;
RT   "Folate receptor-alpha is a cofactor for cellular entry by Marburg and
RT   Ebola viruses.";
RL   Cell 106:117-126(2001).
RN   [18]
RP   DISULFIDE BONDS, GLYCOSYLATION, AND MUTAGENESIS OF ASN-40; CYS-53;
RP   CYS-108; CYS-121; CYS-135; CYS-147; ASN-204; ASN-238; ASN-257;
RP   ASN-296; CYS-511; CYS-556; ASN-563; CYS-601; CYS-608; CYS-609;
RP   ASN-618; CYS-670 AND CYS-672.
RX   PubMed=12438572; DOI=10.1128/JVI.76.24.12463-12472.2002;
RA   Jeffers S.A., Sanders D.A., Sanchez A.;
RT   "Covalent modifications of the ebola virus glycoprotein.";
RL   J. Virol. 76:12463-12472(2002).
RN   [19]
RP   DOWN-MODULATION OF HOST MHC-I; ALPHA/BETA INTEGRINS AND EGFR.
RX   PubMed=11836430; DOI=10.1128/jvi.76.5.2518-2528.2002;
RA   Simmons G., Wool-Lewis R.J., Baribaud F., Netter R.C., Bates P.;
RT   "Ebola virus glycoproteins induce global surface protein down-
RT   modulation and loss of cell adherence.";
RL   J. Virol. 76:2518-2528(2002).
RN   [20]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-670 AND CYS-672.
RX   PubMed=11877482; DOI=10.1084/jem.20011500;
RA   Bavari S., Bosio C.M., Wiegand E., Ruthel G., Will A.B.,
RA   Geisbert T.W., Hevey M., Schmaljohn C., Schmaljohn A., Aman M.J.;
RT   "Lipid raft microdomains: a gateway for compartmentalized trafficking
RT   of Ebola and Marburg viruses.";
RL   J. Exp. Med. 195:593-602(2002).
RN   [21]
RP   INTERACTION WITH HUMAN CD209 AND CLEC4M, AND ROLE IN TRANS INFECTION.
RX   PubMed=12050398; DOI=10.1128/JVI.76.13.6841-6844.2002;
RA   Alvarez C.P., Lasala F., Carrillo J., Muniz O., Corbi A.L.,
RA   Delgado R.;
RT   "C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola
RT   virus in cis and in trans.";
RL   J. Virol. 76:6841-6844(2002).
RN   [22]
RP   PUTATIVE ROLE OF FOLR1 IN VIRUS ENTRY INTO THE CELL.
RX   PubMed=14645601; DOI=10.1128/JVI.77.24.13433-13438.2003;
RA   Simmons G., Rennekamp A.J., Chai N., Vandenberghe L.H., Riley J.L.,
RA   Bates P.;
RT   "Folate receptor alpha and caveolae are not required for Ebola virus
RT   glycoprotein-mediated viral infection.";
RL   J. Virol. 77:13433-13438(2003).
RN   [23]
RP   INTERACTION WITH HUMAN CD209 AND CLEC4M.
RX   PubMed=12504546; DOI=10.1006/viro.2002.1730;
RA   Simmons G., Reeves J.D., Grogan C.C., Vandenberghe L.H., Baribaud F.,
RA   Whitbeck J.C., Burke E., Buchmeier M.J., Soilleux E.J., Riley J.L.,
RA   Doms R.W., Bates P., Poehlmann S.;
RT   "DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection
RT   of macrophages and endothelial cells.";
RL   Virology 305:115-123(2003).
RN   [24]
RP   CLEAVAGE BY HOST ADAM17, MUTAGENESIS OF ASP-632; LYS-633; THR-634;
RP   LEU-635; ASP-637; GLN-638; GLY-639; ASP-640; ASN-641; ASP-642 AND
RP   ASN-643, AND SUBCELLULAR LOCATION.
RX   PubMed=15103332; DOI=10.1038/sj.emboj.7600219;
RA   Dolnik O., Volchkova V., Garten W., Carbonnelle C., Becker S.,
RA   Kahnt J., Stroeher U., Klenk H.-D., Volchkov V.;
RT   "Ectodomain shedding of the glycoprotein GP of Ebola virus.";
RL   EMBO J. 23:2175-2184(2004).
RN   [25]
RP   INTERACTION WITH HUMAN CLEC10A.
RX   PubMed=14990712; DOI=10.1128/JVI.78.6.2943-2947.2004;
RA   Takada A., Fujioka K., Tsuiji M., Morikawa A., Higashi N., Ebihara H.,
RA   Kobasa D., Feldmann H., Irimura T., Kawaoka Y.;
RT   "Human macrophage C-type lectin specific for galactose and N-
RT   acetylgalactosamine promotes filovirus entry.";
RL   J. Virol. 78:2943-2947(2004).
RN   [26]
RP   FUNCTION IN ENDOTHELIAL CELLS ACTIVATION.
RX   PubMed=16051836; DOI=10.1128/JVI.79.16.10442-10450.2005;
RA   Wahl-Jensen V.M., Afanasieva T.A., Seebach J., Stroeher U.,
RA   Feldmann H., Schnittler H.J.;
RT   "Effects of Ebola virus glycoproteins on endothelial cell activation
RT   and barrier function.";
RL   J. Virol. 79:10442-10450(2005).
RN   [27]
RP   PROTEOLYSIS OF GP1.
RX   PubMed=15831716; DOI=10.1126/science.1110656;
RA   Chandran K., Sullivan N.J., Felbor U., Whelan S.P., Cunningham J.M.;
RT   "Endosomal proteolysis of the Ebola virus glycoprotein is necessary
RT   for infection.";
RL   Science 308:1643-1645(2005).
RN   [28]
RP   FUNCTION OF GP1,2DELTA.
RX   PubMed=15681442; DOI=10.1128/JVI.79.4.2413-2419.2005;
RA   Wahl-Jensen V., Kurz S.K., Hazelton P.R., Schnittler H.J.,
RA   Stroeher U., Burton D.R., Feldmann H.;
RT   "Role of Ebola virus secreted glycoproteins and virus-like particles
RT   in activation of human macrophages.";
RL   J. Virol. 79:2413-2419(2005).
RN   [29]
RP   DOWN-MODULATION OF HOST INTEGRIN DIMER ALPHA-V/BETA-3, AND INTERACTION
RP   WITH HUMAN INTEGRIN ITGAV.
RX   PubMed=15596847; DOI=10.1128/JVI.79.1.547-553.2005;
RA   Sullivan N.J., Peterson M., Yang Z.-Y., Kong W.-P., Duckers H.,
RA   Nabel E., Nabel G.J.;
RT   "Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent
RT   protein-trafficking pathway.";
RL   J. Virol. 79:547-553(2005).
RN   [30]
RP   PROTEOLYSIS OF GP1.
RX   PubMed=16571833; DOI=10.1128/JVI.80.8.4174-4178.2006;
RA   Schornberg K., Matsuyama S., Kabsch K., Delos S., Bouton A., White J.;
RT   "Role of endosomal cathepsins in entry mediated by the Ebola virus
RT   glycoprotein.";
RL   J. Virol. 80:4174-4178(2006).
RN   [31]
RP   FUNCTION.
RX   PubMed=16603527; DOI=10.1099/vir.0.81361-0;
RA   Alazard-Dany N., Volchkova V., Reynard O., Carbonnelle C., Dolnik O.,
RA   Ottmann M., Khromykh A., Volchkov V.E.;
RT   "Ebola virus glycoprotein GP is not cytotoxic when expressed
RT   constitutively at a moderate level.";
RL   J. Gen. Virol. 87:1247-1257(2006).
RN   [32]
RP   FUNCTION OF SIGNAL PEPTIDE.
RX   PubMed=16775318; DOI=10.1128/JVI.02545-05;
RA   Marzi A., Akhavan A., Simmons G., Gramberg T., Hofmann H., Bates P.,
RA   Lingappa V.R., Poehlmann S.;
RT   "The signal peptide of the ebolavirus glycoprotein influences
RT   interaction with the cellular lectins DC-SIGN and DC-SIGNR.";
RL   J. Virol. 80:6305-6317(2006).
RN   [33]
RP   RECEPTOR-BINDING REGION.
RX   PubMed=16595665; DOI=10.1074/jbc.M601796200;
RA   Kuhn J.H., Radoshitzky S.R., Guth A.C., Warfield K.L., Li W.,
RA   Vincent M.J., Towner J.S., Nichol S.T., Bavari S., Choe H., Aman M.J.,
RA   Farzan M.;
RT   "Conserved receptor-binding domains of Lake Victoria marburgvirus and
RT   Zaire ebolavirus bind a common receptor.";
RL   J. Biol. Chem. 281:15951-15958(2006).
RN   [34]
RP   FUNCTION.
RX   PubMed=20862315; DOI=10.1371/journal.ppat.1001110;
RA   Saeed M.F., Kolokoltsov A.A., Albrecht T., Davey R.A.;
RT   "Cellular entry of ebola virus involves uptake by a macropinocytosis-
RT   like mechanism and subsequent trafficking through early and late
RT   endosomes.";
RL   PLoS Pathog. 6:0-0(2010).
RN   [35]
RP   FUNCTION.
RX   PubMed=20202662; DOI=10.1016/j.virol.2010.02.015;
RA   Bhattacharyya S., Warfield K.L., Ruthel G., Bavari S., Aman M.J.,
RA   Hope T.J.;
RT   "Ebola virus uses clathrin-mediated endocytosis as an entry pathway.";
RL   Virology 401:18-28(2010).
RN   [36]
RP   INTERACTION WITH HOST NPC1, AND FUNCTION.
RX   PubMed=21866103; DOI=10.1038/nature10348;
RA   Carette J.E., Raaben M., Wong A.C., Herbert A.S., Obernosterer G.,
RA   Mulherkar N., Kuehne A.I., Kranzusch P.J., Griffin A.M., Ruthel G.,
RA   Dal Cin P., Dye J.M., Whelan S.P., Chandran K., Brummelkamp T.R.;
RT   "Ebola virus entry requires the cholesterol transporter Niemann-Pick
RT   C1.";
RL   Nature 477:340-343(2011).
RN   [37]
RP   FUNCTION, AND PROTEOLYTIC CLEAVAGE OF GP1.
RX   PubMed=22031933; DOI=10.1128/JVI.05708-11;
RA   Brecher M., Schornberg K.L., Delos S.E., Fusco M.L., Saphire E.O.,
RA   White J.M.;
RT   "Cathepsin cleavage potentiates the Ebola virus glycoprotein to
RT   undergo a subsequent fusion-relevant conformational change.";
RL   J. Virol. 86:364-372(2012).
RN   [38]
RP   FUNCTION.
RX   PubMed=26516900; DOI=10.3390/v7102888;
RA   Vande Burgt N.H., Kaletsky R.L., Bates P.;
RT   "Requirements within the Ebola viral glycoprotein for tetherin
RT   antagonism.";
RL   Viruses 7:5587-5602(2015).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 557-630.
RX   PubMed=10077567; DOI=10.1073/pnas.96.6.2662;
RA   Malashkevich V.N., Schneider B.J., McNally M.L., Milhollen M.A.,
RA   Pang J.X., Kim P.S.;
RT   "Core structure of the envelope glycoprotein GP2 from Ebola virus at
RT   1.9-A resolution.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2662-2667(1999).
CC   -!- FUNCTION: GP1 is responsible for binding to the receptor(s) on
CC       target cells. Interacts with CD209/DC-SIGN and CLEC4M/DC-SIGNR
CC       which act as cofactors for virus entry into the host cell. Binding
CC       to CD209 and CLEC4M, which are respectively found on dendritic
CC       cells (DCs), and on endothelial cells of liver sinusoids and lymph
CC       node sinuses, facilitate infection of macrophages and endothelial
CC       cells. These interactions not only facilitate virus cell entry,
CC       but also allow capture of viral particles by DCs and subsequent
CC       transmission to susceptible cells without DCs infection (trans
CC       infection). Binding to the macrophage specific lectin CLEC10A also
CC       seem to enhance virus infectivity. Interaction with FOLR1/folate
CC       receptor alpha may be a cofactor for virus entry in some cell
CC       types, although results are contradictory. Members of the Tyro3
CC       receptor tyrosine kinase family also seem to be cell entry factors
CC       in filovirus infection. Once attached, the virions are
CC       internalized through clathrin-dependent endocytosis and/or
CC       macropinocytosis. After internalization of the virus into the
CC       endosomes of the host cell, proteolysis of GP1 by two cysteine
CC       proteases, CTSB/cathepsin B and CTSL/cathepsin L presumably
CC       induces a conformational change of GP2, allowing its binding to
CC       the host entry receptor NPC1 and unmasking its fusion peptide to
CC       initiate membranes fusion (PubMed:22031933) (PubMed:26516900).
CC       {ECO:0000269|PubMed:21866103, ECO:0000269|PubMed:22031933}.
CC   -!- FUNCTION: GP2 acts as a class I viral fusion protein. Under the
CC       current model, the protein has at least 3 conformational states:
CC       pre-fusion native state, pre-hairpin intermediate state, and post-
CC       fusion hairpin state. During viral and target cell membrane
CC       fusion, the coiled coil regions (heptad repeats) assume a trimer-
CC       of-hairpins structure, positioning the fusion peptide in close
CC       proximity to the C-terminal region of the ectodomain. The
CC       formation of this structure appears to drive apposition and
CC       subsequent fusion of viral and target cell membranes. Responsible
CC       for penetration of the virus into the cell cytoplasm by mediating
CC       the fusion of the membrane of the endocytosed virus particle with
CC       the endosomal membrane. Low pH in endosomes induces an
CC       irreversible conformational change in GP2, releasing the fusion
CC       hydrophobic peptide.
CC   -!- FUNCTION: Envelope glycoprotein: GP1,2 which is the disulfid-
CC       linked complex of GP1 and GP2, mediates endothelial cell
CC       activation and decreases endothelial barrier function. Mediates
CC       activation of primary macrophages. At terminal stages of the viral
CC       infection, when its expression is high, GP1,2 down-modulates the
CC       expression of various host cell surface molecules that are
CC       essential for immune surveillance and cell adhesion. Down-
CC       modulates integrins ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6,
CC       ITGAV and ITGB1. GP1,2 alters the cellular recycling of the dimer
CC       alpha-V/beta-3 via a dynamin-dependent pathway. Decrease in the
CC       host cell surface expression of various adhesion molecules may
CC       lead to cell detachment, contributing to the disruption of blood
CC       vessel integrity and hemorrhages developed during Ebola virus
CC       infection (cytotoxicity). This cytotoxicity appears late in the
CC       infection, only after the massive release of viral particles by
CC       infected cells. Down-modulation of host MHC-I, leading to altered
CC       recognition by immune cells, may explain the immune suppression
CC       and inflammatory dysfunction linked to Ebola infection. Also down-
CC       modulates EGFR surface expression. Counteracts the antiviral
CC       effect of host tetherin (PubMed:26516900).
CC       {ECO:0000269|PubMed:26516900}.
CC   -!- FUNCTION: GP2delta is part of the complex GP1,2delta released by
CC       host ADAM17 metalloprotease. This secreted complex may play a role
CC       in the pathogenesis of the virus by efficiently blocking the
CC       neutralizing antibodies that would otherwise neutralize the virus
CC       surface glycoproteins GP1,2. Might therefore contribute to the
CC       lack of inflammatory reaction seen during infection in spite the
CC       of extensive necrosis and massive virus production. GP1,2delta
CC       does not seem to be involved in activation of primary macrophages.
CC   -!- SUBUNIT: Homotrimer; each monomer consists of a GP1 and a GP2
CC       subunit linked by disulfide bonds. The resulting peplomers (GP1,2)
CC       protrude from the virus surface as spikes. GP1 and GP2delta are
CC       part of GP1,2delta soluble complexes released by ectodomain
CC       shedding. GP1,2 interacts with host integrin ITGAV/alpha-V and
CC       CLEC10A. Also binds human CD209 and CLEC4M (collectively referred
CC       to as DC-SIGN(R)), as well as human FOLR1. Interacts with host
CC       entry receptor NPC1. {ECO:0000269|PubMed:11461707,
CC       ECO:0000269|PubMed:12050398, ECO:0000269|PubMed:12504546,
CC       ECO:0000269|PubMed:14990712, ECO:0000269|PubMed:15596847,
CC       ECO:0000269|PubMed:21866103}.
CC   -!- SUBCELLULAR LOCATION: GP2: Virion membrane
CC       {ECO:0000305|PubMed:11877482}; Single-pass type I membrane protein
CC       {ECO:0000255}. Host cell membrane {ECO:0000305|PubMed:11877482};
CC       Single-pass type I membrane protein {ECO:0000255}. Note=In the
CC       cell, localizes to the plasma membrane lipid rafts, which probably
CC       represent the assembly and budding site.
CC       {ECO:0000305|PubMed:11877482}.
CC   -!- SUBCELLULAR LOCATION: GP1: Virion membrane
CC       {ECO:0000305|PubMed:11877482}; Peripheral membrane protein. Host
CC       cell membrane {ECO:0000305|PubMed:11877482}; Peripheral membrane
CC       protein {ECO:0000269|PubMed:9576958}. Note=GP1 is not anchored to
CC       the viral envelope, but forms a disulfid-linked complex with the
CC       extravirion surface GP2 (PubMed:9576958). In the cell, both GP1
CC       and GP2 localize to the plasma membrane lipid rafts, which
CC       probably represent the assembly and budding site
CC       (PubMed:11877482). GP1 can also be shed after proteolytic
CC       processing. {ECO:0000269|PubMed:11877482,
CC       ECO:0000269|PubMed:9576958}.
CC   -!- SUBCELLULAR LOCATION: GP2-delta: Secreted
CC       {ECO:0000269|PubMed:15103332}. Note=GP2-delta bound to GP1 (GP1,2-
CC       delta) is produced by proteolytic cleavage of GP1,2 by host ADAM17
CC       and shed by the virus. {ECO:0000269|PubMed:15103332}.
CC   -!- DOMAIN: The mucin-like region seems to be involved in the
CC       cytotoxic function. This region is also involved in binding to
CC       human CLEC10A.
CC   -!- DOMAIN: The coiled coil regions play a role in oligomerization and
CC       fusion activity.
CC   -!- PTM: The signal peptide region modulates GP's high mannose
CC       glycosylation, thereby determining the efficiency of the
CC       interactions with DC-SIGN(R). {ECO:0000269|PubMed:12438572}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:12438572}.
CC   -!- PTM: O-glycosylated in the mucin-like region.
CC       {ECO:0000269|PubMed:12438572}.
CC   -!- PTM: Palmitoylation of GP2 is not required for its function.
CC       {ECO:0000269|PubMed:11152533}.
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The precursor is processed into GP1 and GP2 by host cell furin in
CC       the trans Golgi, and maybe by other host proteases, to yield the
CC       mature GP1 and GP2 proteins (PubMed:9576958) (PubMed:9614872)
CC       (PubMed:9882347). The cleavage site corresponds to the furin
CC       optimal cleavage sequence [KR]-X-[KR]-R (PubMed:9576958). This
CC       cleavage does not seem to be required for function
CC       (PubMed:9576958). After the internalization of the virus into cell
CC       endosomes, GP1 C-terminus is removed by the endosomal proteases
CC       cathepsin B, cathepsin L, or both, leaving a 19-kDa N-terminal
CC       fragment which is further digested by cathepsin B
CC       (PubMed:16571833). This cleaved 19-kDa GP1 can then bind to the
CC       host entry receptor NPC1 (PubMed:21866103). Proteolytic processing
CC       of GP1,2 by host ADAM17 can remove the transmembrane anchor of GP2
CC       and leads to shedding of complexes consisting in GP1 and truncated
CC       GP2 (GP1,2delta) (PubMed:15103332). {ECO:0000269|PubMed:11152533,
CC       ECO:0000269|PubMed:15103332, ECO:0000269|PubMed:16571833,
CC       ECO:0000269|PubMed:21866103, ECO:0000269|PubMed:9576958,
CC       ECO:0000269|PubMed:9614872, ECO:0000269|PubMed:9882347}.
CC   -!- RNA EDITING: Modified_positions=295 {ECO:0000269|PubMed:8553543,
CC       ECO:0000269|PubMed:8622982}; Note=Partially edited. RNA editing at
CC       this position consists of an insertion of one or two adenine
CC       nucleotides. The sequence displayed here is the full-length
CC       transmembrane glycoprotein GP, derived from the +1A edited RNA.
CC       The unedited RNA gives rise to the small secreted glycoprotein sGP
CC       (AC P60170), the +2A edited RNA gives rise to the super small
CC       secreted glycoprotein ssGP (AC Q9YMG2).;
CC   -!- MISCELLANEOUS: Filoviruses entry requires functional lipid rafts
CC       at the host cell surface.
CC   -!- MISCELLANEOUS: Essential for infectivity, as it is the sole viral
CC       protein expressed at the virion surface.
CC   -!- SIMILARITY: Belongs to the filoviruses glycoprotein family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA96744.1; Type=Frameshift; Positions=296; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L11365; AAB81004.1; -; Genomic_RNA.
DR   EMBL; U31033; AAA96744.1; ALT_FRAME; Genomic_RNA.
DR   EMBL; U23187; AAC54887.1; -; Genomic_RNA.
DR   EMBL; AF272001; AAG40168.1; -; Genomic_RNA.
DR   EMBL; AY142960; AAN37507.1; -; Genomic_RNA.
DR   EMBL; AF086833; AAD14585.1; -; Genomic_RNA.
DR   EMBL; AF499101; AAM76034.1; -; Genomic_RNA.
DR   PIR; S23155; S23155.
DR   RefSeq; NP_066246.1; NC_002549.1.
DR   PDB; 2EBO; X-ray; 1.90 A; A/B/C=557-630.
DR   PDB; 2RLJ; NMR; -; A=524-539.
DR   PDB; 3CSY; X-ray; 3.40 A; I/K/M/O=32-311, J/L/N/P=502-632.
DR   PDBsum; 2EBO; -.
DR   PDBsum; 2RLJ; -.
DR   PDBsum; 3CSY; -.
DR   ProteinModelPortal; Q05320; -.
DR   SMR; Q05320; 32-310, 502-634.
DR   TCDB; 1.G.12.2.2; the avian leukosis virus gp95 fusion protein (alv-gp95) family.
DR   GeneID; 911829; -.
DR   KEGG; vg:911829; -.
DR   EvolutionaryTrace; Q05320; -.
DR   Proteomes; UP000007209; Genome.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0030430; C:host cell cytoplasm; IDA:CACAO.
DR   GO; GO:0044165; C:host cell endoplasmic reticulum; IMP:CACAO.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0045121; C:membrane raft; IDA:CACAO.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0075512; P:clathrin-mediated endocytosis of virus by host cell; IEA:UniProtKB-KW.
DR   GO; GO:0039654; P:fusion of virus membrane with host endosome membrane; IEA:UniProtKB-KW.
DR   GO; GO:0039587; P:suppression by virus of host tetherin activity; IEA:UniProtKB-KW.
DR   GO; GO:0039502; P:suppression by virus of host type I interferon-mediated signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0046761; P:viral budding from plasma membrane; IDA:CACAO.
DR   GO; GO:0046718; P:viral entry into host cell; IMP:CACAO.
DR   GO; GO:0019062; P:virion attachment to host cell; IEA:UniProtKB-KW.
DR   InterPro; IPR014625; GPC_FiloV.
DR   InterPro; IPR002561; GPC_filovir-type_extra_dom.
DR   Pfam; PF01611; Filo_glycop; 1.
DR   PIRSF; PIRSF036874; GPC_FiloV; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Clathrin-mediated endocytosis of virus by host;
KW   Cleavage on pair of basic residues; Coiled coil; Complete proteome;
KW   Disulfide bond; Fusion of virus membrane with host endosomal membrane;
KW   Fusion of virus membrane with host membrane; Glycoprotein;
KW   Host cell membrane; Host membrane; Host-virus interaction;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host interferon signaling pathway by virus;
KW   Inhibition of host tetherin by virus; Lipoprotein; Membrane;
KW   Palmitate; Reference proteome; RNA editing; Secreted; Signal;
KW   Transmembrane; Transmembrane helix; Viral attachment to host cell;
KW   Viral attachment to host entry receptor; Viral envelope protein;
KW   Viral immunoevasion; Viral penetration into host cytoplasm; Virion;
KW   Virus endocytosis by host; Virus entry into host cell.
FT   SIGNAL        1     32       {ECO:0000255}.
FT   CHAIN        33    676       Envelope glycoprotein.
FT                                /FTId=PRO_0000037485.
FT   CHAIN        33    501       GP1.
FT                                /FTId=PRO_0000037486.
FT   CHAIN       502    676       GP2.
FT                                /FTId=PRO_0000037487.
FT   CHAIN       502    637       GP2-delta.
FT                                /FTId=PRO_0000245066.
FT   TOPO_DOM     33    650       Extracellular. {ECO:0000255}.
FT   TRANSMEM    651    671       Helical. {ECO:0000255}.
FT   TOPO_DOM    672    676       Cytoplasmic. {ECO:0000255}.
FT   REGION       54    201       Receptor-binding. {ECO:0000255}.
FT   REGION      305    485       Mucin-like region.
FT   REGION      524    539       Fusion peptide. {ECO:0000305}.
FT   COILED      554    595       {ECO:0000255}.
FT   COILED      615    634       {ECO:0000255}.
FT   SITE         57     57       Involved in receptor recognition and/or
FT                                post-binding events. {ECO:0000255}.
FT   SITE         63     63       Involved in receptor recognition and/or
FT                                post-binding events. {ECO:0000255}.
FT   SITE         64     64       Involved in receptor recognition and/or
FT                                post-binding events. {ECO:0000255}.
FT   SITE         88     88       Involved in receptor recognition and/or
FT                                post-binding events. {ECO:0000255}.
FT   SITE         95     95       Involved in receptor recognition and/or
FT                                post-binding events. {ECO:0000255}.
FT   SITE        170    170       Involved in receptor recognition and/or
FT                                post-binding events. {ECO:0000255}.
FT   SITE        501    502       Cleavage; by host furin.
FT                                {ECO:0000269|PubMed:9576958}.
FT   SITE        637    638       Cleavage; by host ADAM17.
FT                                {ECO:0000269|PubMed:15103332}.
FT   LIPID       670    670       S-palmitoyl cysteine; by host.
FT                                {ECO:0000269|PubMed:11152533}.
FT   LIPID       672    672       S-palmitoyl cysteine; by host.
FT                                {ECO:0000269|PubMed:11152533}.
FT   CARBOHYD     40     40       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    204    204       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    228    228       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    238    238       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    257    257       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    268    268       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    296    296       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    317    317       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    333    333       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    346    346       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    386    386       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    413    413       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    436    436       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    454    454       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    462    462       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    563    563       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    618    618       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   DISULFID     53    609       Interchain (between GP1 and GP2 chains).
FT                                {ECO:0000269|PubMed:12438572}.
FT   DISULFID    108    135       {ECO:0000255}.
FT   DISULFID    121    147       {ECO:0000255}.
FT   DISULFID    511    556       {ECO:0000255}.
FT   DISULFID    601    608       {ECO:0000269|PubMed:12438572}.
FT   VARIANT      65     65       S -> P (in strain: Isolate mouse-
FT                                adapted).
FT   VARIANT     246    246       S -> P (in strain: Isolate mouse-
FT                                adapted).
FT   VARIANT     544    544       I -> T.
FT   MUTAGEN      40     40       N->D: Induces GP1 secretion. Complete
FT                                loss of virus capability to enter into
FT                                host cell. {ECO:0000269|PubMed:12438572}.
FT   MUTAGEN      53     53       C->G: Induces GP1 secretion. Complete
FT                                loss of virus capability to enter into
FT                                host cell. {ECO:0000269|PubMed:12438572}.
FT   MUTAGEN      55     55       D->A: 80% loss of virus capability to
FT                                enter into host cell.
FT   MUTAGEN      55     55       D->E,K: No effect on viral entry.
FT   MUTAGEN      57     57       L->A: Complete loss of virus capability
FT                                to enter into host cell.
FT   MUTAGEN      57     57       L->F,I,K: 90% loss of virus capability to
FT                                enter into host cell.
FT   MUTAGEN      63     63       L->A: 90% loss of virus capability to
FT                                enter into host cell.
FT   MUTAGEN      63     63       L->F: Almost complete loss of virus
FT                                capability to enter into host cell.
FT   MUTAGEN      63     63       L->K: Complete loss of virus capability
FT                                to enter into host cell.
FT   MUTAGEN      64     64       R->A,E: Complete loss of virus capability
FT                                to enter into host cell.
FT   MUTAGEN      64     64       R->K: No loss of virus capability to
FT                                enter into host cell.
FT   MUTAGEN      88     88       F->A,E: Complete loss of virus capability
FT                                to enter into host cell.
FT   MUTAGEN      88     88       F->I: No loss of virus capability to
FT                                enter into host cell.
FT   MUTAGEN      95     95       K->A,E: 80% loss of virus capability to
FT                                enter into host cell.
FT   MUTAGEN      95     95       K->R: 20% loss of virus capability to
FT                                enter into host cell.
FT   MUTAGEN     108    108       C->G: Almost complete loss of expression
FT                                of GP1 and GP2. Almost complete loss of
FT                                virus capability to enter into host cell.
FT                                {ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     121    121       C->G: Reduced levels of expression of GP1
FT                                and GP2. 50% loss of virus capability to
FT                                enter into host cell.
FT                                {ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     135    135       C->S: Almost complete loss of expression
FT                                of GP1 and GP2. Complete loss of virus
FT                                capability to enter into host cell.
FT                                {ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     147    147       C->S: Reduced levels of expression of GP1
FT                                and GP2. Almost complete loss of virus
FT                                capability to enter into host cell.
FT                                {ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     170    170       I->A: 90% loss of virus capability to
FT                                enter into host cell.
FT   MUTAGEN     170    170       I->E: Complete loss of virus capability
FT                                to enter into host cell.
FT   MUTAGEN     170    170       I->F: 50% loss of virus capability to
FT                                enter into host cell.
FT   MUTAGEN     204    204       N->D: No effect on GP1 and GP2
FT                                expression. No loss of virus capability
FT                                to enter into host cell.
FT                                {ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     238    238       N->Y: No effect on GP1 and GP2
FT                                expression. 12% loss of virus capability
FT                                to enter into host cell.
FT                                {ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     257    257       N->D: No effect on GP1 and GP2
FT                                expression. 12% loss of virus capability
FT                                to enter into host cell.
FT                                {ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     296    296       N->D: No effect on GP1 and GP2
FT                                expression. 18% loss of virus capability
FT                                to enter into host cell.
FT                                {ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     497    501       RRTRR->AGTAA: Almost complete loss of
FT                                cleavage between GP1 and GP2. No loss of
FT                                infectivity.
FT                                {ECO:0000269|PubMed:11152533}.
FT   MUTAGEN     498    501       RTRR->ATAA: No effect on cleavage between
FT                                GP1 and GP2.
FT                                {ECO:0000269|PubMed:9882347}.
FT   MUTAGEN     511    511       C->G: Induces GP1 secretion. Complete
FT                                loss of virus capability to enter into
FT                                host cell. {ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     528    528       G->R: Reduced infectivity.
FT                                {ECO:0000269|PubMed:10482652}.
FT   MUTAGEN     529    529       L->A,R: Reduced infectivity.
FT                                {ECO:0000269|PubMed:10482652}.
FT   MUTAGEN     532    532       I->A: Reduced infectivity.
FT                                {ECO:0000269|PubMed:10482652}.
FT   MUTAGEN     532    532       I->R: Almost complete loss of
FT                                infectivity. No effect on transport of GP
FT                                to the cell surface and incorporation
FT                                onto virions.
FT                                {ECO:0000269|PubMed:10482652}.
FT   MUTAGEN     535    535       F->A: Reduced infectivity.
FT                                {ECO:0000269|PubMed:10482652}.
FT   MUTAGEN     535    535       F->R: Almost complete loss of
FT                                infectivity. No effect on transport of GP
FT                                to the cell surface and incorporation
FT                                onto virions.
FT                                {ECO:0000269|PubMed:10482652}.
FT   MUTAGEN     536    536       G->A: Almost complete loss of
FT                                infectivity. No effect on transport of GP
FT                                to the cell surface and incorporation
FT                                onto virions.
FT                                {ECO:0000269|PubMed:10482652}.
FT   MUTAGEN     537    537       P->R: Almost complete loss of
FT                                infectivity. No effect on transport of GP
FT                                to the cell surface and incorporation
FT                                onto virions.
FT                                {ECO:0000269|PubMed:10482652}.
FT   MUTAGEN     556    556       C->S: Induces GP1 secretion. Complete
FT                                loss of virus capability to enter into
FT                                host cell. {ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     563    563       N->D: Reduced levels of expression of GP,
FT                                GP1 and GP2. 20% loss of virus capability
FT                                to enter into host cell.
FT                                {ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     601    601       C->S: Induces GP1 secretion. Complete
FT                                loss of virus capability to enter into
FT                                host cell. {ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     608    608       C->G: Induces GP1 secretion. Complete
FT                                loss of virus capability to enter into
FT                                host cell. {ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     609    609       C->G: Induces GP1 secretion. Complete
FT                                loss of virus capability to enter into
FT                                host cell. {ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     618    618       N->D: Slightly reduced levels of
FT                                expression of GP1 and GP2. No loss of
FT                                virus capability to enter into host cell.
FT                                {ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     632    632       D->V: No effect on release of soluble
FT                                GP1,2delta.
FT                                {ECO:0000269|PubMed:15103332}.
FT   MUTAGEN     633    633       K->R,V: No effect on release of soluble
FT                                GP1,2delta.
FT                                {ECO:0000269|PubMed:15103332}.
FT   MUTAGEN     634    634       T->I: 50% loss of release of soluble
FT                                GP1,2delta.
FT                                {ECO:0000269|PubMed:15103332}.
FT   MUTAGEN     635    635       L->V: 60% loss of release of soluble
FT                                GP1,2delta.
FT                                {ECO:0000269|PubMed:15103332}.
FT   MUTAGEN     636    636       P->A: 60% loss of release of soluble
FT                                GP1,2delta.
FT   MUTAGEN     637    637       D->E: No effect on release of soluble
FT                                GP1,2delta.
FT                                {ECO:0000269|PubMed:15103332}.
FT   MUTAGEN     637    637       D->L,V: Increased release of soluble
FT                                GP1,2delta.
FT                                {ECO:0000269|PubMed:15103332}.
FT   MUTAGEN     638    638       Q->V: No effect on release of soluble
FT                                GP1,2delta.
FT                                {ECO:0000269|PubMed:15103332}.
FT   MUTAGEN     639    639       G->V: 40% loss of release of soluble
FT                                GP1,2delta.
FT                                {ECO:0000269|PubMed:15103332}.
FT   MUTAGEN     640    640       D->V: No effect on release of soluble
FT                                GP1,2delta.
FT                                {ECO:0000269|PubMed:15103332}.
FT   MUTAGEN     641    641       N->A: No effect on release of soluble
FT                                GP1,2delta.
FT                                {ECO:0000269|PubMed:15103332}.
FT   MUTAGEN     642    642       D->V: No effect on release of soluble
FT                                GP1,2delta.
FT                                {ECO:0000269|PubMed:15103332}.
FT   MUTAGEN     643    643       N->A: No effect on release of soluble
FT                                GP1,2delta.
FT                                {ECO:0000269|PubMed:15103332}.
FT   MUTAGEN     670    670       C->A: Reduced palmitoylation. No effect
FT                                on GP processing and association with
FT                                retrovirus particle. No loss of virus
FT                                capability to enter into host cell. Loss
FT                                of localization to the rafts; when
FT                                associated with A-670.
FT                                {ECO:0000269|PubMed:11152533,
FT                                ECO:0000269|PubMed:11877482,
FT                                ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     670    670       C->F: Slightly reduced levels of
FT                                expression of GP1 and GP2. Greatly
FT                                reduced GP processing and association
FT                                with retrovirus particle. 43% loss of
FT                                virus capability to enter into host cell.
FT                                Loss of localization to the rafts; when
FT                                associated with A-672.
FT                                {ECO:0000269|PubMed:11152533,
FT                                ECO:0000269|PubMed:11877482,
FT                                ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     672    672       C->A: Reduced palmitoylation. No effect
FT                                on GP processing and association with
FT                                retrovirus particle. No loss of virus
FT                                capability to enter into host cell.
FT                                {ECO:0000269|PubMed:11152533,
FT                                ECO:0000269|PubMed:12438572}.
FT   MUTAGEN     672    672       C->F: Slightly reduced levels of
FT                                expression of GP1 and GP2. Almost no
FT                                effect on GP processing and association
FT                                with retrovirus particle. 24% loss of
FT                                virus capability to enter into host cell.
FT                                {ECO:0000269|PubMed:11152533,
FT                                ECO:0000269|PubMed:12438572}.
FT   STRAND       35     39       {ECO:0000244|PDB:3CSY}.
FT   STRAND       42     46       {ECO:0000244|PDB:3CSY}.
FT   STRAND       48     50       {ECO:0000244|PDB:3CSY}.
FT   HELIX        60     62       {ECO:0000244|PDB:3CSY}.
FT   STRAND       63     69       {ECO:0000244|PDB:3CSY}.
FT   HELIX        70     73       {ECO:0000244|PDB:3CSY}.
FT   HELIX        79     83       {ECO:0000244|PDB:3CSY}.
FT   STRAND       86     92       {ECO:0000244|PDB:3CSY}.
FT   STRAND       96     98       {ECO:0000244|PDB:3CSY}.
FT   STRAND      100    103       {ECO:0000244|PDB:3CSY}.
FT   STRAND      105    114       {ECO:0000244|PDB:3CSY}.
FT   STRAND      116    118       {ECO:0000244|PDB:3CSY}.
FT   STRAND      120    122       {ECO:0000244|PDB:3CSY}.
FT   STRAND      135    144       {ECO:0000244|PDB:3CSY}.
FT   STRAND      149    154       {ECO:0000244|PDB:3CSY}.
FT   STRAND      159    161       {ECO:0000244|PDB:3CSY}.
FT   STRAND      163    169       {ECO:0000244|PDB:3CSY}.
FT   STRAND      175    185       {ECO:0000244|PDB:3CSY}.
FT   STRAND      216    229       {ECO:0000244|PDB:3CSY}.
FT   STRAND      231    234       {ECO:0000244|PDB:3CSY}.
FT   STRAND      240    243       {ECO:0000244|PDB:3CSY}.
FT   HELIX       250    263       {ECO:0000244|PDB:3CSY}.
FT   STRAND      268    270       {ECO:0000244|PDB:3CSY}.
FT   STRAND      273    276       {ECO:0000244|PDB:3CSY}.
FT   STRAND      305    307       {ECO:0000244|PDB:3CSY}.
FT   STRAND      515    520       {ECO:0000244|PDB:3CSY}.
FT   TURN        528    531       {ECO:0000244|PDB:3CSY}.
FT   STRAND      532    536       {ECO:0000244|PDB:3CSY}.
FT   STRAND      541    548       {ECO:0000244|PDB:3CSY}.
FT   HELIX       560    594       {ECO:0000244|PDB:2EBO}.
FT   HELIX       595    597       {ECO:0000244|PDB:2EBO}.
FT   HELIX       600    604       {ECO:0000244|PDB:2EBO}.
FT   HELIX       605    609       {ECO:0000244|PDB:2EBO}.
FT   HELIX       616    628       {ECO:0000244|PDB:2EBO}.
SQ   SEQUENCE   676 AA;  74464 MW;  BE8AB3B339F63261 CRC64;
     MGVTGILQLP RDRFKRTSFF LWVIILFQRT FSIPLGVIHN STLQVSDVDK LVCRDKLSST
     NQLRSVGLNL EGNGVATDVP SATKRWGFRS GVPPKVVNYE AGEWAENCYN LEIKKPDGSE
     CLPAAPDGIR GFPRCRYVHK VSGTGPCAGD FAFHKEGAFF LYDRLASTVI YRGTTFAEGV
     VAFLILPQAK KDFFSSHPLR EPVNATEDPS SGYYSTTIRY QATGFGTNET EYLFEVDNLT
     YVQLESRFTP QFLLQLNETI YTSGKRSNTT GKLIWKVNPE IDTTIGEWAF WETKKNLTRK
     IRSEELSFTV VSNGAKNISG QSPARTSSDP GTNTTTEDHK IMASENSSAM VQVHSQGREA
     AVSHLTTLAT ISTSPQSLTT KPGPDNSTHN TPVYKLDISE ATQVEQHHRR TDNDSTASDT
     PSATTAAGPP KAENTNTSKS TDFLDPATTT SPQNHSETAG NNNTHHQDTG EESASSGKLG
     LITNTIAGVA GLITGGRRTR REAIVNAQPK CNPNLHYWTT QDEGAAIGLA WIPYFGPAAE
     GIYIEGLMHN QDGLICGLRQ LANETTQALQ LFLRATTELR TFSILNRKAI DFLLQRWGGT
     CHILGPDCCI EPHDWTKNIT DKIDQIIHDF VDKTLPDQGD NDNWWTGWRQ WIPAGIGVTG
     VIIAVIALFC ICKFVF
//
ID   APOA2_HUMAN             Reviewed;         100 AA.
AC   P02652; B2R524;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   17-FEB-2016, entry version 191.
DE   RecName: Full=Apolipoprotein A-II;
DE            Short=Apo-AII;
DE            Short=ApoA-II;
DE   AltName: Full=Apolipoprotein A2;
DE   Contains:
DE     RecName: Full=Proapolipoprotein A-II;
DE              Short=ProapoA-II;
DE   Contains:
DE     RecName: Full=Truncated apolipoprotein A-II;
DE     AltName: Full=Apolipoprotein A-II(1-76);
DE   Flags: Precursor;
GN   Name=APOA2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6428397; DOI=10.1016/S0006-291X(84)80168-0;
RA   Knott T.J., Priestley L.M., Urdea M., Scott J.;
RT   "Isolation and characterisation of a cDNA encoding the precursor for
RT   human apolipoprotein AII.";
RL   Biochem. Biophys. Res. Commun. 120:734-740(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6089788;
RA   Moore M.N., Kao F.-T., Tsao Y.-K., Chan L.;
RT   "Human apolipoprotein A-II: nucleotide sequence of a cloned cDNA, and
RT   localization of its structural gene on human chromosome 1.";
RL   Biochem. Biophys. Res. Commun. 123:1-7(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6328445; DOI=10.1093/nar/12.9.3917;
RA   Sharpe C.R., Sidoli A., Shelley C.S., Lucero M.A., Shoulders C.C.,
RA   Baralle F.E.;
RT   "Human apolipoproteins AI, AII, CII and CIII. cDNA sequences and mRNA
RT   abundance.";
RL   Nucleic Acids Res. 12:3917-3932(1984).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2989800; DOI=10.1093/nar/13.12.4597;
RA   Lackner K.J., Law S.W., Brewer H.B. Jr.;
RT   "The human apolipoprotein A-II gene: complete nucleic acid sequence
RT   and genomic organization.";
RL   Nucleic Acids Res. 13:4597-4608(1985).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2995928; DOI=10.1093/nar/13.17.6387;
RA   Knott T.J., Wallis S.C., Robertson M.E., Priestley L.M., Urdea M.,
RA   Rall L.B., Scott J.;
RT   "The human apolipoprotein AII gene: structural organization and sites
RT   of expression.";
RL   Nucleic Acids Res. 13:6387-6398(1985).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3088392; DOI=10.1016/0076-6879(86)28103-3;
RA   Chan L., Moore M.N., Tsao Y.-K.;
RT   "Molecular cloning and sequence analysis of human apolipoprotein A-II
RT   cDNA.";
RL   Methods Enzymol. 128:745-752(1986).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=12136239; DOI=10.1007/s00439-002-0763-x;
RA   Fullerton S.M., Clark A.G., Weiss K.M., Taylor S.L., Stengard J.H.,
RA   Salomaa V., Boerwinkle E., Nickerson D.A.;
RT   "Sequence polymorphism at the human apolipoprotein AII gene (APOA2):
RT   unexpected deficit of variation in an African-American sample.";
RL   Hum. Genet. 111:75-87(2002).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   PROTEIN SEQUENCE OF 24-100, AND PYROGLUTAMATE FORMATION AT GLN-24.
RX   PubMed=4344225;
RA   Lux S.E., John K.M., Ronan R., Brewer H.B. Jr.;
RT   "Isolation and characterization of the tryptic and cyanogen bromide
RT   peptides of apoLp-Gln-II (apoA-II), plasma high density
RT   apolipoprotein.";
RL   J. Biol. Chem. 247:7519-7527(1972).
RN   [13]
RP   PROTEIN SEQUENCE OF 25-37, MASS SPECTROMETRY, SUBUNIT, SUBCELLULAR
RP   LOCATION, AND PYROGLUTAMATE FORMATION AT GLN-24.
RX   PubMed=24116940; DOI=10.1089/adt.2013.511;
RA   Su M., Qi Y., Wang M., Chang W., Peng S., Xu T., Wang D.;
RT   "Expression and purification of recombinant human apolipoprotein A-II
RT   in Pichia pastoris.";
RL   Assay Drug Dev. Technol. 11:501-507(2013).
RN   [14]
RP   PARTIAL PROTEIN SEQUENCE OF 1-29.
RX   PubMed=6407957;
RA   Stoffel W., Krueger E., Deutzmann R.;
RT   "Cell-free translation of human liver apolipoprotein AI and AII mRNA.
RT   Processing of primary translation products.";
RL   Hoppe-Seyler's Z. Physiol. Chem. 364:227-237(1983).
RN   [15]
RP   POLYMORPHISM.
RX   PubMed=2107739;
RA   Deeb S.S., Takata K., Peng R.L., Kajiyama G., Albers J.J.;
RT   "A splice-junction mutation responsible for familial apolipoprotein A-
RT   II deficiency.";
RL   Am. J. Hum. Genet. 46:822-827(1990).
RN   [16]
RP   INTERCHAIN DISULFIDE BOND WITH APOD.
RC   TISSUE=Plasma;
RX   PubMed=7918467; DOI=10.1021/bi00207a011;
RA   Yang C.-Y., Gu Z.-W., Blanco-Vaca F., Gaskell S.J., Yang M.,
RA   Massey J.B., Gotto A.M. Jr., Pownall H.J.;
RT   "Structure of human apolipoprotein D: locations of the intermolecular
RT   and intramolecular disulfide links.";
RL   Biochemistry 33:12451-12455(1994).
RN   [17]
RP   INTERACTION WITH APOA1BP.
RX   PubMed=11991719; DOI=10.1006/geno.2002.6761;
RA   Ritter M., Buechler C., Boettcher A., Barlage S., Schmitz-Madry A.,
RA   Orso E., Bared S.M., Schmiedeknecht G., Baehr C.H., Fricker G.,
RA   Schmitz G.;
RT   "Cloning and characterization of a novel apolipoprotein A-I-binding
RT   protein, AI-BP, secreted by cells of the kidney proximal tubules in
RT   response to HDL or ApoA-I.";
RL   Genomics 79:693-702(2002).
RN   [18]
RP   MASS SPECTROMETRY, AND OXIDATION AT MET-49.
RX   PubMed=12576517; DOI=10.1194/jlr.M200256-JLR200;
RA   Pankhurst G., Wang X.L., Wilcken D.E., Baernthaler G., Panzenboeck U.,
RA   Raftery M., Stocker R.;
RT   "Characterization of specifically oxidized apolipoproteins in mildly
RT   oxidized high density lipoprotein.";
RL   J. Lipid Res. 44:349-355(2003).
RN   [19]
RP   MASS SPECTROMETRY, AND SUBUNIT.
RX   PubMed=12562854; DOI=10.1194/jlr.D200034-JLR200;
RA   Niederkofler E.E., Tubbs K.A., Kiernan U.A., Nedelkov D., Nelson R.W.;
RT   "Novel mass spectrometric immunoassays for the rapid structural
RT   characterization of plasma apolipoproteins.";
RL   J. Lipid Res. 44:630-639(2003).
RN   [20]
RP   INTERACTION WITH NDRG1.
RX   PubMed=15922294; DOI=10.1016/j.bbrc.2005.05.050;
RA   Hunter M., Angelicheva D., Tournev I., Ingley E., Chan D.C.,
RA   Watts G.F., Kremensky I., Kalaydjieva L.;
RT   "NDRG1 interacts with APO A-I and A-II and is a functional candidate
RT   for the HDL-C QTL on 8q24.";
RL   Biochem. Biophys. Res. Commun. 332:982-992(2005).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-68, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Serum;
RX   PubMed=19824718; DOI=10.1021/pr900603n;
RA   Zhou W., Ross M.M., Tessitore A., Ornstein D., Vanmeter A.,
RA   Liotta L.A., Petricoin E.F. III;
RT   "An initial characterization of the serum phosphoproteome.";
RL   J. Proteome Res. 8:5523-5531(2009).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [23]
RP   GLYCOSYLATION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=23234360; DOI=10.1021/pr300963h;
RA   Halim A., Ruetschi U., Larson G., Nilsson J.;
RT   "LC-MS/MS characterization of O-glycosylation sites and glycan
RT   structures of human cerebrospinal fluid glycoproteins.";
RL   J. Proteome Res. 12:573-584(2013).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [25]
RP   PHOSPHORYLATION AT SER-54 AND SER-68.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 24-100, SUBUNIT, AND
RP   DISULFIDE BOND.
RX   PubMed=12269810; DOI=10.1021/bi026069w;
RA   Kumar M.S., Carson M., Hussain M.M., Murthy H.M.;
RT   "Structures of apolipoprotein A-II and a lipid-surrogate complex
RT   provide insights into apolipoprotein-lipid interactions.";
RL   Biochemistry 41:11681-11691(2002).
CC   -!- FUNCTION: May stabilize HDL (high density lipoprotein) structure
CC       by its association with lipids, and affect the HDL metabolism.
CC   -!- SUBUNIT: Monomer. Homodimer; disulfide-linked. Also forms a
CC       disulfide-linked heterodimer with APOD. Interacts with HCV core
CC       protein. Interacts with APOA1BP and NDRG1.
CC       {ECO:0000269|PubMed:11991719, ECO:0000269|PubMed:12269810,
CC       ECO:0000269|PubMed:12562854, ECO:0000269|PubMed:15922294,
CC       ECO:0000269|PubMed:24116940}.
CC   -!- INTERACTION:
CC       Q8NEC5:CATSPER1; NbExp=3; IntAct=EBI-1171525, EBI-744545;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:24116940}.
CC   -!- TISSUE SPECIFICITY: Plasma; synthesized in the liver and
CC       intestine.
CC   -!- PTM: Phosphorylation sites are present in the extracellular
CC       medium. {ECO:0000269|PubMed:26091039}.
CC   -!- PTM: Apolipoprotein A-II is O-glycosylated.
CC       {ECO:0000269|PubMed:23234360}.
CC   -!- MASS SPECTROMETRY: Mass=17252; Method=Electrospray; Range=24-100;
CC       Note=Homodimer, without methionine sulfoxide.;
CC       Evidence={ECO:0000269|PubMed:12576517};
CC   -!- MASS SPECTROMETRY: Mass=17269; Method=Electrospray; Range=24-100;
CC       Note=Homodimer, with 1 methionine sulfoxide, oxidation at Met-49.;
CC       Evidence={ECO:0000269|PubMed:12576517};
CC   -!- MASS SPECTROMETRY: Mass=8701.2; Method=MALDI; Range=24-100;
CC       Note=Monomer.; Evidence={ECO:0000269|PubMed:12562854};
CC   -!- MASS SPECTROMETRY: Mass=8823.4; Method=MALDI; Range=24-100;
CC       Note=Cysteinylated ApoA-II monomer.;
CC       Evidence={ECO:0000269|PubMed:12562854};
CC   -!- MASS SPECTROMETRY: Mass=17421.3; Method=MALDI; Range=24-100;
CC       Note=Homodimer.; Evidence={ECO:0000269|PubMed:12562854};
CC   -!- MASS SPECTROMETRY: Mass=17293.4; Method=MALDI; Range=24-100;
CC       Note=Heterodimer with truncated apolipoprotein A-II.;
CC       Evidence={ECO:0000269|PubMed:12562854};
CC   -!- MASS SPECTROMETRY: Mass=8578.3; Method=MALDI; Range=24-99;
CC       Note=Monomer.; Evidence={ECO:0000269|PubMed:12562854};
CC   -!- MASS SPECTROMETRY: Mass=17166.2; Method=MALDI; Range=24-99;
CC       Note=Homodimer.; Evidence={ECO:0000269|PubMed:12562854};
CC   -!- MASS SPECTROMETRY: Mass=17380; Method=MALDI; Range=25-100;
CC       Note=Homodimer.; Evidence={ECO:0000269|PubMed:24116940};
CC   -!- POLYMORPHISM: A homozygous transition at position 1 of intron 3 of
CC       APOA2 results in deficiency of apolipoprotein A-II, without
CC       significant influence either on lipid and lipoprotein profiles or
CC       on the occurrence of coronary artery disease [MIM:107670].
CC       {ECO:0000269|PubMed:2107739}.
CC   -!- SIMILARITY: Belongs to the apolipoprotein A2 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=APOA2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04898; CAA28583.1; -; Genomic_DNA.
DR   EMBL; X00955; CAA25467.1; -; mRNA.
DR   EMBL; X02905; CAA26665.1; -; Genomic_DNA.
DR   EMBL; X02619; CAA26474.1; -; Genomic_DNA.
DR   EMBL; M29882; AAA51701.1; -; mRNA.
DR   EMBL; AY100524; AAM49807.1; -; Genomic_DNA.
DR   EMBL; AK312034; BAG34971.1; -; mRNA.
DR   EMBL; BT006786; AAP35432.1; -; mRNA.
DR   EMBL; AL590714; CAH72151.1; -; Genomic_DNA.
DR   EMBL; BC005282; AAH05282.1; -; mRNA.
DR   CCDS; CCDS1226.1; -.
DR   PIR; A93586; LPHUA2.
DR   RefSeq; NP_001634.1; NM_001643.1.
DR   UniGene; Hs.237658; -.
DR   PDB; 1L6L; X-ray; 2.30 A; 1/2/3/4/5/6/7/8/A/B/C/D/E/F/G/H/I/J/K/L/M/N/P/Q/S/T/U/V/W/X/Y/Z=24-100.
DR   PDB; 2OU1; X-ray; 2.00 A; A/B/C/D/E/F/G/H/I/J/K/L=24-100.
DR   PDBsum; 1L6L; -.
DR   PDBsum; 2OU1; -.
DR   ProteinModelPortal; P02652; -.
DR   BioGrid; 106833; 12.
DR   IntAct; P02652; 9.
DR   MINT; MINT-106326; -.
DR   STRING; 9606.ENSP00000356969; -.
DR   iPTMnet; P02652; -.
DR   PhosphoSite; P02652; -.
DR   BioMuta; APOA2; -.
DR   DMDM; 114000; -.
DR   SWISS-2DPAGE; P02652; -.
DR   MaxQB; P02652; -.
DR   PaxDb; P02652; -.
DR   PeptideAtlas; P02652; -.
DR   PRIDE; P02652; -.
DR   DNASU; 336; -.
DR   Ensembl; ENST00000367990; ENSP00000356969; ENSG00000158874.
DR   GeneID; 336; -.
DR   KEGG; hsa:336; -.
DR   UCSC; uc001fzc.1; human.
DR   CTD; 336; -.
DR   GeneCards; APOA2; -.
DR   HGNC; HGNC:601; APOA2.
DR   HPA; CAB025885; -.
DR   MalaCards; APOA2; -.
DR   MIM; 107670; gene+phenotype.
DR   neXtProt; NX_P02652; -.
DR   Orphanet; 238269; Familial renal amyloidosis due to Apolipoprotein AII variant.
DR   PharmGKB; PA24886; -.
DR   eggNOG; ENOG410KCI2; Eukaryota.
DR   eggNOG; ENOG4110NY0; LUCA.
DR   GeneTree; ENSGT00390000003306; -.
DR   HOGENOM; HOG000033999; -.
DR   HOVERGEN; HBG050544; -.
DR   InParanoid; P02652; -.
DR   KO; K08758; -.
DR   OrthoDB; EOG7G4QHG; -.
DR   PhylomeDB; P02652; -.
DR   TreeFam; TF338165; -.
DR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   ChiTaRS; APOA2; human.
DR   EvolutionaryTrace; P02652; -.
DR   GeneWiki; APOA2; -.
DR   GenomeRNAi; 336; -.
DR   NextBio; 1391; -.
DR   PMAP-CutDB; P02652; -.
DR   PRO; PR:P02652; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; P02652; -.
DR   CleanEx; HS_APOA2; -.
DR   ExpressionAtlas; P02652; baseline and differential.
DR   Genevisible; P02652; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0042627; C:chylomicron; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005769; C:early endosome; TAS:Reactome.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0034364; C:high-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034366; C:spherical high-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034190; F:apolipoprotein receptor binding; IPI:BHF-UCL.
DR   GO; GO:0015485; F:cholesterol binding; IDA:BHF-UCL.
DR   GO; GO:0017127; F:cholesterol transporter activity; IEA:Ensembl.
DR   GO; GO:0008035; F:high-density lipoprotein particle binding; IBA:GO_Central.
DR   GO; GO:0070653; F:high-density lipoprotein particle receptor binding; IPI:BHF-UCL.
DR   GO; GO:0055102; F:lipase inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0008289; F:lipid binding; IDA:BHF-UCL.
DR   GO; GO:0005319; F:lipid transporter activity; IDA:BHF-UCL.
DR   GO; GO:0031210; F:phosphatidylcholine binding; IDA:BHF-UCL.
DR   GO; GO:0060228; F:phosphatidylcholine-sterol O-acyltransferase activator activity; IDA:BHF-UCL.
DR   GO; GO:0005543; F:phospholipid binding; IDA:BHF-UCL.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0002526; P:acute inflammatory response; IEA:Ensembl.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0033344; P:cholesterol efflux; IDA:BHF-UCL.
DR   GO; GO:0042632; P:cholesterol homeostasis; IDA:BHF-UCL.
DR   GO; GO:0008203; P:cholesterol metabolic process; IBA:GO_Central.
DR   GO; GO:0046340; P:diacylglycerol catabolic process; IDA:BHF-UCL.
DR   GO; GO:0034380; P:high-density lipoprotein particle assembly; IDA:BHF-UCL.
DR   GO; GO:0034384; P:high-density lipoprotein particle clearance; IDA:BHF-UCL.
DR   GO; GO:0034375; P:high-density lipoprotein particle remodeling; IDA:BHF-UCL.
DR   GO; GO:0042157; P:lipoprotein metabolic process; IBA:GO_Central.
DR   GO; GO:0034374; P:low-density lipoprotein particle remodeling; IDA:BHF-UCL.
DR   GO; GO:0060621; P:negative regulation of cholesterol import; IDA:BHF-UCL.
DR   GO; GO:0032375; P:negative regulation of cholesterol transport; IMP:BHF-UCL.
DR   GO; GO:0060695; P:negative regulation of cholesterol transporter activity; IDA:BHF-UCL.
DR   GO; GO:0002740; P:negative regulation of cytokine secretion involved in immune response; IDA:BHF-UCL.
DR   GO; GO:0060192; P:negative regulation of lipase activity; IDA:BHF-UCL.
DR   GO; GO:0050995; P:negative regulation of lipid catabolic process; IDA:BHF-UCL.
DR   GO; GO:0010903; P:negative regulation of very-low-density lipoprotein particle remodeling; IDA:BHF-UCL.
DR   GO; GO:0031100; P:organ regeneration; IEA:Ensembl.
DR   GO; GO:0018206; P:peptidyl-methionine modification; IDA:UniProtKB.
DR   GO; GO:0006656; P:phosphatidylcholine biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0009395; P:phospholipid catabolic process; IDA:BHF-UCL.
DR   GO; GO:0033700; P:phospholipid efflux; IDA:BHF-UCL.
DR   GO; GO:0007603; P:phototransduction, visible light; TAS:Reactome.
DR   GO; GO:0043085; P:positive regulation of catalytic activity; IDA:GOC.
DR   GO; GO:0010873; P:positive regulation of cholesterol esterification; IDA:BHF-UCL.
DR   GO; GO:0045416; P:positive regulation of interleukin-8 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0050996; P:positive regulation of lipid catabolic process; IDA:BHF-UCL.
DR   GO; GO:0006457; P:protein folding; IDA:BHF-UCL.
DR   GO; GO:0018158; P:protein oxidation; IDA:UniProtKB.
DR   GO; GO:0030300; P:regulation of intestinal cholesterol absorption; IEA:Ensembl.
DR   GO; GO:0031647; P:regulation of protein stability; IDA:BHF-UCL.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; IDA:BHF-UCL.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0043691; P:reverse cholesterol transport; IDA:BHF-UCL.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0006641; P:triglyceride metabolic process; TAS:BHF-UCL.
DR   GO; GO:0034370; P:triglyceride-rich lipoprotein particle remodeling; IDA:BHF-UCL.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   InterPro; IPR006801; ApoA-II.
DR   PANTHER; PTHR11027; PTHR11027; 1.
DR   ProDom; PD010397; ApoA-II; 1.
DR   SUPFAM; SSF82936; SSF82936; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; HDL;
KW   Host-virus interaction; Lipid transport; Oxidation; Phosphoprotein;
KW   Pyrrolidone carboxylic acid; Reference proteome; Secreted; Signal;
KW   Transport.
FT   SIGNAL        1     18       {ECO:0000269|PubMed:6328445}.
FT   CHAIN        19    100       Proapolipoprotein A-II.
FT                                /FTId=PRO_0000425351.
FT   CHAIN        24    100       Apolipoprotein A-II.
FT                                {ECO:0000269|PubMed:4344225}.
FT                                /FTId=PRO_0000002003.
FT   CHAIN        24     99       Truncated apolipoprotein A-II.
FT                                {ECO:0000305|PubMed:12562854}.
FT                                /FTId=PRO_0000002004.
FT   REGION       32     43       O-glycosylated at one site.
FT   MOD_RES      24     24       Pyrrolidone carboxylic acid.
FT                                {ECO:0000269|PubMed:24116940,
FT                                ECO:0000269|PubMed:4344225}.
FT   MOD_RES      49     49       Methionine sulfoxide.
FT                                {ECO:0000269|PubMed:12576517}.
FT   MOD_RES      54     54       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES      68     68       Phosphoserine; by FAM20C.
FT                                {ECO:0000244|PubMed:19824718,
FT                                ECO:0000269|PubMed:26091039}.
FT   DISULFID     29     29       Interchain (with C-136 in APOD); in
FT                                heterodimeric form.
FT                                {ECO:0000269|PubMed:12269810}.
FT   CONFLICT     96     96       Q -> H (in Ref. 1; CAA28583).
FT                                {ECO:0000305}.
FT   HELIX        31     56       {ECO:0000244|PDB:2OU1}.
FT   STRAND       58     60       {ECO:0000244|PDB:2OU1}.
FT   HELIX        63     69       {ECO:0000244|PDB:2OU1}.
FT   TURN         70     72       {ECO:0000244|PDB:2OU1}.
FT   HELIX        74     77       {ECO:0000244|PDB:2OU1}.
FT   HELIX        79     82       {ECO:0000244|PDB:2OU1}.
FT   HELIX        88     95       {ECO:0000244|PDB:2OU1}.
FT   TURN         96     98       {ECO:0000244|PDB:2OU1}.
SQ   SEQUENCE   100 AA;  11175 MW;  1247868A25EC3AF2 CRC64;
     MKLLAATVLL LTICSLEGAL VRRQAKEPCV ESLVSQYFQT VTDYGKDLME KVKSPELQAE
     AKSYFEKSKE QLTPLIKKAG TELVNFLSYF VELGTQPATQ
//
ID   ANGT_RAT                Reviewed;         477 AA.
AC   P01015;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   17-FEB-2016, entry version 133.
DE   RecName: Full=Angiotensinogen;
DE   AltName: Full=Serpin A8;
DE   Contains:
DE     RecName: Full=Angiotensin-1;
DE     AltName: Full=Angiotensin 1-10;
DE     AltName: Full=Angiotensin I;
DE              Short=Ang I;
DE   Contains:
DE     RecName: Full=Angiotensin-2;
DE     AltName: Full=Angiotensin 1-8;
DE     AltName: Full=Angiotensin II;
DE              Short=Ang II;
DE   Contains:
DE     RecName: Full=Angiotensin-3;
DE     AltName: Full=Angiotensin 2-8;
DE     AltName: Full=Angiotensin III;
DE              Short=Ang III;
DE     AltName: Full=Des-Asp[1]-angiotensin II;
DE   Contains:
DE     RecName: Full=Angiotensin-4;
DE     AltName: Full=Angiotensin 3-8;
DE     AltName: Full=Angiotensin IV;
DE              Short=Ang IV;
DE   Contains:
DE     RecName: Full=Angiotensin 1-9;
DE   Contains:
DE     RecName: Full=Angiotensin 1-7;
DE   Contains:
DE     RecName: Full=Angiotensin 1-5;
DE   Contains:
DE     RecName: Full=Angiotensin 1-4;
DE   Flags: Precursor;
GN   Name=Agt; Synonyms=Serpina8;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Wistar;
RX   PubMed=6572971; DOI=10.1073/pnas.80.8.2196;
RA   Ohkubo H., Kageyama R., Ujihara M., Hirose T., Inayama S.,
RA   Nakanishi S.;
RT   "Cloning and sequence analysis of cDNA for rat angiotensinogen.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:2196-2200(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6330095;
RA   Tanaka T., Ohkubo H., Nakanishi S.;
RT   "Common structural organization of the angiotensinogen and the alpha
RT   1-antitrypsin genes.";
RL   J. Biol. Chem. 259:8063-8065(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 25-34.
RX   PubMed=4344907;
RA   Nakayama T., Nakajima T., Sokabe H.;
RT   "Comparative studies on angiotensins. II. Structure of rat angiotensin
RT   and its identification by DNS-method.";
RL   Chem. Pharm. Bull. 20:1579-1581(1972).
RN   [5]
RP   FUNCTION OF ANGIOTENSIN 1-7.
RX   PubMed=18026570; DOI=10.2119/2007-00073.Fraga-Silva;
RA   Fraga-Silva R.A., Pinheiro S.V.B., Goncalves A.C., Alenina N.,
RA   Bader M., Santos R.A.S.;
RT   "The antithrombotic effect of angiotensin-(1-7) involves mas-mediated
RT   NO release from platelets.";
RL   Mol. Med. 14:28-35(2008).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 25-477, AND DISULFIDE BOND.
RX   PubMed=20927107; DOI=10.1038/nature09505;
RA   Zhou A., Carrell R.W., Murphy M.P., Wei Z., Yan Y., Stanley P.L.,
RA   Stein P.E., Broughton Pipkin F., Read R.J.;
RT   "A redox switch in angiotensinogen modulates angiotensin release.";
RL   Nature 468:108-111(2010).
CC   -!- FUNCTION: Essential component of the renin-angiotensin system
CC       (RAS), a potent regulator of blood pressure, body fluid and
CC       electrolyte homeostasis. {ECO:0000250}.
CC   -!- FUNCTION: Angiotensin-2: acts directly on vascular smooth muscle
CC       as a potent vasoconstrictor, affects cardiac contractility and
CC       heart rate through its action on the sympathetic nervous system,
CC       and alters renal sodium and water absorption through its ability
CC       to stimulate the zona glomerulosa cells of the adrenal cortex to
CC       synthesize and secrete aldosterone. {ECO:0000250}.
CC   -!- FUNCTION: Angiotensin-3: stimulates aldosterone release.
CC       {ECO:0000250}.
CC   -!- FUNCTION: Angiotensin 1-7: is a ligand for the G-protein coupled
CC       receptor MAS1 (By similarity). Has vasodilator and antidiuretic
CC       effects (By similarity). Has an antithrombotic effect that
CC       involves MAS1-mediated release of nitric oxide from platelets.
CC       {ECO:0000250, ECO:0000269|PubMed:18026570}.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Expressed by the liver and secreted in plasma.
CC   -!- PTM: In response to low blood pressure, the enzyme renin/REN
CC       cleaves angiotensinogen to produce angiotensin-1. Angiotensin-1 is
CC       a substrate of ACE (angiotensin converting enzyme) that removes a
CC       dipeptide to yield the physiologically active peptide angiotensin-
CC       2. Angiotensin-1 and angiotensin-2 can be further processed to
CC       generate angiotensin-3, angiotensin-4 (By similarity). Angiotensin
CC       1-9 is cleaved from angiotensin-1 by ACE2 and can be further
CC       processed by ACE to produce angiotensin 1-7, angiotensin 1-5 and
CC       angiotensin 1-4. Angiotensin 1-7 has also been proposed to be
CC       cleaved from angiotensin-2 by ACE2 or from angiotensin-1 by MME
CC       (neprilysin) (By similarity). {ECO:0000250}.
CC   -!- PTM: The disulfide bond is labile. Angiotensinogen is present in
CC       the circulation in a near 40:60 ratio with the oxidized disulfide-
CC       bonded form, which preferentially interacts with receptor-bound
CC       renin.
CC   -!- SIMILARITY: Belongs to the serpin family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L00094; AAA98779.1; -; Genomic_DNA.
DR   EMBL; L00091; AAA98779.1; JOINED; Genomic_DNA.
DR   EMBL; L00092; AAA98779.1; JOINED; Genomic_DNA.
DR   EMBL; L00093; AAA98779.1; JOINED; Genomic_DNA.
DR   EMBL; BC078741; AAH78741.1; -; mRNA.
DR   EMBL; BC087679; AAH87679.1; -; mRNA.
DR   PIR; A93945; ANRT.
DR   RefSeq; NP_602308.1; NM_134432.2.
DR   RefSeq; XP_008770819.1; XM_008772597.1.
DR   UniGene; Rn.6319; -.
DR   PDB; 1SMR; X-ray; 2.00 A; B/D/F/H=30-33.
DR   PDB; 2WXZ; X-ray; 2.80 A; A/C=25-477.
DR   PDB; 2WY1; X-ray; 3.15 A; A/B=25-477.
DR   PDBsum; 1SMR; -.
DR   PDBsum; 2WXZ; -.
DR   PDBsum; 2WY1; -.
DR   ProteinModelPortal; P01015; -.
DR   MINT; MINT-1522474; -.
DR   STRING; 10116.ENSRNOP00000024917; -.
DR   BindingDB; P01015; -.
DR   MEROPS; I04.953; -.
DR   PhosphoSite; P01015; -.
DR   PaxDb; P01015; -.
DR   PRIDE; P01015; -.
DR   Ensembl; ENSRNOT00000024917; ENSRNOP00000024917; ENSRNOG00000018445.
DR   GeneID; 24179; -.
DR   KEGG; rno:24179; -.
DR   UCSC; RGD:2069; rat.
DR   CTD; 183; -.
DR   RGD; 2069; Agt.
DR   eggNOG; KOG2392; Eukaryota.
DR   eggNOG; COG4826; LUCA.
DR   GeneTree; ENSGT00830000128420; -.
DR   HOGENOM; HOG000033941; -.
DR   HOVERGEN; HBG004233; -.
DR   InParanoid; P01015; -.
DR   KO; K09821; -.
DR   OMA; RFMQAVT; -.
DR   OrthoDB; EOG7QK0BN; -.
DR   PhylomeDB; P01015; -.
DR   TreeFam; TF343201; -.
DR   Reactome; R-RNO-2022377; Metabolism of Angiotensinogen to Angiotensins.
DR   Reactome; R-RNO-375276; Peptide ligand-binding receptors.
DR   Reactome; R-RNO-416476; G alpha (q) signalling events.
DR   Reactome; R-RNO-418594; G alpha (i) signalling events.
DR   EvolutionaryTrace; P01015; -.
DR   NextBio; 602521; -.
DR   PRO; PR:P01015; -.
DR   Proteomes; UP000002494; Chromosome 19.
DR   Genevisible; P01015; RN.
DR   GO; GO:0072562; C:blood microparticle; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:RGD.
DR   GO; GO:0070062; C:extracellular exosome; IEA:Ensembl.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0031701; F:angiotensin receptor binding; IMP:RGD.
DR   GO; GO:0005179; F:hormone activity; IDA:BHF-UCL.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; IBA:GO_Central.
DR   GO; GO:0017080; F:sodium channel regulator activity; IEA:Ensembl.
DR   GO; GO:0031702; F:type 1 angiotensin receptor binding; IMP:RGD.
DR   GO; GO:0031703; F:type 2 angiotensin receptor binding; IMP:RGD.
DR   GO; GO:0007250; P:activation of NF-kappaB-inducing kinase activity; IEA:Ensembl.
DR   GO; GO:0007202; P:activation of phospholipase C activity; IMP:RGD.
DR   GO; GO:0007568; P:aging; IEP:RGD.
DR   GO; GO:0001998; P:angiotensin mediated vasoconstriction involved in regulation of systemic arterial blood pressure; IEA:Ensembl.
DR   GO; GO:0003051; P:angiotensin-mediated drinking behavior; IDA:RGD.
DR   GO; GO:0014824; P:artery smooth muscle contraction; IDA:RGD.
DR   GO; GO:0048143; P:astrocyte activation; IEA:Ensembl.
DR   GO; GO:0001568; P:blood vessel development; IEA:Ensembl.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IEA:Ensembl.
DR   GO; GO:0035411; P:catenin import into nucleus; IDA:RGD.
DR   GO; GO:0061049; P:cell growth involved in cardiac muscle cell development; IDA:RGD.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:RGD.
DR   GO; GO:0007160; P:cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0006883; P:cellular sodium ion homeostasis; IMP:RGD.
DR   GO; GO:0050663; P:cytokine secretion; IDA:RGD.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IDA:RGD.
DR   GO; GO:0008065; P:establishment of blood-nerve barrier; IEA:Ensembl.
DR   GO; GO:0007588; P:excretion; IEA:Ensembl.
DR   GO; GO:0030198; P:extracellular matrix organization; IEA:Ensembl.
DR   GO; GO:0007565; P:female pregnancy; IEP:RGD.
DR   GO; GO:0048144; P:fibroblast proliferation; IDA:RGD.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IMP:RGD.
DR   GO; GO:0042445; P:hormone metabolic process; IEA:Ensembl.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IDA:RGD.
DR   GO; GO:0030308; P:negative regulation of cell growth; IMP:RGD.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0010951; P:negative regulation of endopeptidase activity; IBA:GOC.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0051387; P:negative regulation of neurotrophin TRK receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0034104; P:negative regulation of tissue remodeling; IDA:RGD.
DR   GO; GO:0001543; P:ovarian follicle rupture; IEA:Ensembl.
DR   GO; GO:0030432; P:peristalsis; IEA:Ensembl.
DR   GO; GO:0010535; P:positive regulation of activation of JAK2 kinase activity; IEA:Ensembl.
DR   GO; GO:0045777; P:positive regulation of blood pressure; IDA:RGD.
DR   GO; GO:0090190; P:positive regulation of branching involved in ureteric bud morphogenesis; IEA:Ensembl.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; IDA:BHF-UCL.
DR   GO; GO:0043085; P:positive regulation of catalytic activity; IMP:RGD.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:RGD.
DR   GO; GO:0010873; P:positive regulation of cholesterol esterification; IEA:Ensembl.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IEA:Ensembl.
DR   GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0003331; P:positive regulation of extracellular matrix constituent secretion; IDA:RGD.
DR   GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0045723; P:positive regulation of fatty acid biosynthetic process; IEA:Ensembl.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IDA:BHF-UCL.
DR   GO; GO:1903598; P:positive regulation of gap junction assembly; IEA:Ensembl.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IEA:Ensembl.
DR   GO; GO:1902632; P:positive regulation of membrane hyperpolarization; IEA:Ensembl.
DR   GO; GO:0040018; P:positive regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IDA:RGD.
DR   GO; GO:0046622; P:positive regulation of organ growth; IEA:Ensembl.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IEA:Ensembl.
DR   GO; GO:1900020; P:positive regulation of protein kinase C activity; IEA:Ensembl.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; IEA:Ensembl.
DR   GO; GO:0035815; P:positive regulation of renal sodium excretion; IDA:RGD.
DR   GO; GO:0032930; P:positive regulation of superoxide anion generation; IDA:RGD.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0045909; P:positive regulation of vasodilation; IDA:RGD.
DR   GO; GO:0051924; P:regulation of calcium ion transport; IDA:RGD.
DR   GO; GO:1903779; P:regulation of cardiac conduction; IEA:Ensembl.
DR   GO; GO:1901201; P:regulation of extracellular matrix assembly; IEA:Ensembl.
DR   GO; GO:0002027; P:regulation of heart rate; IDA:RGD.
DR   GO; GO:0050727; P:regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IMP:RGD.
DR   GO; GO:0014061; P:regulation of norepinephrine secretion; IMP:RGD.
DR   GO; GO:0002019; P:regulation of renal output by angiotensin; IEA:Ensembl.
DR   GO; GO:0035813; P:regulation of renal sodium excretion; IDA:RGD.
DR   GO; GO:0051969; P:regulation of transmission of nerve impulse; IDA:RGD.
DR   GO; GO:0001999; P:renal response to blood flow involved in circulatory renin-angiotensin regulation of systemic arterial blood pressure; IEA:Ensembl.
DR   GO; GO:0002018; P:renin-angiotensin regulation of aldosterone production; IDA:RGD.
DR   GO; GO:0009409; P:response to cold; IEA:Ensembl.
DR   GO; GO:0014873; P:response to muscle activity involved in regulation of muscle adaptation; IMP:BHF-UCL.
DR   GO; GO:0009651; P:response to salt stress; IEA:Ensembl.
DR   GO; GO:0051145; P:smooth muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0048659; P:smooth muscle cell proliferation; IDA:RGD.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; IDA:RGD.
DR   GO; GO:0070471; P:uterine smooth muscle contraction; IDA:RGD.
DR   GO; GO:0042310; P:vasoconstriction; IDA:RGD.
DR   GO; GO:0042311; P:vasodilation; IDA:RGD.
DR   InterPro; IPR000227; Angiotensinogen.
DR   InterPro; IPR023796; Serpin_dom.
DR   InterPro; IPR000215; Serpin_fam.
DR   PANTHER; PTHR11461; PTHR11461; 2.
DR   Pfam; PF00079; Serpin; 1.
DR   PRINTS; PR00654; ANGIOTENSNGN.
DR   SMART; SM00093; SERPIN; 1.
DR   SUPFAM; SSF56574; SSF56574; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Reference proteome; Secreted; Signal;
KW   Vasoactive; Vasoconstrictor.
FT   SIGNAL        1     24       {ECO:0000269|PubMed:4344907}.
FT   CHAIN        25    477       Angiotensinogen.
FT                                /FTId=PRO_0000032468.
FT   PEPTIDE      25     34       Angiotensin-1.
FT                                /FTId=PRO_0000032469.
FT   PEPTIDE      25     33       Angiotensin 1-9.
FT                                /FTId=PRO_0000420674.
FT   PEPTIDE      25     32       Angiotensin-2.
FT                                /FTId=PRO_0000032470.
FT   PEPTIDE      25     31       Angiotensin 1-7.
FT                                /FTId=PRO_0000420675.
FT   PEPTIDE      25     29       Angiotensin 1-5.
FT                                /FTId=PRO_0000420676.
FT   PEPTIDE      25     28       Angiotensin 1-4.
FT                                /FTId=PRO_0000420677.
FT   PEPTIDE      26     32       Angiotensin-3.
FT                                /FTId=PRO_0000032471.
FT   PEPTIDE      27     32       Angiotensin-4.
FT                                /FTId=PRO_0000420678.
FT   CARBOHYD    295    295       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    319    319       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     42    161       {ECO:0000269|PubMed:20927107}.
FT   TURN         33     35       {ECO:0000244|PDB:2WXZ}.
FT   HELIX        39     43       {ECO:0000244|PDB:2WXZ}.
FT   HELIX        72     84       {ECO:0000244|PDB:2WXZ}.
FT   HELIX        88    115       {ECO:0000244|PDB:2WXZ}.
FT   STRAND      120    124       {ECO:0000244|PDB:2WXZ}.
FT   HELIX       126    138       {ECO:0000244|PDB:2WXZ}.
FT   HELIX       142    151       {ECO:0000244|PDB:2WXZ}.
FT   HELIX       167    181       {ECO:0000244|PDB:2WXZ}.
FT   STRAND      193    203       {ECO:0000244|PDB:2WXZ}.
FT   HELIX       211    216       {ECO:0000244|PDB:2WXZ}.
FT   TURN        217    220       {ECO:0000244|PDB:2WXZ}.
FT   STRAND      224    228       {ECO:0000244|PDB:2WXZ}.
FT   STRAND      231    233       {ECO:0000244|PDB:2WXZ}.
FT   HELIX       235    250       {ECO:0000244|PDB:2WXZ}.
FT   STRAND      267    279       {ECO:0000244|PDB:2WXZ}.
FT   STRAND      282    284       {ECO:0000244|PDB:2WY1}.
FT   STRAND      289    294       {ECO:0000244|PDB:2WXZ}.
FT   STRAND      297    301       {ECO:0000244|PDB:2WXZ}.
FT   STRAND      303    315       {ECO:0000244|PDB:2WXZ}.
FT   TURN        316    319       {ECO:0000244|PDB:2WXZ}.
FT   STRAND      320    340       {ECO:0000244|PDB:2WXZ}.
FT   HELIX       341    343       {ECO:0000244|PDB:2WXZ}.
FT   HELIX       344    351       {ECO:0000244|PDB:2WXZ}.
FT   STRAND      353    355       {ECO:0000244|PDB:2WXZ}.
FT   STRAND      366    373       {ECO:0000244|PDB:2WXZ}.
FT   STRAND      375    382       {ECO:0000244|PDB:2WXZ}.
FT   HELIX       383    389       {ECO:0000244|PDB:2WXZ}.
FT   TURN        393    396       {ECO:0000244|PDB:2WXZ}.
FT   HELIX       403    405       {ECO:0000244|PDB:2WXZ}.
FT   STRAND      406    408       {ECO:0000244|PDB:2WXZ}.
FT   STRAND      416    425       {ECO:0000244|PDB:2WXZ}.
FT   STRAND      452    458       {ECO:0000244|PDB:2WXZ}.
FT   TURN        459    462       {ECO:0000244|PDB:2WXZ}.
FT   STRAND      463    471       {ECO:0000244|PDB:2WXZ}.
SQ   SEQUENCE   477 AA;  51982 MW;  689051A5788D693D CRC64;
     MTPTGAGLKA TIFCILTWVS LTAGDRVYIH PFHLLYYSKS TCAQLENPSV ETLPEPTFEP
     VPIQAKTSPV DEKTLRDKLV LATEKLEAED RQRAAQVAMI ANFMGFRMYK MLSEARGVAS
     GAVLSPPALF GTLVSFYLGS LDPTASQLQV LLGVPVKEGD CTSRLDGHKV LTALQAVQGL
     LVTQGGSSSQ TPLLQSTVVG LFTAPGLRLK QPFVESLGPF TPAIFPRSLD LSTDPVLAAQ
     KINRFVQAVT GWKMNLPLEG VSTDSTLFFN TYVHFQGKMR GFSQLTGLHE FWVDNSTSVS
     VPMLSGTGNF QHWSDAQNNF SVTRVPLGES VTLLLIQPQC ASDLDRVEVL VFQHDFLTWI
     KNPPPRAIRL TLPQLEIRGS YNLQDLLAQA KLSTLLGAEA NLGKMGDTNP RVGEVLNSIL
     LELQAGEEEQ PTESAQQPGS PEVLDVTLSS PFLFAIYERD SGALHFLGRV DNPQNVV
//
ID   CADE_DROME              Reviewed;        1507 AA.
AC   Q24298; Q9W2N1;
DT   21-FEB-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2000, sequence version 2.
DT   20-JAN-2016, entry version 157.
DE   RecName: Full=DE-cadherin;
DE   AltName: Full=Protein shotgun;
DE   Flags: Precursor;
GN   Name=shg {ECO:0000312|FlyBase:FBgn0003391};
GN   Synonyms=E-cadherin {ECO:0000312|FlyBase:FBgn0003391};
GN   ORFNames=CG3722 {ECO:0000312|FlyBase:FBgn0003391};
OS   Drosophila melanogaster (Fruit fly).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta;
OC   Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC   Ephydroidea; Drosophilidae; Drosophila; Sophophora.
OX   NCBI_TaxID=7227;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Embryo;
RX   PubMed=7958432; DOI=10.1006/dbio.1994.1287;
RA   Oda H., Uemura T., Harada Y., Iwai Y., Takeichi M.;
RT   "A Drosophila homolog of cadherin associated with armadillo and
RT   essential for embryonic cell-cell adhesion.";
RL   Dev. Biol. 165:716-726(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley;
RX   PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA   Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA   Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA   George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA   Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA   Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,
RA   Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA   Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA   Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA   Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA   Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,
RA   Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA   Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA   de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA   Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA   Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA   Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA   Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA   Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,
RA   Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA   Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA   Kimmel B.E., Kodira C.D., Kraft C.L., Kravitz S., Kulp D., Lai Z.,
RA   Lasko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,
RA   Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA   Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA   Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA   Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA   Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA   Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA   Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.J.,
RA   Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA   Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA   Wang Z.-Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA   Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA   Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA   Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S.C., Zhu X.,
RA   Smith H.O., Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT   "The genome sequence of Drosophila melanogaster.";
RL   Science 287:2185-2195(2000).
RN   [3]
RP   GENOME REANNOTATION.
RC   STRAIN=Berkeley;
RX   PubMed=12537572; DOI=10.1186/gb-2002-3-12-research0083;
RA   Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA   Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,
RA   Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA   Bettencourt B.R., Celniker S.E., de Grey A.D.N.J., Drysdale R.A.,
RA   Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA   Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA   Lewis S.E.;
RT   "Annotation of the Drosophila melanogaster euchromatic genome: a
RT   systematic review.";
RL   Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1493, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY.
RC   TISSUE=Embryo;
RX   PubMed=18327897; DOI=10.1021/pr700696a;
RA   Zhai B., Villen J., Beausoleil S.A., Mintseris J., Gygi S.P.;
RT   "Phosphoproteome analysis of Drosophila melanogaster embryos.";
RL   J. Proteome Res. 7:1675-1682(2008).
RN   [5]
RP   INTERACTION WITH INX2.
RX   PubMed=15047872; DOI=10.1091/mbc.E04-01-0056;
RA   Bauer R., Lehmann C., Martini J., Eckardt F., Hoch M.;
RT   "Gap junction channel protein innexin 2 is essential for epithelial
RT   morphogenesis in the Drosophila embryo.";
RL   Mol. Biol. Cell 15:2992-3004(2004).
RN   [6]
RP   FUNCTION, AND GLYCOSYLATION.
RX   PubMed=24681004; DOI=10.1016/j.ydbio.2014.03.007;
RA   Zhang Y., Kong D., Reichl L., Vogt N., Wolf F., Grosshans J.;
RT   "The glucosyltransferase Xiantuan of the endoplasmic reticulum
RT   specifically affects E-Cadherin expression and is required for
RT   gastrulation movements in Drosophila.";
RL   Dev. Biol. 390:208-220(2014).
CC   -!- FUNCTION: Cadherins are calcium-dependent cell adhesion proteins
CC       (PubMed:7958432). They preferentially interact with themselves in
CC       a homophilic manner in connecting cells; cadherins may thus
CC       contribute to the sorting of heterogeneous cell types
CC       (PubMed:7958432). N-cadherin may be involved in neuronal
CC       recognition mechanism (PubMed:7958432). May function in cell
CC       intercalation in the lateral epidermis during germband extension
CC       (PubMed:24681004). {ECO:0000269|PubMed:24681004,
CC       ECO:0000269|PubMed:7958432}.
CC   -!- SUBUNIT: Interacts (via cytoplasmic region) with Inx2 (via
CC       cytoplasmic loop). {ECO:0000269|PubMed:15047872}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Single-pass
CC       type I membrane protein {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Stage 10 embryos exhibit intense expression in
CC       epithelial cells. Stage 14 embryos show expression in the hindgut
CC       (at the apical poles of cell-cell boundaries), at the apical
CC       junctions of tracheal cells and in the dorsal longitudinal trunk.
CC       In stage 16 embryos the glial midline cells of the central nervous
CC       system show strong expression. {ECO:0000269|PubMed:7958432}.
CC   -!- DOMAIN: Three calcium ions are usually bound at the interface of
CC       each cadherin domain and rigidify the connections, imparting a
CC       strong curvature to the full-length ectodomain. {ECO:0000250}.
CC   -!- PTM: N-glycosylation is important for biosynthesis and function.
CC       {ECO:0000269|PubMed:24681004}.
CC   -!- SIMILARITY: Contains 7 cadherin domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00043}.
CC   -!- SIMILARITY: Contains 1 EGF-like domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 1 laminin G-like domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00122}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D28749; BAA05942.1; -; mRNA.
DR   EMBL; AE013599; AAF46659.1; -; Genomic_DNA.
DR   RefSeq; NP_476722.1; NM_057374.3.
DR   DisProt; DP00269; -.
DR   ProteinModelPortal; Q24298; -.
DR   SMR; Q24298; 81-854, 1171-1300, 1413-1489.
DR   BioGrid; 63025; 10.
DR   DIP; DIP-22198N; -.
DR   IntAct; Q24298; 3.
DR   MINT; MINT-1608719; -.
DR   STRING; 7227.FBpp0071475; -.
DR   iPTMnet; Q24298; -.
DR   PaxDb; Q24298; -.
DR   EnsemblMetazoa; FBtr0071546; FBpp0071475; FBgn0003391.
DR   GeneID; 37386; -.
DR   KEGG; dme:Dmel_CG3722; -.
DR   CTD; 37386; -.
DR   FlyBase; FBgn0003391; shg.
DR   eggNOG; KOG1219; Eukaryota.
DR   eggNOG; ENOG410XPEI; LUCA.
DR   GeneTree; ENSGT00760000118805; -.
DR   InParanoid; Q24298; -.
DR   OMA; DFYNVKV; -.
DR   OrthoDB; EOG718KB7; -.
DR   PhylomeDB; Q24298; -.
DR   GenomeRNAi; 37386; -.
DR   NextBio; 803387; -.
DR   PRO; PR:Q24298; -.
DR   Proteomes; UP000000803; Chromosome 2R.
DR   Bgee; Q24298; -.
DR   ExpressionAtlas; Q24298; differential.
DR   Genevisible; Q24298; DM.
DR   GO; GO:0005912; C:adherens junction; NAS:FlyBase.
DR   GO; GO:0043296; C:apical junction complex; IDA:FlyBase.
DR   GO; GO:0016342; C:catenin complex; IDA:FlyBase.
DR   GO; GO:0005938; C:cell cortex; IDA:FlyBase.
DR   GO; GO:0005913; C:cell-cell adherens junction; IDA:FlyBase.
DR   GO; GO:0030175; C:filopodium; IDA:FlyBase.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:FlyBase.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0055037; C:recycling endosome; IDA:FlyBase.
DR   GO; GO:0005914; C:spot adherens junction; IDA:FlyBase.
DR   GO; GO:0005915; C:zonula adherens; NAS:FlyBase.
DR   GO; GO:0008013; F:beta-catenin binding; NAS:FlyBase.
DR   GO; GO:0005509; F:calcium ion binding; IDA:FlyBase.
DR   GO; GO:0050839; F:cell adhesion molecule binding; ISS:FlyBase.
DR   GO; GO:0017022; F:myosin binding; IPI:FlyBase.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:FlyBase.
DR   GO; GO:0004872; F:receptor activity; ISS:FlyBase.
DR   GO; GO:0045176; P:apical protein localization; IMP:FlyBase.
DR   GO; GO:0008356; P:asymmetric cell division; IMP:FlyBase.
DR   GO; GO:0008105; P:asymmetric protein localization; IMP:FlyBase.
DR   GO; GO:0007411; P:axon guidance; NAS:FlyBase.
DR   GO; GO:0007409; P:axonogenesis; IMP:FlyBase.
DR   GO; GO:0007298; P:border follicle cell migration; IMP:FlyBase.
DR   GO; GO:0007420; P:brain development; IMP:FlyBase.
DR   GO; GO:0035147; P:branch fusion, open tracheal system; IMP:FlyBase.
DR   GO; GO:0016339; P:calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules; IDA:FlyBase.
DR   GO; GO:0007155; P:cell adhesion; IMP:FlyBase.
DR   GO; GO:0035212; P:cell competition in a multicellular organism; IMP:FlyBase.
DR   GO; GO:0000902; P:cell morphogenesis; IMP:FlyBase.
DR   GO; GO:0030031; P:cell projection assembly; IMP:FlyBase.
DR   GO; GO:0044331; P:cell-cell adhesion mediated by cadherin; IDA:FlyBase.
DR   GO; GO:0001745; P:compound eye morphogenesis; IMP:FlyBase.
DR   GO; GO:0050832; P:defense response to fungus; IMP:FlyBase.
DR   GO; GO:0071907; P:determination of digestive tract left/right asymmetry; IMP:FlyBase.
DR   GO; GO:0007163; P:establishment or maintenance of cell polarity; NAS:FlyBase.
DR   GO; GO:0036099; P:female germ-line stem cell population maintenance; IMP:FlyBase.
DR   GO; GO:0010004; P:gastrulation involving germ band extension; IMP:FlyBase.
DR   GO; GO:0007281; P:germ cell development; IMP:FlyBase.
DR   GO; GO:0008354; P:germ cell migration; IMP:FlyBase.
DR   GO; GO:0042078; P:germ-line stem cell division; TAS:FlyBase.
DR   GO; GO:0030708; P:germarium-derived female germ-line cyst encapsulation; TAS:FlyBase.
DR   GO; GO:0008406; P:gonad development; IMP:FlyBase.
DR   GO; GO:0035262; P:gonad morphogenesis; IMP:FlyBase.
DR   GO; GO:0007506; P:gonadal mesoderm development; IMP:FlyBase.
DR   GO; GO:0008258; P:head involution; IMP:FlyBase.
DR   GO; GO:0007507; P:heart development; IMP:FlyBase.
DR   GO; GO:0035099; P:hemocyte migration; IGI:FlyBase.
DR   GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IDA:FlyBase.
DR   GO; GO:0035160; P:maintenance of epithelial integrity, open tracheal system; IMP:FlyBase.
DR   GO; GO:0098730; P:male germline stem cell symmetric division; IMP:FlyBase.
DR   GO; GO:0001738; P:morphogenesis of a polarized epithelium; IMP:FlyBase.
DR   GO; GO:0002009; P:morphogenesis of an epithelium; NAS:FlyBase.
DR   GO; GO:0007399; P:nervous system development; IMP:FlyBase.
DR   GO; GO:0016318; P:ommatidial rotation; IMP:FlyBase.
DR   GO; GO:0007314; P:oocyte anterior/posterior axis specification; NAS:FlyBase.
DR   GO; GO:0030720; P:oocyte localization involved in germarium-derived egg chamber formation; TAS:FlyBase.
DR   GO; GO:0048477; P:oogenesis; IMP:FlyBase.
DR   GO; GO:0007424; P:open tracheal system development; IMP:FlyBase.
DR   GO; GO:0001748; P:optic lobe placode development; IMP:FlyBase.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IMP:FlyBase.
DR   GO; GO:0007297; P:ovarian follicle cell migration; TAS:FlyBase.
DR   GO; GO:0007280; P:pole cell migration; TAS:FlyBase.
DR   GO; GO:0007435; P:salivary gland morphogenesis; IGI:FlyBase.
DR   GO; GO:0007379; P:segment specification; IMP:FlyBase.
DR   GO; GO:0016337; P:single organismal cell-cell adhesion; IMP:FlyBase.
DR   GO; GO:0048103; P:somatic stem cell division; TAS:FlyBase.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IMP:FlyBase.
DR   GO; GO:0007370; P:ventral furrow formation; IMP:FlyBase.
DR   GO; GO:0042060; P:wound healing; IMP:FlyBase.
DR   GO; GO:0045186; P:zonula adherens assembly; IMP:FlyBase.
DR   Gene3D; 2.60.120.200; -; 1.
DR   Gene3D; 2.60.40.60; -; 7.
DR   Gene3D; 4.10.900.10; -; 1.
DR   InterPro; IPR002126; Cadherin.
DR   InterPro; IPR015919; Cadherin-like.
DR   InterPro; IPR020894; Cadherin_CS.
DR   InterPro; IPR000233; Cadherin_cytoplasmic-dom.
DR   InterPro; IPR027397; Catenin_binding_dom.
DR   InterPro; IPR013320; ConA-like_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR001791; Laminin_G.
DR   Pfam; PF00028; Cadherin; 5.
DR   Pfam; PF01049; Cadherin_C; 1.
DR   Pfam; PF02210; Laminin_G_2; 1.
DR   PRINTS; PR00205; CADHERIN.
DR   SMART; SM00112; CA; 7.
DR   SMART; SM00282; LamG; 1.
DR   SUPFAM; SSF49313; SSF49313; 8.
DR   SUPFAM; SSF49899; SSF49899; 1.
DR   PROSITE; PS00232; CADHERIN_1; 5.
DR   PROSITE; PS50268; CADHERIN_2; 7.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50026; EGF_3; 1.
DR   PROSITE; PS50025; LAM_G_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   Calcium; Cell adhesion; Cell membrane;
KW   Cleavage on pair of basic residues; Complete proteome; Disulfide bond;
KW   EGF-like domain; Glycoprotein; Membrane; Metal-binding;
KW   Phosphoprotein; Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     69       {ECO:0000255}.
FT   PROPEP       70    261       {ECO:0000255}.
FT                                /FTId=PRO_0000003879.
FT   CHAIN       262   1507       DE-cadherin.
FT                                /FTId=PRO_0000003880.
FT   TOPO_DOM    262   1328       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1329   1349       Helical. {ECO:0000255}.
FT   TOPO_DOM   1350   1507       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       97    195       Cadherin 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      204    301       Cadherin 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      311    412       Cadherin 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      420    522       Cadherin 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      532    633       Cadherin 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      631    733       Cadherin 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      741    835       Cadherin 7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     1084   1123       EGF-like. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1125   1313       Laminin G-like. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00122}.
FT   REGION     1350   1507       Interaction with Inx2.
FT   MOD_RES    1493   1493       Phosphoserine.
FT                                {ECO:0000269|PubMed:18327897}.
FT   CARBOHYD    317    317       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    466    466       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    552    552       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    766    766       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    949    949       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    983    983       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    999    999       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1073   1073       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1145   1145       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1274   1274       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1290   1290       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID   1098   1112       {ECO:0000250}.
FT   DISULFID   1114   1123       {ECO:0000255}.
FT   DISULFID   1287   1313       {ECO:0000250}.
FT   CONFLICT    974    974       L -> F (in Ref. 1; BAA05942).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1507 AA;  169821 MW;  DF2B5CAAA29D8EE5 CRC64;
     MSTSVQRMSR SYHCINMSAT PQAGHLNPAQ QQTHQQHKRK CRDLGRRLIP ARLLLGVIVA
     ISLLSPALAL HSPPDKNFSG DNRKPAFKNC AGYAPKVKEE QPENTYVLTV EAVDPDPDQV
     IRYSIVQSPF ERPKFFINPS TGVIFTTHTF DRDEPIHEKF VFVTVQATDN GLPPLDDVCT
     FNVTIEDIND NAPAFNKARY DESMSENAQP DAVVMTISAS DFDDGNNSLV EYEILRERDF
     QYFKIDKESG IIYLKRPIDK RPGQSYAIIV RAYNVVPDPP QDAQIEVRIR VVESSIKPPS
     FVNPIDTPIY LKENLKNFTH PIATLRAVSN MPDKPEVIFE LNTGRTEQTN SKNTFVFNQI
     GNEVTISLGK TLDYEAITDY TLTMIVRNTH ELGTEHQIKI QVEDVNDNIP YYTEVKSGTI
     LENEPPGTPV MQVRAFDMDG TSANNIVSFE LADNREYFTI DPNTGNITAL TTFDREERDF
     YNVKVIASDN SPSSLFDNGE PNRGHQVFRI SIGDKNDHKP HFQQDKYLAE RLLEDANTNT
     EVIEVKAEDE DNASQILYSI ESGNVGDAFK IGLKTGKITV NQKLDYETIT EYELKVRAFD
     GIYDDYTTVV IKIEDVNDNP PVFKQDYSVT ILEETTYDDC ILTVEAYDPD IKDRNADQHI
     VYSIHQNDGN RWTIDNSGCL RLVKTLDRDP PNGHKNWQVL IKANDEDGVG TTVSTVKEVT
     VTLKDINDNA PFLINEMPVY WQENRNPGHV VQLQANDYDD TPGAGNFTFG IDSEATPDIK
     TKFSMDGDYL HANVQFDREA QKEYFIPIRI SDSGVPRQSA VSILHLVIGD VNDNAMSEGS
     SRIFIYNYKG EAPETDIGRV FVDDLDDWDL EDKYFEWKDL PHDQFRLNPS TGMITMLVHT
     AEGEYDLSFV VTEDSMFVPR HSVDAYVTVV VRELPEEAVD KSGSIRFINV TKEEFISVPR
     DFQSPDALSL KDRLQLSLAK LFNTSVSNVD VFTVLQNENH TLDVRFSAHG SPYYAPEKLN
     GIVAQNQQRL ENELDLQMLM VNIDECLIEK FKCEESCTNE LHKSSVPYMI YSNTTSFVGV
     NAFVQAQCVC EAPLMRRCLN GGSPRYGEND VCDCIDGFTG PHCELVSVAF YGSGYAFYEP
     IAACNNTKIS LEITPQIDQG LIMYLGPLNF NPLLAISDFL ALELDNGYPV LTVDYGSGAI
     RIRHQHIKMV ADRTYQLDII LQRTSIEMTV DNCRLSTCQT LGAPIGPNEF LNVNAPLQLG
     GTPVDLEQLG RQLNWTHVPN QKGFFGCIRN LTINEQTYNL GMPSVFRNID SGCQQSVAVA
     FSFGIDRNFI IAIIVCLALL LIILLAVVVQ KKQKNGWHEK DIDDIRETII NYEDEGGGER
     DTDYDLNVLR TQPFYEEKLY KDPHALQGNM RDPNDIPDIA DFLGDKKENC DRDVGATTVD
     DVRHYAYEGD GNSDGSLSSL ASCTDDGDLN FDYLSNFGPR FRKLADMYGE EPSDTDSNVD
     DDQGWRI
//
ID   ADIPO_MOUSE             Reviewed;         247 AA.
AC   Q60994; Q62400; Q6GTX4; Q9DC68;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2012, sequence version 2.
DT   17-FEB-2016, entry version 153.
DE   RecName: Full=Adiponectin;
DE   AltName: Full=30 kDa adipocyte complement-related protein;
DE   AltName: Full=Adipocyte complement-related 30 kDa protein;
DE            Short=ACRP30;
DE   AltName: Full=Adipocyte, C1q and collagen domain-containing protein;
DE   AltName: Full=Adipocyte-specific protein AdipoQ;
DE   Flags: Precursor;
GN   Name=Adipoq; Synonyms=Acdc, Acrp30, Apm1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Adipocyte;
RX   PubMed=7592907; DOI=10.1074/jbc.270.45.26746;
RA   Scherer P.E., Williams S., Fogliano M., Baldini G., Lodish H.F.;
RT   "A novel serum protein similar to C1q, produced exclusively in
RT   adipocytes.";
RL   J. Biol. Chem. 270:26746-26749(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fibroblast;
RX   PubMed=8631877; DOI=10.1074/jbc.271.18.10697;
RA   Hu E., Liang P., Spiegelman B.M.;
RT   "AdipoQ is a novel adipose-specific gene dysregulated in obesity.";
RL   J. Biol. Chem. 271:10697-10703(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11162643; DOI=10.1006/bbrc.2001.4217;
RA   Das K., Lin Y., Widen E., Zhang Y., Scherer P.E.;
RT   "Chromosomal localization, expression pattern, and promoter analysis
RT   of the mouse gene encoding adipocyte-specific secretory protein
RT   Acrp30.";
RL   Biochem. Biophys. Res. Commun. 280:1120-1129(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=C57BL/6J, and IRM-2; TISSUE=White adipose tissue;
RA   Wang S.F., Han P.Z., Mu C.J., Zhao M.H.;
RT   "Cloning of murine adipocyte complement-related protein of 30 KDa from
RT   white adipose tissue.";
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Heart, and Thymus;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Thymus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 18-25, HYDROXYLATION AT LYS-68; LYS-71; LYS-80;
RP   PRO-94 AND LYS-104, GLYCOSYLATION AT LYS-68; LYS-71; LYS-80 AND
RP   LYS-104, GLYCAN STRUCTURE, ABSENCE OF HYDROXYLATION AT PRO-79; PRO-98
RP   AND PRO-107, ABSENCE OF GLYCOSYLATION AT ASN-233, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY.
RX   PubMed=11912203; DOI=10.1074/jbc.M200601200;
RA   Wang Y., Xu A., Knight C., Xu L.Y., Cooper G.J.S.;
RT   "Hydroxylation and glycosylation of the four conserved lysine residues
RT   in the collagenous domain of adiponectin. Potential role in the
RT   modulation of its insulin-sensitizing activity.";
RL   J. Biol. Chem. 277:19521-19529(2002).
RN   [10]
RP   STRUCTURE OF CARBOHYDRATES.
RX   PubMed=11382781; DOI=10.1074/jbc.M104148200;
RA   Sato C., Yasukawa Z., Honda N., Matsuda T., Kitajima K.;
RT   "Identification and adipocyte differentiation-dependent expression of
RT   the unique disialic acid residue in an adipose tissue-specific
RT   glycoprotein, adipo Q.";
RL   J. Biol. Chem. 276:28849-28856(2001).
RN   [11]
RP   FUNCTION.
RX   PubMed=11479627; DOI=10.1038/90984;
RA   Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K.,
RA   Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., Ezaki O.,
RA   Akanuma Y., Gavrilova O., Vinson C., Reitman M.L., Kagechika H.,
RA   Shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M.,
RA   Froguel P., Kadowaki T.;
RT   "The fat-derived hormone adiponectin reverses insulin resistance
RT   associated with both lipoatrophy and obesity.";
RL   Nat. Med. 7:941-946(2001).
RN   [12]
RP   FUNCTION.
RX   PubMed=11479628; DOI=10.1038/90992;
RA   Berg A.H., Combs T.P., Du X., Brownlee M., Scherer P.E.;
RT   "The adipocyte-secreted protein Acrp30 enhances hepatic insulin
RT   action.";
RL   Nat. Med. 7:947-953(2001).
RN   [13]
RP   FUNCTION.
RX   PubMed=12840063; DOI=10.1172/JCI200317797;
RA   Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S.L., Cooper G.J.S.;
RT   "The fat-derived hormone adiponectin alleviates alcoholic and
RT   nonalcoholic fatty liver diseases in mice.";
RL   J. Clin. Invest. 112:91-100(2003).
RN   [14]
RP   SUBUNIT, AND FUNCTION.
RX   PubMed=15760892; DOI=10.1074/jbc.M414231200;
RA   Xu A., Chan K.W., Hoo R.L.C., Wang Y., Tan K.C.B., Zhang J., Chen B.,
RA   Lam M.C., Tse C., Cooper G.J.S., Lam K.S.L.;
RT   "Testosterone selectively reduces the high molecular weight form of
RT   adiponectin by inhibiting its secretion from adipocytes.";
RL   J. Biol. Chem. 280:18073-18080(2005).
RN   [15]
RP   SUBUNIT, AND FUNCTION.
RX   PubMed=15734737; DOI=10.1074/jbc.M501149200;
RA   Wang Y., Lam K.S.L., Xu J.Y., Lu G., Xu L.Y., Cooper G.J.S., Xu A.;
RT   "Adiponectin inhibits cell proliferation by interacting with several
RT   growth factors in an oligomerization-dependent manner.";
RL   J. Biol. Chem. 280:18341-18347(2005).
RN   [16]
RP   SUBUNIT, AND MUTAGENESIS OF LYS-68; LYS-71; LYS-80 AND LYS-104.
RX   PubMed=16621799; DOI=10.1074/jbc.M513907200;
RA   Wang Y., Lam K.S.L., Chan L., Chan K.W., Lam J.B.B., Lam M.C.,
RA   Hoo R.C.L., Mak W.W.N., Cooper G.J.S., Xu A.;
RT   "Post-translational modifications of the four conserved lysine
RT   residues within the collagenous domain of adiponectin are required for
RT   the formation of its high molecular weight oligomeric complex.";
RL   J. Biol. Chem. 281:16391-16400(2006).
RN   [17]
RP   SUBUNIT, INTERACTION WITH CTRP9, AND MUTAGENESIS OF CYS-39.
RX   PubMed=18787108; DOI=10.1096/fj.08-114991;
RA   Wong G.W., Krawczyk S.A., Kitidis-Mitrokostas C., Ge G., Spooner E.,
RA   Hug C., Gimeno R., Lodish H.F.;
RT   "Identification and characterization of CTRP9, a novel secreted
RT   glycoprotein, from adipose tissue that reduces serum glucose in mice
RT   and forms heterotrimers with adiponectin.";
RL   FASEB J. 23:241-258(2009).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brown adipose tissue, Heart, and Lung;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [19]
RP   GLYCOSYLATION AT THR-23 AND THR-24, AND SUBUNIT.
RX   PubMed=19855092; DOI=10.1210/me.2009-0133;
RA   Richards A.A., Colgrave M.L., Zhang J., Webster J., Simpson F.,
RA   Preston E., Wilks D., Hoehn K.L., Stephenson M., Macdonald G.A.,
RA   Prins J.B., Cooney G.J., Xu A., Whitehead J.P.;
RT   "Sialic acid modification of adiponectin is not required for
RT   multimerization or secretion but determines half-life in
RT   circulation.";
RL   Mol. Endocrinol. 24:229-239(2010).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 111-247.
RX   PubMed=9512423; DOI=10.1016/S0960-9822(98)70133-2;
RA   Shapiro L., Scherer P.E.;
RT   "The crystal structure of a complement-1q family protein suggests an
RT   evolutionary link to tumor necrosis factor.";
RL   Curr. Biol. 8:335-338(1998).
CC   -!- FUNCTION: Important adipokine involved in the control of fat
CC       metabolism and insulin sensitivity, with direct anti-diabetic,
CC       anti-atherogenic and anti-inflammatory activities. Stimulates AMPK
CC       phosphorylation and activation in the liver and the skeletal
CC       muscle, enhancing glucose utilization and fatty-acid combustion.
CC       Antagonizes TNF-alpha by negatively regulating its expression in
CC       various tissues such as liver and macrophages, and also by
CC       counteracting its effects. Inhibits endothelial NF-kappa-B
CC       signaling through a cAMP-dependent pathway. May play a role in
CC       cell growth, angiogenesis and tissue remodeling by binding and
CC       sequestering various growth factors with distinct binding
CC       affinities, depending on the type of complex, LMW, MMW or HMW.
CC       {ECO:0000269|PubMed:11479627, ECO:0000269|PubMed:11479628,
CC       ECO:0000269|PubMed:12840063, ECO:0000269|PubMed:15734737,
CC       ECO:0000269|PubMed:15760892}.
CC   -!- SUBUNIT: Homomultimer. Forms trimers, hexamers and 12- to 18-mers.
CC       The trimers (low molecular weight complexes / LMW) are assembled
CC       via non-covalent interactions of the collagen-like domains in a
CC       triple helix and hydrophobic interactions within the globular C1q
CC       domain. Several trimers can associate to form disulfide-linked
CC       hexamers (middle molecular weight complexes / MMW) and larger
CC       complexes (higher molecular weight / HMW). The HMW-complex
CC       assembly may rely additionally on lysine hydroxylation and
CC       glycosylation. LMW, MMW and HMW complexes bind to HBEGF, MMW and
CC       HMW complexes bind to PDGFB, and HMW complex binds to FGF2.
CC       Interacts with CTRP9 via the C1q domain (heterotrimeric complex).
CC       {ECO:0000269|PubMed:15734737, ECO:0000269|PubMed:15760892,
CC       ECO:0000269|PubMed:16621799, ECO:0000269|PubMed:18787108,
CC       ECO:0000269|PubMed:19855092}.
CC   -!- INTERACTION:
CC       Self; NbExp=12; IntAct=EBI-7264589, EBI-7264589;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Synthesized exclusively by adipocytes and
CC       secreted into plasma.
CC   -!- INDUCTION: During hormone-induced adipose differentiation and
CC       activated by insulin.
CC   -!- PTM: HMW complexes are more extensively glycosylated than smaller
CC       oligomers. Hydroxylation and glycosylation of the lysine residues
CC       within the collagene-like domain of adiponectin seem to be
CC       critically involved in regulating the formation and/or secretion
CC       of HMW complexes and consequently contribute to the insulin-
CC       sensitizing activity of adiponectin in hepatocytes.
CC       {ECO:0000269|PubMed:11912203}.
CC   -!- PTM: O-glycosylated. Not N-glycosylated (By similarity) O-linked
CC       glycans on hydroxylysine residues consist of Glc-Gal disaccharides
CC       bound to the oxygen atom of post-translationally added hydroxyl
CC       groups (By similarity). O-linked glycosylation in the N-terminal
CC       is disialylated with the structure
CC       Neu5Acalpha2->8Neu5Acalpha2->3Gal. Sialylated by alpha 2,8-
CC       sialyltransferase III. {ECO:0000250}.
CC   -!- MISCELLANEOUS: HMW-complex blood contents are higher in females
CC       than in males, are increased in males by castration and decreased
CC       again upon subsequent testosterone treatment, which blocks HMW-
CC       complex secretion.
CC   -!- SIMILARITY: Contains 1 C1q domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00368}.
CC   -!- SIMILARITY: Contains 1 collagen-like domain. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U37222; AAA80543.1; -; mRNA.
DR   EMBL; U49915; AAB06706.1; -; mRNA.
DR   EMBL; AF304466; AAK13417.1; -; Genomic_DNA.
DR   EMBL; AY749429; AAW70555.1; -; mRNA.
DR   EMBL; AY754346; AAW82905.1; -; mRNA.
DR   EMBL; AK003138; BAB22597.1; -; mRNA.
DR   EMBL; AK134112; BAE22019.1; -; mRNA.
DR   EMBL; AC125396; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH466521; EDK97661.1; -; Genomic_DNA.
DR   EMBL; BC028770; AAH28770.1; -; mRNA.
DR   CCDS; CCDS28075.1; -.
DR   RefSeq; NP_033735.3; NM_009605.4.
DR   UniGene; Mm.3969; -.
DR   PDB; 1C28; X-ray; 2.10 A; A/B/C=114-247.
DR   PDB; 1C3H; X-ray; 2.10 A; A/B/C/D/E/F=111-247.
DR   PDBsum; 1C28; -.
DR   PDBsum; 1C3H; -.
DR   ProteinModelPortal; Q60994; -.
DR   SMR; Q60994; 111-247.
DR   BioGrid; 197940; 3.
DR   DIP; DIP-44111N; -.
DR   IntAct; Q60994; 2.
DR   MINT; MINT-4563800; -.
DR   STRING; 10090.ENSMUSP00000023593; -.
DR   SwissPalm; Q60994; -.
DR   MaxQB; Q60994; -.
DR   PaxDb; Q60994; -.
DR   PRIDE; Q60994; -.
DR   Ensembl; ENSMUST00000023593; ENSMUSP00000023593; ENSMUSG00000022878.
DR   GeneID; 11450; -.
DR   KEGG; mmu:11450; -.
DR   UCSC; uc007ytk.1; mouse.
DR   CTD; 9370; -.
DR   MGI; MGI:106675; Adipoq.
DR   eggNOG; ENOG410IHSJ; Eukaryota.
DR   eggNOG; ENOG4111F5K; LUCA.
DR   GeneTree; ENSGT00760000118830; -.
DR   HOGENOM; HOG000085653; -.
DR   HOVERGEN; HBG108220; -.
DR   InParanoid; Q60994; -.
DR   KO; K07296; -.
DR   OMA; KAMLFTY; -.
DR   OrthoDB; EOG70ZZPW; -.
DR   TreeFam; TF329591; -.
DR   EvolutionaryTrace; Q60994; -.
DR   NextBio; 278770; -.
DR   PRO; PR:Q60994; -.
DR   Proteomes; UP000000589; Chromosome 16.
DR   CleanEx; MM_ADIPOQ; -.
DR   ExpressionAtlas; Q60994; baseline and differential.
DR   Genevisible; Q60994; MM.
DR   GO; GO:0071944; C:cell periphery; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; ISS:BHF-UCL.
DR   GO; GO:0005581; C:collagen trimer; IEA:UniProtKB-KW.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:MGI.
DR   GO; GO:0070062; C:extracellular exosome; ISO:MGI.
DR   GO; GO:0005615; C:extracellular space; IDA:MGI.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005179; F:hormone activity; IDA:MGI.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:MGI.
DR   GO; GO:0005102; F:receptor binding; IDA:MGI.
DR   GO; GO:0033691; F:sialic acid binding; ISO:MGI.
DR   GO; GO:0033211; P:adiponectin-activated signaling pathway; IEA:Ensembl.
DR   GO; GO:0050873; P:brown fat cell differentiation; IDA:MGI.
DR   GO; GO:0071320; P:cellular response to cAMP; IEA:Ensembl.
DR   GO; GO:0035690; P:cellular response to drug; IDA:UniProtKB.
DR   GO; GO:0071872; P:cellular response to epinephrine stimulus; IEA:Ensembl.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IGI:MGI.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0070994; P:detection of oxidative stress; IMP:UniProtKB.
DR   GO; GO:0006635; P:fatty acid beta-oxidation; IMP:MGI.
DR   GO; GO:0019395; P:fatty acid oxidation; IDA:MGI.
DR   GO; GO:0042593; P:glucose homeostasis; IDA:MGI.
DR   GO; GO:0006006; P:glucose metabolic process; IDA:MGI.
DR   GO; GO:0034383; P:low-density lipoprotein particle clearance; ISS:UniProtKB.
DR   GO; GO:0051899; P:membrane depolarization; IEA:Ensembl.
DR   GO; GO:0060081; P:membrane hyperpolarization; IEA:Ensembl.
DR   GO; GO:0045776; P:negative regulation of blood pressure; ISS:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:2000279; P:negative regulation of DNA biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IDA:BHF-UCL.
DR   GO; GO:0045721; P:negative regulation of gluconeogenesis; IDA:MGI.
DR   GO; GO:0030853; P:negative regulation of granulocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0034115; P:negative regulation of heterotypic cell-cell adhesion; ISS:UniProtKB.
DR   GO; GO:0046888; P:negative regulation of hormone secretion; IEA:Ensembl.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; ISS:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IDA:UniProtKB.
DR   GO; GO:0090317; P:negative regulation of intracellular protein transport; ISS:UniProtKB.
DR   GO; GO:0045715; P:negative regulation of low-density lipoprotein particle receptor biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0010745; P:negative regulation of macrophage derived foam cell differentiation; ISS:UniProtKB.
DR   GO; GO:0045650; P:negative regulation of macrophage differentiation; ISS:UniProtKB.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:2000590; P:negative regulation of metanephric mesenchymal cell migration; IDA:UniProtKB.
DR   GO; GO:0050765; P:negative regulation of phagocytosis; ISS:UniProtKB.
DR   GO; GO:0010642; P:negative regulation of platelet-derived growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:2000584; P:negative regulation of platelet-derived growth factor receptor-alpha signaling pathway; IDA:UniProtKB.
DR   GO; GO:0031953; P:negative regulation of protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:1900121; P:negative regulation of receptor binding; ISS:UniProtKB.
DR   GO; GO:0014912; P:negative regulation of smooth muscle cell migration; ISS:UniProtKB.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; ISS:UniProtKB.
DR   GO; GO:0050805; P:negative regulation of synaptic transmission; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; ISS:UniProtKB.
DR   GO; GO:0010804; P:negative regulation of tumor necrosis factor-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045777; P:positive regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:2000481; P:positive regulation of cAMP-dependent protein kinase activity; IMP:UniProtKB.
DR   GO; GO:0032270; P:positive regulation of cellular protein metabolic process; ISS:BHF-UCL.
DR   GO; GO:0010875; P:positive regulation of cholesterol efflux; ISS:BHF-UCL.
DR   GO; GO:0045923; P:positive regulation of fatty acid metabolic process; IMP:MGI.
DR   GO; GO:0046326; P:positive regulation of glucose import; IDA:MGI.
DR   GO; GO:2000467; P:positive regulation of glycogen (starch) synthase activity; ISS:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IDA:MGI.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; ISS:UniProtKB.
DR   GO; GO:2000478; P:positive regulation of metanephric glomerular visceral epithelial cell development; IMP:UniProtKB.
DR   GO; GO:0071639; P:positive regulation of monocyte chemotactic protein-1 production; ISS:UniProtKB.
DR   GO; GO:0033034; P:positive regulation of myeloid cell apoptotic process; ISS:UniProtKB.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:0010739; P:positive regulation of protein kinase A signaling; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:2000534; P:positive regulation of renal albumin absorption; IMP:UniProtKB.
DR   GO; GO:0009967; P:positive regulation of signal transduction; IDA:MGI.
DR   GO; GO:0070208; P:protein heterotrimerization; IPI:MGI.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:MGI.
DR   GO; GO:0072659; P:protein localization to plasma membrane; ISS:UniProtKB.
DR   GO; GO:0010906; P:regulation of glucose metabolic process; ISS:UniProtKB.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; IDA:MGI.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0070543; P:response to linoleic acid; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0009744; P:response to sucrose; IEA:Ensembl.
DR   GO; GO:0034612; P:response to tumor necrosis factor; ISS:UniProtKB.
DR   Gene3D; 2.60.120.40; -; 1.
DR   InterPro; IPR001073; C1q_dom.
DR   InterPro; IPR008160; Collagen.
DR   InterPro; IPR008983; Tumour_necrosis_fac-like_dom.
DR   Pfam; PF00386; C1q; 1.
DR   Pfam; PF01391; Collagen; 1.
DR   PRINTS; PR00007; COMPLEMNTC1Q.
DR   SMART; SM00110; C1Q; 1.
DR   SUPFAM; SSF49842; SSF49842; 1.
DR   PROSITE; PS50871; C1Q; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Collagen; Complete proteome; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Hormone; Hydroxylation;
KW   Reference proteome; Repeat; Secreted; Signal.
FT   SIGNAL        1     17       {ECO:0000269|PubMed:11912203}.
FT   CHAIN        18    247       Adiponectin.
FT                                /FTId=PRO_0000003544.
FT   DOMAIN       45    110       Collagen-like.
FT   DOMAIN      111    247       C1q. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00368}.
FT   SITE         79     79       Not hydroxylated.
FT   SITE         98     98       Not hydroxylated.
FT   SITE        107    107       Not hydroxylated.
FT   SITE        233    233       Not glycosylated.
FT   MOD_RES      47     47       4-hydroxyproline. {ECO:0000250}.
FT   MOD_RES      50     50       4-hydroxyproline. {ECO:0000250}.
FT   MOD_RES      56     56       4-hydroxyproline. {ECO:0000250}.
FT   MOD_RES      68     68       5-hydroxylysine; alternate.
FT                                {ECO:0000269|PubMed:11912203}.
FT   MOD_RES      71     71       5-hydroxylysine; alternate.
FT                                {ECO:0000269|PubMed:11912203}.
FT   MOD_RES      80     80       5-hydroxylysine; alternate.
FT                                {ECO:0000269|PubMed:11912203}.
FT   MOD_RES      94     94       4-hydroxyproline.
FT                                {ECO:0000269|PubMed:11912203}.
FT   MOD_RES     104    104       5-hydroxylysine; alternate.
FT                                {ECO:0000269|PubMed:11912203}.
FT   CARBOHYD     23     23       O-linked (GalNAc...).
FT                                {ECO:0000305|PubMed:19855092}.
FT   CARBOHYD     24     24       O-linked (GalNAc...).
FT                                {ECO:0000305|PubMed:19855092}.
FT   CARBOHYD     68     68       O-linked (Gal...); alternate.
FT                                {ECO:0000269|PubMed:11912203}.
FT   CARBOHYD     71     71       O-linked (Gal...); alternate.
FT                                {ECO:0000269|PubMed:11912203}.
FT   CARBOHYD     80     80       O-linked (Gal...); alternate.
FT                                {ECO:0000269|PubMed:11912203}.
FT   CARBOHYD    104    104       O-linked (Gal...); alternate.
FT                                {ECO:0000269|PubMed:11912203}.
FT   DISULFID     39     39       Interchain. {ECO:0000250}.
FT   MUTAGEN      39     39       C->A: No change in the interaction with
FT                                CTRP9. {ECO:0000269|PubMed:18787108}.
FT   MUTAGEN      68     68       K->R: Impaired formation of HMW
FT                                multimers; when associated with R-71; R-
FT                                80 and R-104.
FT                                {ECO:0000269|PubMed:16621799}.
FT   MUTAGEN      71     71       K->R: Impaired formation of HMW
FT                                multimers; when associated with R-68; R-
FT                                80 and R-104.
FT                                {ECO:0000269|PubMed:16621799}.
FT   MUTAGEN      80     80       K->R: Impaired formation of HMW
FT                                multimers; when associated with R-68; R-
FT                                71 and R-104.
FT                                {ECO:0000269|PubMed:16621799}.
FT   MUTAGEN     104    104       K->R: Impaired formation of HMW
FT                                multimers; when associated with R-68; R-
FT                                71 and R-80.
FT                                {ECO:0000269|PubMed:16621799}.
FT   CONFLICT     50     50       P -> S (in Ref. 2; AAB06706).
FT                                {ECO:0000305}.
FT   CONFLICT     74     74       A -> S (in Ref. 2; AAB06706).
FT                                {ECO:0000305}.
FT   CONFLICT    113    113       V -> M (in Ref. 1; AAA80543 and 3;
FT                                AAK13417). {ECO:0000305}.
FT   CONFLICT    117    117       A -> G (in Ref. 2; AAB06706).
FT                                {ECO:0000305}.
FT   CONFLICT    148    148       G -> N (in Ref. 2; AAB06706).
FT                                {ECO:0000305}.
FT   CONFLICT    243    243       Y -> F (in Ref. 2; AAB06706).
FT                                {ECO:0000305}.
FT   STRAND      117    121       {ECO:0000244|PDB:1C28}.
FT   STRAND      130    132       {ECO:0000244|PDB:1C3H}.
FT   STRAND      137    140       {ECO:0000244|PDB:1C28}.
FT   TURN        148    150       {ECO:0000244|PDB:1C28}.
FT   STRAND      152    154       {ECO:0000244|PDB:1C3H}.
FT   STRAND      159    172       {ECO:0000244|PDB:1C28}.
FT   STRAND      174    180       {ECO:0000244|PDB:1C28}.
FT   STRAND      183    190       {ECO:0000244|PDB:1C28}.
FT   STRAND      197    208       {ECO:0000244|PDB:1C28}.
FT   STRAND      213    218       {ECO:0000244|PDB:1C28}.
FT   STRAND      236    244       {ECO:0000244|PDB:1C28}.
SQ   SEQUENCE   247 AA;  26809 MW;  0ECC687D9A8E8123 CRC64;
     MLLLQALLFL LILPSHAEDD VTTTEELAPA LVPPPKGTCA GWMAGIPGHP GHNGTPGRDG
     RDGTPGEKGE KGDAGLLGPK GETGDVGMTG AEGPRGFPGT PGRKGEPGEA AYVYRSAFSV
     GLETRVTVPN VPIRFTKIFY NQQNHYDGST GKFYCNIPGL YYFSYHITVY MKDVKVSLFK
     KDKAVLFTYD QYQEKNVDQA SGSVLLHLEV GDQVWLQVYG DGDHNGLYAD NVNDSTFTGF
     LLYHDTN
//